ID   ABC3B_HUMAN             Reviewed;         382 AA.
AC   Q9UH17; B0QYD2; O95618; Q20WL1; Q5IFJ4; Q7Z2N3; Q7Z6D6; Q9UE74;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   28-FEB-2018, entry version 147.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3B;
DE            Short=A3B;
DE            EC=3.5.4.-;
DE   AltName: Full=Phorbolin-1-related protein;
DE   AltName: Full=Phorbolin-2/3;
GN   Name=APOBEC3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT LYS-146, AND
RP   INDUCTION.
RC   TISSUE=Keratinocyte;
RX   PubMed=10469298; DOI=10.1046/j.1523-1747.1999.00682.x;
RA   Madsen P.P., Anant S., Rasmussen H.H., Gromov P., Vorum H.,
RA   Dumanski J.P., Tommerup N., Collins J.E., Wright C.L., Dunham I.,
RA   Macginnitie A.J., Davidson N.O., Celis J.E.;
RT   "Psoriasis upregulated phorbolin-1 shares structural but not
RT   functional similarity to the mRNA-editing protein apobec-1.";
RL   J. Invest. Dermatol. 113:162-169(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=16060832; DOI=10.1089/aid.2005.21.611;
RA   Rose K.M., Marin M., Kozak S.L., Kabat D.;
RT   "Regulated production and anti-HIV type 1 activities of cytidine
RT   deaminases APOBEC3B, 3F, and 3G.";
RL   AIDS Res. Hum. Retroviruses 21:611-619(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS
RP   GLU-62 AND LYS-146.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   LYS-146.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   GENE FAMILY ORGANIZATION, TISSUE SPECIFICITY, RNA-BINDING,
RP   ZINC-BINDING, AND INTERACTION WITH APOBEC3G.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [7]
RP   REVIEW ON APOBEC FAMILIES.
RX   PubMed=12683974; DOI=10.1016/S0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family
RT   seeking roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [8]
RP   FUNCTION IN HIV-1 INFECTIVITY.
RX   PubMed=12859895; DOI=10.1016/S0092-8674(03)00515-4;
RA   Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R.,
RA   Bollman B., Muenk C., Nymark-McMahon H., Landau N.R.;
RT   "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.";
RL   Cell 114:21-31(2003).
RN   [9]
RP   FUNCTION IN SIV RESTRICTION.
RX   PubMed=15466872; DOI=10.1074/jbc.M408802200;
RA   Yu Q., Chen D., Koenig R., Mariani R., Unutmaz D., Landau N.R.;
RT   "APOBEC3B and APOBEC3C are potent inhibitors of simian
RT   immunodeficiency virus replication.";
RL   J. Biol. Chem. 279:53379-53386(2004).
RN   [10]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I.,
RA   Landau N.R., Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [11]
RP   DOMAIN CMP/DCMP DEAMINASE.
RX   PubMed=17020885; DOI=10.1074/jbc.M604980200;
RA   Hakata Y., Landau N.R.;
RT   "Reversed functional organization of mouse and human APOBEC3 cytidine
RT   deaminase domains.";
RL   J. Biol. Chem. 281:36624-36631(2006).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16699599; DOI=10.1371/journal.ppat.0020041;
RA   Wichroski M.J., Robb G.B., Rana T.M.;
RT   "Human retroviral host restriction factors APOBEC3G and APOBEC3F
RT   localize to mRNA processing bodies.";
RL   PLoS Pathog. 2:E41-E41(2006).
RN   [13]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [14]
RP   REVIEW ON FUNCTION IN HBV RESTRICTION.
RX   PubMed=18448976; DOI=10.1097/QCO.0b013e3282fe1bb2;
RA   Bonvin M., Greeve J.;
RT   "Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine
RT   deaminases as effectors in innate immunity against the hepatitis B
RT   virus.";
RL   Curr. Opin. Infect. Dis. 21:298-303(2008).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18667511; DOI=10.1128/JVI.02471-07;
RA   Stenglein M.D., Matsuo H., Harris R.S.;
RT   "Two regions within the amino-terminal half of APOBEC3G cooperate to
RT   determine cytoplasmic localization.";
RL   J. Virol. 82:9591-9599(2008).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in
RT   lymphocytes and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [17]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human
RT   cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21835787; DOI=10.1128/JVI.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
RT   demonstrate a conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [19]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [20]
RP   FUNCTION IN HTLV-1 RESTRICTION.
RX   PubMed=22457529; DOI=10.1128/JVI.06570-11;
RA   Ooms M., Krikoni A., Kress A.K., Simon V., Muenk C.;
RT   "APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-
RT   lymphotropic virus type 1.";
RL   J. Virol. 86:6097-6108(2012).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [22]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) which acts as an
CC       inhibitor of retrovirus replication and retrotransposon mobility
CC       via deaminase-dependent and -independent mechanisms. After the
CC       penetration of retroviral nucleocapsids into target cells of
CC       infection and the initiation of reverse transcription, it can
CC       induce the conversion of cytosine to uracil in the minus-sense
CC       single-strand viral DNA, leading to G-to-A hypermutations in the
CC       subsequent plus-strand viral DNA. The resultant detrimental levels
CC       of mutations in the proviral genome, along with a deamination-
CC       independent mechanism that works prior to the proviral
CC       integration, together exert efficient antiretroviral effects in
CC       infected target cells. Selectively targets single-stranded DNA and
CC       does not deaminate double-stranded DNA or single-or double-
CC       stranded RNA. Exhibits antiviral activity against simian
CC       immunodeficiency virus (SIV), hepatitis B virus (HBV) and human T-
CC       cell leukemia virus type 1 (HTLV-1) and may inhibit the mobility
CC       of LTR and non-LTR retrotransposons. {ECO:0000269|PubMed:12859895,
CC       ECO:0000269|PubMed:15466872, ECO:0000269|PubMed:16060832,
CC       ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055,
CC       ECO:0000269|PubMed:22457529}.
CC   -!- CATALYTIC ACTIVITY: Cytidine + H(2)O = uridine + NH(3).
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC   -!- SUBUNIT: Homodimer. Interacts with APOBEC3G. Does not interact
CC       with APOBEC1. {ECO:0000269|PubMed:11863358}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16699599,
CC       ECO:0000269|PubMed:18667511, ECO:0000269|PubMed:21835787,
CC       ECO:0000269|PubMed:22915799}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UH17-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UH17-2; Sequence=VSP_009802;
CC         Note=May be due to a competing donor splice site.;
CC       Name=3;
CC         IsoId=Q9UH17-3; Sequence=VSP_044900;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed at high and moderate levels in
CC       peripheral blood leukocytes, spleen, testes, heart, thymus,
CC       prostate and ovary. Also expressed at low levels in several other
CC       tissues. {ECO:0000269|PubMed:11863358,
CC       ECO:0000269|PubMed:20308164}.
CC   -!- INDUCTION: Phorbol 12-myristate 13-acetate (PMA) induces
CC       overexpression in keratinocytes. Up-regulated by IFN-alpha.
CC       {ECO:0000269|PubMed:10469298}.
CC   -!- DOMAIN: The CMP/dCMP deaminase domain 1 mediates RNA binding, RNA-
CC       dependent oligomerization and virion incorporation whereas the
CC       CMP/dCMP deaminase domain 2 confers deoxycytidine deaminase
CC       activity and substrate sequence specificity.
CC       {ECO:0000269|PubMed:17020885}.
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes
CC       found in a cluster, thought to result from gene duplication, on
CC       chromosome 22.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD00089.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAD00090.1; Type=Frameshift; Positions=59, 134; Note=Frameshifts result in two separate ORFs termed phorbolins 2 and 3.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U61083; AAD00089.1; ALT_INIT; mRNA.
DR   EMBL; U61084; AAD00090.1; ALT_FRAME; mRNA.
DR   EMBL; AY743217; AAW31743.1; -; mRNA.
DR   EMBL; CT841510; CAJ86440.1; -; mRNA.
DR   EMBL; AL022318; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC053859; AAH53859.1; -; mRNA.
DR   CCDS; CCDS13982.1; -. [Q9UH17-1]
DR   CCDS; CCDS58807.1; -. [Q9UH17-3]
DR   RefSeq; NP_001257340.1; NM_001270411.1.
DR   RefSeq; NP_004891.4; NM_004900.4.
DR   UniGene; Hs.226307; -.
DR   UniGene; Hs.658626; -.
DR   PDB; 2NBQ; NMR; -; A=187-382.
DR   PDB; 5CQD; X-ray; 2.08 A; A/C=187-378.
DR   PDB; 5CQH; X-ray; 1.73 A; A=187-378.
DR   PDB; 5CQI; X-ray; 1.68 A; A=187-378.
DR   PDB; 5CQK; X-ray; 1.88 A; A=187-378.
DR   PDB; 5SXG; X-ray; 1.93 A; A/B=191-378.
DR   PDB; 5SXH; X-ray; 1.78 A; A/B=191-378.
DR   PDB; 5TD5; X-ray; 1.72 A; A=187-378.
DR   PDB; 5TKM; X-ray; 1.90 A; A/B=1-191.
DR   PDBsum; 2NBQ; -.
DR   PDBsum; 5CQD; -.
DR   PDBsum; 5CQH; -.
DR   PDBsum; 5CQI; -.
DR   PDBsum; 5CQK; -.
DR   PDBsum; 5SXG; -.
DR   PDBsum; 5SXH; -.
DR   PDBsum; 5TD5; -.
DR   PDBsum; 5TKM; -.
DR   ProteinModelPortal; Q9UH17; -.
DR   SMR; Q9UH17; -.
DR   BioGrid; 114950; 16.
DR   IntAct; Q9UH17; 15.
DR   STRING; 9606.ENSP00000327459; -.
DR   iPTMnet; Q9UH17; -.
DR   PhosphoSitePlus; Q9UH17; -.
DR   BioMuta; APOBEC3B; -.
DR   DMDM; 12643884; -.
DR   EPD; Q9UH17; -.
DR   PaxDb; Q9UH17; -.
DR   PeptideAtlas; Q9UH17; -.
DR   PRIDE; Q9UH17; -.
DR   DNASU; 9582; -.
DR   Ensembl; ENST00000333467; ENSP00000327459; ENSG00000179750. [Q9UH17-1]
DR   Ensembl; ENST00000335760; ENSP00000338897; ENSG00000179750. [Q9UH17-2]
DR   Ensembl; ENST00000407298; ENSP00000385068; ENSG00000179750. [Q9UH17-3]
DR   GeneID; 9582; -.
DR   KEGG; hsa:9582; -.
DR   UCSC; uc003awo.3; human. [Q9UH17-1]
DR   CTD; 9582; -.
DR   DisGeNET; 9582; -.
DR   EuPathDB; HostDB:ENSG00000179750.15; -.
DR   GeneCards; APOBEC3B; -.
DR   HGNC; HGNC:17352; APOBEC3B.
DR   HPA; HPA056980; -.
DR   HPA; HPA066719; -.
DR   MIM; 607110; gene.
DR   neXtProt; NX_Q9UH17; -.
DR   OpenTargets; ENSG00000179750; -.
DR   PharmGKB; PA24892; -.
DR   eggNOG; ENOG410JBA1; Eukaryota.
DR   eggNOG; ENOG41119MS; LUCA.
DR   GeneTree; ENSGT00530000062933; -.
DR   HOGENOM; HOG000033755; -.
DR   HOVERGEN; HBG050434; -.
DR   KO; K18750; -.
DR   PhylomeDB; Q9UH17; -.
DR   TreeFam; TF331356; -.
DR   Reactome; R-HSA-72200; mRNA Editing: C to U Conversion.
DR   Reactome; R-HSA-75094; Formation of the Editosome.
DR   GeneWiki; APOBEC3B; -.
DR   GenomeRNAi; 9582; -.
DR   PRO; PR:Q9UH17; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000179750; -.
DR   CleanEx; HS_APOBEC3B; -.
DR   ExpressionAtlas; Q9UH17; baseline and differential.
DR   Genevisible; Q9UH17; HS.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0047844; F:deoxycytidine deaminase activity; IMP:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR013158; APOBEC_N.
DR   InterPro; IPR002125; CMP_dCMP_dom.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF08210; APOBEC_N; 2.
DR   SUPFAM; SSF53927; SSF53927; 2.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES_1; 2.
DR   PROSITE; PS51747; CYT_DCMP_DEAMINASES_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Antiviral defense;
KW   Complete proteome; Hydrolase; Immunity; Innate immunity;
KW   Metal-binding; Nucleus; Polymorphism; Reference proteome; Repeat;
KW   RNA-binding; Zinc.
FT   CHAIN         1    382       DNA dC->dU-editing enzyme APOBEC-3B.
FT                                /FTId=PRO_0000171753.
FT   DOMAIN       29    138       CMP/dCMP-type deaminase 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01083}.
FT   DOMAIN      210    326       CMP/dCMP-type deaminase 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01083}.
FT   ACT_SITE    255    255       Proton donor. {ECO:0000255}.
FT   METAL        66     66       Zinc. {ECO:0000250}.
FT   METAL        97     97       Zinc. {ECO:0000250}.
FT   METAL       100    100       Zinc. {ECO:0000250}.
FT   METAL       253    253       Zinc. {ECO:0000250}.
FT   METAL       284    284       Zinc. {ECO:0000250}.
FT   METAL       289    289       Zinc. {ECO:0000250}.
FT   VAR_SEQ     191    382       YLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLM
FT                                DQHMGFLCNEAKNLLCGFYGRHAELRFLDLVPSLQLDPAQI
FT                                YRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIY
FT                                DYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGC
FT                                PFQPWDGLEEHSQALSGRLRAILQNQGN -> LRIFSVAFT
FT                                AAMRSCASWTWFLLCSWTRPRSTGSLGSSPGAPASPGAVPG
FT                                KCVRSFRRTHT (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_009802.
FT   VAR_SEQ     242    266       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15461802}.
FT                                /FTId=VSP_044900.
FT   VARIANT      62     62       K -> E (in dbSNP:rs2076109).
FT                                {ECO:0000269|PubMed:15461802}.
FT                                /FTId=VAR_018142.
FT   VARIANT      98     98       P -> L (in dbSNP:rs2076110).
FT                                /FTId=VAR_018143.
FT   VARIANT     109    109       S -> A (in dbSNP:rs17000697).
FT                                /FTId=VAR_033455.
FT   VARIANT     146    146       T -> K (in dbSNP:rs5995649).
FT                                {ECO:0000269|PubMed:10469298,
FT                                ECO:0000269|PubMed:15461802,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_018144.
FT   VARIANT     351    351       R -> H (in dbSNP:rs1053813).
FT                                /FTId=VAR_048722.
FT   CONFLICT    103    104       KL -> NV (in Ref. 1; AAD00090).
FT                                {ECO:0000305}.
FT   CONFLICT    227    228       TW -> WM (in Ref. 1; AAD00089).
FT                                {ECO:0000305}.
FT   CONFLICT    255    256       EL -> DW (in Ref. 1; AAD00089).
FT                                {ECO:0000305}.
FT   CONFLICT    306    306       R -> P (in Ref. 1; AAD00089).
FT                                {ECO:0000305}.
FT   CONFLICT    356    356       F -> S (in Ref. 2; AAW31743).
FT                                {ECO:0000305}.
FT   HELIX        14     21       {ECO:0000244|PDB:5TKM}.
FT   STRAND       32     43       {ECO:0000244|PDB:5TKM}.
FT   STRAND       46     61       {ECO:0000244|PDB:5TKM}.
FT   HELIX        63     65       {ECO:0000244|PDB:5TKM}.
FT   HELIX        67     78       {ECO:0000244|PDB:5TKM}.
FT   STRAND       86     94       {ECO:0000244|PDB:5TKM}.
FT   HELIX        98    110       {ECO:0000244|PDB:5TKM}.
FT   STRAND      114    122       {ECO:0000244|PDB:5TKM}.
FT   HELIX       128    131       {ECO:0000244|PDB:5TKM}.
FT   HELIX       134    140       {ECO:0000244|PDB:5TKM}.
FT   STRAND      144    147       {ECO:0000244|PDB:5TKM}.
FT   HELIX       150    160       {ECO:0000244|PDB:5TKM}.
FT   HELIX       174    188       {ECO:0000244|PDB:5TKM}.
FT   HELIX       195    202       {ECO:0000244|PDB:5CQI}.
FT   STRAND      215    224       {ECO:0000244|PDB:5CQI}.
FT   STRAND      227    230       {ECO:0000244|PDB:5CQI}.
FT   HELIX       232    234       {ECO:0000244|PDB:5CQI}.
FT   STRAND      236    239       {ECO:0000244|PDB:5CQI}.
FT   HELIX       245    247       {ECO:0000244|PDB:2NBQ}.
FT   HELIX       254    261       {ECO:0000244|PDB:5CQI}.
FT   HELIX       262    265       {ECO:0000244|PDB:5CQI}.
FT   STRAND      269    271       {ECO:0000244|PDB:2NBQ}.
FT   STRAND      273    281       {ECO:0000244|PDB:5CQI}.
FT   HELIX       289    299       {ECO:0000244|PDB:5CQI}.
FT   TURN        300    302       {ECO:0000244|PDB:2NBQ}.
FT   STRAND      303    311       {ECO:0000244|PDB:5CQI}.
FT   HELIX       319    328       {ECO:0000244|PDB:5CQI}.
FT   STRAND      332    335       {ECO:0000244|PDB:5CQI}.
FT   HELIX       338    348       {ECO:0000244|PDB:5CQI}.
FT   HELIX       362    377       {ECO:0000244|PDB:5CQI}.
SQ   SEQUENCE   382 AA;  45924 MW;  DA6EDD23E8856240 CRC64;
     MNPQIRNPME RMYRDTFYDN FENEPILYGR SYTWLCYEVK IKRGRSNLLW DTGVFRGQVY
     FKPQYHAEMC FLSWFCGNQL PAYKCFQITW FVSWTPCPDC VAKLAEFLSE HPNVTLTISA
     ARLYYYWERD YRRALCRLSQ AGARVTIMDY EEFAYCWENF VYNEGQQFMP WYKFDENYAF
     LHRTLKEILR YLMDPDTFTF NFNNDPLVLR RRQTYLCYEV ERLDNGTWVL MDQHMGFLCN
     EAKNLLCGFY GRHAELRFLD LVPSLQLDPA QIYRVTWFIS WSPCFSWGCA GEVRAFLQEN
     THVRLRIFAA RIYDYDPLYK EALQMLRDAG AQVSIMTYDE FEYCWDTFVY RQGCPFQPWD
     GLEEHSQALS GRLRAILQNQ GN
//
ID   AT1A1_HUMAN             Reviewed;        1023 AA.
AC   P05023; B2RBR6; B7Z2T5; B7Z3U6; F5H3A1; Q16689; Q6LDM4; Q9UCN1;
AC   Q9UJ20; Q9UJ21;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   28-FEB-2018, entry version 215.
DE   RecName: Full=Sodium/potassium-transporting ATPase subunit alpha-1;
DE            Short=Na(+)/K(+) ATPase alpha-1 subunit;
DE            EC=3.6.3.9;
DE   AltName: Full=Sodium pump subunit alpha-1;
DE   Flags: Precursor;
GN   Name=ATP1A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2430951;
RA   Kawakami K., Ohta T., Nojima H., Nagano K.;
RT   "Primary structure of the alpha-subunit of human Na,K-ATPase deduced
RT   from cDNA sequence.";
RL   J. Biochem. 100:389-397(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Retinal pigment epithelium;
RX   PubMed=7536695; DOI=10.1016/0378-1119(94)00812-7;
RA   Ruiz A., Bhat S.P., Bok D.;
RT   "Characterization and quantification of full-length and truncated
RT   Na,K-ATPase alpha 1 and beta 1 RNA transcripts expressed in human
RT   retinal pigment epithelium.";
RL   Gene 155:179-184(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Cervix, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-61.
RX   PubMed=1970326; DOI=10.1016/0888-7543(90)90475-A;
RA   Shull M.M., Pugh D.G., Lingrel J.B.;
RT   "The human Na, K-ATPase alpha 1 gene: characterization of the 5'-
RT   flanking region and identification of a restriction fragment length
RT   polymorphism.";
RL   Genomics 6:451-460(1990).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 85-148.
RC   TISSUE=Placenta;
RA   Zhang J.-S., Yang J.X., Fang M.W., Lu S.D.;
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 168-189 AND 213-244.
RX   PubMed=3035563; DOI=10.1073/pnas.84.12.4039;
RA   Shull M.M., Lingrel J.B.;
RT   "Multiple genes encode the human Na+,K+-ATPase catalytic subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4039-4043(1987).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 198-943 (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2891135; DOI=10.1073/pnas.84.22.7901;
RA   Chehab F.F., Kan Y.W., Law M.L., Hartz J., Kao F.T., Blostein R.;
RT   "Human placental Na+,K+-ATPase alpha subunit: cDNA cloning, tissue
RT   expression, DNA polymorphism, and chromosomal localization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7901-7905(1987).
RN   [11]
RP   PROTEIN SEQUENCE OF 199-216, AND INTERACTION WITH HLA-DR1.
RX   PubMed=1380674; DOI=10.1038/358764a0;
RA   Chicz R.M., Urban R.G., Lane W.S., Gorga J.C., Stern L.J.,
RA   Vignali D.A.A., Strominger J.L.;
RT   "Predominant naturally processed peptides bound to HLA-DR1 are derived
RT   from MHC-related molecules and are heterogeneous in size.";
RL   Nature 358:764-768(1992).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 253-341 AND 420-444.
RX   PubMed=3036582; DOI=10.1016/0014-5793(87)80677-4;
RA   Sverdlov E.D., Monastyrskaya G.S., Broude N.E., Ushkaryov Y.A.,
RA   Allikmets R.L., Melkov A.M., Smirnov Y.V., Malyshev I.V.,
RA   Dulubova I.E., Petrukhin K.E., Gryshin A.V., Kiyatkin N.I.,
RA   Kostina M.B., Sverdlov V.E., Modyanov N.N., Ovchinnikov Y.A.;
RT   "The family of human Na+,K+-ATPase genes. No less than five genes
RT   and/or pseudogenes related to the alpha-subunit.";
RL   FEBS Lett. 217:275-278(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 471-619.
RA   Ovchinnikov Y.A., Monastyrskaya G.S., Arsenyan S.G., Broude N.E.,
RA   Petrukhin K.E., Grishin A.V., Arzamazova N.M., Severtsova I.V.,
RA   Modyanov N.N.;
RT   "Amino acid sequence of the 17-kilodalton fragment of the cytoplasmic
RT   region of the alpha-subunit of NA+,K+-ATPase.";
RL   Dokl. Biochem. 288:270-272(1986).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=7711835; DOI=10.3109/09687689409160435;
RA   Hundal H.S., Maxwell D.L., Ahmed A., Darakhshan F., Mitsumoto Y.,
RA   Klip A.;
RT   "Subcellular distribution and immunocytochemical localization of Na,K-
RT   ATPase subunit isoforms in human skeletal muscle.";
RL   Mol. Membr. Biol. 11:255-262(1994).
RN   [15]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [16]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-542, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   INTERACTION WITH FXYD3.
RX   PubMed=21454534; DOI=10.1074/jbc.M110.184101;
RA   Bibert S., Liu C.C., Figtree G.A., Garcia A., Hamilton E.J.,
RA   Marassi F.M., Sweadner K.J., Cornelius F., Geering K., Rasmussen H.H.;
RT   "FXYD proteins reverse inhibition of the Na+-K+ pump mediated by
RT   glutathionylation of its beta1 subunit.";
RL   J. Biol. Chem. 286:18562-18572(2011).
RN   [21]
RP   INTERACTION WITH SLC35G1 AND STIM1.
RX   PubMed=22084111; DOI=10.1073/pnas.1117231108;
RA   Krapivinsky G., Krapivinsky L., Stotz S.C., Manasian Y., Clapham D.E.;
RT   "POST, partner of stromal interaction molecule 1 (STIM1), targets
RT   STIM1 to multiple transporters.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:19234-19239(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: This is the catalytic component of the active enzyme,
CC       which catalyzes the hydrolysis of ATP coupled with the exchange of
CC       sodium and potassium ions across the plasma membrane. This action
CC       creates the electrochemical gradient of sodium and potassium ions,
CC       providing the energy for active transport of various nutrients.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Na(+)(In) + K(+)(Out) = ADP +
CC       phosphate + Na(+)(Out) + K(+)(In).
CC   -!- SUBUNIT: The sodium/potassium-transporting ATPase is composed of a
CC       catalytic alpha subunit, an auxiliary non-catalytic beta subunit
CC       and an additional regulatory subunit. Interacts with regulatory
CC       subunit FXYD1 (By similarity). Interacts with regulatory subunit
CC       FXYD3 (PubMed:21454534). Interacts with SIK1 (By similarity).
CC       Binds the HLA class II histocompatibility antigen DR1
CC       (PubMed:1380674). Interacts with SLC35G1 and STIM1
CC       (PubMed:22084111). {ECO:0000250|UniProtKB:P06685,
CC       ECO:0000269|PubMed:1380674, ECO:0000269|PubMed:21454534,
CC       ECO:0000269|PubMed:22084111}.
CC   -!- INTERACTION:
CC       P13693:TPT1; NbExp=5; IntAct=EBI-358778, EBI-1783169;
CC   -!- SUBCELLULAR LOCATION: Cell membrane, sarcolemma
CC       {ECO:0000269|PubMed:7711835}; Multi-pass membrane protein
CC       {ECO:0000255}. Melanosome {ECO:0000269|PubMed:17081065}.
CC       Note=Identified by mass spectrometry in melanosome fractions from
CC       stage I to stage IV. {ECO:0000269|PubMed:17081065}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P05023-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P05023-2; Sequence=VSP_000415, VSP_000416;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=3;
CC         IsoId=P05023-3; Sequence=VSP_044242;
CC       Name=4;
CC         IsoId=P05023-4; Sequence=VSP_047309;
CC   -!- PTM: Phosphorylation on Tyr-10 modulates pumping activity.
CC       Phosphorylation of Ser-943 by PKA modulates the response of ATP1A1
CC       to PKC. Dephosphorylation by protein phosphatase 2A (PP2A)
CC       following increases in intracellular sodium, leading to increase
CC       catalytic activity (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type) (TC
CC       3.A.3) family. Type IIC subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D00099; BAA00061.1; -; mRNA.
DR   EMBL; X04297; CAA27840.1; -; mRNA.
DR   EMBL; U16798; AAC50131.1; -; mRNA.
DR   EMBL; AK295095; BAH11971.1; -; mRNA.
DR   EMBL; AK296362; BAH12332.1; -; mRNA.
DR   EMBL; AK314777; BAG37313.1; -; mRNA.
DR   EMBL; AL136376; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471122; EAW56644.1; -; Genomic_DNA.
DR   EMBL; BC003077; AAH03077.1; -; mRNA.
DR   EMBL; BC001330; AAH01330.1; -; mRNA.
DR   EMBL; BC050359; AAH50359.1; -; mRNA.
DR   EMBL; M30310; AAA51801.1; -; Genomic_DNA.
DR   EMBL; M30309; AAA51801.1; JOINED; Genomic_DNA.
DR   EMBL; L76938; AAA92713.1; -; Genomic_DNA.
DR   EMBL; M16793; AAD56251.1; -; mRNA.
DR   EMBL; M16794; AAD56252.1; -; mRNA.
DR   EMBL; J03007; AAA51803.1; -; mRNA.
DR   EMBL; M27572; AAA35573.1; -; Genomic_DNA.
DR   EMBL; M27579; AAA35574.2; -; Genomic_DNA.
DR   EMBL; X03757; CAA27390.1; -; mRNA.
DR   CCDS; CCDS53351.1; -. [P05023-4]
DR   CCDS; CCDS53352.1; -. [P05023-3]
DR   CCDS; CCDS887.1; -. [P05023-1]
DR   PIR; A24414; A24414.
DR   RefSeq; NP_000692.2; NM_000701.7. [P05023-1]
DR   RefSeq; NP_001153705.1; NM_001160233.1. [P05023-4]
DR   RefSeq; NP_001153706.1; NM_001160234.1. [P05023-3]
DR   RefSeq; XP_016856849.1; XM_017001360.1. [P05023-3]
DR   RefSeq; XP_016856850.1; XM_017001361.1. [P05023-3]
DR   UniGene; Hs.371889; -.
DR   ProteinModelPortal; P05023; -.
DR   SMR; P05023; -.
DR   BioGrid; 106966; 128.
DR   DIP; DIP-38196N; -.
DR   IntAct; P05023; 61.
DR   MINT; P05023; -.
DR   STRING; 9606.ENSP00000295598; -.
DR   BindingDB; P05023; -.
DR   ChEMBL; CHEMBL1807; -.
DR   DrugBank; DB00511; Acetyldigitoxin.
DR   DrugBank; DB01430; Almitrine.
DR   DrugBank; DB01370; Aluminium.
DR   DrugBank; DB01244; Bepridil.
DR   DrugBank; DB01158; Bretylium.
DR   DrugBank; DB01188; Ciclopirox.
DR   DrugBank; DB01078; Deslanoside.
DR   DrugBank; DB01119; Diazoxide.
DR   DrugBank; DB01396; Digitoxin.
DR   DrugBank; DB00390; Digoxin.
DR   DrugBank; DB00903; Etacrynic acid.
DR   DrugBank; DB00774; Hydroflumethiazide.
DR   DrugBank; DB01378; Magnesium.
DR   DrugBank; DB01092; Ouabain.
DR   DrugBank; DB01345; Potassium.
DR   DrugBank; DB09479; Rubidium chloride Rb-82.
DR   DrugBank; DB01021; Trichlormethiazide.
DR   TCDB; 3.A.3.1.1; the p-type atpase (p-atpase) superfamily.
DR   CarbonylDB; P05023; -.
DR   iPTMnet; P05023; -.
DR   PhosphoSitePlus; P05023; -.
DR   SwissPalm; P05023; -.
DR   BioMuta; ATP1A1; -.
DR   DMDM; 114374; -.
DR   EPD; P05023; -.
DR   MaxQB; P05023; -.
DR   PaxDb; P05023; -.
DR   PeptideAtlas; P05023; -.
DR   PRIDE; P05023; -.
DR   DNASU; 476; -.
DR   Ensembl; ENST00000295598; ENSP00000295598; ENSG00000163399. [P05023-1]
DR   Ensembl; ENST00000369496; ENSP00000358508; ENSG00000163399. [P05023-3]
DR   Ensembl; ENST00000537345; ENSP00000445306; ENSG00000163399. [P05023-4]
DR   GeneID; 476; -.
DR   KEGG; hsa:476; -.
DR   UCSC; uc001ege.5; human. [P05023-1]
DR   CTD; 476; -.
DR   DisGeNET; 476; -.
DR   EuPathDB; HostDB:ENSG00000163399.15; -.
DR   GeneCards; ATP1A1; -.
DR   HGNC; HGNC:799; ATP1A1.
DR   HPA; CAB018702; -.
DR   HPA; CAB069993; -.
DR   MIM; 182310; gene.
DR   neXtProt; NX_P05023; -.
DR   OpenTargets; ENSG00000163399; -.
DR   Orphanet; 85142; Aldosterone-producing adenoma.
DR   PharmGKB; PA62; -.
DR   eggNOG; KOG0203; Eukaryota.
DR   eggNOG; COG0474; LUCA.
DR   GeneTree; ENSGT00890000139334; -.
DR   HOGENOM; HOG000265622; -.
DR   HOVERGEN; HBG004298; -.
DR   InParanoid; P05023; -.
DR   KO; K01539; -.
DR   OMA; ARIMPEQ; -.
DR   OrthoDB; EOG091G01BB; -.
DR   PhylomeDB; P05023; -.
DR   TreeFam; TF312838; -.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   Reactome; R-HSA-936837; Ion transport by P-type ATPases.
DR   ChiTaRS; ATP1A1; human.
DR   GeneWiki; ATPase,_Na%2B/K%2B_transporting,_alpha_1; -.
DR   GenomeRNAi; 476; -.
DR   PRO; PR:P05023; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000163399; -.
DR   CleanEx; HS_ATP1A1; -.
DR   ExpressionAtlas; P05023; baseline and differential.
DR   Genevisible; P05023; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0014704; C:intercalated disc; IEA:Ensembl.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0042383; C:sarcolemma; ISS:BHF-UCL.
DR   GO; GO:0005890; C:sodium:potassium-exchanging ATPase complex; IDA:BHF-UCL.
DR   GO; GO:0030315; C:T-tubule; IEA:Ensembl.
DR   GO; GO:0043531; F:ADP binding; IEA:Ensembl.
DR   GO; GO:0030506; F:ankyrin binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; ISS:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0016791; F:phosphatase activity; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IEA:Ensembl.
DR   GO; GO:0030955; F:potassium ion binding; ISS:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0031402; F:sodium ion binding; ISS:BHF-UCL.
DR   GO; GO:0005391; F:sodium:potassium-exchanging ATPase activity; IDA:BHF-UCL.
DR   GO; GO:1990239; F:steroid hormone binding; IDA:BHF-UCL.
DR   GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; TAS:BHF-UCL.
DR   GO; GO:0086064; P:cell communication by electrical coupling involved in cardiac conduction; TAS:BHF-UCL.
DR   GO; GO:0030007; P:cellular potassium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0071383; P:cellular response to steroid hormone stimulus; IDA:BHF-UCL.
DR   GO; GO:0006883; P:cellular sodium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0060081; P:membrane hyperpolarization; IEA:Ensembl.
DR   GO; GO:0086009; P:membrane repolarization; IDA:BHF-UCL.
DR   GO; GO:0086013; P:membrane repolarization during cardiac muscle cell action potential; IC:BHF-UCL.
DR   GO; GO:0031947; P:negative regulation of glucocorticoid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045822; P:negative regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:0045823; P:positive regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:0045989; P:positive regulation of striated muscle contraction; IEA:Ensembl.
DR   GO; GO:0010107; P:potassium ion import; IDA:BHF-UCL.
DR   GO; GO:1990573; P:potassium ion import across plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:1903779; P:regulation of cardiac conduction; TAS:Reactome.
DR   GO; GO:0086004; P:regulation of cardiac muscle cell contraction; IEA:Ensembl.
DR   GO; GO:0002028; P:regulation of sodium ion transport; ISS:UniProtKB.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IEA:Ensembl.
DR   GO; GO:0055119; P:relaxation of cardiac muscle; TAS:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:1903416; P:response to glycoside; IDA:BHF-UCL.
DR   GO; GO:0036376; P:sodium ion export across plasma membrane; IDA:BHF-UCL.
DR   CDD; cd02608; P-type_ATPase_Na-K_like; 1.
DR   Gene3D; 3.40.1110.10; -; 1.
DR   Gene3D; 3.40.50.1000; -; 2.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR023299; ATPase_P-typ_cyto_dom_N.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR023298; ATPase_P-typ_TM_dom_sf.
DR   InterPro; IPR008250; ATPase_P-typ_transduc_dom_A_sf.
DR   InterPro; IPR036412; HAD-like_sf.
DR   InterPro; IPR023214; HAD_sf.
DR   InterPro; IPR005775; P-type_ATPase_IIC.
DR   InterPro; IPR001757; P_typ_ATPase.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   SUPFAM; SSF56784; SSF56784; 3.
DR   SUPFAM; SSF81653; SSF81653; 1.
DR   SUPFAM; SSF81660; SSF81660; 1.
DR   SUPFAM; SSF81665; SSF81665; 3.
DR   TIGRFAMs; TIGR01106; ATPase-IIC_X-K; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 2.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Direct protein sequencing; Hydrolase;
KW   Ion transport; Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Potassium; Potassium transport;
KW   Reference proteome; Sodium; Sodium transport;
KW   Sodium/potassium transport; Transmembrane; Transmembrane helix;
KW   Transport.
FT   PROPEP        1      5
FT                                /FTId=PRO_0000002483.
FT   CHAIN         6   1023       Sodium/potassium-transporting ATPase
FT                                subunit alpha-1.
FT                                /FTId=PRO_0000002484.
FT   TOPO_DOM      6     87       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     88    108       Helical. {ECO:0000255}.
FT   TOPO_DOM    109    131       Extracellular. {ECO:0000255}.
FT   TRANSMEM    132    152       Helical. {ECO:0000255}.
FT   TOPO_DOM    153    288       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    289    308       Helical. {ECO:0000255}.
FT   TOPO_DOM    309    320       Extracellular. {ECO:0000255}.
FT   TRANSMEM    321    338       Helical. {ECO:0000255}.
FT   TOPO_DOM    339    772       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    773    792       Helical. {ECO:0000255}.
FT   TOPO_DOM    793    802       Extracellular. {ECO:0000255}.
FT   TRANSMEM    803    823       Helical. {ECO:0000255}.
FT   TOPO_DOM    824    843       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    844    866       Helical. {ECO:0000255}.
FT   TOPO_DOM    867    918       Extracellular. {ECO:0000255}.
FT   TRANSMEM    919    938       Helical. {ECO:0000255}.
FT   TOPO_DOM    939    951       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    952    970       Helical. {ECO:0000255}.
FT   TOPO_DOM    971    985       Extracellular. {ECO:0000255}.
FT   TRANSMEM    986   1006       Helical. {ECO:0000255}.
FT   TOPO_DOM   1007   1023       Cytoplasmic. {ECO:0000255}.
FT   REGION       82     84       Phosphoinositide-3 kinase binding.
FT                                {ECO:0000250}.
FT   ACT_SITE    376    376       4-aspartylphosphate intermediate.
FT                                {ECO:0000250}.
FT   METAL       717    717       Magnesium. {ECO:0000250}.
FT   METAL       721    721       Magnesium. {ECO:0000250}.
FT   BINDING     487    487       ATP. {ECO:0000250}.
FT   MOD_RES       9      9       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8VDN2}.
FT   MOD_RES      10     10       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P06685}.
FT   MOD_RES      16     16       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      21     21       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8VDN2}.
FT   MOD_RES      40     40       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06685}.
FT   MOD_RES      47     47       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06685}.
FT   MOD_RES     228    228       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VDN2}.
FT   MOD_RES     260    260       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q8VDN2}.
FT   MOD_RES     452    452       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06685}.
FT   MOD_RES     484    484       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06685}.
FT   MOD_RES     542    542       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     661    661       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q8VDN2}.
FT   MOD_RES     668    668       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VDN2}.
FT   MOD_RES     675    675       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VDN2}.
FT   MOD_RES     943    943       Phosphoserine; by PKA.
FT                                {ECO:0000250|UniProtKB:P06685}.
FT   VAR_SEQ       1     31       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044242.
FT   VAR_SEQ       2      4       GKG -> AFK (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047309.
FT   VAR_SEQ     638    681       NETVEDIAARLNIPVSQVNPRDAKACVVHGSDLKDMTSEQL
FT                                DDI -> SGPMSRGKSWSSPATQPSSSVSWWCSGPTWSSVR
FT                                PGGIRSSSRG (in isoform 2).
FT                                {ECO:0000303|PubMed:7536695}.
FT                                /FTId=VSP_000415.
FT   VAR_SEQ     682   1023       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:7536695}.
FT                                /FTId=VSP_000416.
FT   VARIANT      47     47       S -> I (in dbSNP:rs12564026).
FT                                /FTId=VAR_048374.
FT   CONFLICT    248    248       N -> S (in Ref. 3; BAG37313).
FT                                {ECO:0000305}.
FT   CONFLICT    323    323       F -> L (in Ref. 3; BAH11971).
FT                                {ECO:0000305}.
FT   CONFLICT    475    475       A -> T (in Ref. 13; CAA27390).
FT                                {ECO:0000305}.
FT   CONFLICT    499    499       S -> A (in Ref. 13; CAA27390).
FT                                {ECO:0000305}.
FT   CONFLICT    502    502       Q -> R (in Ref. 13; CAA27390).
FT                                {ECO:0000305}.
FT   CONFLICT    523    523       L -> I (in Ref. 13; CAA27390).
FT                                {ECO:0000305}.
FT   CONFLICT    892    892       D -> G (in Ref. 3; BAH11971).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1023 AA;  112896 MW;  F3C6FDE04FB3F667 CRC64;
     MGKGVGRDKY EPAAVSEQGD KKGKKGKKDR DMDELKKEVS MDDHKLSLDE LHRKYGTDLS
     RGLTSARAAE ILARDGPNAL TPPPTTPEWI KFCRQLFGGF SMLLWIGAIL CFLAYSIQAA
     TEEEPQNDNL YLGVVLSAVV IITGCFSYYQ EAKSSKIMES FKNMVPQQAL VIRNGEKMSI
     NAEEVVVGDL VEVKGGDRIP ADLRIISANG CKVDNSSLTG ESEPQTRSPD FTNENPLETR
     NIAFFSTNCV EGTARGIVVY TGDRTVMGRI ATLASGLEGG QTPIAAEIEH FIHIITGVAV
     FLGVSFFILS LILEYTWLEA VIFLIGIIVA NVPEGLLATV TVCLTLTAKR MARKNCLVKN
     LEAVETLGST STICSDKTGT LTQNRMTVAH MWFDNQIHEA DTTENQSGVS FDKTSATWLA
     LSRIAGLCNR AVFQANQENL PILKRAVAGD ASESALLKCI ELCCGSVKEM RERYAKIVEI
     PFNSTNKYQL SIHKNPNTSE PQHLLVMKGA PERILDRCSS ILLHGKEQPL DEELKDAFQN
     AYLELGGLGE RVLGFCHLFL PDEQFPEGFQ FDTDDVNFPI DNLCFVGLIS MIDPPRAAVP
     DAVGKCRSAG IKVIMVTGDH PITAKAIAKG VGIISEGNET VEDIAARLNI PVSQVNPRDA
     KACVVHGSDL KDMTSEQLDD ILKYHTEIVF ARTSPQQKLI IVEGCQRQGA IVAVTGDGVN
     DSPALKKADI GVAMGIAGSD VSKQAADMIL LDDNFASIVT GVEEGRLIFD NLKKSIAYTL
     TSNIPEITPF LIFIIANIPL PLGTVTILCI DLGTDMVPAI SLAYEQAESD IMKRQPRNPK
     TDKLVNERLI SMAYGQIGMI QALGGFFTYF VILAENGFLP IHLLGLRVDW DDRWINDVED
     SYGQQWTYEQ RKIVEFTCHT AFFVSIVVVQ WADLVICKTR RNSVFQQGMK NKILIFGLFE
     ETALAAFLSY CPGMGVALRM YPLKPTWWFC AFPYSLLIFV YDEVRKLIIR RRPGGWVEKE
     TYY
//
ID   A0A087WZX0_HUMAN        Unreviewed;      1462 AA.
AC   A0A087WZX0;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   28-FEB-2018, entry version 30.
DE   SubName: Full=B-cell CLL/lymphoma 9-like protein {ECO:0000313|Ensembl:ENSP00000482938};
GN   Name=BCL9L {ECO:0000313|Ensembl:ENSP00000482938};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000482938, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [2] {ECO:0000213|PubMed:16964243}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [3] {ECO:0000313|Ensembl:ENSP00000482938, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4] {ECO:0000213|PubMed:18220336}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.D., Yates J.R.;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [5] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [6] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [7] {ECO:0000213|PubMed:19608861}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [8] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [9] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [11] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13] {ECO:0000313|Ensembl:ENSP00000482938}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
RN   [14] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000482938}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AP004609; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_005271569.1; XM_005271512.2.
DR   RefSeq; XP_005271570.1; XM_005271513.2.
DR   UniGene; Hs.414740; -.
DR   ProteinModelPortal; A0A087WZX0; -.
DR   PeptideAtlas; A0A087WZX0; -.
DR   PRIDE; A0A087WZX0; -.
DR   Ensembl; ENST00000526143; ENSP00000482938; ENSG00000186174.
DR   GeneID; 283149; -.
DR   UCSC; uc058ibp.1; human.
DR   CTD; 283149; -.
DR   EuPathDB; HostDB:ENSG00000186174.12; -.
DR   HGNC; HGNC:23688; BCL9L.
DR   OpenTargets; ENSG00000186174; -.
DR   eggNOG; ENOG410IEDB; Eukaryota.
DR   eggNOG; ENOG410XRMX; LUCA.
DR   GeneTree; ENSGT00730000110915; -.
DR   ChiTaRS; BCL9L; human.
DR   GenomeRNAi; 283149; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000186174; -.
DR   ExpressionAtlas; A0A087WZX0; baseline and differential.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:InterPro.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:InterPro.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR015668; Bcl-9/Bcl-9l.
DR   InterPro; IPR024670; BCL9_beta-catenin-bd_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR15185; PTHR15185; 1.
DR   Pfam; PF11502; BCL9; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Proteomics identification {ECO:0000213|EPD:A0A087WZX0,
KW   ECO:0000213|MaxQB:A0A087WZX0, ECO:0000213|PeptideAtlas:A0A087WZX0};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN      361    393       BCL9. {ECO:0000259|Pfam:PF11502}.
SQ   SEQUENCE   1462 AA;  153087 MW;  AC6BB84FE844E728 CRC64;
     MHPENKLTNH GKTGNGGAQS QHQNVNQGPT CNVGSKGVGA GNHGAKANQI SPSNSSLKNP
     QAGVPPFSSL KGKVKRDRSV SVDSGEQREA GTPSLDSEAK EVAPRSKRRC VLERKQPYSG
     DEWCSGPDSE EDDKPIGATH NCNVADPAMA APQLGPGQTT QLPLSESSVP GAPHGPPPGL
     RPDAPGGGGG GGGVPGKPPS QFVYVFTTHL ANTAAEAVLQ GRADSILAYH QQNVPRAKLD
     QAPKVPPTPE PLPLSTPSAG TPQSQPPPLP PPPPPAPGSA PPALPPEGPP EDSSQDLAPN
     SVGAASTGGG TGGTHPNTPT ATTANNPLPP GGDPSSAPGP ALLGEAAAPG NGQRSLVGSE
     GLSKEQLEHR ERSLQTLRDI ERLLLRSGET EPFLKGPPGG AGEGGPPAQA PPPPQQPPTA
     PPSGLKKYEE PLQSMISQTQ SLGGPPLEHE VPGHPPGGDM GQQMNMMIQR LGQDSLTPEQ
     VAWRKLQEEY YEEKRRKEEQ IGLHGSRPLQ DMMGMGGMMV RGPPPPYHSK PGDQWPPGMG
     AQLRGPMDVQ DPMQLRGGPP FPGPRFPGNQ IQRVPGFGGM QSMPMEVPMN AMQRPVRPGM
     GWTEDLPPMG GPSNFAQNTM PYPGGQGEAE RFMTPRVREE LLRHQLLEKR SMGMQRPLGM
     AGSGMGQSME MERMMQAHRQ MDPAMFPGQM AGGEGLAGTP MGMEFGGGRG LLSPPMGQSG
     LREVDPPMGP GNLNMNMNVN MNMNMNLNVQ MTPQQQMLMS QKMRGPGDLM GPQGLSPEEM
     ARVRAQNSSG VMGGPQKMLM PSQFPNQGQQ GFSGGQGPYQ AMSQDMGNTQ DMFSPDQSSM
     PMSNVGTTRL SHMPLPPASN PPGTVHSAPN RGLGRRPSDL TISINQMGSP GMGHLKSPTL
     SQVHSPLVTS PSANLKSPQT PSQMVPLPSA NPPGPLKSPQ VLGSSLSVRS PTGSPSRLKS
     PSMAVPSPGW VASPKTAMPS PGVSQNKQPP LNMNSSTTLS NMEQGTLPPS GPRSSSSAPP
     ANPPSGLMNP SLPFTSSPDP TPSQNPLSLM MTQMSKYAMP SSTPLYHNAI KTIATSDDEL
     LPDRPLLPPP PPPQGSGPGI SNSQPSQMHL NSAAAQSPMG MNLPGQQPLS HEPPPAMLPS
     PTPLGSNIPL HPNAQGTGGP PQNSMMMAPG GPDSLNAPCG PVPSSSQMMP FPPRLQQPHG
     AMAPTGGGGG GPGLQQHYPS GMALPPEDLP NQPPGPMPPQ QHLMGKAMAG RMGDAYPPGV
     LPGVASVLND PELSEVIRPT PTGIPEFDLS RIIPSEKPSS TLQYFPKSEN QPPKAQPPNL
     HLMNLQNMMA EQTPSRPPNL PGQQGVQRGL NMSMCHPGQM SLLGRTGVPP QQGMVPHGLH
     QGVMSPPQGL MTQQNFMLMK QRGVGGEVYS QPPHMLSPQG SLMGPPPQQN LMVSHPLRQR
     SVSLDSQMGY LPAPGGMANL PF
//
ID   BCL9L_HUMAN             Reviewed;        1499 AA.
AC   Q86UU0; A1A4C1; Q67FY1; Q6ZWJ0; Q6ZWK2;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   28-FEB-2018, entry version 124.
DE   RecName: Full=B-cell CLL/lymphoma 9-like protein;
DE            Short=B-cell lymphoma 9-like protein;
DE            Short=BCL9-like protein;
DE   AltName: Full=Protein BCL9-2;
GN   Name=BCL9L; Synonyms=DLNB11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=15371335; DOI=10.1101/gad.317604;
RA   Brembeck F.H., Schwarz-Romond T., Bakkers J., Wilhelm S.,
RA   Hammerschmidt M., Birchmeier W.;
RT   "Essential role of BCL9-2 in the switch between beta-catenin's
RT   adhesive and transcriptional functions.";
RL   Genes Dev. 18:2225-2230(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Kubo T., Arai Y., Ohira M., Gamou T., Maeno G., Sakiyama T.,
RA   Toyoda A., Hattori M., Sakaki Y., Nakagawara A., Ohki M.;
RT   "Identification of a 500-kb region of common allelic loss in
RT   chromosome 11q23 in non-MYCN amplified type of neuroblastoma.";
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 707-1499 (ISOFORM 4).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 865-1499 (ISOFORMS 1/2), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 466-1499 (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=12964048;
RA   Katoh M., Katoh M.;
RT   "Identification and characterization of human BCL9L gene and mouse
RT   Bcl9l gene in silico.";
RL   Int. J. Mol. Med. 12:643-649(2003).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-915, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   INTERACTION WITH CTNNB1.
RX   PubMed=17052462; DOI=10.1016/j.molcel.2006.09.001;
RA   Sampietro J., Dahlberg C.L., Cho U.S., Hinds T.R., Kimelman D., Xu W.;
RT   "Crystal structure of a beta-catenin/BCL9/Tcf4 complex.";
RL   Mol. Cell 24:293-300(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17129358; DOI=10.1111/j.1349-7006.2006.00363.x;
RA   Sakamoto I., Ohwada S., Toya H., Togo N., Kashiwabara K., Oyama T.,
RA   Nakajima T., Ito H., Adachi S., Jigami T., Akiyama T.;
RT   "Up-regulation of a BCL9-related beta-catenin-binding protein, B9L, in
RT   different stages of sporadic colorectal adenoma.";
RL   Cancer Sci. 98:83-87(2007).
RN   [11]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17309600; DOI=10.1111/j.1349-7006.2007.00430.x;
RA   Toya H., Oyama T., Ohwada S., Togo N., Sakamoto I., Horiguchi J.,
RA   Koibuchi Y., Adachi S., Jigami T., Nakajima T., Akiyama T.;
RT   "Immunohistochemical expression of the beta-catenin-interacting
RT   protein B9L is associated with histological high nuclear grade and
RT   immunohistochemical ErbB2/HER-2 expression in breast cancers.";
RL   Cancer Sci. 98:484-490(2007).
RN   [12]
RP   IDENTIFICATION IN A COMPLEX WITH CDC73; CTNNB1 AND PYGO1, AND
RP   INTERACTION WITH CTNNB1.
RX   PubMed=17113272; DOI=10.1016/j.mod.2006.09.006;
RA   Hoffmans R., Basler K.;
RT   "BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and
RT   requires Pygopus for its function in Wg/Wnt signaling.";
RL   Mech. Dev. 124:59-67(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-813, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-118; SER-1004; SER-1010
RP   AND SER-1017, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-36; LYS-108 AND LYS-137, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-88; SER-750; SER-813;
RP   SER-1004 AND SER-1010, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-25; SER-88;
RP   SER-116; SER-118 AND SER-975, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-25; SER-88;
RP   SER-424; THR-514; SER-750; SER-813; SER-915; SER-938; SER-947;
RP   SER-997; SER-1004 AND SER-1017, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21 AND SER-1017, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1344, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Transcriptional regulator that acts as an activator.
CC       Promotes beta-catenin transcriptional activity. Plays a role in
CC       tumorigenesis. Enhances the neoplastic transforming activity of
CC       CTNNB1 (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Found in a complex with CDC73; CTNNB1 and PYGO1.
CC       Interacts with CTNNB1. {ECO:0000269|PubMed:17052462,
CC       ECO:0000269|PubMed:17113272}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17129358,
CC       ECO:0000269|PubMed:17309600}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q86UU0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q86UU0-2; Sequence=VSP_030205;
CC       Name=3;
CC         IsoId=Q86UU0-3; Sequence=VSP_030207, VSP_030208;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q86UU0-4; Sequence=VSP_030206;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in breast, ductal and invasive
CC       ductal carcinomas of the breast, sporadic colorectal adenomas and
CC       carcinomas (at protein level). Expressed in fetal brain. Expressed
CC       in lung, amygdala, eye, prostate, pancreatic and prostate cancers,
CC       head and neck tumors and embryonal tumor.
CC       {ECO:0000269|PubMed:12964048, ECO:0000269|PubMed:17129358,
CC       ECO:0000269|PubMed:17309600}.
CC   -!- DOMAIN: Tne C-terminal domain is important for its transactivation
CC       activity. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the BCL9 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH33257.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAC85500.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAC85512.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY296059; AAQ62697.1; -; mRNA.
DR   EMBL; AB094091; BAC76045.1; -; mRNA.
DR   EMBL; CH471065; EAW67418.1; -; Genomic_DNA.
DR   EMBL; BC033257; AAH33257.1; ALT_INIT; mRNA.
DR   EMBL; AK122650; BAC85500.1; ALT_INIT; mRNA.
DR   EMBL; AK122882; BAC85512.1; ALT_INIT; mRNA.
DR   CCDS; CCDS8403.1; -. [Q86UU0-1]
DR   RefSeq; NP_872363.1; NM_182557.2. [Q86UU0-1]
DR   RefSeq; XP_005271568.1; XM_005271511.2. [Q86UU0-1]
DR   RefSeq; XP_006718878.1; XM_006718815.2. [Q86UU0-1]
DR   UniGene; Hs.414740; -.
DR   PDB; 2XB1; X-ray; 1.90 A; A/C=237-271.
DR   PDB; 4UP0; X-ray; 1.28 A; A=240-268.
DR   PDB; 4UP5; X-ray; 1.65 A; A=240-268.
DR   PDBsum; 2XB1; -.
DR   PDBsum; 4UP0; -.
DR   PDBsum; 4UP5; -.
DR   ProteinModelPortal; Q86UU0; -.
DR   SMR; Q86UU0; -.
DR   BioGrid; 129475; 6.
DR   IntAct; Q86UU0; 4.
DR   MINT; Q86UU0; -.
DR   STRING; 9606.ENSP00000335320; -.
DR   iPTMnet; Q86UU0; -.
DR   PhosphoSitePlus; Q86UU0; -.
DR   BioMuta; BCL9L; -.
DR   DMDM; 74750433; -.
DR   EPD; Q86UU0; -.
DR   MaxQB; Q86UU0; -.
DR   PaxDb; Q86UU0; -.
DR   PeptideAtlas; Q86UU0; -.
DR   PRIDE; Q86UU0; -.
DR   DNASU; 283149; -.
DR   Ensembl; ENST00000334801; ENSP00000335320; ENSG00000186174. [Q86UU0-1]
DR   GeneID; 283149; -.
DR   KEGG; hsa:283149; -.
DR   UCSC; uc001pug.5; human. [Q86UU0-1]
DR   CTD; 283149; -.
DR   DisGeNET; 283149; -.
DR   EuPathDB; HostDB:ENSG00000186174.12; -.
DR   GeneCards; BCL9L; -.
DR   HGNC; HGNC:23688; BCL9L.
DR   HPA; HPA049370; -.
DR   HPA; HPA053421; -.
DR   MIM; 609004; gene.
DR   neXtProt; NX_Q86UU0; -.
DR   OpenTargets; ENSG00000186174; -.
DR   PharmGKB; PA134974002; -.
DR   eggNOG; ENOG410IEDB; Eukaryota.
DR   eggNOG; ENOG410XRMX; LUCA.
DR   GeneTree; ENSGT00730000110915; -.
DR   HOGENOM; HOG000060118; -.
DR   HOVERGEN; HBG031116; -.
DR   InParanoid; Q86UU0; -.
DR   OMA; MGGPQKM; -.
DR   OrthoDB; EOG091G00PV; -.
DR   PhylomeDB; Q86UU0; -.
DR   TreeFam; TF331144; -.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   ChiTaRS; BCL9L; human.
DR   GenomeRNAi; 283149; -.
DR   PRO; PR:Q86UU0; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000186174; -.
DR   CleanEx; HS_BCL9L; -.
DR   ExpressionAtlas; Q86UU0; baseline and differential.
DR   Genevisible; Q86UU0; HS.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:MGI.
DR   GO; GO:0003713; F:transcription coactivator activity; NAS:BHF-UCL.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0022604; P:regulation of cell morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR015668; Bcl-9/Bcl-9l.
DR   InterPro; IPR024670; BCL9_beta-catenin-bd_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR15185; PTHR15185; 1.
DR   Pfam; PF11502; BCL9; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Complete proteome; Isopeptide bond; Methylation; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1   1499       B-cell CLL/lymphoma 9-like protein.
FT                                /FTId=PRO_0000314079.
FT   REGION      304    533       Necessary for interaction with CTNNB1.
FT                                {ECO:0000250}.
FT   COMPBIAS    280    493       Pro-rich.
FT   COMPBIAS    689    837       Met-rich.
FT   COMPBIAS    891   1378       Pro-rich.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      25     25       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      36     36       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      88     88       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     108    108       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     110    110       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q67FY2}.
FT   MOD_RES     116    116       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     118    118       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     137    137       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     424    424       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     514    514       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     680    680       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q67FY2}.
FT   MOD_RES     750    750       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     813    813       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     915    915       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     926    926       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q67FY2}.
FT   MOD_RES     938    938       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     942    942       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q67FY2}.
FT   MOD_RES     947    947       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     975    975       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     987    987       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q67FY2}.
FT   MOD_RES     991    991       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q67FY2}.
FT   MOD_RES     997    997       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1004   1004       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1010   1010       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1017   1017       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   CROSSLNK   1344   1344       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ       9     13       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15371335}.
FT                                /FTId=VSP_030205.
FT   VAR_SEQ    1238   1283       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_030206.
FT   VAR_SEQ    1333   1394       EKPSSTLQYFPKSENQPPKAQPPNLHLMNLQNMMAEQTPSR
FT                                PPNLPGQQGVQRGLNMSMCHP -> WFLRTRPFSFCLYLLR
FT                                ILSLLMWLTPLPPLPAGGWPGGQVPAGAVNRALRFCAGLCV
FT                                CCISVF (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_030207.
FT   VAR_SEQ    1395   1499       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_030208.
FT   STRAND      241    243       {ECO:0000244|PDB:4UP0}.
FT   HELIX       245    256       {ECO:0000244|PDB:4UP0}.
FT   STRAND      259    262       {ECO:0000244|PDB:4UP0}.
FT   HELIX       263    266       {ECO:0000244|PDB:4UP0}.
SQ   SEQUENCE   1499 AA;  157129 MW;  8415C2EDB7AA9C0C CRC64;
     MRILANKTRL PHPRRREAPG SPPLSPRGHC PPAPAKPMHP ENKLTNHGKT GNGGAQSQHQ
     NVNQGPTCNV GSKGVGAGNH GAKANQISPS NSSLKNPQAG VPPFSSLKGK VKRDRSVSVD
     SGEQREAGTP SLDSEAKEVA PRSKRRCVLE RKQPYSGDEW CSGPDSEEDD KPIGATHNCN
     VADPAMAAPQ LGPGQTTQLP LSESSVPGAP HGPPPGLRPD APGGGGGGGG VPGKPPSQFV
     YVFTTHLANT AAEAVLQGRA DSILAYHQQN VPRAKLDQAP KVPPTPEPLP LSTPSAGTPQ
     SQPPPLPPPP PPAPGSAPPA LPPEGPPEDS SQDLAPNSVG AASTGGGTGG THPNTPTATT
     ANNPLPPGGD PSSAPGPALL GEAAAPGNGQ RSLVGSEGLS KEQLEHRERS LQTLRDIERL
     LLRSGETEPF LKGPPGGAGE GGPPAQAPPP PQQPPTAPPS GLKKYEEPLQ SMISQTQSLG
     GPPLEHEVPG HPPGGDMGQQ MNMMIQRLGQ DSLTPEQVAW RKLQEEYYEE KRRKEEQIGL
     HGSRPLQDMM GMGGMMVRGP PPPYHSKPGD QWPPGMGAQL RGPMDVQDPM QLRGGPPFPG
     PRFPGNQIQR VPGFGGMQSM PMEVPMNAMQ RPVRPGMGWT EDLPPMGGPS NFAQNTMPYP
     GGQGEAERFM TPRVREELLR HQLLEKRSMG MQRPLGMAGS GMGQSMEMER MMQAHRQMDP
     AMFPGQMAGG EGLAGTPMGM EFGGGRGLLS PPMGQSGLRE VDPPMGPGNL NMNMNVNMNM
     NMNLNVQMTP QQQMLMSQKM RGPGDLMGPQ GLSPEEMARV RAQNSSGVMG GPQKMLMPSQ
     FPNQGQQGFS GGQGPYQAMS QDMGNTQDMF SPDQSSMPMS NVGTTRLSHM PLPPASNPPG
     TVHSAPNRGL GRRPSDLTIS INQMGSPGMG HLKSPTLSQV HSPLVTSPSA NLKSPQTPSQ
     MVPLPSANPP GPLKSPQVLG SSLSVRSPTG SPSRLKSPSM AVPSPGWVAS PKTAMPSPGV
     SQNKQPPLNM NSSTTLSNME QGTLPPSGPR SSSSAPPANP PSGLMNPSLP FTSSPDPTPS
     QNPLSLMMTQ MSKYAMPSST PLYHNAIKTI ATSDDELLPD RPLLPPPPPP QGSGPGISNS
     QPSQMHLNSA AAQSPMGMNL PGQQPLSHEP PPAMLPSPTP LGSNIPLHPN AQGTGGPPQN
     SMMMAPGGPD SLNAPCGPVP SSSQMMPFPP RLQQPHGAMA PTGGGGGGPG LQQHYPSGMA
     LPPEDLPNQP PGPMPPQQHL MGKAMAGRMG DAYPPGVLPG VASVLNDPEL SEVIRPTPTG
     IPEFDLSRII PSEKPSSTLQ YFPKSENQPP KAQPPNLHLM NLQNMMAEQT PSRPPNLPGQ
     QGVQRGLNMS MCHPGQMSLL GRTGVPPQQG MVPHGLHQGV MSPPQGLMTQ QNFMLMKQRG
     VGGEVYSQPP HMLSPQGSLM GPPPQQNLMV SHPLRQRSVS LDSQMGYLPA PGGMANLPF
//
ID   BCORL_HUMAN             Reviewed;        1711 AA.
AC   Q5H9F3; B5MDQ8; Q5H9F2; Q5H9F4; Q6ZVE0; Q8TEN3; Q9Y528;
DT   04-DEC-2007, integrated into UniProtKB/Swiss-Prot.
DT   15-FEB-2005, sequence version 1.
DT   25-OCT-2017, entry version 124.
DE   RecName: Full=BCL-6 corepressor-like protein 1;
DE            Short=BCoR-L1;
DE            Short=BCoR-like protein 1;
GN   Name=BCORL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 16-1711 (ISOFORM 1), AND
RP   VARIANT LEU-111.
RC   TISSUE=Spleen;
RX   PubMed=12693554; DOI=10.1093/dnares/10.1.49;
RA   Jikuya H., Takano J., Kikuno R., Hirosawa M., Nagase T., Nomura N.,
RA   Ohara O.;
RT   "Characterization of long cDNA clones from human adult spleen. II. The
RT   complete sequences of 81 cDNA clones.";
RL   DNA Res. 10:49-57(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 566-1435 (ISOFORM 2).
RA   Rhodes S.;
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1265-1711 (ISOFORM 2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CTBP1; HDAC4; HDAC5
RP   AND HDAC7, MUTAGENESIS OF 623-ASP-LEU-624, AND TISSUE SPECIFICITY.
RX   PubMed=17379597; DOI=10.1074/jbc.M700246200;
RA   Pagan J.K., Arnold J., Hanchard K.J., Kumar R., Bruno T., Jones M.J.,
RA   Richard D.J., Forrest A., Spurdle A., Verdin E., Crossley M.,
RA   Fanciulli M., Chenevix-Trench G., Young D.B., Khanna K.K.;
RT   "A novel corepressor, BCoR-L1, represses transcription through an
RT   interaction with CtBP.";
RL   J. Biol. Chem. 282:15248-15257(2007).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-613; SER-1033 AND
RP   SER-1162, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1476 (ISOFORM
RP   3), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-496; SER-599; SER-1029;
RP   SER-1033 AND SER-1162, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1092, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [10]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1092, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [11]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-747 AND LYS-1092, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1634-1748 IN COMPLEX WITH
RP   PCGF1, INTERACTION WITH PCGF1, AND MUTAGENESIS OF LEU-1665.
RX   PubMed=23523425; DOI=10.1016/j.str.2013.02.013;
RA   Junco S.E., Wang R., Gaipa J.C., Taylor A.B., Schirf V.,
RA   Gearhart M.D., Bardwell V.J., Demeler B., Hart P.J., Kim C.A.;
RT   "Structure of the polycomb group protein PCGF1 in complex with BCOR
RT   reveals basis for binding selectivity of PCGF homologs.";
RL   Structure 21:665-671(2013).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-832.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [14]
RP   VARIANT SER-820.
RX   PubMed=24123876; DOI=10.1136/jmedgenet-2013-101644;
RA   Schuurs-Hoeijmakers J.H., Vulto-van Silfhout A.T., Vissers L.E.,
RA   van de Vondervoort I.I., van Bon B.W., de Ligt J., Gilissen C.,
RA   Hehir-Kwa J.Y., Neveling K., del Rosario M., Hira G., Reitano S.,
RA   Vitello A., Failla P., Greco D., Fichera M., Galesi O., Kleefstra T.,
RA   Greally M.T., Ockeloen C.W., Willemsen M.H., Bongers E.M.,
RA   Janssen I.M., Pfundt R., Veltman J.A., Romano C., Willemsen M.A.,
RA   van Bokhoven H., Brunner H.G., de Vries B.B., de Brouwer A.P.;
RT   "Identification of pathogenic gene variants in small families with
RT   intellectually disabled siblings by exome sequencing.";
RL   J. Med. Genet. 50:802-811(2013).
CC   -!- FUNCTION: Transcriptional corepressor. May specifically inhibit
CC       gene expression when recruited to promoter regions by sequence-
CC       specific DNA-binding proteins such as BCL6. This repression may be
CC       mediated at least in part by histone deacetylase activities which
CC       can associate with this corepressor.
CC       {ECO:0000269|PubMed:17379597}.
CC   -!- SUBUNIT: Interacts with CTBP1. Interacts with HDAC4, HDAC5 and
CC       HDAC7. Interacts with PCGF1; the interaction is direct.
CC       {ECO:0000269|PubMed:17379597, ECO:0000269|PubMed:23523425}.
CC   -!- INTERACTION:
CC       Q9BSM1-1:PCGF1; NbExp=6; IntAct=EBI-16041827, EBI-16041863;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17379597}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q5H9F3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5H9F3-2; Sequence=VSP_029778;
CC       Name=3;
CC         IsoId=Q5H9F3-3; Sequence=VSP_029779;
CC         Note=Contains a phosphoserine at position 1476.
CC         {ECO:0000244|PubMed:18669648};
CC   -!- TISSUE SPECIFICITY: Detected in testis and prostate. Detected at
CC       lower levels in peripheral blood leukocytes and spleen.
CC       {ECO:0000269|PubMed:17379597}.
CC   -!- SIMILARITY: Belongs to the BCOR family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC85922.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL034405; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z82208; CAI42768.1; -; Genomic_DNA.
DR   EMBL; AL136450; CAI42768.1; JOINED; Genomic_DNA.
DR   EMBL; Z82208; CAI42769.1; -; Genomic_DNA.
DR   EMBL; AL136450; CAI42769.1; JOINED; Genomic_DNA.
DR   EMBL; Z82208; CAI42770.1; -; Genomic_DNA.
DR   EMBL; AL136450; CAI42885.1; -; Genomic_DNA.
DR   EMBL; Z82208; CAI42885.1; JOINED; Genomic_DNA.
DR   EMBL; AL136450; CAI42884.1; -; Genomic_DNA.
DR   EMBL; Z82208; CAI42884.1; JOINED; Genomic_DNA.
DR   EMBL; AK074089; BAB84915.1; -; mRNA.
DR   EMBL; AL096777; CAB46626.1; -; mRNA.
DR   EMBL; AK124676; BAC85922.1; ALT_INIT; mRNA.
DR   CCDS; CCDS14616.1; -. [Q5H9F3-1]
DR   RefSeq; NP_068765.3; NM_021946.4.
DR   UniGene; Hs.496748; -.
DR   PDB; 4HPM; X-ray; 1.85 A; A/C=1594-1711.
DR   PDB; 5JH5; X-ray; 2.55 A; D=1594-1711.
DR   PDBsum; 4HPM; -.
DR   PDBsum; 5JH5; -.
DR   ProteinModelPortal; Q5H9F3; -.
DR   SMR; Q5H9F3; -.
DR   BioGrid; 121961; 22.
DR   DIP; DIP-60148N; -.
DR   IntAct; Q5H9F3; 12.
DR   STRING; 9606.ENSP00000218147; -.
DR   iPTMnet; Q5H9F3; -.
DR   PhosphoSitePlus; Q5H9F3; -.
DR   BioMuta; BCORL1; -.
DR   DMDM; 74762178; -.
DR   MaxQB; Q5H9F3; -.
DR   PaxDb; Q5H9F3; -.
DR   PeptideAtlas; Q5H9F3; -.
DR   PRIDE; Q5H9F3; -.
DR   DNASU; 63035; -.
DR   Ensembl; ENST00000218147; ENSP00000218147; ENSG00000085185.
DR   Ensembl; ENST00000540052; ENSP00000437775; ENSG00000085185.
DR   GeneID; 63035; -.
DR   KEGG; hsa:63035; -.
DR   UCSC; uc022cdu.1; human. [Q5H9F3-1]
DR   CTD; 63035; -.
DR   DisGeNET; 63035; -.
DR   EuPathDB; HostDB:ENSG00000085185.15; -.
DR   GeneCards; BCORL1; -.
DR   HGNC; HGNC:25657; BCORL1.
DR   HPA; HPA031775; -.
DR   HPA; HPA031777; -.
DR   HPA; HPA068568; -.
DR   MIM; 300688; gene.
DR   neXtProt; NX_Q5H9F3; -.
DR   eggNOG; ENOG410IFKH; Eukaryota.
DR   eggNOG; ENOG411028G; LUCA.
DR   HOVERGEN; HBG104815; -.
DR   InParanoid; Q5H9F3; -.
DR   OrthoDB; EOG091G0R1A; -.
DR   PhylomeDB; Q5H9F3; -.
DR   TreeFam; TF333317; -.
DR   ChiTaRS; BCORL1; human.
DR   GenomeRNAi; 63035; -.
DR   PRO; PR:Q5H9F3; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000085185; -.
DR   CleanEx; HS_BCORL1; -.
DR   ExpressionAtlas; Q5H9F3; baseline and differential.
DR   Genevisible; Q5H9F3; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0016569; P:covalent chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00204; ANK; 1.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR031628; BCOR.
DR   InterPro; IPR032365; PUFD.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF15808; BCOR; 1.
DR   Pfam; PF16553; PUFD; 1.
DR   SMART; SM00248; ANK; 2.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ANK repeat; Chromatin regulator;
KW   Complete proteome; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1   1711       BCL-6 corepressor-like protein 1.
FT                                /FTId=PRO_0000312268.
FT   REPEAT     1455   1484       ANK 1.
FT   REPEAT     1488   1517       ANK 2.
FT   REPEAT     1521   1549       ANK 3.
FT   MOTIF      1328   1336       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    198    649       Pro-rich.
FT   MOD_RES     496    496       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     599    599       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     613    613       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1029   1029       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1033   1033       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1162   1162       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    747    747       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK   1092   1092       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ    1230   1359       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_029778.
FT   VAR_SEQ    1434   1434       A -> AKGKGRWSQQKTRSPKSPTPVKPTEPCTPSKSRSAS
FT                                SEEASESPTARQIPPEARRLIVNKNAGETLLQRAARLGY
FT                                (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_029779.
FT   VARIANT     111    111       F -> L (in dbSNP:rs4830173).
FT                                {ECO:0000269|PubMed:12693554}.
FT                                /FTId=VAR_061020.
FT   VARIANT     209    209       G -> S (in dbSNP:rs5932715).
FT                                /FTId=VAR_037467.
FT   VARIANT     820    820       N -> S (found in a patient with severe
FT                                intellectual disability, coarse face and
FT                                hypotonia; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24123876}.
FT                                /FTId=VAR_070559.
FT   VARIANT     832    832       G -> D (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_037468.
FT   MUTAGEN     623    624       DL->AS: Strongly reduced repressor
FT                                activity. Interferes with CTBP1 binding.
FT                                {ECO:0000269|PubMed:17379597}.
FT   MUTAGEN    1665   1665       L->D,R: Slightly inhibits interaction
FT                                with PCGF1.
FT                                {ECO:0000269|PubMed:23523425}.
FT   CONFLICT   1564   1564       V -> A (in Ref. 4; BAC85922).
FT                                {ECO:0000305}.
FT   STRAND     1596   1603       {ECO:0000244|PDB:4HPM}.
FT   STRAND     1609   1611       {ECO:0000244|PDB:4HPM}.
FT   STRAND     1620   1624       {ECO:0000244|PDB:4HPM}.
FT   HELIX      1625   1632       {ECO:0000244|PDB:4HPM}.
FT   HELIX      1636   1642       {ECO:0000244|PDB:4HPM}.
FT   STRAND     1648   1652       {ECO:0000244|PDB:4HPM}.
FT   HELIX      1653   1660       {ECO:0000244|PDB:4HPM}.
FT   STRAND     1664   1666       {ECO:0000244|PDB:4HPM}.
FT   TURN       1668   1670       {ECO:0000244|PDB:4HPM}.
FT   STRAND     1686   1691       {ECO:0000244|PDB:4HPM}.
FT   HELIX      1694   1699       {ECO:0000244|PDB:4HPM}.
FT   STRAND     1703   1707       {ECO:0000244|PDB:4HPM}.
SQ   SEQUENCE   1711 AA;  182526 MW;  DD78A00598703C53 CRC64;
     MISTAPLYSG VHNWTSSDRI RMCGINEERR APLSDEESTT GDCQHFGSQE FCVSSSFSKV
     ELTAVGSGSN ARGADPDGSA TEKLGHKSED KPDDPQPKMD YAGNVAEAEG FLVPLSSPGD
     GLKLPASDSA EASNSRADCS WTPLNTQMSK QVDCSPAGVK ALDSRQGVGE KNTFILATLG
     TGVPVEGTLP LVTTNFSPLP APICPPAPGS ASVPHSVPDA FQVPLSVPAP VPHSGLVPVQ
     VATSVPAPSP PLAPVPALAP APPSVPTLIS DSNPLSVSAS VLVPVPASAP PSGPVPLSAP
     APAPLSVPVS APPLALIQAP VPPSAPTLVL APVPTPVLAP MPASTPPAAP APPSVPMPTP
     TPSSGPPSTP TLIPAFAPTP VPAPTPAPIF TPAPTPMPAA TPAAIPTSAP IPASFSLSRV
     CFPAAQAPAM QKVPLSFQPG TVLTPSQPLV YIPPPSCGQP LSVATLPTTL GVSSTLTLPV
     LPSYLQDRCL PGVLASPELR SYPYAFSVAR PLTSDSKLVS LEVNRLPCTS PSGSTTTQPA
     PDGVPGPLAD TSLVTASAKV LPTPQPLLPA PSGSSAPPHP AKMPSGTEQQ TEGTSVTFSP
     LKSPPQLERE MASPPECSEM PLDLSSKSNR QKLPLPNQRK TPPMPVLTPV HTSSKALLST
     VLSRSQRTTQ AAGGNVTSCL GSTSSPFVIF PEIVRNGDPS TWVKNSTALI STIPGTYVGV
     ANPVPASLLL NKDPNLGLNR DPRHLPKQEP ISIIDQGEPK GTGATCGKKG SQAGAEGQPS
     TVKRYTPARI APGLPGCQTK ELSLWKPTGP ANIYPRCSVN GKPTSTQVLP VGWSPYHQAS
     LLSIGISSAG QLTPSQGAPI RPTSVVSEFS GVPSLSSSEA VHGLPEGQPR PGGSFVPEQD
     PVTKNKTCRI AAKPYEEQVN PVLLTLSPQT GTLALSVQPS GGDIRMNQGP EESESHLCSD
     STPKMEGPQG ACGLKLAGDT KPKNQVLATY MSHELVLATP QNLPKMPELP LLPHDSHPKE
     LILDVVPSSR RGSSTERPQL GSQVDLGRVK MEKVDGDVVF NLATCFRADG LPVAPQRGQA
     EVRAKAGQAR VKQESVGVFA CKNKWQPDDV TESLPPKKMK CGKEKDSEEQ QLQPQAKAVV
     RSSHRPKCRK LPSDPQESTK KSPRGASDSG KEHNGVRGKH KHRKPTKPES QSPGKRADSH
     EEGSLEKKAK SSFRDFIPVV LSTRTRSQSG SICSSFAGMA DSDMGSQEVF PTEEEEEVTP
     TPAKRRKVRK TQRDTQYRSH HAQDKSLLSQ GRRHLWRARE MPWRTEAARQ MWDTNEEEEE
     EEEEGLLKRK KRRRQKSRKY QTGEYLTEQE DEQRRKGRAD LKARKQKTSS SQSLEHRLRN
     RNLLLPNKVQ GISDSPNGFL PNNLEEPACL ENSEKPSGKR KCKTKHMATV SEEAKDVVLY
     CLQKDSEDVN HRDNAGYTAL HEACSRGWTD ILNILLEHGA NVNCSAQDGT RPVHDAVVND
     NLETIWLLLS YGADPTLATY SGQTAMKLAS SDTMKRFLSD HLSDLQGRAE GDPGVSWDFY
     SSSVLEEKDG FACDLLHNPP GSSDQEGDDP MEEDDFMFEL SDKPLLPCYN LQVSVSRGPC
     NWFLFSDVLK RLKLSSRIFQ ARFPHFEITT MPKAEFYRQV ASSQLLTPAE RPGGLDDRSP
     PGSSETVELV RYEPDLLRLL GSEVEFQSCN S
//
ID   BMR1A_HUMAN             Reviewed;         532 AA.
AC   P36894; A8K6U9; Q8NEN8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 2.
DT   28-FEB-2018, entry version 210.
DE   RecName: Full=Bone morphogenetic protein receptor type-1A;
DE            Short=BMP type-1A receptor;
DE            Short=BMPR-1A;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 3;
DE            Short=ALK-3;
DE   AltName: Full=Serine/threonine-protein kinase receptor R5;
DE            Short=SKR5;
DE   AltName: CD_antigen=CD292;
DE   Flags: Precursor;
GN   Name=BMPR1A; Synonyms=ACVRLK3, ALK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-2.
RC   TISSUE=Placenta;
RX   PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J.,
RA   Toyoshima H., Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface
RT   receptors with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-2.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH BMP2, AND MUTAGENESIS OF 107-ASP--GLN-109.
RX   PubMed=22799562; DOI=10.1021/bi300942x;
RA   Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P.;
RT   "Structure of the Alk1 extracellular domain and characterization of
RT   its bone morphogenetic protein (BMP) binding properties.";
RL   Biochemistry 51:6328-6341(2012).
RN   [5]
RP   INTERACTION WITH GDF5.
RX   PubMed=24098149; DOI=10.1371/journal.pgen.1003846;
RA   Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C.,
RA   Nickel J., Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T.,
RA   Mundlos S., Doelken S.C., Seemann P.;
RT   "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2.";
RL   PLoS Genet. 9:E1003846-E1003846(2013).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 55-143 IN COMPLEX WITH BMP2,
RP   DISULFIDE BOND, AND INTERACTION WITH BMP2.
RX   PubMed=10881198; DOI=10.1038/75903;
RA   Kirsch T., Sebald W., Dreyer M.K.;
RT   "Crystal structure of the BMP-2-BRIA ectodomain complex.";
RL   Nat. Struct. Biol. 7:492-496(2000).
RN   [7]
RP   DISEASE.
RX   PubMed=11381269; DOI=10.1038/88919;
RA   Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A.,
RA   Petersen G.M., Velculescu V.E., Traverso G., Vogelstein B.;
RT   "Germline mutations of the gene encoding bone morphogenetic protein
RT   receptor 1A in juvenile polyposis.";
RL   Nat. Genet. 28:184-187(2001).
RN   [8]
RP   STRUCTURE BY NMR OF 51-152, DISULFIDE BONDS, AND INTERACTION WITH
RP   BMP2.
RX   PubMed=18937504; DOI=10.1021/bi801059j;
RA   Klages J., Kotzsch A., Coles M., Sebald W., Nickel J., Muller T.,
RA   Kessler H.;
RT   "The solution structure of BMPR-IA reveals a local disorder-to-order
RT   transition upon BMP-2 binding.";
RL   Biochemistry 47:11930-11939(2008).
RN   [9]
RP   VARIANTS JPS ARG-124; ASP-338 AND TYR-376.
RX   PubMed=11536076; DOI=10.1086/323703;
RA   Zhou X.-P., Woodford-Richens K., Lehtonen R., Kurose K., Aldred M.,
RA   Hampel H., Launonen V., Virta S., Pilarski R., Salovaara R.,
RA   Bodmer W.F., Conrad B.A., Dunlop M., Hodgson S.V., Iwama T.,
RA   Jaervinen H., Kellokumpu I., Kim J.C., Leggett B., Markie D.,
RA   Mecklin J.-P., Neale K., Phillips R., Piris J., Rozen P.,
RA   Houlston R.S., Aaltonen L.A., Tomlinson I.P.M., Eng C.;
RT   "Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile
RT   polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba
RT   syndromes.";
RL   Am. J. Hum. Genet. 69:704-711(2001).
RN   [10]
RP   VARIANTS JPS ASP-62; TYR-82 AND CYS-443.
RX   PubMed=12417513; DOI=10.1007/BF02557528;
RA   Sayed M.G., Ahmed A.F., Ringold J.R., Anderson M.E., Bair J.L.,
RA   Mitros F.A., Lynch H.T., Tinley S.T., Petersen G.M., Giardiello F.M.,
RA   Vogelstein B., Howe J.R.;
RT   "Germline SMAD4 or BMPR1A mutations and phenotype of juvenile
RT   polyposis.";
RL   Ann. Surg. Oncol. 9:901-906(2002).
RN   [11]
RP   VARIANT JPS ARG-130.
RX   PubMed=12136244; DOI=10.1007/s00439-002-0748-9;
RA   Friedl W., Uhlhaas S., Schulmann K., Stolte M., Loff S., Back W.,
RA   Mangold E., Stern M., Knaebel H.P., Sutter C., Weber R.G.,
RA   Pistorius S., Burger B., Propping P.;
RT   "Juvenile polyposis: massive gastric polyposis is more common in MADH4
RT   mutation carriers than in BMPR1A mutation carriers.";
RL   Hum. Genet. 111:108-111(2002).
RN   [12]
RP   VARIANT JPS THR-470.
RX   PubMed=12630959; DOI=10.1034/j.1399-0004.2003.00008.x;
RA   Kim I.J., Park J.H., Kang H.C., Kim K.H., Kim J.H., Ku J.L.,
RA   Kang S.B., Park S.Y., Lee J.S., Park J.G.;
RT   "Identification of a novel BMPR1A germline mutation in a Korean
RT   juvenile polyposis patient without SMAD4 mutation.";
RL   Clin. Genet. 63:126-130(2003).
RN   [13]
RP   INVOLVEMENT IN JUVENILE POLYPOSIS OF INFANCY.
RX   PubMed=16685657; DOI=10.1086/504301;
RA   Delnatte C., Sanlaville D., Mougenot J.-F., Vermeesch J.-R.,
RA   Houdayer C., Blois M.-C., Genevieve D., Goulet O., Fryns J.-P.,
RA   Jaubert F., Vekemans M., Lyonnet S., Romana S., Eng C.,
RA   Stoppa-Lyonnet D.;
RT   "Contiguous gene deletion within chromosome arm 10q is associated with
RT   juvenile polyposis of infancy, reflecting cooperation between the
RT   BMPR1A and PTEN tumor-suppressor genes.";
RL   Am. J. Hum. Genet. 78:1066-1074(2006).
RN   [14]
RP   INVOLVEMENT IN HEREDITARY MIXED POLYPOSIS SYNDROME 2.
RX   PubMed=16525031; DOI=10.1136/jmg.2005.034827;
RA   Cao X., Eu K.W., Kumarasinghe M.P., Li H.H., Loi C., Cheah P.Y.;
RT   "Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome
RT   10q23 by genomewide high-density single nucleotide polymorphism (SNP)
RT   scan and identification of BMPR1A loss of function.";
RL   J. Med. Genet. 43:E13-E13(2006).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-2; TYR-58; CYS-443; MET-450 AND
RP   GLN-486.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [16]
RP   VARIANT THR-460.
RX   PubMed=25860647; DOI=10.1007/s10689-015-9803-2;
RA   Hansen M.F., Johansen J., Bjoernevoll I., Sylvander A.E.,
RA   Steinsbekk K.S., Saetrom P., Sandvik A.K., Drabloes F., Sjursen W.;
RT   "A novel POLE mutation associated with cancers of colon, pancreas,
RT   ovaries and small intestine.";
RL   Fam. Cancer 14:437-448(2015).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and
CC       GDF6. Positively regulates chondrocyte differentiation through
CC       GDF5 interaction. Mediates induction of adipogenesis by GDF6.
CC       {ECO:0000250|UniProtKB:P36895}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with BMP2 (PubMed:10881198, PubMed:18937504).
CC       Interacts with low affinity with GDF5; positively regulates
CC       chondrocyte differentiation (PubMed:24098149).
CC       {ECO:0000269|PubMed:10881198, ECO:0000269|PubMed:18937504,
CC       ECO:0000269|PubMed:24098149}.
CC   -!- INTERACTION:
CC       P12643:BMP2; NbExp=17; IntAct=EBI-1029237, EBI-1029262;
CC       P12644:BMP4; NbExp=2; IntAct=EBI-1029237, EBI-1998134;
CC       P43026:GDF5; NbExp=3; IntAct=EBI-1029237, EBI-8571476;
CC       Q8WYB5:KAT6B; NbExp=4; IntAct=EBI-1029237, EBI-948029;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle.
CC   -!- DISEASE: Juvenile polyposis syndrome (JPS) [MIM:174900]: Autosomal
CC       dominant gastrointestinal hamartomatous polyposis syndrome in
CC       which patients are at risk for developing gastrointestinal
CC       cancers. The lesions are typified by a smooth histological
CC       appearance, predominant stroma, cystic spaces and lack of a smooth
CC       muscle core. Multiple juvenile polyps usually occur in a number of
CC       Mendelian disorders. Sometimes, these polyps occur without
CC       associated features as in JPS; here, polyps tend to occur in the
CC       large bowel and are associated with an increased risk of colon and
CC       other gastrointestinal cancers. {ECO:0000269|PubMed:11536076,
CC       ECO:0000269|PubMed:12136244, ECO:0000269|PubMed:12417513,
CC       ECO:0000269|PubMed:12630959}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Polyposis syndrome, mixed hereditary 2 (HMPS2)
CC       [MIM:610069]: A disease is characterized by atypical juvenile
CC       polyps, colonic adenomas, and colorectal carcinomas. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A
CC       and PTEN is a cause of chromosome 10q23 deletion syndrome, which
CC       shows overlapping features of the following three disorders:
CC       Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis
CC       syndrome. {ECO:0000269|PubMed:11381269,
CC       ECO:0000269|PubMed:16525031}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z22535; CAA80257.1; -; mRNA.
DR   EMBL; AK291764; BAF84453.1; -; mRNA.
DR   EMBL; BC028383; AAH28383.1; -; mRNA.
DR   CCDS; CCDS7378.1; -.
DR   PIR; I37163; I37163.
DR   RefSeq; NP_004320.2; NM_004329.2.
DR   RefSeq; XP_011538405.1; XM_011540103.2.
DR   RefSeq; XP_011538406.1; XM_011540104.2.
DR   UniGene; Hs.524477; -.
DR   PDB; 1ES7; X-ray; 2.90 A; B/D=55-143.
DR   PDB; 1REW; X-ray; 1.86 A; C/D=24-152.
DR   PDB; 2GOO; X-ray; 2.20 A; B/E=24-152.
DR   PDB; 2H62; X-ray; 1.85 A; C=24-152.
DR   PDB; 2H64; X-ray; 1.92 A; B=24-152.
DR   PDB; 2K3G; NMR; -; A=51-152.
DR   PDB; 2QJ9; X-ray; 2.44 A; C/D=24-152.
DR   PDB; 2QJA; X-ray; 2.60 A; C/D=24-152.
DR   PDB; 2QJB; X-ray; 2.50 A; C/D=24-152.
DR   PDB; 3NH7; X-ray; 2.70 A; A/B/C/D=24-152.
DR   PDB; 3QB4; X-ray; 2.28 A; B/D=24-152.
DR   PDBsum; 1ES7; -.
DR   PDBsum; 1REW; -.
DR   PDBsum; 2GOO; -.
DR   PDBsum; 2H62; -.
DR   PDBsum; 2H64; -.
DR   PDBsum; 2K3G; -.
DR   PDBsum; 2QJ9; -.
DR   PDBsum; 2QJA; -.
DR   PDBsum; 2QJB; -.
DR   PDBsum; 3NH7; -.
DR   PDBsum; 3QB4; -.
DR   ProteinModelPortal; P36894; -.
DR   SMR; P36894; -.
DR   BioGrid; 107125; 76.
DR   CORUM; P36894; -.
DR   DIP; DIP-5793N; -.
DR   IntAct; P36894; 31.
DR   MINT; P36894; -.
DR   STRING; 9606.ENSP00000224764; -.
DR   BindingDB; P36894; -.
DR   ChEMBL; CHEMBL5275; -.
DR   GuidetoPHARMACOLOGY; 1786; -.
DR   iPTMnet; P36894; -.
DR   PhosphoSitePlus; P36894; -.
DR   BioMuta; BMPR1A; -.
DR   DMDM; 61252444; -.
DR   EPD; P36894; -.
DR   MaxQB; P36894; -.
DR   PaxDb; P36894; -.
DR   PeptideAtlas; P36894; -.
DR   PRIDE; P36894; -.
DR   DNASU; 657; -.
DR   Ensembl; ENST00000372037; ENSP00000361107; ENSG00000107779.
DR   Ensembl; ENST00000635816; ENSP00000489707; ENSG00000107779.
DR   Ensembl; ENST00000636056; ENSP00000490273; ENSG00000107779.
DR   Ensembl; ENST00000638429; ENSP00000492290; ENSG00000107779.
DR   GeneID; 657; -.
DR   KEGG; hsa:657; -.
DR   UCSC; uc001kdy.4; human.
DR   CTD; 657; -.
DR   DisGeNET; 657; -.
DR   EuPathDB; HostDB:ENSG00000107779.11; -.
DR   GeneCards; BMPR1A; -.
DR   GeneReviews; BMPR1A; -.
DR   HGNC; HGNC:1076; BMPR1A.
DR   HPA; CAB019398; -.
DR   MalaCards; BMPR1A; -.
DR   MIM; 174900; phenotype.
DR   MIM; 601299; gene.
DR   MIM; 610069; phenotype.
DR   MIM; 612242; phenotype.
DR   neXtProt; NX_P36894; -.
DR   OpenTargets; ENSG00000107779; -.
DR   Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli.
DR   Orphanet; 157794; Hereditary mixed polyposis syndrome.
DR   Orphanet; 144; Hereditary nonpolyposis colon cancer.
DR   Orphanet; 79076; Juvenile polyposis of infancy.
DR   PharmGKB; PA25386; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P36894; -.
DR   KO; K04673; -.
DR   OMA; EVVCVKG; -.
DR   OrthoDB; EOG091G0BIU; -.
DR   PhylomeDB; P36894; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; P36894; -.
DR   SIGNOR; P36894; -.
DR   ChiTaRS; BMPR1A; human.
DR   EvolutionaryTrace; P36894; -.
DR   GeneWiki; BMPR1A; -.
DR   GenomeRNAi; 657; -.
DR   PRO; PR:P36894; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000107779; -.
DR   CleanEx; HS_BMPR1A; -.
DR   ExpressionAtlas; P36894; baseline and differential.
DR   Genevisible; P36894; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:1990712; C:HFE-transferrin receptor complex; IC:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0098821; F:BMP receptor activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0061312; P:BMP signaling pathway involved in heart development; IC:BHF-UCL.
DR   GO; GO:0003161; P:cardiac conduction system development; ISS:BHF-UCL.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0048589; P:developmental growth; IEA:Ensembl.
DR   GO; GO:0035912; P:dorsal aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl.
DR   GO; GO:0007398; P:ectoderm development; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0048568; P:embryonic organ development; IEA:Ensembl.
DR   GO; GO:0003272; P:endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1905285; P:fibrous ring of heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060914; P:heart formation; IEA:Ensembl.
DR   GO; GO:0035137; P:hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0048368; P:lateral mesoderm development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0048382; P:mesendoderm development; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0003183; P:mitral valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001880; P:Mullerian duct regression; IEA:Ensembl.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IEA:Ensembl.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IMP:BHF-UCL.
DR   GO; GO:0014032; P:neural crest cell development; IEA:Ensembl.
DR   GO; GO:0021998; P:neural plate mediolateral regionalization; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0048352; P:paraxial mesoderm structural organization; IEA:Ensembl.
DR   GO; GO:0061626; P:pharyngeal arch artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:1904414; P:positive regulation of cardiac ventricle development; ISS:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC.
DR   GO; GO:0060043; P:regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:2000772; P:regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003223; P:ventricular compact myocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Magnesium; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Polymorphism; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    532       Bone morphogenetic protein receptor type-
FT                                1A.
FT                                /FTId=PRO_0000024410.
FT   TOPO_DOM     24    152       Extracellular. {ECO:0000255}.
FT   TRANSMEM    153    176       Helical. {ECO:0000255}.
FT   TOPO_DOM    177    532       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      204    233       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      234    525       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     240    248       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      107    109       Mediates specificity for BMP ligand.
FT                                {ECO:0000269|PubMed:22799562}.
FT   ACT_SITE    362    362       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     261    261       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   CARBOHYD     73     73       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     61     82       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   DISULFID     63     67       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   DISULFID     76    100       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   DISULFID    110    124       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   DISULFID    125    130       {ECO:0000269|PubMed:10881198,
FT                                ECO:0000269|PubMed:18937504}.
FT   VARIANT       2      2       P -> T (in dbSNP:rs11528010).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8397373}.
FT                                /FTId=VAR_041397.
FT   VARIANT      58     58       F -> Y (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041398.
FT   VARIANT      62     62       Y -> D (in JPS).
FT                                {ECO:0000269|PubMed:12417513}.
FT                                /FTId=VAR_022828.
FT   VARIANT      82     82       C -> Y (in JPS).
FT                                {ECO:0000269|PubMed:12417513}.
FT                                /FTId=VAR_022829.
FT   VARIANT     124    124       C -> R (in JPS; dbSNP:rs199476087).
FT                                {ECO:0000269|PubMed:11536076}.
FT                                /FTId=VAR_015533.
FT   VARIANT     130    130       C -> R (in JPS).
FT                                {ECO:0000269|PubMed:12136244}.
FT                                /FTId=VAR_022830.
FT   VARIANT     338    338       A -> D (in JPS; dbSNP:rs199476086).
FT                                {ECO:0000269|PubMed:11536076}.
FT                                /FTId=VAR_015534.
FT   VARIANT     376    376       C -> Y (in JPS; dbSNP:rs199476088).
FT                                {ECO:0000269|PubMed:11536076}.
FT                                /FTId=VAR_015535.
FT   VARIANT     443    443       R -> C (in JPS; dbSNP:rs35619497).
FT                                {ECO:0000269|PubMed:12417513,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_022831.
FT   VARIANT     450    450       V -> M (in dbSNP:rs55932635).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041399.
FT   VARIANT     460    460       M -> T (found in a patient with tubular
FT                                adenoma and rectal neuroendocrine tumor;
FT                                unknown pathological significance;
FT                                dbSNP:rs758309022).
FT                                {ECO:0000269|PubMed:25860647}.
FT                                /FTId=VAR_077353.
FT   VARIANT     470    470       M -> T (in JPS; dbSNP:rs199476089).
FT                                {ECO:0000269|PubMed:12630959}.
FT                                /FTId=VAR_022832.
FT   VARIANT     486    486       R -> Q (in a gastric adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs752802257).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041400.
FT   MUTAGEN     107    109       DFQ->REL: Affinity for BMP2 decreased by
FT                                over 200-fold.
FT                                {ECO:0000269|PubMed:22799562}.
FT   STRAND       59     62       {ECO:0000244|PDB:2H62}.
FT   STRAND       64     66       {ECO:0000244|PDB:2H62}.
FT   STRAND       75     88       {ECO:0000244|PDB:2H62}.
FT   STRAND       90     92       {ECO:0000244|PDB:2H62}.
FT   STRAND       94    101       {ECO:0000244|PDB:2H62}.
FT   HELIX       106    111       {ECO:0000244|PDB:2H62}.
FT   STRAND      116    118       {ECO:0000244|PDB:2QJA}.
FT   STRAND      120    125       {ECO:0000244|PDB:2H62}.
FT   HELIX       130    133       {ECO:0000244|PDB:2H62}.
SQ   SEQUENCE   532 AA;  60198 MW;  00CE2DDDA3A44170 CRC64;
     MPQLYIYIRL LGAYLFIISR VQGQNLDSML HGTGMKSDSD QKKSENGVTL APEDTLPFLK
     CYCSGHCPDD AINNTCITNG HCFAIIEEDD QGETTLASGC MKYEGSDFQC KDSPKAQLRR
     TIECCRTNLC NQYLQPTLPP VVIGPFFDGS IRWLVLLISM AVCIIAMIIF SSCFCYKHYC
     KSISSRRRYN RDLEQDEAFI PVGESLKDLI DQSQSSGSGS GLPLLVQRTI AKQIQMVRQV
     GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS WFRETEIYQT VLMRHENILG FIAADIKGTG
     SWTQLYLITD YHENGSLYDF LKCATLDTRA LLKLAYSAAC GLCHLHTEIY GTQGKPAIAH
     RDLKSKNILI KKNGSCCIAD LGLAVKFNSD TNEVDVPLNT RVGTKRYMAP EVLDESLNKN
     HFQPYIMADI YSFGLIIWEM ARRCITGGIV EEYQLPYYNM VPSDPSYEDM REVVCVKRLR
     PIVSNRWNSD ECLRAVLKLM SECWAHNPAS RLTALRIKKT LAKMVESQDV KI
//
ID   BTK_HUMAN               Reviewed;         659 AA.
AC   Q06187; B2RAW1; Q32ML5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   28-FEB-2018, entry version 224.
DE   RecName: Full=Tyrosine-protein kinase BTK;
DE            EC=2.7.10.2;
DE   AltName: Full=Agammaglobulinemia tyrosine kinase;
DE            Short=ATK;
DE   AltName: Full=B-cell progenitor kinase;
DE            Short=BPK;
DE   AltName: Full=Bruton tyrosine kinase;
GN   Name=BTK; Synonyms=AGMX1, ATK, BPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BTK-A).
RX   PubMed=8380905; DOI=10.1038/361226a0;
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A.,
RA   Flinter F., Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M.,
RA   Smith C.I.E., Bentley D.R.;
RT   "The gene involved in X-linked agammaglobulinaemia is a member of the
RT   src family of protein-tyrosine kinases.";
RL   Nature 361:226-233(1993).
RN   [2]
RP   ERRATUM.
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A.,
RA   Flinter F., Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M.,
RA   Smith C.I.E., Bentley D.R.;
RL   Nature 364:362-362(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8090769; DOI=10.1073/pnas.91.19.9062;
RA   Ohta Y., Haire R.N., Litman R.T., Fu S.M., Nelson R.P., Kratz J.,
RA   Kornfeld S.J., la Morena M., Good R.A., Litman G.W.;
RT   "Genomic organization and structure of Bruton agammaglobulinemia
RT   tyrosine kinase: localization of mutations associated with varied
RT   clinical presentations and course in X chromosome-linked
RT   agammaglobulinemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9062-9066(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7927535; DOI=10.1007/BF01246672;
RA   Rohrer J., Parolini O., Belmont J.W., Conley M.E.;
RT   "The genomic structure of human BTK, the defective gene in X-linked
RT   agammaglobulinemia.";
RL   Immunogenetics 40:319-324(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS XLA SER-334; ARG-506;
RP   GLN-520; TRP-562 AND LYS-630.
RX   PubMed=7880320; DOI=10.1093/hmg/3.10.1743;
RA   Hagemann T.L., Chen Y., Rosen F.S., Kwan S.-P.;
RT   "Genomic organization of the Btk gene and exon scanning for mutations
RT   in patients with X-linked agammaglobulinemia.";
RL   Hum. Mol. Genet. 3:1743-1749(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7626884; DOI=10.1007/BF00364796;
RA   Oeltjen J.C., Liu X., Lu J., Allen R.C., Muzny D.M., Belmont J.W.,
RA   Gibbs R.A.;
RT   "Sixty-nine kilobases of contiguous human genomic sequence containing
RT   the alpha-galactosidase A and Bruton's tyrosine kinase loci.";
RL   Mamm. Genome 6:334-338(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BTK-A).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BTK-A).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 1-442.
RX   PubMed=8425221; DOI=10.1016/0092-8674(93)90667-F;
RA   Tsukada S., Saffran D.C., Rawlings D.J., Parolini O., Allen R.C.,
RA   Klisak I., Sparkes R.S., Kubagawa H., Mohandas T., Quan S.,
RA   Belmont J.W., Cooper M.D., Conley M.E., Witte O.N.;
RT   "Deficient expression of a B cell cytoplasmic tyrosine kinase in human
RT   X-linked agammaglobulinemia.";
RL   Cell 72:279-290(1993).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-12 AND 323-332, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 219-235, AND PHOSPHORYLATION AT TYR-223.
RX   PubMed=12573241; DOI=10.1016/S1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [13]
RP   INVOLVEMENT IN XLA-IGHD.
RX   PubMed=8013627; DOI=10.1016/0014-5793(94)00457-9;
RA   Duriez B., Duquesnoy P., Dastot F., Bougneres P., Amselem S.,
RA   Goossens M.;
RT   "An exon-skipping mutation in the btk gene of a patient with X-linked
RT   agammaglobulinemia and isolated growth hormone deficiency.";
RL   FEBS Lett. 346:165-170(1994).
RN   [14]
RP   DOMAIN PH.
RX   PubMed=8070576; DOI=10.1016/0014-5793(94)00783-7;
RA   Vihinen M., Nilsson L., Smith C.I.;
RT   "Tec homology (TH) adjacent to the PH domain.";
RL   FEBS Lett. 350:263-265(1994).
RN   [15]
RP   PHOSPHORYLATION AT TYR-223 AND TYR-551, MUTAGENESIS OF TYR-223, AND
RP   ENZYME REGULATION.
RX   PubMed=8630736; DOI=10.1016/S1074-7613(00)80417-3;
RA   Park H., Wahl M.I., Afar D.E., Turck C.W., Rawlings D.J., Tam C.,
RA   Scharenberg A.M., Kinet J.P., Witte O.N.;
RT   "Regulation of Btk function by a major autophosphorylation site within
RT   the SH3 domain.";
RL   Immunity 4:515-525(1996).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF GTF2I, PHOSPHORYLATION AT TYR-223 AND
RP   TYR-551, AND MUTAGENESIS OF GLU-41; PRO-189; TYR-223; TRP-251; ARG-307
RP   AND TYR-551.
RX   PubMed=9012831; DOI=10.1073/pnas.94.2.604;
RA   Yang W., Desiderio S.;
RT   "BAP-135, a target for Bruton's tyrosine kinase in response to B cell
RT   receptor engagement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:604-609(1997).
RN   [17]
RP   MUTAGENESIS OF 251-TRP-TRP-252, AND INTERACTION WITH SH3BP5.
RX   PubMed=9571151; DOI=10.1006/bbrc.1998.8420;
RA   Matsushita M., Yamadori T., Kato S., Takemoto Y., Inazawa J., Baba Y.,
RA   Hashimoto S., Sekine S., Arai S., Kunikata T., Kurimoto M.,
RA   Kishimoto T., Tsukada S.;
RT   "Identification and characterization of a novel SH3-domain binding
RT   protein, Sab, which preferentially associates with Bruton's tyrosine
RT   kinase (Btk).";
RL   Biochem. Biophys. Res. Commun. 245:337-343(1998).
RN   [18]
RP   DOMAIN PH, AND SUBCELLULAR LOCATION.
RX   PubMed=10196179; DOI=10.1074/jbc.274.16.10983;
RA   Varnai P., Rother K.I., Balla T.;
RT   "Phosphatidylinositol 3-kinase-dependent membrane association of the
RT   Bruton's tyrosine kinase pleckstrin homology domain visualized in
RT   single living cells.";
RL   J. Biol. Chem. 274:10983-10989(1999).
RN   [19]
RP   INTERACTION WITH SH3BP5, AND ENZYME REGULATION.
RX   PubMed=10339589; DOI=10.1073/pnas.96.11.6341;
RA   Yamadori T., Baba Y., Mastushita M., Hashimoto S., Kurosaki M.,
RA   Kurosaki T., Kishimoto T., Tsukada S.;
RT   "Bruton's tyrosine kinase activity is negatively regulated by Sab, the
RT   Btk-SH3 domain-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6341-6346(1999).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10602036;
RX   DOI=10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0;
RA   Nore B.F., Vargas L., Mohamed A.J., Branden L.J., Backesjo C.M.,
RA   Islam T.C., Mattsson P.T., Hultenby K., Christensson B., Smith C.I.;
RT   "Redistribution of Bruton's tyrosine kinase by activation of
RT   phosphatidylinositol 3-kinase and Rho-family GTPases.";
RL   Eur. J. Immunol. 30:145-154(2000).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11016936; DOI=10.1074/jbc.M006952200;
RA   Mohamed A.J., Vargas L., Nore B.F., Backesjo C.M., Christensson B.,
RA   Smith C.I.;
RT   "Nucleocytoplasmic shuttling of Bruton's tyrosine kinase.";
RL   J. Biol. Chem. 275:40614-40619(2000).
RN   [22]
RP   PHOSPHORYLATION AT SER-180, AND ENZYME REGULATION.
RX   PubMed=11598012; DOI=10.1093/emboj/20.20.5692;
RA   Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M.,
RA   Tabuchi R., Tarakhovsky A., Kawakami T., Turck C.W., Witte O.N.,
RA   Rawlings D.J.;
RT   "PKCbeta modulates antigen receptor signaling via regulation of Btk
RT   membrane localization.";
RL   EMBO J. 20:5692-5702(2001).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG2.
RX   PubMed=11606584; DOI=10.1074/jbc.M107577200;
RA   Rodriguez R., Matsuda M., Perisic O., Bravo J., Paul A., Jones N.P.,
RA   Light Y., Swann K., Williams R.L., Katan M.;
RT   "Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme
RT   function in B-cell signaling.";
RL   J. Biol. Chem. 276:47982-47992(2001).
RN   [24]
RP   INTERACTION WITH IBTK, AND ENZYME REGULATION.
RX   PubMed=11577348; DOI=10.1038/ni1001-939;
RA   Liu W., Quinto I., Chen X., Palmieri C., Rabin R.L., Schwartz O.M.,
RA   Nelson D.L., Scala G.;
RT   "Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding
RT   protein.";
RL   Nat. Immunol. 2:939-946(2001).
RN   [25]
RP   DOMAIN, INTERACTION WITH CAV1, SUBCELLULAR LOCATION, AND ENZYME
RP   REGULATION.
RX   PubMed=11751885; DOI=10.1074/jbc.M108537200;
RA   Vargas L., Nore B.F., Berglof A., Heinonen J.E., Mattsson P.T.,
RA   Smith C.I., Mohamed A.J.;
RT   "Functional interaction of caveolin-1 with Bruton's tyrosine kinase
RT   and Bmx.";
RL   J. Biol. Chem. 277:9351-9357(2002).
RN   [26]
RP   PHOSPHORYLATION AT TYR-617 AND SER-623, AND MUTAGENESIS OF TYR-617.
RX   PubMed=15375214; DOI=10.1073/pnas.0405878101;
RA   Guo S., Ferl G.Z., Deora R., Riedinger M., Yin S., Kerwin J.L.,
RA   Loo J.A., Witte O.N.;
RT   "A phosphorylation site in Bruton's tyrosine kinase selectively
RT   regulates B cell calcium signaling efficiency by altering
RT   phospholipase C-gamma activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:14180-14185(2004).
RN   [27]
RP   INTERACTION WITH PIN1, PHOSPHORYLATION AT SER-21 AND SER-115, AND
RP   ENZYME REGULATION.
RX   PubMed=16644721; DOI=10.1074/jbc.M603090200;
RA   Yu L., Mohamed A.J., Vargas L., Berglof A., Finn G., Lu K.P.,
RA   Smith C.I.;
RT   "Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase
RT   Pin1.";
RL   J. Biol. Chem. 281:18201-18207(2006).
RN   [28]
RP   FUNCTION IN THE TLR PATHWAY.
RX   PubMed=16517732; DOI=10.4049/jimmunol.176.6.3635;
RA   Horwood N.J., Page T.H., McDaid J.P., Palmer C.D., Campbell J.,
RA   Mahon T., Brennan F.M., Webster D., Foxwell B.M.;
RT   "Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF,
RT   but not IL-6, production.";
RL   J. Immunol. 176:3635-3641(2006).
RN   [29]
RP   INTERACTION WITH GTF2I AND ARID3A, AND FUNCTION.
RX   PubMed=16738337; DOI=10.1128/MCB.02009-05;
RA   Rajaiya J., Nixon J.C., Ayers N., Desgranges Z.P., Roy A.L.,
RA   Webb C.F.;
RT   "Induction of immunoglobulin heavy-chain transcription through the
RT   transcription factor Bright requires TFII-I.";
RL   Mol. Cell. Biol. 26:4758-4768(2006).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF TIRAP, AND ENZYME REGULATION.
RX   PubMed=16415872; DOI=10.1038/ni1299;
RA   Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J.,
RA   Nicholson S.E., Hilton D.J., O'Neill L.A., Hertzog P.J.;
RT   "Suppressor of cytokine signaling 1 negatively regulates Toll-like
RT   receptor signaling by mediating Mal degradation.";
RL   Nat. Immunol. 7:148-155(2006).
RN   [31]
RP   FUNCTION, INTERACTION WITH TLR8 AND TLR9, ENZYME REGULATION, AND
RP   PHOSPHORYLATION AT TYR-223.
RX   PubMed=17932028; DOI=10.1074/jbc.M707682200;
RA   Doyle S.L., Jefferies C.A., Feighery C., O'Neill L.A.;
RT   "Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine
RT   kinase.";
RL   J. Biol. Chem. 282:36953-36960(2007).
RN   [32]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [33]
RP   REVIEW ON FUNCTION IN REGULATION OF APOPTOSIS.
RX   PubMed=9751072; DOI=10.1016/S0006-2952(98)00122-1;
RA   Uckun F.M.;
RT   "Bruton's tyrosine kinase (BTK) as a dual-function regulator of
RT   apoptosis.";
RL   Biochem. Pharmacol. 56:683-691(1998).
RN   [34]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=19290921; DOI=10.1111/j.1600-065X.2008.00741.x;
RA   Mohamed A.J., Yu L., Backesjo C.M., Vargas L., Faryal R., Aints A.,
RA   Christensson B., Berglof A., Vihinen M., Nore B.F., Smith C.I.;
RT   "Bruton's tyrosine kinase (Btk): function, regulation, and
RT   transformation with special emphasis on the PH domain.";
RL   Immunol. Rev. 228:58-73(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; THR-191; TYR-361 AND
RP   SER-659, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   ALTERNATIVE PROMOTER USAGE (ISOFORM BTK-C).
RX   PubMed=23913792; DOI=10.1002/gcc.22091;
RA   Eifert C., Wang X., Kokabee L., Kourtidis A., Jain R., Gerdes M.J.,
RA   Conklin D.S.;
RT   "A novel isoform of the B cell tyrosine kinase BTK protects breast
RT   cancer cells from apoptosis.";
RL   Genes Chromosomes Cancer 52:961-975(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-191; TYR-223 AND
RP   SER-604, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 2-170 IN COMPLEX WITH ZINC.
RX   PubMed=9218782; DOI=10.1093/emboj/16.12.3396;
RA   Hyvoenen M., Saraste M.;
RT   "Structure of the PH domain and Btk motif from Bruton's tyrosine
RT   kinase: molecular explanations for X-linked agammaglobulinaemia.";
RL   EMBO J. 16:3396-3404(1997).
RN   [41]
RP   STRUCTURE BY NMR OF 212-275.
RX   PubMed=9485443; DOI=10.1021/bi972409f;
RA   Hansson H., Mattsson P.T., Allard P., Haapaniemi P., Vihinen M.,
RA   Smith C.I.E., Haerd T.;
RT   "Solution structure of the SH3 domain from Bruton's tyrosine kinase.";
RL   Biochemistry 37:2912-2924(1998).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-170 IN COMPLEX WITH
RP   INOSITOL-(1,3,4,5)-TETRAKISPHOSPHATE AND ZINC, AND DOMAIN PH.
RX   PubMed=10196129; DOI=10.1016/S0969-2126(99)80057-4;
RA   Baraldi E., Carugo K.D., Hyvoenen M., Surdo P.L., Riley A.M.,
RA   Potter B.V.L., O'Brien R., Ladbury J.E., Saraste M.;
RT   "Structure of the PH domain from Bruton's tyrosine kinase in complex
RT   with inositol 1,3,4,5-tetrakisphosphate.";
RL   Structure 7:449-460(1999).
RN   [43]
RP   STRUCTURE BY NMR OF 216-273.
RX   PubMed=10826882; DOI=10.1023/A:1008376624863;
RA   Tzeng S.R., Lou Y.C., Pai M.T., Jain M.L., Cheng J.W.;
RT   "Solution structure of the human BTK SH3 domain complexed with a
RT   proline-rich peptide from p120cbl.";
RL   J. Biomol. NMR 16:303-312(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 397-659.
RX   PubMed=11527964; DOI=10.1074/jbc.M104828200;
RA   Mao C., Zhou M., Uckun F.M.;
RT   "Crystal structure of Bruton's tyrosine kinase domain suggests a novel
RT   pathway for activation and provides insights into the molecular basis
RT   of X-linked agammaglobulinemia.";
RL   J. Biol. Chem. 276:41435-41443(2001).
RN   [45]
RP   STRUCTURE BY NMR OF 270-386.
RX   PubMed=16969585; DOI=10.1007/s10858-006-9064-3;
RA   Huang K.C., Cheng H.T., Pai M.T., Tzeng S.R., Cheng J.W.;
RT   "Solution structure and phosphopeptide binding of the SH2 domain from
RT   the human Bruton's tyrosine kinase.";
RL   J. Biomol. NMR 36:73-78(2006).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 393-656 IN COMPLEX WITH
RP   INHIBITOR.
RA   Di Paolo J.A., Huang T., Balazs M., Barbosa J., Barck K.H.,
RA   Carano R.A.D., Darrow J., Davies D.R., DeForge L.E., Dennis G. Jr.,
RA   Diehl L., Ferrando R.;
RT   "A novel, specific Btk inhibitor antagonizes BCR and Fc[gamma]R
RT   signaling and suppresses inflammatory arthritis.";
RL   Submitted (AUG-2010) to the PDB data bank.
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF 2-170 IN COMPLEX WITH
RP   INHIBITOR AND ZINC.
RA   Murayama K., Kato-Murayama M., Mishima C., Shirouzu M., Yokoyama S.;
RT   "Crystal structure of PH domain of Bruton's tyrosine kinase.";
RL   Submitted (MAY-2007) to the PDB data bank.
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 382-659 IN COMPLEX WITH
RP   INHIBITOR DASATINIB.
RX   PubMed=20052711; DOI=10.1002/pro.321;
RA   Marcotte D.J., Liu Y.T., Arduini R.M., Hession C.A., Miatkowski K.,
RA   Wildes C.P., Cullen P.F., Hong V., Hopkins B.T., Mertsching E.,
RA   Jenkins T.J., Romanowski M.J., Baker D.P., Silvian L.F.;
RT   "Structures of human Bruton's tyrosine kinase in active and inactive
RT   conformations suggest a mechanism of activation for TEC family
RT   kinases.";
RL   Protein Sci. 19:429-439(2010).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 393-659.
RA   Di Paolo J., Huang T., Balazs M., Barbosa J., Barck K.H., Bravo B.,
RA   Carano R.A.D., Darrow J., Davies D.R., DeForge L.E., Diehl L.,
RA   Ferrando R., Gallion S.L., Gianetti A.M., Gribling P., Hurez V.,
RA   Hymowitz S.G., Jones R., Kropf J.E., Lee W.P., Maciejewski P.M.,
RA   Mitchell S.A., Rong H., Staker B.L., Whitney J.A., Yeh S., Young W.,
RA   Yu C., Zhang J., Reif K., Currie K.S.;
RT   "A novel, specific BTK inhibitor antagonizes BCR and FcgR signaling
RT   and suppresses inflammatory arthritis.";
RL   Submitted (SEP-2010) to the PDB data bank.
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 387-659 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=21280133; DOI=10.1002/pro.575;
RA   Kuglstatter A., Wong A., Tsing S., Lee S.W., Lou Y., Villasenor A.G.,
RA   Bradshaw J.M., Shaw D., Barnett J.W., Browner M.F.;
RT   "Insights into the conformational flexibility of Bruton's tyrosine
RT   kinase from multiple ligand complex structures.";
RL   Protein Sci. 20:428-436(2011).
RN   [51]
RP   REVIEW ON VARIANTS XLA.
RX   PubMed=8594569; DOI=10.1093/nar/24.1.160;
RA   Vihinen M., Iwata T., Kinnon C., Kwan S.-P., Ochs H.D.,
RA   Vorechovsky I., Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 24:160-165(1996).
RN   [52]
RP   REVIEW ON VARIANTS XLA.
RX   PubMed=9016530; DOI=10.1093/nar/25.1.166;
RA   Vihinen M., Belohradsky B.H., Haire R.N., Holinski-Feder E.,
RA   Kwan S.-P., Lappalainen I., Lehvaeslaiho H., Lester T., Meindl A.,
RA   Ochs H.D., Ollila J., Vorechovsky I., Weiss M., Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 25:166-171(1997).
RN   [53]
RP   VARIANTS XLA TRP-288; GLY-307; ASP-607 AND
RP   SER-VAL-PHE-SER-SER-THR-ARG-103 INS.
RX   PubMed=8162056; DOI=10.1093/hmg/3.1.79;
RA   Bradley L.A.D., Sweatman A.K., Lovering R.C., Jones A.M., Morgan G.,
RA   Levinsky R.J., Kinnon C.;
RT   "Mutation detection in the X-linked agammaglobulinemia gene, BTK,
RT   using single strand conformation polymorphism analysis.";
RL   Hum. Mol. Genet. 3:79-83(1994).
RN   [54]
RP   VARIANTS XLA HIS-28 AND TRP-288.
RX   PubMed=8162018; DOI=10.1093/hmg/3.1.161;
RA   de Weers M., Mensink R.G.J., Kraakman M.E.M., Schuurman R.K.B.,
RA   Hendriks R.W.;
RT   "Mutation analysis of the Bruton's tyrosine kinase gene in X-linked
RT   agammaglobulinemia: identification of a mutation which affects the
RT   same codon as is altered in immunodeficient xid mice.";
RL   Hum. Mol. Genet. 3:161-166(1994).
RN   [55]
RP   VARIANTS XLA ASP-113; CYS-361; GLN-520; PRO-542; TRP-562; LYS-630 AND
RP   PRO-652.
RX   PubMed=7849697; DOI=10.1093/hmg/3.10.1751;
RA   Conley M.E., Fitch-Hilgenberg M.E., Cleveland J.L., Parolini O.,
RA   Rohrer J.;
RT   "Screening of genomic DNA to identify mutations in the gene for
RT   Bruton's tyrosine kinase.";
RL   Hum. Mol. Genet. 3:1751-1756(1994).
RN   [56]
RP   VARIANTS XLA HIS-28; PRO-33; PRO-408; GLY-589; ASP-613 AND
RP   260-GLN--GLU-280 DEL.
RX   PubMed=7849721; DOI=10.1093/hmg/3.10.1899;
RA   Zhu Q., Zhang M., Winkelstein J., Chen S.-H., Ochs H.D.;
RT   "Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-
RT   linked agammaglobulinemia families.";
RL   Hum. Mol. Genet. 3:1899-1900(1994).
RN   [57]
RP   VARIANTS XLA GLU-430; GLN-520; GLN-525; PRO-562; VAL-582; GLY-589;
RP   GLU-594 AND ASP-613.
RX   PubMed=7809124; DOI=10.1073/pnas.91.26.12803;
RA   Vihinen M., Vetrie D., Maniar H.S., Ochs H.D., Zhu Q., Vorechovsky I.,
RA   Webster A.D.B., Notarangelo L.D., Nilsson L., Sowadski J.M.,
RA   Smith C.I.E.;
RT   "Structural basis for chromosome X-linked agammaglobulinemia: a
RT   tyrosine kinase disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:12803-12807(1994).
RN   [58]
RP   VARIANT XLA PHE-64, AND CHARACTERIZATION OF OTHER XLA VARIANTS.
RX   PubMed=7849006; DOI=10.1021/bi00005a002;
RA   Vihinen M., Zvelebil J.J.M., Zhu Q., Brooimans R.A., Ochs H.D.,
RA   Zegers B.J.M., Nilsson L., Waterfield M.D., Smith C.I.E.;
RT   "Structural basis for pleckstrin homology domain mutations in X-linked
RT   agammaglobulinemia.";
RL   Biochemistry 34:1475-1481(1995).
RN   [59]
RP   VARIANTS XLA SER-25; TRP-288; MET-370; VAL-509; PRO-525; LYS-526;
RP   TRP-562; VAL-582 AND ARG-594.
RX   PubMed=7711734; DOI=10.1093/hmg/4.1.51;
RA   Vorechovsky I., Vihinen M., de Saint Basile G., Honsova S.,
RA   Hammarstroem L., Mueller S., Nilsson L., Fischer A., Smith C.I.E.;
RT   "DNA-based mutation analysis of Bruton's tyrosine kinase gene in
RT   patients with X-linked agammaglobulinaemia.";
RL   Hum. Mol. Genet. 4:51-58(1995).
RN   [60]
RP   VARIANTS XLA LYS-567; LEU-587 AND HIS-641.
RX   PubMed=7633420; DOI=10.1093/hmg/4.4.693;
RA   Jin H., Webster A.D.B., Vihinen M., Sideras P., Vorechovsky I.,
RA   Hammarstroem L., Bernatowska-Matuszkiewicz E., Smith C.I.E.,
RA   Bobrow M., Vetrie D.;
RT   "Identification of Btk mutations in 20 unrelated patients with X-
RT   linked agammaglobulinaemia (XLA).";
RL   Hum. Mol. Genet. 4:693-700(1995).
RN   [61]
RP   VARIANTS XLA PRO-33; GLY-302 DEL; GLN-520 AND CYS-641.
RX   PubMed=7633429; DOI=10.1093/hmg/4.4.755;
RA   Gaspar H.B., Bradley L.A.D., Katz F., Lovering R.C., Roifman C.M.,
RA   Morgan G., Levinsky R.J., Kinnon C.;
RT   "Mutation analysis in Bruton's tyrosine kinase, the X-linked
RT   agammaglobulinaemia gene, including identification of an insertional
RT   hotspot.";
RL   Hum. Mol. Genet. 4:755-757(1995).
RN   [62]
RP   VARIANTS XLA ASN-429 AND ARG-477.
RX   PubMed=8634718; DOI=10.1093/hmg/4.12.2403;
RA   Vorechovsky I., Luo L., de Saint Basile G., Hammarstroem L.,
RA   Webster A.D.B., Smith C.I.E.;
RT   "Improved oligonucleotide primer set for molecular diagnosis of X-
RT   linked agammaglobulinaemia: predominance of amino acid substitutions
RT   in the catalytic domain of Bruton's tyrosine kinase.";
RL   Hum. Mol. Genet. 4:2403-2405(1995).
RN   [63]
RP   VARIANTS XLA GLU-302 AND ASP-476.
RX   PubMed=7627183; DOI=10.1002/humu.1380050405;
RA   Hagemann T.L., Rosen F.S., Kwan S.-P.;
RT   "Characterization of germline mutations of the gene encoding Bruton's
RT   tyrosine kinase in families with X-linked agammaglobulinemia.";
RL   Hum. Mutat. 5:296-302(1995).
RN   [64]
RP   VARIANT XLA PHE-358.
RX   PubMed=7897635; DOI=10.1136/jmg.32.1.77;
RA   Ohashi Y., Tsuchiya S., Konno T.;
RT   "A new point mutation involving a highly conserved leucine in the Btk
RT   SH2 domain in a family with X linked agammaglobulinaemia.";
RL   J. Med. Genet. 32:77-79(1995).
RN   [65]
RP   VARIANT XLA PRO-295.
RX   PubMed=8723128;
RX   DOI=10.1002/(SICI)1096-8628(19960503)63:1<318::AID-AJMG53>3.0.CO;2-N;
RA   Schuster V., Seidenspinner S., Kreth H.W.;
RT   "Detection of a novel mutation in the SRC homology domain 2 (SH2) of
RT   Bruton's tyrosine kinase and direct female carrier evaluation in a
RT   family with X-linked agammaglobulinemia.";
RL   Am. J. Med. Genet. 63:318-322(1996).
RN   [66]
RP   VARIANTS XLA ARG-12; PRO-28; GLU-302; TRP-502; HIS-521; TYR-633 AND
RP   SER-644.
RX   PubMed=8695804;
RA   Hashimoto S., Tsukada S., Matsushita M., Miyawaki T., Niida Y.,
RA   Yachie A., Kobayashi S., Iwata T., Hayakawa H., Matsuoka H., Tsuge I.,
RA   Yamadori T., Kunikata T., Arai S., Yoshizaki K., Taniguchi N.,
RA   Kishimoto T.;
RT   "Identification of Bruton's tyrosine kinase (Btk) gene mutations and
RT   characterization of the derived proteins in 35 X-linked
RT   agammaglobulinemia families: a nationwide study of Btk deficiency in
RT   Japan.";
RL   Blood 88:561-573(1996).
RN   [67]
RP   VARIANTS XLA TRP-288; LYS-544 AND PRO-592.
RX   PubMed=8834236; DOI=10.1007/BF02267060;
RA   Kobayashi S., Iwata T., Saito M., Iwasaki R., Matsumoto H.,
RA   Naritaka S., Kono Y., Hayashi Y.;
RT   "Mutations of the Btk gene in 12 unrelated families with X-linked
RT   agammaglobulinemia in Japan.";
RL   Hum. Genet. 97:424-430(1996).
RN   [68]
RP   VARIANTS XLA SER-154 AND ARG-155.
RX   PubMed=9280283; DOI=10.1016/S0014-5793(97)00912-5;
RA   Vihinen M., Nore B., Mattsson P.T., Backesj C.-M., Nars M.,
RA   Koutaniemi S., Watanabe C., Lester T., Jones A.M., Ochs H.D.,
RA   Smith C.I.E.;
RT   "Missense mutations affecting a conserved cysteine pair in the TH
RT   domain of Btk.";
RL   FEBS Lett. 413:205-210(1997).
RN   [69]
RP   VARIANTS XLA.
RX   PubMed=9260159;
RA   Saha B.K., Curtis S.K., Vogler L.B., Vihinen M.;
RT   "Molecular and structural characterization of five novel mutations in
RT   the Bruton's tyrosine kinase gene from patients with X-linked
RT   agammaglobulinemia.";
RL   Mol. Med. 3:477-485(1997).
RN   [70]
RP   VARIANTS XLA GLN-288; THR-307; ARG-430; ASP-445; GLY-525; PHE-535;
RP   LEU-563 AND PRO-622.
RX   PubMed=9545398; DOI=10.1086/301828;
RA   Conley M.E., Mathias D., Treadaway J., Minegishi Y., Rohrer J.;
RT   "Mutations in btk in patients with presumed X-linked
RT   agammaglobulinemia.";
RL   Am. J. Hum. Genet. 62:1034-1043(1998).
RN   [71]
RP   VARIANTS XLA GLU-19; HIS-28; ASN-61; PRO-117; HIS-127; ARG-155;
RP   PRO-295; PHE-369; GLY-372; ARG-414; TYR-506; GLY-521; GLN-525;
RP   SER-559; TRP-562; GLU-594; THR-619; GLY-626 AND HIS-641.
RX   PubMed=9445504; DOI=10.1542/peds.101.2.276;
RA   Holinski-Feder E., Weiss M., Brandau O., Jedele K.B., Nore B.,
RA   Baeckesjoe C.-M., Vihinen M., Hubbard S.R., Belohradsky B.H.,
RA   Smith C.I.E., Meindl A.;
RT   "Mutation screening of the BTK gene in 56 families with X-linked
RT   agammaglobulinemia (XLA): 47 unique mutations without correlation to
RT   clinical course.";
RL   Pediatrics 101:276-284(1998).
RN   [72]
RP   VARIANTS XLA.
RX   PubMed=10220140;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L;
RA   Vihinen M., Kwan S.-P., Lester T., Ochs H.D., Resnick I., Vaeliaho J.,
RA   Conley M.E., Smith C.I.E.;
RT   "Mutations of the human BTK gene coding for Bruton tyrosine kinase in
RT   X-linked agammaglobulinemia.";
RL   Hum. Mutat. 13:280-285(1999).
RN   [73]
RP   VARIANT XLA PRO-562.
RX   PubMed=10678660;
RX   DOI=10.1002/(SICI)1096-8628(20000131)90:3<229::AID-AJMG8>3.0.CO;2-Q;
RA   Curtis S.K., Hebert M.D., Saha B.K.;
RT   "Twin carriers of X-linked agammaglobulinemia (XLA) due to germline
RT   mutation in the Btk gene.";
RL   Am. J. Med. Genet. 90:229-232(2000).
RN   [74]
RP   VARIANTS XLA SER-39; PRO-512; GLN-512; GLY-544; TYR-578 AND LYS-589.
RX   PubMed=10612838;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<117::AID-HUMU26>3.0.CO;2-H;
RA   Orlandi P., Ritis K., Moschese V., Angelini F., Arvanitidis K.,
RA   Speletas M., Sideras P., Plebani A., Rossi P.;
RT   "Identification of nine novel mutations in the Bruton's tyrosine
RT   kinase gene in X-linked agammaglobulinaemia patients.";
RL   Hum. Mutat. 15:117-117(2000).
RN   [75]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-82 AND LYS-190.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [76]
RP   VARIANT SER-481, AND CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=24869598; DOI=10.1056/NEJMoa1400029;
RA   Woyach J.A., Furman R.R., Liu T.M., Ozer H.G., Zapatka M.,
RA   Ruppert A.S., Xue L., Li D.H., Steggerda S.M., Versele M., Dave S.S.,
RA   Zhang J., Yilmaz A.S., Jaglowski S.M., Blum K.A., Lozanski A.,
RA   Lozanski G., James D.F., Barrientos J.C., Lichter P., Stilgenbauer S.,
RA   Buggy J.J., Chang B.Y., Johnson A.J., Byrd J.C.;
RT   "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor
RT   ibrutinib.";
RL   N. Engl. J. Med. 370:2286-2294(2014).
RN   [77]
RP   CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=24869597; DOI=10.1056/NEJMc1402716;
RA   Furman R.R., Cheng S., Lu P., Setty M., Perez A.R., Perez A.R.,
RA   Guo A., Racchumi J., Xu G., Wu H., Ma J., Steggerda S.M., Coleman M.,
RA   Leslie C., Wang Y.L.;
RT   "Ibrutinib resistance in chronic lymphocytic leukemia.";
RL   N. Engl. J. Med. 370:2352-2354(2014).
RN   [78]
RP   CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=25189416; DOI=10.1038/leu.2014.263;
RA   Cheng S., Guo A., Lu P., Ma J., Coleman M., Wang Y.L.;
RT   "Functional characterization of BTK(C481S) mutation that confers
RT   ibrutinib resistance: exploration of alternative kinase inhibitors.";
RL   Leukemia 29:895-900(2015).
CC   -!- FUNCTION: Non-receptor tyrosine kinase indispensable for B
CC       lymphocyte development, differentiation and signaling. Binding of
CC       antigen to the B-cell antigen receptor (BCR) triggers signaling
CC       that ultimately leads to B-cell activation. After BCR engagement
CC       and activation at the plasma membrane, phosphorylates PLCG2 at
CC       several sites, igniting the downstream signaling pathway through
CC       calcium mobilization, followed by activation of the protein kinase
CC       C (PKC) family members. PLCG2 phosphorylation is performed in
CC       close cooperation with the adapter protein B-cell linker protein
CC       BLNK. BTK acts as a platform to bring together a diverse array of
CC       signaling proteins and is implicated in cytokine receptor
CC       signaling pathways. Plays an important role in the function of
CC       immune cells of innate as well as adaptive immunity, as a
CC       component of the Toll-like receptors (TLR) pathway. The TLR
CC       pathway acts as a primary surveillance system for the detection of
CC       pathogens and are crucial to the activation of host defense.
CC       Especially, is a critical molecule in regulating TLR9 activation
CC       in splenic B-cells. Within the TLR pathway, induces tyrosine
CC       phosphorylation of TIRAP which leads to TIRAP degradation. BTK
CC       plays also a critical role in transcription regulation. Induces
CC       the activity of NF-kappa-B, which is involved in regulating the
CC       expression of hundreds of genes. BTK is involved on the signaling
CC       pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently
CC       phosphorylates transcription factor GTF2I on tyrosine residues in
CC       response to BCR. GTF2I then translocates to the nucleus to bind
CC       regulatory enhancer elements to modulate gene expression. ARID3A
CC       and NFAT are other transcriptional target of BTK. BTK is required
CC       for the formation of functional ARID3A DNA-binding complexes.
CC       There is however no evidence that BTK itself binds directly to
CC       DNA. BTK has a dual role in the regulation of apoptosis.
CC       {ECO:0000269|PubMed:11606584, ECO:0000269|PubMed:16415872,
CC       ECO:0000269|PubMed:16517732, ECO:0000269|PubMed:16738337,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:9012831}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- ENZYME REGULATION: Activated by phosphorylation. In primary B
CC       lymphocytes, is almost always non-phosphorylated and is thus
CC       catalytically inactive. Stimulation of TLR8 and TLR9 causes BTK
CC       activation. As a negative feedback mechanism to fine-tune BCR
CC       signaling, activated PRKCB down-modulates BTK function via direct
CC       phosphorylation of BTK at Ser-180, resulting in translocation of
CC       BTK back to the cytoplasmic fraction. PIN1, SH3BP5, and IBTK were
CC       also identified as BTK activity inhibitors. Interaction with CAV1
CC       leads to dramatic down-regulation of the kinase activity of BTK.
CC       LFM-13A is a specific inhibitor of BTK. Dasatinib, a cancer drug
CC       acting as a tyrosine kinase inhibitor, also blocks BTK activity.
CC       {ECO:0000269|PubMed:10339589, ECO:0000269|PubMed:11577348,
CC       ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:16415872, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736}.
CC   -!- SUBUNIT: Binds GTF2I through the PH domain. Interacts with SH3BP5
CC       via the SH3 domain. Interacts with IBTK via its PH domain.
CC       Interacts with ARID3A, CAV1, FASLG, PIN1, TLR8 and TLR9.
CC       {ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:10339589,
CC       ECO:0000269|PubMed:11577348, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:16644721, ECO:0000269|PubMed:16738337,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:20052711, ECO:0000269|PubMed:21280133,
CC       ECO:0000269|PubMed:9218782, ECO:0000269|PubMed:9571151,
CC       ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-624835, EBI-624835;
CC       Q99856:ARID3A; NbExp=3; IntAct=EBI-624835, EBI-5458244;
CC       Q8WV28:BLNK; NbExp=2; IntAct=EBI-624835, EBI-2623522;
CC       P78347:GTF2I; NbExp=6; IntAct=EBI-624835, EBI-359622;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-624835, EBI-352572;
CC       P21145:MAL; NbExp=5; IntAct=EBI-624835, EBI-3932027;
CC       P50222:MEOX2; NbExp=3; IntAct=EBI-624835, EBI-748397;
CC       Q04759:PRKCQ; NbExp=2; IntAct=EBI-624835, EBI-374762;
CC       O60239:SH3BP5; NbExp=4; IntAct=EBI-624835, EBI-624860;
CC       P42768:WAS; NbExp=4; IntAct=EBI-624835, EBI-346375;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral
CC       membrane protein. Nucleus. Note=In steady state, BTK is
CC       predominantly cytosolic. Following B-cell receptor (BCR)
CC       engagement by antigen, translocates to the plasma membrane through
CC       its PH domain. Plasma membrane localization is a critical step in
CC       the activation of BTK. A fraction of BTK also shuttles between the
CC       nucleus and the cytoplasm, and nuclear export is mediated by the
CC       nuclear export receptor CRM1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=BTK-A;
CC         IsoId=Q06187-1; Sequence=Displayed;
CC       Name=BTK-C;
CC         IsoId=Q06187-2; Sequence=VSP_053838;
CC         Note=Produced by alternative promoter usage. Predominant form in
CC         many tumor cells where it may function as an anti-apoptotic cell
CC         survival factor.;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in B-lymphocytes.
CC   -!- DOMAIN: The PH domain mediates the binding to inositol
CC       polyphosphate and phosphoinositides, leading to its targeting to
CC       the plasma membrane. It is extended in the BTK kinase family by a
CC       region designated the TH (Tec homology) domain, which consists of
CC       about 80 residues preceding the SH3 domain.
CC       {ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:10196179,
CC       ECO:0000269|PubMed:11751885, ECO:0000269|PubMed:8070576}.
CC   -!- PTM: Following B-cell receptor (BCR) engagement, translocates to
CC       the plasma membrane where it gets phosphorylated at Tyr-551 by LYN
CC       and SYK. Phosphorylation at Tyr-551 is followed by
CC       autophosphorylation of Tyr-223 which may create a docking site for
CC       a SH2 containing protein. Phosphorylation at Ser-180 by PRKCB,
CC       leads in translocation of BTK back to the cytoplasmic fraction.
CC       Phosphorylation at Ser-21 and Ser-115 creates a binding site for
CC       PIN1 at these Ser-Pro motifs, and promotes it's recruitment.
CC       {ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:12573241,
CC       ECO:0000269|PubMed:15375214, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736,
CC       ECO:0000269|PubMed:9012831}.
CC   -!- DISEASE: X-linked agammaglobulinemia (XLA) [MIM:300755]: Humoral
CC       immunodeficiency disease which results in developmental defects in
CC       the maturation pathway of B-cells. Affected boys have normal
CC       levels of pre-B-cells in their bone marrow but virtually no
CC       circulating mature B-lymphocytes. This results in a lack of
CC       immunoglobulins of all classes and leads to recurrent bacterial
CC       infections like otitis, conjunctivitis, dermatitis, sinusitis in
CC       the first few years of life, or even some patients present
CC       overwhelming sepsis or meningitis, resulting in death in a few
CC       hours. Treatment in most cases is by infusion of intravenous
CC       immunoglobulin. {ECO:0000269|PubMed:10220140,
CC       ECO:0000269|PubMed:10612838, ECO:0000269|PubMed:10678660,
CC       ECO:0000269|PubMed:7627183, ECO:0000269|PubMed:7633420,
CC       ECO:0000269|PubMed:7633429, ECO:0000269|PubMed:7711734,
CC       ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849006,
CC       ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7849721,
CC       ECO:0000269|PubMed:7880320, ECO:0000269|PubMed:7897635,
CC       ECO:0000269|PubMed:8013627, ECO:0000269|PubMed:8162018,
CC       ECO:0000269|PubMed:8162056, ECO:0000269|PubMed:8594569,
CC       ECO:0000269|PubMed:8634718, ECO:0000269|PubMed:8695804,
CC       ECO:0000269|PubMed:8723128, ECO:0000269|PubMed:8834236,
CC       ECO:0000269|PubMed:9016530, ECO:0000269|PubMed:9260159,
CC       ECO:0000269|PubMed:9280283, ECO:0000269|PubMed:9445504,
CC       ECO:0000269|PubMed:9545398}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: X-linked hypogammaglobulinemia and isolated growth
CC       hormone deficiency (XLA-IGHD) [MIM:307200]: In rare cases XLA is
CC       inherited together with isolated growth hormone deficiency (IGHD).
CC       {ECO:0000269|PubMed:8013627}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BTKID851chXq22.html";
CC   -!- WEB RESOURCE: Name=BTKbase; Note=BTK mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/BTKbase/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X58957; CAA41728.1; -; mRNA.
DR   EMBL; U10087; AAB60639.1; -; Genomic_DNA.
DR   EMBL; U10084; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10085; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10086; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; L31572; AAA61479.1; -; Genomic_DNA.
DR   EMBL; L31557; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31558; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31559; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31561; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31563; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31564; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31565; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31566; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31567; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31568; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31569; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31570; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31571; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; U13433; AAC51347.1; -; Genomic_DNA.
DR   EMBL; U13410; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13412; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13413; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13414; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13415; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13416; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13417; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13422; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13423; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13424; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13425; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13427; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13428; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13429; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13430; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13431; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13432; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U78027; AAB64205.1; -; Genomic_DNA.
DR   EMBL; AK314382; BAG37008.1; -; mRNA.
DR   EMBL; AL035422; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC109079; AAI09080.1; -; mRNA.
DR   EMBL; BC109080; AAI09081.1; -; mRNA.
DR   CCDS; CCDS14482.1; -. [Q06187-1]
DR   CCDS; CCDS76003.1; -. [Q06187-2]
DR   PIR; I37212; A45184.
DR   RefSeq; NP_000052.1; NM_000061.2. [Q06187-1]
DR   RefSeq; NP_001274273.1; NM_001287344.1. [Q06187-2]
DR   RefSeq; NP_001274274.1; NM_001287345.1.
DR   UniGene; Hs.159494; -.
DR   UniGene; Hs.733206; -.
DR   PDB; 1AWW; NMR; -; A=212-275.
DR   PDB; 1AWX; NMR; -; A=212-275.
DR   PDB; 1B55; X-ray; 2.40 A; A/B=2-170.
DR   PDB; 1BTK; X-ray; 1.60 A; A/B=2-170.
DR   PDB; 1BWN; X-ray; 2.10 A; A/B=2-170.
DR   PDB; 1K2P; X-ray; 2.10 A; A/B=397-659.
DR   PDB; 1QLY; NMR; -; A=216-273.
DR   PDB; 2GE9; NMR; -; A=270-387.
DR   PDB; 2Z0P; X-ray; 2.58 A; A/B/C/D=2-170.
DR   PDB; 3GEN; X-ray; 1.60 A; A=382-659.
DR   PDB; 3K54; X-ray; 1.94 A; A=382-659.
DR   PDB; 3OCS; X-ray; 1.80 A; A=393-656.
DR   PDB; 3OCT; X-ray; 1.95 A; A=393-656.
DR   PDB; 3P08; X-ray; 2.30 A; A/B=393-659.
DR   PDB; 3PIX; X-ray; 1.85 A; A=387-659.
DR   PDB; 3PIY; X-ray; 2.55 A; A=387-659.
DR   PDB; 3PIZ; X-ray; 2.21 A; A=387-659.
DR   PDB; 3PJ1; X-ray; 2.00 A; A=387-659.
DR   PDB; 3PJ2; X-ray; 1.75 A; A=387-659.
DR   PDB; 3PJ3; X-ray; 1.85 A; A=387-659.
DR   PDB; 4NWM; X-ray; 2.03 A; A/B=396-657.
DR   PDB; 4OT5; X-ray; 1.55 A; A=378-659.
DR   PDB; 4OT6; X-ray; 2.05 A; A=378-659.
DR   PDB; 4OTF; X-ray; 1.95 A; A=393-657.
DR   PDB; 4OTQ; X-ray; 1.55 A; A=378-659.
DR   PDB; 4OTR; X-ray; 1.95 A; A=378-659.
DR   PDB; 4RFY; X-ray; 1.70 A; A=378-659.
DR   PDB; 4RFZ; X-ray; 1.17 A; A=378-659.
DR   PDB; 4RG0; X-ray; 2.50 A; A=378-659.
DR   PDB; 4RX5; X-ray; 1.36 A; A=393-657.
DR   PDB; 4YHF; X-ray; 2.20 A; A/B=382-659.
DR   PDB; 4Z3V; X-ray; 1.60 A; A=382-659.
DR   PDB; 4ZLY; X-ray; 1.65 A; A=389-658.
DR   PDB; 4ZLZ; X-ray; 2.00 A; A=389-658.
DR   PDB; 5BPY; X-ray; 2.31 A; A/B=396-659.
DR   PDB; 5BQ0; X-ray; 1.57 A; A=382-659.
DR   PDB; 5FBN; X-ray; 1.80 A; C/D=389-659.
DR   PDB; 5FBO; X-ray; 1.89 A; A=389-659.
DR   PDB; 5J87; X-ray; 1.59 A; A/B/C/D=385-658.
DR   PDB; 5JRS; X-ray; 1.97 A; A/B=396-659.
DR   PDB; 5KUP; X-ray; 1.39 A; A=393-657.
DR   PDB; 5P9F; X-ray; 1.71 A; A=382-659.
DR   PDB; 5P9G; X-ray; 1.75 A; A=382-659.
DR   PDB; 5P9H; X-ray; 1.95 A; A=382-659.
DR   PDB; 5P9I; X-ray; 1.11 A; A=382-659.
DR   PDB; 5P9J; X-ray; 1.08 A; A=382-659.
DR   PDB; 5P9K; X-ray; 1.28 A; A=382-659.
DR   PDB; 5P9L; X-ray; 1.25 A; A=382-659.
DR   PDB; 5P9M; X-ray; 1.41 A; A=382-659.
DR   PDB; 5T18; X-ray; 1.50 A; A=396-659.
DR   PDB; 5U9D; X-ray; 1.33 A; A=389-659.
DR   PDB; 5VGO; X-ray; 1.62 A; A=393-657.
DR   PDBsum; 1AWW; -.
DR   PDBsum; 1AWX; -.
DR   PDBsum; 1B55; -.
DR   PDBsum; 1BTK; -.
DR   PDBsum; 1BWN; -.
DR   PDBsum; 1K2P; -.
DR   PDBsum; 1QLY; -.
DR   PDBsum; 2GE9; -.
DR   PDBsum; 2Z0P; -.
DR   PDBsum; 3GEN; -.
DR   PDBsum; 3K54; -.
DR   PDBsum; 3OCS; -.
DR   PDBsum; 3OCT; -.
DR   PDBsum; 3P08; -.
DR   PDBsum; 3PIX; -.
DR   PDBsum; 3PIY; -.
DR   PDBsum; 3PIZ; -.
DR   PDBsum; 3PJ1; -.
DR   PDBsum; 3PJ2; -.
DR   PDBsum; 3PJ3; -.
DR   PDBsum; 4NWM; -.
DR   PDBsum; 4OT5; -.
DR   PDBsum; 4OT6; -.
DR   PDBsum; 4OTF; -.
DR   PDBsum; 4OTQ; -.
DR   PDBsum; 4OTR; -.
DR   PDBsum; 4RFY; -.
DR   PDBsum; 4RFZ; -.
DR   PDBsum; 4RG0; -.
DR   PDBsum; 4RX5; -.
DR   PDBsum; 4YHF; -.
DR   PDBsum; 4Z3V; -.
DR   PDBsum; 4ZLY; -.
DR   PDBsum; 4ZLZ; -.
DR   PDBsum; 5BPY; -.
DR   PDBsum; 5BQ0; -.
DR   PDBsum; 5FBN; -.
DR   PDBsum; 5FBO; -.
DR   PDBsum; 5J87; -.
DR   PDBsum; 5JRS; -.
DR   PDBsum; 5KUP; -.
DR   PDBsum; 5P9F; -.
DR   PDBsum; 5P9G; -.
DR   PDBsum; 5P9H; -.
DR   PDBsum; 5P9I; -.
DR   PDBsum; 5P9J; -.
DR   PDBsum; 5P9K; -.
DR   PDBsum; 5P9L; -.
DR   PDBsum; 5P9M; -.
DR   PDBsum; 5T18; -.
DR   PDBsum; 5U9D; -.
DR   PDBsum; 5VGO; -.
DR   ProteinModelPortal; Q06187; -.
DR   SMR; Q06187; -.
DR   BioGrid; 107160; 80.
DR   CORUM; Q06187; -.
DR   DIP; DIP-34071N; -.
DR   ELM; Q06187; -.
DR   IntAct; Q06187; 50.
DR   MINT; Q06187; -.
DR   STRING; 9606.ENSP00000308176; -.
DR   BindingDB; Q06187; -.
DR   ChEMBL; CHEMBL5251; -.
DR   DrugBank; DB09053; Ibrutinib.
DR   DrugBank; DB05204; XL418.
DR   GuidetoPHARMACOLOGY; 1948; -.
DR   iPTMnet; Q06187; -.
DR   PhosphoSitePlus; Q06187; -.
DR   BioMuta; BTK; -.
DR   DMDM; 547759; -.
DR   EPD; Q06187; -.
DR   MaxQB; Q06187; -.
DR   PaxDb; Q06187; -.
DR   PeptideAtlas; Q06187; -.
DR   PRIDE; Q06187; -.
DR   DNASU; 695; -.
DR   Ensembl; ENST00000308731; ENSP00000308176; ENSG00000010671. [Q06187-1]
DR   Ensembl; ENST00000621635; ENSP00000483570; ENSG00000010671. [Q06187-2]
DR   GeneID; 695; -.
DR   KEGG; hsa:695; -.
DR   UCSC; uc004ehg.3; human. [Q06187-1]
DR   CTD; 695; -.
DR   DisGeNET; 695; -.
DR   EuPathDB; HostDB:ENSG00000010671.15; -.
DR   GeneCards; BTK; -.
DR   GeneReviews; BTK; -.
DR   HGNC; HGNC:1133; BTK.
DR   HPA; CAB016689; -.
DR   HPA; HPA001198; -.
DR   HPA; HPA002028; -.
DR   MalaCards; BTK; -.
DR   MIM; 300300; gene.
DR   MIM; 300755; phenotype.
DR   MIM; 307200; phenotype.
DR   neXtProt; NX_Q06187; -.
DR   OpenTargets; ENSG00000010671; -.
DR   Orphanet; 632; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia.
DR   Orphanet; 47; X-linked agammaglobulinemia.
DR   PharmGKB; PA25454; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000119011; -.
DR   HOGENOM; HOG000233859; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; Q06187; -.
DR   KO; K07370; -.
DR   OMA; KYGKWQG; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; Q06187; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; Q06187; -.
DR   SIGNOR; Q06187; -.
DR   ChiTaRS; BTK; human.
DR   EvolutionaryTrace; Q06187; -.
DR   GeneWiki; Bruton%27s_tyrosine_kinase; -.
DR   GenomeRNAi; 695; -.
DR   PRO; PR:Q06187; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000010671; -.
DR   CleanEx; HS_BTK; -.
DR   ExpressionAtlas; Q06187; baseline and differential.
DR   Genevisible; Q06187; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0045121; C:membrane raft; IDA:HGNC.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; TAS:HGNC.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0002250; P:adaptive immune response; TAS:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0002344; P:B cell affinity maturation; IEA:Ensembl.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; TAS:HGNC.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0098761; P:cellular response to interleukin-7; IEA:Ensembl.
DR   GO; GO:0071226; P:cellular response to molecule of fungal origin; IEA:Ensembl.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002553; P:histamine secretion by mast cell; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:HGNC.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0001818; P:negative regulation of cytokine production; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:CACAO.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; TAS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0001812; P:positive regulation of type I hypersensitivity; IEA:Ensembl.
DR   GO; GO:0001805; P:positive regulation of type III hypersensitivity; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:HGNC.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; TAS:UniProtKB.
DR   GO; GO:0002721; P:regulation of B cell cytokine production; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd11906; SH3_BTK; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR035574; BTK_SH3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity;
KW   Alternative promoter usage; Apoptosis; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Immunity; Innate immunity; Kinase; Lipid-binding;
KW   Membrane; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; SH2 domain; SH3 domain;
KW   Transcription; Transcription regulation; Transferase;
KW   Tyrosine-protein kinase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.11}.
FT   CHAIN         2    659       Tyrosine-protein kinase BTK.
FT                                /FTId=PRO_0000088065.
FT   DOMAIN        3    133       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      214    274       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      281    377       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      402    655       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     135    171       Btk-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00432}.
FT   NP_BIND     408    416       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       12     24       Inositol-(1,3,4,5)-tetrakisphosphate 1-
FT                                binding.
FT   REGION      474    479       Inhibitor-binding.
FT   MOTIF       581    588       CAV1-binding.
FT   ACT_SITE    521    521       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       143    143       Zinc. {ECO:0000269|PubMed:10196129,
FT                                ECO:0000269|PubMed:9218782,
FT                                ECO:0000269|Ref.47}.
FT   METAL       154    154       Zinc. {ECO:0000269|PubMed:10196129,
FT                                ECO:0000269|PubMed:9218782,
FT                                ECO:0000269|Ref.47}.
FT   METAL       155    155       Zinc. {ECO:0000269|PubMed:10196129,
FT                                ECO:0000269|PubMed:9218782,
FT                                ECO:0000269|Ref.47}.
FT   METAL       165    165       Zinc. {ECO:0000269|PubMed:10196129,
FT                                ECO:0000269|PubMed:9218782,
FT                                ECO:0000269|Ref.47}.
FT   BINDING      26     26       Inositol-(1,3,4,5)-tetrakisphosphate.
FT                                {ECO:0000269|PubMed:10196129}.
FT   BINDING      28     28       Inositol-(1,3,4,5)-tetrakisphosphate.
FT                                {ECO:0000269|PubMed:10196129}.
FT   BINDING      39     39       Inositol-(1,3,4,5)-tetrakisphosphate.
FT                                {ECO:0000269|PubMed:10196129}.
FT   BINDING      53     53       Inositol-(1,3,4,5)-tetrakisphosphate; via
FT                                carbonyl oxygen.
FT                                {ECO:0000269|PubMed:10196129}.
FT   BINDING     430    430       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     445    445       Inhibitor. {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     461    461       Inhibitor. {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     477    477       Inhibitor. {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     538    538       Inhibitor. {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     539    539       Inhibitor; via amide nitrogen.
FT                                {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     542    542       Inhibitor; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.11}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000269|PubMed:16644721}.
FT   MOD_RES      40     40       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P35991}.
FT   MOD_RES      55     55       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     115    115       Phosphoserine.
FT                                {ECO:0000269|PubMed:16644721}.
FT   MOD_RES     180    180       Phosphoserine; by PKC/PRKCB.
FT                                {ECO:0000269|PubMed:11598012}.
FT   MOD_RES     191    191       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     223    223       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:12573241,
FT                                ECO:0000269|PubMed:17932028,
FT                                ECO:0000269|PubMed:8630736,
FT                                ECO:0000269|PubMed:9012831}.
FT   MOD_RES     344    344       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P35991}.
FT   MOD_RES     361    361       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     551    551       Phosphotyrosine; by LYN and SYK.
FT                                {ECO:0000269|PubMed:8630736,
FT                                ECO:0000269|PubMed:9012831}.
FT   MOD_RES     604    604       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     617    617       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15375214}.
FT   MOD_RES     623    623       Phosphoserine.
FT                                {ECO:0000269|PubMed:15375214}.
FT   MOD_RES     659    659       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ       1      1       M -> MASWSIQQMVIGCPLCGRHCSGGEHTGELQKEEAM
FT                                (in isoform BTK-C). {ECO:0000305}.
FT                                /FTId=VSP_053838.
FT   VARIANT      11     11       L -> P (in XLA).
FT                                /FTId=VAR_006216.
FT   VARIANT      12     12       K -> R (in XLA).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006217.
FT   VARIANT      14     14       S -> F (in XLA).
FT                                /FTId=VAR_006218.
FT   VARIANT      19     19       K -> E (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008291.
FT   VARIANT      25     25       F -> S (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006219.
FT   VARIANT      27     27       K -> R (in XLA).
FT                                /FTId=VAR_008292.
FT   VARIANT      28     28       R -> C (in XLA; no effect on
FT                                phosphorylation of GTF2I).
FT                                /FTId=VAR_008293.
FT   VARIANT      28     28       R -> H (in XLA; moderate;
FT                                dbSNP:rs128620185).
FT                                {ECO:0000269|PubMed:7849721,
FT                                ECO:0000269|PubMed:8162018,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006220.
FT   VARIANT      28     28       R -> P (in XLA).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006221.
FT   VARIANT      33     33       T -> P (in XLA; severe;
FT                                dbSNP:rs128620189).
FT                                {ECO:0000269|PubMed:7633429,
FT                                ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006222.
FT   VARIANT      39     39       Y -> S (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008960.
FT   VARIANT      40     40       Y -> C (in XLA).
FT                                /FTId=VAR_008294.
FT   VARIANT      40     40       Y -> N (in XLA).
FT                                /FTId=VAR_008295.
FT   VARIANT      61     61       I -> N (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008296.
FT   VARIANT      64     64       V -> D (in XLA).
FT                                /FTId=VAR_008297.
FT   VARIANT      64     64       V -> F (in XLA).
FT                                {ECO:0000269|PubMed:7849006}.
FT                                /FTId=VAR_006223.
FT   VARIANT      82     82       R -> K (in dbSNP:rs56035945).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041676.
FT   VARIANT     103    103       Q -> QSVFSSTR (in XLA).
FT                                /FTId=VAR_006224.
FT   VARIANT     113    113       V -> D (in XLA; dbSNP:rs128621190).
FT                                {ECO:0000269|PubMed:7849697}.
FT                                /FTId=VAR_006225.
FT   VARIANT     115    115       S -> F (in XLA).
FT                                /FTId=VAR_008298.
FT   VARIANT     117    117       T -> P (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008299.
FT   VARIANT     127    127       Q -> H (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008300.
FT   VARIANT     154    154       C -> S (in XLA).
FT                                {ECO:0000269|PubMed:9280283}.
FT                                /FTId=VAR_008301.
FT   VARIANT     155    155       C -> G (in XLA).
FT                                /FTId=VAR_008302.
FT   VARIANT     155    155       C -> R (in XLA).
FT                                {ECO:0000269|PubMed:9280283,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008303.
FT   VARIANT     184    184       T -> P (in XLA).
FT                                /FTId=VAR_008304.
FT   VARIANT     190    190       P -> K (in a lung large cell carcinoma
FT                                sample; somatic mutation; requires 2
FT                                nucleotide substitutions).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041677.
FT   VARIANT     260    280       Missing (in XLA; severe).
FT                                {ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006226.
FT   VARIANT     288    288       R -> Q (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008305.
FT   VARIANT     288    288       R -> W (in XLA; dbSNP:rs128621194).
FT                                {ECO:0000269|PubMed:7711734,
FT                                ECO:0000269|PubMed:8162018,
FT                                ECO:0000269|PubMed:8162056,
FT                                ECO:0000269|PubMed:8834236}.
FT                                /FTId=VAR_006227.
FT   VARIANT     295    295       L -> P (in XLA).
FT                                {ECO:0000269|PubMed:8723128,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006228.
FT   VARIANT     302    302       G -> E (in XLA).
FT                                {ECO:0000269|PubMed:7627183,
FT                                ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006230.
FT   VARIANT     302    302       G -> R (in XLA).
FT                                /FTId=VAR_008306.
FT   VARIANT     302    302       Missing (in XLA).
FT                                {ECO:0000269|PubMed:7633429}.
FT                                /FTId=VAR_006229.
FT   VARIANT     307    307       R -> G (in XLA; loss of activity;
FT                                dbSNP:rs128621195).
FT                                {ECO:0000269|PubMed:8162056}.
FT                                /FTId=VAR_006231.
FT   VARIANT     307    307       R -> T (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008307.
FT   VARIANT     308    308       D -> E (in XLA).
FT                                /FTId=VAR_008308.
FT   VARIANT     319    319       V -> A (in XLA; moderate).
FT                                /FTId=VAR_008309.
FT   VARIANT     334    334       Y -> S (in XLA; dbSNP:rs128621196).
FT                                {ECO:0000269|PubMed:7880320}.
FT                                /FTId=VAR_006232.
FT   VARIANT     358    358       L -> F (in XLA).
FT                                {ECO:0000269|PubMed:7897635}.
FT                                /FTId=VAR_006233.
FT   VARIANT     361    361       Y -> C (in XLA; mild; dbSNP:rs28935478).
FT                                {ECO:0000269|PubMed:7849697}.
FT                                /FTId=VAR_006234.
FT   VARIANT     362    362       H -> Q (in XLA).
FT                                /FTId=VAR_006235.
FT   VARIANT     364    364       H -> P (in XLA).
FT                                /FTId=VAR_006236.
FT   VARIANT     365    365       N -> Y (in XLA).
FT                                /FTId=VAR_006237.
FT   VARIANT     366    366       S -> F (in XLA).
FT                                /FTId=VAR_008310.
FT   VARIANT     369    369       L -> F (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008311.
FT   VARIANT     370    370       I -> M (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006238.
FT   VARIANT     372    372       R -> G (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008312.
FT   VARIANT     408    408       L -> P (in XLA; moderate;
FT                                dbSNP:rs128621198).
FT                                {ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006239.
FT   VARIANT     414    414       G -> R (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008313.
FT   VARIANT     418    418       Y -> H (in XLA; dbSNP:rs144079566).
FT                                /FTId=VAR_006240.
FT   VARIANT     429    429       I -> N (in XLA).
FT                                {ECO:0000269|PubMed:8634718}.
FT                                /FTId=VAR_006241.
FT   VARIANT     430    430       K -> E (in XLA; loss of phosphorylation
FT                                of GTF2I; dbSNP:rs128620184).
FT                                {ECO:0000269|PubMed:7809124}.
FT                                /FTId=VAR_006242.
FT   VARIANT     430    430       K -> R (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008314.
FT   VARIANT     445    445       E -> D (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008315.
FT   VARIANT     462    462       G -> D (in XLA).
FT                                /FTId=VAR_008316.
FT   VARIANT     462    462       G -> V (in XLA).
FT                                /FTId=VAR_008317.
FT   VARIANT     476    476       Y -> D (in XLA).
FT                                {ECO:0000269|PubMed:7627183}.
FT                                /FTId=VAR_006243.
FT   VARIANT     477    477       M -> R (in XLA).
FT                                {ECO:0000269|PubMed:8634718}.
FT                                /FTId=VAR_006244.
FT   VARIANT     481    481       C -> S (found in patients with chronic
FT                                lymphocytic leukemia; unknown
FT                                pathological significance; results in
FT                                resistance to ibrutinib therapy; results
FT                                in a protein that is reversibly inhibited
FT                                by ibrutinib; disrupts the covalent
FT                                binding between the enzyme and
FT                                ibrutinib). {ECO:0000269|PubMed:24869597,
FT                                ECO:0000269|PubMed:24869598,
FT                                ECO:0000269|PubMed:25189416}.
FT                                /FTId=VAR_074309.
FT   VARIANT     502    502       C -> F (in XLA).
FT                                /FTId=VAR_006245.
FT   VARIANT     502    502       C -> W (in XLA; dbSNP:rs41310709).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006246.
FT   VARIANT     506    506       C -> R (in XLA; dbSNP:rs128621200).
FT                                {ECO:0000269|PubMed:7880320}.
FT                                /FTId=VAR_006247.
FT   VARIANT     506    506       C -> Y (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006248.
FT   VARIANT     508    508       A -> D (in XLA).
FT                                /FTId=VAR_008318.
FT   VARIANT     509    509       M -> I (in XLA).
FT                                /FTId=VAR_008319.
FT   VARIANT     509    509       M -> V (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006249.
FT   VARIANT     512    512       L -> P (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008961.
FT   VARIANT     512    512       L -> Q (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008962.
FT   VARIANT     518    518       L -> R (in XLA).
FT                                /FTId=VAR_008320.
FT   VARIANT     520    520       R -> Q (in XLA; severe; prevents
FT                                activation due to absence of contact
FT                                between the catalytic loop and the
FT                                regulatory phosphorylated residue;
FT                                dbSNP:rs128621202).
FT                                {ECO:0000269|PubMed:7633429,
FT                                ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:7849697,
FT                                ECO:0000269|PubMed:7880320}.
FT                                /FTId=VAR_006251.
FT   VARIANT     521    521       D -> G (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008321.
FT   VARIANT     521    521       D -> H (in XLA; severe).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006252.
FT   VARIANT     521    521       D -> N (in XLA; severe).
FT                                /FTId=VAR_006253.
FT   VARIANT     523    523       A -> E (in XLA).
FT                                /FTId=VAR_008322.
FT   VARIANT     525    525       R -> G (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008323.
FT   VARIANT     525    525       R -> P (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006254.
FT   VARIANT     525    525       R -> Q (in XLA; severe; disturbs ATP-
FT                                binding; dbSNP:rs128620183).
FT                                {ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006255.
FT   VARIANT     526    526       N -> K (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006256.
FT   VARIANT     535    535       V -> F (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008324.
FT   VARIANT     542    542       L -> P (in XLA; growth hormone
FT                                deficiency; dbSNP:rs128621203).
FT                                {ECO:0000269|PubMed:7849697}.
FT                                /FTId=VAR_006257.
FT   VARIANT     544    544       R -> G (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008963.
FT   VARIANT     544    544       R -> K (in XLA).
FT                                {ECO:0000269|PubMed:8834236}.
FT                                /FTId=VAR_006258.
FT   VARIANT     559    559       F -> S (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008325.
FT   VARIANT     562    562       R -> P (in XLA; dbSNP:rs104894770).
FT                                {ECO:0000269|PubMed:10678660,
FT                                ECO:0000269|PubMed:7809124}.
FT                                /FTId=VAR_006259.
FT   VARIANT     562    562       R -> W (in XLA; dbSNP:rs128621204).
FT                                {ECO:0000269|PubMed:7711734,
FT                                ECO:0000269|PubMed:7849697,
FT                                ECO:0000269|PubMed:7880320,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006260.
FT   VARIANT     563    563       W -> L (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008326.
FT   VARIANT     567    567       E -> K (in XLA; severe).
FT                                {ECO:0000269|PubMed:7633420}.
FT                                /FTId=VAR_006261.
FT   VARIANT     578    578       S -> Y (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008964.
FT   VARIANT     581    581       W -> R (in XLA; dbSNP:rs128621205).
FT                                /FTId=VAR_006262.
FT   VARIANT     582    582       A -> V (in XLA).
FT                                {ECO:0000269|PubMed:7711734,
FT                                ECO:0000269|PubMed:7809124}.
FT                                /FTId=VAR_006263.
FT   VARIANT     583    583       F -> S (in XLA).
FT                                /FTId=VAR_008327.
FT   VARIANT     587    587       M -> L (in XLA; mild).
FT                                {ECO:0000269|PubMed:7633420}.
FT                                /FTId=VAR_006264.
FT   VARIANT     589    589       E -> D (in XLA).
FT                                /FTId=VAR_008328.
FT   VARIANT     589    589       E -> G (in XLA; moderate; interferes with
FT                                substrate binding; dbSNP:rs128621206).
FT                                {ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006265.
FT   VARIANT     589    589       E -> K (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008965.
FT   VARIANT     592    592       S -> P (in XLA).
FT                                {ECO:0000269|PubMed:8834236}.
FT                                /FTId=VAR_006267.
FT   VARIANT     594    594       G -> E (in XLA; mild; interferes with
FT                                substrate binding).
FT                                {ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006268.
FT   VARIANT     594    594       G -> R (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006269.
FT   VARIANT     598    598       Y -> C (in XLA).
FT                                /FTId=VAR_006270.
FT   VARIANT     607    607       A -> D (in XLA; mild; dbSNP:rs128621208).
FT                                {ECO:0000269|PubMed:8162056}.
FT                                /FTId=VAR_006271.
FT   VARIANT     613    613       G -> D (in XLA; mild; interferes with
FT                                substrate binding and/or domain
FT                                interactions; dbSNP:rs128621209).
FT                                {ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006272.
FT   VARIANT     619    619       P -> A (in XLA).
FT                                /FTId=VAR_008330.
FT   VARIANT     619    619       P -> S (in XLA).
FT                                /FTId=VAR_006273.
FT   VARIANT     619    619       P -> T (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008331.
FT   VARIANT     622    622       A -> P (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008332.
FT   VARIANT     626    626       V -> G (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008333.
FT   VARIANT     630    630       M -> I (polymorphism, 35%).
FT                                /FTId=VAR_006274.
FT   VARIANT     630    630       M -> K (in XLA; dbSNP:rs128621210).
FT                                {ECO:0000269|PubMed:7849697,
FT                                ECO:0000269|PubMed:7880320}.
FT                                /FTId=VAR_006275.
FT   VARIANT     630    630       M -> T (in XLA).
FT                                /FTId=VAR_008334.
FT   VARIANT     633    633       C -> Y (in XLA).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006276.
FT   VARIANT     641    641       R -> C (in XLA).
FT                                {ECO:0000269|PubMed:7633429}.
FT                                /FTId=VAR_006277.
FT   VARIANT     641    641       R -> H (in XLA; severe).
FT                                {ECO:0000269|PubMed:7633420,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006278.
FT   VARIANT     644    644       F -> L (in XLA).
FT                                /FTId=VAR_008335.
FT   VARIANT     644    644       F -> S (in XLA).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006279.
FT   VARIANT     647    647       L -> P (in XLA).
FT                                /FTId=VAR_006280.
FT   VARIANT     652    652       L -> P (in XLA; dbSNP:rs128622212).
FT                                {ECO:0000269|PubMed:7849697}.
FT                                /FTId=VAR_006281.
FT   MUTAGEN      41     41       E->K: No effect on phosphorylation of
FT                                GTF2I. {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     189    189       P->A: No effect on phosphorylation of
FT                                GTF2I. {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     223    223       Y->F: Loss of phosphorylation of GTF2I.
FT                                {ECO:0000269|PubMed:8630736,
FT                                ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     251    252       WW->LL: Large decrease in binding by
FT                                SH3BP5. {ECO:0000269|PubMed:9571151}.
FT   MUTAGEN     251    251       W->L: No effect on phosphorylation of
FT                                GTF2I. {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     307    307       R->K: Loss of phosphorylation of GTF2I.
FT                                {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     551    551       Y->F: Loss of phosphorylation of GTF2I.
FT                                {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     617    617       Y->E: Defective in mediating calcium
FT                                response. {ECO:0000269|PubMed:15375214}.
FT   CONFLICT    253    253       R -> K (in Ref. 7; BAG37008).
FT                                {ECO:0000305}.
FT   STRAND        6     13       {ECO:0000244|PDB:1BTK}.
FT   STRAND       18     20       {ECO:0000244|PDB:2Z0P}.
FT   STRAND       25     32       {ECO:0000244|PDB:1BTK}.
FT   STRAND       34     43       {ECO:0000244|PDB:1BTK}.
FT   TURN         44     47       {ECO:0000244|PDB:1BTK}.
FT   STRAND       48     57       {ECO:0000244|PDB:1BTK}.
FT   HELIX        58     60       {ECO:0000244|PDB:1BTK}.
FT   STRAND       61     66       {ECO:0000244|PDB:1BTK}.
FT   HELIX        75     77       {ECO:0000244|PDB:1BTK}.
FT   HELIX        93     96       {ECO:0000244|PDB:1BTK}.
FT   STRAND      100    106       {ECO:0000244|PDB:1BTK}.
FT   STRAND      111    116       {ECO:0000244|PDB:1BTK}.
FT   HELIX       118    132       {ECO:0000244|PDB:1BTK}.
FT   STRAND      140    142       {ECO:0000244|PDB:1BTK}.
FT   STRAND      149    152       {ECO:0000244|PDB:2Z0P}.
FT   TURN        153    155       {ECO:0000244|PDB:1BTK}.
FT   STRAND      165    167       {ECO:0000244|PDB:1BTK}.
FT   TURN        212    215       {ECO:0000244|PDB:1AWX}.
FT   STRAND      218    223       {ECO:0000244|PDB:1AWW}.
FT   STRAND      228    232       {ECO:0000244|PDB:1AWW}.
FT   STRAND      240    242       {ECO:0000244|PDB:1AWW}.
FT   STRAND      248    252       {ECO:0000244|PDB:1AWW}.
FT   TURN        257    259       {ECO:0000244|PDB:1QLY}.
FT   STRAND      261    265       {ECO:0000244|PDB:1AWX}.
FT   TURN        266    268       {ECO:0000244|PDB:1AWW}.
FT   STRAND      279    282       {ECO:0000244|PDB:2GE9}.
FT   HELIX       288    298       {ECO:0000244|PDB:2GE9}.
FT   STRAND      303    308       {ECO:0000244|PDB:2GE9}.
FT   STRAND      310    312       {ECO:0000244|PDB:2GE9}.
FT   STRAND      315    326       {ECO:0000244|PDB:2GE9}.
FT   STRAND      330    335       {ECO:0000244|PDB:2GE9}.
FT   STRAND      337    339       {ECO:0000244|PDB:2GE9}.
FT   TURN        340    342       {ECO:0000244|PDB:2GE9}.
FT   STRAND      343    347       {ECO:0000244|PDB:2GE9}.
FT   STRAND      350    354       {ECO:0000244|PDB:2GE9}.
FT   HELIX       355    363       {ECO:0000244|PDB:2GE9}.
FT   STRAND      373    376       {ECO:0000244|PDB:2GE9}.
FT   HELIX       393    395       {ECO:0000244|PDB:5J87}.
FT   HELIX       399    401       {ECO:0000244|PDB:5P9J}.
FT   STRAND      402    410       {ECO:0000244|PDB:5P9J}.
FT   TURN        411    413       {ECO:0000244|PDB:3P08}.
FT   STRAND      415    421       {ECO:0000244|PDB:5P9J}.
FT   TURN        422    424       {ECO:0000244|PDB:5P9J}.
FT   STRAND      425    431       {ECO:0000244|PDB:5P9J}.
FT   TURN        434    436       {ECO:0000244|PDB:5FBO}.
FT   HELIX       439    450       {ECO:0000244|PDB:5P9J}.
FT   STRAND      460    464       {ECO:0000244|PDB:5P9J}.
FT   STRAND      466    469       {ECO:0000244|PDB:5P9J}.
FT   STRAND      471    474       {ECO:0000244|PDB:5P9J}.
FT   HELIX       482    487       {ECO:0000244|PDB:5P9J}.
FT   HELIX       489    491       {ECO:0000244|PDB:5P9J}.
FT   HELIX       495    514       {ECO:0000244|PDB:5P9J}.
FT   TURN        524    526       {ECO:0000244|PDB:5P9J}.
FT   STRAND      527    529       {ECO:0000244|PDB:5P9I}.
FT   STRAND      535    537       {ECO:0000244|PDB:5P9J}.
FT   HELIX       542    545       {ECO:0000244|PDB:5P9J}.
FT   HELIX       549    551       {ECO:0000244|PDB:5P9J}.
FT   STRAND      556    559       {ECO:0000244|PDB:5P9M}.
FT   HELIX       561    563       {ECO:0000244|PDB:5P9J}.
FT   HELIX       566    571       {ECO:0000244|PDB:5P9J}.
FT   HELIX       576    591       {ECO:0000244|PDB:5P9J}.
FT   TURN        592    594       {ECO:0000244|PDB:5P9J}.
FT   TURN        597    600       {ECO:0000244|PDB:5P9J}.
FT   HELIX       603    611       {ECO:0000244|PDB:5P9J}.
FT   HELIX       624    632       {ECO:0000244|PDB:5P9J}.
FT   HELIX       638    640       {ECO:0000244|PDB:5P9J}.
FT   HELIX       644    657       {ECO:0000244|PDB:5P9J}.
SQ   SEQUENCE   659 AA;  76281 MW;  DF06B5D1FEC257CC CRC64;
     MAAVILESIF LKRSQQKKKT SPLNFKKRLF LLTVHKLSYY EYDFERGRRG SKKGSIDVEK
     ITCVETVVPE KNPPPERQIP RRGEESSEME QISIIERFPY PFQVVYDEGP LYVFSPTEEL
     RKRWIHQLKN VIRYNSDLVQ KYHPCFWIDG QYLCCSQTAK NAMGCQILEN RNGSLKPGSS
     HRKTKKPLPP TPEEDQILKK PLPPEPAAAP VSTSELKKVV ALYDYMPMNA NDLQLRKGDE
     YFILEESNLP WWRARDKNGQ EGYIPSNYVT EAEDSIEMYE WYSKHMTRSQ AEQLLKQEGK
     EGGFIVRDSS KAGKYTVSVF AKSTGDPQGV IRHYVVCSTP QSQYYLAEKH LFSTIPELIN
     YHQHNSAGLI SRLKYPVSQQ NKNAPSTAGL GYGSWEIDPK DLTFLKELGT GQFGVVKYGK
     WRGQYDVAIK MIKEGSMSED EFIEEAKVMM NLSHEKLVQL YGVCTKQRPI FIITEYMANG
     CLLNYLREMR HRFQTQQLLE MCKDVCEAME YLESKQFLHR DLAARNCLVN DQGVVKVSDF
     GLSRYVLDDE YTSSVGSKFP VRWSPPEVLM YSKFSSKSDI WAFGVLMWEI YSLGKMPYER
     FTNSETAEHI AQGLRLYRPH LASEKVYTIM YSCWHEKADE RPTFKILLSN ILDVMDEES
//
ID   Q5JY90_HUMAN            Unreviewed;       483 AA.
AC   Q5JY90;
DT   15-FEB-2005, integrated into UniProtKB/TrEMBL.
DT   15-FEB-2005, sequence version 1.
DT   28-FEB-2018, entry version 134.
DE   RecName: Full=Tyrosine-protein kinase {ECO:0000256|RuleBase:RU362096};
DE            EC=2.7.10.2 {ECO:0000256|RuleBase:RU362096};
GN   Name=BTK {ECO:0000313|EMBL:EAX02857.1,
GN   ECO:0000313|Ensembl:ENSP00000361971};
GN   ORFNames=hCG_20400 {ECO:0000313|EMBL:EAX02857.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000361971, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|EMBL:EAX02857.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:BAG51864.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Small intestine {ECO:0000313|EMBL:BAG51864.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4] {ECO:0000313|Ensembl:ENSP00000361971}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5] {ECO:0000313|EMBL:EAX02857.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6] {ECO:0000213|PubMed:19369195}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [7] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8] {ECO:0000313|Ensembl:ENSP00000361971}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (FEB-2012) to UniProtKB.
RN   [9] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10] {ECO:0000213|PubMed:25944712}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000256|RuleBase:RU362096}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000256|RuleBase:RU362096}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL035422; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK057105; BAG51864.1; -; mRNA.
DR   EMBL; CH471115; EAX02857.1; -; Genomic_DNA.
DR   RefSeq; NP_000052.1; NM_000061.2.
DR   RefSeq; NP_001274274.1; NM_001287345.1.
DR   UniGene; Hs.159494; -.
DR   UniGene; Hs.733206; -.
DR   SMR; Q5JY90; -.
DR   MaxQB; Q5JY90; -.
DR   PeptideAtlas; Q5JY90; -.
DR   DNASU; 695; -.
DR   Ensembl; ENST00000372880; ENSP00000361971; ENSG00000010671.
DR   GeneID; 695; -.
DR   KEGG; hsa:695; -.
DR   UCSC; uc010nnn.2; human.
DR   CTD; 695; -.
DR   EuPathDB; HostDB:ENSG00000010671.15; -.
DR   HGNC; HGNC:1133; BTK.
DR   OpenTargets; ENSG00000010671; -.
DR   PharmGKB; PA25454; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000119011; -.
DR   HOGENOM; HOG000233859; -.
DR   HOVERGEN; HBG008761; -.
DR   KO; K07370; -.
DR   ChiTaRS; BTK; human.
DR   GenomeRNAi; 695; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000010671; -.
DR   ExpressionAtlas; Q5JY90; baseline and differential.
DR   GO; GO:0005622; C:intracellular; IEA:GOC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   CDD; cd11906; SH3_BTK; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR035574; BTK_SH3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   ATP-binding {ECO:0000256|RuleBase:RU362096,
KW   ECO:0000256|SAAS:SAAS00990534};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Kinase {ECO:0000256|RuleBase:RU362096, ECO:0000256|SAAS:SAAS00897698};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00432};
KW   Nucleotide-binding {ECO:0000256|RuleBase:RU362096,
KW   ECO:0000256|SAAS:SAAS00990534};
KW   Proteomics identification {ECO:0000213|EPD:Q5JY90,
KW   ECO:0000213|MaxQB:Q5JY90, ECO:0000213|PeptideAtlas:Q5JY90};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   SH2 domain {ECO:0000256|PROSITE-ProRule:PRU00191};
KW   SH3 domain {ECO:0000256|PROSITE-ProRule:PRU00192,
KW   ECO:0000256|SAAS:SAAS00128814};
KW   Transferase {ECO:0000256|RuleBase:RU362096,
KW   ECO:0000256|SAAS:SAAS00897698};
KW   Tyrosine-protein kinase {ECO:0000256|RuleBase:RU362096,
KW   ECO:0000256|SAAS:SAAS00897698};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00432};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00432}.
FT   DOMAIN        3    133       PH. {ECO:0000259|PROSITE:PS50003}.
FT   DOMAIN      166    479       Protein kinase.
FT                                {ECO:0000259|PROSITE:PS50011}.
FT   DOMAIN      214    274       SH3. {ECO:0000259|PROSITE:PS50002}.
FT   DOMAIN      281    349       SH2. {ECO:0000259|PROSITE:PS50001}.
SQ   SEQUENCE   483 AA;  55881 MW;  EC1A5FB717810D71 CRC64;
     MAAVILESIF LKRSQQKKKT SPLNFKKRLF LLTVHKLSYY EYDFERGRRG SKKGSIDVEK
     ITCVETVVPE KNPPPERQIP RRGEESSEME QISIIERFPY PFQVVYDEGP LYVFSPTEEL
     RKRWIHQLKN VIRYNSDLVQ KYHPCFWIDG QYLCCSQTAK NAMGCQILEN RNGSLKPGSS
     HRKTKKPLPP TPEEDQILKK PLPPEPAAAP VSTSELKKVV ALYDYMPMNA NDLQLRKGDE
     YFILEESNLP WWRARDKNGQ EGYIPSNYVT EAEDSIEMYE WYSKHMTRSQ AEQLLKQEGK
     EGGFIVRDSS KAGKYTVSVF AKSTGDPQGV IRHYVVCSTP QSQYYLAARN CLVNDQGVVK
     VSDFGLSRYV LDDEYTSSVG SKFPVRWSPP EVLMYSKFSS KSDIWAFGVL MWEIYSLGKM
     PYERFTNSET AEHIAQGLRL YRPHLASEKV YTIMYSCWHE KADERPTFKI LLSNILDVMD
     EES
//
ID   CBLC_HUMAN              Reviewed;         474 AA.
AC   Q9ULV8; Q8N1E5; Q9Y5Z2; Q9Y5Z3;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 3.
DT   28-FEB-2018, entry version 170.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL-C;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173};
DE   AltName: Full=RING finger protein 57;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL-C {ECO:0000305};
DE   AltName: Full=SH3-binding protein CBL-3;
DE   AltName: Full=SH3-binding protein CBL-C;
DE   AltName: Full=Signal transduction protein CBL-C;
GN   Name=CBLC; Synonyms=CBL3, RNF57;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TYR-405.
RX   PubMed=10571044; DOI=10.1016/S0378-1119(99)00356-X;
RA   Kim M., Tezuka T., Suzuki Y., Sugano S., Hirai M., Yamamoto T.;
RT   "Molecular cloning and characterization of a novel cbl-family gene,
RT   cbl-c.";
RL   Gene 239:145-154(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), VARIANT TYR-405,
RP   FUNCTION AS EGF SIGNALING NEGATIVE REGULATOR, PHOSPHORYLATION BY EGFR
RP   (ISOFORM 1), TISSUE SPECIFICITY, AND INTERACTION WITH CRK AND LYN.
RC   TISSUE=Pancreatic adenocarcinoma;
RX   PubMed=10362357; DOI=10.1038/sj.onc.1202753;
RA   Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M.,
RA   Penninger J., Lipkowitz S.;
RT   "cbl-3: a new mammalian cbl family protein.";
RL   Oncogene 18:3365-3375(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION AS E3 UBIQUITIN-PROTEIN LIGASE, CATALYTIC ACTIVITY,
RP   INTERACTION WITH SRC, AUTOUBIQUITINATION, AND MUTAGENESIS OF GLY-276;
RP   TYR-341 AND CYS-351.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-
RT   dependent protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [5]
RP   FUNCTION IN RET STABILITY, INTERACTION WITH RET, AND MUTAGENESIS OF
RP   GLY-276 AND CYS-351.
RX   PubMed=18753381; DOI=10.1523/JNEUROSCI.2738-08.2008;
RA   Tsui C.C., Pierchala B.A.;
RT   "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the
RT   regulation of ret signal transduction.";
RL   J. Neurosci. 28:8789-8800(2008).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, DOMAIN, INTERACTION
RP   WITH UBE2D2 AND UBE2D3, PHOSPHORYLATION AT TYR-341, AND MUTAGENESIS OF
RP   TYR-341.
RX   PubMed=20525694; DOI=10.1074/jbc.M109.091157;
RA   Ryan P.E., Sivadasan-Nair N., Nau M.M., Nicholas S., Lipkowitz S.;
RT   "The N terminus of Cbl-c regulates ubiquitin ligase activity by
RT   modulating affinity for the ubiquitin-conjugating enzyme.";
RL   J. Biol. Chem. 285:23687-23698(2010).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOUBIQUITINATION, PHOSPHORYLATION AT
RP   TYR-341, INTERACTION WITH TGFB1I1, AND MUTAGENESIS OF TYR-341; CYS-351
RP   AND CYS-366.
RX   PubMed=23145173; DOI=10.1371/journal.pone.0049428;
RA   Ryan P.E., Kales S.C., Yadavalli R., Nau M.M., Zhang H., Lipkowitz S.;
RT   "Cbl-c ubiquitin ligase activity is increased via the interaction of
RT   its RING finger domain with a LIM domain of the paxillin homolog, Hic
RT   5.";
RL   PLoS ONE 7:E49428-E49428(2012).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 9-323 IN COMPLEX WITH EGFR
RP   PEPTIDE.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of Cbl-c (Cbl-3) TKB domain in complex with EGFR
RT   py1069 peptide.";
RL   Submitted (OCT-2010) to the PDB data bank.
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) OF 1-323 IN COMPLEX WITH
RP   CALCIUM; SRC AND EGFR PEPTIDES, CALCIUM-BINDING, INTERACTION WITH EGFR
RP   AND SRC, AND MUTAGENESIS OF TYR-244; ARG-264; PRO-265; SER-266;
RP   THR-268 AND GLY-276.
RX   PubMed=22888118; DOI=10.1093/jb/mvs085;
RA   Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M.,
RA   Yamanashi Y., Yamamoto T., Nakagawa A.;
RT   "Structural flexibility regulates phosphopeptide-binding activity of
RT   the tyrosine kinase binding domain of Cbl-c.";
RL   J. Biochem. 152:487-495(2012).
CC   -!- FUNCTION: Acts as an E3 ubiquitin-protein ligase, which accepts
CC       ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then
CC       transfers it to substrates promoting their degradation by the
CC       proteasome. Functionally coupled with the E2 ubiquitin-protein
CC       ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal
CC       transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1,
CC       but not isoform 2, inhibits EGF stimulated MAPK1 activation.
CC       Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In
CC       collaboration with CD2AP may act as regulatory checkpoint for Ret
CC       signaling by modulating the rate of RET degradation after ligand
CC       activation; CD2AP converts it from an inhibitor to a promoter of
CC       RET degradation; the function limits the potency of GDNF on
CC       neuronal survival. {ECO:0000269|PubMed:10362357,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18753381,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:14661060,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173}.
CC   -!- ENZYME REGULATION: Phosphorylation at Tyr-341 is necessary and
CC       sufficient for the activation of E3 activity.
CC       {ECO:0000269|PubMed:20525694}.
CC   -!- SUBUNIT: Interacts with ubiquitin-conjugating enzyme E2 UBE2D2 and
CC       UBE2D3. Isoform 1 interacts with EGFR (tyrosine phosphorylated).
CC       Interacts with the SH3 domain proteins LYN and CRK. Interacts (via
CC       RING-type zinc finger) with TGFB1I1 (via LIM zinc-binding domain
CC       2); the interaction is direct and enhances the E3 activity.
CC       Interacts directly with RET (inactive) and CD2AP; dissociates from
CC       RET upon RET activation by GDNF which also increases the
CC       interaction with CD2AP suggesting dissociation as CBLC:CD2AP
CC       complex. Interacts with SRC; the interaction is enhanced when SRC
CC       is phosphorylated at 'Tyr-419'. {ECO:0000269|PubMed:10362357,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18753381,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:22888118,
CC       ECO:0000269|PubMed:23145173, ECO:0000269|Ref.8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long;
CC         IsoId=Q9ULV8-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=Q9ULV8-2; Sequence=VSP_005732;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:10362357}.
CC   -!- DOMAIN: EF-hand-like and Sh2-like domains are required for N-
CC       terminal inhibition of E3 activity. {ECO:0000269|PubMed:20525694}.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding
CC       (PTB) domain, a short linker region and the RING-type zinc finger.
CC       The PTB domain, which is also called TKB (tyrosine kinase binding)
CC       domain, is composed of three different subdomains: a four-helix
CC       bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00839,
CC       ECO:0000269|PubMed:20525694}.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on multiple tyrosine residues by SRC. Isoform
CC       1, but not isoform 2, is phosphorylated on tyrosines by EGFR.
CC   -!- PTM: Autoubiquitinated when phosphorylated at Tyr-341, enhanced by
CC       SRC; suggesting proteasomal degradation.
CC       {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:20525694,
CC       ECO:0000269|PubMed:23145173}.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding
CC       site.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBLcID194.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB028645; BAA86298.1; -; mRNA.
DR   EMBL; AF117646; AAD34341.1; -; mRNA.
DR   EMBL; AF117647; AAD34342.1; -; mRNA.
DR   EMBL; BC028915; AAH28915.1; -; mRNA.
DR   CCDS; CCDS12643.1; -. [Q9ULV8-1]
DR   CCDS; CCDS46109.1; -. [Q9ULV8-2]
DR   RefSeq; NP_001124324.1; NM_001130852.1. [Q9ULV8-2]
DR   RefSeq; NP_036248.3; NM_012116.3. [Q9ULV8-1]
DR   UniGene; Hs.466907; -.
DR   PDB; 3OP0; X-ray; 2.52 A; A/B=9-323.
DR   PDB; 3VRN; X-ray; 1.64 A; A=1-323.
DR   PDB; 3VRO; X-ray; 1.80 A; A=1-323.
DR   PDB; 3VRP; X-ray; 1.52 A; A=1-323.
DR   PDB; 3VRQ; X-ray; 2.39 A; A/B=1-323.
DR   PDB; 3VRR; X-ray; 2.00 A; A=1-323.
DR   PDBsum; 3OP0; -.
DR   PDBsum; 3VRN; -.
DR   PDBsum; 3VRO; -.
DR   PDBsum; 3VRP; -.
DR   PDBsum; 3VRQ; -.
DR   PDBsum; 3VRR; -.
DR   ProteinModelPortal; Q9ULV8; -.
DR   SMR; Q9ULV8; -.
DR   BioGrid; 117156; 46.
DR   IntAct; Q9ULV8; 20.
DR   MINT; Q9ULV8; -.
DR   STRING; 9606.ENSP00000270279; -.
DR   iPTMnet; Q9ULV8; -.
DR   PhosphoSitePlus; Q9ULV8; -.
DR   BioMuta; CBLC; -.
DR   DMDM; 125987803; -.
DR   EPD; Q9ULV8; -.
DR   PaxDb; Q9ULV8; -.
DR   PeptideAtlas; Q9ULV8; -.
DR   PRIDE; Q9ULV8; -.
DR   DNASU; 23624; -.
DR   Ensembl; ENST00000270279; ENSP00000270279; ENSG00000142273. [Q9ULV8-1]
DR   Ensembl; ENST00000341505; ENSP00000340250; ENSG00000142273. [Q9ULV8-2]
DR   GeneID; 23624; -.
DR   KEGG; hsa:23624; -.
DR   UCSC; uc002ozs.4; human. [Q9ULV8-1]
DR   CTD; 23624; -.
DR   DisGeNET; 23624; -.
DR   EuPathDB; HostDB:ENSG00000142273.10; -.
DR   GeneCards; CBLC; -.
DR   H-InvDB; HIX0202847; -.
DR   HGNC; HGNC:15961; CBLC.
DR   HPA; CAB008087; -.
DR   HPA; HPA035266; -.
DR   MIM; 608453; gene.
DR   neXtProt; NX_Q9ULV8; -.
DR   OpenTargets; ENSG00000142273; -.
DR   PharmGKB; PA26117; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   eggNOG; ENOG410YDNH; LUCA.
DR   GeneTree; ENSGT00390000011617; -.
DR   HOGENOM; HOG000294176; -.
DR   HOVERGEN; HBG005255; -.
DR   InParanoid; Q9ULV8; -.
DR   KO; K04707; -.
DR   OMA; WQHSDSQ; -.
DR   OrthoDB; EOG091G06R9; -.
DR   PhylomeDB; Q9ULV8; -.
DR   TreeFam; TF314210; -.
DR   SignaLink; Q9ULV8; -.
DR   SIGNOR; Q9ULV8; -.
DR   GeneWiki; CBLC; -.
DR   GenomeRNAi; 23624; -.
DR   PRO; PR:Q9ULV8; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000142273; -.
DR   CleanEx; HS_CBLC; -.
DR   Genevisible; Q9ULV8; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IDA:BHF-UCL.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IDA:BHF-UCL.
DR   GO; GO:0004871; F:signal transducer activity; IEA:InterPro.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007175; P:negative regulation of epidermal growth factor-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   Gene3D; 1.20.930.20; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR036537; Adaptor_Cbl_N_dom_sf.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; PTHR23007; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF47668; SSF47668; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; SH3-binding; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    474       E3 ubiquitin-protein ligase CBL-C.
FT                                /FTId=PRO_0000055866.
FT   DOMAIN        7    321       Cbl-PTB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00839}.
FT   CA_BIND     199    210
FT   ZN_FING     351    390       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        7    145       4H.
FT   REGION      146    218       EF-hand-like.
FT   REGION      219    321       SH2-like.
FT   REGION      322    350       Linker.
FT   REGION      351    474       Interaction with RET.
FT                                {ECO:0000269|PubMed:18753381}.
FT   BINDING     264    264       Phosphotyrosine.
FT   MOD_RES     341    341       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20525694,
FT                                ECO:0000269|PubMed:23145173}.
FT   VAR_SEQ     261    306       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10362357}.
FT                                /FTId=VSP_005732.
FT   VARIANT     405    405       H -> Y (in dbSNP:rs3208856).
FT                                {ECO:0000269|PubMed:10362357,
FT                                ECO:0000269|PubMed:10571044}.
FT                                /FTId=VAR_018298.
FT   MUTAGEN     244    244       Y->A: Abolishes interaction with EGFR.
FT                                Decreases interaction with SRC and
FT                                abolishes SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     244    244       Y->F: No effect on interaction with EGFR
FT                                and SRC as well as on SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     264    264       R->A: Abolishes interaction with EGFR.
FT                                Decreases interaction with SRC and
FT                                abolishes SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     265    265       P->L: Enhances interaction with EGFR and
FT                                SRC as well as SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     266    266       S->A: Decreases interactions with EGFR
FT                                and SRC as well as SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     268    268       T->A: Abolishes interaction with EGFR.
FT                                Decreases interaction with and
FT                                ubiquitination of SRC.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     276    276       G->E: No effect on interaction with RET.
FT                                Binds slightly to SRC, this interaction
FT                                is independent of SRC phosphorylation.
FT                                Strongly decreases SRC ubiquitination.
FT                                Abolishes interaction with EGFR.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:18753381,
FT                                ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     341    341       Y->E: Induces E3 activity and
FT                                autoubiquitination. Releases ubiquitin-
FT                                conjugating enzyme E2 UBE2D2 faster.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:20525694,
FT                                ECO:0000269|PubMed:23145173}.
FT   MUTAGEN     341    341       Y->F: Abolishes activation by EGF
FT                                stimulation and enhancement by TGFB1I1 of
FT                                E3 activity.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:20525694,
FT                                ECO:0000269|PubMed:23145173}.
FT   MUTAGEN     341    341       Missing: Abolishes E3 activity.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:20525694,
FT                                ECO:0000269|PubMed:23145173}.
FT   MUTAGEN     351    351       C->A: No effect on TGFB1I1 and SRC
FT                                interactions. Abolishes SRC
FT                                ubiquitination. Abolishes interaction
FT                                with TGFB1I1; when associated with A-366.
FT                                Abolishes interaction with RET and
FT                                inhibition of RET degradation.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:18753381,
FT                                ECO:0000269|PubMed:23145173}.
FT   MUTAGEN     366    366       C->A: Abolishes interaction with TGFB1I1.
FT                                Abolishes interaction with TGFB1I1; when
FT                                associated with A-351.
FT                                {ECO:0000269|PubMed:23145173}.
FT   CONFLICT    234    234       N -> T (in Ref. 1; BAA86298).
FT                                {ECO:0000305}.
FT   CONFLICT    413    413       S -> P (in Ref. 3; AAH28915).
FT                                {ECO:0000305}.
FT   HELIX        13     31       {ECO:0000244|PDB:3VRP}.
FT   STRAND       40     42       {ECO:0000244|PDB:3OP0}.
FT   HELIX        44     62       {ECO:0000244|PDB:3VRP}.
FT   STRAND       64     66       {ECO:0000244|PDB:3VRP}.
FT   HELIX        76     97       {ECO:0000244|PDB:3VRP}.
FT   STRAND      100    102       {ECO:0000244|PDB:3OP0}.
FT   HELIX       108    111       {ECO:0000244|PDB:3OP0}.
FT   HELIX       116    138       {ECO:0000244|PDB:3VRP}.
FT   HELIX       140    142       {ECO:0000244|PDB:3VRP}.
FT   TURN        146    148       {ECO:0000244|PDB:3VRP}.
FT   HELIX       154    164       {ECO:0000244|PDB:3VRP}.
FT   STRAND      168    171       {ECO:0000244|PDB:3VRP}.
FT   HELIX       172    179       {ECO:0000244|PDB:3VRP}.
FT   TURN        180    182       {ECO:0000244|PDB:3VRP}.
FT   HELIX       189    198       {ECO:0000244|PDB:3VRP}.
FT   STRAND      203    207       {ECO:0000244|PDB:3VRP}.
FT   HELIX       208    217       {ECO:0000244|PDB:3VRP}.
FT   HELIX       221    223       {ECO:0000244|PDB:3VRP}.
FT   HELIX       224    232       {ECO:0000244|PDB:3VRP}.
FT   STRAND      238    241       {ECO:0000244|PDB:3VRQ}.
FT   HELIX       244    251       {ECO:0000244|PDB:3VRP}.
FT   HELIX       252    254       {ECO:0000244|PDB:3VRP}.
FT   STRAND      260    265       {ECO:0000244|PDB:3VRP}.
FT   STRAND      267    269       {ECO:0000244|PDB:3VRP}.
FT   STRAND      273    278       {ECO:0000244|PDB:3VRP}.
FT   STRAND      284    287       {ECO:0000244|PDB:3VRP}.
FT   HELIX       294    303       {ECO:0000244|PDB:3VRP}.
FT   HELIX       320    323       {ECO:0000244|PDB:3OP0}.
SQ   SEQUENCE   474 AA;  52456 MW;  202634AEDE434544 CRC64;
     MALAVAPWGR QWEEARALGR AVRMLQRLEE QCVDPRLSVS PPSLRDLLPR TAQLLREVAH
     SRRAAGGGGP GGPGGSGDFL LIYLANLEAK SRQVAALLPP RGRRSANDEL FRAGSRLRRQ
     LAKLAIIFSH MHAELHALFP GGKYCGHMYQ LTKAPAHTFW RESCGARCVL PWAEFESLLG
     TCHPVEPGCT ALALRTTIDL TCSGHVSIFE FDVFTRLFQP WPTLLKNWQL LAVNHPGYMA
     FLTYDEVQER LQACRDKPGS YIFRPSCTRL GQWAIGYVSS DGSILQTIPA NKPLSQVLLE
     GQKDGFYLYP DGKTHNPDLT ELGQAEPQQR IHVSEEQLQL YWAMDSTFEL CKICAESNKD
     VKIEPCGHLL CSCCLAAWQH SDSQTCPFCR CEIKGWEAVS IYQFHGQATA EDSGNSSDQE
     GRELELGQVP LSAPPLPPRP DLPPRKPRNA QPKVRLLKGN SPPAALGPQD PAPA
//
ID   CUX1_HUMAN              Reviewed;        1505 AA.
AC   P39880; B3KV79; J3KQV9; Q6NYH4; Q75LE5; Q75MT2; Q75MT3; Q86UJ7;
AC   Q9UEV5;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   28-FEB-2018, entry version 172.
DE   RecName: Full=Homeobox protein cut-like 1;
DE   AltName: Full=CCAAT displacement protein;
DE            Short=CDP;
DE   AltName: Full=Homeobox protein cux-1;
GN   Name=CUX1; Synonyms=CUTL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Umbilical vein;
RX   PubMed=1301999; DOI=10.1038/ng0492-50;
RA   Neufeld E.J., Skalnik D.G., Lievens P.M.-J., Orkin S.H.;
RT   "Human CCAAT displacement protein is homologous to the Drosophila
RT   homeoprotein, cut.";
RL   Nat. Genet. 1:50-55(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 11).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 48-224 (ISOFORMS 1/2/3).
RX   PubMed=9799793;
RA   Gloeckner G., Scherer S., Schattevoy R., Boright A.P., Weber J.,
RA   Tsui L.-C., Rosenthal A.;
RT   "Large-scale sequencing of two regions in human chromosome 7q22:
RT   analysis of 650 kb of genomic sequence around the EPO and CUTL1 loci
RT   reveals 17 genes.";
RL   Genome Res. 8:1060-1073(1998).
RN   [6]
RP   ALTERNATIVE SPLICING (ISOFORMS 5; 6 AND 7).
RX   PubMed=10607901; DOI=10.1016/S0378-1119(99)00465-5;
RA   Rong Zeng W., Soucie E., Sung Moon N., Martin-Soudant N., Berube G.,
RA   Leduy L., Nepveu A.;
RT   "Exon/intron structure and alternative transcripts of the CUTL1
RT   gene.";
RL   Gene 241:75-85(2000).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-763, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1059; SER-1270; SER-1455
RP   AND SER-1486, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-540
RP   (ISOFORM 11), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-811, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [15]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-785, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-785; LYS-811; LYS-842 AND
RP   LYS-1284, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Probably has a broad role in mammalian development as a
CC       repressor of developmentally regulated gene expression. May act by
CC       preventing binding of positively-activing CCAAT factors to
CC       promoters. Component of nf-munr repressor; binds to the matrix
CC       attachment regions (MARs) (5' and 3') of the immunoglobulin heavy
CC       chain enhancer. Represses T-cell receptor (TCR) beta enhancer
CC       function by binding to MARbeta, an ATC-rich DNA sequence located
CC       upstream of the TCR beta enhancer. Binds to the TH enhancer; may
CC       require the basic helix-loop-helix protein TCF4 as a coactivator
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with BANP. Interacts with SATB1 (via DNA-
CC       binding domains); the interaction inhibits the attachment of both
CC       proteins to DNA (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P39880-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P39880-2; Sequence=VSP_002310;
CC       Name=3;
CC         IsoId=P39880-3; Sequence=VSP_015747;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=P39880-4; Sequence=VSP_017358;
CC       Name=6;
CC         IsoId=P39880-5; Sequence=VSP_017359;
CC       Name=7;
CC         IsoId=P39880-6; Sequence=VSP_017358, VSP_017359;
CC       Name=11;
CC         IsoId=P39880-9; Sequence=VSP_015747, VSP_045924, VSP_045925,
CC                                  VSP_045926;
CC         Note=No experimental confirmation available. Contains a
CC         phosphoserine at position 540. {ECO:0000244|PubMed:23186163};
CC       Name=4; Synonyms=CASP;
CC         IsoId=Q13948-1; Sequence=External;
CC       Name=8;
CC         IsoId=Q13948-2; Sequence=External;
CC         Note=No experimental confirmation available.;
CC       Name=9;
CC         IsoId=Q13948-9; Sequence=External;
CC         Note=No experimental confirmation available.;
CC       Name=10;
CC         IsoId=Q13948-10; Sequence=External;
CC         Note=No experimental confirmation available.;
CC   -!- MISCELLANEOUS: Asn-1290 may participate in regulating DNA-binding
CC       activity by promoting homo- and heterodimerization.
CC   -!- SIMILARITY: Belongs to the CUT homeobox family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M74099; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK122726; BAG53691.1; -; mRNA.
DR   EMBL; AC005072; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005086; AAP22331.1; -; Genomic_DNA.
DR   EMBL; AC005088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005096; AAS07410.1; -; Genomic_DNA.
DR   EMBL; AC005103; AAS07388.1; -; Genomic_DNA.
DR   EMBL; AC092788; AAS07523.1; -; Genomic_DNA.
DR   EMBL; BC066592; AAH66592.1; -; mRNA.
DR   EMBL; AF047825; AAC78778.1; -; Genomic_DNA.
DR   CCDS; CCDS56498.1; -. [P39880-3]
DR   CCDS; CCDS56499.1; -. [P39880-9]
DR   CCDS; CCDS5721.1; -. [P39880-1]
DR   RefSeq; NP_001189472.1; NM_001202543.1. [P39880-3]
DR   RefSeq; NP_001189473.1; NM_001202544.2.
DR   RefSeq; NP_001189474.1; NM_001202545.2. [P39880-9]
DR   RefSeq; NP_852477.1; NM_181500.3.
DR   RefSeq; NP_853530.2; NM_181552.3. [P39880-1]
DR   UniGene; Hs.191482; -.
DR   ProteinModelPortal; P39880; -.
DR   SMR; P39880; -.
DR   BioGrid; 107903; 56.
DR   ELM; P39880; -.
DR   IntAct; P39880; 26.
DR   MINT; P39880; -.
DR   STRING; 9606.ENSP00000353401; -.
DR   iPTMnet; P39880; -.
DR   PhosphoSitePlus; P39880; -.
DR   BioMuta; UGT3A1; -.
DR   EPD; P39880; -.
DR   PaxDb; P39880; -.
DR   PeptideAtlas; P39880; -.
DR   PRIDE; P39880; -.
DR   DNASU; 1523; -.
DR   Ensembl; ENST00000292535; ENSP00000292535; ENSG00000257923. [P39880-1]
DR   Ensembl; ENST00000360264; ENSP00000353401; ENSG00000257923. [P39880-3]
DR   Ensembl; ENST00000425244; ENSP00000409745; ENSG00000257923. [P39880-9]
DR   Ensembl; ENST00000546411; ENSP00000450125; ENSG00000257923. [P39880-4]
DR   Ensembl; ENST00000549414; ENSP00000446630; ENSG00000257923. [P39880-2]
DR   Ensembl; ENST00000550008; ENSP00000447373; ENSG00000257923. [P39880-5]
DR   Ensembl; ENST00000556210; ENSP00000451558; ENSG00000257923. [P39880-6]
DR   GeneID; 1523; -.
DR   UCSC; uc003uys.5; human. [P39880-1]
DR   CTD; 1523; -.
DR   DisGeNET; 1523; -.
DR   EuPathDB; HostDB:ENSG00000257923.9; -.
DR   GeneCards; CUX1; -.
DR   HGNC; HGNC:2557; CUX1.
DR   HPA; HPA003277; -.
DR   HPA; HPA003317; -.
DR   MIM; 116896; gene.
DR   neXtProt; NX_P39880; -.
DR   OpenTargets; ENSG00000257923; -.
DR   PharmGKB; PA162382924; -.
DR   eggNOG; KOG0963; Eukaryota.
DR   eggNOG; KOG2252; Eukaryota.
DR   eggNOG; ENOG410XPKP; LUCA.
DR   GeneTree; ENSGT00530000063019; -.
DR   HOVERGEN; HBG051268; -.
DR   InParanoid; P39880; -.
DR   OMA; VANWRRT; -.
DR   OrthoDB; EOG091G011E; -.
DR   PhylomeDB; P39880; -.
DR   TreeFam; TF318206; -.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   SIGNOR; P39880; -.
DR   ChiTaRS; CUX1; human.
DR   GeneWiki; CUTL1; -.
DR   GenomeRNAi; 1523; -.
DR   PMAP-CutDB; P39880; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000257923; -.
DR   CleanEx; HS_CUX1; -.
DR   ExpressionAtlas; P39880; baseline and differential.
DR   Genevisible; P39880; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0030674; F:protein binding, bridging; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0048193; P:Golgi vesicle transport; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0000301; P:retrograde transport, vesicle recycling within Golgi; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00086; homeodomain; 1.
DR   InterPro; IPR003350; CUT_dom.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR010982; Lambda_DNA-bd_dom_sf.
DR   Pfam; PF02376; CUT; 3.
DR   Pfam; PF00046; Homeobox; 1.
DR   SMART; SM01109; CUT; 3.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   SUPFAM; SSF47413; SSF47413; 3.
DR   PROSITE; PS51042; CUT; 3.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Complete proteome;
KW   Developmental protein; DNA-binding; Homeobox; Isopeptide bond;
KW   Nucleus; Phosphoprotein; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN         1   1505       Homeobox protein cut-like 1.
FT                                /FTId=PRO_0000202393.
FT   DNA_BIND    542    629       CUT 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00374}.
FT   DNA_BIND    934   1021       CUT 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00374}.
FT   DNA_BIND   1117   1204       CUT 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00374}.
FT   DNA_BIND   1244   1303       Homeobox. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00108}.
FT   COILED       56    407       {ECO:0000255}.
FT   COMPBIAS   1406   1438       Ala-rich.
FT   MOD_RES     763    763       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     909    909       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P53565}.
FT   MOD_RES    1059   1059       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1069   1069       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P53565}.
FT   MOD_RES    1270   1270       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1337   1337       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P53564}.
FT   MOD_RES    1455   1455       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1486   1486       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1496   1496       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P53564}.
FT   CROSSLNK    785    785       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    811    811       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    842    842       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK   1284   1284       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ       1     10       MLCVAGARLK -> MAANVGSMFQYWKRFDLQQLQ (in
FT                                isoform 3 and isoform 11).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015747.
FT   VAR_SEQ      90    135       Missing (in isoform 11).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045924.
FT   VAR_SEQ     408    509       Missing (in isoform 5 and isoform 7).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_017358.
FT   VAR_SEQ     409    667       SARRKGKDQPESRRPGSLPAPPPSQLPRNPGEQASNTNGTH
FT                                QFSPAGLSQDFFSSSLASPSLPLASTGKFALNSLLQRQLMQ
FT                                SFYSKAMQEAGSTSMIFSTGPYSTNSISSQSPLQQSPDVNG
FT                                MAPSPSQSESAGSVSEGEEMDTAEIARQVKEQLIKHNIGQR
FT                                IFGHYVLGLSQGSVSEILARPKPWNKLTVRGKEPFHKMKQF
FT                                LSDEQNILALRSIQGRQRENPGQSLNRLFQEVPKRRNGSEG
FT                                NITTRIRASETGS -> RCAELQVRITEAVATATEQRELIA
FT                                RLEQDLSIIQSIQRPDAEGAAEHRLEKIPEPIKEATALFYG
FT                                PAAPASGALPEGQVDSLLSIISSQRERFRARNQELEAENRL
FT                                AQHTLQALQSELDSLRADNIKLFEKIKFLQSYPGRGSGSDD
FT                                TELRYSSQYEERLDPFSSFSKRERQRKYLSLSPWDKATLSM
FT                                GRLVLSNKMARTIGFFYTLFLHCLVFLVLYKLAWSESMERD
FT                                CATFCAKKFADHLHKFHENDNGAAAGDLWQ (in
FT                                isoform 11).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045925.
FT   VAR_SEQ     632    687       Missing (in isoform 6 and isoform 7).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_017359.
FT   VAR_SEQ     632    653       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1301999}.
FT                                /FTId=VSP_002310.
FT   VAR_SEQ     668   1505       Missing (in isoform 11).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045926.
FT   CONFLICT      5      5       A -> R (in Ref. 1; M74099).
FT                                {ECO:0000305}.
FT   CONFLICT    145    145       K -> I (in Ref. 2; BAG53691).
FT                                {ECO:0000305}.
FT   CONFLICT    260    260       A -> V (in Ref. 2; BAG53691).
FT                                {ECO:0000305}.
FT   CONFLICT    704    705       DA -> EP (in Ref. 1; M74099).
FT                                {ECO:0000305}.
FT   CONFLICT    844    844       E -> R (in Ref. 1; M74099).
FT                                {ECO:0000305}.
FT   CONFLICT   1436   1436       S -> T (in Ref. 1; M74099).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1505 AA;  164187 MW;  0F9027E5B8F08D95 CRC64;
     MLCVAGARLK RELDATATVL ANRQDESEQS RKRLIEQSRE FKKNTPEDLR KQVAPLLKSF
     QGEIDALSKR SKEAEAAFLN VYKRLIDVPD PVPALDLGQQ LQLKVQRLHD IETENQKLRE
     TLEEYNKEFA EVKNQEVTIK ALKEKIREYE QTLKNQAETI ALEKEQKLQN DFAEKERKLQ
     ETQMSTTSKL EEAEHKVQSL QTALEKTRTE LFDLKTKYDE ETTAKADEIE MIMTDLERAN
     QRAEVAQREA ETLREQLSSA NHSLQLASQI QKAPDVEQAI EVLTRSSLEV ELAAKEREIA
     QLVEDVQRLQ ASLTKLRENS ASQISQLEQQ LSAKNSTLKQ LEEKLKGQAD YEEVKKELNI
     LKSMEFAPSE GAGTQDAAKP LEVLLLEKNR SLQSENAALR ISNSDLSGSA RRKGKDQPES
     RRPGSLPAPP PSQLPRNPGE QASNTNGTHQ FSPAGLSQDF FSSSLASPSL PLASTGKFAL
     NSLLQRQLMQ SFYSKAMQEA GSTSMIFSTG PYSTNSISSQ SPLQQSPDVN GMAPSPSQSE
     SAGSVSEGEE MDTAEIARQV KEQLIKHNIG QRIFGHYVLG LSQGSVSEIL ARPKPWNKLT
     VRGKEPFHKM KQFLSDEQNI LALRSIQGRQ RENPGQSLNR LFQEVPKRRN GSEGNITTRI
     RASETGSDEA IKSILEQAKR ELQVQKTAEP AQPSSASGSG NSDDAIRSIL QQARREMEAQ
     QAALDPALKQ APLSQSDITI LTPKLLSTSP MPTVSSYPPL AISLKKPSAA PEAGASALPN
     PPALKKEAQD APGLDPQGAA DCAQGVLRQV KNEVGRSGAW KDHWWSAVQP ERRNAASSEE
     AKAEETGGGK EKGSGGSGGG SQPRAERSQL QGPSSSEYWK EWPSAESPYS QSSELSLTGA
     SRSETPQNSP LPSSPIVPMS KPTKPSVPPL TPEQYEVYMY QEVDTIELTR QVKEKLAKNG
     ICQRIFGEKV LGLSQGSVSD MLSRPKPWSK LTQKGREPFI RMQLWLNGEL GQGVLPVQGQ
     QQGPVLHSVT SLQDPLQQGC VSSESTPKTS ASCSPAPESP MSSSESVKSL TELVQQPCPP
     IEASKDSKPP EPSDPPASDS QPTTPLPLSG HSALSIQELV AMSPELDTYG ITKRVKEVLT
     DNNLGQRLFG ETILGLTQGS VSDLLARPKP WHKLSLKGRE PFVRMQLWLN DPNNVEKLMD
     MKRMEKKAYM KRRHSSVSDS QPCEPPSVGT EYSQGASPQP QHQLKKPRVV LAPEEKEALK
     RAYQQKPYPS PKTIEDLATQ LNLKTSTVIN WFHNYRSRIR RELFIEEIQA GSQGQAGASD
     SPSARSGRAA PSSEGDSCDG VEATEGPGSA DTEEPKSQGE AEREEVPRPA EQTEPPPSGT
     PGPDDARDDD HEGGPVEGPG PLPSPASATA TAAPAAPEDA ATSAAAAPGE GPAAPSSAPP
     PSNSSSSSAP RRPSSLQSLF GLPEAAGARD SRDNPLRKKK AANLNSIIHR LEKAASREEP
     IEWEF
//
ID   CASP_HUMAN              Reviewed;         678 AA.
AC   Q13948; B3KWH3; B3KWH8; B4DZZ2; G3V1Z6; J3KPQ6; Q53GU9; Q8TBS3;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   10-JAN-2006, sequence version 2.
DT   28-FEB-2018, entry version 121.
DE   RecName: Full=Protein CASP;
GN   Name=CUX1; Synonyms=CUTL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical vein;
RX   PubMed=9332351; DOI=10.1016/S0378-1119(97)00243-6;
RA   Lievens P.M.-J., Tufarelli C., Donady J.J., Stagg A., Neufeld E.J.;
RT   "CASP, a novel, highly conserved alternative-splicing product of the
RT   CDP/cut/cux gene, lacks cut-repeat and homeo DNA-binding domains, and
RT   interacts with full-length CDP in vitro.";
RL   Gene 197:73-81(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 9 AND 10), AND
RP   VARIANT THR-464.
RC   TISSUE=Thalamus, Thymus, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   THR-464.
RC   TISSUE=Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   VAL-545.
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   ALTERNATIVE SPLICING.
RX   PubMed=10607901; DOI=10.1016/S0378-1119(99)00465-5;
RA   Rong Zeng W., Soucie E., Sung Moon N., Martin-Soudant N., Berube G.,
RA   Leduy L., Nepveu A.;
RT   "Exon/intron structure and alternative transcripts of the CUTL1
RT   gene.";
RL   Gene 241:75-85(2000).
RN   [8]
RP   SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, SUBUNIT, AND MUTAGENESIS
RP   OF TYR-624 AND HIS-629.
RX   PubMed=12429822; DOI=10.1091/mbc.E02-06-0349;
RA   Gillingham A.K., Pfeifer A.C., Munro S.;
RT   "CASP, the alternatively spliced product of the gene encoding the
RT   CCAAT-displacement protein transcription factor, is a Golgi membrane
RT   protein related to giantin.";
RL   Mol. Biol. Cell 13:3761-3774(2002).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH GOLGA5.
RX   PubMed=15718469; DOI=10.1126/science.1108061;
RA   Malsam J., Satoh A., Pelletier L., Warren G.;
RT   "Golgin tethers define subpopulations of COPI vesicles.";
RL   Science 307:1095-1098(2005).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-586, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-490 AND CYS-609.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: May be involved in intra-Golgi retrograde transport.
CC       {ECO:0000269|PubMed:15718469}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Interacts with GOLGA5.
CC       {ECO:0000269|PubMed:12429822, ECO:0000269|PubMed:15718469}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:12429822}; Single-pass type IV membrane
CC       protein {ECO:0000269|PubMed:12429822}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=4; Synonyms=CASP;
CC         IsoId=Q13948-1; Sequence=Displayed;
CC       Name=11;
CC         IsoId=P39880-9; Sequence=External;
CC         Note=No experimental confirmation available. Contains a
CC         phosphoserine at position 540.;
CC       Name=1;
CC         IsoId=P39880-1; Sequence=External;
CC       Name=2;
CC         IsoId=P39880-2; Sequence=External;
CC       Name=3;
CC         IsoId=P39880-3; Sequence=External;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=P39880-4; Sequence=External;
CC       Name=6;
CC         IsoId=P39880-5; Sequence=External;
CC       Name=7;
CC         IsoId=P39880-6; Sequence=External;
CC       Name=8;
CC         IsoId=Q13948-2; Sequence=VSP_040094;
CC         Note=No experimental confirmation available.;
CC       Name=9;
CC         IsoId=Q13948-9; Sequence=VSP_045593, VSP_040094;
CC         Note=No experimental confirmation available.;
CC       Name=10;
CC         IsoId=Q13948-10; Sequence=VSP_045927;
CC         Note=No experimental confirmation available.;
CC   -!- SIMILARITY: Belongs to the CASP family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CUX1ID403ch7q22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L12579; AAA35654.1; -; mRNA.
DR   EMBL; AK125076; BAG54135.1; -; mRNA.
DR   EMBL; AK125097; BAG54140.1; -; mRNA.
DR   EMBL; AK303151; BAG64254.1; -; mRNA.
DR   EMBL; AK222832; BAD96552.1; -; mRNA.
DR   EMBL; AC005072; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005086; AAP22331.1; -; Genomic_DNA.
DR   EMBL; AC005088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005096; AAS07410.1; -; Genomic_DNA.
DR   EMBL; AC005103; AAS07388.1; -; Genomic_DNA.
DR   EMBL; AC092788; AAS07523.1; -; Genomic_DNA.
DR   EMBL; CH471197; EAW50227.1; -; Genomic_DNA.
DR   EMBL; BC025422; AAH25422.1; -; mRNA.
DR   CCDS; CCDS47672.1; -. [Q13948-2]
DR   CCDS; CCDS56500.1; -. [Q13948-10]
DR   CCDS; CCDS5720.1; -. [Q13948-1]
DR   CCDS; CCDS59071.1; -. [Q13948-9]
DR   RefSeq; NP_001189473.1; NM_001202544.2. [Q13948-10]
DR   RefSeq; NP_001189474.1; NM_001202545.2.
DR   RefSeq; NP_001189475.1; NM_001202546.2. [Q13948-9]
DR   RefSeq; NP_001904.2; NM_001913.4. [Q13948-1]
DR   RefSeq; NP_852477.1; NM_181500.3. [Q13948-2]
DR   UniGene; Hs.191482; -.
DR   ProteinModelPortal; Q13948; -.
DR   SMR; Q13948; -.
DR   BioGrid; 107903; 56.
DR   IntAct; Q13948; 1.
DR   MINT; Q13948; -.
DR   iPTMnet; Q13948; -.
DR   BioMuta; HSPA4L; -.
DR   DMDM; 85681028; -.
DR   EPD; Q13948; -.
DR   MaxQB; Q13948; -.
DR   PeptideAtlas; Q13948; -.
DR   PRIDE; Q13948; -.
DR   DNASU; 1523; -.
DR   Ensembl; ENST00000292538; ENSP00000292538; ENSG00000257923. [Q13948-1]
DR   Ensembl; ENST00000393824; ENSP00000377410; ENSG00000257923. [Q13948-9]
DR   Ensembl; ENST00000437600; ENSP00000414091; ENSG00000257923. [Q13948-1]
DR   Ensembl; ENST00000547394; ENSP00000449371; ENSG00000257923. [Q13948-10]
DR   Ensembl; ENST00000622516; ENSP00000484760; ENSG00000257923. [Q13948-2]
DR   GeneID; 1523; -.
DR   KEGG; hsa:1523; -.
DR   UCSC; uc003uyt.4; human. [Q13948-1]
DR   CTD; 1523; -.
DR   DisGeNET; 1523; -.
DR   EuPathDB; HostDB:ENSG00000257923.9; -.
DR   GeneCards; CUX1; -.
DR   HGNC; HGNC:2557; CUX1.
DR   HPA; HPA003317; -.
DR   MIM; 116896; gene.
DR   neXtProt; NX_Q13948; -.
DR   OpenTargets; ENSG00000257923; -.
DR   PharmGKB; PA162382924; -.
DR   eggNOG; KOG0963; Eukaryota.
DR   eggNOG; KOG2252; Eukaryota.
DR   eggNOG; ENOG410XPKP; LUCA.
DR   GeneTree; ENSGT00530000063019; -.
DR   HOVERGEN; HBG053415; -.
DR   KO; K09313; -.
DR   BioCyc; MetaCyc:ENSG00000170275-MONOMER; -.
DR   Reactome; R-HSA-6811438; Intra-Golgi traffic.
DR   SignaLink; Q13948; -.
DR   ChiTaRS; CUX1; human.
DR   GenomeRNAi; 1523; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000257923; -.
DR   CleanEx; HS_CUX1; -.
DR   ExpressionAtlas; Q13948; baseline and differential.
DR   Genevisible; Q13948; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0030173; C:integral component of Golgi membrane; IEA:InterPro.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0006891; P:intra-Golgi vesicle-mediated transport; IEA:InterPro.
DR   InterPro; IPR012955; CASP_C.
DR   Pfam; PF08172; CASP_C; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Complete proteome; Disulfide bond;
KW   Golgi apparatus; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    678       Protein CASP.
FT                                /FTId=PRO_0000071790.
FT   TOPO_DOM      1    619       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    620    640       Helical; Anchor for type IV membrane
FT                                protein. {ECO:0000255}.
FT   TOPO_DOM    641    678       Lumenal. {ECO:0000255}.
FT   COILED       67    450       {ECO:0000255}.
FT   COILED      502    556       {ECO:0000255}.
FT   MOD_RES     586    586       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ      22     58       Missing (in isoform 9).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045593.
FT   VAR_SEQ      58     73       Missing (in isoform 10).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045927.
FT   VAR_SEQ     288    289       Missing (in isoform 8 and isoform 9).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_040094.
FT   VARIANT     464    464       A -> T (in dbSNP:rs803064).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_024923.
FT   VARIANT     490    490       S -> G (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036285.
FT   VARIANT     545    545       I -> V (in dbSNP:rs2230103).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_024924.
FT   VARIANT     609    609       R -> C (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036286.
FT   MUTAGEN     624    624       Y->L: Retained in the endoplasmic
FT                                reticulum. {ECO:0000269|PubMed:12429822}.
FT   MUTAGEN     629    629       H->L: No effect on subcellular location.
FT                                {ECO:0000269|PubMed:12429822}.
FT   CONFLICT    407    407       N -> S (in Ref. 6; AAH25422).
FT                                {ECO:0000305}.
FT   CONFLICT    455    455       I -> V (in Ref. 2; BAG64254).
FT                                {ECO:0000305}.
FT   CONFLICT    525    525       L -> V (in Ref. 2; BAG64254).
FT                                {ECO:0000305}.
FT   CONFLICT    551    551       I -> V (in Ref. 3; BAD96552).
FT                                {ECO:0000305}.
FT   CONFLICT    613    613       S -> P (in Ref. 2; BAG54140).
FT                                {ECO:0000305}.
FT   CONFLICT    657    657       F -> L (in Ref. 1; AAA35654).
FT                                {ECO:0000305}.
SQ   SEQUENCE   678 AA;  77455 MW;  E587F222825EA47E CRC64;
     MAANVGSMFQ YWKRFDLQQL QRELDATATV LANRQDESEQ SRKRLIEQSR EFKKNTPEDL
     RKQVAPLLKS FQGEIDALSK RSKEAEAAFL NVYKRLIDVP DPVPALDLGQ QLQLKVQRLH
     DIETENQKLR ETLEEYNKEF AEVKNQEVTI KALKEKIREY EQTLKNQAET IALEKEQKLQ
     NDFAEKERKL QETQMSTTSK LEEAEHKVQS LQTALEKTRT ELFDLKTKYD EETTAKADEI
     EMIMTDLERA NQRAEVAQRE AETLREQLSS ANHSLQLASQ IQKAPDVEQA IEVLTRSSLE
     VELAAKEREI AQLVEDVQRL QASLTKLREN SASQISQLEQ QLSAKNSTLK QLEEKLKGQA
     DYEEVKKELN ILKSMEFAPS EGAGTQDAAK PLEVLLLEKN RSLQSENAAL RISNSDLSGR
     CAELQVRITE AVATATEQRE LIARLEQDLS IIQSIQRPDA EGAAEHRLEK IPEPIKEATA
     LFYGPAAPAS GALPEGQVDS LLSIISSQRE RFRARNQELE AENRLAQHTL QALQSELDSL
     RADNIKLFEK IKFLQSYPGR GSGSDDTELR YSSQYEERLD PFSSFSKRER QRKYLSLSPW
     DKATLSMGRL VLSNKMARTI GFFYTLFLHC LVFLVLYKLA WSESMERDCA TFCAKKFADH
     LHKFHENDNG AAAGDLWQ
//
ID   Q3LIA3_HUMAN            Unreviewed;       484 AA.
AC   Q3LIA3;
DT   08-NOV-2005, integrated into UniProtKB/TrEMBL.
DT   08-NOV-2005, sequence version 1.
DT   31-JAN-2018, entry version 64.
DE   SubName: Full=Uncharacterized protein Nbla10317 {ECO:0000313|EMBL:BAE45765.1};
GN   Name=Nbla10317 {ECO:0000313|EMBL:BAE45765.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAE45765.1};
RN   [1] {ECO:0000313|EMBL:BAE45765.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Ohira M., Morohashi A., Nakagawara A.;
RT   "A large-scale cloning from oligo-capping cDNA libraries of primary
RT   neuroblastoma.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB075522; BAE45765.1; -; mRNA.
DR   RefSeq; NP_852477.1; NM_181500.3.
DR   UniGene; Hs.191482; -.
DR   ProteinModelPortal; Q3LIA3; -.
DR   PeptideAtlas; Q3LIA3; -.
DR   PRIDE; Q3LIA3; -.
DR   DNASU; 1523; -.
DR   GeneID; 1523; -.
DR   CTD; 1523; -.
DR   eggNOG; KOG0963; Eukaryota.
DR   eggNOG; KOG2252; Eukaryota.
DR   eggNOG; ENOG410XPKP; LUCA.
DR   HOVERGEN; HBG053415; -.
DR   ChiTaRS; CUX1; human.
DR   GenomeRNAi; 1523; -.
DR   Genevisible; Q3LIA3; HS.
DR   GO; GO:0030173; C:integral component of Golgi membrane; IEA:InterPro.
DR   GO; GO:0006891; P:intra-Golgi vesicle-mediated transport; IEA:InterPro.
DR   InterPro; IPR012955; CASP_C.
DR   Pfam; PF08172; CASP_C; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Membrane {ECO:0000256|SAM:Phobius};
KW   Transmembrane {ECO:0000256|SAM:Phobius};
KW   Transmembrane helix {ECO:0000256|SAM:Phobius}.
FT   TRANSMEM    422    443       Helical. {ECO:0000256|SAM:Phobius}.
FT   DOMAIN      229    447       CASP_C. {ECO:0000259|Pfam:PF08172}.
FT   COILED        7     34       {ECO:0000256|SAM:Coils}.
FT   COILED       43     80       {ECO:0000256|SAM:Coils}.
FT   COILED      102    136       {ECO:0000256|SAM:Coils}.
FT   COILED      141    161       {ECO:0000256|SAM:Coils}.
FT   COILED      234    254       {ECO:0000256|SAM:Coils}.
FT   COILED      308    356       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   484 AA;  54552 MW;  741887B67FABD936 CRC64;
     MSTTSKLEEA EHKVQSLQTA LEKTRTELFD LKTKYDEETT AKADEIEMIM TDLERANQRA
     EVAQREAETL REQLSSANHS LQLASQIQKA PDVEQAIEVL TRSSLEVELA AKEREIAQLV
     EDVQRLQASL TKLRENSASQ ISQLEQQLSA KNSTLKQLEE KLKGQADYEE VKKELNILKS
     MEFAPSEGAG TQDAAKPLEV LLLEKNRSLQ SENAALRISN SGLSGRCAEL QVRITEAVAT
     ATEQRELIAR LEQDLSIIQS IQRPDAEGAA EHRLEKIPEP IKEATALFYG PAAPASGALP
     EGQVDSLLSI ISSQRERFRA RNQELEAENR LAQHTLQALQ SELDSLRADN IKLFEKIKFL
     QSYPGRGSGS DDTELRYSSQ YEERLDPFSS FSKRERQRKY LSLSPWDKAT LSMGRLVLSN
     KMARTIGFFY TLFLHCLVFL ALYKLAWSES MERDCATFCA KKFADHLHKF HENDNGAAAG
     DLWQ
//
ID   A0A024RCS3_HUMAN        Unreviewed;       740 AA.
AC   A0A024RCS3;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-FEB-2018, entry version 30.
DE   SubName: Full=DAXX {ECO:0000313|EMBL:AQY76765.1};
DE   SubName: Full=Death-associated protein 6, isoform CRA_a {ECO:0000313|EMBL:EAX03723.1};
GN   Name=DAXX {ECO:0000313|EMBL:EAX03723.1};
GN   ORFNames=hCG_17515 {ECO:0000313|EMBL:EAX03723.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAX03723.1};
RN   [1] {ECO:0000313|EMBL:EAX03723.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX03723.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:AQY76765.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Norman P.J., Norberg S.J., Nemat-Gorgani N., Ronaghi M., Parham P.;
RT   "CDS alleles of MHC region genes derived from homozygous
RT   individuals.";
RL   Submitted (MAR-2017) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; KY500277; AQY76765.1; -; Genomic_DNA.
DR   EMBL; KY500278; AQY76766.1; -; Genomic_DNA.
DR   EMBL; KY500279; AQY76767.1; -; Genomic_DNA.
DR   EMBL; KY500281; AQY76769.1; -; Genomic_DNA.
DR   EMBL; KY500282; AQY76770.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03723.1; -; Genomic_DNA.
DR   RefSeq; NP_001135441.1; NM_001141969.1.
DR   RefSeq; NP_001341.1; NM_001350.4.
DR   UniGene; Hs.336916; -.
DR   ProteinModelPortal; A0A024RCS3; -.
DR   SMR; A0A024RCS3; -.
DR   PRIDE; A0A024RCS3; -.
DR   GeneID; 1616; -.
DR   KEGG; hsa:1616; -.
DR   CTD; 1616; -.
DR   EuPathDB; HostDB:ENSG00000204209.10; -.
DR   eggNOG; ENOG410IGIP; Eukaryota.
DR   eggNOG; ENOG4111K0B; LUCA.
DR   KO; K02308; -.
DR   OMA; LCKTQTA; -.
DR   OrthoDB; EOG09370P3D; -.
DR   PhylomeDB; A0A024RCS3; -.
DR   ChiTaRS; DAXX; human.
DR   GenomeRNAi; 1616; -.
DR   Bgee; ENSG00000204209; -.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   CDD; cd13151; DAXX_helical_bundle; 1.
DR   InterPro; IPR005012; Daxx.
DR   InterPro; IPR031333; Daxx_N.
DR   PANTHER; PTHR12766; PTHR12766; 1.
DR   Pfam; PF03344; Daxx; 1.
PE   4: Predicted;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN       50    145       Daxx. {ECO:0000259|Pfam:PF03344}.
FT   COILED      188    208       {ECO:0000256|SAM:Coils}.
FT   COILED      379    399       {ECO:0000256|SAM:Coils}.
FT   COILED      435    484       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   740 AA;  81373 MW;  1B309ADDAA878040 CRC64;
     MATANSIIVL DDDDEDEAAA QPGPSHPLPN AASPGAEAPS SSEPHGARGS SSSGGKKCYK
     LENEKLFEEF LELCKMQTAD HPEVVPFLYN RQQRAHSLFL ASAEFCNILS RVLSRARSRP
     AKLYVYINEL CTVLKAHSAK KKLNLAPAAT TSNEPSGNNP PTHLSLDPTN AENTASQSPR
     TRGSRRQIQR LEQLLALYVA EIRRLQEKEL DLSELDDPDS AYLQEARLKR KLIRLFGRLC
     ELKDCSSLTG RVIEQRIPYR GTRYPEVNRR IERLINKPGP DTFPDYGDVL RAVEKAAARH
     SLGLPRQQLQ LMAQDAFRDV GIRLQERRHL DLIYNFGCHL TDDYRPGVDP ALSDPVLARR
     LRENRSLAMS RLDEVISKYA MLQDKSEEGE RKKRRARLQG TSSHSADTPE ASLDSGEGPS
     GMASQGCPSA SRAETDDEDD EESDEEEEEE EEEEEEEATD SEEEEDLEQM QEGQEDDEEE
     DEEEEAAAGK DGDKSPMSSL QISNEKNLEP GKQISRSSGE QQNKGRIVSP SLLSEEPLAP
     SSIDAESNGE QPEELTLEEE SPVSQLFELE IEALPLDTPS SVETDISSSR KQSEEPFTTV
     LENGAGMVSS TSFNGGVSPH NWGDSGPPCK KSRKEKKQTG SGPLGNSYVE RQRSVHEKNG
     KKICTLPSPP SPLASLAPVA DSSTRVDSPS HGLVTSSLCI PSPARLSQTP HSQPPRPGTC
     KTSVATQCDP EEIIVLSDSD
//
ID   B4E1C1_HUMAN            Unreviewed;       752 AA.
AC   B4E1C1;
DT   23-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   23-SEP-2008, sequence version 1.
DT   28-FEB-2018, entry version 57.
DE   SubName: Full=cDNA FLJ55943, highly similar to Death domain-associated protein 6 {ECO:0000313|EMBL:BAG64733.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG64733.1};
RN   [1] {ECO:0000313|EMBL:BAG64733.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver {ECO:0000313|EMBL:BAG64733.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK303767; BAG64733.1; -; mRNA.
DR   RefSeq; NP_001135442.1; NM_001141970.1.
DR   UniGene; Hs.336916; -.
DR   ProteinModelPortal; B4E1C1; -.
DR   MaxQB; B4E1C1; -.
DR   PeptideAtlas; B4E1C1; -.
DR   PRIDE; B4E1C1; -.
DR   DNASU; 1616; -.
DR   GeneID; 1616; -.
DR   CTD; 1616; -.
DR   PharmGKB; PA27148; -.
DR   eggNOG; ENOG410IGIP; Eukaryota.
DR   eggNOG; ENOG4111K0B; LUCA.
DR   HOVERGEN; HBG031495; -.
DR   GenomeRNAi; 1616; -.
DR   Genevisible; B4E1C1; HS.
DR   CDD; cd13151; DAXX_helical_bundle; 1.
DR   InterPro; IPR005012; Daxx.
DR   InterPro; IPR031333; Daxx_N.
DR   PANTHER; PTHR12766; PTHR12766; 1.
DR   Pfam; PF03344; Daxx; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN       62    157       Daxx. {ECO:0000259|Pfam:PF03344}.
FT   COILED      200    220       {ECO:0000256|SAM:Coils}.
FT   COILED      391    411       {ECO:0000256|SAM:Coils}.
FT   COILED      447    496       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   752 AA;  82876 MW;  564F283805B26479 CRC64;
     MRGSENCGEG RLERRFLSII VLDDDDEDEA AAQPGPSHPL PNAASPGAEA PSSSEPHGAR
     GSSSSGGKKC YKLENEKLFE EFLELCKMQT ADHPEVVPFL YNRQQRAHSL FLASAEFCNI
     LSRVLSRARS RPAKLYVYIN ELCTVLKAHS AKKKLNLAPA ATTSNEPSGN NPPTHLSLDP
     TNAENTASQS PRTRGSRRQI QRLEQLLALY VAEIRRLQEK ELDLSELDDP DSAYLQEARL
     KRKLIRLFGR LCELKDCSSL TGRVIEQRIP YRGTRYPEVN RRIERLINKP GPDTFPDYGD
     VLRAVEKAAA RHSLGLPRQQ LQLMAQDAFR DVGIRLQERR HLDLIYNFGC HLTDDYRPGV
     DPALSDPVLA RRLRENRSLA MSRLDEVISK YAMLQDKSEE GERKKRRARL QGTSSHSADT
     PEASLDSGEG PSGMASQGCP SASRAETDDE DDEESDEEEE EEEEEEEEEA TDSEEEEDLE
     QMQEGQEDDE EEDEEEEAAA GKDGDKSPMS SLQISNEKNL EPGKQISRSS GEQQNKGRIV
     SPSLLSEEPL APSSIDAESN GEQPEELTLE EESPVSQLFE LEIEALPLDT PSSVETDISS
     SRKQSEEPFT TVLENGAGMV SSTSFNGGVS PHNWGDSGPP CKKSRKEKKQ TGSGPLGNSY
     VERQRSVHEK NGKKICTLPS PPSPLASLAP VADSSTRVDS PSHGLVTSSL CIPSPARLSQ
     TPHSQPPRPG TCKTSVATQC DPEEIIVLSD SD
//
ID   Q53F85_HUMAN            Unreviewed;       740 AA.
AC   Q53F85;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   28-FEB-2018, entry version 63.
DE   SubName: Full=Death-associated protein 6 variant {ECO:0000313|EMBL:BAD97124.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD97124.1};
RN   [1] {ECO:0000313|EMBL:BAD97124.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=8125298; DOI=10.1016/0378-1119(94)90802-8;
RA   Maruyama K., Sugano S.;
RT   "Oligo-capping: a simple method to replace the cap structure of
RT   eukaryotic mRNAs with oligoribonucleotides.";
RL   Gene 138:171-174(1994).
RN   [2] {ECO:0000313|EMBL:BAD97124.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=9373149; DOI=10.1016/S0378-1119(97)00411-3;
RA   Suzuki Y., Yoshitomo K., Maruyama K., Suyama A., Sugano S.;
RT   "Construction and characterization of a full length-enriched and a 5'-
RT   end-enriched cDNA library.";
RL   Gene 200:149-156(1997).
RN   [3] {ECO:0000313|EMBL:BAD97124.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK223404; BAD97124.1; -; mRNA.
DR   RefSeq; NP_001135441.1; NM_001141969.1.
DR   UniGene; Hs.336916; -.
DR   PeptideAtlas; Q53F85; -.
DR   PRIDE; Q53F85; -.
DR   DNASU; 1616; -.
DR   GeneID; 1616; -.
DR   KEGG; hsa:1616; -.
DR   CTD; 1616; -.
DR   PharmGKB; PA27148; -.
DR   eggNOG; ENOG410IGIP; Eukaryota.
DR   eggNOG; ENOG4111K0B; LUCA.
DR   HOVERGEN; HBG031495; -.
DR   KO; K02308; -.
DR   GenomeRNAi; 1616; -.
DR   Genevisible; Q53F85; HS.
DR   CDD; cd13151; DAXX_helical_bundle; 1.
DR   InterPro; IPR005012; Daxx.
DR   InterPro; IPR031333; Daxx_N.
DR   PANTHER; PTHR12766; PTHR12766; 1.
DR   Pfam; PF03344; Daxx; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN       50    145       Daxx. {ECO:0000259|Pfam:PF03344}.
FT   COILED      188    208       {ECO:0000256|SAM:Coils}.
FT   COILED      379    399       {ECO:0000256|SAM:Coils}.
FT   COILED      435    484       {ECO:0000256|SAM:Coils}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:BAD97124.1}.
SQ   SEQUENCE   740 AA;  81228 MW;  046B3A2A3BAC65E7 CRC64;
     MATANSIIVL DDDDEDEAAA QPGPSHPLPN AASPGAEAPS SSEPHGARGS SSSGGKKCYK
     LENEKLCEEF LGLCKMQTAD HPEVVPFLYN RQQRAHSLFL ASAEFCNILS RVLSRARSRP
     AKLYVYINEL CTVLKAHSAK KKLNLAPAAT TSNEPSGNNP PTHLSLDPTN AENTASQSPR
     TRGSRRQIQR LEQLLALYVA EIRRLQEKEL DLSELDDPDS AYLQEARLKR KLIRLFGRLC
     ELKDCSSLTG RVIEQRIPYR GTRYPEVNRR IERLINKPGP DTFPDYGDVL RAVEKAAARH
     SLGLPRQQLQ LMAQDAFRDA GIRLQERRHL DLIYNFGCHL TDDYRPGVDP ALSDPVLARR
     LRENRSLAMS RLDEVISKYA MLQDKSEEGE RKKRRARLQG TSSHSADTPE ASLDSGEGPS
     GMASQGCPSA SRAETDDEDD EESDEEEEEE EEEEEEEATD SEEEEDLEQM QEGQEDDEEE
     DEEEEAAAGK DGDKSPMSSL QISNEKNLEP GKQISRSSGE QQNKGRIVSP SLLSEEPLAP
     SSIDAESNGE QPEELTLEEE SPVSQLFELE IEALPLDTPS SVETDISSSR KQSEEPFTTV
     LENGAGMVSS TSFNGGVSPH NWGDSGPPCK KSRKEKKQTG SGPLGNSYVE RQRSVHEKNG
     KKICTLPSPP SPLASLAPVA DSSTRVDSPS HGLVTSSLCI PSPARLSQTP HSQPPRPGTC
     KTSVATQCDP EEIIVLSDSD
//
ID   DAXX_HUMAN              Reviewed;         740 AA.
AC   Q9UER7; B4E1I3; F5ANJ6; F5ANJ7; F5H082; O14747; O15141; O15208;
AC   Q5STK9; Q9BWI3;
DT   01-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-2002, sequence version 2.
DT   28-FEB-2018, entry version 179.
DE   RecName: Full=Death domain-associated protein 6;
DE   AltName: Full=Daxx;
DE            Short=hDaxx;
DE   AltName: Full=ETS1-associated protein 1;
DE            Short=EAP1;
DE   AltName: Full=Fas death domain-associated protein;
GN   Name=DAXX; Synonyms=BING2, DAP6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9215629; DOI=10.1016/S0092-8674(00)80294-9;
RA   Yang X., Khosravi-Far R., Chang H.Y., Baltimore D.;
RT   "Daxx, a novel Fas-binding protein that activates JNK and apoptosis.";
RL   Cell 89:1067-1076(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=9407001; DOI=10.1089/dna.1997.16.1289;
RA   Kiriakidou M., Driscoll D.A., Lopez-Guisa J.M., Strauss J.F. III;
RT   "Cloning and expression of primate Daxx cDNAs and mapping of the human
RT   gene to chromosome 6p21.3 in the MHC region.";
RL   DNA Cell Biol. 16:1289-1298(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH CENPC, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9645950;
RA   Pluta A.F., Earnshaw W.C., Goldberg I.G.;
RT   "Interphase-specific association of intrinsic centromere protein CENP-
RT   C with HDaxx, a death domain-binding protein implicated in Fas-
RT   mediated cell death.";
RL   J. Cell Sci. 111:2029-2041(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=9545376; DOI=10.1006/jmbi.1998.1637;
RA   Herberg J.A., Beck S., Trowsdale J.;
RT   "TAPASIN, DAXX, RGL2, HKE2 and four new genes (BING 1, 3 to 5) form a
RT   dense cluster at the centromeric end of the MHC.";
RL   J. Mol. Biol. 277:839-857(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=10698492; DOI=10.1038/sj.onc.1203385;
RA   Li R., Pei H., Watson D.K., Papas T.S.;
RT   "EAP1/Daxx interacts with ETS1 and represses transcriptional
RT   activation of ETS1 target genes.";
RL   Oncogene 19:745-753(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BETA AND GAMMA), SUBCELLULAR
RP   LOCATION (ISOFORMS BETA AND GAMMA), AND ALTERNATIVE SPLICING.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=21482821; DOI=10.1074/jbc.M110.196311;
RA   Wethkamp N., Hanenberg H., Funke S., Suschek C.V., Wetzel W.,
RA   Heikaus S., Grinstein E., Ramp U., Engers R., Gabbert H.E.,
RA   Mahotka C.;
RT   "Daxx-beta and Daxx-gamma, two novel splice variants of the
RT   transcriptional co-repressor Daxx.";
RL   J. Biol. Chem. 286:19576-19588(2011).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Usui T.;
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 334-740 (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   INTERACTION WITH PAX3 AND PAX7, AND PHOSPHORYLATION.
RX   PubMed=10393185; DOI=10.1093/emboj/18.13.3702;
RA   Hollenbach A.D., Sublett J.E., McPherson C.J., Grosveld G.;
RT   "The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated
RT   repressor hDaxx.";
RL   EMBO J. 18:3702-3711(1999).
RN   [14]
RP   INTERACTION WITH PML.
RX   PubMed=10684855; DOI=10.1084/jem.191.4.631;
RA   Zhong S., Salomoni P., Ronchetti S., Guo A., Ruggero D.,
RA   Pandolfi P.P.;
RT   "Promyelocytic leukemia protein (PML) and Daxx participate in a novel
RT   nuclear pathway for apoptosis.";
RL   J. Exp. Med. 191:631-640(2000).
RN   [15]
RP   INTERACTION WITH SUMOYLATED PML; HDAC1; HDAC2 AND HDAC3, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=10669754; DOI=10.1128/MCB.20.5.1784-1796.2000;
RA   Li H., Leo C., Zhu J., Wu X., O'Neil J., Park E.-J., Chen J.D.;
RT   "Sequestration and inhibition of Daxx-mediated transcriptional
RT   repression by PML.";
RL   Mol. Cell. Biol. 20:1784-1796(2000).
RN   [16]
RP   INTERACTION WITH HSPB1.
RX   PubMed=11003656; DOI=10.1128/MCB.20.20.7602-7612.2000;
RA   Charette S.J., Lavoie J.N., Lambert H., Landry J.;
RT   "Inhibition of Daxx-mediated apoptosis by heat shock protein 27.";
RL   Mol. Cell. Biol. 20:7602-7612(2000).
RN   [17]
RP   INTERACTION WITH MAP3K5, AND SUBCELLULAR LOCATION.
RX   PubMed=11495919; DOI=10.1074/jbc.M105928200;
RA   Ko Y.-G., Kang Y.-S., Park H., Seol W., Kim J., Kim T., Park H.-S.,
RA   Choi E.-J., Kim S.;
RT   "Apoptosis signal-regulating kinase 1 controls the proapoptotic
RT   function of death-associated protein (Daxx) in the cytoplasm.";
RL   J. Biol. Chem. 276:39103-39106(2001).
RN   [18]
RP   INTERACTION WITH TGFBR2.
RX   PubMed=11483955; DOI=10.1038/35087019;
RA   Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.;
RT   "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx
RT   that facilitates JNK activation.";
RL   Nat. Cell Biol. 3:708-714(2001).
RN   [19]
RP   SUMOYLATION AT LYS-630 AND LYS-631, AND MUTAGENESIS OF LYS-630 AND
RP   LYS-631.
RX   PubMed=12150977; DOI=10.1016/S0006-291X(02)00699-X;
RA   Jang M.-S., Ryu S.-W., Kim E.;
RT   "Modification of Daxx by small ubiquitin-related modifier-1.";
RL   Biochem. Biophys. Res. Commun. 295:495-500(2002).
RN   [20]
RP   INTERACTION WITH SLC2A4 AND UBE2I, SUMOYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11842083; DOI=10.1074/jbc.M110294200;
RA   Lalioti V.S., Vergarajauregui S., Pulido D., Sandoval I.V.;
RT   "The insulin-sensitive glucose transporter, GLUT4, interacts
RT   physically with Daxx. Two proteins with capacity to bind Ubc9 and
RT   conjugated to SUMO1.";
RL   J. Biol. Chem. 277:19783-19791(2002).
RN   [21]
RP   INTERACTION WITH MCRS1.
RX   PubMed=11948183; DOI=10.1074/jbc.M200633200;
RA   Lin D.-Y., Shih H.-M.;
RT   "Essential role of the 58-kDa microspherule protein in the modulation
RT   of Daxx-dependent transcriptional repression as revealed by nucleolar
RT   sequestration.";
RL   J. Biol. Chem. 277:25446-25456(2002).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH HDAC2; HISTONES AND
RP   DEK.
RX   PubMed=12140263;
RA   Hollenbach A.D., McPherson C.J., Mientjes E.J., Iyengar R.,
RA   Grosveld G.;
RT   "Daxx and histone deacetylase II associate with chromatin through an
RT   interaction with core histones and the chromatin-associated protein
RT   Dek.";
RL   J. Cell Sci. 115:3319-3330(2002).
RN   [23]
RP   INTERACTION WITH HIPK2.
RX   PubMed=14678985;
RA   Hofmann T.G., Stollberg N., Schmitz M.L., Will H.;
RT   "HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-
RT   terminal kinase activation and apoptosis in human hepatoma cells.";
RL   Cancer Res. 63:8271-8277(2003).
RN   [24]
RP   OLIGOMERIZATION, SUBCELLULAR LOCATION, INTERACTION WITH MAP3K5,
RP   MUTAGENESIS OF SER-668 AND SER-671, AND PHOSPHORYLATION AT SER-668.
RX   PubMed=12968034; DOI=10.1074/jbc.M213201200;
RA   Song J.J., Lee Y.J.;
RT   "Role of the ASK1-SEK1-JNK1-HIPK1 signal in Daxx trafficking and ASK1
RT   oligomerization.";
RL   J. Biol. Chem. 278:47245-47252(2003).
RN   [25]
RP   INTERACTION WITH HIPK1.
RX   PubMed=12529400; DOI=10.1128/MCB.23.3.950-960.2003;
RA   Ecsedy J.A., Michaelson J.S., Leder P.;
RT   "Homeodomain-interacting protein kinase 1 modulates Daxx localization,
RT   phosphorylation, and transcriptional activity.";
RL   Mol. Cell. Biol. 23:950-960(2003).
RN   [26]
RP   INTERACTION WITH ATRX, AND SUBCELLULAR LOCATION.
RX   PubMed=12953102; DOI=10.1073/pnas.1937626100;
RA   Xue Y., Gibbons R., Yan Z., Yang D., McDowell T.L., Sechi S., Qin J.,
RA   Zhou S., Higgs D., Wang W.;
RT   "The ATRX syndrome protein forms a chromatin-remodeling complex with
RT   Daxx and localizes in promyelocytic leukemia nuclear bodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:10635-10640(2003).
RN   [27]
RP   INTERACTION WITH HADV5 E1B-55K.
RX   PubMed=14557665; DOI=10.1128/JVI.77.21.11809-11821.2003;
RA   Zhao L.Y., Colosimo A.L., Liu Y., Wan Y., Liao D.;
RT   "Adenovirus E1B 55-kilodalton oncoprotein binds to Daxx and eliminates
RT   enhancement of p53-dependent transcription by DAXX.";
RL   J. Virol. 77:11809-11821(2003).
RN   [28]
RP   INTERACTION WITH SPOP.
RX   PubMed=15240113; DOI=10.1016/j.bbrc.2004.06.022;
RA   La M., Kim K., Park J., Won J., Lee J.-H., Fu Y.M., Meadows G.G.,
RA   Joe C.O.;
RT   "Daxx-mediated transcriptional repression of MMP1 gene is reversed by
RT   SPOP.";
RL   Biochem. Biophys. Res. Commun. 320:760-765(2004).
RN   [29]
RP   FUNCTION, INTERACTION WITH ATRX, AND SUBCELLULAR LOCATION.
RX   PubMed=14990586; DOI=10.1074/jbc.M401321200;
RA   Tang J., Wu S., Liu H., Stratt R., Barak O.G., Shiekhattar R.,
RA   Picketts D.J., Yang X.;
RT   "A novel transcription regulatory complex containing death domain-
RT   associated protein and the ATR-X syndrome protein.";
RL   J. Biol. Chem. 279:20369-20377(2004).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH MDM2 AND TP53.
RX   PubMed=15364927; DOI=10.1074/jbc.M406743200;
RA   Zhao L.Y., Liu J., Sidhu G.S., Niu Y., Liu Y., Wang R., Liao D.;
RT   "Negative regulation of p53 functions by Daxx and the involvement of
RT   MDM2.";
RL   J. Biol. Chem. 279:50566-50579(2004).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH HSF1.
RX   PubMed=15016915; DOI=10.1073/pnas.0304768101;
RA   Boellmann F., Guettouche T., Guo Y., Fenna M., Mnayer L., Voellmy R.;
RT   "DAXX interacts with heat shock factor 1 during stress activation and
RT   enhances its transcriptional activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4100-4105(2004).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [33]
RP   IDENTIFICATION IN A COMPLEX WITH CUL3 AND SPOP, AND UBIQUITINATION.
RX   PubMed=16524876; DOI=10.1074/jbc.M600204200;
RA   Kwon J.E., La M., Oh K.H., Oh Y.M., Kim G.R., Seol J.H., Baek S.H.,
RA   Chiba T., Tanaka K., Bang O.S., Joe C.O., Chung C.H.;
RT   "BTB domain-containing speckle-type POZ protein (SPOP) serves as an
RT   adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase.";
RL   J. Biol. Chem. 281:12664-12672(2006).
RN   [34]
RP   FUNCTION, SUBCELLULAR LOCATION, SUMOYLATION, SUMO INTERACTION MOTIF,
RP   AND MUTAGENESIS OF 733-ILE--ASP-740.
RX   PubMed=17081986; DOI=10.1016/j.molcel.2006.10.019;
RA   Lin D.Y., Huang Y.S., Jeng J.C., Kuo H.Y., Chang C.C., Chao T.T.,
RA   Ho C.C., Chen Y.C., Lin T.P., Fang H.I., Hung C.C., Suen C.S.,
RA   Hwang M.J., Chang K.S., Maul G.G., Shih H.M.;
RT   "Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear
RT   localization, and repression of sumoylated transcription factors.";
RL   Mol. Cell 24:341-354(2006).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-702, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [36]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH MDM2 AND USP7, INTERACTION
RP   WITH MDM2; TP53 AND USP7, AND SUBCELLULAR LOCATION.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [37]
RP   INTERACTION WITH AXIN1.
RX   PubMed=17210684; DOI=10.1158/0008-5472.CAN-06-1671;
RA   Li Q., Wang X., Wu X., Rui Y., Liu W., Wang J., Wang X., Liou Y.C.,
RA   Ye Z., Lin S.C.;
RT   "Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell
RT   death.";
RL   Cancer Res. 67:66-74(2007).
RN   [38]
RP   IDENTIFICATION IN A COMPLEX WITH MDM2; RASSF1 AND USP7, INTERACTION
RP   WITH RASSF1; USP7 AND MDM2, AND SUBCELLULAR LOCATION.
RX   PubMed=18566590; DOI=10.1038/emboj.2008.115;
RA   Song M.S., Song S.J., Kim S.Y., Oh H.J., Lim D.S.;
RT   "The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by
RT   disrupting the MDM2-DAXX-HAUSP complex.";
RL   EMBO J. 27:1863-1874(2008).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-671 AND SER-702, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [40]
RP   FUNCTION IN HCMV RESTRICTION.
RX   PubMed=17942542; DOI=10.1128/JVI.01685-07;
RA   Tavalai N., Papior P., Rechter S., Stamminger T.;
RT   "Nuclear domain 10 components promyelocytic leukemia protein and hDaxx
RT   independently contribute to an intrinsic antiviral defense against
RT   human cytomegalovirus infection.";
RL   J. Virol. 82:126-137(2008).
RN   [41]
RP   INTERACTION WITH HCMV PP71.
RX   PubMed=18922870; DOI=10.1128/JVI.01215-08;
RA   Lukashchuk V., McFarlane S., Everett R.D., Preston C.M.;
RT   "Human cytomegalovirus protein pp71 displaces the chromatin-associated
RT   factor ATRX from nuclear domain 10 at early stages of infection.";
RL   J. Virol. 82:12543-12554(2008).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-213; SER-495;
RP   SER-668; SER-671; SER-688; SER-702; SER-737 AND SER-739, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-702; SER-737 AND
RP   SER-739, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-512, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [46]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP7.
RX   PubMed=20153724; DOI=10.1016/j.bbrc.2010.02.051;
RA   Tang J., Qu L., Pang M., Yang X.;
RT   "Daxx is reciprocally regulated by Mdm2 and Hausp.";
RL   Biochem. Biophys. Res. Commun. 393:542-545(2010).
RN   [47]
RP   FUNCTION AS HISTONE CHAPERONE, FUNCTION OF THE ATRX:DAXX COMPLEX, AND
RP   INTERACTION WITH HISTONE H3.3.
RX   PubMed=20504901; DOI=10.1101/gad.566910;
RA   Drane P., Ouararhni K., Depaux A., Shuaib M., Hamiche A.;
RT   "The death-associated protein DAXX is a novel histone chaperone
RT   involved in the replication-independent deposition of H3.3.";
RL   Genes Dev. 24:1253-1265(2010).
RN   [48]
RP   INTERACTION WITH HHV-5 PROTEIN UL123.
RX   PubMed=20444888; DOI=10.1128/JVI.02231-09;
RA   Reeves M., Woodhall D., Compton T., Sinclair J.;
RT   "Human cytomegalovirus IE72 protein interacts with the transcriptional
RT   repressor hDaxx to regulate LUNA gene expression during lytic
RT   infection.";
RL   J. Virol. 84:7185-7194(2010).
RN   [49]
RP   FUNCTION AS HISTONE H3.3 CHAPERONE, AND INTERACTION WITH HISTONE H3.3.
RX   PubMed=20651253; DOI=10.1073/pnas.1008850107;
RA   Lewis P.W., Elsaesser S.J., Noh K.M., Stadler S.C., Allis C.D.;
RT   "Daxx is an H3.3-specific histone chaperone and cooperates with ATRX
RT   in replication-independent chromatin assembly at telomeres.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14075-14080(2010).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495; SER-702; SER-737
RP   AND SER-739, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495 AND SER-702, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [53]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23222847; DOI=10.1101/gr.142703.112;
RA   Delbarre E., Ivanauskiene K., Kuntziger T., Collas P.;
RT   "DAXX-dependent supply of soluble (H3.3-H4) dimers to PML bodies
RT   pending deposition into chromatin.";
RL   Genome Res. 23:440-451(2013).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-412; SER-424;
RP   SER-495; SER-671; SER-688 AND SER-702, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [55]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24200965; DOI=10.4161/cc.26988;
RA   Corpet A., Olbrich T., Gwerder M., Fink D., Stucki M.;
RT   "Dynamics of histone H3.3 deposition in proliferating and senescent
RT   cells reveals a DAXX-dependent targeting to PML-NBs important for
RT   pericentromeric heterochromatin organization.";
RL   Cell Cycle 13:249-267(2014).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-25, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [57]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS PROTEIN BNRF1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=25275136; DOI=10.1128/JVI.01895-14;
RA   Tsai K., Chan L., Gibeault R., Conn K., Dheekollu J., Domsic J.,
RA   Marmorstein R., Schang L.M., Lieberman P.M.;
RT   "Viral reprogramming of the Daxx histone H3.3 chaperone during early
RT   Epstein-Barr virus infection.";
RL   J. Virol. 88:14350-14363(2014).
RN   [58]
RP   FUNCTION.
RX   PubMed=24530302; DOI=10.1016/j.molcel.2014.01.018;
RA   Lacoste N., Woolfe A., Tachiwana H., Garea A.V., Barth T.,
RA   Cantaloube S., Kurumizaka H., Imhof A., Almouzni G.;
RT   "Mislocalization of the centromeric histone variant CenH3/CENP-A in
RT   human cells depends on the chaperone DAXX.";
RL   Mol. Cell 53:631-644(2014).
RN   [59]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-142, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [60]
RP   STRUCTURE BY NMR OF 55-144 IN COMPLEX WITH RASSF1, AND INTERACTION
RP   WITH RASSF1.
RX   PubMed=21134643; DOI=10.1016/j.str.2010.09.016;
RA   Escobar-Cabrera E., Lau D.K., Giovinazzi S., Ishov A.M.,
RA   McIntosh L.P.;
RT   "Structural characterization of the DAXX N-terminal helical bundle
RT   domain and its complex with Rassf1C.";
RL   Structure 18:1642-1653(2010).
RN   [61]
RP   STRUCTURE BY NMR OF 721-740.
RX   PubMed=20927612; DOI=10.1007/s12104-010-9271-4;
RA   Naik M.T., Chang C.C., Naik N.M., Kung C.C., Shih H.M., Huang T.H.;
RT   "NMR chemical shift assignments of a complex between SUMO-1 and SIM
RT   peptide derived from the C-terminus of Daxx.";
RL   Biomol. NMR. Assign. 5:75-77(2011).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 184-390 IN COMPLEX WITH
RP   HISTONE H3.3/H4 DIMER, AND MUTAGENESIS OF TYR-222.
RX   PubMed=23142979; DOI=10.1038/nsmb.2439;
RA   Liu C.P., Xiong C., Wang M., Yu Z., Yang N., Chen P., Zhang Z., Li G.,
RA   Xu R.M.;
RT   "Structure of the variant histone H3.3-H4 heterodimer in complex with
RT   its chaperone DAXX.";
RL   Nat. Struct. Mol. Biol. 19:1287-1292(2012).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 178-389 IN COMPLEX WITH
RP   HISTONE H3.3/H4 DIMER, AND MUTAGENESIS OF GLN-206; SER-220; TYR-222;
RP   GLU-225; LYS-229; ARG-251; PHE-317; ARG-328 AND ASP-331.
RX   PubMed=23075851; DOI=10.1038/nature11608;
RA   Elsasser S.J., Huang H., Lewis P.W., Chin J.W., Allis C.D.,
RA   Patel D.J.;
RT   "DAXX envelops a histone H3.3-H4 dimer for H3.3-specific
RT   recognition.";
RL   Nature 491:560-565(2012).
CC   -!- FUNCTION: Transcription corepressor known to repress
CC       transcriptional potential of several sumoylated transcription
CC       factors. Down-regulates basal and activated transcription. Its
CC       transcription repressor activity is modulated by recruiting it to
CC       subnuclear compartments like the nucleolus or PML/POD/ND10 nuclear
CC       bodies through interactions with MCSR1 and PML, respectively.
CC       Seems to regulate transcription in PML/POD/ND10 nuclear bodies
CC       together with PML and may influence TNFRSF6-dependent apoptosis
CC       thereby. Inhibits transcriptional activation of PAX3 and ETS1
CC       through direct protein-protein interactions. Modulates PAX5
CC       activity; the function seems to involve CREBBP. Acts as an adapter
CC       protein in a MDM2-DAXX-USP7 complex by regulating the RING-finger
CC       E3 ligase MDM2 ubiquitination activity. Under non-stress
CC       condition, in association with the deubiquitinating USP7, prevents
CC       MDM2 self-ubiquitination and enhances the intrinsic E3 ligase
CC       activity of MDM2 towards TP53, thereby promoting TP53
CC       ubiquitination and subsequent proteasomal degradation. Upon DNA
CC       damage, its association with MDM2 and USP7 is disrupted, resulting
CC       in increased MDM2 autoubiquitination and consequently, MDM2
CC       degradation, which leads to TP53 stabilization. Acts as histone
CC       chaperone that facilitates deposition of histone H3.3. Acts as
CC       targeting component of the chromatin remodeling complex ATRX:DAXX
CC       which has ATP-dependent DNA translocase activity and catalyzes the
CC       replication-independent deposition of histone H3.3 in pericentric
CC       DNA repeats outside S-phase and telomeres, and the in vitro
CC       remodeling of H3.3-containing nucleosomes. Does not affect the
CC       ATPase activity of ATRX but alleviates its transcription
CC       repression activity. Upon neuronal activation associates with
CC       regulatory elements of selected immediate early genes where it
CC       promotes deposition of histone H3.3 which may be linked to
CC       transcriptional induction of these genes. Required for the
CC       recruitment of histone H3.3:H4 dimers to PML-nuclear bodies (PML-
CC       NBs); the process is independent of ATRX and facilitated by ASF1A;
CC       PML-NBs are suggested to function as regulatory sites for the
CC       incorporation of newly synthesized histone H3.3 into chromatin. In
CC       case of overexpression of centromeric histone variant CENPA (as
CC       found in various tumors) is involved in its mislocalization to
CC       chromosomes; the ectopic localization involves a heterotypic
CC       tetramer containing CENPA, and histones H3.3 and H4 and decreases
CC       binding of CTCF to chromatin. Proposed to mediate activation of
CC       the JNK pathway and apoptosis via MAP3K5 in response to signaling
CC       from TNFRSF6 and TGFBR2. Interaction with HSPB1/HSP27 may prevent
CC       interaction with TNFRSF6 and MAP3K5 and block DAXX-mediated
CC       apoptosis. In contrast, in lymphoid cells JNC activation and
CC       TNFRSF6-mediated apoptosis may not involve DAXX. Shows restriction
CC       activity towards human cytomegalovirus (HCMV). Plays a role as a
CC       positive regulator of the heat shock transcription factor HSF1
CC       activity during the stress protein response (PubMed:15016915).
CC       {ECO:0000269|PubMed:12140263, ECO:0000269|PubMed:14990586,
CC       ECO:0000269|PubMed:15016915, ECO:0000269|PubMed:15364927,
CC       ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:17081986,
CC       ECO:0000269|PubMed:17942542, ECO:0000269|PubMed:20504901,
CC       ECO:0000269|PubMed:20651253, ECO:0000269|PubMed:23222847,
CC       ECO:0000269|PubMed:24200965, ECO:0000269|PubMed:24530302}.
CC   -!- SUBUNIT: Homomultimer. Interacts (via C-terminus) with TNFRSF6
CC       (via death domain). Interacts with PAX5, SLC2A4/GLUT4, MAP3K5,
CC       TGFBR2, phosphorylated dimeric HSPB1/HSP27, CENPC, ETS1,
CC       sumoylated PML, UBE2I, MCRS1 and TP53. Interacts (via N-terminus)
CC       with HIPK2 and HIPK3. Interacts with HIPK1, which induces
CC       translocation from PML/POD/ND10 nuclear bodies to chromatin and
CC       enhances association with HDAC1. Interacts (non-phosphorylated)
CC       with PAX3, PAX7, DEK, HDAC1, HDAC2, HDAC3, acetylated histone H4
CC       and histones H2A, H2B, H3, H3.3 and H4. Interacts with SPOP;
CC       mediating CUL3-dependent proteosomal degradation. Interacts with
CC       CBP; the interaction is dependent the sumoylation of CBP and
CC       suppresses CBP transcriptional activity via recruitment of HDAC2
CC       directly in the complex with TP53 and HIPK2. Interacts with AXIN1;
CC       the interaction stimulates the interaction of DAXX with TP53,
CC       stimulates 'Ser-46' phosphorylation of TP53 on and induces cell
CC       death on UV irradiation. Interacts with MDM2; the interaction is
CC       direct. Interacts with USP7; the interaction is direct and
CC       independent of MDM2 and TP53. Part of a complex with DAXX, MDM2
CC       and USP7 under non-stress conditions. Interacts (via N-terminus)
CC       with RASSF1 (via C-terminus); the interaction is independent of
CC       MDM2 and TP53; RASSF1 isoform A disrupts interactions among MDM2,
CC       DAXX and USP7, thus contributing to the efficient activation of
CC       TP53 by promoting MDM2 self-ubiquitination in cell-cycle
CC       checkpoint control in response to DNA damage. Interacts with ATRX
CC       to form the chromatin remodeling complex ATRX:DAXX. Interacts with
CC       human cytomegalovirus/HHV-5 tegument phosphoprotein pp71 and
CC       protein UL123. Interacts with Epstein-Barr virus protein BNRF1.
CC       Interacts with human adenovirus 5 E1B-55K protein; this
CC       interaction might alterate the normal interactions of DAXX, PML,
CC       and TP53, which may contribute to cell transformation
CC       (PubMed:14557665). Interacts with HSF1 (via homotrimeric form
CC       preferentially); this interaction relieves homotrimeric HSF1 from
CC       repression of its transcriptional activity by HSP90-dependent
CC       multichaperone complex upon heat shock (PubMed:15016915).
CC       {ECO:0000269|PubMed:10393185, ECO:0000269|PubMed:10669754,
CC       ECO:0000269|PubMed:10684855, ECO:0000269|PubMed:11003656,
CC       ECO:0000269|PubMed:11483955, ECO:0000269|PubMed:11495919,
CC       ECO:0000269|PubMed:11842083, ECO:0000269|PubMed:11948183,
CC       ECO:0000269|PubMed:12140263, ECO:0000269|PubMed:12529400,
CC       ECO:0000269|PubMed:12953102, ECO:0000269|PubMed:12968034,
CC       ECO:0000269|PubMed:14557665, ECO:0000269|PubMed:14678985,
CC       ECO:0000269|PubMed:14990586, ECO:0000269|PubMed:15016915,
CC       ECO:0000269|PubMed:15240113, ECO:0000269|PubMed:15364927,
CC       ECO:0000269|PubMed:16524876, ECO:0000269|PubMed:16845383,
CC       ECO:0000269|PubMed:17210684, ECO:0000269|PubMed:18566590,
CC       ECO:0000269|PubMed:18922870, ECO:0000269|PubMed:20444888,
CC       ECO:0000269|PubMed:20504901, ECO:0000269|PubMed:20651253,
CC       ECO:0000269|PubMed:21134643, ECO:0000269|PubMed:23075851,
CC       ECO:0000269|PubMed:23142979, ECO:0000269|PubMed:25275136,
CC       ECO:0000269|PubMed:9645950}.
CC   -!- INTERACTION:
CC       P03243:- (xeno); NbExp=4; IntAct=EBI-77321, EBI-1561361;
CC       O43918:AIRE; NbExp=5; IntAct=EBI-77321, EBI-1753081;
CC       P10275:AR; NbExp=5; IntAct=EBI-77321, EBI-608057;
CC       P46100:ATRX; NbExp=7; IntAct=EBI-77321, EBI-396461;
CC       P03179:BNRF1 (xeno); NbExp=5; IntAct=EBI-77321, EBI-9349301;
CC       Q9H257:CARD9; NbExp=3; IntAct=EBI-77321, EBI-751319;
CC       Q96GN5:CDCA7L; NbExp=3; IntAct=EBI-77321, EBI-5278764;
CC       Q8N726:CDKN2A; NbExp=8; IntAct=EBI-77321, EBI-625922;
CC       Q92793:CREBBP; NbExp=2; IntAct=EBI-77321, EBI-81215;
CC       P03244:E1B (xeno); NbExp=4; IntAct=EBI-77321, EBI-1561155;
CC       P14921-1:ETS1; NbExp=3; IntAct=EBI-287635, EBI-913224;
CC       P14921-2:ETS1; NbExp=2; IntAct=EBI-287635, EBI-913228;
CC       Q8IZU0:FAM9B; NbExp=3; IntAct=EBI-77321, EBI-10175124;
CC       P25445:FAS; NbExp=3; IntAct=EBI-77321, EBI-494743;
CC       P25446:Fas (xeno); NbExp=4; IntAct=EBI-77321, EBI-296206;
CC       P02794:FTH1; NbExp=5; IntAct=EBI-77321, EBI-713259;
CC       Q08379:GOLGA2; NbExp=7; IntAct=EBI-77321, EBI-618309;
CC       P84243:H3F3B; NbExp=21; IntAct=EBI-287635, EBI-120658;
CC       Q13547:HDAC1; NbExp=2; IntAct=EBI-77321, EBI-301834;
CC       Q92769:HDAC2; NbExp=2; IntAct=EBI-77321, EBI-301821;
CC       O88904:Hipk1 (xeno); NbExp=3; IntAct=EBI-77321, EBI-692945;
CC       P68431:HIST1H3D; NbExp=6; IntAct=EBI-287635, EBI-79722;
CC       Q71DI3:HIST2H3A; NbExp=5; IntAct=EBI-287635, EBI-750650;
CC       P04792:HSPB1; NbExp=4; IntAct=EBI-77321, EBI-352682;
CC       P15991:HSPB1 (xeno); NbExp=3; IntAct=EBI-77321, EBI-1559114;
CC       Q99683:MAP3K5; NbExp=7; IntAct=EBI-77321, EBI-476263;
CC       Q96EZ8:MCRS1; NbExp=10; IntAct=EBI-77321, EBI-348259;
CC       Q00987:MDM2; NbExp=18; IntAct=EBI-77321, EBI-389668;
CC       Q9UHC7:MKRN1; NbExp=4; IntAct=EBI-77321, EBI-373524;
CC       Q7Z6G3-2:NECAB2; NbExp=3; IntAct=EBI-77321, EBI-10172876;
CC       Q9BZ95:NSD3; NbExp=2; IntAct=EBI-77321, EBI-3390132;
CC       Q99497:PARK7; NbExp=3; IntAct=EBI-77321, EBI-1164361;
CC       Q02650:Pax5 (xeno); NbExp=4; IntAct=EBI-77321, EBI-296260;
CC       Q96AQ6:PBXIP1; NbExp=3; IntAct=EBI-77321, EBI-740845;
CC       P29590:PML; NbExp=6; IntAct=EBI-77321, EBI-295890;
CC       Q8ND90:PNMA1; NbExp=4; IntAct=EBI-77321, EBI-302345;
CC       Q9NS23:RASSF1; NbExp=6; IntAct=EBI-77321, EBI-367363;
CC       Q9NS23-4:RASSF1; NbExp=5; IntAct=EBI-77321, EBI-438710;
CC       Q04206:RELA; NbExp=5; IntAct=EBI-77321, EBI-73886;
CC       Q9QZL0:Ripk3 (xeno); NbExp=2; IntAct=EBI-77321, EBI-2367423;
CC       O43791:SPOP; NbExp=5; IntAct=EBI-77321, EBI-743549;
CC       Q9Y2D8:SSX2IP; NbExp=3; IntAct=EBI-77321, EBI-2212028;
CC       P40763:STAT3; NbExp=4; IntAct=EBI-77321, EBI-518675;
CC       P63165:SUMO1; NbExp=7; IntAct=EBI-77321, EBI-80140;
CC       Q9NQB0:TCF7L2; NbExp=5; IntAct=EBI-77321, EBI-924724;
CC       P37173:TGFBR2; NbExp=2; IntAct=EBI-77321, EBI-296151;
CC       P04637:TP53; NbExp=12; IntAct=EBI-77321, EBI-366083;
CC       Q99816:TSG101; NbExp=4; IntAct=EBI-77321, EBI-346882;
CC       P0CG48:UBC; NbExp=2; IntAct=EBI-77321, EBI-3390054;
CC       P63279:UBE2I; NbExp=3; IntAct=EBI-77321, EBI-80168;
CC       Q93009:USP7; NbExp=13; IntAct=EBI-77321, EBI-302474;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11495919,
CC       ECO:0000269|PubMed:11842083, ECO:0000269|PubMed:12968034,
CC       ECO:0000269|PubMed:9407001}. Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:10669754, ECO:0000269|PubMed:16845383,
CC       ECO:0000269|PubMed:18566590, ECO:0000269|PubMed:23222847,
CC       ECO:0000269|PubMed:9407001}. Nucleus, PML body
CC       {ECO:0000269|PubMed:10669754, ECO:0000269|PubMed:11842083,
CC       ECO:0000269|PubMed:14990586, ECO:0000269|PubMed:17081986,
CC       ECO:0000269|PubMed:21482821, ECO:0000269|PubMed:23222847,
CC       ECO:0000269|PubMed:24200965, ECO:0000269|PubMed:25275136}.
CC       Nucleus, nucleolus {ECO:0000269|PubMed:23222847}. Chromosome,
CC       centromere {ECO:0000269|PubMed:24200965,
CC       ECO:0000269|PubMed:9645950}. Note=Dispersed throughout the
CC       nucleoplasm, in PML/POD/ND10 nuclear bodies, and in nucleoli
CC       (Probable). Colocalizes with histone H3.3, ATRX, HIRA and ASF1A at
CC       PML-nuclear bodies (PubMed:12953102, PubMed:14990586,
CC       PubMed:23222847, PubMed:24200965). Colocalizes with a subset of
CC       interphase centromeres, but is absent from mitotic centromeres
CC       (PubMed:9645950). Detected in cytoplasmic punctate structures
CC       (PubMed:11842083). Translocates from the nucleus to the cytoplasm
CC       upon glucose deprivation or oxidative stress (PubMed:12968034).
CC       Colocalizes with RASSF1 in the nucleus (PubMed:18566590).
CC       Colocalizes with USP7 in nucleoplasma with accumulation in
CC       speckled structures (PubMed:16845383).
CC       {ECO:0000269|PubMed:11842083, ECO:0000269|PubMed:12953102,
CC       ECO:0000269|PubMed:12968034, ECO:0000269|PubMed:14990586,
CC       ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:18566590,
CC       ECO:0000269|PubMed:23222847, ECO:0000269|PubMed:24200965,
CC       ECO:0000269|PubMed:9645950, ECO:0000305|PubMed:10669754}.
CC   -!- SUBCELLULAR LOCATION: Isoform beta: Nucleus
CC       {ECO:0000269|PubMed:21482821}. Note=Diffuse nuclear distribution
CC       pattern and no comparable dot-like accumulation of isoform 1.
CC       {ECO:0000269|PubMed:21482821}.
CC   -!- SUBCELLULAR LOCATION: Isoform gamma: Nucleus
CC       {ECO:0000269|PubMed:21482821}. Note=Diffuse nuclear distribution
CC       pattern and no comparable dot-like accumulation of isoform 1.
CC       {ECO:0000269|PubMed:21482821}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q9UER7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UER7-2; Sequence=VSP_001270;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q9UER7-3; Sequence=VSP_045588;
CC         Note=No experimental confirmation available.;
CC       Name=beta;
CC         IsoId=Q9UER7-4; Sequence=VSP_057438, VSP_057440;
CC         Note=Markedly decreased affinity for PML and TP53/p53, unable to
CC         repress p53-mediated transcription.
CC         {ECO:0000269|PubMed:21482821};
CC       Name=gamma;
CC         IsoId=Q9UER7-5; Sequence=VSP_057437, VSP_057439;
CC         Note=Markedly decreased affinity for PML and TP53/p53, unable to
CC         repress p53-mediated transcription.
CC         {ECO:0000269|PubMed:21482821};
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- INDUCTION: Upon mitogenic stimulation by concanavalin-A.
CC   -!- DOMAIN: The Sumo interaction motif mediates Sumo binding, and is
CC       required both for sumoylation and binding to sumoylated targets.
CC   -!- PTM: Sumoylated with SUMO1 on multiple lysine residues.
CC       {ECO:0000269|PubMed:11842083, ECO:0000269|PubMed:12150977,
CC       ECO:0000269|PubMed:17081986}.
CC   -!- PTM: Phosphorylated by HIPK1 upon glucose deprivation.
CC       {ECO:0000269|PubMed:10393185, ECO:0000269|PubMed:12140263,
CC       ECO:0000269|PubMed:12968034}.
CC   -!- PTM: Polyubiquitinated; which is promoted by CUL3 and SPOP and
CC       results in proteasomal degradation. Ubiquitinated by MDM2;
CC       inducing its degradation. Deubiquitinated by USP7; leading to
CC       stabilize it. {ECO:0000269|PubMed:16524876,
CC       ECO:0000269|PubMed:20153724}.
CC   -!- SIMILARITY: Belongs to the DAXX family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DAXXID40265ch6p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF039136; AAB92671.1; -; mRNA.
DR   EMBL; AF006041; AAB63043.1; -; mRNA.
DR   EMBL; AF015956; AAB66585.2; -; mRNA.
DR   EMBL; AF050179; AAC39853.1; -; mRNA.
DR   EMBL; AF097742; AAC72843.1; -; mRNA.
DR   EMBL; HQ436528; AEC33235.1; -; mRNA.
DR   EMBL; HQ436529; AEC33236.1; -; mRNA.
DR   EMBL; AB015051; BAA34295.1; -; mRNA.
DR   EMBL; AK303854; BAG64795.1; -; mRNA.
DR   EMBL; CR457085; CAG33366.1; -; mRNA.
DR   EMBL; AL662827; CAI17527.1; -; Genomic_DNA.
DR   EMBL; AL662820; CAI18124.1; -; Genomic_DNA.
DR   EMBL; BX248088; CAI41788.1; -; Genomic_DNA.
DR   EMBL; CR759793; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759817; CAQ08035.1; -; Genomic_DNA.
DR   EMBL; CR759786; CAQ08265.1; -; Genomic_DNA.
DR   EMBL; Z97183; CAB09986.2; -; Genomic_DNA.
DR   EMBL; Z97184; CAB09986.2; JOINED; Genomic_DNA.
DR   EMBL; Z97184; CAB09989.2; -; Genomic_DNA.
DR   EMBL; Z97183; CAB09989.2; JOINED; Genomic_DNA.
DR   EMBL; CH471081; EAX03722.1; -; Genomic_DNA.
DR   EMBL; BC000220; AAH00220.1; -; mRNA.
DR   EMBL; BC109073; AAI09074.1; -; mRNA.
DR   EMBL; BC109074; AAI09075.1; -; mRNA.
DR   CCDS; CCDS4776.1; -. [Q9UER7-1]
DR   CCDS; CCDS59008.1; -. [Q9UER7-3]
DR   PIR; T03847; T03847.
DR   RefSeq; NP_001135441.1; NM_001141969.1. [Q9UER7-1]
DR   RefSeq; NP_001241646.1; NM_001254717.1. [Q9UER7-3]
DR   RefSeq; NP_001341.1; NM_001350.4. [Q9UER7-1]
DR   UniGene; Hs.336916; -.
DR   PDB; 2KQS; NMR; -; B=721-740.
DR   PDB; 2KZS; NMR; -; A=55-144.
DR   PDB; 2KZU; NMR; -; A=55-144.
DR   PDB; 4H9N; X-ray; 1.95 A; C=178-389.
DR   PDB; 4H9O; X-ray; 2.05 A; C=178-389.
DR   PDB; 4H9P; X-ray; 2.20 A; C=178-389.
DR   PDB; 4H9Q; X-ray; 1.95 A; C=178-389.
DR   PDB; 4H9R; X-ray; 2.20 A; C=178-389.
DR   PDB; 4H9S; X-ray; 2.60 A; E/F=183-398.
DR   PDB; 4HGA; X-ray; 2.80 A; A=184-390.
DR   PDB; 5GRQ; X-ray; 1.58 A; A=55-144, B=55-143.
DR   PDB; 5KDM; X-ray; 3.50 A; C=178-389.
DR   PDB; 5Y6O; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I=50-144.
DR   PDBsum; 2KQS; -.
DR   PDBsum; 2KZS; -.
DR   PDBsum; 2KZU; -.
DR   PDBsum; 4H9N; -.
DR   PDBsum; 4H9O; -.
DR   PDBsum; 4H9P; -.
DR   PDBsum; 4H9Q; -.
DR   PDBsum; 4H9R; -.
DR   PDBsum; 4H9S; -.
DR   PDBsum; 4HGA; -.
DR   PDBsum; 5GRQ; -.
DR   PDBsum; 5KDM; -.
DR   PDBsum; 5Y6O; -.
DR   DisProt; DP00707; -.
DR   ProteinModelPortal; Q9UER7; -.
DR   SMR; Q9UER7; -.
DR   BioGrid; 107985; 234.
DR   CORUM; Q9UER7; -.
DR   DIP; DIP-27628N; -.
DR   IntAct; Q9UER7; 124.
DR   MINT; Q9UER7; -.
DR   STRING; 9606.ENSP00000266000; -.
DR   iPTMnet; Q9UER7; -.
DR   PhosphoSitePlus; Q9UER7; -.
DR   BioMuta; DAXX; -.
DR   DMDM; 24636785; -.
DR   EPD; Q9UER7; -.
DR   PaxDb; Q9UER7; -.
DR   PeptideAtlas; Q9UER7; -.
DR   PRIDE; Q9UER7; -.
DR   DNASU; 1616; -.
DR   Ensembl; ENST00000266000; ENSP00000266000; ENSG00000204209. [Q9UER7-1]
DR   Ensembl; ENST00000374542; ENSP00000363668; ENSG00000204209. [Q9UER7-1]
DR   Ensembl; ENST00000383062; ENSP00000372539; ENSG00000206206. [Q9UER7-1]
DR   Ensembl; ENST00000383194; ENSP00000372681; ENSG00000206279. [Q9UER7-1]
DR   Ensembl; ENST00000399060; ENSP00000382014; ENSG00000206206. [Q9UER7-1]
DR   Ensembl; ENST00000399344; ENSP00000382281; ENSG00000206279. [Q9UER7-1]
DR   Ensembl; ENST00000414083; ENSP00000396876; ENSG00000204209. [Q9UER7-3]
DR   Ensembl; ENST00000433482; ENSP00000404623; ENSG00000231617. [Q9UER7-1]
DR   Ensembl; ENST00000436311; ENSP00000404376; ENSG00000227046. [Q9UER7-1]
DR   Ensembl; ENST00000445009; ENSP00000394108; ENSG00000231617. [Q9UER7-1]
DR   Ensembl; ENST00000455860; ENSP00000410772; ENSG00000227046. [Q9UER7-1]
DR   Ensembl; ENST00000612868; ENSP00000479172; ENSG00000227046. [Q9UER7-3]
DR   Ensembl; ENST00000612888; ENSP00000483394; ENSG00000206206. [Q9UER7-3]
DR   Ensembl; ENST00000613912; ENSP00000477633; ENSG00000206206. [Q9UER7-4]
DR   Ensembl; ENST00000616312; ENSP00000483517; ENSG00000227046. [Q9UER7-4]
DR   Ensembl; ENST00000617660; ENSP00000480448; ENSG00000206279. [Q9UER7-3]
DR   Ensembl; ENST00000619421; ENSP00000478810; ENSG00000206279. [Q9UER7-4]
DR   Ensembl; ENST00000620164; ENSP00000482399; ENSG00000204209. [Q9UER7-4]
DR   Ensembl; ENST00000622655; ENSP00000484830; ENSG00000231617. [Q9UER7-4]
DR   GeneID; 1616; -.
DR   KEGG; hsa:1616; -.
DR   UCSC; uc003oec.4; human. [Q9UER7-1]
DR   UCSC; uc063nwl.1; human.
DR   CTD; 1616; -.
DR   DisGeNET; 1616; -.
DR   EuPathDB; HostDB:ENSG00000204209.10; -.
DR   GeneCards; DAXX; -.
DR   HGNC; HGNC:2681; DAXX.
DR   HPA; CAB002224; -.
DR   HPA; CAB025546; -.
DR   HPA; HPA008736; -.
DR   HPA; HPA008797; -.
DR   HPA; HPA065779; -.
DR   MIM; 603186; gene.
DR   neXtProt; NX_Q9UER7; -.
DR   OpenTargets; ENSG00000204209; -.
DR   PharmGKB; PA27148; -.
DR   eggNOG; ENOG410IGIP; Eukaryota.
DR   eggNOG; ENOG4111K0B; LUCA.
DR   GeneTree; ENSGT00390000009448; -.
DR   HOGENOM; HOG000112148; -.
DR   HOVERGEN; HBG031495; -.
DR   InParanoid; Q9UER7; -.
DR   KO; K02308; -.
DR   OMA; LCKTQTA; -.
DR   OrthoDB; EOG09370P3D; -.
DR   PhylomeDB; Q9UER7; -.
DR   TreeFam; TF325803; -.
DR   BRENDA; 2.7.7.19; 2681.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   SignaLink; Q9UER7; -.
DR   SIGNOR; Q9UER7; -.
DR   ChiTaRS; DAXX; human.
DR   EvolutionaryTrace; Q9UER7; -.
DR   GeneWiki; Death-associated_protein_6; -.
DR   GenomeRNAi; 1616; -.
DR   PRO; PR:Q9UER7; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000204209; -.
DR   CleanEx; HS_DAXX; -.
DR   ExpressionAtlas; Q9UER7; baseline and differential.
DR   Genevisible; Q9UER7; HS.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:CACAO.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0070603; C:SWI/SNF superfamily-type complex; IDA:UniProtKB.
DR   GO; GO:0050681; F:androgen receptor binding; IPI:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0031072; F:heat shock protein binding; TAS:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:CAFA.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0030295; F:protein kinase activator activity; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0005057; F:signal transducer activity, downstream of receptor; TAS:ProtInc.
DR   GO; GO:0032183; F:SUMO binding; IPI:CAFA.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; TAS:ProtInc.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IDA:UniProtKB.
DR   GO; GO:0071280; P:cellular response to copper ion; IDA:UniProtKB.
DR   GO; GO:0072738; P:cellular response to diamide; IDA:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; IDA:UniProtKB.
DR   GO; GO:1903936; P:cellular response to sodium arsenite; IDA:UniProtKB.
DR   GO; GO:0034620; P:cellular response to unfolded protein; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB.
DR   GO; GO:0016569; P:covalent chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; TAS:ProtInc.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006334; P:nucleosome assembly; IDA:UniProtKB.
DR   GO; GO:1901216; P:positive regulation of neuron death; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd13151; DAXX_helical_bundle; 1.
DR   InterPro; IPR005012; Daxx.
DR   InterPro; IPR031333; Daxx_N.
DR   PANTHER; PTHR12766; PTHR12766; 1.
DR   Pfam; PF03344; Daxx; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   Centromere; Chaperone; Chromatin regulator; Chromosome; Coiled coil;
KW   Complete proteome; Cytoplasm; Host-virus interaction; Isopeptide bond;
KW   Nucleus; Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1    740       Death domain-associated protein 6.
FT                                /FTId=PRO_0000151258.
FT   REGION        1    160       Necessary for interaction with USP7 and
FT                                ATRX.
FT   REGION      183    417       Interaction with histone H3.3.
FT   REGION      347    570       Necessary for interaction with USP7.
FT   REGION      501    625       Interaction with MAP3K5.
FT   REGION      626    740       Interaction with SPOP.
FT                                {ECO:0000269|PubMed:15240113}.
FT   REGION      733    740       Sumo interaction motif (SIM).
FT   COILED      180    217       {ECO:0000255}.
FT   COILED      358    399       {ECO:0000255}.
FT   COILED      430    489       {ECO:0000255}.
FT   MOTIF       391    395       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOTIF       628    634       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS     11     16       Poly-Asp.
FT   COMPBIAS    434    572       Asp/Glu-rich (acidic).
FT   MOD_RES      25     25       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     178    178       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     213    213       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     412    412       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     424    424       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     459    459       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:O35613}.
FT   MOD_RES     495    495       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     498    498       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VIB2}.
FT   MOD_RES     512    512       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     561    561       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VIB2}.
FT   MOD_RES     580    580       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VIB2}.
FT   MOD_RES     668    668       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000269|PubMed:12968034}.
FT   MOD_RES     671    671       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     688    688       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     702    702       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     737    737       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     739    739       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231}.
FT   CROSSLNK    142    142       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    630    630       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000269|PubMed:12150977}.
FT   CROSSLNK    631    631       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000269|PubMed:12150977}.
FT   VAR_SEQ       1     75       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045588.
FT   VAR_SEQ     648    682       YVERQRSVHEKNGKKICTLPSPPSPLASLAPVADS -> PA
FT                                VPNPPFTASSAWYLQDKCGHTMRSRRDHRALRL (in
FT                                isoform gamma).
FT                                {ECO:0000303|PubMed:21482821}.
FT                                /FTId=VSP_057437.
FT   VAR_SEQ     653    688       RSVHEKNGKKICTLPSPPSPLASLAPVADSSTRVDS -> S
FT                                PAVPNPPFTASSAWYLQDKCGHTMRSRRDHRALRL (in
FT                                isoform beta).
FT                                {ECO:0000303|PubMed:21482821}.
FT                                /FTId=VSP_057438.
FT   VAR_SEQ     683    740       Missing (in isoform gamma).
FT                                {ECO:0000303|PubMed:21482821}.
FT                                /FTId=VSP_057439.
FT   VAR_SEQ     689    740       Missing (in isoform beta).
FT                                {ECO:0000303|PubMed:21482821}.
FT                                /FTId=VSP_057440.
FT   VAR_SEQ     696    740       SSLCIPSPARLSQTPHSQPPRPGTCKTSVATQCDPEEIIVL
FT                                SDSD -> PAKNLGRRRSKQDQG (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_001270.
FT   MUTAGEN     206    206       Q->L: Impairs interaction with histones
FT                                H3 and H4. {ECO:0000269|PubMed:23075851}.
FT   MUTAGEN     220    220       S->A: Abolishes interaction with histones
FT                                H3 and H4. {ECO:0000269|PubMed:23075851}.
FT   MUTAGEN     222    222       Y->A,S: Abolishes interaction with
FT                                histones H3 and H4.
FT                                {ECO:0000269|PubMed:23075851,
FT                                ECO:0000269|PubMed:23142979}.
FT   MUTAGEN     222    222       Y->E: Abolishes interaction with histone
FT                                H3.3. {ECO:0000269|PubMed:23075851,
FT                                ECO:0000269|PubMed:23142979}.
FT   MUTAGEN     225    225       E->L: Impairs interaction with histones
FT                                H3 and H4. {ECO:0000269|PubMed:23075851}.
FT   MUTAGEN     229    229       K->A,L: Impairs interaction with histones
FT                                H3 and H4. {ECO:0000269|PubMed:23075851}.
FT   MUTAGEN     251    251       R->A: Abolishes interaction with histones
FT                                H3 and H4. {ECO:0000269|PubMed:23075851}.
FT   MUTAGEN     317    317       F->A: Abolishes interaction with histones
FT                                H3 and H4. {ECO:0000269|PubMed:23075851}.
FT   MUTAGEN     328    328       R->A: Abolishes interaction with histones
FT                                H3 and H4. {ECO:0000269|PubMed:23075851}.
FT   MUTAGEN     331    331       D->A: Abolishes interaction with histones
FT                                H3 and H4. {ECO:0000269|PubMed:23075851}.
FT   MUTAGEN     630    630       K->A: Abolishes sumoylation; when
FT                                associated with A-631.
FT                                {ECO:0000269|PubMed:12150977}.
FT   MUTAGEN     631    631       K->A: Abolishes sumoylation; when
FT                                associated with A-630.
FT                                {ECO:0000269|PubMed:12150977}.
FT   MUTAGEN     668    668       S->A: No translocation to the cytosol
FT                                upon glucose deprivation.
FT                                {ECO:0000269|PubMed:12968034}.
FT   MUTAGEN     671    671       S->A: No effect on cytosol translocation.
FT                                upon glucose deprivation.
FT                                {ECO:0000269|PubMed:12968034}.
FT   MUTAGEN     733    740       Missing: Abolishes sumoylation.
FT                                {ECO:0000269|PubMed:17081986}.
FT   CONFLICT    177    177       Q -> R (in Ref. 2; AAB66585).
FT                                {ECO:0000305}.
FT   CONFLICT    263    263       R -> H (in Ref. 5; AAC72843).
FT                                {ECO:0000305}.
FT   CONFLICT    323    323       R -> W (in Ref. 2; AAB66585).
FT                                {ECO:0000305}.
FT   CONFLICT    365    365       R -> Q (in Ref. 2; AAB66585).
FT                                {ECO:0000305}.
FT   CONFLICT    382    382       L -> S (in Ref. 2; AAB66585).
FT                                {ECO:0000305}.
FT   CONFLICT    505    505       E -> G (in Ref. 8; BAG64795).
FT                                {ECO:0000305}.
FT   CONFLICT    647    647       S -> R (in Ref. 10; CAB09986/CAB09989).
FT                                {ECO:0000305}.
FT   CONFLICT    722    722       T -> A (in Ref. 10; CAB09986/CAB09989).
FT                                {ECO:0000305}.
FT   CONFLICT    731    732       EE -> KK (in Ref. 5; AAC72843).
FT                                {ECO:0000305}.
FT   HELIX        60     77       {ECO:0000244|PDB:5GRQ}.
FT   TURN         78     80       {ECO:0000244|PDB:2KZU}.
FT   HELIX        84     93       {ECO:0000244|PDB:5GRQ}.
FT   HELIX        97    100       {ECO:0000244|PDB:5GRQ}.
FT   HELIX       103    118       {ECO:0000244|PDB:5GRQ}.
FT   HELIX       120    122       {ECO:0000244|PDB:5GRQ}.
FT   HELIX       123    136       {ECO:0000244|PDB:5GRQ}.
FT   STRAND      138    140       {ECO:0000244|PDB:2KZS}.
FT   HELIX       185    206       {ECO:0000244|PDB:4H9N}.
FT   HELIX       214    216       {ECO:0000244|PDB:4H9N}.
FT   HELIX       221    242       {ECO:0000244|PDB:4H9N}.
FT   HELIX       252    254       {ECO:0000244|PDB:4H9N}.
FT   HELIX       265    275       {ECO:0000244|PDB:4H9N}.
FT   STRAND      278    280       {ECO:0000244|PDB:4H9S}.
FT   HELIX       286    299       {ECO:0000244|PDB:4H9N}.
FT   HELIX       306    333       {ECO:0000244|PDB:4H9N}.
FT   HELIX       339    341       {ECO:0000244|PDB:4H9N}.
FT   HELIX       346    348       {ECO:0000244|PDB:4H9N}.
FT   HELIX       350    353       {ECO:0000244|PDB:4H9N}.
FT   HELIX       355    384       {ECO:0000244|PDB:4H9N}.
SQ   SEQUENCE   740 AA;  81373 MW;  1B309ADDAA878040 CRC64;
     MATANSIIVL DDDDEDEAAA QPGPSHPLPN AASPGAEAPS SSEPHGARGS SSSGGKKCYK
     LENEKLFEEF LELCKMQTAD HPEVVPFLYN RQQRAHSLFL ASAEFCNILS RVLSRARSRP
     AKLYVYINEL CTVLKAHSAK KKLNLAPAAT TSNEPSGNNP PTHLSLDPTN AENTASQSPR
     TRGSRRQIQR LEQLLALYVA EIRRLQEKEL DLSELDDPDS AYLQEARLKR KLIRLFGRLC
     ELKDCSSLTG RVIEQRIPYR GTRYPEVNRR IERLINKPGP DTFPDYGDVL RAVEKAAARH
     SLGLPRQQLQ LMAQDAFRDV GIRLQERRHL DLIYNFGCHL TDDYRPGVDP ALSDPVLARR
     LRENRSLAMS RLDEVISKYA MLQDKSEEGE RKKRRARLQG TSSHSADTPE ASLDSGEGPS
     GMASQGCPSA SRAETDDEDD EESDEEEEEE EEEEEEEATD SEEEEDLEQM QEGQEDDEEE
     DEEEEAAAGK DGDKSPMSSL QISNEKNLEP GKQISRSSGE QQNKGRIVSP SLLSEEPLAP
     SSIDAESNGE QPEELTLEEE SPVSQLFELE IEALPLDTPS SVETDISSSR KQSEEPFTTV
     LENGAGMVSS TSFNGGVSPH NWGDSGPPCK KSRKEKKQTG SGPLGNSYVE RQRSVHEKNG
     KKICTLPSPP SPLASLAPVA DSSTRVDSPS HGLVTSSLCI PSPARLSQTP HSQPPRPGTC
     KTSVATQCDP EEIIVLSDSD
//
ID   DDB2_HUMAN              Reviewed;         427 AA.
AC   Q92466; B2R875; Q76E54; Q76E55; Q76E56; Q76E57;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   22-NOV-2017, entry version 181.
DE   RecName: Full=DNA damage-binding protein 2;
DE   AltName: Full=DDB p48 subunit;
DE            Short=DDBb;
DE   AltName: Full=Damage-specific DNA-binding protein 2;
DE   AltName: Full=UV-damaged DNA-binding protein 2;
DE            Short=UV-DDB 2;
GN   Name=DDB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Epidermis;
RX   PubMed=8530102; DOI=10.1006/geno.1995.1215;
RA   Dualan R., Brody T., Keeney S., Nichols A.F., Admon A., Linn S.;
RT   "Chromosomal localization and cDNA cloning of the genes (DDB1 and
RT   DDB2) for the p127 and p48 subunits of a human damage-specific DNA
RT   binding protein.";
RL   Genomics 29:62-69(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS D1; D2; D3 AND D4), FUNCTION,
RP   INTERACTION WITH DDB1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Epithelium;
RX   PubMed=14751237; DOI=10.1016/j.bbrc.2004.01.003;
RA   Inoki T., Yamagami S., Inoki Y., Tsuru T., Hamamoto T., Kagawa Y.,
RA   Mori T., Endo H.;
RT   "Human DDB2 splicing variants are dominant negative inhibitors of UV-
RT   damaged DNA repair.";
RL   Biochem. Biophys. Res. Commun. 314:1036-1043(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-215 AND THR-293.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH DDB1, DNA-BINDING, AND CHARACTERIZATION OF VARIANTS
RP   GLU-244 AND HIS-273.
RX   PubMed=9632823; DOI=10.1128/MCB.18.7.4391;
RA   Hwang B.J., Toering S., Francke U., Chu G.;
RT   "p48 Activates a UV-damaged-DNA binding factor and is defective in
RT   xeroderma pigmentosum group E cells that lack binding activity.";
RL   Mol. Cell. Biol. 18:4391-4399(1998).
RN   [9]
RP   FUNCTION, AND DNA-BINDING.
RX   PubMed=9892649; DOI=10.1073/pnas.96.2.424;
RA   Hwang B.J., Ford J.M., Hanawalt P.C., Chu G.;
RT   "Expression of the p48 xeroderma pigmentosum gene is p53-dependent and
RT   is involved in global genomic repair.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:424-428(1999).
RN   [10]
RP   DNA-BINDING, SUBCELLULAR LOCATION, INDUCTION, AND CHARACTERIZATION OF
RP   VARIANTS GLU-244 AND HIS-273.
RX   PubMed=10777490; DOI=10.1074/jbc.M000960200;
RA   Nichols A.F., Itoh T., Graham J.A., Liu W., Yamaizumi M., Linn S.;
RT   "Human damage-specific DNA-binding protein p48. Characterization of
RT   XPE mutations and regulation following UV irradiation.";
RL   J. Biol. Chem. 275:21422-21428(2000).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10777491; DOI=10.1074/jbc.M000961200;
RA   Liu W., Nichols A.F., Graham J.A., Dualan R., Abbas A., Linn S.;
RT   "Nuclear transport of human DDB protein induced by ultraviolet
RT   light.";
RL   J. Biol. Chem. 275:21429-21434(2000).
RN   [12]
RP   FUNCTION.
RX   PubMed=10882109; DOI=10.1016/S1097-2765(00)80252-X;
RA   Tang J.Y., Hwang B.J., Ford J.M., Hanawalt P.C., Chu G.;
RT   "Xeroderma pigmentosum p48 gene enhances global genomic repair and
RT   suppresses UV-induced mutagenesis.";
RL   Mol. Cell 5:737-744(2000).
RN   [13]
RP   FUNCTION, AND DNA-BINDING.
RX   PubMed=11278856; DOI=10.1074/jbc.M011177200;
RA   Wakasugi M., Shimizu M., Morioka H., Linn S., Nikaido O.,
RA   Matsunaga T.;
RT   "Damaged DNA-binding protein DDB stimulates the excision of
RT   cyclobutane pyrimidine dimers in vitro in concert with XPA and
RT   replication protein A.";
RL   J. Biol. Chem. 276:15434-15440(2001).
RN   [14]
RP   INTERACTION WITH CUL4A, UBIQUITINATION, AND CHARACTERIZATION OF
RP   VARIANT HIS-273.
RX   PubMed=11673459; DOI=10.1074/jbc.M106808200;
RA   Chen X., Zhang Y., Douglas L., Zhou P.;
RT   "UV-damaged DNA-binding proteins are targets of CUL-4A-mediated
RT   ubiquitination and degradation.";
RL   J. Biol. Chem. 276:48175-48182(2001).
RN   [15]
RP   FUNCTION, DNA-BINDING, AND SUBCELLULAR LOCATION.
RX   PubMed=11705987; DOI=10.1074/jbc.C100610200;
RA   Wakasugi M., Kawashima A., Morioka H., Linn S., Sancar A., Mori T.,
RA   Nikaido O., Matsunaga T.;
RT   "DDB accumulates at DNA damage sites immediately after UV irradiation
RT   and directly stimulates nucleotide excision repair.";
RL   J. Biol. Chem. 277:1637-1640(2002).
RN   [16]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A
RP   COMPLEX WITH CUL4A; DDB1 AND RBX1 AND THE COP9 SIGNALOSOME, AND
RP   DNA-BINDING.
RX   PubMed=12732143; DOI=10.1016/S0092-8674(03)00316-7;
RA   Groisman R., Polanowska J., Kuraoka I., Sawada J., Saijo M.,
RA   Drapkin R., Kisselev A.F., Tanaka K., Nakatani Y.;
RT   "The ubiquitin ligase activity in the DDB2 and CSA complexes is
RT   differentially regulated by the COP9 signalosome in response to DNA
RT   damage.";
RL   Cell 113:357-367(2003).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12944386; DOI=10.1074/jbc.M307254200;
RA   Fitch M.E., Nakajima S., Yasui A., Ford J.M.;
RT   "In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine
RT   dimers by the DDB2 gene product.";
RL   J. Biol. Chem. 278:46906-46910(2003).
RN   [18]
RP   FUNCTION, INTERACTION WITH CUL4A; DDB1; RBX1 AND XPC, DNA-BINDING, AND
RP   UBIQUITINATION.
RX   PubMed=15882621; DOI=10.1016/j.cell.2005.02.035;
RA   Sugasawa K., Okuda Y., Saijo M., Nishi R., Matsuda N., Chu G.,
RA   Mori T., Iwai S., Tanaka K., Tanaka K., Hanaoka F.;
RT   "UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin
RT   ligase complex.";
RL   Cell 121:387-400(2005).
RN   [19]
RP   INTERACTION WITH DDB1, DNA-BINDING, AND CHARACTERIZATION OF VARIANTS
RP   GLU-244 AND HIS-273.
RX   PubMed=16223728; DOI=10.1074/jbc.M507854200;
RA   Wittschieben B.O., Iwai S., Wood R.D.;
RT   "DDB1-DDB2 (xeroderma pigmentosum group E) protein complex recognizes
RT   a cyclobutane pyrimidine dimer, mismatches, apurinic/apyrimidinic
RT   sites, and compound lesions in DNA.";
RL   J. Biol. Chem. 280:39982-39989(2005).
RN   [20]
RP   FUNCTION, INTERACTION WITH CUL4A; DDB1; RBX1 AND THE COP9 SIGNALOSOME,
RP   AND DNA-BINDING.
RX   PubMed=16260596; DOI=10.1128/MCB.25.22.9784-9792.2005;
RA   Kulaksiz G., Reardon J.T., Sancar A.;
RT   "Xeroderma pigmentosum complementation group E protein (XPE/DDB2):
RT   purification of various complexes of XPE and analyses of their damaged
RT   DNA binding and putative DNA repair properties.";
RL   Mol. Cell. Biol. 25:9784-9792(2005).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24 AND SER-26, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [22]
RP   INTERACTION WITH CUL4A AND DDB1, DOMAIN DWD BOX MOTIF, AND MUTAGENESIS
RP   OF LEU-258; SER-262; ASP-264; ILE-269; TRP-270; LEU-272 AND ARG-273.
RX   PubMed=17079684; DOI=10.1101/gad.1483206;
RA   He Y.J., McCall C.M., Hu J., Zeng Y., Xiong Y.;
RT   "DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-
RT   ROC1 ubiquitin ligases.";
RL   Genes Dev. 20:2949-2954(2006).
RN   [23]
RP   INTERACTION WITH CUL4A AND DDB1, AND UBIQUITINATION.
RX   PubMed=16527807; DOI=10.1074/jbc.M511834200;
RA   El-Mahdy M.A., Zhu Q., Wang Q.-E., Wani G., Praetorius-Ibba M.,
RA   Wani A.A.;
RT   "Cullin 4A-mediated proteolysis of DDB2 protein at DNA damage sites
RT   regulates in vivo lesion recognition by XPC.";
RL   J. Biol. Chem. 281:13404-13411(2006).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A COMPLEX WITH
RP   DDB1; CUL4A; CUL4B AND RBX1, AND FUNCTION.
RX   PubMed=16678110; DOI=10.1016/j.molcel.2006.03.035;
RA   Wang H., Zhai L., Xu J., Joo H.-Y., Jackson S., Erdjument-Bromage H.,
RA   Tempst P., Xiong Y., Zhang Y.;
RT   "Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin
RT   ligase facilitates cellular response to DNA damage.";
RL   Mol. Cell 22:383-394(2006).
RN   [25]
RP   SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=16713579; DOI=10.1016/j.molcel.2006.04.021;
RA   Chen X., Zhang J., Lee J., Lin P.S., Ford J.M., Zheng N., Zhou P.;
RT   "A kinase-independent function of c-Abl in promoting proteolytic
RT   destruction of damaged DNA binding proteins.";
RL   Mol. Cell 22:489-499(2006).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH DDB1,
RP   MUTAGENESIS OF LEU-350, AND CHARACTERIZATION OF VARIANT HIS-273.
RX   PubMed=16949367; DOI=10.1016/j.molcel.2006.08.010;
RA   Jin J., Arias E.E., Chen J., Harper J.W., Walter J.C.;
RT   "A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2,
RT   which is required for S phase destruction of the replication factor
RT   Cdt1.";
RL   Mol. Cell 23:709-721(2006).
RN   [27]
RP   INTERACTION WITH DDB1, AND CHARACTERIZATION OF VARIANT HIS-273.
RX   PubMed=16964240; DOI=10.1038/nature05175;
RA   Angers S., Li T., Yi X., MacCoss M.J., Moon R.T., Zheng N.;
RT   "Molecular architecture and assembly of the DDB1-CUL4A ubiquitin
RT   ligase machinery.";
RL   Nature 443:590-593(2006).
RN   [28]
RP   INTERACTION WITH CUL4A AND CUL4B.
RX   PubMed=17041588; DOI=10.1038/ncb1490;
RA   Higa L.A., Wu M., Ye T., Kobayashi R., Sun H., Zhang H.;
RT   "CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat
RT   proteins and regulates histone methylation.";
RL   Nat. Cell Biol. 8:1277-1283(2006).
RN   [29]
RP   FUNCTION, INTERACTION WITH CUL4A; DDB1; HISTONE H2A AND RBX1,
RP   DNA-BINDING, AND SUBCELLULAR LOCATION.
RX   PubMed=16473935; DOI=10.1073/pnas.0511160103;
RA   Kapetanaki M.G., Guerrero-Santoro J., Bisi D.C., Hsieh C.L.,
RA   Rapic-Otrin V., Levine A.S.;
RT   "The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma
RT   pigmentosum group E and targets histone H2A at UV-damaged DNA sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:2588-2593(2006).
RN   [30]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17635991; DOI=10.1242/jcs.008367;
RA   Luijsterburg M.S., Goedhart J., Moser J., Kool H., Geverts B.,
RA   Houtsmuller A.B., Mullenders L.H.F., Vermeulen W., van Driel R.;
RT   "Dynamic in vivo interaction of DDB2 E3 ubiquitin ligase with UV-
RT   damaged DNA is independent of damage-recognition protein XPC.";
RL   J. Cell Sci. 120:2706-2716(2007).
RN   [31]
RP   FUNCTION, INTERACTION WITH CUL4A; CUL4B AND DDB1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18593899; DOI=10.1158/0008-5472.CAN-07-6162;
RA   Guerrero-Santoro J., Kapetanaki M.G., Hsieh C.L., Gorbachinsky I.,
RA   Levine A.S., Rapic-Otrin V.;
RT   "The cullin 4B-based UV-damaged DNA-binding protein ligase binds to
RT   UV-damaged chromatin and ubiquitinates histone H2A.";
RL   Cancer Res. 68:5014-5022(2008).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [36]
RP   DEUBIQUITINATION BY USP24.
RX   PubMed=23159851; DOI=10.4161/cc.22688;
RA   Zhang L., Lubin A., Chen H., Sun Z., Gong F.;
RT   "The deubiquitinating protein USP24 interacts with DDB2 and regulates
RT   DDB2 stability.";
RL   Cell Cycle 11:4378-4384(2012).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24 AND SER-26, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 10-427 IN COMPLEX WITH DDB1
RP   AND DNA, AND WD REPEATS.
RX   PubMed=19109893; DOI=10.1016/j.cell.2008.10.045;
RA   Scrima A., Konickova R., Czyzewski B.K., Kawasaki Y., Jeffrey P.D.,
RA   Groisman R., Nakatani Y., Iwai S., Pavletich N.P., Thoma N.H.;
RT   "Structural basis of UV DNA-damage recognition by the DDB1-DDB2
RT   complex.";
RL   Cell 135:1213-1223(2008).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 68-81 IN COMPLEX WITH DDB1.
RX   PubMed=19966799; DOI=10.1038/nsmb.1719;
RA   Li T., Robert E.I., van Breugel P.C., Strubin M., Zheng N.;
RT   "A promiscuous alpha-helical motif anchors viral hijackers and
RT   substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery.";
RL   Nat. Struct. Mol. Biol. 17:105-111(2010).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) IN COMPLEX WITH DDB1.
RX   PubMed=22822215; DOI=10.1073/pnas.1110067109;
RA   Yeh J.I., Levine A.S., Du S., Chinte U., Ghodke H., Wang H., Shi H.,
RA   Hsieh C.L., Conway J.F., Van Houten B., Rapic-Otrin V.;
RT   "Damaged DNA induced UV-damaged DNA-binding protein (UV-DDB)
RT   dimerization and its roles in chromatinized DNA repair.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:E2737-E2746(2012).
RN   [41]
RP   VARIANTS XP-E GLU-244 AND HIS-273.
RX   PubMed=8798680; DOI=10.1074/jbc.271.40.24317;
RA   Nichols A.F., Ong P., Linn S.;
RT   "Mutations specific to the xeroderma pigmentosum group E Ddb-
RT   phenotype.";
RL   J. Biol. Chem. 271:24317-24320(1996).
CC   -!- FUNCTION: Required for DNA repair. Binds to DDB1 to form the UV-
CC       damaged DNA-binding protein complex (the UV-DDB complex). The UV-
CC       DDB complex may recognize UV-induced DNA damage and recruit
CC       proteins of the nucleotide excision repair pathway (the NER
CC       pathway) to initiate DNA repair. The UV-DDB complex preferentially
CC       binds to cyclobutane pyrimidine dimers (CPD), 6-4 photoproducts
CC       (6-4 PP), apurinic sites and short mismatches. Also appears to
CC       function as the substrate recognition module for the DCX (DDB1-
CC       CUL4-X-box) E3 ubiquitin-protein ligase complex DDB1-CUL4-ROC1
CC       (also known as CUL4-DDB-ROC1 and CUL4-DDB-RBX1). The DDB1-CUL4-
CC       ROC1 complex may ubiquitinate histone H2A, histone H3 and histone
CC       H4 at sites of UV-induced DNA damage. The ubiquitination of
CC       histones may facilitate their removal from the nucleosome and
CC       promote subsequent DNA repair. The DDB1-CUL4-ROC1 complex also
CC       ubiquitinates XPC, which may enhance DNA-binding by XPC and
CC       promote NER. Isoform D1 and isoform D2 inhibit UV-damaged DNA
CC       repair. {ECO:0000269|PubMed:10882109, ECO:0000269|PubMed:11278856,
CC       ECO:0000269|PubMed:11705987, ECO:0000269|PubMed:12732143,
CC       ECO:0000269|PubMed:12944386, ECO:0000269|PubMed:14751237,
CC       ECO:0000269|PubMed:15882621, ECO:0000269|PubMed:16260596,
CC       ECO:0000269|PubMed:16473935, ECO:0000269|PubMed:16678110,
CC       ECO:0000269|PubMed:18593899, ECO:0000269|PubMed:9892649}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Component of the UV-DDB complex which includes DDB1 and
CC       DDB2. The UV-DDB complex interacts with monoubiquitinated histone
CC       H2A and binds to XPC via the DDB2 subunit. Component of the DCX
CC       (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex DDB1-CUL4-
CC       ROC1 (also known as CUL4-DDB-ROC1 and CUL4-DDB-RBX1), which
CC       includes CUL4A or CUL4B, DDB1, DDB2 and RBX1. DDB2 may function as
CC       the substrate recognition module within this complex. The DDB1-
CC       CUL4-ROC1 complex may associate with the COP9 signalosome, and
CC       this inhibits the E3 ubiquitin-protein ligase activity of the
CC       complex. A large number of other DCX complexes may also exist in
CC       which an alternate substrate targeting subunit replaces DDB2.
CC       These targeting subunits are generally known as DCAF (DDB1- and
CC       CUL4-associated factor) or CDW (CUL4-DDB1-associated WD40-repeat)
CC       proteins. Isoform D1 and isoform D2 do not interact with DDB1.
CC       {ECO:0000269|PubMed:11673459, ECO:0000269|PubMed:12732143,
CC       ECO:0000269|PubMed:14751237, ECO:0000269|PubMed:15882621,
CC       ECO:0000269|PubMed:16223728, ECO:0000269|PubMed:16260596,
CC       ECO:0000269|PubMed:16473935, ECO:0000269|PubMed:16527807,
CC       ECO:0000269|PubMed:16678110, ECO:0000269|PubMed:16949367,
CC       ECO:0000269|PubMed:16964240, ECO:0000269|PubMed:17041588,
CC       ECO:0000269|PubMed:17079684, ECO:0000269|PubMed:18593899,
CC       ECO:0000269|PubMed:19109893, ECO:0000269|PubMed:19966799,
CC       ECO:0000269|PubMed:22822215, ECO:0000269|PubMed:9632823}.
CC   -!- INTERACTION:
CC       Q13619:CUL4A; NbExp=5; IntAct=EBI-1176171, EBI-456106;
CC       Q16531:DDB1; NbExp=19; IntAct=EBI-1176171, EBI-350322;
CC       Q01094:E2F1; NbExp=2; IntAct=EBI-1176171, EBI-448924;
CC       Q01831-1:XPC; NbExp=4; IntAct=EBI-1176171, EBI-15950383;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10777490,
CC       ECO:0000269|PubMed:10777491, ECO:0000269|PubMed:11705987,
CC       ECO:0000269|PubMed:12944386, ECO:0000269|PubMed:14751237,
CC       ECO:0000269|PubMed:16473935, ECO:0000269|PubMed:16713579,
CC       ECO:0000269|PubMed:17635991, ECO:0000269|PubMed:18593899}.
CC       Note=Accumulates at sites of DNA damage following UV irradiation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q92466-1; Sequence=Displayed;
CC       Name=D1;
CC         IsoId=Q92466-2; Sequence=VSP_014675;
CC       Name=D2;
CC         IsoId=Q92466-3; Sequence=VSP_014676, VSP_014677;
CC       Name=D3;
CC         IsoId=Q92466-4; Sequence=VSP_014674;
CC       Name=D4;
CC         IsoId=Q92466-5; Sequence=VSP_014678, VSP_014679;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed; with highest levels in
CC       corneal endothelium and lowest levels in brain. Isoform D1 is
CC       highly expressed in brain and heart. Isoform D2, isoform D3 and
CC       isoform D4 are weakly expressed. {ECO:0000269|PubMed:14751237}.
CC   -!- INDUCTION: Expression is induced in response to treatment with IR
CC       or UV and this requires p53/TP53 activity.
CC       {ECO:0000269|PubMed:10777490}.
CC   -!- DOMAIN: The DWD box is required for interaction with DDB1.
CC       {ECO:0000269|PubMed:17079684}.
CC   -!- DOMAIN: Interblade loops of the WD repeat region mediate most of
CC       the interaction with DNA. A hairpin between blades 5 and 6 inserts
CC       into DNA minor groove and mediates recognition of lesions and
CC       separation of the damaged and undamaged strands.
CC       {ECO:0000269|PubMed:17079684}.
CC   -!- PTM: Phosphorylation by ABL1 negatively regulate UV-DDB activity.
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by CUL4A in response to UV irradiation.
CC       Ubiquitination appears to both impair DNA-binding and promotes
CC       ubiquitin-dependent proteolysis. Degradation of DDB2 at sites of
CC       DNA damage may be a prerequisite for their recognition by XPC and
CC       subsequent repair. CUL4A-mediated degradation appears to be
CC       promoted by ABL1. {ECO:0000269|PubMed:23159851}.
CC   -!- PTM: Ubiquitinated, leading to proteasomal degradation, and
CC       deubiquitinated by USP24. {ECO:0000269|PubMed:23159851}.
CC   -!- DISEASE: Xeroderma pigmentosum complementation group E (XP-E)
CC       [MIM:278740]: An autosomal recessive pigmentary skin disorder
CC       characterized by solar hypersensitivity of the skin, high
CC       predisposition for developing cancers on areas exposed to sunlight
CC       and, in some cases, neurological abnormalities. The skin develops
CC       marked freckling and other pigmentation abnormalities. XP-E
CC       patients show a mild phenotype with minimal or no neurologic
CC       features. {ECO:0000269|PubMed:8798680}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the WD repeat DDB2/WDR76 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/XPEID298.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ddb2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U18300; AAB07897.1; -; mRNA.
DR   EMBL; AB107037; BAD12557.1; -; mRNA.
DR   EMBL; AB107038; BAD12558.1; -; mRNA.
DR   EMBL; AB107039; BAD12559.1; -; mRNA.
DR   EMBL; AB107040; BAD12560.1; -; mRNA.
DR   EMBL; BT007139; AAP35803.1; -; mRNA.
DR   EMBL; AY220533; AAO25655.1; -; Genomic_DNA.
DR   EMBL; AK313262; BAG36072.1; -; mRNA.
DR   EMBL; CH471064; EAW67952.1; -; Genomic_DNA.
DR   EMBL; BC000093; AAH00093.1; -; mRNA.
DR   CCDS; CCDS73284.1; -. [Q92466-2]
DR   CCDS; CCDS7927.1; -. [Q92466-1]
DR   PIR; I38909; I38909.
DR   RefSeq; NP_000098.1; NM_000107.2. [Q92466-1]
DR   RefSeq; NP_001287663.1; NM_001300734.1. [Q92466-2]
DR   UniGene; Hs.700338; -.
DR   PDB; 3EI4; X-ray; 3.30 A; B/D/F=10-427.
DR   PDB; 3I7L; X-ray; 2.80 A; B=68-81.
DR   PDB; 4E54; X-ray; 2.85 A; B=2-427.
DR   PDB; 4E5Z; X-ray; 3.22 A; B=2-427.
DR   PDBsum; 3EI4; -.
DR   PDBsum; 3I7L; -.
DR   PDBsum; 4E54; -.
DR   PDBsum; 4E5Z; -.
DR   ProteinModelPortal; Q92466; -.
DR   SMR; Q92466; -.
DR   BioGrid; 108010; 86.
DR   CORUM; Q92466; -.
DR   DIP; DIP-36670N; -.
DR   IntAct; Q92466; 27.
DR   STRING; 9606.ENSP00000256996; -.
DR   iPTMnet; Q92466; -.
DR   PhosphoSitePlus; Q92466; -.
DR   BioMuta; DDB2; -.
DR   DMDM; 12230033; -.
DR   EPD; Q92466; -.
DR   MaxQB; Q92466; -.
DR   PaxDb; Q92466; -.
DR   PeptideAtlas; Q92466; -.
DR   PRIDE; Q92466; -.
DR   DNASU; 1643; -.
DR   Ensembl; ENST00000256996; ENSP00000256996; ENSG00000134574. [Q92466-1]
DR   Ensembl; ENST00000378600; ENSP00000367863; ENSG00000134574. [Q92466-2]
DR   Ensembl; ENST00000378601; ENSP00000367864; ENSG00000134574. [Q92466-5]
DR   Ensembl; ENST00000378603; ENSP00000367866; ENSG00000134574. [Q92466-4]
DR   Ensembl; ENST00000616278; ENSP00000478411; ENSG00000134574. [Q92466-3]
DR   GeneID; 1643; -.
DR   KEGG; hsa:1643; -.
DR   UCSC; uc001neb.3; human. [Q92466-1]
DR   CTD; 1643; -.
DR   DisGeNET; 1643; -.
DR   EuPathDB; HostDB:ENSG00000134574.11; -.
DR   GeneCards; DDB2; -.
DR   GeneReviews; DDB2; -.
DR   HGNC; HGNC:2718; DDB2.
DR   HPA; CAB025912; -.
DR   HPA; HPA058406; -.
DR   MalaCards; DDB2; -.
DR   MIM; 278740; phenotype.
DR   MIM; 600811; gene.
DR   neXtProt; NX_Q92466; -.
DR   OpenTargets; ENSG00000134574; -.
DR   Orphanet; 276261; Xeroderma pigmentosum complementation group E.
DR   PharmGKB; PA27188; -.
DR   eggNOG; ENOG410IMQS; Eukaryota.
DR   eggNOG; COG2319; LUCA.
DR   GeneTree; ENSGT00510000047881; -.
DR   HOGENOM; HOG000231440; -.
DR   HOVERGEN; HBG000713; -.
DR   InParanoid; Q92466; -.
DR   KO; K10140; -.
DR   OMA; VTCLEWH; -.
DR   OrthoDB; EOG091G06BL; -.
DR   PhylomeDB; Q92466; -.
DR   TreeFam; TF331587; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5696394; DNA Damage Recognition in GG-NER.
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   SignaLink; Q92466; -.
DR   SIGNOR; Q92466; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; DDB2; human.
DR   EvolutionaryTrace; Q92466; -.
DR   GeneWiki; DDB2; -.
DR   GenomeRNAi; 1643; -.
DR   PRO; PR:Q92466; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000134574; -.
DR   CleanEx; HS_DDB2; -.
DR   ExpressionAtlas; Q92466; baseline and differential.
DR   Genevisible; Q92466; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0080008; C:Cul4-RING E3 ubiquitin ligase complex; IMP:UniProtKB.
DR   GO; GO:0031465; C:Cul4B-RING E3 ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; TAS:ProtInc.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0032403; F:protein complex binding; IPI:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0070911; P:global genome nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0035518; P:histone H2A monoubiquitination; IDA:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; TAS:ProtInc.
DR   GO; GO:0000715; P:nucleotide-excision repair, DNA damage recognition; TAS:Reactome.
DR   GO; GO:0000717; P:nucleotide-excision repair, DNA duplex unwinding; TAS:Reactome.
DR   GO; GO:0033683; P:nucleotide-excision repair, DNA incision; TAS:Reactome.
DR   GO; GO:0006295; P:nucleotide-excision repair, DNA incision, 3'-to lesion; TAS:Reactome.
DR   GO; GO:0006296; P:nucleotide-excision repair, DNA incision, 5'-to lesion; TAS:Reactome.
DR   GO; GO:0006294; P:nucleotide-excision repair, preincision complex assembly; TAS:Reactome.
DR   GO; GO:0006293; P:nucleotide-excision repair, preincision complex stabilization; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0006290; P:pyrimidine dimer repair; IEA:Ensembl.
DR   GO; GO:0009411; P:response to UV; IDA:UniProtKB.
DR   GO; GO:0070914; P:UV-damage excision repair; IDA:UniProtKB.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR033312; DDB2.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   PANTHER; PTHR15169; PTHR15169; 1.
DR   Pfam; PF00400; WD40; 1.
DR   SMART; SM00320; WD40; 5.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 1.
DR   PROSITE; PS50082; WD_REPEATS_2; 1.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Disease mutation; DNA damage; DNA repair; DNA-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Ubl conjugation; Ubl conjugation pathway; WD repeat;
KW   Xeroderma pigmentosum.
FT   CHAIN         1    427       DNA damage-binding protein 2.
FT                                /FTId=PRO_0000050953.
FT   REPEAT      116    151       WD 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00221,
FT                                ECO:0000269|PubMed:19109893}.
FT   REPEAT      159    194       WD 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00221,
FT                                ECO:0000269|PubMed:19109893}.
FT   REPEAT      203    238       WD 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00221,
FT                                ECO:0000269|PubMed:19109893}.
FT   REPEAT      244    287       WD 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00221,
FT                                ECO:0000269|PubMed:19109893}.
FT   REPEAT      290    329       WD 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00221,
FT                                ECO:0000269|PubMed:19109893}.
FT   REPEAT      343    386       WD 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00221,
FT                                ECO:0000269|PubMed:19109893}.
FT   REPEAT      396    420       WD 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00221,
FT                                ECO:0000269|PubMed:19109893}.
FT   REGION       68     79       Required for interaction with DDB1.
FT   REGION       87     98       Required for interaction with DDB1.
FT   REGION      334    336       Photolesion recognition.
FT   MOTIF       256    274       DWD box.
FT   MOD_RES      24     24       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      26     26       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ      89    152       Missing (in isoform D3).
FT                                {ECO:0000303|PubMed:14751237}.
FT                                /FTId=VSP_014674.
FT   VAR_SEQ     153    341       Missing (in isoform D1).
FT                                {ECO:0000303|PubMed:14751237}.
FT                                /FTId=VSP_014675.
FT   VAR_SEQ     153    156       IGAG -> HLVL (in isoform D2).
FT                                {ECO:0000303|PubMed:14751237}.
FT                                /FTId=VSP_014676.
FT   VAR_SEQ     157    427       Missing (in isoform D2).
FT                                {ECO:0000303|PubMed:14751237}.
FT                                /FTId=VSP_014677.
FT   VAR_SEQ     236    244       WNLRMHKKK -> VSVPMEPGS (in isoform D4).
FT                                {ECO:0000303|PubMed:14751237}.
FT                                /FTId=VSP_014678.
FT   VAR_SEQ     245    427       Missing (in isoform D4).
FT                                {ECO:0000303|PubMed:14751237}.
FT                                /FTId=VSP_014679.
FT   VARIANT     215    215       M -> T (in dbSNP:rs4647750).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016337.
FT   VARIANT     244    244       K -> E (in XP-E; impairs DNA-binding of
FT                                the UV-DDB complex; dbSNP:rs121434639).
FT                                {ECO:0000269|PubMed:10777490,
FT                                ECO:0000269|PubMed:16223728,
FT                                ECO:0000269|PubMed:8798680,
FT                                ECO:0000269|PubMed:9632823}.
FT                                /FTId=VAR_010141.
FT   VARIANT     273    273       R -> H (in XP-E; impairs interaction with
FT                                DDB1 and CUL4A; dbSNP:rs121434640).
FT                                {ECO:0000269|PubMed:10777490,
FT                                ECO:0000269|PubMed:11673459,
FT                                ECO:0000269|PubMed:16223728,
FT                                ECO:0000269|PubMed:16949367,
FT                                ECO:0000269|PubMed:16964240,
FT                                ECO:0000269|PubMed:8798680,
FT                                ECO:0000269|PubMed:9632823}.
FT                                /FTId=VAR_010142.
FT   VARIANT     293    293       A -> T (in dbSNP:rs4647751).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016338.
FT   MUTAGEN     258    258       L->A: Impairs interaction with DDB1.
FT                                {ECO:0000269|PubMed:17079684}.
FT   MUTAGEN     262    262       S->A: Impairs interaction with DDB1.
FT                                {ECO:0000269|PubMed:17079684}.
FT   MUTAGEN     264    264       D->A: Impairs interaction with DDB1.
FT                                {ECO:0000269|PubMed:17079684}.
FT   MUTAGEN     269    269       I->A: Impairs interaction with DDB1.
FT                                {ECO:0000269|PubMed:17079684}.
FT   MUTAGEN     270    270       W->A: Impairs interaction with DDB1.
FT                                {ECO:0000269|PubMed:17079684}.
FT   MUTAGEN     272    272       L->A: Impairs interaction with DDB1.
FT                                {ECO:0000269|PubMed:17079684}.
FT   MUTAGEN     273    273       R->A: Impairs interaction with DDB1.
FT                                {ECO:0000269|PubMed:17079684}.
FT   MUTAGEN     350    350       L->P: Impairs interaction with DDB1.
FT                                {ECO:0000269|PubMed:16949367}.
FT   HELIX        21     25       {ECO:0000244|PDB:4E54}.
FT   STRAND       30     32       {ECO:0000244|PDB:4E54}.
FT   HELIX        39     42       {ECO:0000244|PDB:4E54}.
FT   TURN         44     47       {ECO:0000244|PDB:4E54}.
FT   STRAND       49     51       {ECO:0000244|PDB:4E54}.
FT   HELIX        58     62       {ECO:0000244|PDB:4E54}.
FT   TURN         63     65       {ECO:0000244|PDB:4E54}.
FT   HELIX        69     77       {ECO:0000244|PDB:3I7L}.
FT   HELIX        83     91       {ECO:0000244|PDB:4E54}.
FT   TURN         92     94       {ECO:0000244|PDB:4E54}.
FT   TURN         96    102       {ECO:0000244|PDB:4E54}.
FT   STRAND      106    109       {ECO:0000244|PDB:4E54}.
FT   STRAND      114    119       {ECO:0000244|PDB:4E54}.
FT   STRAND      127    131       {ECO:0000244|PDB:4E54}.
FT   STRAND      136    139       {ECO:0000244|PDB:4E54}.
FT   STRAND      148    150       {ECO:0000244|PDB:4E54}.
FT   STRAND      154    156       {ECO:0000244|PDB:4E54}.
FT   STRAND      161    164       {ECO:0000244|PDB:4E54}.
FT   STRAND      171    175       {ECO:0000244|PDB:4E54}.
FT   STRAND      177    179       {ECO:0000244|PDB:4E54}.
FT   STRAND      181    185       {ECO:0000244|PDB:4E54}.
FT   TURN        186    188       {ECO:0000244|PDB:3EI4}.
FT   STRAND      190    195       {ECO:0000244|PDB:4E54}.
FT   STRAND      198    201       {ECO:0000244|PDB:4E5Z}.
FT   STRAND      207    210       {ECO:0000244|PDB:4E54}.
FT   TURN        211    214       {ECO:0000244|PDB:4E54}.
FT   STRAND      215    219       {ECO:0000244|PDB:4E54}.
FT   STRAND      221    232       {ECO:0000244|PDB:4E54}.
FT   STRAND      241    243       {ECO:0000244|PDB:4E5Z}.
FT   STRAND      245    250       {ECO:0000244|PDB:4E54}.
FT   TURN        252    254       {ECO:0000244|PDB:4E5Z}.
FT   STRAND      255    262       {ECO:0000244|PDB:4E54}.
FT   TURN        263    265       {ECO:0000244|PDB:4E5Z}.
FT   STRAND      269    271       {ECO:0000244|PDB:4E54}.
FT   TURN        272    274       {ECO:0000244|PDB:4E54}.
FT   STRAND      277    279       {ECO:0000244|PDB:4E54}.
FT   STRAND      282    286       {ECO:0000244|PDB:3EI4}.
FT   STRAND      291    293       {ECO:0000244|PDB:4E54}.
FT   STRAND      300    310       {ECO:0000244|PDB:4E54}.
FT   STRAND      312    326       {ECO:0000244|PDB:4E54}.
FT   STRAND      335    337       {ECO:0000244|PDB:4E54}.
FT   STRAND      346    349       {ECO:0000244|PDB:4E54}.
FT   STRAND      351    354       {ECO:0000244|PDB:4E54}.
FT   STRAND      359    361       {ECO:0000244|PDB:4E5Z}.
FT   STRAND      364    366       {ECO:0000244|PDB:3EI4}.
FT   STRAND      372    375       {ECO:0000244|PDB:4E54}.
FT   STRAND      377    379       {ECO:0000244|PDB:4E54}.
FT   STRAND      382    386       {ECO:0000244|PDB:4E54}.
FT   TURN        389    391       {ECO:0000244|PDB:3EI4}.
FT   STRAND      397    400       {ECO:0000244|PDB:4E54}.
FT   STRAND      407    410       {ECO:0000244|PDB:4E54}.
FT   STRAND      412    417       {ECO:0000244|PDB:4E54}.
SQ   SEQUENCE   427 AA;  47864 MW;  E881F21242CA44D2 CRC64;
     MAPKKRPETQ KTSEIVLRPR NKRSRSPLEL EPEAKKLCAK GSGPSRRCDS DCLWVGLAGP
     QILPPCRSIV RTLHQHKLGR ASWPSVQQGL QQSFLHTLDS YRILQKAAPF DRRATSLAWH
     PTHPSTVAVG SKGGDIMLWN FGIKDKPTFI KGIGAGGSIT GLKFNPLNTN QFYASSMEGT
     TRLQDFKGNI LRVFASSDTI NIWFCSLDVS ASSRMVVTGD NVGNVILLNM DGKELWNLRM
     HKKKVTHVAL NPCCDWFLAT ASVDQTVKIW DLRQVRGKAS FLYSLPHRHP VNAACFSPDG
     ARLLTTDQKS EIRVYSASQW DCPLGLIPHP HRHFQHLTPI KAAWHPRYNL IVVGRYPDPN
     FKSCTPYELR TIDVFDGNSG KMMCQLYDPE SSGISSLNEF NPMGDTLASA MGYHILIWSQ
     EEARTRK
//
ID   B3KW07_HUMAN            Unreviewed;       336 AA.
AC   B3KW07;
DT   02-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   02-SEP-2008, sequence version 1.
DT   31-JAN-2018, entry version 57.
DE   SubName: Full=cDNA FLJ41851 fis, clone NT2RI3003925, highly similar to Endothelial PAS domain-containing protein 1 {ECO:0000313|EMBL:BAG53969.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG53969.1};
RN   [1] {ECO:0000313|EMBL:BAG53969.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK123845; BAG53969.1; -; mRNA.
DR   RefSeq; NP_001421.2; NM_001430.4.
DR   UniGene; Hs.468410; -.
DR   PeptideAtlas; B3KW07; -.
DR   PRIDE; B3KW07; -.
DR   GeneID; 2034; -.
DR   KEGG; hsa:2034; -.
DR   CTD; 2034; -.
DR   PharmGKB; PA27809; -.
DR   eggNOG; KOG3558; Eukaryota.
DR   eggNOG; ENOG410YK57; LUCA.
DR   HOVERGEN; HBG101948; -.
DR   KO; K09095; -.
DR   GenomeRNAi; 2034; -.
DR   Genevisible; B3KW07; HS.
DR   InterPro; IPR014887; HIF-1_TAD_C.
DR   InterPro; IPR021537; HIF_alpha_subunit.
DR   Pfam; PF11413; HIF-1; 1.
DR   Pfam; PF08778; HIF-1a_CTAD; 1.
PE   2: Evidence at transcript level;
FT   DOMAIN      299    335       HIF-1a_CTAD. {ECO:0000259|Pfam:PF08778}.
SQ   SEQUENCE   336 AA;  36509 MW;  D5C86DD03FDE0B34 CRC64;
     MDGEDFQLSP ICPEERLLAE NPQSTPQHCF SAMTNIFQPL APVAPHSPFL LDKFQQQLES
     KKTEPEHRPM SSIFFDAGSK ASLPPCCGQA STPLSSMGGR SNTQWPPDPP LHFGPTKWAV
     GDQRTEFLGA APLGPPVSPP HVSTFKTRSA KGFGARGPDV LSPAMVALSN KLKLKRQLEY
     EEQAFQDLSG GDPPGGSTSH LMWKRMKNLR GGSCPLMPDK PLSANVPNDK FTQNPMRGLG
     HPLRHLPLPQ PPSAISPGEN SKSRFPPQCY ATQYQDYSLS SAHKVSGMAS RLLGPSFESY
     LLPELTRYDC EVNVPVLGSS TLLQGGDLLR ALDQAT
//
ID   EPAS1_HUMAN             Reviewed;         870 AA.
AC   Q99814; Q86VA2; Q99630;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   03-JUL-2003, sequence version 3.
DT   28-FEB-2018, entry version 193.
DE   RecName: Full=Endothelial PAS domain-containing protein 1;
DE            Short=EPAS-1;
DE   AltName: Full=Basic-helix-loop-helix-PAS protein MOP2;
DE   AltName: Full=Class E basic helix-loop-helix protein 73;
DE            Short=bHLHe73;
DE   AltName: Full=HIF-1-alpha-like factor;
DE            Short=HLF;
DE   AltName: Full=Hypoxia-inducible factor 2-alpha;
DE            Short=HIF-2-alpha;
DE            Short=HIF2-alpha;
DE   AltName: Full=Member of PAS protein 2;
DE   AltName: Full=PAS domain-containing protein 2;
GN   Name=EPAS1; Synonyms=BHLHE73, HIF2A, MOP2, PASD2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9000051; DOI=10.1101/gad.11.1.72;
RA   Tian H., McKnight S.L., Russell D.W.;
RT   "Endothelial PAS domain protein 1 (EPAS1), a transcription factor
RT   selectively expressed in endothelial cells.";
RL   Genes Dev. 11:72-82(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hepatoma;
RX   PubMed=9079689; DOI=10.1074/jbc.272.13.8581;
RA   Hogenesch J.B., Chan W.K., Jackiw V.H., Brown R.C., Gu Y.-Z.,
RA   Pray-Grant M., Perdew G.H., Bradfield C.A.;
RT   "Characterization of a subset of the basic-helix-loop-helix-PAS
RT   superfamily that interacts with components of the dioxin signaling
RT   pathway.";
RL   J. Biol. Chem. 272:8581-8593(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   TRANSACTIVATION DOMAINS NTAD AND CTAD, INTERACTION WITH APEX, AND
RP   MUTAGENESIS OF CYS-844.
RX   PubMed=10202154; DOI=10.1093/emboj/18.7.1905;
RA   Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K.,
RA   Poellinger L., Fujii-Kuriyama Y.;
RT   "Molecular mechanisms of transcription activation by HLF and HIF1alpha
RT   in response to hypoxia: their stabilization and redox signal-induced
RT   interaction with CBP/p300.";
RL   EMBO J. 18:1905-1914(1999).
RN   [5]
RP   INTERACTION WITH EGLN1 AND VHL, VARIANT ECYT4 LEU-534, AND
RP   CHARACTERIZATION OF VARIANTS ECYT4 LEU-534; VAL-535 AND ARG-537.
RX   PubMed=19208626; DOI=10.1074/jbc.M808737200;
RA   Furlow P.W., Percy M.J., Sutherland S., Bierl C., McMullin M.F.,
RA   Master S.R., Lappin T.R., Lee F.S.;
RT   "Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical
RT   role for residues C-terminal to the hydroxylacceptor proline.";
RL   J. Biol. Chem. 284:9050-9058(2009).
RN   [6]
RP   VARIANTS ECYT4 VAL-535 AND ARG-537.
RX   PubMed=18378852; DOI=10.1182/blood-2008-02-137703;
RA   Percy M.J., Beer P.A., Campbell G., Dekker A.W., Green A.R.,
RA   Oscier D., Rainey M.G., van Wijk R., Wood M., Lappin T.R.,
RA   McMullin M.F., Lee F.S.;
RT   "Novel exon 12 mutations in the HIF2A gene associated with
RT   erythrocytosis.";
RL   Blood 111:5400-5402(2008).
RN   [7]
RP   VARIANT ECYT4 TRP-537, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   CHARACTERIZATION OF VARIANT ECYT4 TRP-537.
RX   PubMed=18184961; DOI=10.1056/NEJMoa073123;
RA   Percy M.J., Furlow P.W., Lucas G.S., Li X., Lappin T.R.,
RA   McMullin M.F., Lee F.S.;
RT   "A gain-of-function mutation in the HIF2A gene in familial
RT   erythrocytosis.";
RL   N. Engl. J. Med. 358:162-168(2008).
RN   [8]
RP   VARIANTS ECYT4 THR-535 AND LEU-540, AND CHARACTERIZATION OF VARIANT
RP   ECYT4 LEU-540.
RX   PubMed=22367913; DOI=10.1002/ajh.23123;
RA   Percy M.J., Chung Y.J., Harrison C., Mercieca J., Hoffbrand A.V.,
RA   Dinardo C.L., Santos P.C., Fonseca G.H., Gualandro S.F., Pereira A.C.,
RA   Lappin T.R., McMullin M.F., Lee F.S.;
RT   "Two new mutations in the HIF2A gene associated with erythrocytosis.";
RL   Am. J. Hematol. 87:439-442(2012).
CC   -!- FUNCTION: Transcription factor involved in the induction of oxygen
CC       regulated genes. Binds to core DNA sequence 5'-[AG]CGTG-3' within
CC       the hypoxia response element (HRE) of target gene promoters.
CC       Regulates the vascular endothelial growth factor (VEGF) expression
CC       and seems to be implicated in the development of blood vessels and
CC       the tubular system of lung. May also play a role in the formation
CC       of the endothelium that gives rise to the blood brain barrier.
CC       Potent activator of the Tie-2 tyrosine kinase expression.
CC       Activation seems to require recruitment of transcriptional
CC       coactivators such as CREBBP and probably EP300. Interaction with
CC       redox regulatory protein APEX seems to activate CTAD.
CC   -!- SUBUNIT: Interacts with HIF3A (By similarity). Efficient DNA
CC       binding requires dimerization with another bHLH protein.
CC       Heterodimerizes with ARNT. Interacts with CREBBP (By similarity).
CC       Interacts with EGLN1. Interacts with VHL.
CC       {ECO:0000250|UniProtKB:P97481, ECO:0000269|PubMed:10202154,
CC       ECO:0000269|PubMed:19208626}.
CC   -!- INTERACTION:
CC       P27540:ARNT; NbExp=6; IntAct=EBI-447470, EBI-80809;
CC       Q96RK4:BBS4; NbExp=2; IntAct=EBI-447470, EBI-1805814;
CC       Q9GZT9:EGLN1; NbExp=2; IntAct=EBI-447470, EBI-1174818;
CC       P60228:EIF3E; NbExp=10; IntAct=EBI-447470, EBI-347740;
CC       O60573:EIF4E2; NbExp=2; IntAct=EBI-447470, EBI-398610;
CC       P09467:FBP1; NbExp=4; IntAct=EBI-447470, EBI-712740;
CC       P61244:MAX; NbExp=2; IntAct=EBI-447470, EBI-751711;
CC       Q9BWF3-1:RBM4; NbExp=6; IntAct=EBI-447470, EBI-15621561;
CC       P84022:SMAD3; NbExp=2; IntAct=EBI-447470, EBI-347161;
CC       P08047:SP1; NbExp=2; IntAct=EBI-447470, EBI-298336;
CC       P40818:USP8; NbExp=2; IntAct=EBI-447470, EBI-1050865;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P97481,
CC       ECO:0000255|PROSITE-ProRule:PRU00981}. Nucleus speckle
CC       {ECO:0000250|UniProtKB:P97481}. Note=Colocalizes with HIF3A in the
CC       nucleus and speckles. {ECO:0000250|UniProtKB:P97481}.
CC   -!- TISSUE SPECIFICITY: Expressed in most tissues, with highest levels
CC       in placenta, lung and heart. Selectively expressed in endothelial
CC       cells.
CC   -!- PTM: In normoxia, is probably hydroxylated on Pro-405 and Pro-531
CC       by EGLN1/PHD1, EGLN2/PHD2 and/or EGLN3/PHD3. The hydroxylated
CC       prolines promote interaction with VHL, initiating rapid
CC       ubiquitination and subsequent proteasomal degradation. Under
CC       hypoxia, proline hydroxylation is impaired and ubiquitination is
CC       attenuated, resulting in stabilization (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: In normoxia, is hydroxylated on Asn-847 by HIF1AN thus
CC       probably abrogating interaction with CREBBP and EP300 and
CC       preventing transcriptional activation. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on multiple sites in the CTAD. {ECO:0000250}.
CC   -!- PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of
CC       asparagine is (S) stereospecific within HIF CTAD domains.
CC       {ECO:0000250}.
CC   -!- DISEASE: Erythrocytosis, familial, 4 (ECYT4) [MIM:611783]: An
CC       autosomal dominant disorder characterized by increased serum red
CC       blood cell mass, elevated serum hemoglobin and hematocrit, and
CC       normal platelet and leukocyte counts.
CC       {ECO:0000269|PubMed:18184961, ECO:0000269|PubMed:18378852,
CC       ECO:0000269|PubMed:19208626, ECO:0000269|PubMed:22367913}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U81984; AAB41495.1; -; mRNA.
DR   EMBL; U51626; AAC51212.1; -; mRNA.
DR   EMBL; BC051338; AAH51338.1; -; mRNA.
DR   CCDS; CCDS1825.1; -.
DR   RefSeq; NP_001421.2; NM_001430.4.
DR   UniGene; Hs.468410; -.
DR   PDB; 1P97; NMR; -; A=240-350.
DR   PDB; 2A24; NMR; -; A=242-348.
DR   PDB; 3F1N; X-ray; 1.48 A; A=239-350.
DR   PDB; 3F1O; X-ray; 1.60 A; A=239-350.
DR   PDB; 3F1P; X-ray; 1.17 A; A=239-350.
DR   PDB; 3H7W; X-ray; 1.65 A; A=239-350.
DR   PDB; 3H82; X-ray; 1.50 A; A=239-350.
DR   PDB; 4GHI; X-ray; 1.50 A; A=239-350.
DR   PDB; 4GS9; X-ray; 1.72 A; A=239-350.
DR   PDB; 4PKY; X-ray; 3.20 A; G=239-350.
DR   PDB; 4XT2; X-ray; 1.70 A; A/C=239-350.
DR   PDB; 5KIZ; NMR; -; A=239-349.
DR   PDB; 5TBM; X-ray; 1.85 A; A=239-348.
DR   PDB; 5UFP; X-ray; 1.90 A; A=239-348.
DR   PDBsum; 1P97; -.
DR   PDBsum; 2A24; -.
DR   PDBsum; 3F1N; -.
DR   PDBsum; 3F1O; -.
DR   PDBsum; 3F1P; -.
DR   PDBsum; 3H7W; -.
DR   PDBsum; 3H82; -.
DR   PDBsum; 4GHI; -.
DR   PDBsum; 4GS9; -.
DR   PDBsum; 4PKY; -.
DR   PDBsum; 4XT2; -.
DR   PDBsum; 5KIZ; -.
DR   PDBsum; 5TBM; -.
DR   PDBsum; 5UFP; -.
DR   ProteinModelPortal; Q99814; -.
DR   SMR; Q99814; -.
DR   BioGrid; 108348; 106.
DR   CORUM; Q99814; -.
DR   DIP; DIP-32857N; -.
DR   ELM; Q99814; -.
DR   IntAct; Q99814; 36.
DR   MINT; Q99814; -.
DR   STRING; 9606.ENSP00000263734; -.
DR   BindingDB; Q99814; -.
DR   ChEMBL; CHEMBL1744522; -.
DR   iPTMnet; Q99814; -.
DR   PhosphoSitePlus; Q99814; -.
DR   BioMuta; EPAS1; -.
DR   DMDM; 32470617; -.
DR   MaxQB; Q99814; -.
DR   PaxDb; Q99814; -.
DR   PeptideAtlas; Q99814; -.
DR   PRIDE; Q99814; -.
DR   Ensembl; ENST00000263734; ENSP00000263734; ENSG00000116016.
DR   GeneID; 2034; -.
DR   KEGG; hsa:2034; -.
DR   UCSC; uc002ruv.3; human.
DR   CTD; 2034; -.
DR   DisGeNET; 2034; -.
DR   EuPathDB; HostDB:ENSG00000116016.13; -.
DR   GeneCards; EPAS1; -.
DR   HGNC; HGNC:3374; EPAS1.
DR   HPA; HPA031200; -.
DR   MalaCards; EPAS1; -.
DR   MIM; 603349; gene.
DR   MIM; 611783; phenotype.
DR   neXtProt; NX_Q99814; -.
DR   OpenTargets; ENSG00000116016; -.
DR   Orphanet; 247511; Autosomal dominant secondary polycythemia.
DR   Orphanet; 324299; Multiple paragangliomas associated with polycythemia.
DR   Orphanet; 276624; Sporadic pheochromocytoma.
DR   Orphanet; 276627; Sporadic secreting paraganglioma.
DR   PharmGKB; PA27809; -.
DR   eggNOG; KOG3558; Eukaryota.
DR   eggNOG; ENOG410YK57; LUCA.
DR   GeneTree; ENSGT00760000118788; -.
DR   HOGENOM; HOG000234306; -.
DR   HOVERGEN; HBG060456; -.
DR   InParanoid; Q99814; -.
DR   KO; K09095; -.
DR   OMA; DFQLSPI; -.
DR   OrthoDB; EOG091G0486; -.
DR   PhylomeDB; Q99814; -.
DR   TreeFam; TF317772; -.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1234162; Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha.
DR   Reactome; R-HSA-1234176; Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha.
DR   Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR   Reactome; R-HSA-8849473; PTK6 Expression.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   SignaLink; Q99814; -.
DR   SIGNOR; Q99814; -.
DR   ChiTaRS; EPAS1; human.
DR   EvolutionaryTrace; Q99814; -.
DR   GeneWiki; EPAS1; -.
DR   GenomeRNAi; 2034; -.
DR   PRO; PR:Q99814; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000116016; -.
DR   CleanEx; HS_EPAS1; -.
DR   ExpressionAtlas; Q99814; baseline and differential.
DR   Genevisible; Q99814; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IGI:MGI.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0055072; P:iron ion homeostasis; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0007005; P:mitochondrion organization; IEA:Ensembl.
DR   GO; GO:0048625; P:myoblast fate commitment; ISS:BHF-UCL.
DR   GO; GO:0042415; P:norepinephrine metabolic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   GO; GO:0002027; P:regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0043619; P:regulation of transcription from RNA polymerase II promoter in response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IDA:MGI.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; TAS:Reactome.
DR   GO; GO:0043129; P:surfactant homeostasis; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0007601; P:visual perception; IEA:Ensembl.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR014887; HIF-1_TAD_C.
DR   InterPro; IPR021537; HIF_alpha_subunit.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   InterPro; IPR013655; PAS_fold_3.
DR   Pfam; PF11413; HIF-1; 1.
DR   Pfam; PF08778; HIF-1a_CTAD; 1.
DR   Pfam; PF00989; PAS; 1.
DR   Pfam; PF08447; PAS_3; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   TIGRFAMs; TIGR00229; sensory_box; 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Angiogenesis; Complete proteome;
KW   Congenital erythrocytosis; Developmental protein; Differentiation;
KW   Disease mutation; DNA-binding; Hydroxylation; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1    870       Endothelial PAS domain-containing protein
FT                                1.
FT                                /FTId=PRO_0000127419.
FT   DOMAIN       14     67       bHLH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00981}.
FT   DOMAIN       84    154       PAS 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   DOMAIN      230    300       PAS 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   DOMAIN      304    347       PAC.
FT   REGION      496    542       NTAD.
FT   REGION      830    870       CTAD.
FT   COMPBIAS    474    480       Poly-Ser.
FT   MOD_RES     405    405       4-hydroxyproline. {ECO:0000250}.
FT   MOD_RES     531    531       4-hydroxyproline. {ECO:0000250}.
FT   MOD_RES     840    840       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P97481}.
FT   MOD_RES     847    847       (3S)-3-hydroxyasparagine. {ECO:0000250}.
FT   VARIANT     534    534       P -> L (in ECYT4; impairs interaction
FT                                with EGLN1 and VHL).
FT                                {ECO:0000269|PubMed:19208626}.
FT                                /FTId=VAR_067358.
FT   VARIANT     535    535       M -> T (in ECYT4).
FT                                {ECO:0000269|PubMed:22367913}.
FT                                /FTId=VAR_067359.
FT   VARIANT     535    535       M -> V (in ECYT4; impairs interaction
FT                                with EGLN1; dbSNP:rs137853037).
FT                                {ECO:0000269|PubMed:18378852,
FT                                ECO:0000269|PubMed:19208626}.
FT                                /FTId=VAR_067360.
FT   VARIANT     537    537       G -> R (in ECYT4; impairs interaction
FT                                with EGLN1 and VHL; dbSNP:rs137853036).
FT                                {ECO:0000269|PubMed:18378852,
FT                                ECO:0000269|PubMed:19208626}.
FT                                /FTId=VAR_067361.
FT   VARIANT     537    537       G -> W (in ECYT4; gain of function;
FT                                affects hydroxylation;
FT                                dbSNP:rs137853036).
FT                                {ECO:0000269|PubMed:18184961}.
FT                                /FTId=VAR_042443.
FT   VARIANT     540    540       F -> L (in ECYT4; affects the interaction
FT                                with EGLN1 and VHL).
FT                                {ECO:0000269|PubMed:22367913}.
FT                                /FTId=VAR_067362.
FT   VARIANT     766    766       T -> P (in dbSNP:rs59901247).
FT                                /FTId=VAR_061261.
FT   VARIANT     785    785       P -> T (in dbSNP:rs61518065).
FT                                /FTId=VAR_061262.
FT   MUTAGEN     844    844       C->S: Abolishes hypoxia-inducible
FT                                transcriptional activation of ctaD.
FT                                {ECO:0000269|PubMed:10202154}.
FT   CONFLICT     60     60       A -> E (in Ref. 1; AAB41495).
FT                                {ECO:0000305}.
FT   CONFLICT    539    539       D -> G (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   CONFLICT    601    601       H -> R (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   CONFLICT    693    693       D -> N (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   CONFLICT    716    716       E -> K (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   CONFLICT    722    722       L -> P (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   CONFLICT    765    765       F -> L (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   CONFLICT    769    769       P -> S (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   CONFLICT    844    844       C -> R (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   CONFLICT    847    847       N -> K (in Ref. 2; AAC51212).
FT                                {ECO:0000305}.
FT   HELIX       240    242       {ECO:0000244|PDB:3F1P}.
FT   STRAND      243    248       {ECO:0000244|PDB:3F1P}.
FT   TURN        250    252       {ECO:0000244|PDB:2A24}.
FT   STRAND      253    257       {ECO:0000244|PDB:3F1P}.
FT   HELIX       260    265       {ECO:0000244|PDB:3F1P}.
FT   HELIX       269    272       {ECO:0000244|PDB:3F1P}.
FT   HELIX       277    280       {ECO:0000244|PDB:3F1P}.
FT   HELIX       283    285       {ECO:0000244|PDB:3F1P}.
FT   HELIX       286    299       {ECO:0000244|PDB:3F1P}.
FT   STRAND      300    303       {ECO:0000244|PDB:3F1P}.
FT   STRAND      307    310       {ECO:0000244|PDB:3F1P}.
FT   STRAND      314    327       {ECO:0000244|PDB:3F1P}.
FT   TURN        329    331       {ECO:0000244|PDB:3F1P}.
FT   STRAND      334    343       {ECO:0000244|PDB:3F1P}.
SQ   SEQUENCE   870 AA;  96459 MW;  4838989598234FC1 CRC64;
     MTADKEKKRS SSERRKEKSR DAARCRRSKE TEVFYELAHE LPLPHSVSSH LDKASIMRLA
     ISFLRTHKLL SSVCSENESE AEADQQMDNL YLKALEGFIA VVTQDGDMIF LSENISKFMG
     LTQVELTGHS IFDFTHPCDH EEIRENLSLK NGSGFGKKSK DMSTERDFFM RMKCTVTNRG
     RTVNLKSATW KVLHCTGQVK VYNNCPPHNS LCGYKEPLLS CLIIMCEPIQ HPSHMDIPLD
     SKTFLSRHSM DMKFTYCDDR ITELIGYHPE ELLGRSAYEF YHALDSENMT KSHQNLCTKG
     QVVSGQYRML AKHGGYVWLE TQGTVIYNPR NLQPQCIMCV NYVLSEIEKN DVVFSMDQTE
     SLFKPHLMAM NSIFDSSGKG AVSEKSNFLF TKLKEEPEEL AQLAPTPGDA IISLDFGNQN
     FEESSAYGKA ILPPSQPWAT ELRSHSTQSE AGSLPAFTVP QAAAPGSTTP SATSSSSSCS
     TPNSPEDYYT SLDNDLKIEV IEKLFAMDTE AKDQCSTQTD FNELDLETLA PYIPMDGEDF
     QLSPICPEER LLAENPQSTP QHCFSAMTNI FQPLAPVAPH SPFLLDKFQQ QLESKKTEPE
     HRPMSSIFFD AGSKASLPPC CGQASTPLSS MGGRSNTQWP PDPPLHFGPT KWAVGDQRTE
     FLGAAPLGPP VSPPHVSTFK TRSAKGFGAR GPDVLSPAMV ALSNKLKLKR QLEYEEQAFQ
     DLSGGDPPGG STSHLMWKRM KNLRGGSCPL MPDKPLSANV PNDKFTQNPM RGLGHPLRHL
     PLPQPPSAIS PGENSKSRFP PQCYATQYQD YSLSSAHKVS GMASRLLGPS FESYLLPELT
     RYDCEVNVPV LGSSTLLQGG DLLRALDQAT
//
ID   ERBB4_HUMAN             Reviewed;        1308 AA.
AC   Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-FEB-2018, entry version 203.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-4;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene-like protein c-ErbB-4;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER4;
DE   AltName: Full=p180erbB4;
DE   Contains:
DE     RecName: Full=ERBB4 intracellular domain;
DE              Short=4ICD;
DE              Short=E4ICD;
DE     AltName: Full=s80HER4;
DE   Flags: Precursor;
GN   Name=ERBB4; Synonyms=HER4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL
RP   SURFACE RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=8383326; DOI=10.1073/pnas.90.5.1746;
RA   Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W.,
RA   Foy L., Neubauer M.G., Shoyab M.;
RT   "Ligand-specific activation of HER4/p180erbB4, a fourth member of the
RT   epidermal growth factor receptor family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1),
RP   TISSUE SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND
RP   BTC, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC
RP   PROCESSING.
RC   TISSUE=Fetal brain;
RX   PubMed=9334263; DOI=10.1074/jbc.272.42.26761;
RA   Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D.,
RA   Klagsbrun M.;
RT   "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific
RT   tissue distribution and differential processing in response to phorbol
RT   ester.";
RL   J. Biol. Chem. 272:26761-26768(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B
RP   CYT-1; JM-A CYT-2 AND JM-B CYT-2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A
RP   CYT-2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION.
RX   PubMed=7689552;
RA   Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.;
RT   "Characterization of a breast cancer cell differentiation factor that
RT   specifically activates the HER4/p180erbB4 receptor.";
RL   J. Biol. Chem. 268:18407-18410(1993).
RN   [6]
RP   INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION.
RX   PubMed=7902537; DOI=10.1038/366473a0;
RA   Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M.,
RA   Buckley S.;
RT   "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.";
RL   Nature 366:473-475(1993).
RN   [7]
RP   FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION,
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, AUTOPHOSPHORYLATION,
RP   PHOSPHORYLATION AT TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION
RP   WITH EGFR; SHC1 AND PIK3R1.
RX   PubMed=8617750; DOI=10.1074/jbc.271.9.4813;
RA   Cohen B.D., Green J.M., Foy L., Fell H.P.;
RT   "HER4-mediated biological and biochemical properties in NIH 3T3 cells.
RT   Evidence for HER1-HER4 heterodimers.";
RL   J. Biol. Chem. 271:4813-4818(1996).
RN   [8]
RP   INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION.
RX   PubMed=8570211;
RA   Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S.,
RA   Plowman G.D., Stern D.F.;
RT   "Betacellulin activates the epidermal growth factor receptor and erbB-
RT   4, and induces cellular response patterns distinct from those
RT   stimulated by epidermal growth factor or neuregulin-beta.";
RL   Oncogene 12:345-353(1996).
RN   [9]
RP   FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND
RP   IN ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=9135143; DOI=10.1093/emboj/16.6.1268;
RA   Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.;
RT   "Activation of HER4 by heparin-binding EGF-like growth factor
RT   stimulates chemotaxis but not proliferation.";
RL   EMBO J. 16:1268-1278(1997).
RN   [10]
RP   INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION.
RX   PubMed=9168115; DOI=10.1038/387512a0;
RA   Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N.,
RA   Gassmann M., Lai C.;
RT   "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine
RT   kinases.";
RL   Nature 387:512-516(1997).
RN   [11]
RP   INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION.
RX   PubMed=9419975; DOI=10.1038/sj.onc.1201458;
RA   Komurasaki T., Toyoda H., Uchida D., Morimoto S.;
RT   "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and
RT   induces tyrosine phosphorylation of epidermal growth factor receptor,
RT   ErbB-2, ErbB-3 and ErbB-4.";
RL   Oncogene 15:2841-2848(1997).
RN   [12]
RP   INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION.
RX   PubMed=9275162; DOI=10.1073/pnas.94.18.9562;
RA   Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y.,
RA   Hillan K., Crowley C., Brush J., Godowski P.J.;
RT   "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that
RT   binds and activates ErbB4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997).
RN   [13]
RP   INTERACTION WITH GRB7.
RX   PubMed=9516479; DOI=10.1074/jbc.273.13.7717;
RA   Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H.,
RA   Wallasch C., Daly R.J.;
RT   "Analysis of Grb7 recruitment by heregulin-activated erbB receptors
RT   reveals a novel target selectivity for erbB3.";
RL   J. Biol. Chem. 273:7717-7724(1998).
RN   [14]
RP   INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A.
RX   PubMed=10358079; DOI=10.1074/jbc.274.24.17209;
RA   Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.;
RT   "ErbB receptor-induced activation of stat transcription factors is
RT   mediated by Src tyrosine kinases.";
RL   J. Biol. Chem. 274:17209-17218(1999).
RN   [15]
RP   ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF
RP   PIK3R1, INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=10353604; DOI=10.1038/sj.onc.1202612;
RA   Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E.,
RA   Klagsbrun M.;
RT   "Characterization of a naturally occurring ErbB4 isoform that does not
RT   bind or activate phosphatidyl inositol 3-kinase.";
RL   Oncogene 18:2607-2615(1999).
RN   [16]
RP   FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1
RP   AND IN CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10348342; DOI=10.1038/sj.onc.1202631;
RA   Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C.,
RA   Yarden Y.;
RT   "Neuregulin-4: a novel growth factor that acts through the ErbB-4
RT   receptor tyrosine kinase.";
RL   Oncogene 18:2681-2689(1999).
RN   [17]
RP   FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL
RP   AND IN PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND
RP   MAPK3/ERK1, AND ALTERNATIVE SPLICING.
RX   PubMed=10722704; DOI=10.1074/jbc.275.12.8641;
RA   Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E.,
RA   Klagsbrun M., Elenius K.;
RT   "A natural ErbB4 isoform that does not activate phosphoinositide 3-
RT   kinase mediates proliferation but not survival or chemotaxis.";
RL   J. Biol. Chem. 275:8641-8649(2000).
RN   [18]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=10744726; DOI=10.1074/jbc.275.14.10379;
RA   Rio C., Buxbaum J.D., Peschon J.J., Corfas G.;
RT   "Tumor necrosis factor-alpha-converting enzyme is required for
RT   cleavage of erbB4/HER4.";
RL   J. Biol. Chem. 275:10379-10387(2000).
RN   [19]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION
RP   WITH PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC
RP   AUTOPHOSPHORYLATION.
RX   PubMed=10867024; DOI=10.1074/jbc.C901015199;
RA   Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C.,
RA   Carraway K.L. III;
RT   "Ligand discrimination in signaling through an ErbB4 receptor
RT   homodimer.";
RL   J. Biol. Chem. 275:19803-19807(2000).
RN   [20]
RP   INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2.
RX   PubMed=10725395; DOI=10.1073/pnas.97.7.3596;
RA   Garcia R.A., Vasudevan K., Buonanno A.;
RT   "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins
RT   at neuronal synapses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000).
RN   [21]
RP   FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES,
RP   AUTOPHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=11178955; DOI=10.1006/bbrc.2001.4302;
RA   Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.;
RT   "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at
RT   different concentrations in intact cells.";
RL   Biochem. Biophys. Res. Commun. 281:25-31(2001).
RN   [22]
RP   MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION
RP   AND INHIBITING CELL PROLIFERATION.
RX   PubMed=11390655; DOI=10.1128/MCB.21.13.4265-4275.2001;
RA   Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E.,
RA   Caskey L., Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III;
RT   "Her4 mediates ligand-dependent antiproliferative and differentiation
RT   responses in human breast cancer cells.";
RL   Mol. Cell. Biol. 21:4265-4275(2001).
RN   [23]
RP   FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION
RP   WITH YAP1, AND MUTAGENESIS OF TYR-1301.
RX   PubMed=12807903; DOI=10.1074/jbc.M305597200;
RA   Komuro A., Nagai M., Navin N.E., Sudol M.;
RT   "WW domain-containing protein YAP associates with ErbB-4 and acts as a
RT   co-transcriptional activator for the carboxyl-terminal fragment of
RT   ErbB-4 that translocates to the nucleus.";
RL   J. Biol. Chem. 278:33334-33341(2003).
RN   [24]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [25]
RP   INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR
RP   LOCALIZATION OF STAT5A; DNA-BINDING, AND MUTAGENESIS OF
RP   681-LYS--ARG-684.
RX   PubMed=15534001; DOI=10.1083/jcb.200403155;
RA   Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S.,
RA   Marrero L., Jones F.E.;
RT   "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by
RT   functioning as a STAT5A nuclear chaperone.";
RL   J. Cell Biol. 167:469-478(2004).
RN   [26]
RP   INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND
RP   TYR-1301.
RX   PubMed=16061658; DOI=10.1158/0008-5472.CAN-05-1150;
RA   Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M.,
RA   Pekarsky Y., Sudol M., Croce C.M.;
RT   "WW domain-containing proteins, WWOX and YAP, compete for interaction
RT   with ErbB-4 and modulate its transcriptional function.";
RL   Cancer Res. 65:6764-6772(2005).
RN   [27]
RP   FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675.
RX   PubMed=15746097; DOI=10.1074/jbc.M412457200;
RA   Vidal G.A., Naresh A., Marrero L., Jones F.E.;
RT   "Presenilin-dependent gamma-secretase processing regulates multiple
RT   ERBB4/HER4 activities.";
RL   J. Biol. Chem. 280:19777-19783(2005).
RN   [28]
RP   FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH BCL2.
RX   PubMed=16778220; DOI=10.1158/0008-5472.CAN-05-2368;
RA   Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I.,
RA   Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.;
RT   "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein
RT   promoting apoptosis of breast cancer cells.";
RL   Cancer Res. 66:6412-6420(2006).
RN   [29]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=16815842; DOI=10.1074/jbc.M603998200;
RA   Linggi B., Carpenter G.;
RT   "ErbB-4 s80 intracellular domain abrogates ETO2-dependent
RT   transcriptional repression.";
RL   J. Biol. Chem. 281:25373-25380(2006).
RN   [30]
RP   FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=16251361; DOI=10.1091/mbc.E05-05-0402;
RA   Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J.,
RA   Isola J., Egeblad M., Elenius K.;
RT   "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4
RT   isoform promote ligand-independent survival and cancer cell growth.";
RL   Mol. Biol. Cell 17:67-79(2006).
RN   [31]
RP   FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC
RP   PROCESSING, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH STAT5A.
RX   PubMed=16837552; DOI=10.1091/mbc.E06-02-0101;
RA   Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L.,
RA   Feng S.M., Elenius K., Earp H.S. III;
RT   "The intracellular domain of ErbB4 induces differentiation of mammary
RT   epithelial cells.";
RL   Mol. Biol. Cell 17:4118-4129(2006).
RN   [32]
RP   MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056.
RX   PubMed=17120616;
RA   Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II;
RT   "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4
RT   coupling to inhibition of colony formation by human mammary cell
RT   lines.";
RL   Oncol. Res. 16:179-193(2006).
RN   [33]
RP   FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING,
RP   SUBCELLULAR LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN,
RP   AND MUTAGENESIS OF VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000.
RX   PubMed=17638867; DOI=10.1158/0008-5472.CAN-06-4145;
RA   Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A.,
RA   Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.;
RT   "HER4 D-box sequences regulate mitotic progression and degradation of
RT   the nuclear HER4 cleavage product s80HER4.";
RL   Cancer Res. 67:6582-6590(2007).
RN   [34]
RP   INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND
RP   AUTOPHOSPHORYLATION IN TRANS.
RX   PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020;
RA   Li Z., Mei Y., Liu X., Zhou M.;
RT   "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor
RT   heterodimer partners.";
RL   Cell. Signal. 19:466-471(2007).
RN   [35]
RP   FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND
RP   MUTAGENESIS OF LYS-751.
RX   PubMed=17486069; DOI=10.1038/sj.onc.1210501;
RA   Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I.,
RA   Savisalo M., Silvennoinen O., Yarden Y., Elenius K.;
RT   "Differential nuclear localization and kinase activity of alternative
RT   ErbB4 intracellular domains.";
RL   Oncogene 26:6905-6914(2007).
RN   [36]
RP   PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162;
RP   TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH
RP   PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006;
RA   Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J.,
RA   MacBeath G.;
RT   "System-wide investigation of ErbB4 reveals 19 sites of Tyr
RT   phosphorylation that are unusually selective in their recruitment
RT   properties.";
RL   Chem. Biol. 15:808-817(2008).
RN   [37]
RP   INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF
RP   E4ICD1.
RX   PubMed=19193720; DOI=10.1096/fj.08-121947;
RA   Zeng F., Xu J., Harris R.C.;
RT   "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in
RT   MDCK II cells.";
RL   FASEB J. 23:1935-1945(2009).
RN   [38]
RP   FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2,
RP   ENZYME REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782;
RP   GLU-810; PRO-854; ASP-861; GLU-872 AND THR-926.
RX   PubMed=19098003; DOI=10.1074/jbc.M805438200;
RA   Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S.,
RA   Johnson M.S., Elenius K.;
RT   "Somatic mutations of ErbB4: selective loss-of-function phenotype
RT   affecting signal transduction pathways in cancer.";
RL   J. Biol. Chem. 284:5582-5591(2009).
RN   [39]
RP   INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301.
RX   PubMed=19561640; DOI=10.1038/onc.2009.162;
RA   Li Y., Zhou Z., Alimandi M., Chen C.;
RT   "WW domain containing E3 ubiquitin protein ligase 1 targets the full-
RT   length ErbB4 for ubiquitin-mediated degradation in breast cancer.";
RL   Oncogene 28:2948-2958(2009).
RN   [40]
RP   INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1;
RP   U2SURP; ITCH; HNRNPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND ARS2,
RP   FUNCTION, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20858735; DOI=10.1158/1541-7786.MCR-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA
RT   damage response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [41]
RP   ENZYME REGULATION.
RX   PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015;
RA   Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L.,
RA   Conde M., Gomez-Martinez A., Garcia-Morales P., Ferragut J.A.,
RA   Martinez-Lacaci I.;
RT   "Small tyrosine kinase inhibitors interrupt EGFR signaling by
RT   interacting with erbB3 and erbB4 in glioblastoma cell lines.";
RL   Exp. Cell Res. 317:1476-1489(2011).
RN   [42]
RP   REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT.
RX   PubMed=14504474;
RA   Jones F.E., Golding J.P., Gassmann M.;
RT   "ErbB4 signaling during breast and neural development: novel genetic
RT   models reveal unique ErbB4 activities.";
RL   Cell Cycle 2:555-559(2003).
RN   [43]
RP   REVIEW.
RX   PubMed=15944951;
RA   Zaczek A., Brandt B., Bielawski K.P.;
RT   "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine
RT   kinase receptors and the consequences for therapeutic approaches.";
RL   Histol. Histopathol. 20:1005-1015(2005).
RN   [44]
RP   REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT.
RX   PubMed=18437540; DOI=10.1007/s10911-008-9080-x;
RA   Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III;
RT   "ErbB4/HER4: role in mammary gland development, differentiation and
RT   growth inhibition.";
RL   J. Mammary Gland Biol. Neoplasia 13:235-246(2008).
RN   [45]
RP   REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN.
RX   PubMed=18473151; DOI=10.1007/s10911-008-9076-6;
RA   Jones F.E.;
RT   "HER4 intracellular domain (4ICD) activity in the developing mammary
RT   gland and breast cancer.";
RL   J. Mammary Gland Biol. Neoplasia 13:247-258(2008).
RN   [46]
RP   REVIEW ON LIGAND SPECIFICITY AND SIGNALING.
RX   PubMed=18454307; DOI=10.1007/s10911-008-9079-3;
RA   Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P.,
RA   Elenius K.;
RT   "Role of ErbB4 in breast cancer.";
RL   J. Mammary Gland Biol. Neoplasia 13:259-268(2008).
RN   [47]
RP   REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH.
RX   PubMed=20933198; DOI=10.1016/S1054-3589(10)59002-1;
RA   Xu Y., Li X., Liu X., Zhou M.;
RT   "Neuregulin-1/ErbB signaling and chronic heart failure.";
RL   Adv. Pharmacol. 59:31-51(2010).
RN   [48]
RP   REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE
RP   SPECIFICITY; SIGNALING AND ROLE IN DISEASE.
RX   PubMed=21811097; DOI=10.4161/cc.10.16.17194;
RA   Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M.,
RA   Elenius K.;
RT   "Function of ERBB4 is determined by alternative splicing.";
RL   Cell Cycle 10:2647-2657(2011).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473;
RP   ASN-495 AND ASN-576.
RX   PubMed=16203964; DOI=10.1073/pnas.0507591102;
RA   Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.;
RT   "The extracellular region of ErbB4 adopts a tethered conformation in
RT   the absence of ligand.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   LEU-710; MET-766; LEU-864 AND ILE-947.
RX   PubMed=18287036; DOI=10.1073/pnas.0708281105;
RA   Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L.,
RA   Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M.,
RA   Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G.,
RA   Reno M.J., Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D.,
RA   Vanderwall D.E., Waterson A.G., Williams J.D., White W.L.,
RA   Uehling D.E.;
RT   "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-
RT   anilines as tunable covalent modifiers of ErbB kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN
RP   COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ENZYME REGULATION,
RP   AUTOPHOSPHORYLATION, AND SUBUNIT.
RX   PubMed=18334220; DOI=10.1016/j.str.2007.12.016;
RA   Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S.,
RA   Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.;
RT   "Mechanism of activation and inhibition of the HER4/ErbB4 kinase.";
RL   Structure 16:460-467(2008).
RN   [52]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [53]
RP   VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS
RP   ASL19 GLN-927 AND TRP-1275.
RX   PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008;
RA   Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K.,
RA   Moritoyo H., Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H.,
RA   Mitsui J., Date H., Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T.,
RA   Ikoma M., Hashimoto T., Kimura F., Murayama S., Onodera O.,
RA   Nishizawa M., Yoshida M., Atsuta N., Sobue G., Fifita J.A.,
RA   Williams K.L., Blair I.P., Nicholson G.A., Gonzalez-Perez P.,
RA   Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A., Fujiyama A.,
RA   Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H., Izumi Y.,
RA   Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I., Mizoguchi K.,
RA   Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I., Abe K.,
RA   Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H.,
RA   Nishizawa M.;
RT   "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause
RT   amyotrophic lateral sclerosis type 19.";
RL   Am. J. Hum. Genet. 93:900-905(2013).
CC   -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as
CC       cell surface receptor for neuregulins and EGF family members and
CC       regulates development of the heart, the central nervous system and
CC       the mammary gland, gene transcription, cell proliferation,
CC       differentiation, migration and apoptosis. Required for normal
CC       cardiac muscle differentiation during embryonic development, and
CC       for postnatal cardiomyocyte proliferation. Required for normal
CC       development of the embryonic central nervous system, especially
CC       for normal neural crest cell migration and normal axon guidance.
CC       Required for mammary gland differentiation, induction of milk
CC       proteins and lactation. Acts as cell-surface receptor for the
CC       neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members
CC       BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization
CC       and autophosphorylation at specific tyrosine residues that then
CC       serve as binding sites for scaffold proteins and effectors. Ligand
CC       specificity and signaling is modulated by alternative splicing,
CC       proteolytic processing, and by the formation of heterodimers with
CC       other ERBB family members, thereby creating multiple combinations
CC       of intracellular phosphotyrosines that trigger ligand- and
CC       context-specific cellular responses. Mediates phosphorylation of
CC       SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1.
CC       Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1,
CC       leading to the activation of phosphatidylinositol 3-kinase and
CC       AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and
CC       isoform JM-B CYT-1 mediate reorganization of the actin
CC       cytoskeleton and promote cell migration in response to NRG1.
CC       Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine
CC       that mediates interaction with PIK3R1, and hence do not
CC       phosphorylate PIK3R1, do not protect cells against apoptosis, and
CC       do not promote reorganization of the actin cytoskeleton and cell
CC       migration. Proteolytic processing of isoform JM-A CYT-1 and
CC       isoform JM-A CYT-2 gives rise to the corresponding soluble
CC       intracellular domains (4ICD) that translocate to the nucleus,
CC       promote nuclear import of STAT5A, activation of STAT5A, mammary
CC       epithelium differentiation, cell proliferation and activation of
CC       gene expression. The ERBB4 soluble intracellular domains (4ICD)
CC       colocalize with STAT5A at the CSN2 promoter to regulate
CC       transcription of milk proteins during lactation. The ERBB4 soluble
CC       intracellular domains can also translocate to mitochondria and
CC       promote apoptosis. {ECO:0000269|PubMed:10348342,
CC       ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079,
CC       ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024,
CC       ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655,
CC       ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361,
CC       ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750,
CC       ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115,
CC       ECO:0000269|PubMed:9334263}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:18287036,
CC       ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:19098003,
CC       ECO:0000269|PubMed:8617750}.
CC   -!- ENZYME REGULATION: Binding of a cognate ligand leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. In vitro kinase activity is increased by Mg(2+).
CC       Inhibited by PD153035, lapatinib, gefitinib (iressa, ZD1839),
CC       AG1478 and BIBX1382BS. {ECO:0000269|PubMed:11178955,
CC       ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:19098003,
CC       ECO:0000269|PubMed:21439954, ECO:0000269|PubMed:8617750}.
CC   -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or
CC       heterodimer with another ERBB family member upon ligand binding,
CC       thus forming heterotetramers. Interacts with EGFR and ERBB2.
CC       Interacts with CBFA2T3 (By similarity). Interacts with DLG2 (via
CC       its PDZ domain), DLG3 (via its PDZ domain), DLG4 (via its PDZ
CC       domain) and SNTB2 (via its PDZ domain). Interacts with MUC1.
CC       Interacts (via its PPxy motifs) with WWOX. Interacts (via the PPxY
CC       motif 3 of isoform JM-A CYT-2) with YAP1 (via the WW domain 1 of
CC       isoform 1). Interacts (isoform JM-A CYT-1 and isoform JM-B CYT-1)
CC       with WWP1. Interacts (via its intracellular domain) with TRIM28.
CC       Interacts (via the intracellular domains of both CYT-1 and CYT-2
CC       isoforms) with KAP1; the interaction does not phosphorylate KAP1
CC       but represses ERBB4-mediated transcriptional activity. Interacts
CC       with PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH,
CC       HNRNPU, AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 AND ARS2.
CC       Interacts (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-
CC       1) with PIK3R1. Interacts with SHC1. Interacts with GRB2.
CC       Interacts (soluble intracellular domain) with STAT5A. Interacts
CC       (soluble intracellular domain) with BCL2. Interacts
CC       (phosphorylated) with STAT1. {ECO:0000250,
CC       ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604,
CC       ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395,
CC       ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903,
CC       ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220,
CC       ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036,
CC       ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752,
CC       ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720,
CC       ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537,
CC       ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750,
CC       ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115,
CC       ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975,
CC       ECO:0000269|PubMed:9516479}.
CC   -!- INTERACTION:
CC       P42684:ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694;
CC       Q13895:BYSL; NbExp=3; IntAct=EBI-80371, EBI-358049;
CC       P78352:DLG4; NbExp=6; IntAct=EBI-80371, EBI-80389;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-80371, EBI-297353;
CC       P04626:ERBB2; NbExp=4; IntAct=EBI-80371, EBI-641062;
CC       P21860:ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572;
CC       Q96J02-2:ITCH; NbExp=3; IntAct=EBI-80371, EBI-6672198;
CC       P29353:SHC1; NbExp=2; IntAct=EBI-80371, EBI-78835;
CC       Q12815:TROAP; NbExp=3; IntAct=EBI-80371, EBI-2349743;
CC       P46937:YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342,
CC       ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001,
CC       ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220,
CC       ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069,
CC       ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720,
CC       ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326,
CC       ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903,
CC       ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361,
CC       ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552,
CC       ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In
CC       response to NRG1 treatment, the activated receptor is
CC       internalized.
CC   -!- SUBCELLULAR LOCATION: ERBB4 intracellular domain: Nucleus
CC       {ECO:0000269|PubMed:17486069}. Mitochondrion
CC       {ECO:0000269|PubMed:17486069}. Note=Following proteolytical
CC       processing E4ICD (E4ICD1 or E4ICD2 generated from the respective
CC       isoforms) is translocated to the nucleus. Significantly more
CC       E4ICD2 than E4ICD1 is found in the nucleus. E4ICD2 colocalizes
CC       with YAP1 in the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=JM-A CYT-1;
CC         IsoId=Q15303-1; Sequence=Displayed;
CC         Note=Proteolytical processing generates E4ICD1 (s80Cyt1).;
CC       Name=JM-B CYT-1;
CC         IsoId=Q15303-2; Sequence=VSP_002895;
CC       Name=JM-A CYT-2;
CC         IsoId=Q15303-3; Sequence=VSP_022148;
CC         Note=Proteolytical processing generates E4ICD2 (s80Cyt2).;
CC       Name=JM-B CYT-2;
CC         IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148;
CC   -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart,
CC       kidney, in addition to skeletal muscle, parathyroid, cerebellum,
CC       pituitary, spleen, testis and breast. Lower levels in thymus,
CC       lung, salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform
CC       JM-B CYT-1 are expressed in cerebellum, but only the isoform JM-B
CC       is expressed in the heart. {ECO:0000269|PubMed:10353604,
CC       ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}.
CC   -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by
CC       ADAM17. Proteolytic processing in response to ligand or 12-O-
CC       tetradecanoylphorbol-13-acetate stimulation results in the
CC       production of 120 kDa soluble receptor forms and intermediate
CC       membrane-anchored 80 kDa fragments (m80HER4), which are further
CC       processed by a presenilin-dependent gamma-secretase to release a
CC       cytoplasmic intracellular domain (E4ICD; E4ICD1/s80Cyt1 or
CC       E4ICD2/s80Cyt2, depending on the isoform). Membrane-anchored 80
CC       kDa fragments of the processed isoform JM-A CYT-1 are more readily
CC       degraded by the proteasome than fragments of isoform JM-A CYT-2,
CC       suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CYT-1
CC       and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not
CC       processed by ADAM17, precluding further processing by gamma-
CC       secretase. {ECO:0000269|PubMed:10744726,
CC       ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15746097,
CC       ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17638867,
CC       ECO:0000269|PubMed:9334263}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Ligands trigger phosphorylation at specific tyrosine
CC       residues, thereby creating binding sites for scaffold proteins and
CC       effectors. Constitutively phosphorylated at a basal level when
CC       overexpressed in heterologous systems; ligand binding leads to
CC       increased phosphorylation. Phosphorylation at Tyr-1035 is
CC       important for interaction with STAT1. Phosphorylation at Tyr-1056
CC       is important for interaction with PIK3R1. Phosphorylation at Tyr-
CC       1242 is important for interaction with SHC1. Phosphorylation at
CC       Tyr-1188 may also contribute to the interaction with SHC1. Isoform
CC       JM-A CYT-2 is constitutively phosphorylated on tyrosine residues
CC       in a ligand-independent manner. E4ICD2 but not E4ICD1 is
CC       phosphorylated on tyrosine residues. {ECO:0000269|PubMed:16251361,
CC       ECO:0000269|PubMed:17120616, ECO:0000269|PubMed:17486069,
CC       ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:19098003,
CC       ECO:0000269|PubMed:8617750, ECO:0000269|PubMed:9168115}.
CC   -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain
CC       is ubiquitinated by the APC/C complex and targeted to proteasomal
CC       degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are
CC       ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is
CC       ubiquitinated, and this involves NEDD4.
CC       {ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720}.
CC   -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A
CC       neurodegenerative disorder affecting upper motor neurons in the
CC       brain and lower motor neurons in the brain stem and spinal cord,
CC       resulting in fatal paralysis. Sensory abnormalities are absent.
CC       The pathologic hallmarks of the disease include pallor of the
CC       corticospinal tract due to loss of motor neurons, presence of
CC       ubiquitin-positive inclusions within surviving motor neurons, and
CC       deposition of pathologic aggregates. The etiology of amyotrophic
CC       lateral sclerosis is likely to be multifactorial, involving both
CC       genetic and environmental factors. The disease is inherited in 5-
CC       10% of the cases. {ECO:0000269|PubMed:24119685}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating
CC       apoptosis, differentiation, or tumor cell proliferation may be
CC       explained by the opposite functions of the different isoforms and
CC       their intracellular fragments, and by the formation of
CC       heterodimers with other EGF receptor family members
CC       (PubMed:18454307 and PubMed:21811097). Thus, heterodimer formation
CC       of a kinase-dead ERBB4 mutant with ERBB2 is sufficient for the
CC       activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 (PubMed:19098003).
CC       {ECO:0000305|PubMed:19098003}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L07868; AAB59446.1; -; mRNA.
DR   EMBL; BC112199; AAI12200.1; -; mRNA.
DR   EMBL; BC143741; AAI43742.1; -; mRNA.
DR   EMBL; BC143747; AAI43748.1; -; mRNA.
DR   EMBL; BC143749; AAI43750.1; -; mRNA.
DR   EMBL; AB209697; BAD92934.1; -; mRNA.
DR   CCDS; CCDS2394.1; -. [Q15303-1]
DR   CCDS; CCDS42811.1; -. [Q15303-3]
DR   PIR; A47253; A47253.
DR   RefSeq; NP_001036064.1; NM_001042599.1. [Q15303-3]
DR   RefSeq; NP_005226.1; NM_005235.2. [Q15303-1]
DR   RefSeq; XP_005246433.1; XM_005246376.2. [Q15303-2]
DR   RefSeq; XP_005246434.1; XM_005246377.2. [Q15303-4]
DR   UniGene; Hs.390729; -.
DR   PDB; 2AHX; X-ray; 2.40 A; A/B=26-641.
DR   PDB; 2L2T; NMR; -; A/B=642-685.
DR   PDB; 2LCX; NMR; -; A/B=642-685.
DR   PDB; 2R4B; X-ray; 2.40 A; A/B=690-999.
DR   PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029.
DR   PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029.
DR   PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029.
DR   PDB; 3U2P; X-ray; 2.57 A; A=26-522.
DR   PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640.
DR   PDB; 3U9U; X-ray; 3.42 A; E/F=26-650.
DR   PDBsum; 2AHX; -.
DR   PDBsum; 2L2T; -.
DR   PDBsum; 2LCX; -.
DR   PDBsum; 2R4B; -.
DR   PDBsum; 3BBT; -.
DR   PDBsum; 3BBW; -.
DR   PDBsum; 3BCE; -.
DR   PDBsum; 3U2P; -.
DR   PDBsum; 3U7U; -.
DR   PDBsum; 3U9U; -.
DR   ProteinModelPortal; Q15303; -.
DR   SMR; Q15303; -.
DR   BioGrid; 108378; 75.
DR   DIP; DIP-29650N; -.
DR   ELM; Q15303; -.
DR   IntAct; Q15303; 30.
DR   MINT; Q15303; -.
DR   STRING; 9606.ENSP00000342235; -.
DR   BindingDB; Q15303; -.
DR   ChEMBL; CHEMBL3009; -.
DR   DrugBank; DB08916; Afatinib.
DR   GuidetoPHARMACOLOGY; 1799; -.
DR   TCDB; 1.A.87.2.6; the mechanosensitive calcium channel (mca) family.
DR   iPTMnet; Q15303; -.
DR   PhosphoSitePlus; Q15303; -.
DR   BioMuta; ERBB4; -.
DR   DMDM; 3913590; -.
DR   MaxQB; Q15303; -.
DR   PaxDb; Q15303; -.
DR   PeptideAtlas; Q15303; -.
DR   PRIDE; Q15303; -.
DR   DNASU; 2066; -.
DR   Ensembl; ENST00000342788; ENSP00000342235; ENSG00000178568. [Q15303-1]
DR   Ensembl; ENST00000436443; ENSP00000403204; ENSG00000178568. [Q15303-3]
DR   GeneID; 2066; -.
DR   KEGG; hsa:2066; -.
DR   UCSC; uc002veg.2; human. [Q15303-1]
DR   CTD; 2066; -.
DR   DisGeNET; 2066; -.
DR   EuPathDB; HostDB:ENSG00000178568.13; -.
DR   GeneCards; ERBB4; -.
DR   HGNC; HGNC:3432; ERBB4.
DR   HPA; CAB000276; -.
DR   HPA; CAB025522; -.
DR   HPA; HPA012016; -.
DR   MalaCards; ERBB4; -.
DR   MIM; 600543; gene.
DR   MIM; 615515; phenotype.
DR   neXtProt; NX_Q15303; -.
DR   OpenTargets; ENSG00000178568; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   PharmGKB; PA27847; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000230982; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; Q15303; -.
DR   KO; K05085; -.
DR   OMA; RTRIDSN; -.
DR   OrthoDB; EOG091G00EY; -.
DR   PhylomeDB; Q15303; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling.
DR   Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling.
DR   SignaLink; Q15303; -.
DR   SIGNOR; Q15303; -.
DR   ChiTaRS; ERBB4; human.
DR   EvolutionaryTrace; Q15303; -.
DR   GeneWiki; ERBB4; -.
DR   GenomeRNAi; 2066; -.
DR   PMAP-CutDB; Q15303; -.
DR   PRO; PR:Q15303; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000178568; -.
DR   CleanEx; HS_ERBB4; -.
DR   ExpressionAtlas; Q15303; baseline and differential.
DR   Genevisible; Q15303; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004716; F:signal transducer, downstream of receptor, with protein tyrosine kinase activity; IEA:InterPro.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IMP:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0007595; P:lactation; IMP:UniProtKB.
DR   GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:1901185; P:negative regulation of ERBB signaling pathway; TAS:Reactome.
DR   GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; ISS:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB.
DR   GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; TAS:Reactome.
DR   GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB.
DR   GO; GO:2000366; P:positive regulation of STAT protein import into nucleus; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR036941; Rcpt_L-dom_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 5.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing;
KW   Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane;
KW   Complete proteome; Developmental protein; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Lactation; Membrane;
KW   Mitochondrion; Neurodegeneration; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26   1308       Receptor tyrosine-protein kinase erbB-4.
FT                                /FTId=PRO_0000016674.
FT   CHAIN       676   1308       ERBB4 intracellular domain.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000396797.
FT   TOPO_DOM     26    651       Extracellular. {ECO:0000255}.
FT   TRANSMEM    652    675       Helical. {ECO:0000255}.
FT   TOPO_DOM    676   1308       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      718    985       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     724    732       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     797    799       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     843    848       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       676    684       Nuclear localization signal.
FT   MOTIF      1032   1035       PPxY motif 1.
FT   MOTIF      1053   1056       PPxY motif 2.
FT   MOTIF      1298   1301       PPxY motif 3.
FT   MOTIF      1306   1308       PDZ-binding.
FT   COMPBIAS    186    334       Cys-rich.
FT   COMPBIAS    496    633       Cys-rich.
FT   ACT_SITE    843    843       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     751    751       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     875    875       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1035   1035       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1056   1056       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17120616,
FT                                ECO:0000269|PubMed:18721752,
FT                                ECO:0000269|PubMed:8617750}.
FT   MOD_RES    1150   1150       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1162   1162       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1188   1188       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752,
FT                                ECO:0000269|PubMed:8617750}.
FT   MOD_RES    1202   1202       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1242   1242       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752,
FT                                ECO:0000269|PubMed:8617750}.
FT   MOD_RES    1258   1258       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   MOD_RES    1284   1284       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18721752}.
FT   CARBOHYD    138    138       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    174    174       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    181    181       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    253    253       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    358    358       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    410    410       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    473    473       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    495    495       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    548    548       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    576    576       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16203964}.
FT   CARBOHYD    620    620       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     29     56       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    156    186       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    189    197       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    193    205       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    213    221       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    217    229       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    230    238       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    234    246       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    249    258       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    262    289       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    293    304       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    308    323       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    326    330       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    503    512       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    507    520       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    523    532       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    536    552       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    555    569       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    559    577       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    580    589       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    593    614       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    617    625       {ECO:0000269|PubMed:16203964}.
FT   DISULFID    621    633       {ECO:0000269|PubMed:16203964}.
FT   VAR_SEQ     626    648       NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD
FT                                (in isoform JM-B CYT-1 and isoform JM-B
FT                                CYT-2). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9334263}.
FT                                /FTId=VSP_002895.
FT   VAR_SEQ    1046   1061       Missing (in isoform JM-A CYT-2 and
FT                                isoform JM-B CYT-2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_022148.
FT   VARIANT     140    140       T -> I (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042113.
FT   VARIANT     303    303       S -> Y (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042114.
FT   VARIANT     927    927       R -> Q (in ALS19; reduces
FT                                autophosphorylation upon NRG1
FT                                stimulation; dbSNP:rs397514262).
FT                                {ECO:0000269|PubMed:24119685}.
FT                                /FTId=VAR_070810.
FT   VARIANT    1275   1275       R -> W (in ALS19; reduces
FT                                autophosphorylation upon NRG1
FT                                stimulation; dbSNP:rs397514263).
FT                                {ECO:0000269|PubMed:24119685}.
FT                                /FTId=VAR_070811.
FT   MUTAGEN     646    646       Q->C: Constitutively activated kinase.
FT                                {ECO:0000269|PubMed:17120616}.
FT   MUTAGEN     675    675       V->A: Abolishes proteolytic processing
FT                                and nuclear localization.
FT                                {ECO:0000269|PubMed:15746097,
FT                                ECO:0000269|PubMed:17638867}.
FT   MUTAGEN     681    684       KKKR->EIMG: Abolishes nuclear
FT                                localization of the ERBB4 intracellular
FT                                domain. {ECO:0000269|PubMed:15534001}.
FT   MUTAGEN     710    710       L->N: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:18287036}.
FT   MUTAGEN     721    721       V->I: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     751    751       K->R: Abolishes kinase activity.
FT                                Abolishes phosphorylation, proteolytic
FT                                processing and nuclear localization.
FT                                {ECO:0000269|PubMed:11390655,
FT                                ECO:0000269|PubMed:17486069,
FT                                ECO:0000269|PubMed:17638867}.
FT   MUTAGEN     766    766       M->R: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:18287036}.
FT   MUTAGEN     773    773       A->S: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     782    782       R->Q: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     810    810       E->K: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     843    843       D->N: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:16978839}.
FT   MUTAGEN     854    854       P->Q: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     861    861       D->Y: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     864    864       L->R: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:18287036}.
FT   MUTAGEN     872    872       E->K: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     926    926       T->M: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19098003}.
FT   MUTAGEN     947    947       I->R: Constitutively autophosphorylated.
FT                                {ECO:0000269|PubMed:18287036}.
FT   MUTAGEN     992    992       R->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-995
FT                                and A-1000.
FT                                {ECO:0000269|PubMed:17638867}.
FT   MUTAGEN     995    995       L->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-992
FT                                and A-1000.
FT                                {ECO:0000269|PubMed:17638867}.
FT   MUTAGEN    1000   1000       D->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-992
FT                                and A-995. {ECO:0000269|PubMed:17638867}.
FT   MUTAGEN    1035   1035       Y->A: No effect on interaction with WWOX.
FT                                Abolishes interaction with WWOX; when
FT                                associated with A-1301.
FT                                {ECO:0000269|PubMed:16061658}.
FT   MUTAGEN    1056   1056       Y->A: Abolishes interaction with NEDD4
FT                                and impairs ubiquitination. Promotes
FT                                nuclear translocation of ERBB4
FT                                intracellular domain E4ICD1.
FT                                {ECO:0000269|PubMed:19561640}.
FT   MUTAGEN    1056   1056       Y->F: Abolishes interaction with WWP1;
FT                                when associated with F-1301.
FT                                {ECO:0000269|PubMed:19561640}.
FT   MUTAGEN    1301   1301       Y->A: Abolishes interaction with NEDD4
FT                                and impairs ubiquitination.
FT                                {ECO:0000269|PubMed:12807903,
FT                                ECO:0000269|PubMed:16061658,
FT                                ECO:0000269|PubMed:19561640}.
FT   MUTAGEN    1301   1301       Y->A: No effect on interaction with WWOX.
FT                                Abolishes interaction with WWOX; when
FT                                associated with A-1035. Loss of
FT                                interaction with YAP1 and stimulation of
FT                                transcription.
FT                                {ECO:0000269|PubMed:12807903,
FT                                ECO:0000269|PubMed:16061658,
FT                                ECO:0000269|PubMed:19561640}.
FT   MUTAGEN    1301   1301       Y->F: Abolishes interaction with WWP1;
FT                                when associated with F-1056.
FT                                {ECO:0000269|PubMed:12807903,
FT                                ECO:0000269|PubMed:16061658,
FT                                ECO:0000269|PubMed:19561640}.
FT   STRAND       28     30       {ECO:0000244|PDB:2AHX}.
FT   STRAND       38     41       {ECO:0000244|PDB:3U7U}.
FT   HELIX        42     53       {ECO:0000244|PDB:2AHX}.
FT   STRAND       57     61       {ECO:0000244|PDB:2AHX}.
FT   STRAND       63     67       {ECO:0000244|PDB:2AHX}.
FT   HELIX        75     79       {ECO:0000244|PDB:2AHX}.
FT   STRAND       82     85       {ECO:0000244|PDB:2AHX}.
FT   STRAND       87     91       {ECO:0000244|PDB:2AHX}.
FT   STRAND       95     98       {ECO:0000244|PDB:2AHX}.
FT   TURN        112    114       {ECO:0000244|PDB:2AHX}.
FT   STRAND      115    120       {ECO:0000244|PDB:2AHX}.
FT   STRAND      125    128       {ECO:0000244|PDB:3U2P}.
FT   STRAND      133    135       {ECO:0000244|PDB:2AHX}.
FT   STRAND      144    150       {ECO:0000244|PDB:2AHX}.
FT   HELIX       158    160       {ECO:0000244|PDB:2AHX}.
FT   HELIX       163    165       {ECO:0000244|PDB:2AHX}.
FT   HELIX       173    175       {ECO:0000244|PDB:2AHX}.
FT   STRAND      176    178       {ECO:0000244|PDB:2AHX}.
FT   TURN        191    193       {ECO:0000244|PDB:2AHX}.
FT   STRAND      197    201       {ECO:0000244|PDB:2AHX}.
FT   HELIX       202    204       {ECO:0000244|PDB:2AHX}.
FT   STRAND      221    225       {ECO:0000244|PDB:2AHX}.
FT   HELIX       226    228       {ECO:0000244|PDB:2AHX}.
FT   STRAND      234    242       {ECO:0000244|PDB:2AHX}.
FT   STRAND      245    254       {ECO:0000244|PDB:2AHX}.
FT   STRAND      257    261       {ECO:0000244|PDB:2AHX}.
FT   STRAND      265    269       {ECO:0000244|PDB:2AHX}.
FT   TURN        270    273       {ECO:0000244|PDB:2AHX}.
FT   STRAND      274    277       {ECO:0000244|PDB:2AHX}.
FT   STRAND      283    285       {ECO:0000244|PDB:2AHX}.
FT   STRAND      288    292       {ECO:0000244|PDB:2AHX}.
FT   STRAND      298    300       {ECO:0000244|PDB:2AHX}.
FT   STRAND      303    307       {ECO:0000244|PDB:2AHX}.
FT   STRAND      312    317       {ECO:0000244|PDB:2AHX}.
FT   STRAND      320    325       {ECO:0000244|PDB:2AHX}.
FT   STRAND      327    329       {ECO:0000244|PDB:3U2P}.
FT   STRAND      333    335       {ECO:0000244|PDB:2AHX}.
FT   HELIX       340    342       {ECO:0000244|PDB:2AHX}.
FT   TURN        350    352       {ECO:0000244|PDB:2AHX}.
FT   HELIX       353    356       {ECO:0000244|PDB:2AHX}.
FT   STRAND      360    364       {ECO:0000244|PDB:2AHX}.
FT   STRAND      366    368       {ECO:0000244|PDB:2AHX}.
FT   HELIX       370    374       {ECO:0000244|PDB:2AHX}.
FT   HELIX       377    379       {ECO:0000244|PDB:2AHX}.
FT   HELIX       386    394       {ECO:0000244|PDB:2AHX}.
FT   STRAND      397    400       {ECO:0000244|PDB:2AHX}.
FT   STRAND      402    405       {ECO:0000244|PDB:2AHX}.
FT   HELIX       415    417       {ECO:0000244|PDB:2AHX}.
FT   STRAND      432    438       {ECO:0000244|PDB:2AHX}.
FT   STRAND      455    461       {ECO:0000244|PDB:2AHX}.
FT   HELIX       469    471       {ECO:0000244|PDB:2AHX}.
FT   HELIX       474    476       {ECO:0000244|PDB:2AHX}.
FT   STRAND      479    482       {ECO:0000244|PDB:2AHX}.
FT   STRAND      485    487       {ECO:0000244|PDB:2AHX}.
FT   STRAND      489    491       {ECO:0000244|PDB:2AHX}.
FT   HELIX       493    497       {ECO:0000244|PDB:2AHX}.
FT   TURN        498    500       {ECO:0000244|PDB:2AHX}.
FT   STRAND      512    516       {ECO:0000244|PDB:2AHX}.
FT   STRAND      519    528       {ECO:0000244|PDB:2AHX}.
FT   STRAND      531    534       {ECO:0000244|PDB:2AHX}.
FT   STRAND      537    543       {ECO:0000244|PDB:2AHX}.
FT   STRAND      545    548       {ECO:0000244|PDB:2AHX}.
FT   STRAND      551    554       {ECO:0000244|PDB:2AHX}.
FT   STRAND      568    573       {ECO:0000244|PDB:2AHX}.
FT   STRAND      576    585       {ECO:0000244|PDB:2AHX}.
FT   STRAND      588    592       {ECO:0000244|PDB:2AHX}.
FT   STRAND      595    608       {ECO:0000244|PDB:2AHX}.
FT   STRAND      612    616       {ECO:0000244|PDB:2AHX}.
FT   STRAND      625    629       {ECO:0000244|PDB:2AHX}.
FT   HELIX       651    676       {ECO:0000244|PDB:2L2T}.
FT   HELIX       715    717       {ECO:0000244|PDB:2R4B}.
FT   STRAND      718    729       {ECO:0000244|PDB:2R4B}.
FT   STRAND      731    737       {ECO:0000244|PDB:2R4B}.
FT   STRAND      740    743       {ECO:0000244|PDB:3BBT}.
FT   STRAND      746    752       {ECO:0000244|PDB:2R4B}.
FT   HELIX       762    773       {ECO:0000244|PDB:2R4B}.
FT   STRAND      778    780       {ECO:0000244|PDB:3BBT}.
FT   STRAND      783    787       {ECO:0000244|PDB:2R4B}.
FT   STRAND      789    791       {ECO:0000244|PDB:2R4B}.
FT   STRAND      793    797       {ECO:0000244|PDB:2R4B}.
FT   HELIX       804    810       {ECO:0000244|PDB:2R4B}.
FT   HELIX       812    814       {ECO:0000244|PDB:2R4B}.
FT   HELIX       817    836       {ECO:0000244|PDB:2R4B}.
FT   HELIX       846    848       {ECO:0000244|PDB:2R4B}.
FT   STRAND      849    853       {ECO:0000244|PDB:2R4B}.
FT   STRAND      856    859       {ECO:0000244|PDB:2R4B}.
FT   HELIX       864    869       {ECO:0000244|PDB:2R4B}.
FT   HELIX       884    886       {ECO:0000244|PDB:2R4B}.
FT   HELIX       889    893       {ECO:0000244|PDB:2R4B}.
FT   HELIX       899    914       {ECO:0000244|PDB:2R4B}.
FT   TURN        920    923       {ECO:0000244|PDB:2R4B}.
FT   TURN        926    928       {ECO:0000244|PDB:2R4B}.
FT   HELIX       929    934       {ECO:0000244|PDB:2R4B}.
FT   HELIX       947    955       {ECO:0000244|PDB:2R4B}.
FT   HELIX       961    963       {ECO:0000244|PDB:2R4B}.
FT   HELIX       967    977       {ECO:0000244|PDB:2R4B}.
FT   HELIX       981    983       {ECO:0000244|PDB:2R4B}.
SQ   SEQUENCE   1308 AA;  146808 MW;  5E4AE80985D88761 CRC64;
     MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM
     GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF
     LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST
     NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG
     PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD
     SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT
     KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL
     VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST
     INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD
     GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA
     NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG
     LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR
     VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL
     VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV
     HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ
     SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID
     ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE
     EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP
     YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS
     PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED
     EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ
     EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV
//
ID   A0A090N8E9_HUMAN        Unreviewed;       751 AA.
AC   A0A090N8E9;
DT   26-NOV-2014, integrated into UniProtKB/TrEMBL.
DT   26-NOV-2014, sequence version 1.
DT   28-FEB-2018, entry version 30.
DE   SubName: Full=Enhancer of zeste homolog 2 (Drosophila) {ECO:0000313|EMBL:EAL24424.1};
GN   Name=EZH2 {ECO:0000313|EMBL:EAL24424.1};
GN   ORFNames=tcag7.507 {ECO:0000313|EMBL:EAL24424.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAL24424.1};
RN   [1] {ECO:0000313|EMBL:EAL24424.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D., Zhang Q., Gu Z., Lu F.,
RA   Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J., Grzeschik K.H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Dohner H., Dohner K.,
RA   Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [2] {ECO:0000313|EMBL:EAL24424.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Nusskern D., Zhang Q., Gu Z., Lu F.,
RA   Zeesman S., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P., Lococo F., Belloni E.,
RA   Shaffer L.G., Morton C.C., Pober B., Gusella J., Bruns G., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M.,
RA   Gripp K.W., Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H.,
RA   Teebi A., Minassian B.A., Kere J., Armengol L., Pujana M.Angel.,
RA   Estivill X., Wilson M.D., Koop B.F., Tosi S., Moore G.E.,
RA   Boright A.P., Zlotorynski E., Kerem B., Kroisel P.M., Petek E.,
RA   Oscier D.G., Mould S.J., Doehner H., Doehner K., Rommens J.M.,
RA   Vincent J.B., Venter J.C., Li P.W., Mural R.J., Adams M.D.,
RA   Tsui L.-C.;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
CC   -!- CAUTION: The sequence shown here is derived from an
CC       EMBL/GenBank/DDBJ whole genome shotgun (WGS) entry which is
CC       preliminary data. {ECO:0000313|EMBL:EAL24424.1}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AACC02000041; EAL24424.1; -; Genomic_DNA.
DR   RefSeq; NP_004447.2; NM_004456.4.
DR   RefSeq; XP_011514186.1; XM_011515884.2.
DR   UniGene; Hs.444082; -.
DR   UniGene; Hs.732308; -.
DR   ProteinModelPortal; A0A090N8E9; -.
DR   SMR; A0A090N8E9; -.
DR   PRIDE; A0A090N8E9; -.
DR   GeneID; 2146; -.
DR   CTD; 2146; -.
DR   EuPathDB; HostDB:ENSG00000106462.10; -.
DR   eggNOG; KOG1079; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   OMA; VYNYTPC; -.
DR   OrthoDB; EOG091G09L0; -.
DR   PhylomeDB; A0A090N8E9; -.
DR   ChiTaRS; EZH2; human.
DR   GenomeRNAi; 2146; -.
DR   Bgee; ENSG00000106462; -.
DR   ExpressionAtlas; A0A090N8E9; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0035098; C:ESC/E(Z) complex; IEA:Ensembl.
DR   GO; GO:0000790; C:nuclear chromatin; IEA:Ensembl.
DR   GO; GO:0045120; C:pronucleus; IEA:Ensembl.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IEA:InterPro.
DR   GO; GO:0070878; F:primary miRNA binding; IEA:Ensembl.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0035984; P:cellular response to trichostatin A; IEA:Ensembl.
DR   GO; GO:0021695; P:cerebellar cortex development; IEA:Ensembl.
DR   GO; GO:0006306; P:DNA methylation; IEA:Ensembl.
DR   GO; GO:0070314; P:G1 to G0 transition; IEA:Ensembl.
DR   GO; GO:0036333; P:hepatocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0098532; P:histone H3-K27 trimethylation; IEA:Ensembl.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0043433; P:negative regulation of DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0045605; P:negative regulation of epidermal cell differentiation; IEA:Ensembl.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0051154; P:negative regulation of striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:1900006; P:positive regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0071168; P:protein localization to chromatin; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IEA:Ensembl.
DR   GO; GO:0014013; P:regulation of gliogenesis; IEA:Ensembl.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:1904772; P:response to tetrachloromethane; IEA:Ensembl.
DR   GO; GO:0014834; P:skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration; IEA:Ensembl.
DR   CDD; cd00167; SANT; 1.
DR   InterPro; IPR026489; CXC_dom.
DR   InterPro; IPR021654; EZH1/EZH2.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR033467; Tesmin/TSO1-like_CXC.
DR   Pfam; PF11616; EZH2_WD-Binding; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM01114; CXC; 1.
DR   SMART; SM00717; SANT; 2.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51633; CXC; 1.
DR   PROSITE; PS50280; SET; 1.
PE   4: Predicted;
FT   DOMAIN      508    610       CXC. {ECO:0000259|PROSITE:PS51633}.
FT   DOMAIN      617    732       SET. {ECO:0000259|PROSITE:PS50280}.
SQ   SEQUENCE   751 AA;  86018 MW;  D885CF02E60EF836 CRC64;
     MGQTGKKSEK GPVCWRKRVK SEYMRLRQLK RFRRADEVKS MFSSNRQKIL ERTEILNQEW
     KQRRIQPVHI LTSVSSLRGT RECSVTSDLD FPTQVIPLKT LNAVASVPIM YSWSPLQQNF
     MVEDETVLHN IPYMGDEVLD QDGTFIEELI KNYDGKVHGD RECGFINDEI FVELVNALGQ
     YNDDDDDDDG DDPEEREEKQ KDLEDHRDDK ESRPPRKFPS DKIFEAISSM FPDKGTAEEL
     KEKYKELTEQ QLPGALPPEC TPNIDGPNAK SVQREQSLHS FHTLFCRRCF KYDCFLHRKC
     NYSFHATPNT YKRKNTETAL DNKPCGPQCY QHLEGAKEFA AALTAERIKT PPKRPGGRRR
     GRLPNNSSRP STPTINVLES KDTDSDREAG TETGGENNDK EEEEKKDETS SSSEANSRCQ
     TPIKMKPNIE PPENVEWSGA EASMFRVLIG TYYDNFCAIA RLIGTKTCRQ VYEFRVKESS
     IIAPAPAEDV DTPPRKKKRK HRLWAAHCRK IQLKKDGSSN HVYNYQPCDH PRQPCDSSCP
     CVIAQNFCEK FCQCSSECQN RFPGCRCKAQ CNTKQCPCYL AVRECDPDLC LTCGAADHWD
     SKNVSCKNCS IQRGSKKHLL LAPSDVAGWG IFIKDPVQKN EFISEYCGEI ISQDEADRRG
     KVYDKYMCSF LFNLNNDFVV DATRKGNKIR FANHSVNPNC YAKVMMVNGD HRIGIFAKRA
     IQTGEELFFD YRYSQADALK YVGIEREMEI P
//
ID   EZH2_HUMAN              Reviewed;         746 AA.
AC   Q15910; B2RAQ1; B3KS30; B7Z1D6; B7Z7L6; Q15755; Q75MG3; Q92857;
AC   Q96FI6;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   28-FEB-2018, entry version 179.
DE   RecName: Full=Histone-lysine N-methyltransferase EZH2 {ECO:0000305};
DE            EC=2.1.1.43 {ECO:0000269|PubMed:22323599};
DE   AltName: Full=ENX-1;
DE   AltName: Full=Enhancer of zeste homolog 2 {ECO:0000303|PubMed:28229514};
DE   AltName: Full=Lysine N-methyltransferase 6;
GN   Name=EZH2 {ECO:0000312|HGNC:HGNC:3527}; Synonyms=KMT6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8954776; DOI=10.1006/geno.1996.0588;
RA   Chen H., Rossier C., Antonarakis S.E.;
RT   "Cloning of a human homolog of the Drosophila enhancer of zeste gene
RT   (EZH2) that maps to chromosome 21q22.2.";
RL   Genomics 38:30-37(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9214638; DOI=10.1093/emboj/16.11.3219;
RA   Laible G., Wolf A., Dorn R., Reuter G., Nislow C., Lebersorger A.,
RA   Popkin D., Pillus L., Jenuwein T.;
RT   "Mammalian homologues of the Polycomb-group gene Enhancer of zeste
RT   mediate gene silencing in Drosophila heterochromatin and at S.
RT   cerevisiae telomeres.";
RL   EMBO J. 16:3219-3232(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4 AND 5).
RC   TISSUE=Brain, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 134-746.
RX   PubMed=8649418; DOI=10.1128/MCB.16.6.3066;
RA   Hobert O., Jallal B., Ullrich A.;
RT   "Interaction of Vav with ENX-1, a putative transcriptional regulator
RT   of homeobox gene expression.";
RL   Mol. Cell. Biol. 16:3066-3073(1996).
RN   [8]
RP   INTERACTION WITH ATRX.
RX   PubMed=9499421; DOI=10.1093/hmg/7.4.679;
RA   Cardoso C., Timsit S., Villard L., Khrestchatisky M., Fontes M.,
RA   Colleaux L.;
RT   "Specific interaction between the XNP/ATR-X gene product and the SET
RT   domain of the human EZH2 protein.";
RL   Hum. Mol. Genet. 7:679-684(1998).
RN   [9]
RP   INTERACTION WITH EED, AND SUBCELLULAR LOCATION.
RX   PubMed=9584199; DOI=10.1128/MCB.18.6.3586;
RA   Sewalt R.G.A.B., van der Vlag J., Gunster M.J., Hamer K.M.,
RA   den Blaauwen J.L., Satijn D.P.E., Hendrix T., van Driel R., Otte A.P.;
RT   "Characterization of interactions between the mammalian polycomb-group
RT   proteins Enx1/EZH2 and EED suggests the existence of different
RT   mammalian polycomb-group protein complexes.";
RL   Mol. Cell. Biol. 18:3586-3595(1998).
RN   [10]
RP   INTERACTION WITH EED; HDAC1 AND HDAC2.
RX   PubMed=10581039; DOI=10.1038/70602;
RA   van der Vlag J., Otte A.P.;
RT   "Transcriptional repression mediated by the human polycomb-group
RT   protein EED involves histone deacetylation.";
RL   Nat. Genet. 23:474-478(1999).
RN   [11]
RP   INTERACTION WITH EED.
RX   PubMed=11158321; DOI=10.1128/MCB.21.4.1360-1369.2001;
RA   Satijn D.P.E., Hamer K.M., den Blaauwen J., Otte A.P.;
RT   "The polycomb group protein EED interacts with YY1, and both proteins
RT   induce neural tissue in Xenopus embryos.";
RL   Mol. Cell. Biol. 21:1360-1369(2001).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX WITH EED; RBBP4; RBBP7 AND SUZ12, METHYLTRANSFERASE ACTIVITY
RP   OF THE PRC2 COMPLEX, AND MUTAGENESIS OF CYS-588 AND HIS-689.
RX   PubMed=12435631; DOI=10.1101/gad.1035902;
RA   Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P.,
RA   Reinberg D.;
RT   "Histone methyltransferase activity associated with a human
RT   multiprotein complex containing the Enhancer of Zeste protein.";
RL   Genes Dev. 16:2893-2905(2002).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12101246; DOI=10.1128/MCB.22.15.5539-5553.2002;
RA   Sewalt R.G.A.B., Lachner M., Vargas M., Hamer K.M., den Blaauwen J.L.,
RA   Hendrix T., Melcher M., Schweizer D., Jenuwein T., Otte A.P.;
RT   "Selective interactions between vertebrate polycomb homologs and the
RT   SUV39H1 histone lysine methyltransferase suggest that histone H3-K9
RT   methylation contributes to chromosomal targeting of Polycomb group
RT   proteins.";
RL   Mol. Cell. Biol. 22:5539-5553(2002).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX WITH EED; RBBP4; RBBP7 AND SUZ12, AND METHYLTRANSFERASE
RP   ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=12351676; DOI=10.1126/science.1076997;
RA   Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P.,
RA   Jones R.S., Zhang Y.;
RT   "Role of histone H3 lysine 27 methylation in Polycomb-group
RT   silencing.";
RL   Science 298:1039-1043(2002).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, INDUCTION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=14532106; DOI=10.1093/emboj/cdg542;
RA   Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K.;
RT   "EZH2 is downstream of the pRB-E2F pathway, essential for
RT   proliferation and amplified in cancer.";
RL   EMBO J. 22:5323-5335(2003).
RN   [16]
RP   FUNCTION, INTERACTION WITH EED AND SUZ12, AND METHYLTRANSFERASE
RP   ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=15385962; DOI=10.1038/sj.emboj.7600402;
RA   Pasini D., Bracken A.P., Jensen M.R., Lazzerini Denchi E., Helin K.;
RT   "Suz12 is essential for mouse development and for EZH2 histone
RT   methyltransferase activity.";
RL   EMBO J. 23:4061-4071(2004).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15231737; DOI=10.1101/gad.1200204;
RA   Kirmizis A., Bartley S.M., Kuzmichev A., Margueron R., Reinberg D.,
RA   Green R., Farnham P.J.;
RT   "Silencing of human polycomb target genes is associated with
RT   methylation of histone H3 Lys 27.";
RL   Genes Dev. 18:1592-1605(2004).
RN   [18]
RP   CHARACTERIZATION OF THE PRC2 AND PRC3 COMPLEXES INCLUDING EED; EZH2;
RP   RBBP4; RBBP7 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 AND
RP   PRC3 COMPLEXES.
RX   PubMed=15099518; DOI=10.1016/S1097-2765(04)00185-6;
RA   Kuzmichev A., Jenuwein T., Tempst P., Reinberg D.;
RT   "Different EZH2-containing complexes target methylation of histone H1
RT   or nucleosomal histone H3.";
RL   Mol. Cell 14:183-193(2004).
RN   [19]
RP   FUNCTION, CHARACTERIZATION OF THE PRC2 COMPLEX INCLUDING AEBP2; EED;
RP   EZH2; RBBP4 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2
RP   COMPLEX.
RX   PubMed=15225548; DOI=10.1016/j.molcel.2004.06.020;
RA   Cao R., Zhang Y.;
RT   "SUZ12 is required for both the histone methyltransferase activity and
RT   the silencing function of the EED-EZH2 complex.";
RL   Mol. Cell 15:57-67(2004).
RN   [20]
RP   DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=15208672; DOI=10.1038/sj.onc.1207706;
RA   Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., Rotter V.;
RT   "Activated p53 suppresses the histone methyltransferase EZH2 gene.";
RL   Oncogene 23:5759-5769(2004).
RN   [21]
RP   FUNCTION IN RETINOIC ACID SIGNALING, AND INTERACTION WITH PRAME.
RX   PubMed=16179254; DOI=10.1016/j.cell.2005.07.003;
RA   Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., Bernards R.;
RT   "The human tumor antigen PRAME is a dominant repressor of retinoic
RT   acid receptor signaling.";
RL   Cell 122:835-847(2005).
RN   [22]
RP   CHARACTERIZATION OF THE PRC4 COMPLEX INCLUDING EED; EZH2; RBBP4;
RP   RBBP7; SUZ12 AND SIRT1, AND METHYLTRANSFERASE ACTIVITY OF THE PRC4
RP   COMPLEX.
RX   PubMed=15684044; DOI=10.1073/pnas.0409875102;
RA   Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M.,
RA   Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P.J.,
RA   Reinberg D.;
RT   "Composition and histone substrates of polycomb repressive group
RT   complexes change during cellular differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1859-1864(2005).
RN   [23]
RP   INTERACTION WITH EED AND SUZ12, PHOSPHORYLATION AT SER-21 BY AKT1, AND
RP   MUTAGENESIS OF SER-21.
RX   PubMed=16224021; DOI=10.1126/science.1118947;
RA   Cha T.-L., Zhou B.P., Xia W., Wu Y., Yang C.-C., Chen C.-T., Ping B.,
RA   Otte A.P., Hung M.-C.;
RT   "Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine
RT   27 in histone H3.";
RL   Science 310:306-310(2005).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [25]
RP   FUNCTION.
RX   PubMed=16618801; DOI=10.1101/gad.381706;
RA   Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K.;
RT   "Genome-wide mapping of Polycomb target genes unravels their roles in
RT   cell fate transitions.";
RL   Genes Dev. 20:1123-1136(2006).
RN   [26]
RP   METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=16431907; DOI=10.1074/jbc.M513425200;
RA   Martin C., Cao R., Zhang Y.;
RT   "Substrate preferences of the EZH2 histone methyltransferase
RT   complex.";
RL   J. Biol. Chem. 281:8365-8370(2006).
RN   [27]
RP   FUNCTION.
RX   PubMed=16717091; DOI=10.1074/jbc.M603722200;
RA   Etchegaray J.P., Yang X., DeBruyne J.P., Peters A.H., Weaver D.R.,
RA   Jenuwein T., Reppert S.M.;
RT   "The polycomb group protein EZH2 is required for mammalian circadian
RT   clock function.";
RL   J. Biol. Chem. 281:21209-21215(2006).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [29]
RP   FUNCTION, AND INTERACTION OF THE PRC2 COMPLEX WITH DNMT1; DNMT3A AND
RP   DNMT3B.
RX   PubMed=16357870; DOI=10.1038/nature04431;
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RT   "The Polycomb group protein EZH2 directly controls DNA methylation.";
RL   Nature 439:871-874(2006).
RN   [30]
RP   ERRATUM.
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RL   Nature 446:824-824(2006).
RN   [31]
RP   FUNCTION.
RX   PubMed=16936726; DOI=10.1038/nsmb1142;
RA   Kim D.H., Villeneuve L.M., Morris K.V., Rossi J.J.;
RT   "Argonaute-1 directs siRNA-mediated transcriptional gene silencing in
RT   human cells.";
RL   Nat. Struct. Mol. Biol. 13:793-797(2006).
RN   [32]
RP   FUNCTION.
RX   PubMed=17210787; DOI=10.1101/gad.1499407;
RA   Kotake Y., Cao R., Viatour P., Sage J., Zhang Y., Xiong Y.;
RT   "pRB family proteins are required for H3K27 trimethylation and
RT   Polycomb repression complexes binding to and silencing p16INK4alpha
RT   tumor suppressor gene.";
RL   Genes Dev. 21:49-54(2007).
RN   [33]
RP   FUNCTION, DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=17344414; DOI=10.1101/gad.415507;
RA   Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D.,
RA   Gargiulo G., Beekman C., Theilgaard-Moench K., Minucci S., Porse B.T.,
RA   Marine J.-C., Hansen K.H., Helin K.;
RT   "The Polycomb group proteins bind throughout the INK4A-ARF locus and
RT   are disassociated in senescent cells.";
RL   Genes Dev. 21:525-530(2007).
RN   [34]
RP   DE NOVO DNA METHYLATION OF PRC2 TARGET GENES.
RX   PubMed=17200670; DOI=10.1038/ng1950;
RA   Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M.,
RA   Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E.,
RA   Bergman Y., Simon I., Cedar H.;
RT   "Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes
RT   for de novo methylation in cancer.";
RL   Nat. Genet. 39:232-236(2007).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [37]
RP   FUNCTION, AND IDENTIFICATION IN THE PRC2/EED-EZH1 COMPLEX.
RX   PubMed=19026781; DOI=10.1016/j.molcel.2008.11.004;
RA   Margueron R., Li G., Sarma K., Blais A., Zavadil J., Woodcock C.L.,
RA   Dynlacht B.D., Reinberg D.;
RT   "Ezh1 and Ezh2 maintain repressive chromatin through different
RT   mechanisms.";
RL   Mol. Cell 32:503-518(2008).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=18086877; DOI=10.1128/MCB.01589-07;
RA   Cao R., Wang H., He J., Erdjument-Bromage H., Tempst P., Zhang Y.;
RT   "Role of hPHF1 in H3K27 methylation and Hox gene silencing.";
RL   Mol. Cell. Biol. 28:1862-1872(2008).
RN   [39]
RP   FUNCTION, INTERACTION WITH EED; SUZ12 AND PHF1, METHYLTRANSFERASE
RP   ACTIVITY OF THE PRC2 COMPLEX, AND MUTAGENESIS OF HIS-689.
RX   PubMed=18285464; DOI=10.1128/MCB.02017-07;
RA   Sarma K., Margueron R., Ivanov A., Pirrotta V., Reinberg D.;
RT   "Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27
RT   trimethylation in vivo.";
RL   Mol. Cell. Biol. 28:2718-2731(2008).
RN   [40]
RP   SUMOYLATION.
RX   PubMed=18628979; DOI=10.1371/journal.pone.0002704;
RA   Riising E.M., Boggio R., Chiocca S., Helin K., Pasini D.;
RT   "The polycomb repressive complex 2 is a potential target of SUMO
RT   modifications.";
RL   PLoS ONE 3:E2704-E2704(2008).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-366; THR-367 AND
RP   THR-487, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [44]
RP   FUNCTION, PHOSPHORYLATION AT THR-345 BY CDK1 AND CDK2, AND MUTAGENESIS
RP   OF THR-345.
RX   PubMed=20935635; DOI=10.1038/ncb2116;
RA   Chen S., Bohrer L.R., Rai A.N., Pan Y., Gan L., Zhou X., Bagchi A.,
RA   Simon J.A., Huang H.;
RT   "Cyclin-dependent kinases regulate epigenetic gene silencing through
RT   phosphorylation of EZH2.";
RL   Nat. Cell Biol. 12:1108-1114(2010).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [46]
RP   INTERACTION WITH CDYL.
RX   PubMed=22009739; DOI=10.1074/jbc.M111.271064;
RA   Zhang Y., Yang X., Gui B., Xie G., Zhang D., Shang Y., Liang J.;
RT   "Corepressor protein CDYL functions as a molecular bridge between
RT   polycomb repressor complex 2 and repressive chromatin mark
RT   trimethylated histone lysine 27.";
RL   J. Biol. Chem. 286:42414-42425(2011).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [48]
RP   FUNCTION.
RX   PubMed=23063525; DOI=10.1016/j.molcel.2012.09.004;
RA   Lee J.M., Lee J.S., Kim H., Kim K., Park H., Kim J.Y., Lee S.H.,
RA   Kim I.S., Kim J., Lee M., Chung C.H., Seo S.B., Yoon J.B., Ko E.,
RA   Noh D.Y., Kim K.I., Kim K.K., Baek S.H.;
RT   "EZH2 generates a methyl degron that is recognized by the
RT   DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex.";
RL   Mol. Cell 48:572-586(2012).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; THR-339; SER-363;
RP   THR-367 AND THR-487, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [50]
RP   GLYCOSYLATION AT SER-75, MUTAGENESIS OF SER-75, AND FUNCTION.
RX   PubMed=24474760; DOI=10.1073/pnas.1323226111;
RA   Chu C.S., Lo P.W., Yeh Y.H., Hsu P.H., Peng S.H., Teng Y.C.,
RA   Kang M.L., Wong C.H., Juan L.J.;
RT   "O-GlcNAcylation regulates EZH2 protein stability and function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:1355-1360(2014).
RN   [51]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-634, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [52]
RP   VARIANTS PHE-641; SER-641; ASN-641; HIS-641 AND CYS-641.
RX   PubMed=20081860; DOI=10.1038/ng.518;
RA   Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R.,
RA   Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., Yap D.,
RA   Humphries R.K., Griffith O.L., Shah S., Zhu H., Kimbara M.,
RA   Shashkin P., Charlot J.F., Tcherpakov M., Corbett R., Tam A.,
RA   Varhol R., Smailus D., Moksa M., Zhao Y., Delaney A., Qian H.,
RA   Birol I., Schein J., Moore R., Holt R., Horsman D.E., Connors J.M.,
RA   Jones S., Aparicio S., Hirst M., Gascoyne R.D., Marra M.A.;
RT   "Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse
RT   large B-cell lymphomas of germinal-center origin.";
RL   Nat. Genet. 42:181-185(2010).
RN   [53]
RP   VARIANTS TRP-571; CYS-641; CYS-685 AND ASP-726, AND CHARACTERIZATION
RP   OF VARIANTS TRP-571; CYS-641; CYS-685 AND ASP-726.
RX   PubMed=20601953; DOI=10.1038/ng.621;
RA   Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C.,
RA   Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., Hochhaus A.,
RA   Drexler H.G., Duncombe A., Cervantes F., Oscier D., Boultwood J.,
RA   Grand F.H., Cross N.C.;
RT   "Inactivating mutations of the histone methyltransferase gene EZH2 in
RT   myeloid disorders.";
RL   Nat. Genet. 42:722-726(2010).
RN   [54]
RP   CHARACTERIZATION OF VARIANTS PHE-641 AND ASN-641.
RX   PubMed=21190999; DOI=10.1182/blood-2010-11-321208;
RA   Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A.,
RA   Morin R.D., Mungall A.J., Meissner B., Boyle M., Marquez V.E.,
RA   Marra M.A., Gascoyne R.D., Humphries R.K., Arrowsmith C.H.,
RA   Morin G.B., Aparicio S.A.;
RT   "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of
RT   selectively altered PRC2 catalytic activity, to increase H3K27
RT   trimethylation.";
RL   Blood 117:2451-2459(2011).
RN   [55]
RP   VARIANT HIS-685.
RX   PubMed=21828135; DOI=10.1182/blood-2010-10-311019;
RA   Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y.,
RA   Traina F., Visconte V., Sugimoto Y., Prince C., O'Keefe C., Hsi E.D.,
RA   List A., Sekeres M.A., Rao A., McDevitt M.A., Maciejewski J.P.;
RT   "Mutational spectrum analysis of chronic myelomonocytic leukemia
RT   includes genes associated with epigenetic regulation: UTX, EZH2, and
RT   DNMT3A.";
RL   Blood 118:3932-3941(2011).
RN   [56]
RP   VARIANTS WVS THR-134; GLU-156; ARG-279; MET-621; ASN-658; THR-677;
RP   CYS-679; LEU-690; 728-TYR--PRO-746 DEL AND CYS-736.
RX   PubMed=22190405; DOI=10.18632/oncotarget.385;
RG   Childhood Overgrowth Collaboration;
RA   Tatton-Brown K., Hanks S., Ruark E., Zachariou A., Duarte S.V.,
RA   Ramsay E., Snape K., Murray A., Perdeaux E.R., Seal S., Loveday C.,
RA   Banka S., Clericuzio C., Flinter F., Magee A., McConnell V.,
RA   Patton M., Raith W., Rankin J., Splitt M., Strenger V., Taylor C.,
RA   Wheeler P., Temple K.I., Cole T., Douglas J., Rahman N.;
RT   "Germline mutations in the oncogene EZH2 cause Weaver syndrome and
RT   increased human height.";
RL   Oncotarget 2:1127-1133(2011).
RN   [57]
RP   VARIANTS WVS SER-132; TYR-153 DEL AND TYR-689.
RX   PubMed=22177091; DOI=10.1016/j.ajhg.2011.11.018;
RA   Gibson W.T., Hood R.L., Zhan S.H., Bulman D.E., Fejes A.P., Moore R.,
RA   Mungall A.J., Eydoux P., Babul-Hirji R., An J., Marra M.A.,
RA   Chitayat D., Boycott K.M., Weaver D.D., Jones S.J.;
RT   "Mutations in EZH2 cause Weaver syndrome.";
RL   Am. J. Hum. Genet. 90:110-118(2012).
RN   [58]
RP   VARIANT GLY-677, CHARACTERIZATION OF VARIANTS ASN-641; CYS-641;
RP   HIS-641; PHE-641 AND GLY-677, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22323599; DOI=10.1073/pnas.1116418109;
RA   McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y.,
RA   Smitheman K.N., Ott H.M., Pappalardi M.B., Allen K.E., Chen S.B.,
RA   Della Pietra A. III, Dul E., Hughes A.M., Gilbert S.A., Thrall S.H.,
RA   Tummino P.J., Kruger R.G., Brandt M., Schwartz B., Creasy C.L.;
RT   "Mutation of A677 in histone methyltransferase EZH2 in human B-cell
RT   lymphoma promotes hypertrimethylation of histone H3 on lysine 27
RT   (H3K27).";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:2989-2994(2012).
RN   [59]
RP   VARIANT WVS LYS-740.
RX   PubMed=23239504; DOI=10.1002/ajmg.a.35660;
RA   Al-Salem A., Alshammari M.J., Hassan H., Alazami A.M., Alkuraya F.S.;
RT   "Weaver syndrome and defective cortical development: a rare
RT   association.";
RL   Am. J. Med. Genet. A 161A:225-227(2013).
RN   [60]
RP   VARIANTS WVS CYS-133 AND CYS-679, CHARACTERIZATION OF VARIANTS WVS
RP   SER-132; CYS-133; TYR-153 DEL; CYS-679 AND TYR-689, VARIANT HIS-185,
RP   CHARACTERIZATION OF VARIANT HIS-185, AND MUTAGENESIS OF PHE-667.
RX   PubMed=26694085; DOI=10.1002/humu.22946;
RA   Cohen A.S., Yap D.B., Lewis M.E., Chijiwa C., Ramos-Arroyo M.A.,
RA   Tkachenko N., Milano V., Fradin M., McKinnon M.L., Townsend K.N.,
RA   Xu J., Van Allen M.I., Ross C.J., Dobyns W.B., Weaver D.D.,
RA   Gibson W.T.;
RT   "Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired
RT   Histone Methyltransferase Function In Vitro.";
RL   Hum. Mutat. 37:301-307(2016).
RN   [61]
RP   INVOLVEMENT IN WVS.
RX   PubMed=28229514; DOI=10.1002/humu.23200;
RA   Imagawa E., Higashimoto K., Sakai Y., Numakura C., Okamoto N.,
RA   Matsunaga S., Ryo A., Sato Y., Sanefuji M., Ihara K., Takada Y.,
RA   Nishimura G., Saitsu H., Mizuguchi T., Miyatake S., Nakashima M.,
RA   Miyake N., Soejima H., Matsumoto N.;
RT   "Mutations in genes encoding polycomb repressive complex 2 subunits
RT   cause Weaver syndrome.";
RL   Hum. Mutat. 38:637-648(2017).
CC   -!- FUNCTION: Polycomb group (PcG) protein. Catalytic subunit of the
CC       PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-
CC       27' (H3K27me) of histone H3, leading to transcriptional repression
CC       of the affected target gene. Able to mono-, di- and trimethylate
CC       'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3,
CC       respectively. Displays a preference for substrates with less
CC       methylation, loses activity when progressively more methyl groups
CC       are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2
CC       (PubMed:22323599). Compared to EZH1-containing complexes, it is
CC       more abundant in embryonic stem cells and plays a major role in
CC       forming H3K27me3, which is required for embryonic stem cell
CC       identity and proper differentiation. The PRC2/EED-EZH2 complex may
CC       also serve as a recruiting platform for DNA methyltransferases,
CC       thereby linking two epigenetic repression systems. Genes repressed
CC       by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A
CC       and retinoic acid target genes. EZH2 can also methylate non-
CC       histone proteins such as the transcription factor GATA4 and the
CC       nuclear receptor RORA. Regulates the circadian clock via histone
CC       methylation at the promoter of the circadian genes. Essential for
CC       the CRY1/2-mediated repression of the transcriptional activation
CC       of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di
CC       and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters
CC       which is necessary for the CRY1/2 proteins to inhibit
CC       transcription. {ECO:0000269|PubMed:14532106,
CC       ECO:0000269|PubMed:15225548, ECO:0000269|PubMed:15231737,
CC       ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16179254,
CC       ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:16618801,
CC       ECO:0000269|PubMed:16717091, ECO:0000269|PubMed:16936726,
CC       ECO:0000269|PubMed:17210787, ECO:0000269|PubMed:17344414,
CC       ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:19026781,
CC       ECO:0000269|PubMed:20935635, ECO:0000269|PubMed:22323599,
CC       ECO:0000269|PubMed:23063525, ECO:0000269|PubMed:24474760}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + L-lysine-[histone] =
CC       S-adenosyl-L-homocysteine + N(6)-methyl-L-lysine-[histone].
CC       {ECO:0000269|PubMed:22323599}.
CC   -!- SUBUNIT: Binds ATRX via the SET domain (Probable). Component of
CC       the PRC2/EED-EZH2 complex, which includes EED, EZH2, SUZ12, RBBP4
CC       and RBBP7 and possibly AEBP2. The minimum components required for
CC       methyltransferase activity of the PRC2/EED-EZH2 complex are EED,
CC       EZH2 and SUZ12. The PRC2 complex may also interact with DNMT1,
CC       DNMT3A, DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via
CC       the SUZ12 subunit. Interacts with HDAC1 and HDAC2. Interacts with
CC       PRAME. Interacts with CDYL. Interacts with CLOCK, ARNTL/BMAL1 and
CC       CRY1 (By similarity). Interacts with DNMT3L; the interaction is
CC       direct (By similarity). {ECO:0000250|UniProtKB:Q61188,
CC       ECO:0000269|PubMed:10581039, ECO:0000269|PubMed:11158321,
CC       ECO:0000269|PubMed:12351676, ECO:0000269|PubMed:12435631,
CC       ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16179254,
CC       ECO:0000269|PubMed:16224021, ECO:0000269|PubMed:16357870,
CC       ECO:0000269|PubMed:18086877, ECO:0000269|PubMed:18285464,
CC       ECO:0000269|PubMed:19026781, ECO:0000269|PubMed:22009739,
CC       ECO:0000269|PubMed:9499421, ECO:0000269|PubMed:9584199,
CC       ECO:0000305}.
CC   -!- INTERACTION:
CC       Q8IXJ9:ASXL1; NbExp=6; IntAct=EBI-530054, EBI-1646500;
CC       P46100:ATRX; NbExp=2; IntAct=EBI-530054, EBI-396461;
CC       Q96MT8:CEP63; NbExp=3; IntAct=EBI-530054, EBI-741977;
CC       P26358:DNMT1; NbExp=8; IntAct=EBI-530054, EBI-719459;
CC       Q9Y6K1:DNMT3A; NbExp=6; IntAct=EBI-530054, EBI-923653;
CC       Q9UBC3:DNMT3B; NbExp=14; IntAct=EBI-530054, EBI-80125;
CC       Q9CWR8:Dnmt3l (xeno); NbExp=2; IntAct=EBI-530054, EBI-3043871;
CC       O75530:EED; NbExp=11; IntAct=EBI-530054, EBI-923794;
CC       Q92833-1:JARID2; NbExp=7; IntAct=EBI-530054, EBI-15825247;
CC       P60411:KRTAP10-9; NbExp=4; IntAct=EBI-10699473, EBI-10172052;
CC       O43189:PHF1; NbExp=5; IntAct=EBI-530054, EBI-530034;
CC       Q15156:PML-RAR; NbExp=8; IntAct=EBI-530054, EBI-867256;
CC       P10276:RARA; NbExp=2; IntAct=EBI-530054, EBI-413374;
CC       P40763:STAT3; NbExp=5; IntAct=EBI-530054, EBI-518675;
CC       O43463:SUV39H1; NbExp=2; IntAct=EBI-530054, EBI-349968;
CC       Q15022:SUZ12; NbExp=22; IntAct=EBI-530054, EBI-1264675;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12101246,
CC       ECO:0000269|PubMed:14532106, ECO:0000269|PubMed:15231737,
CC       ECO:0000269|PubMed:9584199}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q15910-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15910-2; Sequence=VSP_038815;
CC       Name=3;
CC         IsoId=Q15910-3; Sequence=VSP_038814;
CC       Name=4;
CC         IsoId=Q15910-4; Sequence=VSP_038813;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=Q15910-5; Sequence=VSP_038813, VSP_038816;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in many tissues. Overexpressed in
CC       numerous tumor types including carcinomas of the breast, colon,
CC       larynx, lymphoma and testis. {ECO:0000269|PubMed:14532106}.
CC   -!- DEVELOPMENTAL STAGE: Expression decreases during senescence of
CC       embryonic fibroblasts (HEFs). Expression peaks at the G1/S phase
CC       boundary. {ECO:0000269|PubMed:14532106,
CC       ECO:0000269|PubMed:15208672, ECO:0000269|PubMed:17344414}.
CC   -!- INDUCTION: Expression is induced by E2F1, E2F2 and E2F3.
CC       Expression is reduced in cells subject to numerous types of stress
CC       including UV-, IR- and bleomycin-induced DNA damage and by
CC       activation of p53/TP53. {ECO:0000269|PubMed:14532106,
CC       ECO:0000269|PubMed:15208672, ECO:0000269|PubMed:17344414}.
CC   -!- PTM: Phosphorylated by AKT1. Phosphorylation by AKT1 reduces
CC       methyltransferase activity. Phosphorylation at Thr-345 by CDK1 and
CC       CDK2 promotes maintenance of H3K27me3 levels at EZH2-target loci,
CC       thus leading to epigenetic gene silencing.
CC       {ECO:0000269|PubMed:16224021, ECO:0000269|PubMed:20935635}.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:18628979}.
CC   -!- PTM: Glycosylated: O-GlcNAcylation at Ser-75 by OGT increases
CC       stability of EZH2 and facilitates the formation of H3K27me3 by the
CC       PRC2/EED-EZH2 complex. {ECO:0000269|PubMed:24474760}.
CC   -!- DISEASE: Weaver syndrome (WVS) [MIM:277590]: A syndrome of
CC       accelerated growth and osseous maturation, unusual craniofacial
CC       appearance, hoarse and low-pitched cry, and hypertonia with
CC       camptodactyly. Distinguishing features of Weaver syndrome include
CC       broad forehead and face, ocular hypertelorism, prominent wide
CC       philtrum, micrognathia, deep horizontal chin groove, and deep-set
CC       nails. In addition, carpal bone development is advanced over the
CC       rest of the hand. {ECO:0000269|PubMed:22177091,
CC       ECO:0000269|PubMed:22190405, ECO:0000269|PubMed:23239504,
CC       ECO:0000269|PubMed:26694085, ECO:0000269|PubMed:28229514}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding
CC       methyltransferase superfamily. Histone-lysine methyltransferase
CC       family. EZ subfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC   -!- CAUTION: Two variants of the PRC2 complex have been described,
CC       termed PRC3 and PRC4. Each of the three complexes may include a
CC       different complement of EED isoforms, although the precise
CC       sequences of the isoforms in each complex have not been
CC       determined. The PRC2 and PRC4 complexes may also methylate 'Lys-
CC       26' of histone H1 in addition to 'Lys-27' of histone H3
CC       (PubMed:15099518 and PubMed:15684044), although other studies have
CC       demonstrated no methylation of 'Lys-26' of histone H1 by PRC2
CC       (PubMed:16431907). {ECO:0000305|PubMed:16431907}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAS07448.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X95653; CAA64955.1; -; mRNA.
DR   EMBL; U61145; AAC51520.1; -; mRNA.
DR   EMBL; AK302216; BAH13652.1; -; mRNA.
DR   EMBL; AK092676; BAG52592.1; -; mRNA.
DR   EMBL; AK293239; BAH11472.1; -; mRNA.
DR   EMBL; AK314291; BAG36948.1; -; mRNA.
DR   EMBL; AC006323; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073140; AAS07448.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471146; EAW80067.1; -; Genomic_DNA.
DR   EMBL; CH471146; EAW80070.1; -; Genomic_DNA.
DR   EMBL; BC010858; AAH10858.1; -; mRNA.
DR   EMBL; U52965; AAC50591.1; -; Genomic_DNA.
DR   CCDS; CCDS56516.1; -. [Q15910-1]
DR   CCDS; CCDS56517.1; -. [Q15910-5]
DR   CCDS; CCDS56518.1; -. [Q15910-4]
DR   CCDS; CCDS5891.1; -. [Q15910-2]
DR   CCDS; CCDS5892.1; -. [Q15910-3]
DR   PIR; G02838; G02838.
DR   RefSeq; NP_001190176.1; NM_001203247.1. [Q15910-1]
DR   RefSeq; NP_001190177.1; NM_001203248.1. [Q15910-4]
DR   RefSeq; NP_001190178.1; NM_001203249.1. [Q15910-5]
DR   RefSeq; NP_004447.2; NM_004456.4. [Q15910-2]
DR   RefSeq; NP_694543.1; NM_152998.2. [Q15910-3]
DR   RefSeq; XP_011514186.1; XM_011515884.2. [Q15910-2]
DR   UniGene; Hs.444082; -.
DR   UniGene; Hs.732308; -.
DR   PDB; 2C6V; Model; -; A=508-734.
DR   PDB; 4MI0; X-ray; 2.00 A; A=520-746.
DR   PDB; 4MI5; X-ray; 2.00 A; A=521-746.
DR   PDB; 5GSA; X-ray; 2.49 A; C/D=40-68.
DR   PDB; 5H14; X-ray; 1.90 A; C/D=40-68.
DR   PDB; 5H15; X-ray; 2.27 A; C/D=40-68.
DR   PDB; 5H17; X-ray; 2.30 A; B=40-68.
DR   PDB; 5H19; X-ray; 1.90 A; B=40-68.
DR   PDB; 5H24; X-ray; 2.50 A; C/D=40-68.
DR   PDB; 5H25; X-ray; 2.88 A; C/D=40-68.
DR   PDB; 5HYN; X-ray; 2.95 A; A/F/K/Q=1-746.
DR   PDB; 5IJ7; X-ray; 2.62 A; A/B=429-487, A/B=511-746.
DR   PDB; 5IJ8; X-ray; 2.99 A; A/B=429-487, A/B=511-531, A/B=533-746.
DR   PDB; 5LS6; X-ray; 3.47 A; A/D/G/J=1-385, A/D/G/J=421-746.
DR   PDB; 5U5T; X-ray; 1.60 A; C/D=39-68.
DR   PDB; 5U62; X-ray; 1.90 A; C/D=39-68.
DR   PDB; 5WUK; X-ray; 2.03 A; B=41-68.
DR   PDBsum; 2C6V; -.
DR   PDBsum; 4MI0; -.
DR   PDBsum; 4MI5; -.
DR   PDBsum; 5GSA; -.
DR   PDBsum; 5H14; -.
DR   PDBsum; 5H15; -.
DR   PDBsum; 5H17; -.
DR   PDBsum; 5H19; -.
DR   PDBsum; 5H24; -.
DR   PDBsum; 5H25; -.
DR   PDBsum; 5HYN; -.
DR   PDBsum; 5IJ7; -.
DR   PDBsum; 5IJ8; -.
DR   PDBsum; 5LS6; -.
DR   PDBsum; 5U5T; -.
DR   PDBsum; 5U62; -.
DR   PDBsum; 5WUK; -.
DR   ProteinModelPortal; Q15910; -.
DR   SMR; Q15910; -.
DR   BioGrid; 108446; 280.
DR   CORUM; Q15910; -.
DR   DIP; DIP-34002N; -.
DR   IntAct; Q15910; 113.
DR   MINT; Q15910; -.
DR   STRING; 9606.ENSP00000320147; -.
DR   BindingDB; Q15910; -.
DR   ChEMBL; CHEMBL2189110; -.
DR   GuidetoPHARMACOLOGY; 2654; -.
DR   iPTMnet; Q15910; -.
DR   PhosphoSitePlus; Q15910; -.
DR   BioMuta; EZH2; -.
DR   DMDM; 3334180; -.
DR   EPD; Q15910; -.
DR   MaxQB; Q15910; -.
DR   PaxDb; Q15910; -.
DR   PeptideAtlas; Q15910; -.
DR   PRIDE; Q15910; -.
DR   DNASU; 2146; -.
DR   Ensembl; ENST00000320356; ENSP00000320147; ENSG00000106462. [Q15910-2]
DR   Ensembl; ENST00000350995; ENSP00000223193; ENSG00000106462. [Q15910-3]
DR   Ensembl; ENST00000460911; ENSP00000419711; ENSG00000106462. [Q15910-1]
DR   Ensembl; ENST00000476773; ENSP00000419050; ENSG00000106462. [Q15910-5]
DR   Ensembl; ENST00000478654; ENSP00000417062; ENSG00000106462. [Q15910-5]
DR   Ensembl; ENST00000483967; ENSP00000419856; ENSG00000106462. [Q15910-4]
DR   GeneID; 2146; -.
DR   KEGG; hsa:2146; -.
DR   UCSC; uc003wfb.3; human. [Q15910-1]
DR   CTD; 2146; -.
DR   DisGeNET; 2146; -.
DR   EuPathDB; HostDB:ENSG00000106462.10; -.
DR   GeneCards; EZH2; -.
DR   GeneReviews; EZH2; -.
DR   HGNC; HGNC:3527; EZH2.
DR   HPA; CAB009589; -.
DR   HPA; HPA029131; -.
DR   MalaCards; EZH2; -.
DR   MIM; 277590; phenotype.
DR   MIM; 601573; gene.
DR   neXtProt; NX_Q15910; -.
DR   OpenTargets; ENSG00000106462; -.
DR   Orphanet; 3447; Weaver syndrome.
DR   PharmGKB; PA27939; -.
DR   eggNOG; KOG1079; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   GeneTree; ENSGT00780000121845; -.
DR   HOVERGEN; HBG002453; -.
DR   InParanoid; Q15910; -.
DR   KO; K11430; -.
DR   OMA; VYNYTPC; -.
DR   PhylomeDB; Q15910; -.
DR   TreeFam; TF314509; -.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-8953750; Transcriptional Regulation by E2F6.
DR   SignaLink; Q15910; -.
DR   SIGNOR; Q15910; -.
DR   ChiTaRS; EZH2; human.
DR   GeneWiki; EZH2; -.
DR   GenomeRNAi; 2146; -.
DR   PRO; PR:Q15910; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000106462; -.
DR   CleanEx; HS_EZH2; -.
DR   ExpressionAtlas; Q15910; baseline and differential.
DR   Genevisible; Q15910; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0035098; C:ESC/E(Z) complex; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0045120; C:pronucleus; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0042054; F:histone methyltransferase activity; IDA:MGI.
DR   GO; GO:0046976; F:histone methyltransferase activity (H3-K27 specific); IDA:UniProtKB.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IDA:MGI.
DR   GO; GO:0070878; F:primary miRNA binding; IEA:Ensembl.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0016279; F:protein-lysine N-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0035984; P:cellular response to trichostatin A; IEA:Ensembl.
DR   GO; GO:0021695; P:cerebellar cortex development; IEA:Ensembl.
DR   GO; GO:0006325; P:chromatin organization; TAS:ProtInc.
DR   GO; GO:0006306; P:DNA methylation; IEA:Ensembl.
DR   GO; GO:0070314; P:G1 to G0 transition; IEA:Ensembl.
DR   GO; GO:0036333; P:hepatocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0070734; P:histone H3-K27 methylation; IDA:UniProtKB.
DR   GO; GO:0098532; P:histone H3-K27 trimethylation; IEA:Ensembl.
DR   GO; GO:0016571; P:histone methylation; IMP:UniProtKB.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0043433; P:negative regulation of DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0045605; P:negative regulation of epidermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0070317; P:negative regulation of G0 to G1 transition; TAS:Reactome.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; IDA:UniProtKB.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051154; P:negative regulation of striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:1900006; P:positive regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0071168; P:protein localization to chromatin; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IMP:UniProtKB.
DR   GO; GO:0014013; P:regulation of gliogenesis; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:1904772; P:response to tetrachloromethane; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0014834; P:skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00167; SANT; 1.
DR   InterPro; IPR026489; CXC_dom.
DR   InterPro; IPR021654; EZH1/EZH2.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR033467; Tesmin/TSO1-like_CXC.
DR   Pfam; PF11616; EZH2_WD-Binding; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM01114; CXC; 1.
DR   SMART; SM00717; SANT; 2.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51633; CXC; 1.
DR   PROSITE; PS50280; SET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms;
KW   Chromatin regulator; Complete proteome; Disease mutation;
KW   Glycoprotein; Isopeptide bond; Methyltransferase; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repressor;
KW   S-adenosyl-L-methionine; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1    746       Histone-lysine N-methyltransferase EZH2.
FT                                /FTId=PRO_0000213992.
FT   DOMAIN      503    605       CXC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00970}.
FT   DOMAIN      612    727       SET. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00190}.
FT   REGION        1    340       Interaction with DNMT1, DNMT3A and
FT                                DNMT3B.
FT   REGION       39     68       Interaction with EED. {ECO:0000250}.
FT   REGION      329    522       Interaction with CDYL.
FT                                {ECO:0000269|PubMed:22009739}.
FT   COMPBIAS    523    605       Cys-rich.
FT   MOD_RES      21     21       Phosphoserine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:16224021}.
FT   MOD_RES      76     76       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     339    339       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     345    345       Phosphothreonine; by CDK1 and CDK2.
FT                                {ECO:0000269|PubMed:20935635}.
FT   MOD_RES     363    363       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     366    366       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     367    367       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     487    487       Phosphothreonine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   CARBOHYD     75     75       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:24474760}.
FT   CROSSLNK    634    634       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ      74     82       Missing (in isoform 4 and isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038813.
FT   VAR_SEQ      83    121       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038814.
FT   VAR_SEQ     297    298       HP -> HRKCNYS (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_038815.
FT   VAR_SEQ     511    553       DGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSS
FT                                EC -> G (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038816.
FT   VARIANT     132    132       P -> S (in WVS; decreased histone
FT                                methyltransferase activity;
FT                                dbSNP:rs193921148).
FT                                {ECO:0000269|PubMed:22177091,
FT                                ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_067595.
FT   VARIANT     133    133       Y -> C (in WVS; decreased histone
FT                                methyltransferase activity).
FT                                {ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_078320.
FT   VARIANT     134    134       M -> T (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078321.
FT   VARIANT     153    153       Missing (in WVS; decreased histone
FT                                methyltransferase activity).
FT                                {ECO:0000269|PubMed:22177091,
FT                                ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_067596.
FT   VARIANT     156    156       K -> E (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078322.
FT   VARIANT     185    185       D -> H (polymorhism; decreased histone
FT                                methyltransferase activity;
FT                                dbSNP:rs2302427).
FT                                {ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_055795.
FT   VARIANT     279    279       H -> R (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078323.
FT   VARIANT     571    571       C -> W (found in a patient with
FT                                myelodysplastic syndrome and
FT                                myelodysplastic-myeloproliferative
FT                                neoplasms; somatic mutation; loss of
FT                                histone methyltransferase activity).
FT                                {ECO:0000269|PubMed:20601953}.
FT                                /FTId=VAR_078324.
FT   VARIANT     621    621       V -> M (in WVS; unknown pathological
FT                                significance; dbSNP:rs587783625).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078325.
FT   VARIANT     641    641       Y -> C (in a patient with diffuse large
FT                                B-cell lymphoma; somatic mutation;
FT                                changed substrate preferences; prefers
FT                                substrates with greater methylation
FT                                H3K27me0<me1<me2).
FT                                {ECO:0000269|PubMed:20081860,
FT                                ECO:0000269|PubMed:20601953,
FT                                ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_067228.
FT   VARIANT     641    641       Y -> F (found in a patient with
FT                                follicular lymphoma; also in diffuse
FT                                large B-cell lymphoma; somatic mutation;
FT                                changed substrate preferences; prefers
FT                                substrates with greater methylation
FT                                H3K27me0<me1<me2; dbSNP:rs267601394).
FT                                {ECO:0000269|PubMed:20081860,
FT                                ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_067229.
FT   VARIANT     641    641       Y -> H (found in patients with follicular
FT                                lymphoma; also in diffuse large B-cell
FT                                lymphoma; somatic mutation; changed
FT                                substrate preferences; prefers substrates
FT                                with greater methylation
FT                                H3K27me0<me1<me2; dbSNP:rs267601395).
FT                                {ECO:0000269|PubMed:20081860,
FT                                ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_067230.
FT   VARIANT     641    641       Y -> N (found in patients with follicular
FT                                lymphoma; also in diffuse large B-cell
FT                                lymphoma; somatic mutation; changed
FT                                substrate preferences; prefers substrates
FT                                with greater methylation
FT                                H3K27me0<me1<me2).
FT                                {ECO:0000269|PubMed:20081860,
FT                                ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_067231.
FT   VARIANT     641    641       Y -> S (found in patients with follicular
FT                                lymphoma; also in diffuse large B-cell
FT                                lymphoma; somatic mutation).
FT                                {ECO:0000269|PubMed:20081860}.
FT                                /FTId=VAR_067232.
FT   VARIANT     658    658       Y -> N (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078326.
FT   VARIANT     677    677       A -> G (found in a patient with B-cell
FT                                lymphoma; increased hypertrimethylation
FT                                of H3K27; changed substrate preferences;
FT                                confers biochemical activity independent
FT                                of H3K27 methylation state).
FT                                {ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_078327.
FT   VARIANT     677    677       A -> T (in WVS; dbSNP:rs397515547).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078328.
FT   VARIANT     679    679       R -> C (in WVS; decreased histone
FT                                methyltransferase activity;
FT                                dbSNP:rs587783626).
FT                                {ECO:0000269|PubMed:22190405,
FT                                ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_078329.
FT   VARIANT     685    685       R -> C (found in a patient with myeloid
FT                                disorders; somatic mutation; loss of
FT                                histone methyltransferase activity).
FT                                {ECO:0000269|PubMed:20601953}.
FT                                /FTId=VAR_078330.
FT   VARIANT     685    685       R -> H (in a patient with chronic
FT                                myelomonocytic leukemia).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067233.
FT   VARIANT     689    689       H -> Y (in WVS; decreased histone
FT                                methyltransferase activity;
FT                                dbSNP:rs193921147).
FT                                {ECO:0000269|PubMed:22177091,
FT                                ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_067597.
FT   VARIANT     690    690       S -> L (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078331.
FT   VARIANT     726    726       Y -> D (found in a patient with chronic
FT                                myelomonocytic leukemia; somatic
FT                                mutation; loss of histone
FT                                methyltransferase activity).
FT                                {ECO:0000269|PubMed:20601953}.
FT                                /FTId=VAR_078332.
FT   VARIANT     728    746       Missing (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078333.
FT   VARIANT     736    736       Y -> C (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078334.
FT   VARIANT     740    740       E -> K (in WVS; unknown pathological
FT                                significance; dbSNP:rs397515548).
FT                                {ECO:0000269|PubMed:23239504}.
FT                                /FTId=VAR_078335.
FT   MUTAGEN      21     21       S->A: Enhances methyltransferase activity
FT                                towards 'Lys-27' of histone H3 and
FT                                abrogates phosphorylation by PKB/AKT1.
FT                                {ECO:0000269|PubMed:16224021}.
FT   MUTAGEN      21     21       S->D: Reduces methyltransferase activity
FT                                towards 'Lys-27' of histone H3 and
FT                                abrogates phosphorylation by PKB/AKT1.
FT                                {ECO:0000269|PubMed:16224021}.
FT   MUTAGEN      75     75       S->A: Reduced protein stability.
FT                                {ECO:0000269|PubMed:24474760}.
FT   MUTAGEN     345    345       T->A: Impaired CDK1- and CDK-2 mediated
FT                                phosphorylation and subsequent gene
FT                                silencing. Altered EZH2-mediated cell
FT                                proliferation and migration.
FT                                {ECO:0000269|PubMed:20935635}.
FT   MUTAGEN     588    588       C->Y: Strongly impairs methyltransferase
FT                                activity towards 'Lys-27' of histone H3.
FT                                {ECO:0000269|PubMed:12435631}.
FT   MUTAGEN     667    667       F->I: Strongly decreases histone
FT                                methyltransferase activity.
FT                                {ECO:0000269|PubMed:26694085}.
FT   MUTAGEN     689    689       H->A: Abrogates methyltransferase
FT                                activity. {ECO:0000269|PubMed:12435631,
FT                                ECO:0000269|PubMed:18285464}.
FT   CONFLICT     39     39       K -> N (in Ref. 3; BAG52592).
FT                                {ECO:0000305}.
FT   CONFLICT    224    224       F -> L (in Ref. 1; CAA64955).
FT                                {ECO:0000305}.
FT   CONFLICT    724    724       F -> V (in Ref. 1; CAA64955).
FT                                {ECO:0000305}.
FT   HELIX        44     62       {ECO:0000244|PDB:5U5T}.
FT   STRAND       82     87       {ECO:0000244|PDB:5HYN}.
FT   STRAND       94     97       {ECO:0000244|PDB:5HYN}.
FT   STRAND       99    101       {ECO:0000244|PDB:5HYN}.
FT   STRAND      126    129       {ECO:0000244|PDB:5HYN}.
FT   HELIX       135    138       {ECO:0000244|PDB:5HYN}.
FT   TURN        139    143       {ECO:0000244|PDB:5HYN}.
FT   HELIX       144    152       {ECO:0000244|PDB:5HYN}.
FT   TURN        153    155       {ECO:0000244|PDB:5HYN}.
FT   STRAND      161    163       {ECO:0000244|PDB:5LS6}.
FT   HELIX       168    181       {ECO:0000244|PDB:5HYN}.
FT   HELIX       221    230       {ECO:0000244|PDB:5HYN}.
FT   TURN        232    234       {ECO:0000244|PDB:5HYN}.
FT   HELIX       237    248       {ECO:0000244|PDB:5HYN}.
FT   STRAND      264    266       {ECO:0000244|PDB:5LS6}.
FT   HELIX       274    284       {ECO:0000244|PDB:5HYN}.
FT   TURN        287    289       {ECO:0000244|PDB:5HYN}.
FT   STRAND      291    293       {ECO:0000244|PDB:5HYN}.
FT   TURN        304    306       {ECO:0000244|PDB:5HYN}.
FT   HELIX       332    343       {ECO:0000244|PDB:5HYN}.
FT   HELIX       434    447       {ECO:0000244|PDB:5HYN}.
FT   HELIX       451    458       {ECO:0000244|PDB:5HYN}.
FT   HELIX       463    474       {ECO:0000244|PDB:5HYN}.
FT   STRAND      526    528       {ECO:0000244|PDB:5HYN}.
FT   HELIX       535    538       {ECO:0000244|PDB:4MI0}.
FT   STRAND      563    565       {ECO:0000244|PDB:4MI0}.
FT   HELIX       572    575       {ECO:0000244|PDB:4MI0}.
FT   TURN        582    584       {ECO:0000244|PDB:4MI0}.
FT   STRAND      587    589       {ECO:0000244|PDB:4MI0}.
FT   STRAND      590    592       {ECO:0000244|PDB:5LS6}.
FT   STRAND      594    596       {ECO:0000244|PDB:5HYN}.
FT   STRAND      600    603       {ECO:0000244|PDB:4MI0}.
FT   HELIX       605    608       {ECO:0000244|PDB:4MI0}.
FT   STRAND      614    618       {ECO:0000244|PDB:4MI0}.
FT   STRAND      620    630       {ECO:0000244|PDB:4MI0}.
FT   STRAND      637    640       {ECO:0000244|PDB:4MI0}.
FT   STRAND      643    647       {ECO:0000244|PDB:4MI0}.
FT   HELIX       648    656       {ECO:0000244|PDB:4MI0}.
FT   STRAND      666    668       {ECO:0000244|PDB:4MI0}.
FT   STRAND      670    676       {ECO:0000244|PDB:4MI0}.
FT   TURN        678    680       {ECO:0000244|PDB:4MI0}.
FT   HELIX       683    686       {ECO:0000244|PDB:4MI0}.
FT   STRAND      687    689       {ECO:0000244|PDB:4MI0}.
FT   STRAND      694    702       {ECO:0000244|PDB:4MI0}.
FT   STRAND      705    714       {ECO:0000244|PDB:4MI0}.
FT   STRAND      721    723       {ECO:0000244|PDB:5LS6}.
SQ   SEQUENCE   746 AA;  85363 MW;  1B5029EB9D509BE5 CRC64;
     MGQTGKKSEK GPVCWRKRVK SEYMRLRQLK RFRRADEVKS MFSSNRQKIL ERTEILNQEW
     KQRRIQPVHI LTSVSSLRGT RECSVTSDLD FPTQVIPLKT LNAVASVPIM YSWSPLQQNF
     MVEDETVLHN IPYMGDEVLD QDGTFIEELI KNYDGKVHGD RECGFINDEI FVELVNALGQ
     YNDDDDDDDG DDPEEREEKQ KDLEDHRDDK ESRPPRKFPS DKIFEAISSM FPDKGTAEEL
     KEKYKELTEQ QLPGALPPEC TPNIDGPNAK SVQREQSLHS FHTLFCRRCF KYDCFLHPFH
     ATPNTYKRKN TETALDNKPC GPQCYQHLEG AKEFAAALTA ERIKTPPKRP GGRRRGRLPN
     NSSRPSTPTI NVLESKDTDS DREAGTETGG ENNDKEEEEK KDETSSSSEA NSRCQTPIKM
     KPNIEPPENV EWSGAEASMF RVLIGTYYDN FCAIARLIGT KTCRQVYEFR VKESSIIAPA
     PAEDVDTPPR KKKRKHRLWA AHCRKIQLKK DGSSNHVYNY QPCDHPRQPC DSSCPCVIAQ
     NFCEKFCQCS SECQNRFPGC RCKAQCNTKQ CPCYLAVREC DPDLCLTCGA ADHWDSKNVS
     CKNCSIQRGS KKHLLLAPSD VAGWGIFIKD PVQKNEFISE YCGEIISQDE ADRRGKVYDK
     YMCSFLFNLN NDFVVDATRK GNKIRFANHS VNPNCYAKVM MVNGDHRIGI FAKRAIQTGE
     ELFFDYRYSQ ADALKYVGIE REMEIP
//
ID   S4S3R8_HUMAN            Unreviewed;       707 AA.
AC   S4S3R8;
DT   16-OCT-2013, integrated into UniProtKB/TrEMBL.
DT   16-OCT-2013, sequence version 1.
DT   28-FEB-2018, entry version 40.
DE   SubName: Full=EZH2b {ECO:0000313|EMBL:AEN79481.1};
DE   SubName: Full=Enhancer of zeste homolog 2 (Drosophila) {ECO:0000313|EMBL:EAL24423.1};
GN   Name=EZH2 {ECO:0000313|EMBL:EAL24423.1};
GN   ORFNames=tcag7.507 {ECO:0000313|EMBL:EAL24423.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AEN79481.1};
RN   [1] {ECO:0000313|EMBL:EAL24423.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D., Zhang Q., Gu Z., Lu F.,
RA   Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J., Grzeschik K.H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Dohner H., Dohner K.,
RA   Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [2] {ECO:0000313|EMBL:EAL24423.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Nusskern D., Zhang Q., Gu Z., Lu F.,
RA   Zeesman S., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P., Lococo F., Belloni E.,
RA   Shaffer L.G., Morton C.C., Pober B., Gusella J., Bruns G., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M.,
RA   Gripp K.W., Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H.,
RA   Teebi A., Minassian B.A., Kere J., Armengol L., Pujana M.Angel.,
RA   Estivill X., Wilson M.D., Koop B.F., Tosi S., Moore G.E.,
RA   Boright A.P., Zlotorynski E., Kerem B., Kroisel P.M., Petek E.,
RA   Oscier D.G., Mould S.J., Doehner H., Doehner K., Rommens J.M.,
RA   Vincent J.B., Venter J.C., Li P.W., Mural R.J., Adams M.D.,
RA   Tsui L.-C.;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:AEN79481.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Grzenda A.L., Urrutia R.A., Gwen L.A.;
RT   "Polycomb repressive complexes utilize distinct EZH2 isoforms to
RT   mediate gene silencing.";
RL   Submitted (MAY-2011) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; JF939048; AEN79481.1; -; Genomic_RNA.
DR   EMBL; AACC02000041; EAL24423.1; -; Genomic_DNA.
DR   RefSeq; NP_694543.1; NM_152998.2.
DR   UniGene; Hs.444082; -.
DR   UniGene; Hs.732308; -.
DR   SMR; S4S3R8; -.
DR   MaxQB; S4S3R8; -.
DR   GeneID; 2146; -.
DR   UCSC; uc003wfc.3; human.
DR   CTD; 2146; -.
DR   EuPathDB; HostDB:ENSG00000106462.10; -.
DR   ChiTaRS; EZH2; human.
DR   GenomeRNAi; 2146; -.
DR   Bgee; ENSG00000106462; -.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IEA:InterPro.
DR   CDD; cd00167; SANT; 1.
DR   InterPro; IPR026489; CXC_dom.
DR   InterPro; IPR021654; EZH1/EZH2.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR033467; Tesmin/TSO1-like_CXC.
DR   Pfam; PF11616; EZH2_WD-Binding; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM01114; CXC; 1.
DR   SMART; SM00717; SANT; 2.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51633; CXC; 1.
DR   PROSITE; PS50280; SET; 1.
PE   4: Predicted;
FT   DOMAIN      464    566       CXC. {ECO:0000259|PROSITE:PS51633}.
FT   DOMAIN      573    688       SET. {ECO:0000259|PROSITE:PS50280}.
SQ   SEQUENCE   707 AA;  81038 MW;  48EAF1393A9EA4F2 CRC64;
     MGQTGKKSEK GPVCWRKRVK SEYMRLRQLK RFRRADEVKS MFSSNRQKIL ERTEILNQEW
     KQRRIQPVHI LTSVSSLRGT REVEDETVLH NIPYMGDEVL DQDGTFIEEL IKNYDGKVHG
     DRECGFINDE IFVELVNALG QYNDDDDDDD GDDPEEREEK QKDLEDHRDD KESRPPRKFP
     SDKIFEAISS MFPDKGTAEE LKEKYKELTE QQLPGALPPE CTPNIDGPNA KSVQREQSLH
     SFHTLFCRRC FKYDCFLHPF HATPNTYKRK NTETALDNKP CGPQCYQHLE GAKEFAAALT
     AERIKTPPKR PGGRRRGRLP NNSSRPSTPT INVLESKDTD SDREAGTETG GENNDKEEEE
     KKDETSSSSE ANSRCQTPIK MKPNIEPPEN VEWSGAEASM FRVLIGTYYD NFCAIARLIG
     TKTCRQVYEF RVKESSIIAP APAEDVDTPP RKKKRKHRLW AAHCRKIQLK KDGSSNHVYN
     YQPCDHPRQP CDSSCPCVIA QNFCEKFCQC SSECQNRFPG CRCKAQCNTK QCPCYLAVRE
     CDPDLCLTCG AADHWDSKNV SCKNCSIQRG SKKHLLLAPS DVAGWGIFIK DPVQKNEFIS
     EYCGEIISQD EADRRGKVYD KYMCSFLFNL NNDFVVDATR KGNKIRFANH SVNPNCYAKV
     MMVNGDHRIG IFAKRAIQTG EELFFDYRYS QADALKYVGI EREMEIP
//
ID   A0A024RC92_HUMAN        Unreviewed;       822 AA.
AC   A0A024RC92;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-FEB-2018, entry version 38.
DE   RecName: Full=Tyrosine-protein kinase {ECO:0000256|PIRNR:PIRNR000632};
DE            EC=2.7.10.2 {ECO:0000256|PIRNR:PIRNR000632};
GN   Name=FES {ECO:0000313|EMBL:EAX02116.1};
GN   ORFNames=hCG_32581 {ECO:0000313|EMBL:EAX02116.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAX02116.1};
RN   [1] {ECO:0000313|EMBL:EAX02116.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX02116.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000256|PIRNR:PIRNR000632,
CC       ECO:0000256|SAAS:SAAS00897325}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton
CC       {ECO:0000256|PIRNR:PIRNR000632}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fes/fps subfamily. {ECO:0000256|PIRNR:PIRNR000632}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471101; EAX02115.1; -; Genomic_DNA.
DR   EMBL; CH471101; EAX02116.1; -; Genomic_DNA.
DR   RefSeq; NP_001996.1; NM_002005.3.
DR   RefSeq; XP_016877494.1; XM_017022005.1.
DR   RefSeq; XP_016877498.1; XM_017022009.1.
DR   UniGene; Hs.7636; -.
DR   SMR; A0A024RC92; -.
DR   GeneID; 2242; -.
DR   KEGG; hsa:2242; -.
DR   CTD; 2242; -.
DR   EuPathDB; HostDB:ENSG00000182511.11; -.
DR   eggNOG; KOG0194; Eukaryota.
DR   eggNOG; ENOG410Y6RP; LUCA.
DR   KO; K07527; -.
DR   OMA; PKDKWAL; -.
DR   OrthoDB; EOG091G01S4; -.
DR   GenomeRNAi; 2242; -.
DR   Bgee; ENSG00000182511; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008017; F:microtubule binding; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0007098; P:centrosome cycle; IEA:Ensembl.
DR   GO; GO:0001578; P:microtubule bundle formation; IEA:Ensembl.
DR   CDD; cd10361; SH2_Fps_family; 1.
DR   Gene3D; 1.20.1270.60; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR027267; AH/BAR_dom_sf.
DR   InterPro; IPR031160; F_BAR.
DR   InterPro; IPR001060; FCH_dom.
DR   InterPro; IPR035849; Fes/Fps/Fer_SH2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR016250; Tyr-prot_kinase_Fes/Fps.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PIRSF; PIRSF000632; TyrPK_fps; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00055; FCH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF103657; SSF103657; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51741; F_BAR; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   3: Inferred from homology;
KW   ATP-binding {ECO:0000256|PIRNR:PIRNR000632,
KW   ECO:0000256|PIRSR:PIRSR000632-2, ECO:0000256|SAAS:SAAS00990534};
KW   Coiled coil {ECO:0000256|PROSITE-ProRule:PRU01077,
KW   ECO:0000256|SAM:Coils}; Cytoplasm {ECO:0000256|PIRNR:PIRNR000632};
KW   Cytoskeleton {ECO:0000256|PIRNR:PIRNR000632};
KW   Kinase {ECO:0000256|PIRNR:PIRNR000632, ECO:0000256|SAAS:SAAS00897698};
KW   Nucleotide-binding {ECO:0000256|PIRNR:PIRNR000632,
KW   ECO:0000256|PIRSR:PIRSR000632-2, ECO:0000256|SAAS:SAAS00990534};
KW   SH2 domain {ECO:0000256|PROSITE-ProRule:PRU00191};
KW   Transferase {ECO:0000256|PIRNR:PIRNR000632,
KW   ECO:0000256|SAAS:SAAS00897698};
KW   Tyrosine-protein kinase {ECO:0000256|PIRNR:PIRNR000632,
KW   ECO:0000256|SAAS:SAAS00897698}.
FT   DOMAIN        1    260       F-BAR. {ECO:0000259|PROSITE:PS51741}.
FT   DOMAIN      460    549       SH2. {ECO:0000259|PROSITE:PS50001}.
FT   DOMAIN      561    822       Protein kinase.
FT                                {ECO:0000259|PROSITE:PS50011}.
FT   NP_BIND     567    575       ATP. {ECO:0000256|PIRSR:PIRSR000632-2}.
FT   COILED      135    169       {ECO:0000256|SAM:Coils}.
FT   COILED      324    344       {ECO:0000256|SAM:Coils}.
FT   ACT_SITE    683    683       Proton acceptor.
FT                                {ECO:0000256|PIRSR:PIRSR000632-1}.
FT   BINDING     590    590       ATP. {ECO:0000256|PIRSR:PIRSR000632-2}.
SQ   SEQUENCE   822 AA;  93497 MW;  4C2A90555857F045 CRC64;
     MGFSSELCSP QGHGVLQQMQ EAELRLLEGM RKWMAQRVKS DREYAGLLHH MSLQDSGGQS
     RAISPDSPIS QSWAEITSQT EGLSRLLRQH AEDLNSGPLS KLSLLIRERQ QLRKTYSEQW
     QQLQQELTKT HSQDIEKLKS QYRALARDSA QAKRKYQEAS KDKDRDKAKD KYVRSLWKLF
     AHHNRYVLGV RAAQLHHQHH HQLLLPGLLR SLQDLHEEMA CILKEILQEY LEISSLVQDE
     VVAIHREMAA AAARIQPEAE YQGFLRQYGS APDVPPCVTF DESLLEEGEP LEPGELQLNE
     LTVESVQHTL TSVTDELAVA TEMVFRRQEM VTQLQQELRN EEENTHPRER VQLLGKRQVL
     QEALQGLQVA LCSQAKLQAQ QELLQTKLEH LGPGEPPPVL LLQDDRHSTS SSEQEREGGR
     TPTLEILKSH ISGIFRPKFS LPPPLQLIPE VQKPLHEQLW YHGAIPRAEV AELLVHSGDF
     LVRESQGKQE YVLSVLWDGL PRHFIIQSLD NLYRLEGEGF PSIPLLIDHL LSTQQPLTKK
     SGVVLHRAVP KDKWVLNHED LVLGEQIGRG NFGEVFSGRL RADNTLVAVK SCRETLPPDL
     KAKFLQEARI LKQYSHPNIV RLIGVCTQKQ PIYIVMELVQ GGDFLTFLRT EGARLRVKTL
     LQMVGDAAAG MEYLESKCCI HRDLAARNCL VTEKNVLKIS DFGMSREEAD GVYAASGGLR
     QVPVKWTAPE ALNYGRYSSE SDVWSFGILL WETFSLGASP YPNLSNQQTR EFVEKGGRLP
     CPELCPDAVF RLMEQCWAYE PGQRPSFSTI YQELQSIRKR HR
//
ID   FES_HUMAN               Reviewed;         822 AA.
AC   P07332; B2R6E6; B4DUD0; E9PC94; E9PC95; Q2VXS7; Q2VXS8; Q2VXT0;
AC   Q6GTU5;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 3.
DT   28-FEB-2018, entry version 200.
DE   RecName: Full=Tyrosine-protein kinase Fes/Fps;
DE            EC=2.7.10.2;
DE   AltName: Full=Feline sarcoma/Fujinami avian sarcoma oncogene homolog;
DE   AltName: Full=Proto-oncogene c-Fes;
DE   AltName: Full=Proto-oncogene c-Fps;
DE   AltName: Full=p93c-fes;
GN   Name=FES; Synonyms=FPS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2179816;
RA   Alcalay M., Antolini F., van de Ven W.J.M., Lanfrancone L.,
RA   Grignani F., Pelicci P.G.;
RT   "Characterization of human and mouse c-fes cDNA clones and
RT   identification of the 5' end of the gene.";
RL   Oncogene 5:267-275(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=4065096;
RA   Roebroek A.J.M., Schalken J.A., Verbeek J.S., van den Ouweland A.M.W.,
RA   Onnekink C., Bloemers H.P.J., van de Ven W.J.M.;
RT   "The structure of the human c-fes/fps proto-oncogene.";
RL   EMBO J. 4:2897-2903(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4).
RA   Lefebvre J.-C.;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN CELL DIFFERENTIATION AND AS TUMOR SUPPRESSOR, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=2656706;
RA   Yu G., Smithgall T.E., Glazer R.I.;
RT   "K562 leukemia cells transfected with the human c-fes gene acquire the
RT   ability to undergo myeloid differentiation.";
RL   J. Biol. Chem. 264:10276-10281(1989).
RN   [9]
RP   PHOSPHORYLATION AT TYR-713, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   TYR-713.
RX   PubMed=7687763;
RA   Hjermstad S.J., Peters K.L., Briggs S.D., Glazer R.I., Smithgall T.E.;
RT   "Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by
RT   its src homology 2 domain and major autophosphorylation site (Tyr-
RT   713).";
RL   Oncogene 8:2283-2292(1993).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF BCR, AUTOPHOSPHORYLATION, AND ENZYME
RP   REGULATION.
RX   PubMed=8955135; DOI=10.1074/jbc.271.51.32930;
RA   Li J., Smithgall T.E.;
RT   "Co-expression with BCR induces activation of the FES tyrosine kinase
RT   and phosphorylation of specific N-terminal BCR tyrosine residues.";
RL   J. Biol. Chem. 271:32930-32936(1996).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11339827; DOI=10.1006/excr.2001.5217;
RA   Zirngibl R., Schulze D., Mirski S.E., Cole S.P., Greer P.A.;
RT   "Subcellular localization analysis of the closely related Fps/Fes and
RT   Fer protein-tyrosine kinases suggests a distinct role for Fps/Fes in
RT   vesicular trafficking.";
RL   Exp. Cell Res. 266:87-94(2001).
RN   [12]
RP   FUNCTION IN CELL PROLIFERATION AND CELL SPREADING, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, SUBUNIT, DOMAIN, AND MUTAGENESIS OF LEU-145 AND
RP   LEU-334.
RX   PubMed=11509660; DOI=10.1128/MCB.21.18.6170-6180.2001;
RA   Cheng H.Y., Schiavone A.P., Smithgall T.E.;
RT   "A point mutation in the N-terminal coiled-coil domain releases c-Fes
RT   tyrosine kinase activity and survival signaling in myeloid leukemia
RT   cells.";
RL   Mol. Cell. Biol. 21:6170-6180(2001).
RN   [13]
RP   REVIEW.
RX   PubMed=11994747; DOI=10.1038/nrm783;
RA   Greer P.;
RT   "Closing in on the biological functions of Fps/Fes and Fer.";
RL   Nat. Rev. Mol. Cell Biol. 3:278-289(2002).
RN   [14]
RP   FUNCTION IN REORGANIZATION OF THE ACTIN CYTOSKELETON AND CELL
RP   DIFFERENTIATION, AND INTERACTION WITH BCR.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster
RT   region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-
RT   dependent manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH TUBULIN AND
RP   MICROTUBULES, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-713,
RP   PHOSPHORYLATION BY HCK, AND MUTAGENESIS OF LEU-145; ARG-483 AND
RP   LYS-590.
RX   PubMed=15485904; DOI=10.1128/MCB.24.21.9351-9358.2004;
RA   Laurent C.E., Delfino F.J., Cheng H.Y., Smithgall T.E.;
RT   "The human c-Fes tyrosine kinase binds tubulin and microtubules
RT   through separate domains and promotes microtubule assembly.";
RL   Mol. Cell. Biol. 24:9351-9358(2004).
RN   [16]
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF MET-704;
RP   ARG-706; VAL-743 AND SER-759.
RX   PubMed=15867340; DOI=10.1158/0008-5472.CAN-04-3468;
RA   Sangrar W., Zirgnibl R.A., Gao Y., Muller W.J., Jia Z., Greer P.A.;
RT   "An identity crisis for fps/fes: oncogene or tumor suppressor?";
RL   Cancer Res. 65:3518-3522(2005).
RN   [17]
RP   ALTERNATIVE SPLICING.
RX   PubMed=15869408; DOI=10.1089/dna.2005.24.311;
RA   Carlson A., Berkowitz J.M., Browning D., Slamon D.J., Gasson J.C.,
RA   Yates K.E.;
RT   "Expression of c-Fes protein isoforms correlates with differentiation
RT   in myeloid leukemias.";
RL   DNA Cell Biol. 24:311-316(2005).
RN   [18]
RP   INTERACTION WITH TRIM28.
RX   PubMed=16792528; DOI=10.1042/BJ20060194;
RA   Delfino F.J., Shaffer J.M., Smithgall T.E.;
RT   "The KRAB-associated co-repressor KAP-1 is a coiled-coil binding
RT   partner, substrate and activator of the c-Fes protein tyrosine
RT   kinase.";
RL   Biochem. J. 399:141-150(2006).
RN   [19]
RP   FUNCTION IN STAT3 PHOSPHORYLATION, ROLE AS PUTATIVE TUMOR SUPPRESSOR
RP   IN COLON CANCER, MUTAGENESIS OF MET-704; ARG-706; VAL-743 AND SER-759,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16455651; DOI=10.1074/jbc.M507331200;
RA   Delfino F.J., Stevenson H., Smithgall T.E.;
RT   "A growth-suppressive function for the c-fes protein-tyrosine kinase
RT   in colorectal cancer.";
RL   J. Biol. Chem. 281:8829-8835(2006).
RN   [20]
RP   FUNCTION IN KIT SIGNALING, AND POSSIBLE ROLE IN CANCER CELL
RP   PROLIFERATION.
RX   PubMed=17595334; DOI=10.1182/blood-2007-02-076471;
RA   Voisset E., Lopez S., Dubreuil P., De Sepulveda P.;
RT   "The tyrosine kinase FES is an essential effector of KITD816V
RT   proliferation signal.";
RL   Blood 110:2593-2599(2007).
RN   [21]
RP   FUNCTION IN CYTOSKELETON REORGANIZATION, INTERACTION WITH EZR,
RP   PHOSPHORYLATION AT TYR-713, AND SUBCELLULAR LOCATION.
RX   PubMed=18046454; DOI=10.1038/sj.emboj.7601943;
RA   Naba A., Reverdy C., Louvard D., Arpin M.;
RT   "Spatial recruitment and activation of the Fes kinase by ezrin
RT   promotes HGF-induced cell scattering.";
RL   EMBO J. 27:38-50(2008).
RN   [22]
RP   SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-713,
RP   PHOSPHORYLATION BY HCK, AND DOMAIN.
RX   PubMed=19382747; DOI=10.1021/bi900238f;
RA   Shaffer J.M., Hellwig S., Smithgall T.E.;
RT   "Bimolecular fluorescence complementation demonstrates that the c-Fes
RT   protein-tyrosine kinase forms constitutive oligomers in living
RT   cells.";
RL   Biochemistry 48:4780-4788(2009).
RN   [23]
RP   FUNCTION, TISSUE SPECIFICITY, AND ROLE AS PUTATIVE TUMOR SUPPRESSOR IN
RP   COLON CANCER.
RX   PubMed=19051325; DOI=10.1002/gcc.20638;
RA   Shaffer J.M., Smithgall T.E.;
RT   "Promoter methylation blocks FES protein-tyrosine kinase gene
RT   expression in colorectal cancer.";
RL   Genes Chromosomes Cancer 48:272-284(2009).
RN   [24]
RP   PUTATIVE ROLE IN RENAL CARCINOMA.
RX   PubMed=19082481;
RA   Kanda S., Miyata Y., Kanetake H., Smithgall T.E.;
RT   "Downregulation of the c-Fes protein-tyrosine kinase inhibits the
RT   proliferation of human renal carcinoma cells.";
RL   Int. J. Oncol. 34:89-96(2009).
RN   [25]
RP   FUNCTION, INTERACTION WITH MS4A2/FCER1B AND HCLS1/HS1, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION, INTERACTION WITH
RP   PHOSPHOINOSITIDE-CONTAINING MEMBRANES, AND MUTAGENESIS OF
RP   113-ARG-LYS-114.
RX   PubMed=19001085; DOI=10.1128/MCB.00904-08;
RA   McPherson V.A., Everingham S., Karisch R., Smith J.A., Udell C.M.,
RA   Zheng J., Jia Z., Craig A.W.;
RT   "Contributions of F-BAR and SH2 domains of Fes protein tyrosine kinase
RT   for coupling to the FcepsilonRI pathway in mast cells.";
RL   Mol. Cell. Biol. 29:389-401(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64; SER-67; TYR-261;
RP   TYR-713 AND SER-716, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION AT THR-421, AND INTERACTION WITH FLT3.
RX   PubMed=20111072; DOI=10.1038/leu.2009.301;
RA   Voisset E., Lopez S., Chaix A., Georges C., Hanssens K., Prebet T.,
RA   Dubreuil P., De Sepulveda P.;
RT   "FES kinases are required for oncogenic FLT3 signaling.";
RL   Leukemia 24:721-728(2010).
RN   [28]
RP   REVIEW.
RX   PubMed=21622225; DOI=10.2741/3902;
RA   Hellwig S., Smithgall T.E.;
RT   "Structure and regulation of the c-Fes protein-tyrosine kinase.";
RL   Front. Biosci. 16:3146-3155(2011).
RN   [29]
RP   POSSIBLE ROLE IN PROSTATE CANCER.
RX   PubMed=21563194; DOI=10.1002/pros.21422;
RA   Miyata Y., Watanabe S.I., Matsuo T., Hayashi T., Sakai H., Xuan J.W.,
RA   Greer P.A., Kanda S.;
RT   "Pathological significance and predictive value for biochemical
RT   recurrence of c-Fes expression in prostate cancer.";
RL   Prostate 72:201-208(2012).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-408 AND SER-411, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   STRUCTURE BY NMR OF 450-550.
RX   PubMed=15929003; DOI=10.1007/s10858-005-0946-6;
RA   Scott A., Pantoja-Uceda D., Koshiba S., Inoue M., Kigawa T.,
RA   Terada T., Shirouzu M., Tanaka A., Sugano S., Yokoyama S.,
RA   Guentert P.;
RT   "Solution structure of the Src homology 2 domain from the human feline
RT   sarcoma oncogene Fes.";
RL   J. Biomol. NMR 31:357-361(2005).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.78 ANGSTROMS) OF 448-822 OF UNPHOSPHORYLATED
RP   APOPROTEIN AND IN COMPLEX WITH STAUROSPORINE AND A SUBSTRATE PEPTIDE,
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, PHOSPHORYLATION AT TYR-713, NMR
RP   SPECTROSCOPY, AND MUTAGENESIS OF GLY-463 AND ARG-483.
RX   PubMed=18775312; DOI=10.1016/j.cell.2008.07.047;
RA   Filippakopoulos P., Kofler M., Hantschel O., Gish G.D., Grebien F.,
RA   Salah E., Neudecker P., Kay L.E., Turk B.E., Superti-Furga G.,
RA   Pawson T., Knapp S.;
RT   "Structural coupling of SH2-kinase domains links Fes and Abl substrate
RT   recognition and kinase activation.";
RL   Cell 134:793-803(2008).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-85; GLN-246 AND VAL-323.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts downstream of cell
CC       surface receptors and plays a role in the regulation of the actin
CC       cytoskeleton, microtubule assembly, cell attachment and cell
CC       spreading. Plays a role in FCER1 (high affinity immunoglobulin
CC       epsilon receptor)-mediated signaling in mast cells. Acts down-
CC       stream of the activated FCER1 receptor and the mast/stem cell
CC       growth factor receptor KIT. Plays a role in the regulation of mast
CC       cell degranulation. Plays a role in the regulation of cell
CC       differentiation and promotes neurite outgrowth in response to NGF
CC       signaling. Plays a role in cell scattering and cell migration in
CC       response to HGF-induced activation of EZR. Phosphorylates BCR and
CC       down-regulates BCR kinase activity. Phosphorylates HCLS1/HS1,
CC       PECAM1, STAT3 and TRIM28. {ECO:0000269|PubMed:11509660,
CC       ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15485904,
CC       ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:17595334,
CC       ECO:0000269|PubMed:18046454, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19051325, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:2656706, ECO:0000269|PubMed:8955135}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11509660,
CC       ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:15867340,
CC       ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:2656706,
CC       ECO:0000269|PubMed:7687763}.
CC   -!- ENZYME REGULATION: Kinase activity is tightly regulated. Activated
CC       in response to signaling from a cell surface receptor. Activation
CC       probably requires binding of a substrate via the SH2 domain, plus
CC       autophosphorylation at Tyr-713. Present in an inactive form in the
CC       absence of activating stimuli. {ECO:0000269|PubMed:18775312,
CC       ECO:0000269|PubMed:8955135}.
CC   -!- SUBUNIT: Homooligomer. Interacts with BCR. Interacts (when
CC       activated, via coiled coil domain) with TRIM28. Interacts (via SH2
CC       domain) with phosphorylated EZR, MS4A2/FCER1B and HCLS1/HS1.
CC       Interacts with phosphorylated KIT. Interacts with FLT3. Interacts
CC       (via F-BAR domain) with soluble tubulin. Interacts (via SH2
CC       domain) with microtubules. {ECO:0000269|PubMed:11509660,
CC       ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15485904,
CC       ECO:0000269|PubMed:16792528, ECO:0000269|PubMed:18046454,
CC       ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19382747, ECO:0000269|PubMed:20111072}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=3; IntAct=EBI-1055635, EBI-608057;
CC       P15311:EZR; NbExp=8; IntAct=EBI-1055635, EBI-1056902;
CC       Q13480:GAB1; NbExp=2; IntAct=EBI-1055635, EBI-517684;
CC       P10721:KIT; NbExp=2; IntAct=EBI-1055635, EBI-1379503;
CC       P54274:TERF1; NbExp=2; IntAct=EBI-1055635, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton.
CC       Cell membrane; Peripheral membrane protein; Cytoplasmic side.
CC       Cytoplasmic vesicle. Golgi apparatus. Cell junction, focal
CC       adhesion. Note=Distributed throughout the cytosol when the kinase
CC       is not activated. Association with microtubules requires
CC       activation of the kinase activity. Shuttles between focal
CC       adhesions and cell-cell contacts in epithelial cells. Recruited to
CC       the lateral cell membrane in polarized epithelial cells by
CC       interaction with phosphorylated EZR. Detected at tubular membrane
CC       structures in the cytoplasm and at the cell periphery.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P07332-1; Sequence=Displayed;
CC       Name=2; Synonyms=Variant 1;
CC         IsoId=P07332-2; Sequence=VSP_041748, VSP_041749;
CC       Name=3; Synonyms=Variant 3;
CC         IsoId=P07332-3; Sequence=VSP_041748;
CC       Name=4; Synonyms=Variant 4;
CC         IsoId=P07332-4; Sequence=VSP_041749;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Detected in adult colon
CC       epithelium. {ECO:0000269|PubMed:16455651,
CC       ECO:0000269|PubMed:19051325}.
CC   -!- DOMAIN: The coiled coil domains are important for regulating the
CC       kinase activity. They mediate homooligomerization and probably
CC       also interaction with other proteins.
CC   -!- DOMAIN: The N-terminal region including the first coiled coil
CC       domain mediates interaction with phosphoinositide-containing
CC       membranes.
CC   -!- PTM: Autophosphorylated on Tyr-713. Phosphorylated by LYN in
CC       response to FCER1 activation. Phosphorylated by HCK.
CC       {ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:18046454,
CC       ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19382747, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:7687763}.
CC   -!- DISEASE: Note=Has been shown to act as proto-oncogene in some
CC       types of cancer, possibly due to abnormal activation of the
CC       kinase. Has been shown to act as tumor suppressor in other types
CC       of cancer. Expressed and present as activated kinase in a subset
CC       of acute myeloid leukemia patients; promotes survival of leukemia
CC       cells (PubMed:20111072). Expression is absent in K562 leukemia
CC       cells; ectopic expression of FSP/FES restores myeloid
CC       differentiation (PubMed:2656706). May function as tumor suppressor
CC       in colorectal cancer; expression is reduced or absent in samples
CC       from some colon cancer patients (PubMed:16455651). Ectopic
CC       expression of FSP/FES suppresses anchorage-independent growth in
CC       colon cancer cell lines (PubMed:16455651). Up-regulated in
CC       prostate cancer, and might be a predictor of recurrence after
CC       radical surgery (PubMed:21563194). May promote growth of renal
CC       carcinoma cells (PubMed:19082481). {ECO:0000269|PubMed:16455651,
CC       ECO:0000269|PubMed:19082481, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:21563194, ECO:0000269|PubMed:2656706}.
CC   -!- MISCELLANEOUS: Cellular homolog of retroviral oncogenes. In
CC       contrast to the viral oncoproteins, the kinase activity of
CC       cellular FSP/FES is tightly regulated, and the kinase is inactive
CC       in normal cells in the absence of activating stimuli
CC       (PubMed:15485904). {ECO:0000305|PubMed:15485904}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fes/fps subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52192; CAA36438.1; -; mRNA.
DR   EMBL; X06292; CAA29619.1; -; Genomic_DNA.
DR   EMBL; AY513654; AAS82866.1; -; mRNA.
DR   EMBL; AY513656; AAS82868.1; -; mRNA.
DR   EMBL; AY513657; AAS82869.1; -; mRNA.
DR   EMBL; AK300595; BAG62292.1; -; mRNA.
DR   EMBL; AK312545; BAG35443.1; -; mRNA.
DR   EMBL; AC124248; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471101; EAX02114.1; -; Genomic_DNA.
DR   EMBL; BC035357; AAH35357.1; -; mRNA.
DR   CCDS; CCDS10365.1; -. [P07332-1]
DR   CCDS; CCDS45349.1; -. [P07332-4]
DR   CCDS; CCDS45350.1; -. [P07332-3]
DR   CCDS; CCDS45351.1; -. [P07332-2]
DR   PIR; A24673; TVHUFF.
DR   RefSeq; NP_001137255.1; NM_001143783.1. [P07332-3]
DR   RefSeq; NP_001137256.1; NM_001143784.1. [P07332-4]
DR   RefSeq; NP_001137257.1; NM_001143785.1. [P07332-2]
DR   RefSeq; NP_001996.1; NM_002005.3. [P07332-1]
DR   RefSeq; XP_005254937.1; XM_005254880.1. [P07332-3]
DR   RefSeq; XP_005254939.1; XM_005254882.1. [P07332-4]
DR   RefSeq; XP_016877494.1; XM_017022005.1. [P07332-1]
DR   RefSeq; XP_016877495.1; XM_017022006.1. [P07332-3]
DR   RefSeq; XP_016877496.1; XM_017022007.1. [P07332-4]
DR   RefSeq; XP_016877497.1; XM_017022008.1. [P07332-2]
DR   RefSeq; XP_016877498.1; XM_017022009.1. [P07332-1]
DR   RefSeq; XP_016877499.1; XM_017022010.1. [P07332-3]
DR   UniGene; Hs.7636; -.
DR   PDB; 1WQU; NMR; -; A=450-550.
DR   PDB; 2DCR; NMR; -; A=450-550.
DR   PDB; 3BKB; X-ray; 1.78 A; A=448-822.
DR   PDB; 3CBL; X-ray; 1.75 A; A=448-822.
DR   PDB; 3CD3; X-ray; 1.98 A; A=448-822.
DR   PDB; 4DYL; X-ray; 2.18 A; A=1-405.
DR   PDB; 4E93; X-ray; 1.84 A; A=448-822.
DR   PDBsum; 1WQU; -.
DR   PDBsum; 2DCR; -.
DR   PDBsum; 3BKB; -.
DR   PDBsum; 3CBL; -.
DR   PDBsum; 3CD3; -.
DR   PDBsum; 4DYL; -.
DR   PDBsum; 4E93; -.
DR   ProteinModelPortal; P07332; -.
DR   SMR; P07332; -.
DR   BioGrid; 108533; 25.
DR   IntAct; P07332; 22.
DR   MINT; P07332; -.
DR   STRING; 9606.ENSP00000331504; -.
DR   BindingDB; P07332; -.
DR   ChEMBL; CHEMBL5455; -.
DR   GuidetoPHARMACOLOGY; 2023; -.
DR   iPTMnet; P07332; -.
DR   PhosphoSitePlus; P07332; -.
DR   BioMuta; FES; -.
DR   DMDM; 115502390; -.
DR   EPD; P07332; -.
DR   MaxQB; P07332; -.
DR   PaxDb; P07332; -.
DR   PeptideAtlas; P07332; -.
DR   PRIDE; P07332; -.
DR   DNASU; 2242; -.
DR   Ensembl; ENST00000328850; ENSP00000331504; ENSG00000182511. [P07332-1]
DR   Ensembl; ENST00000394300; ENSP00000377837; ENSG00000182511. [P07332-3]
DR   Ensembl; ENST00000414248; ENSP00000414629; ENSG00000182511. [P07332-2]
DR   Ensembl; ENST00000444422; ENSP00000400868; ENSG00000182511. [P07332-4]
DR   GeneID; 2242; -.
DR   KEGG; hsa:2242; -.
DR   UCSC; uc002bpv.4; human. [P07332-1]
DR   CTD; 2242; -.
DR   DisGeNET; 2242; -.
DR   EuPathDB; HostDB:ENSG00000182511.11; -.
DR   GeneCards; FES; -.
DR   HGNC; HGNC:3657; FES.
DR   HPA; HPA001376; -.
DR   MIM; 190030; gene.
DR   neXtProt; NX_P07332; -.
DR   OpenTargets; ENSG00000182511; -.
DR   PharmGKB; PA28098; -.
DR   eggNOG; KOG0194; Eukaryota.
DR   eggNOG; ENOG410Y6RP; LUCA.
DR   GeneTree; ENSGT00760000119011; -.
DR   HOVERGEN; HBG005655; -.
DR   InParanoid; P07332; -.
DR   KO; K07527; -.
DR   OMA; PKDKWAL; -.
DR   OrthoDB; EOG091G01S4; -.
DR   PhylomeDB; P07332; -.
DR   TreeFam; TF315363; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-HSA-399956; CRMPs in Sema3A signaling.
DR   SignaLink; P07332; -.
DR   SIGNOR; P07332; -.
DR   EvolutionaryTrace; P07332; -.
DR   GeneWiki; Feline_sarcoma_oncogene; -.
DR   GenomeRNAi; 2242; -.
DR   PRO; PR:P07332; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000182511; -.
DR   CleanEx; HS_FES; -.
DR   ExpressionAtlas; P07332; baseline and differential.
DR   Genevisible; P07332; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0034987; F:immunoglobulin receptor binding; IDA:UniProtKB.
DR   GO; GO:0008017; F:microtubule binding; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007098; P:centrosome cycle; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0001578; P:microtubule bundle formation; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:UniProtKB.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0030155; P:regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IMP:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; IMP:UniProtKB.
DR   GO; GO:0060627; P:regulation of vesicle-mediated transport; TAS:UniProtKB.
DR   CDD; cd10361; SH2_Fps_family; 1.
DR   Gene3D; 1.20.1270.60; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR027267; AH/BAR_dom_sf.
DR   InterPro; IPR031160; F_BAR.
DR   InterPro; IPR001060; FCH_dom.
DR   InterPro; IPR035849; Fes/Fps/Fer_SH2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR016250; Tyr-prot_kinase_Fes/Fps.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PIRSF; PIRSF000632; TyrPK_fps; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00055; FCH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF103657; SSF103657; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51741; F_BAR; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Coiled coil; Complete proteome; Cytoplasm;
KW   Cytoplasmic vesicle; Cytoskeleton; Golgi apparatus; Kinase;
KW   Lipid-binding; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; SH2 domain;
KW   Transferase; Tumor suppressor; Tyrosine-protein kinase.
FT   CHAIN         1    822       Tyrosine-protein kinase Fes/Fps.
FT                                /FTId=PRO_0000088088.
FT   DOMAIN        1    260       F-BAR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01077}.
FT   DOMAIN      460    549       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      561    822       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     567    575       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    300       Important for interaction with membranes
FT                                containing phosphoinositides.
FT   COILED      125    169       {ECO:0000255}.
FT   COILED      324    368       {ECO:0000255}.
FT   ACT_SITE    683    683       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     590    590       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      64     64       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES      67     67       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     261    261       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     408    408       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     411    411       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     421    421       Phosphothreonine.
FT                                {ECO:0000269|PubMed:20111072}.
FT   MOD_RES     713    713       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:15485904,
FT                                ECO:0000269|PubMed:18046454,
FT                                ECO:0000269|PubMed:18775312,
FT                                ECO:0000269|PubMed:19382747,
FT                                ECO:0000269|PubMed:7687763}.
FT   MOD_RES     716    716       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ      72    129       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_041748.
FT   VAR_SEQ     441    510       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_041749.
FT   VARIANT      85     85       R -> C (in dbSNP:rs56041861).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041697.
FT   VARIANT     246    246       R -> Q (in dbSNP:rs34573430).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041698.
FT   VARIANT     323    323       M -> V (in dbSNP:rs56296062).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041699.
FT   MUTAGEN     113    114       RK->EE: Reduced binding to membranes
FT                                containing phosphoinositides.
FT                                {ECO:0000269|PubMed:19001085}.
FT   MUTAGEN     113    114       RK->QQ: Reduced binding to membranes
FT                                containing phosphoinositides.
FT                                {ECO:0000269|PubMed:19001085}.
FT   MUTAGEN     145    145       L->P: Constitutively activated kinase
FT                                that can act as oncogene. Promotes
FT                                myeloid cell survival and proliferation.
FT                                {ECO:0000269|PubMed:11509660,
FT                                ECO:0000269|PubMed:15485904}.
FT   MUTAGEN     334    334       L->P: Abolishes autophosphorylation.
FT                                {ECO:0000269|PubMed:11509660}.
FT   MUTAGEN     463    463       G->V: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:18775312}.
FT   MUTAGEN     483    483       R->M: Abolishes pTyr binding. Abolishes
FT                                association with microtubules. Abolishes
FT                                autophosphorylation. Reduced kinase
FT                                activity. {ECO:0000269|PubMed:15485904,
FT                                ECO:0000269|PubMed:18775312}.
FT   MUTAGEN     590    590       K->E: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:15485904}.
FT   MUTAGEN     704    704       M->V: Reduced autophosphorylation and
FT                                strongly reduced kinase activity.
FT                                {ECO:0000269|PubMed:15867340,
FT                                ECO:0000269|PubMed:16455651}.
FT   MUTAGEN     706    706       R->Q: Negligible effect on
FT                                autophosphorylation and kinase activity.
FT                                {ECO:0000269|PubMed:15867340,
FT                                ECO:0000269|PubMed:16455651}.
FT   MUTAGEN     713    713       Y->F: Reduces kinase activity by over
FT                                90%. {ECO:0000269|PubMed:7687763}.
FT   MUTAGEN     743    743       V->M: Strongly reduced
FT                                autophosphorylation and kinase activity.
FT                                {ECO:0000269|PubMed:15867340,
FT                                ECO:0000269|PubMed:16455651}.
FT   MUTAGEN     759    759       S->F: Reduced autophosphorylation and
FT                                strongly reduced kinase activity.
FT                                {ECO:0000269|PubMed:15867340,
FT                                ECO:0000269|PubMed:16455651}.
FT   CONFLICT    719    719       L -> S (in Ref. 1; CAA36438 and 3;
FT                                AAS82866/AAS82869/AAS82868).
FT                                {ECO:0000305}.
FT   HELIX         3      6       {ECO:0000244|PDB:4DYL}.
FT   HELIX        10     51       {ECO:0000244|PDB:4DYL}.
FT   HELIX        68     96       {ECO:0000244|PDB:4DYL}.
FT   HELIX        98    131       {ECO:0000244|PDB:4DYL}.
FT   HELIX       133    154       {ECO:0000244|PDB:4DYL}.
FT   HELIX       167    202       {ECO:0000244|PDB:4DYL}.
FT   HELIX       204    234       {ECO:0000244|PDB:4DYL}.
FT   STRAND      236    238       {ECO:0000244|PDB:4DYL}.
FT   HELIX       239    254       {ECO:0000244|PDB:4DYL}.
FT   HELIX       257    259       {ECO:0000244|PDB:4DYL}.
FT   HELIX       262    268       {ECO:0000244|PDB:4DYL}.
FT   TURN        300    302       {ECO:0000244|PDB:4DYL}.
FT   HELIX       303    344       {ECO:0000244|PDB:4DYL}.
FT   HELIX       350    353       {ECO:0000244|PDB:4DYL}.
FT   HELIX       354    389       {ECO:0000244|PDB:4DYL}.
FT   TURN        390    393       {ECO:0000244|PDB:4DYL}.
FT   HELIX       450    452       {ECO:0000244|PDB:3CBL}.
FT   HELIX       455    457       {ECO:0000244|PDB:3CBL}.
FT   STRAND      461    464       {ECO:0000244|PDB:1WQU}.
FT   HELIX       467    473       {ECO:0000244|PDB:3CBL}.
FT   STRAND      479    484       {ECO:0000244|PDB:3CBL}.
FT   TURN        486    489       {ECO:0000244|PDB:3BKB}.
FT   STRAND      491    494       {ECO:0000244|PDB:3CBL}.
FT   STRAND      503    506       {ECO:0000244|PDB:3CBL}.
FT   STRAND      507    509       {ECO:0000244|PDB:3BKB}.
FT   STRAND      512    517       {ECO:0000244|PDB:3BKB}.
FT   STRAND      520    522       {ECO:0000244|PDB:3BKB}.
FT   HELIX       523    533       {ECO:0000244|PDB:3CBL}.
FT   TURN        539    541       {ECO:0000244|PDB:3BKB}.
FT   HELIX       558    560       {ECO:0000244|PDB:3CBL}.
FT   STRAND      561    570       {ECO:0000244|PDB:3CBL}.
FT   STRAND      573    580       {ECO:0000244|PDB:3CBL}.
FT   TURN        581    583       {ECO:0000244|PDB:3CBL}.
FT   STRAND      586    591       {ECO:0000244|PDB:3CBL}.
FT   HELIX       598    601       {ECO:0000244|PDB:3CBL}.
FT   HELIX       602    605       {ECO:0000244|PDB:3CBL}.
FT   HELIX       606    611       {ECO:0000244|PDB:3CBL}.
FT   STRAND      622    626       {ECO:0000244|PDB:3CBL}.
FT   STRAND      628    631       {ECO:0000244|PDB:3CBL}.
FT   STRAND      633    637       {ECO:0000244|PDB:3CBL}.
FT   HELIX       644    651       {ECO:0000244|PDB:3CBL}.
FT   HELIX       652    654       {ECO:0000244|PDB:3CBL}.
FT   HELIX       657    676       {ECO:0000244|PDB:3CBL}.
FT   HELIX       686    688       {ECO:0000244|PDB:3CBL}.
FT   STRAND      689    691       {ECO:0000244|PDB:3CBL}.
FT   STRAND      697    699       {ECO:0000244|PDB:3CBL}.
FT   HELIX       702    704       {ECO:0000244|PDB:3CBL}.
FT   STRAND      711    714       {ECO:0000244|PDB:3CBL}.
FT   STRAND      720    723       {ECO:0000244|PDB:3CBL}.
FT   HELIX       724    726       {ECO:0000244|PDB:3CBL}.
FT   HELIX       729    734       {ECO:0000244|PDB:3CBL}.
FT   STRAND      736    738       {ECO:0000244|PDB:3CBL}.
FT   HELIX       739    754       {ECO:0000244|PDB:3CBL}.
FT   TURN        755    757       {ECO:0000244|PDB:4E93}.
FT   HELIX       766    774       {ECO:0000244|PDB:3CBL}.
FT   HELIX       787    796       {ECO:0000244|PDB:3CBL}.
FT   HELIX       801    803       {ECO:0000244|PDB:3CBL}.
FT   HELIX       807    820       {ECO:0000244|PDB:3CBL}.
SQ   SEQUENCE   822 AA;  93497 MW;  4C2A90555857F045 CRC64;
     MGFSSELCSP QGHGVLQQMQ EAELRLLEGM RKWMAQRVKS DREYAGLLHH MSLQDSGGQS
     RAISPDSPIS QSWAEITSQT EGLSRLLRQH AEDLNSGPLS KLSLLIRERQ QLRKTYSEQW
     QQLQQELTKT HSQDIEKLKS QYRALARDSA QAKRKYQEAS KDKDRDKAKD KYVRSLWKLF
     AHHNRYVLGV RAAQLHHQHH HQLLLPGLLR SLQDLHEEMA CILKEILQEY LEISSLVQDE
     VVAIHREMAA AAARIQPEAE YQGFLRQYGS APDVPPCVTF DESLLEEGEP LEPGELQLNE
     LTVESVQHTL TSVTDELAVA TEMVFRRQEM VTQLQQELRN EEENTHPRER VQLLGKRQVL
     QEALQGLQVA LCSQAKLQAQ QELLQTKLEH LGPGEPPPVL LLQDDRHSTS SSEQEREGGR
     TPTLEILKSH ISGIFRPKFS LPPPLQLIPE VQKPLHEQLW YHGAIPRAEV AELLVHSGDF
     LVRESQGKQE YVLSVLWDGL PRHFIIQSLD NLYRLEGEGF PSIPLLIDHL LSTQQPLTKK
     SGVVLHRAVP KDKWVLNHED LVLGEQIGRG NFGEVFSGRL RADNTLVAVK SCRETLPPDL
     KAKFLQEARI LKQYSHPNIV RLIGVCTQKQ PIYIVMELVQ GGDFLTFLRT EGARLRVKTL
     LQMVGDAAAG MEYLESKCCI HRDLAARNCL VTEKNVLKIS DFGMSREEAD GVYAASGGLR
     QVPVKWTAPE ALNYGRYSSE SDVWSFGILL WETFSLGASP YPNLSNQQTR EFVEKGGRLP
     CPELCPDAVF RLMEQCWAYE PGQRPSFSTI YQELQSIRKR HR
//
ID   FOXL2_HUMAN             Reviewed;         376 AA.
AC   P58012; Q4ZGJ3;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   27-APR-2001, sequence version 1.
DT   28-FEB-2018, entry version 170.
DE   RecName: Full=Forkhead box protein L2;
GN   Name=FOXL2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT BPES
RP   ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-234 INS.
RX   PubMed=11175783; DOI=10.1038/84781;
RA   Crisponi L., Deiana M., Loi A., Chiappe F., Uda M., Amati P.,
RA   Bisceglia L., Zelante L., Nagaraja R., Porcu S., Ristaldi M.S.,
RA   Marzella R., Rocchi M., Nicolino M., Lienhardt-Roussie A., Nivelon A.,
RA   Verloes A., Schlessinger D., Gasparini P., Bonneau D., Cao A.,
RA   Pilia G.;
RT   "The putative forkhead transcription factor FOXL2 is mutated in
RT   blepharophimosis/ptosis/epicanthus inversus syndrome.";
RL   Nat. Genet. 27:159-166(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT BPES
RP   ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-234 INS.
RA   Xu Y.;
RT   "Study of mutations of FOXL2 gene in a Chinese TongHai family with
RT   blepharophimosis-ptosis-epicanthus inversus syndrome.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH DDX20.
RX   PubMed=16153597; DOI=10.1016/j.bbrc.2005.08.184;
RA   Lee K., Pisarska M.D., Ko J.J., Kang Y., Yoon S., Ryou S.M., Cha K.Y.,
RA   Bae J.;
RT   "Transcriptional factor FOXL2 interacts with DP103 and induces
RT   apoptosis.";
RL   Biochem. Biophys. Res. Commun. 336:876-881(2005).
RN   [5]
RP   FUNCTION AS TRANSCRIPTIONAL REPRESSOR OF STAR, INTERACTION WITH UBE2I,
RP   SUMOYLATION AT LYS-25, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-25.
RX   PubMed=19744555; DOI=10.1016/j.cellsig.2009.09.001;
RA   Kuo F.T., Bentsi-Barnes I.K., Barlow G.M., Bae J., Pisarska M.D.;
RT   "Sumoylation of forkhead L2 by Ubc9 is required for its activity as a
RT   transcriptional repressor of the steroidogenic acute regulatory
RT   gene.";
RL   Cell. Signal. 21:1935-1944(2009).
RN   [6]
RP   FUNCTION AS TRANSCRIPTIONAL ACTIVATOR OF SIRT1, AND INDUCTION.
RX   PubMed=19010791; DOI=10.1093/hmg/ddn389;
RA   Benayoun B.A., Batista F., Auer J., Dipietromaria A., L'Hote D.,
RA   De Baere E., Veitia R.A.;
RT   "Positive and negative feedback regulates the transcription factor
RT   FOXL2 in response to cell stress: evidence for a regulatory imbalance
RT   induced by disease-causing mutations.";
RL   Hum. Mol. Genet. 18:632-644(2009).
RN   [7]
RP   FUNCTION AS TRANSCRIPTIONAL ACTIVATOR OF OSR2, VARIANT POF3 ASP-187,
RP   AND CHARACTERIZATION OF VARIANT POF3 ASP-187.
RX   PubMed=19429596; DOI=10.1136/jmg.2008.065086;
RA   Laissue P., Lakhal B., Benayoun B.A., Dipietromaria A., Braham R.,
RA   Elghezal H., Philibert P., Saad A., Sultan C., Fellous M.,
RA   Veitia R.A.;
RT   "Functional evidence implicating FOXL2 in non-syndromic premature
RT   ovarian failure and in the regulation of the transcription factor
RT   OSR2.";
RL   J. Med. Genet. 46:455-457(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   DATABASE OF FOXL2 VARIANTS.
RX   PubMed=15300845; DOI=10.1002/humu.20079;
RA   Beysen D., Vandesompele J., Messiaen L., De Paepe A., De Baere E.;
RT   "The human FOXL2 mutation database.";
RL   Hum. Mutat. 24:189-193(2004).
RN   [10]
RP   VARIANTS BPES ILE-85 DEL AND PHE-217.
RX   PubMed=11468277; DOI=10.1093/hmg/10.15.1591;
RA   De Baere E., Dixon M.J., Small K.W., Jabs E.W., Leroy B.P.,
RA   Devriendt K., Gillerot Y., Mortier G., Meire F., Van Maldergem L.,
RA   Courtens W., Hjalgrim H., Huang S., Liebaers I., Van Regemorter N.,
RA   Touraine P., Praphanphoj V., Verloes A., Udar N., Yellore V.,
RA   Chalukya M., Yelchits S., De Paepe A., Kuttenn F., Fellous M.,
RA   Veitia R., Messiaen L.;
RT   "Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-
RT   epicanthus inversus (BPES) families demonstrates a genotype
RT   -- phenotype correlation.";
RL   Hum. Mol. Genet. 10:1591-1600(2001).
RN   [11]
RP   VARIANT BPES ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-234 INS.
RX   PubMed=12400065; DOI=10.1002/ajmg.10741;
RA   Ramirez-Castro J.L., Pineda-Trujillo N., Valencia A.V., Muneton C.M.,
RA   Botero O., Trujillo O., Vasquez G., Mora B.E., Durango N., Bedoya G.,
RA   Ruiz-Linares A.;
RT   "Mutations in FOXL2 underlying BPES (types 1 and 2) in Colombian
RT   families.";
RL   Am. J. Med. Genet. 113:47-51(2002).
RN   [12]
RP   VARIANTS ASP-187 AND SER-285.
RX   PubMed=12161610; DOI=10.1136/jmg.39.8.e43;
RA   De Baere E., Lemercier B., Christin-Maitre S., Durval D., Messiaen L.,
RA   Fellous M., Veitia R.;
RT   "FOXL2 mutation screening in a large panel of POF patients and XX
RT   males.";
RL   J. Med. Genet. 39:E43-E43(2002).
RN   [13]
RP   VARIANTS POF3 221-ALA--ALA-230 DEL AND ASN-258, AND VARIANT GLY-179.
RX   PubMed=12149404; DOI=10.1093/molehr/8.8.729;
RA   Harris S.E., Chand A.L., Winship I.M., Gersak K., Aittomaeki K.,
RA   Shelling A.N.;
RT   "Identification of novel mutations in FOXL2 associated with premature
RT   ovarian failure.";
RL   Mol. Hum. Reprod. 8:729-733(2002).
RN   [14]
RP   VARIANTS BPES PHE-106; LYS-109 AND PHE-217.
RX   PubMed=12529855; DOI=10.1086/346118;
RA   De Baere E., Beysen D., Oley C., Lorenz B., Cocquet J., De Sutter P.,
RA   Devriendt K., Dixon M.J., Fellous M., Fryns J.-P., Garza A.,
RA   Jonsrud C., Koivisto P.A., Krause A., Leroy B.P., Meire F., Plomp A.,
RA   Van Maldergem L., De Paepe A., Veitia R., Messiaen L.;
RT   "FOXL2 and BPES: mutational hotspots, phenotypic variability, and
RT   revision of the genotype-phenotype correlation.";
RL   Am. J. Hum. Genet. 72:478-487(2003).
RN   [15]
RP   VARIANT BPES SER-84.
RX   PubMed=12630957; DOI=10.1034/j.1399-0004.2003.00011.x;
RA   Dollfus H., Stoetzel C., Riehm S., Lahlou Boukoffa W.,
RA   Bediard Boulaneb F., Quillet R., Abu-Eid M., Speeg-Schatz C.,
RA   Francfort J.J., Flament J., Veillon F., Perrin-Schmitt F.;
RT   "Sporadic and familial blepharophimosis -ptosis-epicanthus inversus
RT   syndrome: FOXL2 mutation screen and MRI study of the superior levator
RT   eyelid muscle.";
RL   Clin. Genet. 63:117-120(2003).
RN   [16]
RP   VARIANT BPES ARG-104.
RX   PubMed=12938087; DOI=10.1002/humu.10251;
RA   Udar N., Yellore V., Chalukya M., Yelchits S., Silva-Garcia R.,
RA   Small K.;
RT   "Comparative analysis of the FOXL2 gene and characterization of
RT   mutations in BPES patients.";
RL   Hum. Mutat. 22:222-228(2003).
RN   [17]
RP   VARIANT BPES CYS-215.
RX   PubMed=15257268;
RA   Kumar A., Babu M., Raghunath A., Venkatesh C.P.;
RT   "Genetic analysis of a five generation Indian family with BPES: a
RT   novel missense mutation (p.Y215C).";
RL   Mol. Vis. 10:445-449(2004).
RN   [18]
RP   VARIANT BPES THR-63.
RX   PubMed=16454982;
RA   Or S.F., Tong M.F., Lo F.M., Lam T.S.;
RT   "Three novel FOXL2 gene mutations in Chinese patients with
RT   blepharophimosis-ptosis-epicanthus inversus syndrome.";
RL   Chin. Med. J. 119:49-52(2006).
RN   [19]
RP   VARIANT BPES ALA-ALA-ALA-ALA-ALA-234 INS, AND CHARACTERIZATION OF
RP   VARIANT BPES ALA-ALA-ALA-ALA-ALA-234 INS.
RX   PubMed=17089161; DOI=10.1007/s00439-006-0276-0;
RA   Nallathambi J., Moumne L., De Baere E., Beysen D., Usha K.,
RA   Sundaresan P., Veitia R.A.;
RT   "A novel polyalanine expansion in FOXL2: the first evidence for a
RT   recessive form of the blepharophimosis syndrome (BPES) associated with
RT   ovarian dysfunction.";
RL   Hum. Genet. 121:107-112(2007).
RN   [20]
RP   CHARACTERIZATION OF VARIANTS BPES LEU-58; VAL-66; LYS-69; THR-80;
RP   ASN-84; SER-90; GLY-98; ARG-101; THR-102; CYS-103; ARG-104; PHE-106;
RP   PRO-106; LYS-109 AND PHE-217.
RX   PubMed=18372316; DOI=10.1093/hmg/ddn100;
RA   Beysen D., Moumne L., Veitia R., Peters H., Leroy B.P., De Paepe A.,
RA   De Baere E.;
RT   "Missense mutations in the forkhead domain of FOXL2 lead to
RT   subcellular mislocalization, protein aggregation and impaired
RT   transactivation.";
RL   Hum. Mol. Genet. 17:2030-2038(2008).
RN   [21]
RP   VARIANTS BPES ARG-98; PRO-108; CYS-215; CYS-217 AND
RP   ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-ALA-234 INS, VARIANT GLY-179, AND
RP   CHARACTERIZATION OF VARIANTS BPES PRO-108 AND CYS-217.
RX   PubMed=18484667; DOI=10.1002/humu.20809;
RA   Nallathambi J., Laissue P., Batista F., Benayoun B.A., Lesaffre C.,
RA   Moumne L., Pandaranayaka P.E., Usha K., Krishnaswamy S.,
RA   Sundaresan P., Veitia R.A.;
RT   "Differential functional effects of novel mutations of the
RT   transcription factor FOXL2 in BPES patients.";
RL   Hum. Mutat. 29:E123-E131(2008).
RN   [22]
RP   VARIANTS BPES LEU-58; VAL-65; VAL-66; LYS-69; THR-80; ASN-84; SER-90;
RP   GLY-98; ARG-101; THR-102; CYS-103 AND PRO-106.
RX   PubMed=18642388; DOI=10.1002/humu.20819;
RA   Beysen D., De Jaegere S., Amor D., Bouchard P., Christin-Maitre S.,
RA   Fellous M., Touraine P., Grix A.W., Hennekam R., Meire F., Oyen N.,
RA   Wilson L.C., Barel D., Clayton-Smith J., de Ravel T., Decock C.,
RA   Delbeke P., Ensenauer R., Ebinger F., Gillessen-Kaesbach G.,
RA   Hendriks Y., Kimonis V., Laframboise R., Laissue P., Leppig K.,
RA   Leroy B.P., Miller D.T., Mowat D., Neumann L., Plomp A.,
RA   Van Regemorter N., Wieczorek D., Veitia R.A., De Paepe A.,
RA   De Baere E.;
RT   "Identification of 34 novel and 56 known FOXL2 mutations in patients
RT   with blepharophimosis syndrome.";
RL   Hum. Mutat. 29:E205-E219(2008).
RN   [23]
RP   VARIANT TRP-134.
RX   PubMed=19516027; DOI=10.1056/NEJMoa0902542;
RA   Shah S.P., Kobel M., Senz J., Morin R.D., Clarke B.A., Wiegand K.C.,
RA   Leung G., Zayed A., Mehl E., Kalloger S.E., Sun M., Giuliany R.,
RA   Yorida E., Jones S., Varhol R., Swenerton K.D., Miller D.,
RA   Clement P.B., Crane C., Madore J., Provencher D., Leung P.,
RA   DeFazio A., Khattra J., Turashvili G., Zhao Y., Zeng T., Glover J.N.,
RA   Vanderhyden B., Zhao C., Parkinson C.A., Jimenez-Linan M.,
RA   Bowtell D.D., Mes-Masson A.M., Brenton J.D., Aparicio S.A., Boyd N.,
RA   Hirst M., Gilks C.B., Marra M., Huntsman D.G.;
RT   "Mutation of FOXL2 in granulosa-cell tumors of the ovary.";
RL   N. Engl. J. Med. 360:2719-2729(2009).
RN   [24]
RP   VARIANT TRP-134.
RX   PubMed=19956657; DOI=10.1371/journal.pone.0007988;
RA   Schrader K.A., Gorbatcheva B., Senz J., Heravi-Moussavi A., Melnyk N.,
RA   Salamanca C., Maines-Bandiera S., Cooke S.L., Leung P., Brenton J.D.,
RA   Gilks C.B., Monahan J., Huntsman D.G.;
RT   "The specificity of the FOXL2 c.402C>G Somatic mutation: a survey of
RT   solid tumors.";
RL   PLoS ONE 4:E7988-E7988(2009).
RN   [25]
RP   VARIANT GLY-349.
RX   PubMed=27610946; DOI=10.1002/humu.23116;
RA   Igarashi M., Takasawa K., Hakoda A., Kanno J., Takada S., Miyado M.,
RA   Baba T., Morohashi K.I., Tajima T., Hata K., Nakabayashi K.,
RA   Matsubara Y., Sekido R., Ogata T., Kashimada K., Fukami M.;
RT   "Identical NR5A1 missense mutations in two unrelated 46,XX individuals
RT   with testicular tissues.";
RL   Hum. Mutat. 38:39-42(2017).
CC   -!- FUNCTION: Transcriptional regulator. Critical factor essential for
CC       ovary differentiation and maintenance, and repression of the
CC       genetic program for somatic testis determination. Prevents trans-
CC       differentiation of ovary to testis through transcriptional
CC       repression of the Sertoli cell-promoting gene SOX9 (By
CC       similarity). Has apoptotic activity in ovarian cells. Suppresses
CC       ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen
CC       (By similarity). Is a regulator of CYP19 expression (By
CC       similarity). Participates in SMAD3-dependent transcription of FST
CC       via the intronic SMAD-binding element (By similarity). Is a
CC       transcriptional repressor of STAR. Activates SIRT1 transcription
CC       under cellular stress conditions. Activates transcription of OSR2.
CC       {ECO:0000250, ECO:0000269|PubMed:16153597,
CC       ECO:0000269|PubMed:19010791, ECO:0000269|PubMed:19429596,
CC       ECO:0000269|PubMed:19744555}.
CC   -!- SUBUNIT: Interacts with ESR1 (By similarity). Interacts with SMAD3
CC       (By similarity). Interacts with DDX20. Interacts with UBE2I/UBC9.
CC       {ECO:0000250, ECO:0000269|PubMed:16153597,
CC       ECO:0000269|PubMed:19744555}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00089, ECO:0000269|PubMed:19744555}.
CC   -!- TISSUE SPECIFICITY: In addition to its expression in the
CC       developing eyelid, it is transcribed very early in somatic cells
CC       of the developing gonad (before sex determination) and its
CC       expression persists in the follicular cells of the adult ovary.
CC   -!- INDUCTION: In granulosa-like cells, up-regulated at transcript and
CC       protein levels under oxidative stress and heat-shock conditions.
CC       Down-regulated by SIRT1. {ECO:0000269|PubMed:19010791}.
CC   -!- PTM: Sumoylated with SUMO1; sumoylation is required for
CC       transcriptional repression activity.
CC       {ECO:0000269|PubMed:19744555}.
CC   -!- DISEASE: Blepharophimosis, ptosis, and epicanthus inversus
CC       syndrome (BPES) [MIM:110100]: A disorder characterized by eyelid
CC       dysplasia, small palpebral fissures, drooping eyelids and a skin
CC       fold curving in the mediolateral direction, inferior to the inner
CC       canthus. In type I BPSE (BPES1) eyelid abnormalities are
CC       associated with female infertility. Affected females show an
CC       ovarian deficit due to primary amenorrhea or to premature ovarian
CC       failure (POF). In type II BPSE (BPES2) affected individuals show
CC       only the eyelid defects. {ECO:0000269|PubMed:11175783,
CC       ECO:0000269|PubMed:11468277, ECO:0000269|PubMed:12400065,
CC       ECO:0000269|PubMed:12529855, ECO:0000269|PubMed:12630957,
CC       ECO:0000269|PubMed:12938087, ECO:0000269|PubMed:15257268,
CC       ECO:0000269|PubMed:16454982, ECO:0000269|PubMed:17089161,
CC       ECO:0000269|PubMed:18372316, ECO:0000269|PubMed:18484667,
CC       ECO:0000269|PubMed:18642388, ECO:0000269|Ref.2}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry. There is a mutational hotspot in the region coding for the
CC       poly-Ala domain, since 30% of all mutations in the ORF lead to
CC       poly-Ala expansions, resulting mainly in BPES type II.
CC   -!- DISEASE: Premature ovarian failure 3 (POF3) [MIM:608996]: An
CC       ovarian disorder defined as the cessation of ovarian function
CC       under the age of 40 years. It is characterized by oligomenorrhea
CC       or amenorrhea, in the presence of elevated levels of serum
CC       gonadotropins and low estradiol. {ECO:0000269|PubMed:12149404,
CC       ECO:0000269|PubMed:19429596}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Forkhead box L2 (FOXL2); Note=Leiden Open
CC       Variation Database (LOVD);
CC       URL="https://lovd.cmgg.be/index.php?select_db=FOXL2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF301906; AAK01352.1; -; mRNA.
DR   EMBL; DQ016609; AAY21823.1; -; Genomic_DNA.
DR   EMBL; BC062549; AAH62549.1; -; mRNA.
DR   CCDS; CCDS3105.1; -.
DR   RefSeq; NP_075555.1; NM_023067.3.
DR   UniGene; Hs.289292; -.
DR   ProteinModelPortal; P58012; -.
DR   SMR; P58012; -.
DR   BioGrid; 107136; 66.
DR   IntAct; P58012; 50.
DR   MINT; P58012; -.
DR   STRING; 9606.ENSP00000333188; -.
DR   iPTMnet; P58012; -.
DR   PhosphoSitePlus; P58012; -.
DR   BioMuta; FOXL2; -.
DR   DMDM; 13626838; -.
DR   EPD; P58012; -.
DR   PaxDb; P58012; -.
DR   PeptideAtlas; P58012; -.
DR   PRIDE; P58012; -.
DR   Ensembl; ENST00000330315; ENSP00000333188; ENSG00000183770.
DR   GeneID; 668; -.
DR   KEGG; hsa:668; -.
DR   CTD; 668; -.
DR   DisGeNET; 668; -.
DR   EuPathDB; HostDB:ENSG00000183770.5; -.
DR   GeneCards; FOXL2; -.
DR   GeneReviews; FOXL2; -.
DR   HGNC; HGNC:1092; FOXL2.
DR   HPA; HPA069613; -.
DR   MalaCards; FOXL2; -.
DR   MIM; 110100; phenotype.
DR   MIM; 605597; gene.
DR   MIM; 608996; phenotype.
DR   neXtProt; NX_P58012; -.
DR   OpenTargets; ENSG00000183770; -.
DR   Orphanet; 261559; Blepharophimosis - epicanthus inversus - ptosis due to 3q23 microdeletion.
DR   Orphanet; 261572; Blepharophimosis - epicanthus inversus - ptosis due to a point mutation.
DR   Orphanet; 619; Primary ovarian failure.
DR   PharmGKB; PA28235; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00760000118904; -.
DR   HOVERGEN; HBG051651; -.
DR   InParanoid; P58012; -.
DR   KO; K09405; -.
DR   OMA; SMMHCSY; -.
DR   OrthoDB; EOG091G0ESH; -.
DR   PhylomeDB; P58012; -.
DR   TreeFam; TF316127; -.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   SIGNOR; P58012; -.
DR   GeneWiki; Forkhead_box_L2; -.
DR   GenomeRNAi; 668; -.
DR   PRO; PR:P58012; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000183770; -.
DR   CleanEx; HS_FOXL2; -.
DR   ExpressionAtlas; P58012; baseline and differential.
DR   Genevisible; P58012; HS.
DR   GO; GO:0045171; C:intercellular bridge; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043028; F:cysteine-type endopeptidase regulator activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central.
DR   GO; GO:0006309; P:apoptotic DNA fragmentation; IMP:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0048048; P:embryonic eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0002074; P:extraocular skeletal muscle development; IMP:UniProtKB.
DR   GO; GO:0019101; P:female somatic sex determination; IEA:Ensembl.
DR   GO; GO:0060014; P:granulosa cell differentiation; IEA:Ensembl.
DR   GO; GO:0042703; P:menstruation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0001555; P:oocyte growth; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl.
DR   GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0007338; P:single fertilization; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR018122; TF_fork_head_CS_1.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00657; FORK_HEAD_1; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Differentiation; Disease mutation; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Polymorphism;
KW   Premature ovarian failure; Reference proteome; Transcription;
KW   Transcription regulation; Triplet repeat expansion; Ubl conjugation.
FT   CHAIN         1    376       Forkhead box protein L2.
FT                                /FTId=PRO_0000091861.
FT   DNA_BIND     54    148       Fork-head. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00089}.
FT   COMPBIAS     35     43       Poly-Gly.
FT   COMPBIAS    221    234       Poly-Ala.
FT   COMPBIAS    284    292       Poly-Pro.
FT   COMPBIAS    301    304       Poly-Ala.
FT   MOD_RES      33     33       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK     25     25       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   VARIANT      58     58       S -> L (in BPES; sporadic; nuclear and
FT                                cytoplasmic aggregation; impaired
FT                                transactivation activity).
FT                                {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_021196.
FT   VARIANT      63     63       I -> T (in BPES).
FT                                {ECO:0000269|PubMed:16454982}.
FT                                /FTId=VAR_062545.
FT   VARIANT      65     65       M -> V (in BPES).
FT                                {ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046490.
FT   VARIANT      66     66       A -> V (in BPES; nuclear and cytoplasmic
FT                                aggregation; impaired transactivation
FT                                activity). {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_021197.
FT   VARIANT      69     69       E -> K (in BPES; sporadic; nuclear
FT                                aggregation; normal transactivation
FT                                activity; dbSNP:rs387906920).
FT                                {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_021198.
FT   VARIANT      80     80       I -> T (in BPES; nuclear and cytoplasmic
FT                                aggregation; impaired transactivation
FT                                activity). {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046491.
FT   VARIANT      84     84       I -> N (in BPES; nuclear and cytoplasmic
FT                                aggregation; impaired transactivation
FT                                activity). {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046492.
FT   VARIANT      84     84       I -> S (in BPES; type I;
FT                                dbSNP:rs28937884).
FT                                {ECO:0000269|PubMed:12630957}.
FT                                /FTId=VAR_016883.
FT   VARIANT      85     85       Missing (in BPES; sporadic).
FT                                {ECO:0000269|PubMed:11468277}.
FT                                /FTId=VAR_016884.
FT   VARIANT      90     90       F -> S (in BPES; nuclear and cytoplasmic
FT                                aggregation; impaired transactivation
FT                                activity). {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046493.
FT   VARIANT      98     98       W -> G (in BPES; nuclear and cytoplasmic
FT                                aggregation; impaired transactivation
FT                                activity). {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046494.
FT   VARIANT      98     98       W -> R (in BPES; dbSNP:rs1057516149).
FT                                {ECO:0000269|PubMed:18484667}.
FT                                /FTId=VAR_062546.
FT   VARIANT     101    101       S -> R (in BPES; nuclear aggregation;
FT                                impaired transactivation activity;
FT                                dbSNP:rs1057516151).
FT                                {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046495.
FT   VARIANT     102    102       I -> T (in BPES; nuclear and cytoplasmic
FT                                aggregation; impaired transactivation
FT                                activity). {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046496.
FT   VARIANT     103    103       R -> C (in BPES; nuclear and cytoplasmic
FT                                aggregation; normal transactivation
FT                                activity). {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046497.
FT   VARIANT     104    104       H -> R (in BPES; diffuse nuclear
FT                                localization as wild type; normal
FT                                transactivation activity;
FT                                dbSNP:rs1057516153).
FT                                {ECO:0000269|PubMed:12938087,
FT                                ECO:0000269|PubMed:18372316}.
FT                                /FTId=VAR_021199.
FT   VARIANT     105    105       N -> S (in BPES; type II).
FT                                /FTId=VAR_021200.
FT   VARIANT     106    106       L -> F (in BPES; sporadic; nuclear and
FT                                cytoplasmic aggregation; impaired
FT                                transactivation activity;
FT                                dbSNP:rs1057516156).
FT                                {ECO:0000269|PubMed:12529855,
FT                                ECO:0000269|PubMed:18372316}.
FT                                /FTId=VAR_016885.
FT   VARIANT     106    106       L -> P (in BPES; nuclear and cytoplasmic
FT                                aggregation; impaired transactivation
FT                                activity). {ECO:0000269|PubMed:18372316,
FT                                ECO:0000269|PubMed:18642388}.
FT                                /FTId=VAR_046498.
FT   VARIANT     108    108       L -> P (in BPES; nuclear aggregation and
FT                                cytoplasmic mislocalization; impaired
FT                                transactivation activity).
FT                                {ECO:0000269|PubMed:18484667}.
FT                                /FTId=VAR_062547.
FT   VARIANT     109    109       N -> K (in BPES; type II; diffuse nuclear
FT                                localization as wild type; impaired
FT                                transactivation activity).
FT                                {ECO:0000269|PubMed:12529855,
FT                                ECO:0000269|PubMed:18372316}.
FT                                /FTId=VAR_016886.
FT   VARIANT     134    134       C -> W (in granulosa-cell tumors of the
FT                                ovary; not commonly found in other tumor
FT                                types). {ECO:0000269|PubMed:19516027,
FT                                ECO:0000269|PubMed:19956657}.
FT                                /FTId=VAR_062548.
FT   VARIANT     179    179       A -> G (in dbSNP:rs7432551).
FT                                {ECO:0000269|PubMed:12149404,
FT                                ECO:0000269|PubMed:18484667}.
FT                                /FTId=VAR_021201.
FT   VARIANT     187    187       G -> D (in POF3; does not affect nuclear
FT                                localization; reduces transcriptional
FT                                activation of OSR2; dbSNP:rs121908359).
FT                                {ECO:0000269|PubMed:12161610,
FT                                ECO:0000269|PubMed:19429596}.
FT                                /FTId=VAR_015181.
FT   VARIANT     193    193       K -> R (in BPES; type II;
FT                                dbSNP:rs1057516162).
FT                                /FTId=VAR_021202.
FT   VARIANT     215    215       Y -> C (in BPES; dbSNP:rs1057516168).
FT                                {ECO:0000269|PubMed:15257268,
FT                                ECO:0000269|PubMed:18484667}.
FT                                /FTId=VAR_021203.
FT   VARIANT     217    217       S -> C (in BPES; diffuse nuclear
FT                                localization; normal transcriptional
FT                                activation).
FT                                {ECO:0000269|PubMed:18484667}.
FT                                /FTId=VAR_062549.
FT   VARIANT     217    217       S -> F (in BPES; diffuse nuclear
FT                                localization; increased transactivation
FT                                activity; dbSNP:rs797044527).
FT                                {ECO:0000269|PubMed:11468277,
FT                                ECO:0000269|PubMed:12529855,
FT                                ECO:0000269|PubMed:18372316}.
FT                                /FTId=VAR_016887.
FT   VARIANT     234    234       A -> AAAAAA (in BPES; significant higher
FT                                cytoplasmic retention compared to the
FT                                wild-type protein).
FT                                {ECO:0000269|PubMed:17089161}.
FT                                /FTId=VAR_037303.
FT   VARIANT     234    234       A -> AAAAAAAAAAA (in BPES; type II).
FT                                {ECO:0000269|PubMed:11175783,
FT                                ECO:0000269|PubMed:12400065}.
FT                                /FTId=VAR_010782.
FT   VARIANT     234    234       A -> AAAAAAAAAAAA (in BPES).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_025306.
FT   VARIANT     258    258       Y -> N (in POF3; dbSNP:rs28937885).
FT                                {ECO:0000269|PubMed:12149404}.
FT                                /FTId=VAR_021204.
FT   VARIANT     285    285       P -> S. {ECO:0000269|PubMed:12161610}.
FT                                /FTId=VAR_015182.
FT   VARIANT     349    349       R -> G (in dbSNP:rs201840174).
FT                                {ECO:0000269|PubMed:27610946}.
FT                                /FTId=VAR_078138.
FT   MUTAGEN      25     25       K->R: Results in reduced sumoylation.
FT                                Loss of transcriptional repression
FT                                activity. {ECO:0000269|PubMed:19744555}.
SQ   SEQUENCE   376 AA;  38772 MW;  B4952F2A0380E533 CRC64;
     MMASYPEPED AAGALLAPET GRTVKEPEGP PPSPGKGGGG GGGTAPEKPD PAQKPPYSYV
     ALIAMAIRES AEKRLTLSGI YQYIIAKFPF YEKNKKGWQN SIRHNLSLNE CFIKVPREGG
     GERKGNYWTL DPACEDMFEK GNYRRRRRMK RPFRPPPAHF QPGKGLFGAG GAAGGCGVAG
     AGADGYGYLA PPKYLQSGFL NNSWPLPQPP SPMPYASCQM AAAAAAAAAA AAAAGPGSPG
     AAAVVKGLAG PAASYGPYTR VQSMALPPGV VNSYNGLGGP PAAPPPPPHP HPHPHAHHLH
     AAAAPPPAPP HHGAAAPPPG QLSPASPATA APPAPAPTSA PGLQFACARQ PELAMMHCSY
     WDHDSKTGAL HSRLDL
//
ID   Q53ZD3_HUMAN            Unreviewed;       376 AA.
AC   Q53ZD3;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   28-FEB-2018, entry version 121.
DE   SubName: Full=FOXL2 {ECO:0000313|EMBL:AAY21821.1};
DE   SubName: Full=Forkhead box L2 {ECO:0000313|EMBL:AAQ01519.1};
GN   Name=FOXL2 {ECO:0000313|EMBL:AAQ01519.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAQ01519.1};
RN   [1] {ECO:0000313|EMBL:AAQ01519.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Brathwaite M.E., Uda M., Nagaraja R., Schlessinger D.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000313|EMBL:AAQ01519.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Crisponi L., Loi A., Deiana M., Pilia G.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:AAQ01519.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Uda M., Nagaraja R., Schlessinger D.;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000313|EMBL:AAQ01519.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=15081106; DOI=10.1016/j.ygeno.2003.11.010;
RA   Crisponi L., Uda M., Deiana M., Loi A., Nagaraja R., Chiappe F.,
RA   Schlessinger D., Cao A., Pilia G.;
RT   "FOXL2 inactivation by a translocation 171 kb away: analysis of 500 kb
RT   of chromosome 3 for candidate long-range regulatory sequences.";
RL   Genomics 83:757-764(2004).
RN   [5] {ECO:0000313|EMBL:AAY21821.1}
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=Mutant 101 {ECO:0000313|EMBL:AAY21821.1}, and
RC   Mutant 102 {ECO:0000313|EMBL:AAY21822.1};
RA   Xu Y.;
RT   "Study of mutations of FOXL2 gene in a Chinese TongHai family with
RT   blepharophimosis-ptosis-epicanthus inversus syndrome.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-
CC       ProRule:PRU00089}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY331134; AAQ01519.1; -; Genomic_DNA.
DR   EMBL; DQ016593; AAY21821.1; -; Genomic_DNA.
DR   EMBL; DQ016608; AAY21822.1; -; Genomic_DNA.
DR   RefSeq; NP_075555.1; NM_023067.3.
DR   UniGene; Hs.289292; -.
DR   SMR; Q53ZD3; -.
DR   MaxQB; Q53ZD3; -.
DR   GeneID; 668; -.
DR   KEGG; hsa:668; -.
DR   UCSC; uc003esw.3; human.
DR   CTD; 668; -.
DR   EuPathDB; HostDB:ENSG00000183770.5; -.
DR   PharmGKB; PA28235; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   HOVERGEN; HBG051651; -.
DR   KO; K09405; -.
DR   OMA; SMMHCSY; -.
DR   OrthoDB; EOG091G0ESH; -.
DR   GenomeRNAi; 668; -.
DR   Bgee; ENSG00000183770; -.
DR   GO; GO:0045171; C:intercellular bridge; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0030331; F:estrogen receptor binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0048048; P:embryonic eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0019101; P:female somatic sex determination; IEA:Ensembl.
DR   GO; GO:0060014; P:granulosa cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0001555; P:oocyte growth; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl.
DR   GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl.
DR   GO; GO:0007338; P:single fertilization; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR018122; TF_fork_head_CS_1.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00657; FORK_HEAD_1; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   4: Predicted;
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00089,
KW   ECO:0000256|SAAS:SAAS00582228};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00089}.
FT   DOMAIN       54    148       Fork-head. {ECO:0000259|PROSITE:PS50039}.
FT   DNA_BIND     54    148       Fork-head. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00089}.
SQ   SEQUENCE   376 AA;  38772 MW;  B4952F2A0380E533 CRC64;
     MMASYPEPED AAGALLAPET GRTVKEPEGP PPSPGKGGGG GGGTAPEKPD PAQKPPYSYV
     ALIAMAIRES AEKRLTLSGI YQYIIAKFPF YEKNKKGWQN SIRHNLSLNE CFIKVPREGG
     GERKGNYWTL DPACEDMFEK GNYRRRRRMK RPFRPPPAHF QPGKGLFGAG GAAGGCGVAG
     AGADGYGYLA PPKYLQSGFL NNSWPLPQPP SPMPYASCQM AAAAAAAAAA AAAAGPGSPG
     AAAVVKGLAG PAASYGPYTR VQSMALPPGV VNSYNGLGGP PAAPPPPPHP HPHPHAHHLH
     AAAAPPPAPP HHGAAAPPPG QLSPASPATA APPAPAPTSA PGLQFACARQ PELAMMHCSY
     WDHDSKTGAL HSRLDL
//
ID   GATA1_HUMAN             Reviewed;         413 AA.
AC   P15976; Q96GB8;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   28-FEB-2018, entry version 193.
DE   RecName: Full=Erythroid transcription factor;
DE   AltName: Full=Eryf1;
DE   AltName: Full=GATA-binding factor 1;
DE            Short=GATA-1;
DE            Short=GF-1;
DE   AltName: Full=NF-E1 DNA-binding protein;
GN   Name=GATA1; Synonyms=ERYF1, GF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=2104960; DOI=10.1038/343092a0;
RA   Trainor C.D., Evans T., Felsenfeld G., Boguski M.S.;
RT   "Structure and evolution of a human erythroid transcription factor.";
RL   Nature 343:92-96(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Erythrocyte;
RX   PubMed=2300555; DOI=10.1073/pnas.87.2.668;
RA   Zon L.I., Tsai S.-F., Burgess S., Matsudaira P., Bruns G.A.P.,
RA   Orkin S.H.;
RT   "The major human erythroid DNA-binding protein (GF-1): primary
RT   sequence and localization of the gene to the X chromosome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:668-672(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Bone marrow;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   ALTERNATIVE INITIATION (ISOFORM 3), SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=8524811; DOI=10.1073/pnas.92.25.11598;
RA   Calligaris R., Bottardi S., Cogoi S., Apezteguia I., Santoro C.;
RT   "Alternative translation initiation site usage results in two
RT   functionally distinct forms of the GATA-1 transcription factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:11598-11602(1995).
RN   [6]
RP   INTERACTION WITH EP300, AND ACETYLATION AT LYS-233; LYS-245 AND
RP   LYS-246.
RX   PubMed=9859997; DOI=10.1038/25166;
RA   Boyes J., Byfield P., Nakatani Y., Ogryzko V.;
RT   "Regulation of activity of the transcription factor GATA-1 by
RT   acetylation.";
RL   Nature 396:594-598(1998).
RN   [7]
RP   INVOLVEMENT IN XLAWT.
RX   PubMed=16783379; DOI=10.1038/ng1825;
RA   Hollanda L.M., Lima C.S., Cunha A.F., Albuquerque D.M., Vassallo J.,
RA   Ozelo M.C., Joazeiro P.P., Saad S.T., Costa F.F.;
RT   "An inherited mutation leading to production of only the short isoform
RT   of GATA-1 is associated with impaired erythropoiesis.";
RL   Nat. Genet. 38:807-812(2006).
RN   [8]
RP   SUMOYLATION AT LYS-137, PHOSPHORYLATION AT SER-142, AND MUTAGENESIS OF
RP   LYS-137 AND SER-142.
RX   PubMed=16371476; DOI=10.1073/pnas.0503698102;
RA   Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J.,
RA   Nakai A., Sistonen L.;
RT   "PDSM, a motif for phosphorylation-dependent SUMO modification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:45-50(2006).
RN   [9]
RP   INTERACTION WITH GFI1B.
RX   PubMed=17420275; DOI=10.1128/MCB.02212-06;
RA   Kuo Y.-Y., Chang Z.-F.;
RT   "GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription.";
RL   Mol. Cell. Biol. 27:4261-4272(2007).
RN   [10]
RP   FUNCTION, AND DNA-BINDING.
RX   PubMed=22235304; DOI=10.1371/journal.pone.0029518;
RA   Zeng Y., Wang W., Ma J., Wang X., Guo M., Li W.;
RT   "Knockdown of ZNF268, which is transcriptionally downregulated by
RT   GATA-1, promotes proliferation of K562 cells.";
RL   PLoS ONE 7:E29518-E29518(2012).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-116 AND SER-131, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH MED1; CCAR1 AND CALCOCO1.
RX   PubMed=24245781; DOI=10.1111/gtc.12104;
RA   Mizuta S., Minami T., Fujita H., Kaminaga C., Matsui K., Ishino R.,
RA   Fujita A., Oda K., Kawai A., Hasegawa N., Urahama N., Roeder R.G.,
RA   Ito M.;
RT   "CCAR1/CoCoA pair-mediated recruitment of the Mediator defines a novel
RT   pathway for GATA1 function.";
RL   Genes Cells 19:28-51(2014).
RN   [13]
RP   INTERACTION WITH CEBPE.
RX   PubMed=26019275; DOI=10.4049/jimmunol.1402222;
RA   Wada T., Akagi T., Muraoka M., Toma T., Kaji K., Agematsu K.,
RA   Koeffler H.P., Yokota T., Yachie A.;
RT   "A novel in-frame deletion in the leucine zipper domain of
RT   C/EBPepsilon leads to neutrophil-specific granule deficiency.";
RL   J. Immunol. 195:80-86(2015).
RN   [14]
RP   VARIANT XDAT MET-205, INTERACTION WITH ZFPM1, CHARACTERIZATION OF
RP   VARIANT XDAT MET-205, AND MUTAGENESIS OF CYS-204.
RC   TISSUE=Peripheral blood;
RX   PubMed=10700180; DOI=10.1038/73480;
RA   Nichols K.E., Crispino J.D., Poncz M., White J.G., Orkin S.H.,
RA   Maris J.M., Weiss M.J.;
RT   "Familial dyserythropoietic anaemia and thrombocytopenia due to an
RT   inherited mutation in GATA1.";
RL   Nat. Genet. 24:266-270(2000).
RN   [15]
RP   VARIANT XDAT GLY-218, INTERACTION WITH ZFPM1, AND CHARACTERIZATION OF
RP   VARIANT XDAT GLY-218.
RX   PubMed=11418466; DOI=10.1182/blood.V98.1.85;
RA   Freson K., Devriendt K., Matthijs G., Van Hoof A., De Vos R., Thys C.,
RA   Minner K., Hoylaerts M.F., Vermylen J., Van Geet C.;
RT   "Platelet characteristics in patients with X-linked
RT   macrothrombocytopenia because of a novel GATA1 mutation.";
RL   Blood 98:85-92(2001).
RN   [16]
RP   VARIANT XDAT SER-208, INTERACTION WITH ZFPM1, AND CHARACTERIZATION OF
RP   VARIANT XDAT SER-208.
RX   PubMed=11675338; DOI=10.1182/blood.V98.9.2681;
RA   Mehaffey M.G., Newton A.L., Gandhi M.J., Crossley M., Drachman J.G.;
RT   "X-linked thrombocytopenia caused by a novel mutation of GATA-1.";
RL   Blood 98:2681-2688(2001).
RN   [17]
RP   VARIANT XLTT GLN-216, INTERACTION WITH ZFPM1, AND CHARACTERIZATION OF
RP   VARIANT XLTT GLN-216.
RX   PubMed=12200364; DOI=10.1182/blood-2002-02-0387;
RA   Yu C., Niakan K.K., Matsushita M., Stamatoyannopoulos G., Orkin S.H.,
RA   Raskind W.H.;
RT   "X-linked thrombocytopenia with thalassemia from a mutation in the
RT   amino finger of GATA-1 affecting DNA binding rather than FOG-1
RT   interaction.";
RL   Blood 100:2040-2045(2002).
RN   [18]
RP   VARIANT XDAT TYR-218, INTERACTION WITH ZFPM1, AND CHARACTERIZATION OF
RP   VARIANT XDAT TYR-218.
RX   PubMed=11809723; DOI=10.1093/hmg/11.2.147;
RA   Freson K., Matthijs G., Thys C., Marieen P., Hoylaerts M.F.,
RA   Vermylen J., Van Geet C.;
RT   "Different substitutions at residue D218 of the X-linked transcription
RT   factor GATA1 lead to altered clinical severity of
RT   macrothrombocytopenia and anemia and are associated with variable
RT   skewed X inactivation.";
RL   Hum. Mol. Genet. 11:147-152(2002).
CC   -!- FUNCTION: Transcriptional activator or repressor which probably
CC       serves as a general switch factor for erythroid development. It
CC       binds to DNA sites with the consensus sequence 5'-[AT]GATA[AG]-3'
CC       within regulatory regions of globin genes and of other genes
CC       expressed in erythroid cells. Activates the transcription of genes
CC       involved in erythroid differentiation of K562 erythroleukemia
CC       cells, including HBB, HBG1/2, ALAS2 and HMBS (PubMed:24245781).
CC       {ECO:0000269|PubMed:22235304, ECO:0000269|PubMed:24245781}.
CC   -!- SUBUNIT: May form homodimers or heterodimers with other isoforms.
CC       Interacts (via the N-terminal zinc finger) with ZFPM1. Interacts
CC       with GFI1B. Interacts with PIAS4; the interaction enhances
CC       sumoylation and represses the transactivational activity in a
CC       sumoylation-independent manner. Interacts with LMCD1. Interacts
CC       with BRD3 (By similarity). Interacts with CREBBP; the interaction
CC       stimulates acetylation and transcriptional activity in vivo (By
CC       similarity). Interacts with EP300. Interacts with MED1, CCAR1 and
CC       CALCOCO1. Interacts with CEBPE (PubMed:26019275).
CC       {ECO:0000250|UniProtKB:P17679, ECO:0000269|PubMed:10700180,
CC       ECO:0000269|PubMed:11418466, ECO:0000269|PubMed:11675338,
CC       ECO:0000269|PubMed:11809723, ECO:0000269|PubMed:12200364,
CC       ECO:0000269|PubMed:17420275, ECO:0000269|PubMed:24245781,
CC       ECO:0000269|PubMed:26019275, ECO:0000269|PubMed:8524811,
CC       ECO:0000269|PubMed:9859997}.
CC   -!- INTERACTION:
CC       Q8N4L8:CCDC24; NbExp=3; IntAct=EBI-3909284, EBI-1104933;
CC       Q8TES7-6:FBF1; NbExp=3; IntAct=EBI-3909284, EBI-10244131;
CC       Q13643:FHL3; NbExp=4; IntAct=EBI-9090198, EBI-741101;
CC       O43559:FRS3; NbExp=3; IntAct=EBI-3909284, EBI-725515;
CC       Q96MH2:HEXIM2; NbExp=3; IntAct=EBI-3909284, EBI-5460660;
CC       P49639:HOXA1; NbExp=3; IntAct=EBI-3909284, EBI-740785;
CC       P08107:HSPA1B; NbExp=5; IntAct=EBI-3909284, EBI-629985;
CC       P60370:KRTAP10-5; NbExp=3; IntAct=EBI-3909284, EBI-10172150;
CC       Q9BYR7:KRTAP3-2; NbExp=3; IntAct=EBI-9090198, EBI-751260;
CC       Q9BYQ4:KRTAP9-2; NbExp=3; IntAct=EBI-3909284, EBI-1044640;
CC       Q9BRK4:LZTS2; NbExp=3; IntAct=EBI-9090198, EBI-741037;
CC       Q99750:MDFI; NbExp=5; IntAct=EBI-9090198, EBI-724076;
CC       Q15648:MED1; NbExp=6; IntAct=EBI-3909284, EBI-394459;
CC       O43741:PRKAB2; NbExp=4; IntAct=EBI-9090198, EBI-1053424;
CC       Q96JH8:RADIL; NbExp=3; IntAct=EBI-3909284, EBI-744267;
CC       P06400:RB1; NbExp=2; IntAct=EBI-3909284, EBI-491274;
CC       P13405:Rb1 (xeno); NbExp=2; IntAct=EBI-3909284, EBI-971782;
CC       Q13077:TRAF1; NbExp=3; IntAct=EBI-9090198, EBI-359224;
CC       Q15654:TRIP6; NbExp=3; IntAct=EBI-9090198, EBI-742327;
CC       Q8IX07:ZFPM1; NbExp=2; IntAct=EBI-3909284, EBI-3942619;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=3;
CC       Name=1;
CC         IsoId=P15976-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15976-2; Sequence=VSP_014782;
CC         Note=No experimental confirmation available.;
CC       Name=3; Synonyms=GATA-1s;
CC         IsoId=P15976-3; Sequence=VSP_041451;
CC         Note=Produced by alternative initiation at Met-84 of isoform 1.;
CC   -!- TISSUE SPECIFICITY: Erythrocytes. {ECO:0000269|PubMed:8524811}.
CC   -!- DOMAIN: The two fingers are functionally distinct and cooperate to
CC       achieve specific, stable DNA binding. The first finger is
CC       necessary only for full specificity and stability of binding,
CC       whereas the second one is required for binding (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Highly phosphorylated on serine residues. Phosphorylation on
CC       Ser-310 is enhanced on erythroid differentiation. Phosphorylation
CC       on Ser-142 promotes sumoylation on Lys-137 (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Sumoylation on Lys-137 is enhanced by phosphorylation on Ser-
CC       142 and by interaction with PIAS4. Sumoylation with SUMO1 has no
CC       effect on transcriptional activity (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated at 2 conserved lysine-rich motifs by CREBBP in
CC       vitro. Acetylation does not affect DNA-binding in vitro but is
CC       essential to induce erythroid differentiation and for binding
CC       chromatin in vivo (By similarity). Acetylated on Lys-233, Lys-245
CC       Lys-246 by EP300. {ECO:0000250, ECO:0000269|PubMed:9859997}.
CC   -!- DISEASE: X-linked dyserythropoietic anemia and thrombocytopenia
CC       (XDAT) [MIM:300367]: Disorder characterized by erythrocytes with
CC       abnormal size and shape, and paucity of platelets in peripheral
CC       blood. The bone marrow contains abundant and abnormally small
CC       megakaryocytes. {ECO:0000269|PubMed:10700180,
CC       ECO:0000269|PubMed:11418466, ECO:0000269|PubMed:11675338,
CC       ECO:0000269|PubMed:11809723}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Thrombocytopenia with beta-thalassemia, X-linked (XLTT)
CC       [MIM:314050]: An unusual form of thrombocytopenia associated with
CC       beta-thalassemia. Patients have splenomegaly and petechiae,
CC       moderate thrombocytopenia, prolonged bleeding time due to platelet
CC       dysfunction, reticulocytosis and unbalanced (hemo)globin chain
CC       synthesis resembling that of beta-thalassemia minor.
CC       {ECO:0000269|PubMed:12200364}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Anemia without thrombocytopenia, X-linked (XLAWT)
CC       [MIM:300835]: A form of anemia characterized by abnormal
CC       morphology of erythrocytes and granulocytes in peripheral blood,
CC       bone marrow dysplasia with hypocellularity of erythroid and
CC       granulocytic lineages, and normal or increased number of
CC       megakaryocytes. Neutropenia of a variable degree is present in
CC       affected individuals. {ECO:0000269|PubMed:16783379}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GATA1ID40689chXp11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X17254; CAA35120.1; -; mRNA.
DR   EMBL; M30601; AAA35885.1; -; mRNA.
DR   EMBL; AF196971; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009797; AAH09797.1; -; mRNA.
DR   CCDS; CCDS14305.1; -. [P15976-1]
DR   PIR; A34888; A34888.
DR   RefSeq; NP_002040.1; NM_002049.3. [P15976-1]
DR   UniGene; Hs.765; -.
DR   ProteinModelPortal; P15976; -.
DR   SMR; P15976; -.
DR   BioGrid; 108893; 61.
DR   DIP; DIP-41431N; -.
DR   IntAct; P15976; 57.
DR   MINT; P15976; -.
DR   STRING; 9606.ENSP00000365858; -.
DR   iPTMnet; P15976; -.
DR   PhosphoSitePlus; P15976; -.
DR   BioMuta; GATA1; -.
DR   DMDM; 120956; -.
DR   MaxQB; P15976; -.
DR   PaxDb; P15976; -.
DR   PeptideAtlas; P15976; -.
DR   PRIDE; P15976; -.
DR   DNASU; 2623; -.
DR   Ensembl; ENST00000376670; ENSP00000365858; ENSG00000102145. [P15976-1]
DR   GeneID; 2623; -.
DR   KEGG; hsa:2623; -.
DR   UCSC; uc004dkq.5; human. [P15976-1]
DR   CTD; 2623; -.
DR   DisGeNET; 2623; -.
DR   EuPathDB; HostDB:ENSG00000102145.13; -.
DR   GeneCards; GATA1; -.
DR   GeneReviews; GATA1; -.
DR   HGNC; HGNC:4170; GATA1.
DR   HPA; CAB009195; -.
DR   HPA; HPA000232; -.
DR   HPA; HPA000233; -.
DR   MalaCards; GATA1; -.
DR   MIM; 300367; phenotype.
DR   MIM; 300835; phenotype.
DR   MIM; 305371; gene.
DR   MIM; 314050; phenotype.
DR   neXtProt; NX_P15976; -.
DR   OpenTargets; ENSG00000102145; -.
DR   Orphanet; 86849; Acute basophilic leukemia.
DR   Orphanet; 231393; Beta-thalassemia - X-linked thrombocytopenia.
DR   Orphanet; 124; Blackfan-Diamond anemia.
DR   Orphanet; 79277; Congenital erythropoietic porphyria.
DR   Orphanet; 67044; Thrombocytopenia with congenital dyserythropoietic anemia.
DR   Orphanet; 363727; X-linked dyserythropoetic anemia with abnormal platelets and neutropenia.
DR   PharmGKB; PA28584; -.
DR   eggNOG; KOG1601; Eukaryota.
DR   eggNOG; COG5641; LUCA.
DR   GeneTree; ENSGT00760000119221; -.
DR   HOGENOM; HOG000047701; -.
DR   HOVERGEN; HBG051705; -.
DR   InParanoid; P15976; -.
DR   KO; K09182; -.
DR   OMA; TLKTERM; -.
DR   OrthoDB; EOG091G0AUR; -.
DR   PhylomeDB; P15976; -.
DR   TreeFam; TF315391; -.
DR   Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P15976; -.
DR   SIGNOR; P15976; -.
DR   ChiTaRS; GATA1; human.
DR   GeneWiki; GATA1; -.
DR   GenomeRNAi; 2623; -.
DR   PMAP-CutDB; P15976; -.
DR   PRO; PR:P15976; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000102145; -.
DR   CleanEx; HS_GATA1; -.
DR   ExpressionAtlas; P15976; baseline and differential.
DR   Genevisible; P15976; HS.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:BHF-UCL.
DR   GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:BHF-UCL.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0008301; F:DNA binding, bending; IEA:Ensembl.
DR   GO; GO:0001158; F:enhancer sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0002039; F:p53 binding; IEA:Ensembl.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IMP:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IMP:BHF-UCL.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IMP:BHF-UCL.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030221; P:basophil differentiation; IEP:BHF-UCL.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007267; P:cell-cell signaling; IEA:Ensembl.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IEA:Ensembl.
DR   GO; GO:0030222; P:eosinophil differentiation; IEP:BHF-UCL.
DR   GO; GO:0035854; P:eosinophil fate commitment; IDA:BHF-UCL.
DR   GO; GO:0048821; P:erythrocyte development; IMP:BHF-UCL.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEP:BHF-UCL.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IMP:BHF-UCL.
DR   GO; GO:0030219; P:megakaryocyte differentiation; IMP:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030502; P:negative regulation of bone mineralization; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:2000678; P:negative regulation of transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0070527; P:platelet aggregation; IMP:BHF-UCL.
DR   GO; GO:0030220; P:platelet formation; IMP:BHF-UCL.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0010724; P:regulation of definitive erythrocyte differentiation; IDA:BHF-UCL.
DR   GO; GO:0010559; P:regulation of glycoprotein biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0045652; P:regulation of megakaryocyte differentiation; TAS:Reactome.
DR   GO; GO:0010725; P:regulation of primitive erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0071733; P:transcriptional activation by promoter-enhancer looping; ISS:BHF-UCL.
DR   Gene3D; 3.30.50.10; -; 2.
DR   InterPro; IPR029524; GATA-1.
DR   InterPro; IPR000679; Znf_GATA.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR10071:SF190; PTHR10071:SF190; 1.
DR   Pfam; PF00320; GATA; 2.
DR   PRINTS; PR00619; GATAZNFINGER.
DR   SMART; SM00401; ZnF_GATA; 2.
DR   PROSITE; PS00344; GATA_ZN_FINGER_1; 2.
DR   PROSITE; PS50114; GATA_ZN_FINGER_2; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Alternative initiation; Alternative splicing;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   DNA-binding; Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    413       Erythroid transcription factor.
FT                                /FTId=PRO_0000083397.
FT   ZN_FING     204    228       GATA-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00094}.
FT   ZN_FING     258    282       GATA-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00094}.
FT   REGION      200    330       Interaction with MED1 and CCAR1.
FT                                {ECO:0000269|PubMed:24245781}.
FT   REGION      203    222       Required for interaction with ZFPM1.
FT   REGION      249    315       Interaction with CALCOCO1.
FT                                {ECO:0000269|PubMed:24245781}.
FT   MOD_RES      26     26       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES      72     72       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     116    116       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     131    131       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     142    142       Phosphoserine.
FT                                {ECO:0000269|PubMed:16371476}.
FT   MOD_RES     178    178       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     187    187       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     233    233       N6-acetyllysine; by EP300.
FT                                {ECO:0000305|PubMed:9859997}.
FT   MOD_RES     245    245       N6-acetyllysine; by EP300.
FT                                {ECO:0000305|PubMed:9859997}.
FT   MOD_RES     246    246       N6-acetyllysine; by CREBBP.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     246    246       N6-acetyllysine; by EP300.
FT                                {ECO:0000305|PubMed:9859997}.
FT   MOD_RES     252    252       N6-acetyllysine; by CREBBP.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     308    308       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     310    310       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     312    312       N6-acetyllysine; by CREBBP.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     314    314       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   MOD_RES     315    315       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17679}.
FT   CROSSLNK    137    137       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:16371476}.
FT   VAR_SEQ       1     83       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_041451.
FT   VAR_SEQ     290    413       QVNRPLTMRKDGIQTRNRKASGKGKKKRGSSLGGTGAAEGP
FT                                AGGFMVVAGGSGSGNCGEVASGLTLGPPGTAHLYQGLGPVV
FT                                LSGPVSHLMPFPGPLLGSPTGSFPTGPMPPTTSTTVVAPLS
FT                                S -> HQHYCGGSAQLMRAQSMASRGGVVSFSSCSQNSGQP
FT                                KSLGPRHPLA (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014782.
FT   VARIANT     205    205       V -> M (in XDAT; severe impairment of
FT                                ZFPM1 binding and erythroid
FT                                differentiation in vitro;
FT                                dbSNP:rs104894815).
FT                                {ECO:0000269|PubMed:10700180}.
FT                                /FTId=VAR_010115.
FT   VARIANT     208    208       G -> S (in XDAT; partially disrupts the
FT                                interaction with ZFPM1;
FT                                dbSNP:rs137852312).
FT                                {ECO:0000269|PubMed:11675338}.
FT                                /FTId=VAR_012706.
FT   VARIANT     216    216       R -> Q (in XLTT; does not affect ZFPM1
FT                                binding; reduced affinity to palindromic
FT                                GATA sites; supports erythroid maturation
FT                                less efficiently than wild-type GATA1;
FT                                dbSNP:rs104894809).
FT                                {ECO:0000269|PubMed:12200364}.
FT                                /FTId=VAR_033114.
FT   VARIANT     218    218       D -> G (in XDAT; partially disrupts the
FT                                interaction with ZFPM1;
FT                                dbSNP:rs104894816).
FT                                {ECO:0000269|PubMed:11418466}.
FT                                /FTId=VAR_012707.
FT   VARIANT     218    218       D -> Y (in XDAT; stronger loss of
FT                                affinity than of G-218-GATA1 for ZFPM1
FT                                and disturbed GATA1 self-association;
FT                                dbSNP:rs104894808).
FT                                {ECO:0000269|PubMed:11809723}.
FT                                /FTId=VAR_033115.
FT   MUTAGEN     137    137       K->R: Abolishes sumoylation.
FT                                {ECO:0000269|PubMed:16371476}.
FT   MUTAGEN     142    142       S->A: Loss of sumoylation.
FT                                {ECO:0000269|PubMed:16371476}.
FT   MUTAGEN     142    142       S->D: Increased sumoylation in vitro.
FT                                {ECO:0000269|PubMed:16371476}.
FT   MUTAGEN     204    204       C->R: Increase of dissociation rate from
FT                                bound DNA. {ECO:0000269|PubMed:10700180}.
SQ   SEQUENCE   413 AA;  42751 MW;  822BD2DE14B908AD CRC64;
     MEFPGLGSLG TSEPLPQFVD PALVSSTPES GVFFPSGPEG LDAAASSTAP STATAAAAAL
     AYYRDAEAYR HSPVFQVYPL LNCMEGIPGG SPYAGWAYGK TGLYPASTVC PTREDSPPQA
     VEDLDGKGST SFLETLKTER LSPDLLTLGP ALPSSLPVPN SAYGGPDFSS TFFSPTGSPL
     NSAAYSSPKL RGTLPLPPCE ARECVNCGAT ATPLWRRDRT GHYLCNACGL YHKMNGQNRP
     LIRPKKRLIV SKRAGTQCTN CQTTTTTLWR RNASGDPVCN ACGLYYKLHQ VNRPLTMRKD
     GIQTRNRKAS GKGKKKRGSS LGGTGAAEGP AGGFMVVAGG SGSGNCGEVA SGLTLGPPGT
     AHLYQGLGPV VLSGPVSHLM PFPGPLLGSP TGSFPTGPMP PTTSTTVVAP LSS
//
ID   GATA3_HUMAN             Reviewed;         443 AA.
AC   P23771; Q5VWG7; Q5VWG8; Q96J16;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 1.
DT   28-FEB-2018, entry version 188.
DE   RecName: Full=Trans-acting T-cell-specific transcription factor GATA-3;
DE   AltName: Full=GATA-binding factor 3;
GN   Name=GATA3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=2050118;
RA   Joulin V., Bories D., Eleouet J.-F., Labastie M.-C., Chretien S.,
RA   Mattei M.-G., Romeo P.-H.;
RT   "A T-cell specific TCR delta DNA binding protein is a member of the
RT   human GATA family.";
RL   EMBO J. 10:1809-1816(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=1827068;
RA   Ho I.-C., Vorhees P., Marin N., Oakley B.K., Tsai S.-F., Orkin S.H.,
RA   Leiden J.M.;
RT   "Human GATA-3: a lineage-restricted transcription factor that
RT   regulates the expression of the T cell receptor alpha gene.";
RL   EMBO J. 10:1187-1192(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=T-cell;
RX   PubMed=2017177; DOI=10.1128/MCB.11.5.2778;
RA   Ko L.J., Yamamoto M., Leonard M.W., George K.M., Ting P., Engel J.D.;
RT   "Murine and human T-lymphocyte GATA-3 factors mediate transcription
RT   through a cis-regulatory element within the human T-cell receptor
RT   delta gene enhancer.";
RL   Mol. Cell. Biol. 11:2778-2784(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1871134; DOI=10.1073/pnas.88.16.7284;
RA   Marine J., Winoto A.;
RT   "The human enhancer-binding protein Gata3 binds to several T-cell
RT   receptor regulatory elements.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:7284-7288(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-242.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cervix, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INVOLVEMENT IN HDR.
RX   PubMed=10935639; DOI=10.1038/35019088;
RA   Van Esch H., Groenen P., Nesbit M.A., Schuffenhauer S., Lichtner P.,
RA   Vanderlinden G., Harding B., Beetz R., Bilous R.W., Holdaway I.,
RA   Shaw N.J., Fryns J.-P., Van de Ven W., Thakker R.V., Devriendt K.;
RT   "GATA3 haplo-insufficiency causes human HDR syndrome.";
RL   Nature 406:419-422(2000).
RN   [10]
RP   INTERACTION WITH TBX21.
RX   PubMed=15662016; DOI=10.1126/science.1103336;
RA   Hwang E.S., Szabo S.J., Schwartzberg P.L., Glimcher L.H.;
RT   "T helper cell fate specified by kinase-mediated interaction of T-bet
RT   with GATA-3.";
RL   Science 307:430-433(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115 AND SER-162, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=23824597; DOI=10.1371/journal.pone.0066468;
RA   Sasaki T., Onodera A., Hosokawa H., Watanabe Y., Horiuchi S.,
RA   Yamashita J., Tanaka H., Ogawa Y., Suzuki Y., Nakayama T.;
RT   "Genome-wide gene expression profiling revealed a critical role for
RT   GATA3 in the maintenance of the Th2 cell identity.";
RL   PLoS ONE 8:E66468-E66468(2013).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 260-370 IN COMPLEX WITH DNA,
RP   AND GATA-TYPE ZINC FINGERS.
RX   PubMed=23142663; DOI=10.1016/j.celrep.2012.10.012;
RA   Chen Y., Bates D.L., Dey R., Chen P.H., Machado A.C.,
RA   Laird-Offringa I.A., Rohs R., Chen L.;
RT   "DNA binding by GATA transcription factor suggests mechanisms of DNA
RT   looping and long-range gene regulation.";
RL   Cell Rep. 2:1197-1206(2012).
RN   [14]
RP   VARIANT HDR ARG-274.
RX   PubMed=11389161; DOI=10.1136/jmg.38.6.374;
RA   Muroya K., Hasegawa T., Ito Y., Nagai T., Isotani H., Iwata Y.,
RA   Yamamoto K., Fujimoto S., Seishu S., Fukushima Y., Hasegawa Y.,
RA   Ogata T.;
RT   "GATA3 abnormalities and the phenotypic spectrum of HDR syndrome.";
RL   J. Med. Genet. 38:374-380(2001).
RN   [15]
RP   VARIANT LEU-366.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A.,
RA   Presswalla S., Kaaresen R., Strausberg R.L., Gerhard D.S.,
RA   Kristensen V., Perou C.M., Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by
RT   expression profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [16]
RP   VARIANT HDR GLN-298, AND CHARACTERIZATION OF VARIANT HDR GLN-298.
RX   PubMed=26514990; DOI=10.1186/s12902-015-0065-7;
RA   Okawa T., Yoshida M., Usui T., Kudou T., Iwasaki Y., Fukuoka K.,
RA   Takahashi N., Uehara Y., Oiso Y.;
RT   "A novel loss-of-function mutation of GATA3 (p.R299Q) in a Japanese
RT   family with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR)
RT   syndrome.";
RL   BMC Endocr. Disord. 15:66-66(2015).
CC   -!- FUNCTION: Transcriptional activator which binds to the enhancer of
CC       the T-cell receptor alpha and delta genes. Binds to the consensus
CC       sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2)
CC       differentiation process following immune and inflammatory
CC       responses. {ECO:0000269|PubMed:23824597}.
CC   -!- SUBUNIT: Interacts with TBX21 ('Tyr-530' phosphorylated form).
CC       {ECO:0000269|PubMed:15662016}.
CC   -!- INTERACTION:
CC       P35609:ACTN2; NbExp=3; IntAct=EBI-6664760, EBI-77797;
CC       Q96KQ7:EHMT2; NbExp=20; IntAct=EBI-6664760, EBI-744366;
CC       O15379:HDAC3; NbExp=7; IntAct=EBI-6664760, EBI-607682;
CC       Q9UQL6:HDAC5; NbExp=4; IntAct=EBI-6664760, EBI-715576;
CC       P06239:LCK; NbExp=3; IntAct=EBI-6664760, EBI-1348;
CC       Q9BTC8:MTA3; NbExp=18; IntAct=EBI-6664760, EBI-2461787;
CC       P25788:PSMA3; NbExp=3; IntAct=EBI-6664760, EBI-348380;
CC       Q9UL17:TBX21; NbExp=6; IntAct=EBI-6664760, EBI-3922312;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P23771-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P23771-2; Sequence=VSP_001598;
CC   -!- TISSUE SPECIFICITY: T-cells and endothelial cells.
CC   -!- DOMAIN: Binds DNA via the 2 GATA-type zinc fingers. Each zinc
CC       finger may bind either adjacent sites in a palindromic motif, or a
CC       different DNA molecule allowing looping and long-range gene
CC       regulation.
CC   -!- DOMAIN: The YxKxHxxxRP motif is critical for DNA-binding and
CC       function. {ECO:0000250}.
CC   -!- DISEASE: Hypoparathyroidism, sensorineural deafness, and renal
CC       disease (HDR) [MIM:146255]: A disease characterized by steroid-
CC       resistant nephrosis with progressive renal failure,
CC       hypoparathyroidism, sensorineural deafness, and renal dysplasia.
CC       {ECO:0000269|PubMed:10935639, ECO:0000269|PubMed:11389161,
CC       ECO:0000269|PubMed:26514990}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/gata3/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GATA3ID107ch10p14.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X58072; CAA41102.1; -; mRNA.
DR   EMBL; X55037; CAA38877.1; -; mRNA.
DR   EMBL; X55122; CAA38916.1; -; mRNA.
DR   EMBL; M69106; AAA35870.1; -; mRNA.
DR   EMBL; AY497006; AAR32096.1; -; Genomic_DNA.
DR   EMBL; AL390294; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86367.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86368.1; -; Genomic_DNA.
DR   EMBL; BC003070; AAH03070.1; -; mRNA.
DR   EMBL; BC006793; AAH06793.1; -; mRNA.
DR   CCDS; CCDS31143.1; -. [P23771-2]
DR   CCDS; CCDS7083.1; -. [P23771-1]
DR   PIR; A39794; A39794.
DR   RefSeq; NP_001002295.1; NM_001002295.1. [P23771-2]
DR   RefSeq; NP_002042.1; NM_002051.2. [P23771-1]
DR   RefSeq; XP_005252499.1; XM_005252442.2. [P23771-2]
DR   RefSeq; XP_005252500.1; XM_005252443.4. [P23771-2]
DR   UniGene; Hs.524134; -.
DR   PDB; 4HC7; X-ray; 2.65 A; A/B=260-370.
DR   PDB; 4HC9; X-ray; 1.60 A; A=260-370.
DR   PDB; 4HCA; X-ray; 2.80 A; A=260-370.
DR   PDBsum; 4HC7; -.
DR   PDBsum; 4HC9; -.
DR   PDBsum; 4HCA; -.
DR   ProteinModelPortal; P23771; -.
DR   SMR; P23771; -.
DR   BioGrid; 108895; 22.
DR   DIP; DIP-61302N; -.
DR   IntAct; P23771; 40.
DR   MINT; P23771; -.
DR   STRING; 9606.ENSP00000368632; -.
DR   iPTMnet; P23771; -.
DR   PhosphoSitePlus; P23771; -.
DR   BioMuta; GATA3; -.
DR   DMDM; 120962; -.
DR   MaxQB; P23771; -.
DR   PaxDb; P23771; -.
DR   PeptideAtlas; P23771; -.
DR   PRIDE; P23771; -.
DR   DNASU; 2625; -.
DR   Ensembl; ENST00000346208; ENSP00000341619; ENSG00000107485. [P23771-1]
DR   Ensembl; ENST00000379328; ENSP00000368632; ENSG00000107485. [P23771-2]
DR   GeneID; 2625; -.
DR   KEGG; hsa:2625; -.
DR   UCSC; uc001ijz.4; human. [P23771-1]
DR   CTD; 2625; -.
DR   DisGeNET; 2625; -.
DR   EuPathDB; HostDB:ENSG00000107485.15; -.
DR   GeneCards; GATA3; -.
DR   HGNC; HGNC:4172; GATA3.
DR   HPA; CAB016217; -.
DR   HPA; HPA029730; -.
DR   HPA; HPA029731; -.
DR   MalaCards; GATA3; -.
DR   MIM; 131320; gene.
DR   MIM; 146255; phenotype.
DR   neXtProt; NX_P23771; -.
DR   OpenTargets; ENSG00000107485; -.
DR   Orphanet; 2237; Hypoparathyroidism - deafness - renal disease.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA28586; -.
DR   eggNOG; KOG1601; Eukaryota.
DR   eggNOG; COG5641; LUCA.
DR   GeneTree; ENSGT00760000119221; -.
DR   HOGENOM; HOG000047701; -.
DR   HOVERGEN; HBG051705; -.
DR   InParanoid; P23771; -.
DR   KO; K17895; -.
DR   OMA; QRYPPTH; -.
DR   OrthoDB; EOG091G0AUR; -.
DR   PhylomeDB; P23771; -.
DR   TreeFam; TF315391; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P23771; -.
DR   SIGNOR; P23771; -.
DR   GeneWiki; GATA3; -.
DR   GenomeRNAi; 2625; -.
DR   PRO; PR:P23771; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000107485; -.
DR   CleanEx; HS_GATA3; -.
DR   Genevisible; P23771; HS.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0070888; F:E-box binding; IDA:BHF-UCL.
DR   GO; GO:0001158; F:enhancer sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0071837; F:HMG box domain binding; IPI:UniProtKB.
DR   GO; GO:0005134; F:interleukin-2 receptor binding; IEA:Ensembl.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:Ensembl.
DR   GO; GO:0000987; F:proximal promoter sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IBA:GO_Central.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IMP:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0003180; P:aortic valve morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0061290; P:canonical Wnt signaling pathway involved in metanephric kidney development; ISS:UniProtKB.
DR   GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001709; P:cell fate determination; ISS:UniProtKB.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IEA:Ensembl.
DR   GO; GO:0035457; P:cellular response to interferon-alpha; IEP:UniProtKB.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IEP:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0048589; P:developmental growth; IEA:Ensembl.
DR   GO; GO:0043583; P:ear development; IMP:UniProtKB.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0072643; P:interferon-gamma secretion; IEA:Ensembl.
DR   GO; GO:0072602; P:interleukin-4 secretion; IEA:Ensembl.
DR   GO; GO:0001822; P:kidney development; IMP:UniProtKB.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0072676; P:lymphocyte migration; IDA:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; ISS:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; IEA:Ensembl.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; IDA:UniProtKB.
DR   GO; GO:0001823; P:mesonephros development; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:2000146; P:negative regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:2000607; P:negative regulation of cell proliferation involved in mesonephros development; ISS:UniProtKB.
DR   GO; GO:1901536; P:negative regulation of DNA demethylation; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IMP:UniProtKB.
DR   GO; GO:2000703; P:negative regulation of fibroblast growth factor receptor signaling pathway involved in ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:2000734; P:negative regulation of glial cell-derived neurotrophic factor receptor signaling pathway involved in ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IEA:Ensembl.
DR   GO; GO:0033600; P:negative regulation of mammary gland epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0072179; P:nephric duct formation; ISS:UniProtKB.
DR   GO; GO:0072178; P:nephric duct morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0042421; P:norepinephrine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0071599; P:otic vesicle development; IEA:Ensembl.
DR   GO; GO:0060017; P:parathyroid gland development; IEA:Ensembl.
DR   GO; GO:0035898; P:parathyroid hormone secretion; IEA:Ensembl.
DR   GO; GO:0060037; P:pharyngeal system development; ISS:UniProtKB.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0071442; P:positive regulation of histone H3-K14 acetylation; IEA:Ensembl.
DR   GO; GO:2000617; P:positive regulation of histone H3-K9 acetylation; IEA:Ensembl.
DR   GO; GO:2000667; P:positive regulation of interleukin-13 secretion; IDA:UniProtKB.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:2000664; P:positive regulation of interleukin-5 secretion; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0009967; P:positive regulation of signal transduction; IMP:UniProtKB.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; IEA:Ensembl.
DR   GO; GO:2000611; P:positive regulation of thyroid hormone generation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0072107; P:positive regulation of ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0002572; P:pro-T cell differentiation; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0043370; P:regulation of CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:2000683; P:regulation of cellular response to X-ray; IMP:UniProtKB.
DR   GO; GO:0042035; P:regulation of cytokine biosynthetic process; ISS:UniProtKB.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0061085; P:regulation of histone H3-K27 methylation; IEA:Ensembl.
DR   GO; GO:0051569; P:regulation of histone H3-K4 methylation; IEA:Ensembl.
DR   GO; GO:0072182; P:regulation of nephron tubule epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0010975; P:regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEP:UniProtKB.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; ISS:UniProtKB.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045064; P:T-helper 2 cell differentiation; IEA:Ensembl.
DR   GO; GO:0045061; P:thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0031929; P:TOR signaling; ISS:UniProtKB.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0001806; P:type IV hypersensitivity; IEA:Ensembl.
DR   GO; GO:0035799; P:ureter maturation; IEA:Ensembl.
DR   GO; GO:0060676; P:ureteric bud formation; ISS:UniProtKB.
DR   GO; GO:0060065; P:uterus development; ISS:UniProtKB.
DR   GO; GO:0003281; P:ventricular septum development; ISS:UniProtKB.
DR   Gene3D; 3.30.50.10; -; 2.
DR   InterPro; IPR029521; GATA-3.
DR   InterPro; IPR016374; TF_GATA-2/3.
DR   InterPro; IPR000679; Znf_GATA.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR10071:SF106; PTHR10071:SF106; 1.
DR   Pfam; PF00320; GATA; 2.
DR   PIRSF; PIRSF003027; TF_GATA-1/2/3; 1.
DR   PRINTS; PR00619; GATAZNFINGER.
DR   SMART; SM00401; ZnF_GATA; 2.
DR   PROSITE; PS00344; GATA_ZN_FINGER_1; 2.
DR   PROSITE; PS50114; GATA_ZN_FINGER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Complete proteome;
KW   Deafness; Disease mutation; DNA-binding; Immunity; Innate immunity;
KW   Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Zinc; Zinc-finger.
FT   CHAIN         1    443       Trans-acting T-cell-specific
FT                                transcription factor GATA-3.
FT                                /FTId=PRO_0000083408.
FT   ZN_FING     263    287       GATA-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00094}.
FT   ZN_FING     317    341       GATA-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00094}.
FT   REGION        1    258       Interaction with TBX21.
FT                                {ECO:0000250|UniProtKB:P23772}.
FT   REGION      288    316       Flexible linker.
FT   MOTIF       344    353       YxKxHxxxRP. {ECO:0000250}.
FT   COMPBIAS    137    142       Poly-Ser.
FT   COMPBIAS    322    326       Poly-Thr.
FT   MOD_RES     115    115       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     162    162       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   VAR_SEQ     259    259       T -> TE (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1871134,
FT                                ECO:0000303|PubMed:2017177}.
FT                                /FTId=VSP_001598.
FT   VARIANT     242    242       G -> S (in dbSNP:rs11567901).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019202.
FT   VARIANT     274    274       W -> R (in HDR; dbSNP:rs104894163).
FT                                {ECO:0000269|PubMed:11389161}.
FT                                /FTId=VAR_017818.
FT   VARIANT     298    298       R -> Q (in HDR; loss of enhancer activity
FT                                on PTH gene promoter and on GATA
FT                                responsive element).
FT                                {ECO:0000269|PubMed:26514990}.
FT                                /FTId=VAR_075427.
FT   VARIANT     366    366       R -> L (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033025.
FT   CONFLICT     11     11       V -> L (in Ref. 4; AAA35870).
FT                                {ECO:0000305}.
FT   CONFLICT    102    102       A -> V (in Ref. 2; CAA38877).
FT                                {ECO:0000305}.
FT   CONFLICT    173    173       A -> G (in Ref. 2; CAA38877).
FT                                {ECO:0000305}.
FT   CONFLICT    219    219       I -> Y (in Ref. 4; AAA35870).
FT                                {ECO:0000305}.
FT   CONFLICT    225    226       YV -> TC (in Ref. 4; AAA35870).
FT                                {ECO:0000305}.
FT   CONFLICT    285    286       NA -> RR (in Ref. 4; AAA35870).
FT                                {ECO:0000305}.
FT   CONFLICT    425    425       P -> A (in Ref. 4; AAA35870).
FT                                {ECO:0000305}.
FT   CONFLICT    441    441       A -> G (in Ref. 4; AAA35870).
FT                                {ECO:0000305}.
FT   TURN        264    266       {ECO:0000244|PDB:4HC9}.
FT   HELIX       285    294       {ECO:0000244|PDB:4HC9}.
FT   STRAND      307    313       {ECO:0000244|PDB:4HC7}.
FT   TURN        318    320       {ECO:0000244|PDB:4HC9}.
FT   HELIX       339    348       {ECO:0000244|PDB:4HC9}.
FT   HELIX       354    356       {ECO:0000244|PDB:4HC9}.
SQ   SEQUENCE   443 AA;  47916 MW;  F24C58681E1D02A5 CRC64;
     MEVTADQPRW VSHHHPAVLN GQHPDTHHPG LSHSYMDAAQ YPLPEEVDVL FNIDGQGNHV
     PPYYGNSVRA TVQRYPPTHH GSQVCRPPLL HGSLPWLDGG KALGSHHTAS PWNLSPFSKT
     SIHHGSPGPL SVYPPASSSS LSGGHASPHL FTFPPTPPKD VSPDPSLSTP GSAGSARQDE
     KECLKYQVPL PDSMKLESSH SRGSMTALGG ASSSTHHPIT TYPPYVPEYS SGLFPPSSLL
     GGSPTGFGCK SRPKARSSTG RECVNCGATS TPLWRRDGTG HYLCNACGLY HKMNGQNRPL
     IKPKRRLSAA RRAGTSCANC QTTTTTLWRR NANGDPVCNA CGLYYKLHNI NRPLTMKKEG
     IQTRNRKMSS KSKKCKKVHD SLEDFPKNSS FNPAALSRHM SSLSHISPFS HSSHMLTTPT
     PMHPPSSLSF GPHHPSSMVT AMG
//
ID   B4DTD8_HUMAN            Unreviewed;       564 AA.
AC   B4DTD8;
DT   23-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   23-SEP-2008, sequence version 1.
DT   25-OCT-2017, entry version 51.
DE   SubName: Full=cDNA FLJ53916, highly similar to Glypican-3 {ECO:0000313|EMBL:BAG61950.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG61950.1};
RN   [1] {ECO:0000313|EMBL:BAG61950.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Placenta {ECO:0000313|EMBL:BAG61950.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate.
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000256|RuleBase:RU003519}; Lipid-anchor, GPI-anchor
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SIMILARITY: Belongs to the glypican family.
CC       {ECO:0000256|RuleBase:RU003518}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK300168; BAG61950.1; -; mRNA.
DR   RefSeq; NP_001158090.1; NM_001164618.1.
DR   UniGene; Hs.644108; -.
DR   ProteinModelPortal; B4DTD8; -.
DR   MaxQB; B4DTD8; -.
DR   PeptideAtlas; B4DTD8; -.
DR   PRIDE; B4DTD8; -.
DR   DNASU; 2719; -.
DR   GeneID; 2719; -.
DR   CTD; 2719; -.
DR   PharmGKB; PA28832; -.
DR   HOVERGEN; HBG005896; -.
DR   GenomeRNAi; 2719; -.
DR   Genevisible; B4DTD8; HS.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:InterPro.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IEA:InterPro.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR015501; Glypican-3.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; PTHR10822; 1.
DR   PANTHER; PTHR10822:SF4; PTHR10822:SF4; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   2: Evidence at transcript level;
KW   Glycoprotein {ECO:0000256|RuleBase:RU003519};
KW   GPI-anchor {ECO:0000256|RuleBase:RU003519};
KW   Heparan sulfate {ECO:0000256|RuleBase:RU003519};
KW   Lipoprotein {ECO:0000256|RuleBase:RU003519};
KW   Membrane {ECO:0000256|RuleBase:RU003519};
KW   Proteoglycan {ECO:0000256|RuleBase:RU003519};
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL        1     24       {ECO:0000256|SAM:SignalP}.
FT   CHAIN        25    564       {ECO:0000256|SAM:SignalP}.
FT                                /FTId=PRO_5002801027.
SQ   SEQUENCE   564 AA;  63728 MW;  FC5B36FD989E8414 CRC64;
     MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS
     DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSAKAFE IVVRHAKNYT NAMFKNNYPS
     LTPQAFEFVG EFFTDVSLYI LGSDINVDDM VNELFDSLFP VIYTQLMNPG LPDSALDINE
     CLRGARRDLK VFGNFPKLIM TQVSKSLQVT RIFLQALNLG IEVINTTDHL KFSKDCGRML
     TRMWYCSYCQ GLMMVKPCGG YCNVVMQGCM AGVVEIDKYW REYILSLEEL VNGMYRIYDM
     ENVLLGLFST IHDSIQYVQK NAGKLTTTIG KLCAHSQQRQ YRSAYYPEDL FIDKKVLKVA
     HVEHEETLSS RRRELIQKLK SFISFYSALP GYICSHSPVA ENDTLCWNGQ ELVERYSQKA
     ARNGMKNQFN LHELKMKGPE PVVSQIIDKL KHINQLLRTM SMPKGRVLDK NLDEEGFESG
     DCGDDEDECI GGSGDGMIKV KNQLRFLAEL AYDLDVDDAP GNSQQATPKD NEISTFHNLG
     NVHSPLKLLT SMAISVVCFF FLVH
//
ID   I6QTG3_HUMAN            Unreviewed;       580 AA.
AC   I6QTG3;
DT   03-OCT-2012, integrated into UniProtKB/TrEMBL.
DT   03-OCT-2012, sequence version 1.
DT   31-JAN-2018, entry version 45.
DE   SubName: Full=Glypican 3 isoform 2 {ECO:0000313|EMBL:AFM30911.1};
DE   SubName: Full=Glypican 3, isoform CRA_b {ECO:0000313|EMBL:EAX11770.1};
GN   Name=GPC3 {ECO:0000313|EMBL:AFM30911.1};
GN   ORFNames=hCG_14619 {ECO:0000313|EMBL:EAX11770.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AFM30911.1};
RN   [1] {ECO:0000313|EMBL:EAX11770.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX11770.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:AFM30911.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Hepatocellular carcinoma {ECO:0000313|EMBL:AFM30911.1};
RA   Gao W., Ho M.;
RT   "Discovery of monoclonal antibodies to glypican-3.";
RL   Submitted (APR-2012) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate.
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000256|RuleBase:RU003519}; Lipid-anchor, GPI-anchor
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SIMILARITY: Belongs to the glypican family.
CC       {ECO:0000256|RuleBase:RU003518}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; JQ943686; AFM30911.1; -; mRNA.
DR   EMBL; CH471107; EAX11770.1; -; Genomic_DNA.
DR   RefSeq; NP_004475.1; NM_004484.3.
DR   UniGene; Hs.644108; -.
DR   SMR; I6QTG3; -.
DR   GeneID; 2719; -.
DR   KEGG; hsa:2719; -.
DR   CTD; 2719; -.
DR   EuPathDB; HostDB:ENSG00000147257.13; -.
DR   eggNOG; KOG3821; Eukaryota.
DR   eggNOG; ENOG410XST2; LUCA.
DR   KO; K08109; -.
DR   ChiTaRS; GPC3; human.
DR   GenomeRNAi; 2719; -.
DR   Bgee; ENSG00000147257; -.
DR   ExpressionAtlas; I6QTG3; baseline and differential.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:InterPro.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IEA:InterPro.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR015501; Glypican-3.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; PTHR10822; 1.
DR   PANTHER; PTHR10822:SF4; PTHR10822:SF4; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   2: Evidence at transcript level;
KW   Glycoprotein {ECO:0000256|RuleBase:RU003519};
KW   GPI-anchor {ECO:0000256|RuleBase:RU003519};
KW   Heparan sulfate {ECO:0000256|RuleBase:RU003519};
KW   Lipoprotein {ECO:0000256|RuleBase:RU003519};
KW   Membrane {ECO:0000256|RuleBase:RU003519};
KW   Proteoglycan {ECO:0000256|RuleBase:RU003519};
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL        1     24       {ECO:0000256|SAM:SignalP}.
FT   CHAIN        25    580       {ECO:0000256|SAM:SignalP}.
FT                                /FTId=PRO_5010125021.
SQ   SEQUENCE   580 AA;  65563 MW;  19485B76D3CE15FC CRC64;
     MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS
     DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSASMEL KFLIIQNAAV FQEAFEIVVR
     HAKNYTNAMF KNNYPSLTPQ AFEFVGEFFT DVSLYILGSD INVDDMVNEL FDSLFPVIYT
     QLMNPGLPDS ALDINECLRG ARRDLKVFGN FPKLIMTQVS KSLQVTRIFL QALNLGIEVI
     NTTDHLKFSK DCGRMLTRMW YCSYCQGLMM VKPCGGYCNV VMQGCMAGVV EIDKYWREYI
     LSLEELVNGM YRIYDMENVL LGLFSTIHDS IQYVQKNAGK LTTTIGKLCA HSQQRQYRSA
     YYPEDLFIDK KVLKVAHVEH EETLSSRRRE LIQKLKSFIS FYSALPGYIC SHSPVAENDT
     LCWNGQELVE RYSQKAARNG MKNQFNLHEL KMKGPEPVVS QIIDKLKHIN QLLRTMSMPK
     GRVLDKNLDE EGFESGDCGD DEDECIGGSG DGMIKVKNQL RFLAELAYDL DVDDAPGNSQ
     QATPKDNEIS TFHNLGNVHS PLKLLTSMAI SVVCFFFLVH
//
ID   GPC3_HUMAN              Reviewed;         580 AA.
AC   P51654; C9JLE3; G3V1R0; Q2L880; Q2L882;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   28-FEB-2018, entry version 167.
DE   RecName: Full=Glypican-3;
DE   AltName: Full=GTR2-2;
DE   AltName: Full=Intestinal protein OCI-5;
DE   AltName: Full=MXR7;
DE   Contains:
DE     RecName: Full=Secreted glypican-3;
DE   Flags: Precursor;
GN   Name=GPC3; Synonyms=OCI5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9021160; DOI=10.1007/s003359900357;
RA   Shen T., Sonoda G., Hamid J., Li M., Filmus J., Buick R.N.,
RA   Testa J.R.;
RT   "Mapping of the Simpson-Golabi-Behmel overgrowth syndrome gene (GPC3)
RT   to chromosome X in human and rat by fluorescence in situ
RT   hybridization.";
RL   Mamm. Genome 8:72-72(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND DISEASE.
RC   TISSUE=Embryo;
RX   PubMed=8589713; DOI=10.1038/ng0396-241;
RA   Pilia G., Hughes-Benzie R.M., Mackenzie A., Baybayan P., Chen E.Y.,
RA   Huber R., Neri G., Cao A., Forabosco A., Schlessinger D.;
RT   "Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel
RT   overgrowth syndrome.";
RL   Nat. Genet. 12:241-247(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9133586; DOI=10.1016/S0378-1119(96)00689-0;
RA   Lage H., Dietel M.;
RT   "Cloning and characterization of human cDNAs encoding a protein with
RT   high homology to rat intestinal development protein OCI-5.";
RL   Gene 188:151-156(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), AND VARIANT MET-429.
RA   Grozdanov P.N., Yovchev M.I., Dabeva M.D.;
RT   "Expression of the Glypican-3 protein in hepatoma cells.";
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-58.
RX   PubMed=9339360; DOI=10.1006/geno.1997.4916;
RA   Huber R., Crisponi L., Mazzarella R., Chen C.N., Su Y., Shizuya H.,
RA   Chen E.Y., Cao A., Pilia G.;
RT   "Analysis of exon/intron structure and 400 kb of genomic sequence
RT   surrounding the 5'-promoter and 3'-terminal ends of the human glypican
RT   3 (GPC3) gene.";
RL   Genomics 45:48-58(1997).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH DPP4.
RX   PubMed=17549790; DOI=10.1002/pmic.200600654;
RA   Davoodi J., Kelly J., Gendron N.H., MacKenzie A.E.;
RT   "The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and
RT   inhibits the dipeptidyl peptidase activity of CD26.";
RL   Proteomics 7:2300-2310(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   PHOSPHORYLATION AT SER-352.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [11]
RP   VARIANT SGBS1 ARG-296.
RX   PubMed=10814714; DOI=10.1093/hmg/9.9.1321;
RA   Veugelers M., Cat B.D., Muyldermans S.Y., Reekmans G., Delande N.,
RA   Frints S., Legius E., Fryns J.-P., Schrander-Stumpel C., Weidle B.,
RA   Magdalena N., David G.;
RT   "Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in
RT   patients with Simpson-Golabi-Behmel syndrome: identification of loss-
RT   of-function mutations in the GPC3 gene.";
RL   Hum. Mol. Genet. 9:1321-1328(2000).
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate.
CC       Inhibits the dipeptidyl peptidase activity of DPP4. May be
CC       involved in the suppression/modulation of growth in the
CC       predominantly mesodermal tissues and organs. May play a role in
CC       the modulation of IGF2 interactions with its receptor and thereby
CC       modulate its function. May regulate growth and tumor
CC       predisposition. {ECO:0000269|PubMed:17549790}.
CC   -!- SUBUNIT: Interacts with DPP4. {ECO:0000269|PubMed:17549790}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Lipid-anchor,
CC       GPI-anchor {ECO:0000250}; Extracellular side {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted glypican-3: Secreted, extracellular
CC       space {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P51654-1; Sequence=Displayed;
CC       Name=2; Synonyms=Variant B;
CC         IsoId=P51654-2; Sequence=VSP_046117;
CC       Name=3; Synonyms=Variant C;
CC         IsoId=P51654-3; Sequence=VSP_046703;
CC   -!- TISSUE SPECIFICITY: Highly expressed in lung, liver and kidney.
CC   -!- DISEASE: Simpson-Golabi-Behmel syndrome 1 (SGBS1) [MIM:312870]: A
CC       condition characterized by pre- and postnatal overgrowth
CC       (gigantism), facial dysmorphism and a variety of inconstant
CC       visceral and skeletal malformations. Characteristic dysmorphic
CC       features include macrocephaly with coarse, distinctive facies with
CC       a large protruding jaw, broad nasal bridge and cleft palate.
CC       Cardiac defects are frequent. {ECO:0000269|PubMed:10814714}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the glypican family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GPC3ID156.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U50410; AAA93471.1; -; mRNA.
DR   EMBL; L47124; AAA98131.1; -; Genomic_DNA.
DR   EMBL; L47125; AAA98132.1; -; mRNA.
DR   EMBL; L47176; AAB58806.1; -; mRNA.
DR   EMBL; Z37987; CAA86069.1; -; mRNA.
DR   EMBL; DQ349136; ABC72125.1; -; mRNA.
DR   EMBL; DQ349138; ABC72127.1; -; mRNA.
DR   EMBL; AL008712; CAI43110.1; -; Genomic_DNA.
DR   EMBL; AC002420; CAI43110.1; JOINED; Genomic_DNA.
DR   EMBL; AF003529; CAI43110.1; JOINED; Genomic_DNA.
DR   EMBL; AL009174; CAI43110.1; JOINED; Genomic_DNA.
DR   EMBL; Z99570; CAI43110.1; JOINED; Genomic_DNA.
DR   EMBL; AL009174; CAI42761.1; -; Genomic_DNA.
DR   EMBL; AC002420; CAI42761.1; JOINED; Genomic_DNA.
DR   EMBL; AF003529; CAI42761.1; JOINED; Genomic_DNA.
DR   EMBL; AL008712; CAI42761.1; JOINED; Genomic_DNA.
DR   EMBL; Z99570; CAI42761.1; JOINED; Genomic_DNA.
DR   EMBL; Z99570; CAI42277.1; -; Genomic_DNA.
DR   EMBL; AC002420; CAI42277.1; JOINED; Genomic_DNA.
DR   EMBL; AF003529; CAI42277.1; JOINED; Genomic_DNA.
DR   EMBL; AL008712; CAI42277.1; JOINED; Genomic_DNA.
DR   EMBL; AL009174; CAI42277.1; JOINED; Genomic_DNA.
DR   EMBL; AL034401; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662851; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z97196; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471107; EAX11771.1; -; Genomic_DNA.
DR   EMBL; AF003529; AAB87062.1; -; Genomic_DNA.
DR   CCDS; CCDS14638.1; -. [P51654-1]
DR   CCDS; CCDS55495.1; -. [P51654-2]
DR   CCDS; CCDS55496.1; -. [P51654-3]
DR   RefSeq; NP_001158089.1; NM_001164617.1. [P51654-3]
DR   RefSeq; NP_001158091.1; NM_001164619.1. [P51654-2]
DR   RefSeq; NP_004475.1; NM_004484.3. [P51654-1]
DR   UniGene; Hs.644108; -.
DR   ProteinModelPortal; P51654; -.
DR   SMR; P51654; -.
DR   BioGrid; 108983; 24.
DR   DIP; DIP-61509N; -.
DR   IntAct; P51654; 5.
DR   STRING; 9606.ENSP00000377836; -.
DR   iPTMnet; P51654; -.
DR   PhosphoSitePlus; P51654; -.
DR   BioMuta; GPC3; -.
DR   DMDM; 1708022; -.
DR   MaxQB; P51654; -.
DR   PaxDb; P51654; -.
DR   PeptideAtlas; P51654; -.
DR   PRIDE; P51654; -.
DR   TopDownProteomics; P51654-1; -. [P51654-1]
DR   DNASU; 2719; -.
DR   Ensembl; ENST00000370818; ENSP00000359854; ENSG00000147257. [P51654-1]
DR   Ensembl; ENST00000394299; ENSP00000377836; ENSG00000147257. [P51654-3]
DR   Ensembl; ENST00000631057; ENSP00000486325; ENSG00000147257. [P51654-2]
DR   GeneID; 2719; -.
DR   KEGG; hsa:2719; -.
DR   UCSC; uc004exe.4; human. [P51654-1]
DR   CTD; 2719; -.
DR   DisGeNET; 2719; -.
DR   EuPathDB; HostDB:ENSG00000147257.13; -.
DR   GeneCards; GPC3; -.
DR   GeneReviews; GPC3; -.
DR   HGNC; HGNC:4451; GPC3.
DR   HPA; HPA006316; -.
DR   MalaCards; GPC3; -.
DR   MIM; 300037; gene.
DR   MIM; 312870; phenotype.
DR   neXtProt; NX_P51654; -.
DR   OpenTargets; ENSG00000147257; -.
DR   Orphanet; 373; Simpson-Golabi-Behmel syndrome.
DR   PharmGKB; PA28832; -.
DR   eggNOG; KOG3821; Eukaryota.
DR   eggNOG; ENOG410XST2; LUCA.
DR   GeneTree; ENSGT00550000074430; -.
DR   HOGENOM; HOG000049177; -.
DR   HOVERGEN; HBG005896; -.
DR   InParanoid; P51654; -.
DR   KO; K08109; -.
DR   OMA; MNPGLPE; -.
DR   OrthoDB; EOG091G06T6; -.
DR   PhylomeDB; P51654; -.
DR   TreeFam; TF105317; -.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3656237; Defective EXT2 causes exostoses 2.
DR   Reactome; R-HSA-3656253; Defective EXT1 causes exostoses 1, TRPS2 and CHDS.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SignaLink; P51654; -.
DR   SIGNOR; P51654; -.
DR   ChiTaRS; GPC3; human.
DR   GeneWiki; Glypican_3; -.
DR   GenomeRNAi; 2719; -.
DR   PRO; PR:P51654; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000147257; -.
DR   CleanEx; HS_GPC3; -.
DR   ExpressionAtlas; P51654; baseline and differential.
DR   Genevisible; P51654; HS.
DR   GO; GO:0046658; C:anchored component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:InterPro.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IEA:InterPro.
DR   GO; GO:0060422; F:peptidyl-dipeptidase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl.
DR   GO; GO:0010171; P:body morphogenesis; IEA:Ensembl.
DR   GO; GO:0030282; P:bone mineralization; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0072203; P:cell proliferation involved in metanephros development; IEA:Ensembl.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0060976; P:coronary vasculature development; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; TAS:Reactome.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0072138; P:mesenchymal cell proliferation involved in ureteric bud development; ISS:UniProtKB.
DR   GO; GO:0072180; P:mesonephric duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl.
DR   GO; GO:0045879; P:negative regulation of smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:2000096; P:positive regulation of Wnt signaling pathway, planar cell polarity pathway; IEA:Ensembl.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR015501; Glypican-3.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; PTHR10822; 1.
DR   PANTHER; PTHR10822:SF4; PTHR10822:SF4; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Glycoprotein; GPI-anchor; Heparan sulfate;
KW   Lipoprotein; Membrane; Phosphoprotein; Protease inhibitor;
KW   Proteoglycan; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25      ?       Glypican-3.
FT                                /FTId=PRO_0000012309.
FT   CHAIN        25      ?       Secreted glypican-3.
FT                                /FTId=PRO_0000333844.
FT   PROPEP        ?    580       Removed in mature form. {ECO:0000255}.
FT                                /FTId=PRO_0000012310.
FT   MOD_RES     352    352       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   CARBOHYD    124    124       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    418    418       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    495    495       O-linked (Xyl...) (heparan sulfate)
FT                                serine. {ECO:0000255}.
FT   CARBOHYD    509    509       O-linked (Xyl...) (heparan sulfate)
FT                                serine. {ECO:0000255}.
FT   VAR_SEQ      59    112       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_046117.
FT   VAR_SEQ     344    344       T -> TETEKKIWHFKYPIFFLCIGLDLQ (in isoform
FT                                3). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_046703.
FT   VARIANT     296    296       W -> R (in SGBS1; dbSNP:rs104894854).
FT                                {ECO:0000269|PubMed:10814714}.
FT                                /FTId=VAR_021385.
FT   VARIANT     429    429       V -> M (in dbSNP:rs11539789).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_069139.
SQ   SEQUENCE   580 AA;  65563 MW;  19485B76D3CE15FC CRC64;
     MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS
     DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSASMEL KFLIIQNAAV FQEAFEIVVR
     HAKNYTNAMF KNNYPSLTPQ AFEFVGEFFT DVSLYILGSD INVDDMVNEL FDSLFPVIYT
     QLMNPGLPDS ALDINECLRG ARRDLKVFGN FPKLIMTQVS KSLQVTRIFL QALNLGIEVI
     NTTDHLKFSK DCGRMLTRMW YCSYCQGLMM VKPCGGYCNV VMQGCMAGVV EIDKYWREYI
     LSLEELVNGM YRIYDMENVL LGLFSTIHDS IQYVQKNAGK LTTTIGKLCA HSQQRQYRSA
     YYPEDLFIDK KVLKVAHVEH EETLSSRRRE LIQKLKSFIS FYSALPGYIC SHSPVAENDT
     LCWNGQELVE RYSQKAARNG MKNQFNLHEL KMKGPEPVVS QIIDKLKHIN QLLRTMSMPK
     GRVLDKNLDE EGFESGDCGD DEDECIGGSG DGMIKVKNQL RFLAELAYDL DVDDAPGNSQ
     QATPKDNEIS TFHNLGNVHS PLKLLTSMAI SVVCFFFLVH
//
ID   Q53H15_HUMAN            Unreviewed;       580 AA.
AC   Q53H15;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   28-FEB-2018, entry version 76.
DE   SubName: Full=Glypican 3 variant {ECO:0000313|EMBL:BAD96486.1};
DE   SubName: Full=Glypican-3 splice variant A {ECO:0000313|EMBL:ABC72126.1};
DE   Flags: Fragment;
GN   Name=GPC3 {ECO:0000313|EMBL:ABC72126.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD96486.1};
RN   [1] {ECO:0000313|EMBL:BAD96486.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver {ECO:0000313|EMBL:BAD96486.1};
RX   PubMed=8125298; DOI=10.1016/0378-1119(94)90802-8;
RA   Maruyama K., Sugano S.;
RT   "Oligo-capping: a simple method to replace the cap structure of
RT   eukaryotic mRNAs with oligoribonucleotides.";
RL   Gene 138:171-174(1994).
RN   [2] {ECO:0000313|EMBL:BAD96486.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver {ECO:0000313|EMBL:BAD96486.1};
RX   PubMed=9373149; DOI=10.1016/S0378-1119(97)00411-3;
RA   Suzuki Y., Yoshitomo K., Maruyama K., Suyama A., Sugano S.;
RT   "Construction and characterization of a full length-enriched and a 5'-
RT   end-enriched cDNA library.";
RL   Gene 200:149-156(1997).
RN   [3] {ECO:0000313|EMBL:BAD96486.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver {ECO:0000313|EMBL:BAD96486.1};
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000313|EMBL:ABC72126.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Grozdanov P.N., Yovchev M.I., Dabeva M.D.;
RT   "Expression of the Glypican-3 protein in hepatoma cells.";
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Cell surface proteoglycan that bears heparan sulfate.
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000256|RuleBase:RU003519}; Lipid-anchor, GPI-anchor
CC       {ECO:0000256|RuleBase:RU003519}.
CC   -!- SIMILARITY: Belongs to the glypican family.
CC       {ECO:0000256|RuleBase:RU003518}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ349137; ABC72126.1; -; mRNA.
DR   EMBL; AK222761; BAD96481.1; -; mRNA.
DR   EMBL; AK222766; BAD96486.1; -; mRNA.
DR   RefSeq; NP_001158089.1; NM_001164617.1.
DR   RefSeq; NP_001158090.1; NM_001164618.1.
DR   RefSeq; NP_001158091.1; NM_001164619.1.
DR   RefSeq; NP_004475.1; NM_004484.3.
DR   UniGene; Hs.644108; -.
DR   PeptideAtlas; Q53H15; -.
DR   DNASU; 2719; -.
DR   GeneID; 2719; -.
DR   KEGG; hsa:2719; -.
DR   CTD; 2719; -.
DR   PharmGKB; PA28832; -.
DR   eggNOG; KOG3821; Eukaryota.
DR   eggNOG; ENOG410XST2; LUCA.
DR   HOVERGEN; HBG005896; -.
DR   KO; K08109; -.
DR   ChiTaRS; GPC3; human.
DR   GenomeRNAi; 2719; -.
DR   GO; GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:InterPro.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; IEA:InterPro.
DR   InterPro; IPR001863; Glypican.
DR   InterPro; IPR015501; Glypican-3.
DR   InterPro; IPR019803; Glypican_CS.
DR   PANTHER; PTHR10822; PTHR10822; 1.
DR   PANTHER; PTHR10822:SF4; PTHR10822:SF4; 1.
DR   Pfam; PF01153; Glypican; 1.
DR   PROSITE; PS01207; GLYPICAN; 1.
PE   2: Evidence at transcript level;
KW   Glycoprotein {ECO:0000256|RuleBase:RU003519};
KW   GPI-anchor {ECO:0000256|RuleBase:RU003519};
KW   Heparan sulfate {ECO:0000256|RuleBase:RU003519};
KW   Lipoprotein {ECO:0000256|RuleBase:RU003519};
KW   Membrane {ECO:0000256|RuleBase:RU003519};
KW   Proteoglycan {ECO:0000256|RuleBase:RU003519};
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL        1     24       {ECO:0000256|SAM:SignalP}.
FT   CHAIN        25    580       {ECO:0000256|SAM:SignalP}.
FT                                /FTId=PRO_5010139063.
FT   NON_TER       1      1       {ECO:0000313|EMBL:BAD96486.1}.
SQ   SEQUENCE   580 AA;  65595 MW;  ECA8BADDD3D4A45C CRC64;
     MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS
     DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSASMEL KFLIIQNAAV FQEAFEIVVR
     HAKNYTNAMF KNNYPSLTPQ AFEFVGEFFT DVSLYILGSD INVDDMVNEL FDSLFPVIYT
     QLMNPGLPDS ALDINECLRG ARRDLKVFGN FPKLIMTQVS KSLQVTRIFL QALNLGIEVI
     NTTDHLKFSK DCGRMLTRMW YCSYCQGLMM VKPCGGYCNV VMQGCMAGVV EIDKYWREYI
     LSLEELVNGM YRIYDMENVL LGLFSTIHDS IQYVQKNAGK LTTTIGKLCA HSQQRQYRSA
     YYPEDLFIDK KVLKVAHVEH EETLSSRRRE LIQKLKSFIS FYSALPGYIC SHSPVAENDT
     LCWNGQELME RYSQKAARNG MKNQFNLHEL KMKGPEPVVS QIIDKLKHIN QLLRTMSMPK
     GRVLDKNLDE EGFESGDCGD DEDECIGGSG DGMIKVKNQL RFLAELAYDL DVDDAPGNSQ
     QATPKDNEIS TFHNLGNVHS PLKLLTSMAI SVVCFFFLVH
//
ID   IRS4_HUMAN              Reviewed;        1257 AA.
AC   O14654;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   28-FEB-2018, entry version 152.
DE   RecName: Full=Insulin receptor substrate 4;
DE            Short=IRS-4;
DE   AltName: Full=160 kDa phosphotyrosine protein;
DE            Short=py160;
DE   AltName: Full=Phosphoprotein of 160 kDa;
DE            Short=pp160;
GN   Name=IRS4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 100-117; 233-240;
RP   613-618; 836-843 AND 844-852, AND PHOSPHORYLATION.
RC   TISSUE=Kidney;
RX   PubMed=9261155; DOI=10.1074/jbc.272.34.21403;
RA   Lavan B.E., Fantin V.R., Chang E.T., Lane W.S., Keller S.R.,
RA   Lienhard G.E.;
RT   "A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic
RT   kidney cells is a new member of the insulin receptor substrate
RT   family.";
RL   J. Biol. Chem. 272:21403-21407(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH GRB2 AND PIK3R1, AND
RP   PHOSPHORYLATION.
RX   PubMed=9553137; DOI=10.1074/jbc.273.17.10726;
RA   Fantin V.R., Sparling J.D., Slot J.W., Keller S.R., Lienhard G.E.,
RA   Lavan B.E.;
RT   "Characterization of insulin receptor substrate 4 in human embryonic
RT   kidney 293 cells.";
RL   J. Biol. Chem. 273:10726-10732(1998).
RN   [5]
RP   INTERACTION WITH CRK AND CRKL.
RX   PubMed=9614078; DOI=10.1074/jbc.273.24.14780;
RA   Koval A.P., Karas M., Zick Y., LeRoith D.;
RT   "Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-
RT   like growth factor-I receptor-mediated signal transduction.";
RL   J. Biol. Chem. 273:14780-14787(1998).
RN   [6]
RP   FUNCTION.
RX   PubMed=10531310; DOI=10.1074/jbc.274.44.31179;
RA   Qu B.-H., Karas M., Koval A., LeRoith D.;
RT   "Insulin receptor substrate-4 enhances insulin-like growth factor-I-
RT   induced cell proliferation.";
RL   J. Biol. Chem. 274:31179-31184(1999).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH GRB2 AND PIK3R1.
RX   PubMed=10594015; DOI=10.1128/MCB.20.1.126-138.2000;
RA   Uchida T., Myers M.G. Jr., White M.F.;
RT   "IRS-4 mediates protein kinase B signaling during insulin stimulation
RT   without promoting antiapoptosis.";
RL   Mol. Cell. Biol. 20:126-138(2000).
RN   [8]
RP   INTERACTION WITH CRK, AND MUTAGENESIS OF TYR-700; TYR-717; TYR-743 AND
RP   TYR-779.
RX   PubMed=11316748; DOI=10.1210/endo.142.5.8135;
RA   Karas M., Koval A.P., Zick Y., LeRoith D.;
RT   "The insulin-like growth factor I receptor-induced interaction of
RT   insulin receptor substrate-4 and Crk-II.";
RL   Endocrinology 142:1835-1840(2001).
RN   [9]
RP   INTERACTION WITH NISCH.
RX   PubMed=11912194; DOI=10.1074/jbc.M111838200;
RA   Sano H., Liu S.C.H., Lane W.S., Piletz J.E., Lienhard G.E.;
RT   "Insulin receptor substrate 4 associates with the protein IRAS.";
RL   J. Biol. Chem. 277:19439-19447(2002).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=12639902; DOI=10.1210/en.2002-220723;
RA   Schreyer S., Ledwig D., Rakatzi I., Kloeting I., Eckel J.;
RT   "Insulin receptor substrate-4 is expressed in muscle tissue without
RT   acting as a substrate for the insulin receptor.";
RL   Endocrinology 144:1211-1218(2003).
RN   [11]
RP   PHOSPHORYLATION AT TYR-921, INTERACTION WITH SHC1; GRB2; PHOSPHOLIPASE
RP   C-GAMMA AND PHOSPHATIDYLINOSITOL 3-KINASE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=15316024; DOI=10.1074/jbc.M404537200;
RA   Hinsby A.M., Olsen J.V., Mann M.;
RT   "Tyrosine phosphoproteomics of fibroblast growth factor signaling: a
RT   role for insulin receptor substrate-4.";
RL   J. Biol. Chem. 279:46438-46447(2004).
RN   [12]
RP   INTERACTION WITH PPP4C, INDUCTION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=15331607; DOI=10.1074/jbc.M408067200;
RA   Mihindukulasuriya K.A., Zhou G., Qin J., Tan T.-H.;
RT   "Protein phosphatase 4 interacts with and down-regulates insulin
RT   receptor substrate 4 following tumor necrosis factor-alpha
RT   stimulation.";
RL   J. Biol. Chem. 279:46588-46594(2004).
RN   [13]
RP   INTERACTION WITH PTK6, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15870689; DOI=10.1038/sj.onc.1208721;
RA   Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.;
RT   "Interaction between Brk kinase and insulin receptor substrate-4.";
RL   Oncogene 24:5656-5664(2005).
RN   [14]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17408801; DOI=10.1016/j.jhep.2007.01.031;
RA   Cuevas E.P., Escribano O., Chiloeches A., Ramirez Rubio S.,
RA   Roman I.D., Fernandez-Moreno M.D., Guijarro L.G.;
RT   "Role of insulin receptor substrate-4 in IGF-I-stimulated HEPG2
RT   proliferation.";
RL   J. Hepatol. 46:1089-1098(2007).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-20; GLU-215 AND ARG-557.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Acts as an interface between multiple growth factor
CC       receptors possessing tyrosine kinase activity, such as insulin
CC       receptor, IGF1R and FGFR1, and a complex network of intracellular
CC       signaling molecules containing SH2 domains. Involved in the IGF1R
CC       mitogenic signaling pathway. Promotes the AKT1 signaling pathway
CC       and BAD phosphorylation during insulin stimulation without
CC       activation of RPS6KB1 or the inhibition of apoptosis. Interaction
CC       with GRB2 enhances insulin-stimulated mitogen-activated protein
CC       kinase activity. May be involved in nonreceptor tyrosine kinase
CC       signaling in myoblasts. Plays a pivotal role in the
CC       proliferation/differentiation of hepatoblastoma cell through EPHB2
CC       activation upon IGF1 stimulation. May play a role in the signal
CC       transduction in response to insulin and to a lesser extent in
CC       response to IL4 and GH on mitogenesis. Plays a role in growth,
CC       reproduction and glucose homeostasis. May act as negative
CC       regulators of the IGF1 signaling pathway by suppressing the
CC       function of IRS1 and IRS2. {ECO:0000269|PubMed:10531310,
CC       ECO:0000269|PubMed:10594015, ECO:0000269|PubMed:12639902,
CC       ECO:0000269|PubMed:17408801, ECO:0000269|PubMed:9553137}.
CC   -!- SUBUNIT: Interacts with SOCS6 in response to stimulation with
CC       either insulin or IGF1 (By similarity). Interacts with CRK and
CC       CRKL. Interaction with CRK is stronger than with CRKL. Interacts
CC       with CRK via the phosphorylated YXXM motifs. Interacts with GRB2
CC       and PIK3R1. Interacts with PLC-gamma, SHC1, PTK6, PPP4C and NISCH.
CC       {ECO:0000250, ECO:0000269|PubMed:10594015,
CC       ECO:0000269|PubMed:11316748, ECO:0000269|PubMed:11912194,
CC       ECO:0000269|PubMed:15316024, ECO:0000269|PubMed:15331607,
CC       ECO:0000269|PubMed:15870689, ECO:0000269|PubMed:9553137,
CC       ECO:0000269|PubMed:9614078}.
CC   -!- INTERACTION:
CC       P46108:CRK; NbExp=8; IntAct=EBI-356594, EBI-886;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-356594, EBI-297353;
CC       Q15185:PTGES3; NbExp=2; IntAct=EBI-356594, EBI-1049387;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:9553137};
CC       Peripheral membrane protein {ECO:0000269|PubMed:9553137};
CC       Cytoplasmic side {ECO:0000269|PubMed:9553137}.
CC   -!- TISSUE SPECIFICITY: Expressed in myoblasts. Expressed in liver and
CC       hepatocellular carcinoma. {ECO:0000269|PubMed:12639902,
CC       ECO:0000269|PubMed:17408801}.
CC   -!- INDUCTION: Down-regulated by PPP4C in a phosphatase activity-
CC       dependent manner. {ECO:0000269|PubMed:15331607}.
CC   -!- PTM: Phosphorylated on tyrosine residues in response to both
CC       insulin and IGF1 signaling. Phosphorylated on Tyr-921 in response
CC       to FGF2 signaling. Phosphorylation of Tyr-921 is required for
CC       GRB2, phospholipase C-gamma and phosphatidylinositol 3-kinase
CC       interaction. {ECO:0000269|PubMed:15316024,
CC       ECO:0000269|PubMed:9261155, ECO:0000269|PubMed:9553137}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF007567; AAC51738.1; -; mRNA.
DR   EMBL; AL035425; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471120; EAX02682.1; -; Genomic_DNA.
DR   CCDS; CCDS14544.1; -.
DR   RefSeq; NP_003595.1; NM_003604.2.
DR   UniGene; Hs.407141; -.
DR   UniGene; Hs.460872; -.
DR   ProteinModelPortal; O14654; -.
DR   SMR; O14654; -.
DR   BioGrid; 114048; 105.
DR   IntAct; O14654; 92.
DR   MINT; O14654; -.
DR   STRING; 9606.ENSP00000361202; -.
DR   iPTMnet; O14654; -.
DR   PhosphoSitePlus; O14654; -.
DR   BioMuta; IRS4; -.
DR   EPD; O14654; -.
DR   MaxQB; O14654; -.
DR   PaxDb; O14654; -.
DR   PeptideAtlas; O14654; -.
DR   PRIDE; O14654; -.
DR   DNASU; 8471; -.
DR   Ensembl; ENST00000372129; ENSP00000361202; ENSG00000133124.
DR   GeneID; 8471; -.
DR   KEGG; hsa:8471; -.
DR   UCSC; uc004eoc.3; human.
DR   CTD; 8471; -.
DR   DisGeNET; 8471; -.
DR   EuPathDB; HostDB:ENSG00000133124.11; -.
DR   GeneCards; IRS4; -.
DR   HGNC; HGNC:6128; IRS4.
DR   HPA; HPA017372; -.
DR   MIM; 300904; gene.
DR   neXtProt; NX_O14654; -.
DR   OpenTargets; ENSG00000133124; -.
DR   PharmGKB; PA29923; -.
DR   eggNOG; ENOG410IXEK; Eukaryota.
DR   eggNOG; ENOG410Z9EP; LUCA.
DR   GeneTree; ENSGT00530000063420; -.
DR   HOGENOM; HOG000113104; -.
DR   HOVERGEN; HBG107140; -.
DR   InParanoid; O14654; -.
DR   KO; K17446; -.
DR   OMA; DPFSECC; -.
DR   OrthoDB; EOG091G02EF; -.
DR   PhylomeDB; O14654; -.
DR   TreeFam; TF325994; -.
DR   Reactome; R-HSA-2428928; IRS-related events triggered by IGF1R.
DR   SignaLink; O14654; -.
DR   SIGNOR; O14654; -.
DR   GeneWiki; IRS4; -.
DR   GenomeRNAi; 8471; -.
DR   PRO; PR:O14654; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000133124; -.
DR   CleanEx; HS_IRS4; -.
DR   Genevisible; O14654; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005158; F:insulin receptor binding; IBA:GO_Central.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IBA:GO_Central.
DR   GO; GO:0005070; F:SH3/SH2 adaptor activity; TAS:ProtInc.
DR   GO; GO:0004871; F:signal transducer activity; IBA:GO_Central.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd01204; PTB_IRS; 1.
DR   Gene3D; 2.30.29.30; -; 2.
DR   InterPro; IPR002404; IRS_PTB.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   Pfam; PF02174; IRS; 1.
DR   PRINTS; PR00628; INSULINRSI.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00310; PTBI; 1.
DR   SUPFAM; SSF50729; SSF50729; 2.
DR   PROSITE; PS51064; IRS_PTB; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Direct protein sequencing; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Transducer.
FT   CHAIN         1   1257       Insulin receptor substrate 4.
FT                                /FTId=PRO_0000314678.
FT   DOMAIN       78    199       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      231    335       IRS-type PTB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00389}.
FT   REGION      678    800       CRK-binding.
FT   REGION      895    897       GRB2-binding.
FT   MOTIF       487    490       YXXM motif 1.
FT   MOTIF       700    703       YXXM motif 2.
FT   MOTIF       717    720       YXXM motif 3.
FT   MOTIF       743    746       YXXM motif 4.
FT   MOTIF       779    782       YXXM motif 5.
FT   MOTIF       828    831       YXXM motif 6.
FT   MOTIF       921    924       YXXM motif 7.
FT   COMPBIAS     18     28       Poly-Ala.
FT   COMPBIAS    124    137       Ala-rich.
FT   COMPBIAS    218    226       Poly-Ala.
FT   COMPBIAS    628    639       Pro-rich.
FT   COMPBIAS   1094   1212       Ala-rich.
FT   MOD_RES     921    921       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15316024}.
FT   VARIANT      20     20       A -> V (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_038042.
FT   VARIANT      34     34       L -> F (in dbSNP:rs1801162).
FT                                /FTId=VAR_051078.
FT   VARIANT     215    215       G -> E (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_038043.
FT   VARIANT     508    508       N -> K (in dbSNP:rs34287560).
FT                                /FTId=VAR_051079.
FT   VARIANT     557    557       G -> R (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_038044.
FT   VARIANT     879    879       H -> D (in dbSNP:rs1801164).
FT                                /FTId=VAR_051080.
FT   VARIANT    1230   1230       D -> Y (in dbSNP:rs28546943).
FT                                /FTId=VAR_061669.
FT   MUTAGEN     700    700       Y->F: No effect. Reduces interaction with
FT                                CRK by 50%; when associated with F-717.
FT                                Abolishes interaction with CRK; when
FT                                associated with F-717; F-743 and F-779.
FT                                {ECO:0000269|PubMed:11316748}.
FT   MUTAGEN     717    717       Y->F: No effect. Reduces interaction with
FT                                CRK by 50%; when associated with F-700.
FT                                Abolishes interaction with CRK; when
FT                                associated with F-700; F-743 and F-779.
FT                                {ECO:0000269|PubMed:11316748}.
FT   MUTAGEN     743    743       Y->F: No effect. Reduces interaction with
FT                                CRK by 50%; when associated with F-779.
FT                                Abolishes interaction with CRK; when
FT                                associated with F-700; F-717 and F-779.
FT                                {ECO:0000269|PubMed:11316748}.
FT   MUTAGEN     779    779       Y->F: No effect. Reduces interaction with
FT                                CRK by 50%; when associated with F-743.
FT                                Abolishes interaction with CRK; when
FT                                associated with F-700; F-717 and F-743.
FT                                {ECO:0000269|PubMed:11316748}.
SQ   SEQUENCE   1257 AA;  133768 MW;  4D512D65A7A80374 CRC64;
     MASCSFTRDQ ATRRLRGAAA AAAAALAAVV TTPLLSSGTP TALIGTGSSC PGAMWLSTAT
     GSRSDSESEE EDLPVGEEVC KRGYLRKQKH GHRRYFVLKL ETADAPARLE YYENARKFRH
     SVRAAAAAAA AAASGAAIPP LIPPRRVITL YQCFSVSQRA DARYRHLIAL FTQDEYFAMV
     AENESEQESW YLLLSRLILE SKRRRCGTLG AQPDGEPAAL AAAAAAEPPF YKDVWQVIVK
     PRGLGHRKEL SGVFRLCLTD EEVVFVRLNT EVASVVVQLL SIRRCGHSEQ YFFLEVGRST
     VIGPGELWMQ VDDCVVAQNM HELFLEKMRA LCADEYRARC RSYSISIGAH LLTLLSARRH
     LGLVPLEPGG WLRRSRFEQF CHLRAIGDGE DEMLFTRRFV TPSEPVAHSR RGRLHLPRGR
     RSRRAVSVPA SFFRRLAPSP ARPRHPAEAP NNGARLSSEV SGSGSGNFGE EGNPQGKEDQ
     EGSGGDYMPM NNWGSGNGRG SGGGQGSNGQ GSSSHSSGGN QCSGEGQGSR GGQGSNGQGS
     GGNQCSRDGQ GTAGGHGSGG GQRPGGGHGS GGGQGPGDGH GSGGGKNSGG GKGSGSGKGS
     DGDGERGKSL KKRSYFGKLT QSKQQQMPPP PPPPPPPPPA GGTGGKGKSG GRFRLYFCVD
     RGATKECKEA KEVKDAEIPE GAARGPHRAR AFDEDEDDPY VPMRPGVATP LVSSSDYMPM
     APQNVSASKK RHSRSPFEDS RGYMMMFPRV SPPPAPSPPK APDTNKEDDS KDNDSESDYM
     FMAPGAGAIP KNPRNPQGGS SSKSWSSYFS LPNPFRSSPL GQNDNSEYVP MLPGKFLGRG
     LDKEVSYNWD PKDAASKPSG EGSFSKPGDG GSPSKPSDHE PPKNKAKRPN RLSFITKGYK
     IKPKPQKPTH EQREADSSSD YVNMDFTKRE SNTPAPSTQG LPDSWGIIAE PRQSAFSNYV
     NVEFGVPFPN PANDLSDLLR AIPRANPLSL DSARWPLPPL PLSATGSNAI EEEGDYIEVI
     FNSAMTPAMA LADSAIRYDA ETGRIYVVDP FSECCMDISL SPSRCSEPPP VARLLQEEEQ
     ERRRPQSRSQ SFFAAARAAV SAFPTDSLER DLSPSSAPAV ASAAEPTLAL SQVVAAASAL
     AAAPGIGAAA AAAGFDSASA RWFQPVANAA DAEAVRGAQD VAGGSNPGAH NPSANLARGD
     NQAGGAAAAA AAPEPPPRSR RVPRPPERED SDNDDDTHVR MDFARRDNQF DSPKRGR
//
ID   JAK1_HUMAN              Reviewed;        1154 AA.
AC   P23458; Q59GQ2; Q9UD26;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   28-FEB-2018, entry version 199.
DE   RecName: Full=Tyrosine-protein kinase JAK1;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:1848670, ECO:0000269|PubMed:7615558};
DE   AltName: Full=Janus kinase 1;
DE            Short=JAK-1;
GN   Name=JAK1; Synonyms=JAK1A, JAK1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY.
RX   PubMed=1848670; DOI=10.1128/MCB.11.4.2057;
RA   Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zuercher G.,
RA   Ziemiecki A.;
RT   "Two novel protein-tyrosine kinases, each with a second
RT   phosphotransferase-related catalytic domain, define a new class of
RT   protein kinase.";
RL   Mol. Cell. Biol. 11:2057-2065(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1005-1062.
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1008-1062, AND TISSUE SPECIFICITY.
RC   TISSUE=Colon tumor;
RX   PubMed=7896447; DOI=10.1002/ijc.2910600611;
RA   Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A.,
RA   Srivastava S., Varnum B., Liu E.T., Cance W.G.;
RT   "Receptor tyrosine kinases expressed in metastatic colon cancer.";
RL   Int. J. Cancer 60:791-797(1995).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH IFNGR1, AND
RP   PHOSPHORYLATION.
RX   PubMed=7615558; DOI=10.1074/jbc.270.29.17528;
RA   Sakatsume M., Igarashi K., Winestock K.D., Garotta G., Larner A.C.,
RA   Finbloom D.S.;
RT   "The Jak kinases differentially associate with the alpha and beta
RT   (accessory factor) chains of the interferon gamma receptor to form a
RT   functional receptor unit capable of activating STAT transcription
RT   factors.";
RL   J. Biol. Chem. 270:17528-17534(1995).
RN   [9]
RP   INTERACTION WITH IFNAR2.
RX   PubMed=7759950;
RA   Novick D., Cohen B., Tal N., Rubinstein M.;
RT   "Soluble and membrane-anchored forms of the human IFN-alpha/beta
RT   receptor.";
RL   J. Leukoc. Biol. 57:712-718(1995).
RN   [10]
RP   INTERACTION WITH SHB.
RX   PubMed=12200137; DOI=10.1016/S0006-291X(02)02016-8;
RA   Lindholm C.K.;
RT   "IL-2 receptor signaling through the Shb adapter protein in T and NK
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 296:929-936(2002).
RN   [11]
RP   FUNCTION IN CYTOKINE SIGNALING, PHOSPHORYLATION AT TYR-1034 AND
RP   TYR-1035, AND DEPHOSPHORYLATION AT TYR-1034 AND TYR-1035 BY PTPN2.
RX   PubMed=11909529; DOI=10.1016/S0960-9822(02)00697-8;
RA   Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J.;
RT   "The T cell protein tyrosine phosphatase is a negative regulator of
RT   janus family kinases 1 and 3.";
RL   Curr. Biol. 12:446-453(2002).
RN   [12]
RP   INTERACTION WITH IL31RA.
RX   PubMed=15194700; DOI=10.1074/jbc.M401122200;
RA   Dreuw A., Radtke S., Pflanz S., Lippok B.E., Heinrich P.C.,
RA   Hermanns H.M.;
RT   "Characterization of the signaling capacities of the novel gp130-like
RT   cytokine receptor.";
RL   J. Biol. Chem. 279:36112-36120(2004).
RN   [13]
RP   INTERACTION WITH JAKMIP1.
RX   PubMed=15277531; DOI=10.1074/jbc.M401915200;
RA   Steindler C., Li Z., Algarte M., Alcover A., Libri V., Ragimbeau J.,
RA   Pellegrini S.;
RT   "Jamip1 (marlin-1) defines a family of proteins interacting with Janus
RT   kinases and microtubules.";
RL   J. Biol. Chem. 279:43168-43177(2004).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT TYR-3 AND SER-228, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   UBIQUITINATION.
RX   PubMed=26027934; DOI=10.1016/j.celrep.2015.04.049;
RA   Kim H., Frederick D.T., Levesque M.P., Cooper Z.A., Feng Y.,
RA   Krepler C., Brill L., Samuels Y., Hayward N.K., Perlina A., Piris A.,
RA   Zhang T., Halaban R., Herlyn M.M., Brown K.M., Wargo J.A., Dummer R.,
RA   Flaherty K.T., Ronai Z.A.;
RT   "Downregulation of the ubiquitin ligase RNF125 underlies resistance of
RT   melanoma cells to BRAF inhibitors via JAK1 deregulation.";
RL   Cell Rep. 11:1458-1473(2015).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 865-1154 IN COMPLEXES WITH
RP   SYNTHETIC INHIBITORS CMP6 AND CP-690,550.
RX   PubMed=19361440; DOI=10.1016/j.jmb.2009.01.041;
RA   Williams N.K., Bamert R.S., Patel O., Wang C., Walden P.M.,
RA   Wilks A.F., Fantino E., Rossjohn J., Lucet I.S.;
RT   "Dissecting specificity in the Janus kinases: the structures of JAK-
RT   specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine
RT   kinase domains.";
RL   J. Mol. Biol. 387:219-232(2009).
RN   [19]
RP   VARIANT [LARGE SCALE ANALYSIS] LYS-973.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine kinase of the non-receptor type, involved in
CC       the IFN-alpha/beta/gamma signal pathway (PubMed:7615558). Kinase
CC       partner for the interleukin (IL)-2 receptor (PubMed:11909529).
CC       {ECO:0000269|PubMed:11909529, ECO:0000269|PubMed:7615558}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:1848670,
CC       ECO:0000269|PubMed:7615558}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000305|PubMed:7615558};
CC       Note=Mn(2+) was used in the in vitro kinase assay but Mg(2+) is
CC       likely to be the in vivo cofactor. {ECO:0000305|PubMed:7615558};
CC   -!- SUBUNIT: Interacts with IL31RA (PubMed:15194700). Interacts with
CC       IFNAR2 (PubMed:7759950). Interacts with IFNGR1 (PubMed:7615558).
CC       Interacts with JAKMIP1 (PubMed:15277531). Interacts with SHB
CC       (PubMed:12200137). Interacts with FER (By similarity).
CC       {ECO:0000250|UniProtKB:P52332, ECO:0000269|PubMed:12200137,
CC       ECO:0000269|PubMed:15194700, ECO:0000269|PubMed:15277531,
CC       ECO:0000269|PubMed:7615558, ECO:0000269|PubMed:7759950}.
CC   -!- INTERACTION:
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-1383438, EBI-641062;
CC       P48551:IFNAR2; NbExp=3; IntAct=EBI-1383438, EBI-958408;
CC       P40189-1:IL6ST; NbExp=3; IntAct=EBI-1383438, EBI-15742214;
CC       O60674:JAK2; NbExp=4; IntAct=EBI-1383438, EBI-518647;
CC   -!- SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane
CC       protein. Note=Wholly intracellular, possibly membrane associated.
CC   -!- TISSUE SPECIFICITY: Expressed at higher levels in primary colon
CC       tumors than in normal colon tissue. The expression level in
CC       metastatic colon tumors is comparable to the expression level in
CC       normal colon tissue. {ECO:0000269|PubMed:7896447}.
CC   -!- DOMAIN: Possesses two phosphotransferase domains. The second one
CC       probably contains the catalytic domain, while the presence of
CC       slight differences suggest a different role for domain 1.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The FERM domain mediates interaction with JAKMIP1.
CC   -!- PTM: Autophosphorylated (PubMed:7615558). Phosphorylated on
CC       tyrosine residues in response to interferon gamma signaling
CC       (PubMed:7615558). Dephosphorylation of Tyr-1034 and Tyr-1035 by
CC       PTPN2 negatively regulates cytokine-mediated signaling
CC       (PubMed:11909529). {ECO:0000269|PubMed:11909529,
CC       ECO:0000269|PubMed:7615558}.
CC   -!- PTM: Ubiquitinated by RNF125; leading to its degradation by the
CC       proteasome. {ECO:0000269|PubMed:26027934}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. JAK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36527.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAA36527.1; Type=Frameshift; Positions=858, 862; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JAK1ID41031ch1p31.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M64174; AAA36527.1; ALT_SEQ; mRNA.
DR   EMBL; AB209057; BAD92294.1; -; mRNA.
DR   EMBL; AC093427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX06547.1; -; Genomic_DNA.
DR   EMBL; BC132729; AAI32730.1; -; mRNA.
DR   CCDS; CCDS41346.1; -.
DR   PIR; A39577; A39577.
DR   RefSeq; NP_001307852.1; NM_001320923.1.
DR   RefSeq; NP_001308781.1; NM_001321852.1.
DR   RefSeq; NP_001308782.1; NM_001321853.1.
DR   RefSeq; NP_001308783.1; NM_001321854.1.
DR   RefSeq; NP_001308784.1; NM_001321855.1.
DR   RefSeq; NP_001308785.1; NM_001321856.1.
DR   RefSeq; NP_002218.2; NM_002227.3.
DR   UniGene; Hs.207538; -.
DR   PDB; 3EYG; X-ray; 1.90 A; A=865-1154.
DR   PDB; 3EYH; X-ray; 2.00 A; A=865-1154.
DR   PDB; 4E4L; X-ray; 2.00 A; A/B/D/E=854-1154.
DR   PDB; 4E4N; X-ray; 1.90 A; A/B=854-1154.
DR   PDB; 4E5W; X-ray; 1.86 A; A/B=854-1154.
DR   PDB; 4EHZ; X-ray; 2.17 A; A/B/C/D=854-1154.
DR   PDB; 4EI4; X-ray; 2.22 A; A/B=854-1154.
DR   PDB; 4FK6; X-ray; 2.20 A; A/B=854-1154.
DR   PDB; 4GS0; X-ray; 1.80 A; C=1033-1036.
DR   PDB; 4I5C; X-ray; 2.10 A; A/B=854-1154.
DR   PDB; 4IVB; X-ray; 1.90 A; A/B=854-1154.
DR   PDB; 4IVC; X-ray; 2.35 A; A/B=854-1154.
DR   PDB; 4IVD; X-ray; 1.93 A; A/B=854-1154.
DR   PDB; 4K6Z; X-ray; 2.73 A; A=854-1154.
DR   PDB; 4K77; X-ray; 2.40 A; A/B=854-1154.
DR   PDB; 4L00; X-ray; 1.80 A; A/B=561-860.
DR   PDB; 4L01; X-ray; 1.90 A; A/B=561-860.
DR   PDB; 5E1E; X-ray; 2.30 A; A/B=865-1154.
DR   PDB; 5HX8; X-ray; 2.20 A; A/B=854-1154.
DR   PDB; 5IXD; X-ray; 2.85 A; A=35-559.
DR   PDB; 5IXI; X-ray; 2.57 A; A=35-559.
DR   PDB; 5KHW; X-ray; 2.47 A; A/B=841-1154.
DR   PDB; 5KHX; X-ray; 2.40 A; A=841-1154.
DR   PDB; 5L04; X-ray; 2.10 A; A=31-577.
DR   PDB; 5WO4; X-ray; 1.84 A; A/B=854-1154.
DR   PDB; 6BBU; X-ray; 2.08 A; A=841-1154.
DR   PDBsum; 3EYG; -.
DR   PDBsum; 3EYH; -.
DR   PDBsum; 4E4L; -.
DR   PDBsum; 4E4N; -.
DR   PDBsum; 4E5W; -.
DR   PDBsum; 4EHZ; -.
DR   PDBsum; 4EI4; -.
DR   PDBsum; 4FK6; -.
DR   PDBsum; 4GS0; -.
DR   PDBsum; 4I5C; -.
DR   PDBsum; 4IVB; -.
DR   PDBsum; 4IVC; -.
DR   PDBsum; 4IVD; -.
DR   PDBsum; 4K6Z; -.
DR   PDBsum; 4K77; -.
DR   PDBsum; 4L00; -.
DR   PDBsum; 4L01; -.
DR   PDBsum; 5E1E; -.
DR   PDBsum; 5HX8; -.
DR   PDBsum; 5IXD; -.
DR   PDBsum; 5IXI; -.
DR   PDBsum; 5KHW; -.
DR   PDBsum; 5KHX; -.
DR   PDBsum; 5L04; -.
DR   PDBsum; 5WO4; -.
DR   PDBsum; 6BBU; -.
DR   ProteinModelPortal; P23458; -.
DR   SMR; P23458; -.
DR   BioGrid; 109919; 105.
DR   CORUM; P23458; -.
DR   DIP; DIP-133N; -.
DR   IntAct; P23458; 51.
DR   MINT; P23458; -.
DR   STRING; 9606.ENSP00000343204; -.
DR   BindingDB; P23458; -.
DR   ChEMBL; CHEMBL2835; -.
DR   DrugBank; DB08877; Ruxolitinib.
DR   DrugBank; DB08895; Tofacitinib.
DR   GuidetoPHARMACOLOGY; 2047; -.
DR   CarbonylDB; P23458; -.
DR   iPTMnet; P23458; -.
DR   PhosphoSitePlus; P23458; -.
DR   SwissPalm; P23458; -.
DR   BioMuta; JAK1; -.
DR   DMDM; 215274013; -.
DR   EPD; P23458; -.
DR   MaxQB; P23458; -.
DR   PaxDb; P23458; -.
DR   PeptideAtlas; P23458; -.
DR   PRIDE; P23458; -.
DR   Ensembl; ENST00000342505; ENSP00000343204; ENSG00000162434.
DR   GeneID; 3716; -.
DR   KEGG; hsa:3716; -.
DR   UCSC; uc001dbu.2; human.
DR   CTD; 3716; -.
DR   DisGeNET; 3716; -.
DR   EuPathDB; HostDB:ENSG00000162434.11; -.
DR   GeneCards; JAK1; -.
DR   HGNC; HGNC:6190; JAK1.
DR   HPA; CAB013088; -.
DR   MIM; 147795; gene.
DR   neXtProt; NX_P23458; -.
DR   OpenTargets; ENSG00000162434; -.
DR   PharmGKB; PA29988; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00900000140909; -.
DR   HOGENOM; HOG000049158; -.
DR   HOVERGEN; HBG006195; -.
DR   InParanoid; P23458; -.
DR   KO; K11217; -.
DR   OMA; PLDLFMH; -.
DR   OrthoDB; EOG091G01IS; -.
DR   PhylomeDB; P23458; -.
DR   TreeFam; TF327041; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-449836; Other interleukin signaling.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-6788467; IL-6-type cytokine receptor ligand interactions.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   Reactome; R-HSA-8854691; Interleukin-20 family signaling.
DR   Reactome; R-HSA-8983432; Interleukin-15 signaling.
DR   Reactome; R-HSA-8984722; Interleukin-35 Signalling.
DR   Reactome; R-HSA-8985947; Interleukin-9 signaling.
DR   Reactome; R-HSA-9020558; Interleukin-2 signaling.
DR   Reactome; R-HSA-9020591; Interleukin-12 signaling.
DR   Reactome; R-HSA-9020956; Interleukin-27 signaling.
DR   Reactome; R-HSA-9020958; Interleukin-21 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912694; Regulation of IFNA signaling.
DR   SignaLink; P23458; -.
DR   SIGNOR; P23458; -.
DR   ChiTaRS; JAK1; human.
DR   EvolutionaryTrace; P23458; -.
DR   GeneWiki; Janus_kinase_1; -.
DR   GenomeRNAi; 3716; -.
DR   PRO; PR:P23458; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000162434; -.
DR   CleanEx; HS_JAK1; -.
DR   Genevisible; P23458; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031730; F:CCR5 chemokine receptor binding; IEA:Ensembl.
DR   GO; GO:0005131; F:growth hormone receptor binding; ISS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035722; P:interleukin-12-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035723; P:interleukin-15-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038110; P:interleukin-2-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0038114; P:interleukin-21-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070106; P:interleukin-27-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070757; P:interleukin-35-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038111; P:interleukin-7-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038113; P:interleukin-9-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; IGI:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0060334; P:regulation of interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060338; P:regulation of type I interferon-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0046677; P:response to antibiotic; IDA:MGI.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   CDD; cd14473; FERM_B-lobe; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR035963; FERM_2.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016251; Tyr_kinase_non-rcpt_Jak/Tyk2.
DR   InterPro; IPR020776; Tyr_kinase_non-rcpt_Jak1.
DR   Pfam; PF07714; Pkinase_Tyr; 2.
DR   PIRSF; PIRSF000636; TyrPK_Jak; 1.
DR   PRINTS; PR01823; JANUSKINASE.
DR   PRINTS; PR01824; JANUSKINASE1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 2.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Kinase;
KW   Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; SH2 domain;
KW   Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN         1   1154       Tyrosine-protein kinase JAK1.
FT                                /FTId=PRO_0000088108.
FT   DOMAIN       34    420       FERM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00084}.
FT   DOMAIN      439    544       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      583    855       Protein kinase 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      875   1153       Protein kinase 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     881    889       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1003   1003       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     908    908       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES       3      3       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     228    228       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES    1034   1034       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11909529}.
FT   MOD_RES    1035   1035       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11909529}.
FT   VARIANT     973    973       N -> K (in dbSNP:rs34680086).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041715.
FT   CONFLICT    350    350       H -> D (in Ref. 1; AAA36527).
FT                                {ECO:0000305}.
FT   CONFLICT    368    368       Y -> F (in Ref. 1; AAA36527).
FT                                {ECO:0000305}.
FT   CONFLICT    898    898       Missing (in Ref. 1; AAA36527).
FT                                {ECO:0000305}.
FT   STRAND       36     39       {ECO:0000244|PDB:5L04}.
FT   STRAND       43     45       {ECO:0000244|PDB:5IXI}.
FT   STRAND       48     50       {ECO:0000244|PDB:5L04}.
FT   STRAND       52     56       {ECO:0000244|PDB:5L04}.
FT   HELIX        57     67       {ECO:0000244|PDB:5L04}.
FT   TURN         72     74       {ECO:0000244|PDB:5L04}.
FT   HELIX        75     77       {ECO:0000244|PDB:5L04}.
FT   STRAND       78     82       {ECO:0000244|PDB:5L04}.
FT   TURN         83     86       {ECO:0000244|PDB:5L04}.
FT   STRAND       94     97       {ECO:0000244|PDB:5L04}.
FT   STRAND      103    109       {ECO:0000244|PDB:5L04}.
FT   TURN        114    117       {ECO:0000244|PDB:5L04}.
FT   STRAND      121    123       {ECO:0000244|PDB:5IXI}.
FT   STRAND      149    151       {ECO:0000244|PDB:5L04}.
FT   HELIX       152    167       {ECO:0000244|PDB:5L04}.
FT   HELIX       179    204       {ECO:0000244|PDB:5L04}.
FT   TURN        208    210       {ECO:0000244|PDB:5IXD}.
FT   HELIX       217    220       {ECO:0000244|PDB:5L04}.
FT   HELIX       223    230       {ECO:0000244|PDB:5L04}.
FT   HELIX       234    252       {ECO:0000244|PDB:5L04}.
FT   HELIX       254    259       {ECO:0000244|PDB:5L04}.
FT   HELIX       263    277       {ECO:0000244|PDB:5L04}.
FT   STRAND      278    280       {ECO:0000244|PDB:5L04}.
FT   STRAND      284    289       {ECO:0000244|PDB:5L04}.
FT   STRAND      291    293       {ECO:0000244|PDB:5L04}.
FT   STRAND      299    304       {ECO:0000244|PDB:5IXI}.
FT   STRAND      313    318       {ECO:0000244|PDB:5L04}.
FT   TURN        319    321       {ECO:0000244|PDB:5L04}.
FT   STRAND      322    327       {ECO:0000244|PDB:5L04}.
FT   STRAND      364    367       {ECO:0000244|PDB:5L04}.
FT   HELIX       369    371       {ECO:0000244|PDB:5L04}.
FT   STRAND      372    378       {ECO:0000244|PDB:5L04}.
FT   STRAND      381    386       {ECO:0000244|PDB:5L04}.
FT   STRAND      391    395       {ECO:0000244|PDB:5L04}.
FT   HELIX       399    416       {ECO:0000244|PDB:5L04}.
FT   HELIX       425    427       {ECO:0000244|PDB:5L04}.
FT   HELIX       430    437       {ECO:0000244|PDB:5L04}.
FT   HELIX       446    456       {ECO:0000244|PDB:5L04}.
FT   STRAND      463    467       {ECO:0000244|PDB:5L04}.
FT   STRAND      472    482       {ECO:0000244|PDB:5L04}.
FT   STRAND      493    503       {ECO:0000244|PDB:5L04}.
FT   STRAND      506    509       {ECO:0000244|PDB:5L04}.
FT   STRAND      516    518       {ECO:0000244|PDB:5L04}.
FT   HELIX       519    527       {ECO:0000244|PDB:5L04}.
FT   STRAND      529    533       {ECO:0000244|PDB:5L04}.
FT   STRAND      536    538       {ECO:0000244|PDB:5L04}.
FT   STRAND      555    557       {ECO:0000244|PDB:5L04}.
FT   HELIX       559    562       {ECO:0000244|PDB:5L04}.
FT   HELIX       569    572       {ECO:0000244|PDB:4L00}.
FT   STRAND      575    578       {ECO:0000244|PDB:4L00}.
FT   HELIX       580    582       {ECO:0000244|PDB:4L00}.
FT   STRAND      583    592       {ECO:0000244|PDB:4L00}.
FT   STRAND      595    603       {ECO:0000244|PDB:4L00}.
FT   STRAND      616    624       {ECO:0000244|PDB:4L00}.
FT   HELIX       629    644       {ECO:0000244|PDB:4L00}.
FT   STRAND      653    659       {ECO:0000244|PDB:4L00}.
FT   STRAND      662    668       {ECO:0000244|PDB:4L00}.
FT   HELIX       675    682       {ECO:0000244|PDB:4L00}.
FT   TURN        683    685       {ECO:0000244|PDB:4L00}.
FT   HELIX       688    707       {ECO:0000244|PDB:4L00}.
FT   HELIX       717    719       {ECO:0000244|PDB:4L00}.
FT   STRAND      720    724       {ECO:0000244|PDB:4L00}.
FT   STRAND      727    731       {ECO:0000244|PDB:4L00}.
FT   STRAND      734    737       {ECO:0000244|PDB:4L00}.
FT   HELIX       744    746       {ECO:0000244|PDB:4L00}.
FT   HELIX       749    754       {ECO:0000244|PDB:4L00}.
FT   TURN        755    758       {ECO:0000244|PDB:4L00}.
FT   HELIX       761    765       {ECO:0000244|PDB:4L00}.
FT   HELIX       767    769       {ECO:0000244|PDB:4L00}.
FT   HELIX       774    787       {ECO:0000244|PDB:4L00}.
FT   TURN        788    790       {ECO:0000244|PDB:4L00}.
FT   TURN        793    796       {ECO:0000244|PDB:4L00}.
FT   HELIX       799    807       {ECO:0000244|PDB:4L00}.
FT   HELIX       818    827       {ECO:0000244|PDB:4L00}.
FT   HELIX       832    834       {ECO:0000244|PDB:4L00}.
FT   HELIX       838    848       {ECO:0000244|PDB:4L00}.
FT   HELIX       872    874       {ECO:0000244|PDB:5WO4}.
FT   STRAND      875    884       {ECO:0000244|PDB:5WO4}.
FT   STRAND      887    894       {ECO:0000244|PDB:5WO4}.
FT   STRAND      898    900       {ECO:0000244|PDB:5WO4}.
FT   STRAND      902    910       {ECO:0000244|PDB:5WO4}.
FT   HELIX       919    930       {ECO:0000244|PDB:5WO4}.
FT   STRAND      940    945       {ECO:0000244|PDB:5WO4}.
FT   TURN        947    950       {ECO:0000244|PDB:5KHX}.
FT   STRAND      952    957       {ECO:0000244|PDB:5WO4}.
FT   HELIX       964    970       {ECO:0000244|PDB:5WO4}.
FT   TURN        972    974       {ECO:0000244|PDB:5WO4}.
FT   HELIX       977    996       {ECO:0000244|PDB:5WO4}.
FT   STRAND      998   1000       {ECO:0000244|PDB:4K6Z}.
FT   HELIX      1006   1008       {ECO:0000244|PDB:5WO4}.
FT   STRAND     1009   1013       {ECO:0000244|PDB:5WO4}.
FT   STRAND     1016   1019       {ECO:0000244|PDB:5WO4}.
FT   STRAND     1034   1036       {ECO:0000244|PDB:5WO4}.
FT   STRAND     1039   1041       {ECO:0000244|PDB:5KHX}.
FT   HELIX      1045   1047       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1050   1055       {ECO:0000244|PDB:5WO4}.
FT   STRAND     1057   1059       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1060   1075       {ECO:0000244|PDB:5WO4}.
FT   TURN       1076   1078       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1080   1082       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1084   1092       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1097   1099       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1100   1109       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1122   1129       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1130   1132       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1136   1138       {ECO:0000244|PDB:5WO4}.
FT   HELIX      1142   1153       {ECO:0000244|PDB:5WO4}.
SQ   SEQUENCE   1154 AA;  133277 MW;  A2C4BE27851ACABB CRC64;
     MQYLNIKEDC NAMAFCAKMR SSKKTEVNLE APEPGVEVIF YLSDREPLRL GSGEYTAEEL
     CIRAAQACRI SPLCHNLFAL YDENTKLWYA PNRTITVDDK MSLRLHYRMR FYFTNWHGTN
     DNEQSVWRHS PKKQKNGYEK KKIPDATPLL DASSLEYLFA QGQYDLVKCL APIRDPKTEQ
     DGHDIENECL GMAVLAISHY AMMKKMQLPE LPKDISYKRY IPETLNKSIR QRNLLTRMRI
     NNVFKDFLKE FNNKTICDSS VSTHDLKVKY LATLETLTKH YGAEIFETSM LLISSENEMN
     WFHSNDGGNV LYYEVMVTGN LGIQWRHKPN VVSVEKEKNK LKRKKLENKH KKDEEKNKIR
     EEWNNFSYFP EITHIVIKES VVSINKQDNK KMELKLSSHE EALSFVSLVD GYFRLTADAH
     HYLCTDVAPP LIVHNIQNGC HGPICTEYAI NKLRQEGSEE GMYVLRWSCT DFDNILMTVT
     CFEKSEQVQG AQKQFKNFQI EVQKGRYSLH GSDRSFPSLG DLMSHLKKQI LRTDNISFML
     KRCCQPKPRE ISNLLVATKK AQEWQPVYPM SQLSFDRILK KDLVQGEHLG RGTRTHIYSG
     TLMDYKDDEG TSEEKKIKVI LKVLDPSHRD ISLAFFEAAS MMRQVSHKHI VYLYGVCVRD
     VENIMVEEFV EGGPLDLFMH RKSDVLTTPW KFKVAKQLAS ALSYLEDKDL VHGNVCTKNL
     LLAREGIDSE CGPFIKLSDP GIPITVLSRQ ECIERIPWIA PECVEDSKNL SVAADKWSFG
     TTLWEICYNG EIPLKDKTLI EKERFYESRC RPVTPSCKEL ADLMTRCMNY DPNQRPFFRA
     IMRDINKLEE QNPDIVSEKK PATEVDPTHF EKRFLKRIRD LGEGHFGKVE LCRYDPEGDN
     TGEQVAVKSL KPESGGNHIA DLKKEIEILR NLYHENIVKY KGICTEDGGN GIKLIMEFLP
     SGSLKEYLPK NKNKINLKQQ LKYAVQICKG MDYLGSRQYV HRDLAARNVL VESEHQVKIG
     DFGLTKAIET DKEYYTVKDD RDSPVFWYAP ECLMQSKFYI ASDVWSFGVT LHELLTYCDS
     DSSPMALFLK MIGPTHGQMT VTRLVNTLKE GKRLPCPPNC PDEVYQLMRK CWEFQPSNRT
     SFQNLIEGFE ALLK
//
ID   Q6P669_HUMAN            Unreviewed;       351 AA.
AC   Q6P669;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   05-JUL-2004, sequence version 1.
DT   28-FEB-2018, entry version 67.
DE   SubName: Full=JAK1 protein {ECO:0000313|EMBL:AAH62431.1};
DE   Flags: Fragment;
GN   Name=JAK1 {ECO:0000313|EMBL:AAH62431.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH62431.1};
RN   [1] {ECO:0000313|EMBL:AAH62431.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung {ECO:0000313|EMBL:AAH62431.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC062431; AAH62431.1; -; mRNA.
DR   RefSeq; NP_001307852.1; NM_001320923.1.
DR   UniGene; Hs.207538; -.
DR   ProteinModelPortal; Q6P669; -.
DR   PeptideAtlas; Q6P669; -.
DR   GeneID; 3716; -.
DR   KEGG; hsa:3716; -.
DR   CTD; 3716; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   KO; K11217; -.
DR   ChiTaRS; JAK1; human.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   CDD; cd14473; FERM_B-lobe; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR035963; FERM_2.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   SMART; SM00295; B41; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   PROSITE; PS50057; FERM_3; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN       34    351       FERM. {ECO:0000259|PROSITE:PS50057}.
FT   COILED      331    351       {ECO:0000256|SAM:Coils}.
FT   NON_TER     351    351       {ECO:0000313|EMBL:AAH62431.1}.
SQ   SEQUENCE   351 AA;  40931 MW;  9763318A8CBF7B3E CRC64;
     MQYLNIKEDC NAMAFCAKMR SSKKTEVNLE APEPGVEVIF YLSDREPLRL GSGEYTAEEL
     CIRAAQACRI SPLCHNLFAL YDENTKLWYA PNRTITVDDK MSLRLHYRMR FYFTNWHGTN
     DNEQSVWRHS PKKQKNGYEK KKIPDATPLL DASSLEYLFA QGQYDLVKCL APIRDPKTEQ
     DGHDIENECL GMAVLAISHY AMMKKMQLPE LPKDISYKRY IPETLNKSIR QRNLLTRMRI
     NNVFKDFLKE FNNKTICDSS VSTHDLKVKY LATLETLTKH YGAEIFETSM LLISSENEMN
     WFHSNDGGNV LYYEVMVTGN LGIQWRHKPN VVSVEKEKNK LKKKKKKKKK K
//
ID   B4E0L8_HUMAN            Unreviewed;      1040 AA.
AC   B4E0L8;
DT   23-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   23-SEP-2008, sequence version 1.
DT   22-NOV-2017, entry version 52.
DE   SubName: Full=cDNA FLJ54396, highly similar to Ubiquitously transcribed X chromosome tetratricopeptide repeat protein {ECO:0000313|EMBL:BAG64480.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG64480.1};
RN   [1] {ECO:0000313|EMBL:BAG64480.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAG64480.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK303430; BAG64480.1; -; mRNA.
DR   RefSeq; NP_001278346.1; NM_001291417.1.
DR   UniGene; Hs.522616; -.
DR   ProteinModelPortal; B4E0L8; -.
DR   PeptideAtlas; B4E0L8; -.
DR   PRIDE; B4E0L8; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   HOGENOM; HOG000220834; -.
DR   HOVERGEN; HBG018063; -.
DR   GenomeRNAi; 7403; -.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:InterPro.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:InterPro.
DR   Gene3D; 1.25.40.10; -; 1.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029516; KDM6C.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   PANTHER; PTHR14017:SF9; PTHR14017:SF9; 3.
DR   Pfam; PF02373; JmjC; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SUPFAM; SSF48452; SSF48452; 1.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
FT   DOMAIN        1     51       TPR_REGION.
FT                                {ECO:0000259|PROSITE:PS50293}.
FT   DOMAIN      734    897       JmjC. {ECO:0000259|PROSITE:PS51184}.
SQ   SEQUENCE   1040 AA;  113266 MW;  3F1788AB9AD07098 CRC64;
     MDALQAYICA VQLDHGHAAA WMDLGTLYES CNQPQDAIKC YLNATRSKSC SNTSALAARI
     KYLQACKPHH PNTEPVLGLS QTPISQQSLP LHMIPSSQVD DLSSPAKRKR TSSPTKNTSD
     NWSGGHAVSH PPVQQQAHSW CLTPQKLQMR PTGVAQVRST GIPNGPTADS SLPTNSVSGQ
     QPQLALTRVP SVSQPGVRPA CPGQPLANGP FSAGHVPCST SRTLGSTDTI LIGNNHITGS
     GSNGNVPYLQ RNALTLPHNR TNLTSSAEEP WKNQLSNSTQ GLHKGQSSHS AGPNGERPLS
     STGPSQHLQA AGSGIQNQNG HPTLPSNSVT QGAALNHLSS HTATSGGQQG ITLTKESKPS
     GNILTVPETS RHTGETPNST ASVEGLPNHV HQMTADAVCS PSHGDSKSPG LLSSDNPQLS
     ALLMGKANNN VGTGTCDKVN NIHPAVHTKT DNSVASSPSS AISTATPSPK STEQTTTNSV
     TSLNSPHSGL HTINGEGMEE SQSPMKTDLL LVNHKPSPQI IPSMSVSIYP SSAEVLKACR
     NLGKNGLSNS SILLDKCPPP RPPSSPYPPL PKDKLNPPTP SIYLENKRDA FFPPLHQFCT
     NPNNPVTVIR GLAGALKLDL GLFSTKTLVE ANNEHMVEVR TQLLQPADEN WDPTGTKKIW
     HCESNRSHTT IAKYAQYQAS SFQESLREEN EKRSHHKDHS DSESTSSDNS GRRRKGPFKT
     IKFGTNIDLS DDKKWKLQLH ELTKLPAFVR VVSAGNLLSH VGHTILGMNT VQLYMKVPGS
     RTPGHQENNN FCSVNINIGP GDCEWFVVPE GYWGVLNDFC EKNNLNFLMG SWWPNLEDLY
     EANVPVYRFI QRPGDLVWIN AGTVHWVQAI GWCNNIAWNV GPLTACQYKL AVERYEWNKL
     QSVKSIVPMV HLSWNMARNI KVSDPKLFEM IKYCLLRTLK QCQTLREALI AAGKEIIWHG
     RTKEEPAHYC SICEVEVFDL LFVTNESNSR KTYIVHCQDC ARKTSGNLEN FVVLEQYKME
     DLMQVYDQFT LAPPLPSASS
//
ID   B7ZKN1_HUMAN            Unreviewed;      1408 AA.
AC   B7ZKN1;
DT   03-MAR-2009, integrated into UniProtKB/TrEMBL.
DT   03-MAR-2009, sequence version 1.
DT   28-FEB-2018, entry version 56.
DE   SubName: Full=UTX protein {ECO:0000313|EMBL:AAI43273.1};
GN   Name=UTX {ECO:0000313|EMBL:AAI43273.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAI43273.1};
RN   [1] {ECO:0000313|EMBL:AAI43273.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAI43273.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC143272; AAI43273.1; -; mRNA.
DR   RefSeq; NP_001278345.1; NM_001291416.1.
DR   UniGene; Hs.522616; -.
DR   ProteinModelPortal; B7ZKN1; -.
DR   MaxQB; B7ZKN1; -.
DR   PeptideAtlas; B7ZKN1; -.
DR   PRIDE; B7ZKN1; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   HOVERGEN; HBG018063; -.
DR   ChiTaRS; KDM6A; human.
DR   GenomeRNAi; 7403; -.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:InterPro.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:InterPro.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029516; KDM6C.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   PANTHER; PTHR14017:SF9; PTHR14017:SF9; 2.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 1.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN       93    385       TPR_REGION.
FT                                {ECO:0000259|PROSITE:PS50293}.
FT   REPEAT       93    126       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      130    163       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      205    238       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      250    283       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      284    317       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      318    351       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      352    385       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   DOMAIN     1102   1265       JmjC. {ECO:0000259|PROSITE:PS51184}.
SQ   SEQUENCE   1408 AA;  154955 MW;  F6DFF398109BE162 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASPS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLYGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIQFH IAHLYETQRK YHSAKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQAC KPHHPNTEPV LGLSQTPISQ
     QSLPLHMIPS SQVDDLSSPA KRKRTSSPTK NTSDNWSGGH AVSHPPVQQQ AHSWCLTPQK
     LQHLEQLRAN RNNLNPAQKL MLEQLESQFV LMQQHQMRPT GVAQVRSTGI PNGPTADSSL
     PTNSVSGQQP QLALTRVPSV SQPGVRPACP GQPLANGPFS AGHVPCSTSR TLGSTDTILI
     GNNHITGSGS NGNVPYLQRN ALTLPHNRTN LTSSAEEPWK NQLSNSTQGL HKGQSSHSAG
     PNGERPLSST GPSQHLQAAG SGIQNQNGHP TLPSNSVTQG AALNHLSSHT ATSGGQQGIT
     LTKESKPSGN ILKVPETSRH TGETPNSTAS VEGLPNHVHQ MTADAVCSPS HGDSKSPGLL
     SSDNPQLSAL LMGKANNNVG TGTCDKVNNI HPAVHTKTDN SVASSPSSAI STATPSPKST
     EQTTTNSVTS LNSPHSGLHT INGEGMEESQ SPMKTDLLLV NHKPSPQIIP SMSVSIYPSS
     AEVLKACRNL GKNGLSNSSI LLDKCPPPRP PSSPYPPLPK DKLNPPTPSI YLENKRDAFF
     PPLHQFCTNP NNPVTVIRGL AGALKLDLGL FSTKTLVEAN NEHMVEVRTQ LLQPADENWD
     PTGTKKIWHC ESNRSHTTIA KYAQYQASSF QESLREENEK RSHHKDHSDS ESTSSDNSGR
     RRKGPFKTIK FGTNIDLSDD KKWKLQLHEL TKLPAFVRVV SAGNLLSHVG HTILGMNTVQ
     LYMKVPGSRT PGHQENNNFC SVNINIGPGD CEWFVVPEGY WGVLNDFCEK NNLNFLMGSW
     WPNLEDLYEA NVPVYRFIQR PGDLVWINAG TVHWVQAIGW CNNIAWNVGP LTACQYKLAV
     ERYEWNKLQS VKSIVPMVHL SWNMARNIKV SDPKLFEMIK YCLLRTLKQC QTLREALIAA
     GKEIIWHGRT KEEPAHYCSI CEVEVFDLLF VTNESNSRKT YIVHCQDCAR KTSGNLENFV
     VLEQYKMEDL MQVYDQFTLA PPLPSASS
//
ID   B7ZKN5_HUMAN            Unreviewed;      1453 AA.
AC   B7ZKN5;
DT   03-MAR-2009, integrated into UniProtKB/TrEMBL.
DT   03-MAR-2009, sequence version 1.
DT   28-FEB-2018, entry version 60.
DE   SubName: Full=UTX protein {ECO:0000313|EMBL:AAI43278.1};
GN   Name=UTX {ECO:0000313|EMBL:AAI43278.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAI43278.1};
RN   [1] {ECO:0000313|EMBL:AAI43278.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAI43278.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC143277; AAI43278.1; -; mRNA.
DR   RefSeq; NP_001278344.1; NM_001291415.1.
DR   UniGene; Hs.522616; -.
DR   SMR; B7ZKN5; -.
DR   MaxQB; B7ZKN5; -.
DR   PeptideAtlas; B7ZKN5; -.
DR   PRIDE; B7ZKN5; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   HOGENOM; HOG000220834; -.
DR   HOVERGEN; HBG018063; -.
DR   ChiTaRS; KDM6A; human.
DR   GenomeRNAi; 7403; -.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:InterPro.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:InterPro.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029516; KDM6C.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   PANTHER; PTHR14017:SF9; PTHR14017:SF9; 1.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN       93    385       TPR_REGION.
FT                                {ECO:0000259|PROSITE:PS50293}.
FT   REPEAT       93    126       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      130    163       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      205    238       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      250    283       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      284    317       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      318    351       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      352    385       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   DOMAIN     1147   1310       JmjC. {ECO:0000259|PROSITE:PS51184}.
SQ   SEQUENCE   1453 AA;  159815 MW;  3E833ACA6C55C587 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASPS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLYGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIQFH IAHLYETQRK YHSAKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQAQ LCNLPQGSLQ NKTKLLPSIE
     EAWSLPIPAE LTSRQGAMNT AQQACKPHHP NTEPVLGLSQ TPISQQSLPL HMIPSSQVDD
     LSSPAKRKRT SSPTKNTSDN WSGGHAVSHP PVQQQAHSWC LTPQKLQHLE QLRANRNNLN
     PAQKLMLEQL ESQFVLMQQH QMRPTGVAQV RSTGIPNGPT ADSSLPTNSV SGQQPQLALT
     RVPSVSQPGV RPACPGQPLA NGPFSAGHVP CSTSRTLGST DTILIGNNHI TGSGSNGNVP
     YLQRNALTLP HNRTNLTSSA EEPWKNQLSN STQGLHKGQS SHSAGPNGER PLSSTGPSQH
     LQAAGSGIQN QNGHPTLPSN SVTQGAALNH LSSHTATSGG QQGITLTKES KPSGNILKVP
     ETSRHTGETP NSTASVEGLP NHVHQMTADA VCSPSHGDSK SPGLLSSDNP QLSALLMGKA
     NNNVGTGTCD KVNNIHPAVH TKTDNSVASS PSSAISTATP SPKSTEQTTT NSVTSLNSPH
     SGLHTINGEG MEESQSPMKT DLLLVNHKPS PQIIPSMSVS IYPSSAEVLK ACRNLGKNGL
     SNSSILLDKC PPPRPPSSPY PPLPKDKLNP PTPSIYLENK RDAFFPPLHQ FCTNPNNPVT
     VIRGLAGALK LDLGLFSTKT LVEANNEHMV EVRTQLLQPA DENWDPTGTK KIWHCESNRS
     HTTIAKYAQY QASSFQESLR EENEKRSHHK DHSDSESTSS DNSGRRRKGP FKTIKFGTNI
     DLSDDKKWKL QLHELTKLPA FVRVVSAGNL LSHVGHTILG MNTVQLYMKV PGSRTPGHQE
     NNNFCSVNIN IGPGDCEWFV VPEGYWGVLN DFCEKNNLNF LMGSWWPNLE DLYEANVPVY
     RFIQRPGDLV WINAGTVHWV QAIGWCNNIA WNVGPLTACQ YKLAVERYEW NKLQSVKSIV
     PMVHLSWNMA RNIKVSDPKL FEMIKYCLLR TLKQCQTLRE ALIAAGKEII WHGRTKEEPA
     HYCSICEVEV FDLLFVTNES NSRKTYIVHC QDCARKTSGN LENFVVLEQY KMEDLMQVYD
     QFTLAPPLPS ASS
//
ID   B7ZKN6_HUMAN            Unreviewed;      1356 AA.
AC   B7ZKN6;
DT   03-MAR-2009, integrated into UniProtKB/TrEMBL.
DT   03-MAR-2009, sequence version 1.
DT   28-FEB-2018, entry version 52.
DE   SubName: Full=UTX protein {ECO:0000313|EMBL:AAI43279.1};
GN   Name=UTX {ECO:0000313|EMBL:AAI43279.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAI43279.1};
RN   [1] {ECO:0000313|EMBL:AAI43279.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAI43279.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC143278; AAI43279.1; -; mRNA.
DR   RefSeq; NP_001278344.1; NM_001291415.1.
DR   RefSeq; NP_001278345.1; NM_001291416.1.
DR   RefSeq; NP_001278346.1; NM_001291417.1.
DR   RefSeq; NP_001278347.1; NM_001291418.1.
DR   RefSeq; NP_001278350.1; NM_001291421.1.
DR   UniGene; Hs.522616; -.
DR   ProteinModelPortal; B7ZKN6; -.
DR   PeptideAtlas; B7ZKN6; -.
DR   PRIDE; B7ZKN6; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   HOVERGEN; HBG018063; -.
DR   ChiTaRS; KDM6A; human.
DR   GenomeRNAi; 7403; -.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:InterPro.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:InterPro.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029516; KDM6C.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   PANTHER; PTHR14017:SF9; PTHR14017:SF9; 2.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN       93    385       TPR_REGION.
FT                                {ECO:0000259|PROSITE:PS50293}.
FT   REPEAT       93    126       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      130    163       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      205    238       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      250    283       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      284    317       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      318    351       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      352    385       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   DOMAIN     1050   1213       JmjC. {ECO:0000259|PROSITE:PS51184}.
SQ   SEQUENCE   1356 AA;  149287 MW;  C64C8E56F8301807 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASPS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLYGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIQFH IAHLYETQRK YHSAKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQNT SDNWSGGHAV SHPPVQQQAH
     SWCLTPQKLQ HLEQLRANRN NLNPAQKLML EQLESQFVLM QQHQMRPTGV AQVRSTGIPN
     GPTADSSLPT NSVSGQQPQL ALTRVPSVSQ PGVRPACPGQ PLANGPFSAG HVPCSTSRTL
     GSTDTILIGN NHITGSGSNG NVPYLQRNAL TLPHNRTNLT SSAEEPWKNQ LSNSTQGLHK
     GQSSHSAGPN GERPLSSTGP SQHLQAAGSG IQNQNGHPTL PSNSVTQGAA LNHLSSHTAT
     SGGQQGITLT KESKPSGNIL TVPETSRHTG ETPNSTASVE GLPNHVHQMT ADAVCSPSHG
     DSKSPGLLSS DNPQLSALLM GKANNNVGTG TCDKVNNIHP AVHTKTDNSV ASSPSSAIST
     ATPSPKSTEQ TTTNSVTSLN SPHSGLHTIN GEGMEESQSP MKTDLLLVNH KPSPQIIPSM
     SVSIYPSSAE VLKACRNLGK NGLSNSSILL DKCPPPRPPS SPYPPLPKDK LNPPTPSIYL
     ENKRDAFFPP LHQFCTNPNN PVTVIRGLAG ALKLDLGLFS TKTLVEANNE HMVEVRTQLL
     QPADENWDPT GTKKIWHCES NRSHTTIAKY AQYQASSFQE SLREENEKRS HHKDHSDSES
     TSSDNSGRRR KGPFKTIKFG TNIDLSDDKK WKLQLHELTK LPAFVRVVSA GNLLSHVGHT
     ILGTNTVQLY MKVPGSRTPG HQENNNFCSV NINIGPGDCE WFVVPEGYWG VLNDFCEKNN
     LNFLMGSWWP NLEDLYEANV PVYRFIQRPG DLVWINAGTV HWVQAIGWCN NIAWNVGPLT
     ACQYKLAVER YEWNKLQSVK SIVPMVHLSW NMARNIKVSD PKLFEMIKYC LLRTLKQCQT
     LREALIAAGK EIIWHGRTKE EPAHYCSICE VEVFDLLFVT NESNSRKTYI VHCQDCARKT
     SGNLENFVVL EQYKMEDLMQ VYDQFTLAPP LPSASS
//
ID   E1U0S6_HUMAN            Unreviewed;      1322 AA.
AC   E1U0S6;
DT   30-NOV-2010, integrated into UniProtKB/TrEMBL.
DT   30-NOV-2010, sequence version 1.
DT   28-FEB-2018, entry version 40.
DE   SubName: Full=Ubiquitously transcribed tetratricopeptide repeat protein X-linked, transcript variant 5 {ECO:0000313|EMBL:AAZ06656.1};
GN   Name=UTX {ECO:0000313|EMBL:AAZ06656.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAZ06656.1};
RN   [1] {ECO:0000313|EMBL:AAZ06656.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Laaser I., Kolb H.-J., Adamski J.;
RT   "Splice variants of human UTX.";
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ062677; AAZ06656.1; -; mRNA.
DR   RefSeq; NP_001278347.1; NM_001291418.1.
DR   UniGene; Hs.522616; -.
DR   PeptideAtlas; E1U0S6; -.
DR   PRIDE; E1U0S6; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   ChiTaRS; KDM6A; human.
DR   GenomeRNAi; 7403; -.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:InterPro.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:InterPro.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029516; KDM6C.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   PANTHER; PTHR14017:SF9; PTHR14017:SF9; 3.
DR   Pfam; PF02373; JmjC; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN       93    385       TPR_REGION.
FT                                {ECO:0000259|PROSITE:PS50293}.
FT   REPEAT       93    126       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      130    163       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      205    238       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      250    283       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      284    317       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      318    351       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      352    385       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   DOMAIN     1016   1179       JmjC. {ECO:0000259|PROSITE:PS51184}.
SQ   SEQUENCE   1322 AA;  145156 MW;  90449E57B0D81F04 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASLS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLHGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIPFH IAHLYETQRK YHSTKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQNT SDNWSGGHAV SHPPVQQQAH
     SWCLTPQKLQ MSPTGVAQVR STGIPNGPTA DSSLPTNSVS GQQPRLALTR VPSVSQPGVR
     PACPGQPLAN GPFSAGHVPC STSRTLGSTD TILIGNNHIT GSGSNGNVPY LQRNALTLPH
     NRTNLTSSAE EPWKNQLSNS TQGLHKGQSS HSAGPNGERP LSSTGPSQHL QAAGSGIQNQ
     NGHPTLPSNS VTQGAALNHL SSHTATSGGQ QGITLTKESK PSGNILTVPE TSRHTGETPN
     STASVEGLPN HVHQMTADAV CSPSHGDSKS PGLLSSDNPQ LSALLMGKAN NNVGTGTCDK
     VNNIHPAVHT KTDNSVASSP SSAISTATPS PKSTEQTTTN SVTSLNSPHS GLHTINGEGM
     EESQSPMKTD LLLVNHKPSP QIIPSMSVSI YPSSAEVLKA CRNLGKNGLS NSSILLDKCP
     PPRPPSSPYP PLPKDKLNPP TPSIYLENKR DAFFPPLHQF CTNPNNPVTV IRGLAGALKL
     DLGLFSTKTL VEANNEHMVE VRTQSLQPAD ENWDPTGTKK IWHCESNRSH TTIAKYAQYQ
     ASSFQESLRE ENEKRSHHKD HSDSESTSSD NSGRRRKGPF KTIKFGTNID LSDDKKWKLQ
     LHELTKLPAF VRVVSAGNLL SHVGHTILGM NTVQLYMKVP GSRTPGHQEN NNFCSVNINI
     GPGDCEWFVV PEGYWGVLND FCEKNNLNFL MGSWWPNLED LYEANVPVYR FIQRPGDLVW
     INAGTVHWVQ AIGWCNNIAW NVGPLTACQY KLAVERYEWN KLQSVKSIVP MVHLSWNMAR
     NIKVSDPKLF EMIKYCLLRT LKQCQTLREA LIAAGKEIIW HGRTKEEPAH YCSICEVEVF
     DLLFVTNESN SRKTYIVHCQ DCARKTSGNL ENFVVLEQYK MEDLMQVYDQ FTLAPPLPSA
     SS
//
ID   KDM6A_HUMAN             Reviewed;        1401 AA.
AC   O15550; Q52LL9; Q5JVQ7;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 2.
DT   28-FEB-2018, entry version 176.
DE   RecName: Full=Lysine-specific demethylase 6A;
DE            EC=1.14.11.- {ECO:0000269|PubMed:17713478, ECO:0000269|PubMed:17761849, ECO:0000269|PubMed:17851529, ECO:0000269|PubMed:18003914};
DE   AltName: Full=Histone demethylase UTX;
DE   AltName: Full=Ubiquitously-transcribed TPR protein on the X chromosome;
DE   AltName: Full=Ubiquitously-transcribed X chromosome tetratricopeptide repeat protein;
GN   Name=KDM6A; Synonyms=UTX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9381176; DOI=10.1126/science.278.5338.675;
RA   Lahn B.T., Page D.C.;
RT   "Functional coherence of the human Y chromosome.";
RL   Science 278:675-680(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-726.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MLL2/3
RP   COMPLEX.
RX   PubMed=17500065; DOI=10.1074/jbc.M701574200;
RA   Cho Y.-W., Hong T., Hong S., Guo H., Yu H., Kim D., Guszczynski T.,
RA   Dressler G.R., Copeland T.D., Kalkum M., Ge K.;
RT   "PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4
RT   methyltransferase complex.";
RL   J. Biol. Chem. 282:20395-20406(2007).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-1146.
RX   PubMed=17851529; DOI=10.1038/nature06192;
RA   Lan F., Bayliss P.E., Rinn J.L., Whetstine J.R., Wang J.K., Chen S.,
RA   Iwase S., Alpatov R., Issaeva I., Canaani E., Roberts T.M.,
RA   Chang H.Y., Shi Y.;
RT   "A histone H3 lysine 27 demethylase regulates animal posterior
RT   development.";
RL   Nature 449:689-694(2007).
RN   [7]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=17713478; DOI=10.1038/nature06145;
RA   Agger K., Cloos P.A., Christensen J., Pasini D., Rose S.,
RA   Rappsilber J., Issaeva I., Canaani E., Salcini A.E., Helin K.;
RT   "UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene
RT   regulation and development.";
RL   Nature 449:731-734(2007).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-1146.
RX   PubMed=18003914; DOI=10.1073/pnas.0707292104;
RA   Hong S., Cho Y.W., Yu L.-R., Yu H., Veenstra T.D., Ge K.;
RT   "Identification of JmjC domain-containing UTX and JMJD3 as histone H3
RT   lysine 27 demethylases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:18439-18444(2007).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, MUTAGENESIS OF HIS-1146, AND
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17761849; DOI=10.1126/science.1149042;
RA   Lee M.G., Villa R., Trojer P., Norman J., Yan K.P., Reinberg D.,
RA   Di Croce L., Shiekhattar R.;
RT   "Demethylation of H3K27 regulates polycomb recruitment and H2A
RT   ubiquitination.";
RL   Science 318:447-450(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-769 AND SER-829, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   INVOLVEMENT IN KABUK2.
RX   PubMed=22197486; DOI=10.1016/j.ajhg.2011.11.021;
RA   Lederer D., Grisart B., Digilio M.C., Benoit V., Crespin M.,
RA   Ghariani S.C., Maystadt I., Dallapiccola B., Verellen-Dumoulin C.;
RT   "Deletion of KDM6A, a histone demethylase interacting with MLL2, in
RT   three patients with Kabuki syndrome.";
RL   Am. J. Hum. Genet. 90:119-124(2012).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-829, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 880-1401 IN COMPLEX WITH
RP   HISTONE H3 PEPTIDE, IRON-BINDING SITES, AND ZINC-BINDING SITES.
RX   PubMed=22002947; DOI=10.1101/gad.172296.111;
RA   Sengoku T., Yokoyama S.;
RT   "Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A.";
RL   Genes Dev. 25:2266-2277(2011).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-1106.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [16]
RP   VARIANTS VAL-270; ASP-834 AND LYS-922.
RX   PubMed=21828135; DOI=10.1182/blood-2010-10-311019;
RA   Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y.,
RA   Traina F., Visconte V., Sugimoto Y., Prince C., O'Keefe C., Hsi E.D.,
RA   List A., Sekeres M.A., Rao A., McDevitt M.A., Maciejewski J.P.;
RT   "Mutational spectrum analysis of chronic myelomonocytic leukemia
RT   includes genes associated with epigenetic regulation: UTX, EZH2, and
RT   DNMT3A.";
RL   Blood 118:3932-3941(2011).
CC   -!- FUNCTION: Histone demethylase that specifically demethylates 'Lys-
CC       27' of histone H3, thereby playing a central role in histone code
CC       (PubMed:17851529, PubMed:17713478, PubMed:17761849). Demethylates
CC       trimethylated and dimethylated but not monomethylated H3 'Lys-27'
CC       (PubMed:17851529, PubMed:17713478, PubMed:17761849). Plays a
CC       central role in regulation of posterior development, by regulating
CC       HOX gene expression (PubMed:17851529). Demethylation of 'Lys-27'
CC       of histone H3 is concomitant with methylation of 'Lys-4' of
CC       histone H3, and regulates the recruitment of the PRC1 complex and
CC       monoubiquitination of histone H2A (PubMed:17761849). Plays a
CC       demethylase-independent role in chromatin remodeling to regulate
CC       T-box family member-dependent gene expression (By similarity).
CC       {ECO:0000250|UniProtKB:O70546, ECO:0000269|PubMed:17713478,
CC       ECO:0000269|PubMed:17761849, ECO:0000269|PubMed:17851529,
CC       ECO:0000269|PubMed:18003914}.
CC   -!- COFACTOR:
CC       Name=L-ascorbate; Xref=ChEBI:CHEBI:38290;
CC         Evidence={ECO:0000269|PubMed:17761849};
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:17761849};
CC   -!- SUBUNIT: Interacts with TLE1 (By similarity). Component of the
CC       MLL2/3 complex (also named ASCOM complex), at least composed of
CC       KMT2D/MLL2 or KMT2C/MLL3, ASH2L, RBBP5, WDR5, NCOA6, DPY30, KDM6A
CC       (or KDM6B), PAXIP1/PTIP, PAGR1 and alpha- and beta-tubulin
CC       (PubMed:17500065, PubMed:17713478). Interacts with SUPT6H.
CC       Interacts with SMARCA4 (By similarity).
CC       {ECO:0000250|UniProtKB:O70546, ECO:0000269|PubMed:17500065,
CC       ECO:0000269|PubMed:17713478}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- DISEASE: Kabuki syndrome 2 (KABUK2) [MIM:300867]: A congenital
CC       mental retardation syndrome with additional features, including
CC       postnatal dwarfism, a peculiar facies characterized by long
CC       palpebral fissures with eversion of the lateral third of the lower
CC       eyelids, a broad and depressed nasal tip, large prominent
CC       earlobes, a cleft or high-arched palate, scoliosis, short fifth
CC       finger, persistence of fingerpads, radiographic abnormalities of
CC       the vertebrae, hands, and hip joints, and recurrent otitis media
CC       in infancy. {ECO:0000269|PubMed:22197486}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Escapes X chromosome inactivation.
CC   -!- SIMILARITY: Belongs to the UTX family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF000992; AAC51839.1; -; mRNA.
DR   EMBL; AF000993; AAC51840.1; -; mRNA.
DR   EMBL; AL133545; CAI40508.1; -; Genomic_DNA.
DR   EMBL; AC136488; CAI40508.1; JOINED; Genomic_DNA.
DR   EMBL; AL138744; CAI40508.1; JOINED; Genomic_DNA.
DR   EMBL; AL138744; CAI41479.1; -; Genomic_DNA.
DR   EMBL; AC136488; CAI41479.1; JOINED; Genomic_DNA.
DR   EMBL; AL133545; CAI41479.1; JOINED; Genomic_DNA.
DR   EMBL; CH471141; EAW59368.1; -; Genomic_DNA.
DR   EMBL; BC093868; AAH93868.1; -; mRNA.
DR   EMBL; BC113381; AAI13382.1; -; mRNA.
DR   CCDS; CCDS14265.1; -.
DR   PIR; T02255; T02255.
DR   RefSeq; NP_066963.2; NM_021140.3.
DR   UniGene; Hs.522616; -.
DR   PDB; 3AVR; X-ray; 1.80 A; A=880-1401.
DR   PDB; 3AVS; X-ray; 1.85 A; A=880-1401.
DR   PDBsum; 3AVR; -.
DR   PDBsum; 3AVS; -.
DR   ProteinModelPortal; O15550; -.
DR   SMR; O15550; -.
DR   BioGrid; 113246; 32.
DR   CORUM; O15550; -.
DR   DIP; DIP-46192N; -.
DR   IntAct; O15550; 17.
DR   MINT; O15550; -.
DR   STRING; 9606.ENSP00000367203; -.
DR   BindingDB; O15550; -.
DR   ChEMBL; CHEMBL2069164; -.
DR   GuidetoPHARMACOLOGY; 2684; -.
DR   iPTMnet; O15550; -.
DR   PhosphoSitePlus; O15550; -.
DR   BioMuta; KDM6A; -.
DR   EPD; O15550; -.
DR   MaxQB; O15550; -.
DR   PaxDb; O15550; -.
DR   PeptideAtlas; O15550; -.
DR   PRIDE; O15550; -.
DR   Ensembl; ENST00000377967; ENSP00000367203; ENSG00000147050.
DR   GeneID; 7403; -.
DR   KEGG; hsa:7403; -.
DR   UCSC; uc004dge.5; human.
DR   CTD; 7403; -.
DR   DisGeNET; 7403; -.
DR   EuPathDB; HostDB:ENSG00000147050.14; -.
DR   GeneCards; KDM6A; -.
DR   GeneReviews; KDM6A; -.
DR   H-InvDB; HIX0019137; -.
DR   HGNC; HGNC:12637; KDM6A.
DR   HPA; HPA000568; -.
DR   HPA; HPA001165; -.
DR   HPA; HPA002111; -.
DR   MalaCards; KDM6A; -.
DR   MIM; 300128; gene.
DR   MIM; 300867; phenotype.
DR   neXtProt; NX_O15550; -.
DR   OpenTargets; ENSG00000147050; -.
DR   Orphanet; 2322; Kabuki syndrome.
DR   PharmGKB; PA37262; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   GeneTree; ENSGT00410000025758; -.
DR   InParanoid; O15550; -.
DR   KO; K11447; -.
DR   PhylomeDB; O15550; -.
DR   TreeFam; TF317405; -.
DR   Reactome; R-HSA-3214842; HDMs demethylate histones.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   ChiTaRS; KDM6A; human.
DR   GeneWiki; UTX_(gene); -.
DR   GenomeRNAi; 7403; -.
DR   PRO; PR:O15550; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000147050; -.
DR   CleanEx; HS_UTX; -.
DR   ExpressionAtlas; O15550; baseline and differential.
DR   Genevisible; O15550; HS.
DR   GO; GO:0035097; C:histone methyltransferase complex; IDA:MGI.
DR   GO; GO:0044666; C:MLL3/4 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0051213; F:dioxygenase activity; IEA:UniProtKB-KW.
DR   GO; GO:0032452; F:histone demethylase activity; TAS:Reactome.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0072358; P:cardiovascular system development; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0051568; P:histone H3-K4 methylation; ISS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0048333; P:mesodermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0001843; P:neural tube closure; IEA:Ensembl.
DR   GO; GO:0048570; P:notochord morphogenesis; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0003016; P:respiratory system process; IEA:Ensembl.
DR   GO; GO:0032525; P:somite rostral/caudal axis specification; IEA:Ensembl.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029516; KDM6C.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   PANTHER; PTHR14017:SF9; PTHR14017:SF9; 2.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chromatin regulator; Complete proteome; Dioxygenase;
KW   Iron; Mental retardation; Metal-binding; Methylation; Nucleus;
KW   Oxidoreductase; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; TPR repeat; Zinc.
FT   CHAIN         1   1401       Lysine-specific demethylase 6A.
FT                                /FTId=PRO_0000106409.
FT   REPEAT       93    126       TPR 1.
FT   REPEAT      130    163       TPR 2.
FT   REPEAT      170    199       TPR 3.
FT   REPEAT      205    238       TPR 4.
FT   REPEAT      250    283       TPR 5.
FT   REPEAT      284    317       TPR 6.
FT   REPEAT      318    351       TPR 7.
FT   REPEAT      352    385       TPR 8.
FT   DOMAIN     1095   1258       JmjC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00538}.
FT   REGION        1   1095       Interaction with SUPT6H. {ECO:0000250}.
FT   COMPBIAS      9     17       Poly-Ala.
FT   METAL      1146   1146       Iron. {ECO:0000269|PubMed:22002947}.
FT   METAL      1148   1148       Iron. {ECO:0000269|PubMed:22002947}.
FT   METAL      1226   1226       Iron. {ECO:0000269|PubMed:22002947}.
FT   METAL      1331   1331       Zinc. {ECO:0000269|PubMed:22002947}.
FT   METAL      1334   1334       Zinc. {ECO:0000269|PubMed:22002947}.
FT   METAL      1358   1358       Zinc. {ECO:0000269|PubMed:22002947}.
FT   METAL      1361   1361       Zinc. {ECO:0000269|PubMed:22002947}.
FT   MOD_RES     519    519       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:O70546}.
FT   MOD_RES     549    549       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:O70546}.
FT   MOD_RES     769    769       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     827    827       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:O70546}.
FT   MOD_RES     829    829       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   VARIANT      30     30       A -> T (in dbSNP:rs6529).
FT                                /FTId=VAR_014492.
FT   VARIANT     270    270       I -> V (in a patient with chronic
FT                                myelomonocytic leukemia).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067225.
FT   VARIANT     497    497       Q -> H (in dbSNP:rs6530).
FT                                /FTId=VAR_014493.
FT   VARIANT     581    581       T -> A (in dbSNP:rs34922269).
FT                                /FTId=VAR_046527.
FT   VARIANT     726    726       T -> K (in dbSNP:rs2230018).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_020313.
FT   VARIANT     834    834       E -> D (in a patient with chronic
FT                                myelomonocytic leukemia).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067226.
FT   VARIANT     922    922       R -> K (in a patient with chronic
FT                                myelomonocytic leukemia).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067227.
FT   VARIANT    1106   1106       L -> R (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035871.
FT   MUTAGEN    1146   1146       H->A: Abolishes histone demethylase
FT                                activity. {ECO:0000269|PubMed:17761849,
FT                                ECO:0000269|PubMed:17851529,
FT                                ECO:0000269|PubMed:18003914}.
FT   CONFLICT    173    173       L -> V (in Ref. 1; AAC51839/AAC51840).
FT                                {ECO:0000305}.
FT   CONFLICT    585    585       L -> R (in Ref. 1; AAC51839/AAC51840).
FT                                {ECO:0000305}.
FT   CONFLICT    601    601       S -> N (in Ref. 1; AAC51839/AAC51840).
FT                                {ECO:0000305}.
FT   CONFLICT    629    629       E -> K (in Ref. 1; AAC51839/AAC51840).
FT                                {ECO:0000305}.
FT   HELIX       893    900       {ECO:0000244|PDB:3AVR}.
FT   HELIX       933    935       {ECO:0000244|PDB:3AVR}.
FT   STRAND      942    944       {ECO:0000244|PDB:3AVR}.
FT   HELIX       948    951       {ECO:0000244|PDB:3AVR}.
FT   HELIX       954    961       {ECO:0000244|PDB:3AVR}.
FT   STRAND      966    971       {ECO:0000244|PDB:3AVR}.
FT   HELIX       973    977       {ECO:0000244|PDB:3AVR}.
FT   HELIX       981    984       {ECO:0000244|PDB:3AVR}.
FT   HELIX       986    992       {ECO:0000244|PDB:3AVR}.
FT   STRAND      997   1004       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1016   1019       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1025   1031       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1032   1045       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1081   1089       {ECO:0000244|PDB:3AVR}.
FT   TURN       1093   1096       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1097   1102       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1103   1105       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1108   1110       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1118   1121       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1122   1124       {ECO:0000244|PDB:3AVS}.
FT   TURN       1127   1129       {ECO:0000244|PDB:3AVS}.
FT   STRAND     1133   1137       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1142   1146       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1149   1151       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1153   1162       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1164   1169       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1171   1173       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1174   1183       {ECO:0000244|PDB:3AVR}.
FT   TURN       1188   1190       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1197   1202       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1208   1212       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1217   1220       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1225   1241       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1243   1245       {ECO:0000244|PDB:3AVS}.
FT   HELIX      1246   1262       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1270   1280       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1286   1312       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1317   1319       {ECO:0000244|PDB:3AVR}.
FT   TURN       1332   1334       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1340   1346       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1351   1357       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1359   1365       {ECO:0000244|PDB:3AVR}.
FT   STRAND     1373   1376       {ECO:0000244|PDB:3AVR}.
FT   HELIX      1380   1388       {ECO:0000244|PDB:3AVR}.
SQ   SEQUENCE   1401 AA;  154177 MW;  9DD7EA6C61E79229 CRC64;
     MKSCGVSLAT AAAAAAAFGD EEKKMAAGKA SGESEEASPS LTAEEREALG GLDSRLFGFV
     RFHEDGARTK ALLGKAVRCY ESLILKAEGK VESDFFCQLG HFNLLLEDYP KALSAYQRYY
     SLQSDYWKNA AFLYGLGLVY FHYNAFQWAI KAFQEVLYVD PSFCRAKEIH LRLGLMFKVN
     TDYESSLKHF QLALVDCNPC TLSNAEIQFH IAHLYETQRK YHSAKEAYEQ LLQTENLSAQ
     VKATVLQQLG WMHHTVDLLG DKATKESYAI QYLQKSLEAD PNSGQSWYFL GRCYSSIGKV
     QDAFISYRQS IDKSEASADT WCSIGVLYQQ QNQPMDALQA YICAVQLDHG HAAAWMDLGT
     LYESCNQPQD AIKCYLNATR SKSCSNTSAL AARIKYLQAQ LCNLPQGSLQ NKTKLLPSIE
     EAWSLPIPAE LTSRQGAMNT AQQNTSDNWS GGHAVSHPPV QQQAHSWCLT PQKLQHLEQL
     RANRNNLNPA QKLMLEQLES QFVLMQQHQM RPTGVAQVRS TGIPNGPTAD SSLPTNSVSG
     QQPQLALTRV PSVSQPGVRP ACPGQPLANG PFSAGHVPCS TSRTLGSTDT ILIGNNHITG
     SGSNGNVPYL QRNALTLPHN RTNLTSSAEE PWKNQLSNST QGLHKGQSSH SAGPNGERPL
     SSTGPSQHLQ AAGSGIQNQN GHPTLPSNSV TQGAALNHLS SHTATSGGQQ GITLTKESKP
     SGNILTVPET SRHTGETPNS TASVEGLPNH VHQMTADAVC SPSHGDSKSP GLLSSDNPQL
     SALLMGKANN NVGTGTCDKV NNIHPAVHTK TDNSVASSPS SAISTATPSP KSTEQTTTNS
     VTSLNSPHSG LHTINGEGME ESQSPMKTDL LLVNHKPSPQ IIPSMSVSIY PSSAEVLKAC
     RNLGKNGLSN SSILLDKCPP PRPPSSPYPP LPKDKLNPPT PSIYLENKRD AFFPPLHQFC
     TNPNNPVTVI RGLAGALKLD LGLFSTKTLV EANNEHMVEV RTQLLQPADE NWDPTGTKKI
     WHCESNRSHT TIAKYAQYQA SSFQESLREE NEKRSHHKDH SDSESTSSDN SGRRRKGPFK
     TIKFGTNIDL SDDKKWKLQL HELTKLPAFV RVVSAGNLLS HVGHTILGMN TVQLYMKVPG
     SRTPGHQENN NFCSVNINIG PGDCEWFVVP EGYWGVLNDF CEKNNLNFLM GSWWPNLEDL
     YEANVPVYRF IQRPGDLVWI NAGTVHWVQA IGWCNNIAWN VGPLTACQYK LAVERYEWNK
     LQSVKSIVPM VHLSWNMARN IKVSDPKLFE MIKYCLLRTL KQCQTLREAL IAAGKEIIWH
     GRTKEEPAHY CSICEVEVFD LLFVTNESNS RKTYIVHCQD CARKTSGNLE NFVVLEQYKM
     EDLMQVYDQF TLAPPLPSAS S
//
ID   Q59HG3_HUMAN            Unreviewed;      1406 AA.
AC   Q59HG3;
DT   26-APR-2005, integrated into UniProtKB/TrEMBL.
DT   26-APR-2005, sequence version 1.
DT   28-FEB-2018, entry version 89.
DE   SubName: Full=Ubiquitously transcribed tetratricopeptide repeat variant {ECO:0000313|EMBL:BAD92032.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD92032.1};
RN   [1] {ECO:0000313|EMBL:BAD92032.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAD92032.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB208795; BAD92032.1; -; mRNA.
DR   RefSeq; NP_001278347.1; NM_001291418.1.
DR   RefSeq; NP_066963.2; NM_021140.3.
DR   UniGene; Hs.522616; -.
DR   PRIDE; Q59HG3; -.
DR   GeneID; 7403; -.
DR   KEGG; hsa:7403; -.
DR   CTD; 7403; -.
DR   PharmGKB; PA37262; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG1246; Eukaryota.
DR   eggNOG; COG0457; LUCA.
DR   HOGENOM; HOG000220834; -.
DR   HOVERGEN; HBG018063; -.
DR   KO; K11447; -.
DR   GenomeRNAi; 7403; -.
DR   Genevisible; Q59HG3; HS.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:InterPro.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:InterPro.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029516; KDM6C.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   InterPro; IPR019734; TPR_repeat.
DR   PANTHER; PTHR14017:SF9; PTHR14017:SF9; 2.
DR   Pfam; PF02373; JmjC; 1.
DR   Pfam; PF13181; TPR_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   SMART; SM00028; TPR; 6.
DR   SUPFAM; SSF48452; SSF48452; 2.
DR   PROSITE; PS51184; JMJC; 1.
DR   PROSITE; PS50005; TPR; 7.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   2: Evidence at transcript level;
KW   TPR repeat {ECO:0000256|PROSITE-ProRule:PRU00339}.
FT   DOMAIN       98    390       TPR_REGION.
FT                                {ECO:0000259|PROSITE:PS50293}.
FT   REPEAT       98    131       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      135    168       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      210    243       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      255    288       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      289    322       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      323    356       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   REPEAT      357    390       TPR. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00339}.
FT   DOMAIN     1100   1263       JmjC. {ECO:0000259|PROSITE:PS51184}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:BAD92032.1}.
SQ   SEQUENCE   1406 AA;  154735 MW;  ECB54A9C1B838DC3 CRC64;
     IRCVSMKSCG VSLATAAAAA AAFGDEEKKM AAGKASGESE EASPSLTAEE REALGGLDSR
     LFGFVRFHED GARTKALLGK AVRCYESLIL KAEGKVESDF FCQLGHFNLL LEDYPKALSA
     YQRYYSLQSD YWKNAAFLYG LGLVYFHYNA FQWAIKAFQE VLYVDPSFCR AKEIHLRLGL
     MFKVNTDYES SLKHFQLALV DCNPCTLSNA EIQFHIAHLY ETQRKYHSAK EAYEQLLQTE
     NLSAQVKATV LQQLGWMHHT VDLLGDKATK ESYAIQYLQK SLEADPNSGQ SWYFLGRCYS
     SIGKVQDAFI SYRQSIDKSE ASADTWCSIG VLYQQQNQPM DALQAYICAV QLDHGHAAAW
     MDLGTLYESC NQPQDAIKCY LNATRSKSCS NTSALAARIK YLQAQLCNLP QGSLQNKTKL
     LPSIEEAWSL PIPAELTSRQ GAMNTAQQNT SDNWSGGHAV SHPPVQQQAH SWCLTPQKLQ
     HLEQLRANRN NLNPAQKLML EQLESQFVLM QQHQMRPTGV AQVRSTGIPN GPTADSSLPT
     NSVSGQQPQL ALTRVPSVSQ PGVRPACPGQ PLANGPFSAG HVPCSTSRTL GSTDTILIGN
     NHITGSGSNG NVPYLQRNAL TLPHNRTNLT SSAEEPWKNQ LSNSTQGLHK GQSSHSAGPN
     GERPLSSTGP SQHLQAAGSG IQNQNGHPTL PSNSVTQGAA LNHLSSHTAT SGGQQGITLT
     KESKPSGNIL TVPETSRHTG ETPNSTASVE GLPNHVHQMT ADAVCSPSHG DSKSPGLLSS
     DNPQLSALLM GKANNNVGTG TCDKVNNIHP AVHTKTDNSV ASSPSSAIST ATPSPKSTEQ
     TTTNSVTSLN SPHSGLHTIN GEGMEESQSP MKTDLLLVNH KPSPQIIPSM SVSIYPSSAE
     VLKACRNLGK NGLSNSSILL DKCPPPRPPS SPYPPLPKDK LNPPTPSIYL ENKRDAFFPP
     LHQFCTNPNN PVTVIRGLAG ALKLDLGLFS TKTLVEANNE HMVEVRTQLL QPADENWDPT
     GTKKIWHCES NRSHTTIAKY AQYQASSFQE SLREENEKRS HHKDHSDSES TSSDNSGRRR
     KGPFKTIKFG TNIDLSDDKK WKLQLHELTK LPAFVRVVSA GNLLSHVGHT ILGMNTVQLY
     MKVPGSRTPG HQENNNFCSV NINIGPGDCE WFVVPEGYWG VLNDFCEKNN LNFLMGSWWP
     NLEDLYEANV PVYRFIQRPG DLVWINAGTV HWVQAIGWCN NIAWNVGPLT ACQYKLAVER
     YEWNKLQSVK SIVPMVHLSW NMARNIKVSD PKLFEMIKYC LLRTLKQCQT LREALIAAGK
     EIIWHGRTKE EPAHYCSICE VEVFDLLFVT NESNSRKTYI VHCQDCARKT SGNLENFVVL
     EQYKMEDLMQ VYDQFTLAPP LPSASS
//
ID   Q86TD1_HUMAN            Unreviewed;      1035 AA.
AC   Q86TD1;
DT   01-JUN-2003, integrated into UniProtKB/TrEMBL.
DT   01-JUN-2003, sequence version 1.
DT   25-OCT-2017, entry version 64.
DE   SubName: Full=Uncharacterized protein DKFZp451J023 {ECO:0000313|EMBL:CAD89904.1};
DE   Flags: Fragment;
GN   Name=DKFZp451J023 {ECO:0000313|EMBL:CAD89904.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:CAD89904.1};
RN   [1] {ECO:0000313|EMBL:CAD89904.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Human skeletal muscle {ECO:0000313|EMBL:CAD89904.1};
RA   Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA   Fobo G., Han M., Wiemann S.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL831996; CAD89904.1; -; mRNA.
DR   RefSeq; NP_001278344.1; NM_001291415.1.
DR   RefSeq; NP_001278345.1; NM_001291416.1.
DR   RefSeq; NP_001278346.1; NM_001291417.1.
DR   RefSeq; NP_001278350.1; NM_001291421.1.
DR   UniGene; Hs.522616; -.
DR   ProteinModelPortal; Q86TD1; -.
DR   PeptideAtlas; Q86TD1; -.
DR   GeneID; 7403; -.
DR   CTD; 7403; -.
DR   HOVERGEN; HBG018063; -.
DR   GenomeRNAi; 7403; -.
DR   GO; GO:0071558; F:histone demethylase activity (H3-K27 specific); IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:InterPro.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:InterPro.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029516; KDM6C.
DR   PANTHER; PTHR14017:SF9; PTHR14017:SF9; 1.
DR   Pfam; PF02373; JmjC; 1.
DR   SMART; SM00558; JmjC; 1.
DR   PROSITE; PS51184; JMJC; 1.
PE   2: Evidence at transcript level;
FT   DOMAIN      729    892       JmjC. {ECO:0000259|PROSITE:PS51184}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:CAD89904.1}.
SQ   SEQUENCE   1035 AA;  113020 MW;  9E77CD6FEA9B1495 CRC64;
     IEEAWSLPIP AELTSRQGAM NTAQQACKPH HPNTEPVLGL SQTPISQQSL PLHMIPSSQV
     DDLSSPAKRK RTSSPTKNTS DNWSGGHAVS HPPVQQQAHS WCLTPQKLQH LEQLRANRNN
     LNPAQKLMLE QLESQFVLMQ QHQMRPTGVA QVRSTGIPNG PTADSSLPTN SVSGQQPQLA
     LTRVPSVSQP GVRPACPGQP LANGPFSAGH VPCSTSRTLG STDTILIGNN HITGSGSNGN
     VPYLQRNALT LPHNRTNLTS SAEEPWKNQL SNSTQGLHKG QSSHSAGPNG ERPLSSTGPS
     QHLQAAGSGI QNQNGHPTLP SNSVTQGAAL NHLSSHTATS GGQQGITLTK ESKPSGNILK
     VPETSRHTGE TPNSTASVEG LPNHVHQMTA DAVCSPSHGD SKSPGLLSSD NPQLSALLMG
     KANNNVGTGT CDKVNNIHPA VHTKTDNSVA SSPSSAISTA TPSPKSTEQT TTNSVTSLNS
     PHSGLHTING EGMEESQSPM KTDLLLVNHK PSPQIIPSMS VSIYPSSAEV LKACRNLGKN
     GLSNSSILLD KCPPPRPPSS PYPPLPKDKL NPPTPSIYLE NKRDAFFPPL HQFCTNPNNP
     VTVIRGLAGA LKLDLGLFST KTLVEANNEH MVEVRTQLLQ PADENWDPTG TKKIWHCESN
     RSHTTIAKYA QYQASSFQES LREENEKRSH HKDHSDSEST SSDNSGRRRK GPFKTIKFGT
     NIDLSDDKKW KLQLHELTKL PAFVRVVSAG NLLSHVGHTI LGMNTVQLYM KVPGSRTPGH
     QENNNFCSVN INIGPGDCEW FVVPEGYWGV LNDFCEKNNL NFLMGSWWPN LEDLYEANVP
     VYRFIQRPGD LVWINAGTVH WVQAIGWCNN IAWNVGPLTA CQYKLAVERY EWNKLQSVKS
     IVPMVHLSWN MARNIKVSDP KLFEMIKYCL LRTLKQCQTL REALIAAGKE IIWHGRTKEE
     PAHYCSICEV EVFDLLFVTN ESNSRKTYIV HCQDCARKTS GNLENFVVLE QYKMEDLMQV
     CDQFTLAPPL PSASS
//
ID   KLF4_HUMAN              Reviewed;         513 AA.
AC   O43474; B2R8S4; B3KT79; L0R3I6; L0R4N5; P78338; Q5T3J8; Q5T3J9;
AC   Q8N717; Q9UNP3;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2009, sequence version 3.
DT   28-FEB-2018, entry version 173.
DE   RecName: Full=Krueppel-like factor 4;
DE   AltName: Full=Epithelial zinc finger protein EZF;
DE   AltName: Full=Gut-enriched krueppel-like factor;
GN   Name=KLF4; Synonyms=EZF, GKLF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=9422764; DOI=10.1074/jbc.273.2.1026;
RA   Yet S.-F., McA'Nulty M.M., Folta S.C., Yen H.-W., Yoshizumi M.,
RA   Hsieh C.-M., Layne M.D., Chin M.T., Wang H., Perrella M.A., Jain M.K.,
RA   Lee M.-E.;
RT   "Human EZF, a Kruppel-like zinc finger protein, is expressed in
RT   vascular endothelial cells and contains transcriptional activation and
RT   repression domains.";
RL   J. Biol. Chem. 273:1026-1031(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=10392904;
RA   Foster K.W., Ren S., Louro I.D., Lobo-Ruppert S.M., McKie-Bell P.,
RA   Grizzle W., Hayes M.R., Broker T.R., Chow L.T., Ruppert J.M.;
RT   "Oncogene expression cloning by retroviral transduction of adenovirus
RT   E1A-immortalized rat kidney RK3E cells: transformation of a host with
RT   epithelial features by c-MYC and the zinc finger protein GKLF.";
RL   Cell Growth Differ. 10:423-434(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=23134681; DOI=10.1096/fj.12-220319;
RA   Camacho-Vanegas O., Till J., Miranda-Lorenzo I., Ozturk B.,
RA   Camacho S.C., Martignetti J.A.;
RT   "Shaking the family tree: Identification of novel and biologically
RT   active alternatively spliced isoforms across the KLF family of
RT   transcription factors.";
RL   FASEB J. 27:432-436(2013).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS SER-315 AND
RP   PHE-321.
RC   TISSUE=Placenta;
RA   Garrett-Sinha L.A., de Crombrugghe B.;
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Substantia nigra, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cervix, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH MUC1, AND FUNCTION.
RX   PubMed=17308127; DOI=10.1158/0008-5472.CAN-06-3063;
RA   Wei X., Xu H., Kufe D.;
RT   "Human mucin 1 oncoprotein represses transcription of the p53 tumor
RT   suppressor gene.";
RL   Cancer Res. 67:1853-1858(2007).
RN   [11]
RP   BIOTECHNOLOGY.
RX   PubMed=18035408; DOI=10.1016/j.cell.2007.11.019;
RA   Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K.,
RA   Yamanaka S.;
RT   "Induction of pluripotent stem cells from adult human fibroblasts by
RT   defined factors.";
RL   Cell 131:861-872(2007).
RN   [12]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P.,
RA   Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-32, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=18655026; DOI=10.1002/pmic.200700887;
RA   Tan F., Lu L., Cai Y., Wang J., Xie Y., Wang L., Gong Y., Xu B.-E.,
RA   Wu J., Luo Y., Qiang B., Yuan J., Sun X., Peng X.;
RT   "Proteomic analysis of ubiquitinated proteins in normal hepatocyte
RT   cell line Chang liver cells.";
RL   Proteomics 8:2885-2896(2008).
RN   [15]
RP   FUNCTION.
RX   PubMed=20071344; DOI=10.1074/jbc.M109.077958;
RA   Zhang P., Andrianakos R., Yang Y., Liu C., Lu W.;
RT   "Kruppel-like factor 4 (Klf4) prevents embryonic stem (ES) cell
RT   differentiation by regulating Nanog gene expression.";
RL   J. Biol. Chem. 285:9180-9189(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-254, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   INTERACTION WITH PBX1 AND MEIS2.
RX   PubMed=21746878; DOI=10.1128/MCB.01456-10;
RA   Bjerke G.A., Hyman-Walsh C., Wotton D.;
RT   "Cooperative transcriptional activation by Klf4, Meis2, and Pbx1.";
RL   Mol. Cell. Biol. 31:3723-3733(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Transcription factor; can act both as activator and as
CC       repressor. Binds the 5'-CACCC-3' core sequence. Binds to the
CC       promoter region of its own gene and can activate its own
CC       transcription. Regulates the expression of key transcription
CC       factors during embryonic development. Plays an important role in
CC       maintaining embryonic stem cells, and in preventing their
CC       differentiation. Required for establishing the barrier function of
CC       the skin and for postnatal maturation and maintenance of the
CC       ocular surface. Involved in the differentiation of epithelial
CC       cells and may also function in skeletal and kidney development.
CC       Contributes to the down-regulation of p53/TP53 transcription.
CC       {ECO:0000269|PubMed:17308127, ECO:0000269|PubMed:20071344}.
CC   -!- SUBUNIT: Interacts with POU5F1/OCT4 and SOX2 (By similarity).
CC       Interacts with MUC1 (via the C-terminal domain) (PubMed:17308127).
CC       Interacts with MEIS2 isoform 4 and PBX1 isoform PBX1a
CC       (PubMed:21746878). Interacts with ZNF296 (By similarity).
CC       {ECO:0000250|UniProtKB:Q60793, ECO:0000269|PubMed:17308127,
CC       ECO:0000269|PubMed:21746878}.
CC   -!- INTERACTION:
CC       Q13363:CTBP1; NbExp=4; IntAct=EBI-7232405, EBI-908846;
CC       O95983:MBD3; NbExp=3; IntAct=EBI-7232405, EBI-1783068;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O43474-3; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43474-1; Sequence=VSP_036399;
CC       Name=3;
CC         IsoId=O43474-4; Sequence=VSP_040569, VSP_036399;
CC         Note=No experimental confirmation available.;
CC       Name=4; Synonyms=1a;
CC         IsoId=O43474-5; Sequence=VSP_047470, VSP_047473;
CC       Name=5;
CC         IsoId=O43474-6; Sequence=VSP_047471, VSP_047472;
CC   -!- DOMAIN: the 9aaTAD motif is a transactivation domain present in a
CC       large number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:17467953}.
CC   -!- BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the four
CC       Yamanaka factors. When combined, these factors are sufficient to
CC       reprogram differentiated cells to an embryonic-like state
CC       designated iPS (induced pluripotent stem) cells. iPS cells exhibit
CC       the morphology and growth properties of ES cells and express ES
CC       cell marker genes. {ECO:0000269|PubMed:18035408}.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB48399.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAC03462.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAD42165.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH29923.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH30811.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=ABG25917.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAG36271.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=EAW59020.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW59021.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/KLF4ID44316ch9q31.html";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/klf4/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF022184; AAC03462.1; ALT_INIT; mRNA.
DR   EMBL; AF105036; AAD42165.1; ALT_INIT; mRNA.
DR   EMBL; HF546201; CCO02787.1; -; mRNA.
DR   EMBL; HF546202; CCO02788.1; -; mRNA.
DR   EMBL; U70663; AAB48399.1; ALT_INIT; mRNA.
DR   EMBL; AK095134; BAG52991.1; -; mRNA.
DR   EMBL; AK313489; BAG36271.1; ALT_INIT; mRNA.
DR   EMBL; DQ658241; ABG25917.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL360218; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471105; EAW59020.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471105; EAW59021.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; BC029923; AAH29923.1; ALT_INIT; mRNA.
DR   EMBL; BC030811; AAH30811.1; ALT_INIT; mRNA.
DR   CCDS; CCDS6770.2; -. [O43474-1]
DR   RefSeq; NP_001300981.1; NM_001314052.1. [O43474-3]
DR   RefSeq; NP_004226.3; NM_004235.5. [O43474-1]
DR   UniGene; Hs.376206; -.
DR   ProteinModelPortal; O43474; -.
DR   SMR; O43474; -.
DR   BioGrid; 114726; 32.
DR   DIP; DIP-57667N; -.
DR   IntAct; O43474; 15.
DR   MINT; O43474; -.
DR   iPTMnet; O43474; -.
DR   PhosphoSitePlus; O43474; -.
DR   BioMuta; KLF4; -.
DR   MaxQB; O43474; -.
DR   PeptideAtlas; O43474; -.
DR   PRIDE; O43474; -.
DR   DNASU; 9314; -.
DR   Ensembl; ENST00000374672; ENSP00000363804; ENSG00000136826. [O43474-1]
DR   GeneID; 9314; -.
DR   KEGG; hsa:9314; -.
DR   UCSC; uc004bdg.4; human. [O43474-3]
DR   CTD; 9314; -.
DR   DisGeNET; 9314; -.
DR   EuPathDB; HostDB:ENSG00000136826.14; -.
DR   GeneCards; KLF4; -.
DR   HGNC; HGNC:6348; KLF4.
DR   HPA; HPA002926; -.
DR   MIM; 602253; gene.
DR   neXtProt; NX_O43474; -.
DR   OpenTargets; ENSG00000136826; -.
DR   PharmGKB; PA30138; -.
DR   GeneTree; ENSGT00760000118998; -.
DR   HOVERGEN; HBG006220; -.
DR   InParanoid; O43474; -.
DR   KO; K17846; -.
DR   OMA; STCSFSY; -.
DR   OrthoDB; EOG091G1BN0; -.
DR   PhylomeDB; O43474; -.
DR   TreeFam; TF350556; -.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR   SignaLink; O43474; -.
DR   SIGNOR; O43474; -.
DR   ChiTaRS; KLF4; human.
DR   GeneWiki; KLF4; -.
DR   GenomeRNAi; 9314; -.
DR   PRO; PR:O43474; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000136826; -.
DR   CleanEx; HS_KLF4; -.
DR   ExpressionAtlas; O43474; baseline and differential.
DR   Genevisible; O43474; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005719; C:nuclear euchromatin; IEA:Ensembl.
DR   GO; GO:0044798; C:nuclear transcription factor complex; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:Ensembl.
DR   GO; GO:0001047; F:core promoter binding; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0042826; F:histone deacetylase binding; IEA:Ensembl.
DR   GO; GO:0035014; F:phosphatidylinositol 3-kinase regulator activity; IEA:Ensembl.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0000987; F:proximal promoter sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001221; F:transcription cofactor binding; IEA:Ensembl.
DR   GO; GO:0001010; F:transcription factor activity, sequence-specific DNA binding transcription factor recruiting; ISS:BHF-UCL.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; ISS:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IMP:BHF-UCL.
DR   GO; GO:0001190; F:transcriptional activator activity, RNA polymerase II transcription factor binding; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; NAS:UniProtKB.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0071409; P:cellular response to cycloheximide; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:BHF-UCL.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0009913; P:epidermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0048730; P:epidermis morphogenesis; IEA:Ensembl.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0007500; P:mesodermal cell fate determination; TAS:ProtInc.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:2000342; P:negative regulation of chemokine (C-X-C motif) ligand 2 production; IDA:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IGI:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; TAS:BHF-UCL.
DR   GO; GO:0045415; P:negative regulation of interleukin-8 biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:1904998; P:negative regulation of leukocyte adhesion to arterial endothelial cell; IGI:BHF-UCL.
DR   GO; GO:0014740; P:negative regulation of muscle hyperplasia; IEA:Ensembl.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0014067; P:negative regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0060761; P:negative regulation of response to cytokine stimulus; IDA:BHF-UCL.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IMP:BHF-UCL.
DR   GO; GO:1904798; P:positive regulation of core promoter binding; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:BHF-UCL.
DR   GO; GO:0046985; P:positive regulation of hemoglobin biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; IGI:BHF-UCL.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; IEA:Ensembl.
DR   GO; GO:0035166; P:post-embryonic hemopoiesis; IMP:BHF-UCL.
DR   GO; GO:0061614; P:pri-miRNA transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0048679; P:regulation of axon regeneration; IEA:Ensembl.
DR   GO; GO:0045595; P:regulation of cell differentiation; ISS:UniProtKB.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; TAS:Reactome.
DR   GO; GO:0019827; P:stem cell population maintenance; ISS:UniProtKB.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   SMART; SM00355; ZnF_C2H2; 3.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; Complete proteome; DNA-binding;
KW   Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    513       Krueppel-like factor 4.
FT                                /FTId=PRO_0000047167.
FT   ZN_FING     430    454       C2H2-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     460    484       C2H2-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     490    512       C2H2-type 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   REGION      416    513       Interaction with ZNF296.
FT                                {ECO:0000250|UniProtKB:Q60793}.
FT   REGION      473    504       Interaction with target DNA.
FT                                {ECO:0000250}.
FT   MOTIF       101    109       9aaTAD.
FT   COMPBIAS    125    149       Ser-rich.
FT   COMPBIAS    179    415       Pro-rich.
FT   MOD_RES     254    254       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   CROSSLNK     32     32       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18655026}.
FT   VAR_SEQ       1     50       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_040569.
FT   VAR_SEQ      43    118       RWREELSHMKRLPPVLPGRPYDLAAATVATDLESGGAGAAC
FT                                GGSNLAPLPRRETEEFNDLLDLDFILSNSLTHPPE -> SS
FT                                CHPVPACQRSPSQRGEDDRGPGKGPPPTLVITRAAAKPTQR
FT                                VPISRHTCEPTQVRNLTTVTGTAVDGNSPAQMN (in
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:23134681}.
FT                                /FTId=VSP_047470.
FT   VAR_SEQ      43     63       RWREELSHMKRLPPVLPGRPY -> VRNLTTVTGTAVDGNS
FT                                PAQMN (in isoform 5).
FT                                {ECO:0000303|PubMed:23134681}.
FT                                /FTId=VSP_047471.
FT   VAR_SEQ      64    513       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:23134681}.
FT                                /FTId=VSP_047472.
FT   VAR_SEQ     119    513       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:23134681}.
FT                                /FTId=VSP_047473.
FT   VAR_SEQ     367    400       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:10392904,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9422764,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_036399.
FT   VARIANT     315    315       T -> S (in dbSNP:rs1059913).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_059888.
FT   VARIANT     321    321       L -> F (in dbSNP:rs1059914).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_059889.
FT   CONFLICT     60     61       GR -> AG (in Ref. 1; AAC03462).
FT                                {ECO:0000305}.
FT   CONFLICT     77     77       G -> A (in Ref. 1; AAC03462).
FT                                {ECO:0000305}.
FT   CONFLICT    251    251       S -> T (in Ref. 1; AAC03462).
FT                                {ECO:0000305}.
FT   CONFLICT    304    304       D -> N (in Ref. 4; AAB48399).
FT                                {ECO:0000305}.
FT   CONFLICT    329    329       D -> E (in Ref. 4; AAB48399).
FT                                {ECO:0000305}.
SQ   SEQUENCE   513 AA;  54671 MW;  3B6113A3EF333935 CRC64;
     MRQPPGESDM AVSDALLPSF STFASGPAGR EKTLRQAGAP NNRWREELSH MKRLPPVLPG
     RPYDLAAATV ATDLESGGAG AACGGSNLAP LPRRETEEFN DLLDLDFILS NSLTHPPESV
     AATVSSSASA SSSSSPSSSG PASAPSTCSF TYPIRAGNDP GVAPGGTGGG LLYGRESAPP
     PTAPFNLADI NDVSPSGGFV AELLRPELDP VYIPPQQPQP PGGGLMGKFV LKASLSAPGS
     EYGSPSVISV SKGSPDGSHP VVVAPYNGGP PRTCPKIKQE AVSSCTHLGA GPPLSNGHRP
     AAHDFPLGRQ LPSRTTPTLG LEEVLSSRDC HPALPLPPGF HPHPGPNYPS FLPDQMQPQV
     PPLHYQGQSR GFVARAGEPC VCWPHFGTHG MMLTPPSSPL ELMPPGSCMP EEPKPKRGRR
     SWPRKRTATH TCDYAGCGKT YTKSSHLKAH LRTHTGEKPY HCDWDGCGWK FARSDELTRH
     YRKHTGHRPF QCQKCDRAFS RSDHLALHMK RHF
//
ID   KMT2D_HUMAN             Reviewed;        5537 AA.
AC   O14686; O14687;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 2.
DT   28-FEB-2018, entry version 171.
DE   RecName: Full=Histone-lysine N-methyltransferase 2D;
DE            Short=Lysine N-methyltransferase 2D;
DE            EC=2.1.1.43;
DE   AltName: Full=ALL1-related protein;
DE   AltName: Full=Myeloid/lymphoid or mixed-lineage leukemia protein 2;
GN   Name=KMT2D; Synonyms=ALR, MLL2, MLL4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RX   PubMed=9247308; DOI=10.1038/sj.onc.1201211;
RA   Prasad R., Zhadanov A.B., Sedkov Y., Bullrich F., Druck T.,
RA   Rallapalli R., Yano T., Alder H., Croce C.M., Huebner K., Mazo A.,
RA   Canaani E.;
RT   "Structure and expression pattern of human ALR, a novel gene with
RT   strong homology to ALL-1 involved in acute leukemia and to Drosophila
RT   trithorax.";
RL   Oncogene 15:549-560(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12482968; DOI=10.1128/MCB.23.1.140-149.2003;
RA   Goo Y.-H., Sohn Y.C., Kim D.-H., Kim S.-W., Kang M.-J., Jung D.-J.,
RA   Kwak E., Barlev N.A., Berger S.L., Chow V.T., Roeder R.G.,
RA   Azorsa D.O., Meltzer P.S., Suh P.-G., Song E.J., Lee K.-J., Lee Y.C.,
RA   Lee J.W.;
RT   "Activating signal cointegrator 2 belongs to a novel steady-state
RT   complex that contains a subset of trithorax group proteins.";
RL   Mol. Cell. Biol. 23:140-149(2003).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3130, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [5]
RP   FUNCTION, ENZYME ACTIVITY, IDENTIFICATION IN THE MLL2 COMPLEX, LXXLL
RP   MOTIFS, AND INTERACTION WITH ESR1.
RX   PubMed=16603732; DOI=10.1074/jbc.M513245200;
RA   Mo R., Rao S.M., Zhu Y.-J.;
RT   "Identification of the MLL2 complex as a coactivator for estrogen
RT   receptor alpha.";
RL   J. Biol. Chem. 281:15714-15720(2006).
RN   [6]
RP   IDENTIFICATION IN THE MLL2/3 (ASCOM) COMPLEX.
RX   PubMed=17021013; DOI=10.1073/pnas.0607313103;
RA   Lee S., Lee D.K., Dou Y., Lee J., Lee B., Kwak E., Kong Y.Y.,
RA   Lee S.K., Roeder R.G., Lee J.W.;
RT   "Coactivator as a target gene specificity determinant for histone H3
RT   lysine 4 methyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15392-15397(2006).
RN   [7]
RP   FUNCTION, ENZYME ACTIVITY, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17500065; DOI=10.1074/jbc.M701574200;
RA   Cho Y.-W., Hong T., Hong S., Guo H., Yu H., Kim D., Guszczynski T.,
RA   Dressler G.R., Copeland T.D., Kalkum M., Ge K.;
RT   "PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4
RT   methyltransferase complex.";
RL   J. Biol. Chem. 282:20395-20406(2007).
RN   [8]
RP   FUNCTION, AND IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17851529; DOI=10.1038/nature06192;
RA   Lan F., Bayliss P.E., Rinn J.L., Whetstine J.R., Wang J.K., Chen S.,
RA   Iwase S., Alpatov R., Issaeva I., Canaani E., Roberts T.M.,
RA   Chang H.Y., Shi Y.;
RT   "A histone H3 lysine 27 demethylase regulates animal posterior
RT   development.";
RL   Nature 449:689-694(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [10]
RP   IDENTIFICATION IN THE MLL2/3 COMPLEX.
RX   PubMed=17761849; DOI=10.1126/science.1149042;
RA   Lee M.G., Villa R., Trojer P., Norman J., Yan K.P., Reinberg D.,
RA   Di Croce L., Shiekhattar R.;
RT   "Demethylation of H3K27 regulates polycomb recruitment and H2A
RT   ubiquitination.";
RL   Science 318:447-450(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4738, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-2274; SER-2309;
RP   SER-2311; THR-3197 AND SER-4822, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1671; SER-2274;
RP   THR-3197; SER-4359 AND SER-4822, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-2246; LYS-3079; LYS-3433;
RP   LYS-4465 AND LYS-4776, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1606; THR-3197;
RP   SER-3199; SER-4215; SER-4359 AND SER-4738, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1671; SER-2274 AND
RP   SER-4738, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1606; SER-1671;
RP   SER-1820; SER-1834; THR-1843; THR-2240; SER-2260; SER-2274; SER-2640;
RP   SER-3130; SER-3199; SER-4359; SER-4738; SER-4822 AND SER-4849, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1151; THR-1195;
RP   SER-1249; SER-2239 AND SER-4738, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-3727, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-4756, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-4756 AND LYS-4880, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [23]
RP   VARIANTS KABUK1 PHE-5109; HIS-5179; HIS-5214; LEU-5340 AND MET-5464,
RP   AND INVOLVEMENT IN KABUK1.
RX   PubMed=20711175; DOI=10.1038/ng.646;
RA   Ng S.B., Bigham A.W., Buckingham K.J., Hannibal M.C., McMillin M.J.,
RA   Gildersleeve H.I., Beck A.E., Tabor H.K., Cooper G.M., Mefford H.C.,
RA   Lee C., Turner E.H., Smith J.D., Rieder M.J., Yoshiura K.,
RA   Matsumoto N., Ohta T., Niikawa N., Nickerson D.A., Bamshad M.J.,
RA   Shendure J.;
RT   "Exome sequencing identifies MLL2 mutations as a cause of Kabuki
RT   syndrome.";
RL   Nat. Genet. 42:790-793(2010).
RN   [24]
RP   VARIANTS KABUK1 LEU-1388; ARG-1430; TYR-1471; CYS-5048; PHE-5109;
RP   HIS-5179; CYS-5214; HIS-5214; LEU-5340; MET-5464 AND THR-5471.
RX   PubMed=21671394; DOI=10.1002/ajmg.a.34074;
RA   Hannibal M.C., Buckingham K.J., Ng S.B., Ming J.E., Beck A.E.,
RA   McMillin M.J., Gildersleeve H.I., Bigham A.W., Tabor H.K.,
RA   Mefford H.C., Cook J., Yoshiura K., Matsumoto T., Matsumoto N.,
RA   Miyake N., Tonoki H., Naritomi K., Kaname T., Nagai T., Ohashi H.,
RA   Kurosawa K., Hou J.W., Ohta T., Liang D., Sudo A., Morris C.A.,
RA   Banka S., Black G.C., Clayton-Smith J., Nickerson D.A., Zackai E.H.,
RA   Shaikh T.H., Donnai D., Niikawa N., Shendure J., Bamshad M.J.;
RT   "Spectrum of MLL2 (ALR) mutations in 110 cases of Kabuki syndrome.";
RL   Am. J. Med. Genet. A 155A:1511-1516(2011).
RN   [25]
RP   VARIANTS KABUK1 LEU-543; GLN-647; MET-1192; ARG-1453; VAL-1718;
RP   GLN-5154 AND PHE-5498.
RX   PubMed=21607748; DOI=10.1007/s00439-011-1004-y;
RA   Li Y., Boegershausen N., Alanay Y., Simsek Kiper P.O., Plume N.,
RA   Keupp K., Pohl E., Pawlik B., Rachwalski M., Milz E., Thoenes M.,
RA   Albrecht B., Prott E.C., Lehmkuehler M., Demuth S., Utine G.E.,
RA   Boduroglu K., Frankenbusch K., Borck G., Gillessen-Kaesbach G.,
RA   Yigit G., Wieczorek D., Wollnik B.;
RT   "A mutation screen in patients with Kabuki syndrome.";
RL   Hum. Genet. 130:715-724(2011).
RN   [26]
RP   VARIANTS KABUK1 CYS-5210 AND ASP-5428, AND VARIANTS THR-692; LEU-813;
RP   SER-2382; CYS-2460; LEU-2557; VAL-3398; GLY-3419 AND SER-4357.
RX   PubMed=21280141; DOI=10.1002/humu.21416;
RA   Paulussen A.D., Stegmann A.P., Blok M.J., Tserpelis D.,
RA   Posma-Velter C., Detisch Y., Smeets E.E., Wagemans A., Schrander J.J.,
RA   van den Boogaard M.J., van der Smagt J., van Haeringen A.,
RA   Stolte-Dijkstra I., Kerstjens-Frederikse W.S., Mancini G.M.,
RA   Wessels M.W., Hennekam R.C., Vreeburg M., Geraedts J., de Ravel T.,
RA   Fryns J.P., Smeets H.J., Devriendt K., Schrander-Stumpel C.T.;
RT   "MLL2 mutation spectrum in 45 patients with Kabuki syndrome.";
RL   Hum. Mutat. 32:E2018-E2025(2011).
RN   [27]
RP   VARIANTS KABUK1 GLN-1258; VAL-1417; MET-1418; ARG-1522; THR-2841;
RP   GLU-5028; VAL-5034; PRO-5059 AND GLN-5340.
RX   PubMed=21658225; DOI=10.1186/1750-1172-6-38;
RA   Micale L., Augello B., Fusco C., Selicorni A., Loviglio M.N.,
RA   Silengo M.C., Reymond A., Gumiero B., Zucchetti F., D'Addetta E.V.,
RA   Belligni E., Calcagni A., Digilio M.C., Dallapiccola B., Faravelli F.,
RA   Forzano F., Accadia M., Bonfante A., Clementi M., Daolio C.,
RA   Douzgou S., Ferrari P., Fischetto R., Garavelli L., Lapi E.,
RA   Mattina T., Melis D., Patricelli M.G., Priolo M., Prontera P.,
RA   Renieri A., Mencarelli M.A., Scarano G., della Monica M., Toschi B.,
RA   Turolla L., Vancini A., Zatterale A., Gabrielli O., Zelante L.,
RA   Merla G.;
RT   "Mutation spectrum of MLL2 in a cohort of Kabuki syndrome patients.";
RL   Orphanet J. Rare Dis. 6:38-38(2011).
RN   [28]
RP   VARIANTS KABUK1 LEU-337; LEU-4353; VAL-5047; CYS-5048; CYS-5214;
RP   THR-5471 AND TYR-5481.
RX   PubMed=22126750; DOI=10.1038/ejhg.2011.220;
RA   Banka S., Veeramachaneni R., Reardon W., Howa rd E., Bunstone S.,
RA   Ragge N., Parker M.J., Crow Y.J., Kerr B., Kingston H., Metcalfe K.,
RA   Chandler K., Magee A., Stewart F., McConnell V.P., Donnelly D.E.,
RA   Berland S., Houge G., Morton J.E., Oley C., Revencu N., Park S.M.,
RA   Davies S.J., Fry A.E., Lynch S.A., Gill H., Schweiger S., Lam W.W.,
RA   Tolmie J., Mohammed S.N., Hobson E., Smith A., Blyth M., Bennett C.,
RA   Vasudevan P.C., Garcia-Minaur S., Henderson A., Goodship J.,
RA   Wright M.J., Fisher R., Gibbons R., Price S.M., C de Silva D.,
RA   Temple I.K., Collins A.L., Lachlan K., Elmslie F., McEntagart M.,
RA   Castle B., Clayton-Smith J., Black G.C., Donnai D.;
RT   "How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in
RT   116 patients, review and analyses of mutation and phenotypic
RT   spectrum.";
RL   Eur. J. Hum. Genet. 20:381-388(2012).
RN   [29]
RP   VARIANTS KABUK1 ARG-1376; CYS-1423; GLY-1445; PHE-1526; CYS-5030;
RP   GLY-5040; CYS-5048; HIS-5048; GLN-5154; HIS-5179; ARG-5189 AND
RP   GLN-5351.
RX   PubMed=23913813; DOI=10.1002/ajmg.a.36072;
RA   Miyake N., Koshimizu E., Okamoto N., Mizuno S., Ogata T., Nagai T.,
RA   Kosho T., Ohashi H., Kato M., Sasaki G., Mabe H., Watanabe Y.,
RA   Yoshino M., Matsuishi T., Takanashi J., Shotelersuk V., Tekin M.,
RA   Ochi N., Kubota M., Ito N., Ihara K., Hara T., Tonoki H., Ohta T.,
RA   Saito K., Matsuo M., Urano M., Enokizono T., Sato A., Tanaka H.,
RA   Ogawa A., Fujita T., Hiraki Y., Kitanaka S., Matsubara Y., Makita T.,
RA   Taguri M., Nakashima M., Tsurusaki Y., Saitsu H., Yoshiura K.,
RA   Matsumoto N., Niikawa N.;
RT   "MLL2 and KDM6A mutations in patients with Kabuki syndrome.";
RL   Am. J. Med. Genet. A 161A:2234-2243(2013).
RN   [30]
RP   VARIANTS KABUK1 PHE-1424 AND GLN-4420.
RX   PubMed=24739679; DOI=10.1038/jhg.2014.25;
RA   Cheon C.K., Sohn Y.B., Ko J.M., Lee Y.J., Song J.S., Moon J.W.,
RA   Yang B.K., Ha I.S., Bae E.J., Jin H.S., Jeong S.Y.;
RT   "Identification of KMT2D and KDM6A mutations by exome sequencing in
RT   Korean patients with Kabuki syndrome.";
RL   J. Hum. Genet. 59:321-325(2014).
RN   [31]
RP   VARIANTS KABUK1 HIS-170; LEU-170; GLN-647; ARG-1380; ARG-1471;
RP   ARG-3876; SER-3897; CYS-5030; CYS-5048; HIS-5048; CYS-5214; TRP-5432
RP   AND PHE-5498, AND VARIANTS LEU-2557; LEU-2652 AND PRO-4010.
RX   PubMed=23320472; DOI=10.1111/cge.12081;
RA   Makrythanasis P., van Bon B.W., Steehouwer M., Rodriguez-Santiago B.,
RA   Simpson M., Dias P., Anderlid B.M., Arts P., Bhat M., Augello B.,
RA   Biamino E., Bongers E.M., Del Campo M., Cordeiro I.,
RA   Cueto-Gonzalez A.M., Cusco I., Deshpande C., Frysira E., Izatt L.,
RA   Flores R., Galan E., Gener B., Gilissen C., Granneman S.M., Hoyer J.,
RA   Yntema H.G., Kets C.M., Koolen D.A., Marcelis C.L., Medeira A.,
RA   Micale L., Mohammed S., de Munnik S.A., Nordgren A., Psoni S.,
RA   Reardon W., Revencu N., Roscioli T., Ruiterkamp-Versteeg M.,
RA   Santos H.G., Schoumans J., Schuurs-Hoeijmakers J.H., Silengo M.C.,
RA   Toledo L., Vendrell T., van der Burgt I., van Lier B., Zweier C.,
RA   Reymond A., Trembath R.C., Perez-Jurado L., Dupont J., de Vries B.B.,
RA   Brunner H.G., Veltman J.A., Merla G., Antonarakis S.E., Hoischen A.;
RT   "MLL2 mutation detection in 86 patients with Kabuki syndrome: a
RT   genotype-phenotype study.";
RL   Clin. Genet. 84:539-545(2013).
CC   -!- FUNCTION: Histone methyltransferase. Methylates 'Lys-4' of histone
CC       H3 (H3K4me). H3K4me represents a specific tag for epigenetic
CC       transcriptional activation. Acts as a coactivator for estrogen
CC       receptor by being recruited by ESR1, thereby activating
CC       transcription. {ECO:0000269|PubMed:16603732,
CC       ECO:0000269|PubMed:17500065, ECO:0000269|PubMed:17851529}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + L-lysine-[histone] =
CC       S-adenosyl-L-homocysteine + N(6)-methyl-L-lysine-[histone].
CC       {ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17500065}.
CC   -!- SUBUNIT: Component of the MLL2/3 complex (also named ASCOM
CC       complex), at least composed of KMT2D/MLL2 or KMT2C/MLL3, ASH2L,
CC       RBBP5, WDR5, NCOA6, DPY30, KDM6A, PAXIP1/PTIP, PAGR1 and
CC       alpha- and beta-tubulin. Interacts with ESR1; interaction is
CC       direct. {ECO:0000269|PubMed:12482968, ECO:0000269|PubMed:16603732,
CC       ECO:0000269|PubMed:17021013, ECO:0000269|PubMed:17500065,
CC       ECO:0000269|PubMed:17761849, ECO:0000269|PubMed:17851529}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=2; IntAct=EBI-996065, EBI-608057;
CC       Q9UBL3-3:ASH2L; NbExp=2; IntAct=EBI-996065, EBI-16130425;
CC       P03372:ESR1; NbExp=3; IntAct=EBI-996065, EBI-78473;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O14686-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=O14686-3; Sequence=VSP_008560;
CC   -!- TISSUE SPECIFICITY: Expressed in most adult tissues, including a
CC       variety of hematoipoietic cells, with the exception of the liver.
CC   -!- DOMAIN: LXXLL motifs 5 and 6 are essential for the association
CC       with ESR1 nuclear receptor.
CC   -!- DISEASE: Kabuki syndrome 1 (KABUK1) [MIM:147920]: A congenital
CC       mental retardation syndrome with additional features, including
CC       postnatal dwarfism, a peculiar facies characterized by long
CC       palpebral fissures with eversion of the lateral third of the lower
CC       eyelids, a broad and depressed nasal tip, large prominent
CC       earlobes, a cleft or high-arched palate, scoliosis, short fifth
CC       finger, persistence of fingerpads, radiographic abnormalities of
CC       the vertebrae, hands, and hip joints, and recurrent otitis media
CC       in infancy. {ECO:0000269|PubMed:20711175,
CC       ECO:0000269|PubMed:21280141, ECO:0000269|PubMed:21607748,
CC       ECO:0000269|PubMed:21658225, ECO:0000269|PubMed:21671394,
CC       ECO:0000269|PubMed:22126750, ECO:0000269|PubMed:23320472,
CC       ECO:0000269|PubMed:23913813, ECO:0000269|PubMed:24739679}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: This gene mapped to a chromosomal region involved
CC       in duplications and translocations associated with cancer.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding
CC       methyltransferase superfamily. Histone-lysine methyltransferase
CC       family. TRX/MLL subfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC   -!- CAUTION: Another protein KMT2B/MLL4, located on chromosome 19, was
CC       first named MLL2 (see AC Q9UMN6). Thus, KMT2B/MLL4 is often
CC       referred to as MLL2 and vice versa in the literature.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF010403; AAC51734.1; -; mRNA.
DR   EMBL; AF010404; AAC51735.1; -; mRNA.
DR   EMBL; AC011603; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS44873.1; -. [O14686-1]
DR   PIR; T03454; T03454.
DR   PIR; T03455; T03455.
DR   RefSeq; NP_003473.3; NM_003482.3. [O14686-1]
DR   RefSeq; XP_005269219.1; XM_005269162.4. [O14686-1]
DR   RefSeq; XP_006719677.1; XM_006719614.3. [O14686-3]
DR   UniGene; Hs.731384; -.
DR   PDB; 3UVK; X-ray; 1.40 A; B=5337-5347.
DR   PDB; 4ERQ; X-ray; 1.91 A; D/E/F=5333-5346.
DR   PDB; 4Z4P; X-ray; 2.20 A; A=5382-5536.
DR   PDBsum; 3UVK; -.
DR   PDBsum; 4ERQ; -.
DR   PDBsum; 4Z4P; -.
DR   ProteinModelPortal; O14686; -.
DR   SMR; O14686; -.
DR   BioGrid; 113758; 37.
DR   CORUM; O14686; -.
DR   DIP; DIP-37875N; -.
DR   ELM; O14686; -.
DR   IntAct; O14686; 24.
DR   MINT; O14686; -.
DR   STRING; 9606.ENSP00000301067; -.
DR   BindingDB; O14686; -.
DR   ChEMBL; CHEMBL2189114; -.
DR   iPTMnet; O14686; -.
DR   PhosphoSitePlus; O14686; -.
DR   BioMuta; KMT2D; -.
DR   EPD; O14686; -.
DR   MaxQB; O14686; -.
DR   PaxDb; O14686; -.
DR   PeptideAtlas; O14686; -.
DR   PRIDE; O14686; -.
DR   Ensembl; ENST00000301067; ENSP00000301067; ENSG00000167548. [O14686-1]
DR   GeneID; 8085; -.
DR   KEGG; hsa:8085; -.
DR   UCSC; uc001rta.4; human. [O14686-1]
DR   CTD; 8085; -.
DR   DisGeNET; 8085; -.
DR   EuPathDB; HostDB:ENSG00000167548.14; -.
DR   GeneCards; KMT2D; -.
DR   GeneReviews; KMT2D; -.
DR   HGNC; HGNC:7133; KMT2D.
DR   HPA; HPA035977; -.
DR   MalaCards; KMT2D; -.
DR   MIM; 147920; phenotype.
DR   MIM; 602113; gene.
DR   neXtProt; NX_O14686; -.
DR   OpenTargets; ENSG00000167548; -.
DR   Orphanet; 2322; Kabuki syndrome.
DR   PharmGKB; PA30846; -.
DR   eggNOG; KOG4443; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   GeneTree; ENSGT00760000119228; -.
DR   HOVERGEN; HBG006738; -.
DR   InParanoid; O14686; -.
DR   KO; K09187; -.
DR   OMA; QSTNYAV; -.
DR   OrthoDB; EOG091G000T; -.
DR   PhylomeDB; O14686; -.
DR   TreeFam; TF354317; -.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function.
DR   SIGNOR; O14686; -.
DR   ChiTaRS; KMT2D; human.
DR   GeneWiki; MLL2; -.
DR   GenomeRNAi; 8085; -.
DR   PRO; PR:O14686; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000167548; -.
DR   CleanEx; HS_MLL2; -.
DR   ExpressionAtlas; O14686; baseline and differential.
DR   Genevisible; O14686; HS.
DR   GO; GO:0035097; C:histone methyltransferase complex; IPI:MGI.
DR   GO; GO:0044666; C:MLL3/4 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0042800; F:histone methyltransferase activity (H3-K4 specific); TAS:Reactome.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0006342; P:chromatin silencing; ISS:UniProtKB.
DR   GO; GO:0051568; P:histone H3-K4 methylation; ISS:UniProtKB.
DR   GO; GO:0001555; P:oocyte growth; ISS:UniProtKB.
DR   GO; GO:0048477; P:oogenesis; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0045652; P:regulation of megakaryocyte differentiation; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0043627; P:response to estrogen; IDA:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.30.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 6.
DR   InterPro; IPR034732; EPHD.
DR   InterPro; IPR003889; FYrich_C.
DR   InterPro; IPR003888; FYrich_N.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR003616; Post-SET_dom.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF05965; FYRC; 1.
DR   Pfam; PF05964; FYRN; 1.
DR   Pfam; PF00628; PHD; 2.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM00542; FYRC; 1.
DR   SMART; SM00541; FYRN; 1.
DR   SMART; SM00398; HMG; 1.
DR   SMART; SM00249; PHD; 7.
DR   SMART; SM00508; PostSET; 1.
DR   SMART; SM00184; RING; 6.
DR   SMART; SM00317; SET; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   SUPFAM; SSF57903; SSF57903; 5.
DR   PROSITE; PS51805; EPHD; 2.
DR   PROSITE; PS51543; FYRC; 1.
DR   PROSITE; PS51542; FYRN; 1.
DR   PROSITE; PS50868; POST_SET; 1.
DR   PROSITE; PS50280; SET; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 5.
DR   PROSITE; PS50016; ZF_PHD_2; 5.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromatin regulator;
KW   Coiled coil; Complete proteome; Disease mutation; Isopeptide bond;
KW   Mental retardation; Metal-binding; Methylation; Methyltransferase;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   S-adenosyl-L-methionine; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1   5537       Histone-lysine N-methyltransferase 2D.
FT                                /FTId=PRO_0000124878.
FT   REPEAT      442    446       1.
FT   REPEAT      460    464       2.
FT   REPEAT      469    473       3.
FT   REPEAT      496    500       4.
FT   REPEAT      504    508       5.
FT   REPEAT      521    525       6.
FT   REPEAT      555    559       7.
FT   REPEAT      564    568       8.
FT   REPEAT      573    577       9.
FT   REPEAT      582    586       10.
FT   REPEAT      609    613       11.
FT   REPEAT      618    622       12.
FT   REPEAT      627    631       13.
FT   REPEAT      645    649       14.
FT   REPEAT      663    667       15.
FT   DOMAIN     5175   5235       FYR N-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00875}.
FT   DOMAIN     5236   5321       FYR C-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00876}.
FT   DOMAIN     5397   5513       SET. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00190}.
FT   DOMAIN     5521   5537       Post-SET. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00155}.
FT   ZN_FING     104    149       C2HC pre-PHD-type 1; degenerate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01146}.
FT   ZN_FING     170    218       PHD-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01146}.
FT   ZN_FING     226    276       PHD-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     229    274       RING-type 1; atypical.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00175}.
FT   ZN_FING     273    323       PHD-type 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     276    321       RING-type 2; degenerate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00175}.
FT   ZN_FING    1377   1430       PHD-type 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING    1427   1477       PHD-type 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING    1504   1559       PHD-type 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING    1507   1557       RING-type 3; atypical.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00175}.
FT   ZN_FING    5029   5069       C2HC pre-PHD-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01146}.
FT   ZN_FING    5090   5137       PHD-type 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01146}.
FT   REGION      439    668       15 X 5 AA repeats of S/P-P-P-E/P-E/A.
FT   REGION     5474   5475       S-adenosyl-L-methionine binding.
FT                                {ECO:0000250}.
FT   COILED     2669   2707       {ECO:0000255}.
FT   COILED     3249   3282       {ECO:0000255}.
FT   COILED     3562   3614       {ECO:0000255}.
FT   COILED     3714   3750       {ECO:0000255}.
FT   COILED     3897   3975       {ECO:0000255}.
FT   MOTIF      2686   2690       LXXLL motif 1.
FT   MOTIF      3038   3042       LXXLL motif 2.
FT   MOTIF      4222   4236       LXXLL motif 3.
FT   MOTIF      4253   4257       LXXLL motif 4.
FT   MOTIF      4463   4467       LXXLL motif 5.
FT   MOTIF      4990   4994       LXXLL motif 6.
FT   COMPBIAS    229    326       Cys-rich.
FT   COMPBIAS    374   1197       Pro-rich.
FT   COMPBIAS   1290   1328       Arg-rich.
FT   COMPBIAS   1351   1355       Poly-Glu.
FT   COMPBIAS   1397   1510       Cys-rich.
FT   COMPBIAS   2107   2626       Pro-rich.
FT   COMPBIAS   2385   2392       Poly-Pro.
FT   COMPBIAS   2707   2713       Poly-Ala.
FT   COMPBIAS   2811   2822       Gln-rich.
FT   COMPBIAS   2862   2978       Pro-rich.
FT   COMPBIAS   3261   4275       Gln-rich.
FT   COMPBIAS   4241   4360       Pro-rich.
FT   COMPBIAS   4909   4977       Pro-rich.
FT   COMPBIAS   5494   5497       Poly-Ile.
FT   METAL      5477   5477       Zinc. {ECO:0000250}.
FT   METAL      5525   5525       Zinc. {ECO:0000250}.
FT   METAL      5527   5527       Zinc. {ECO:0000250}.
FT   METAL      5532   5532       Zinc. {ECO:0000250}.
FT   BINDING    5451   5451       S-adenosyl-L-methionine.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00190}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     744    744       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDK2}.
FT   MOD_RES    1151   1151       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1195   1195       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1249   1249       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1267   1267       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q6PDK2}.
FT   MOD_RES    1270   1270       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDK2}.
FT   MOD_RES    1606   1606       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1671   1671       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1820   1820       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1834   1834       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1843   1843       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1865   1865       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q6PDK2}.
FT   MOD_RES    2239   2239       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2240   2240       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2246   2246       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2260   2260       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2274   2274       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2309   2309       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2311   2311       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2342   2342       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6PDK2}.
FT   MOD_RES    2535   2535       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q6PDK2}.
FT   MOD_RES    2640   2640       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2836   2836       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q6PDK2}.
FT   MOD_RES    3079   3079       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3130   3130       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3197   3197       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES    3199   3199       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3433   3433       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3727   3727       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES    4198   4198       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q6PDK2}.
FT   MOD_RES    4215   4215       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    4359   4359       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    4465   4465       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    4738   4738       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    4776   4776       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    4822   4822       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    4849   4849       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK   4756   4756       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK   4880   4880       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ    1729   1729       E -> EGET (in isoform 3).
FT                                {ECO:0000303|PubMed:9247308}.
FT                                /FTId=VSP_008560.
FT   VARIANT     170    170       Q -> H (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074216.
FT   VARIANT     170    170       Q -> L (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074217.
FT   VARIANT     337    337       S -> L (in KABUK1; unknown pathological
FT                                significance; dbSNP:rs200245957).
FT                                {ECO:0000269|PubMed:22126750}.
FT                                /FTId=VAR_074218.
FT   VARIANT     476    476       A -> T (in dbSNP:rs1064210).
FT                                /FTId=VAR_057359.
FT   VARIANT     543    543       S -> L (in KABUK1; unknown pathological
FT                                significance; dbSNP:rs776242478).
FT                                {ECO:0000269|PubMed:21607748}.
FT                                /FTId=VAR_074219.
FT   VARIANT     647    647       P -> Q (in KABUK1; dbSNP:rs200088180).
FT                                {ECO:0000269|PubMed:21607748,
FT                                ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074220.
FT   VARIANT     692    692       P -> T (in dbSNP:rs202076833).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064370.
FT   VARIANT     813    813       P -> L (in dbSNP:rs75226229).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064371.
FT   VARIANT    1192   1192       V -> M (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21607748}.
FT                                /FTId=VAR_074221.
FT   VARIANT    1258   1258       R -> Q (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074222.
FT   VARIANT    1376   1376       M -> R (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074223.
FT   VARIANT    1380   1380       C -> R (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074224.
FT   VARIANT    1388   1388       R -> L (in KABUK1; unknown pathological
FT                                significance; dbSNP:rs202217665).
FT                                {ECO:0000269|PubMed:21671394}.
FT                                /FTId=VAR_074225.
FT   VARIANT    1417   1417       M -> V (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074226.
FT   VARIANT    1418   1418       L -> M (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074227.
FT   VARIANT    1423   1423       R -> C (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074228.
FT   VARIANT    1424   1424       C -> F (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24739679}.
FT                                /FTId=VAR_074229.
FT   VARIANT    1430   1430       C -> R (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21671394}.
FT                                /FTId=VAR_074230.
FT   VARIANT    1445   1445       C -> G (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074231.
FT   VARIANT    1453   1453       H -> R (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21607748}.
FT                                /FTId=VAR_074232.
FT   VARIANT    1471   1471       C -> R (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074233.
FT   VARIANT    1471   1471       C -> Y (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21671394}.
FT                                /FTId=VAR_074234.
FT   VARIANT    1522   1522       Q -> R (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074235.
FT   VARIANT    1526   1526       C -> F (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074236.
FT   VARIANT    1718   1718       A -> V (in KABUK1; unknown pathological
FT                                significance; dbSNP:rs111266743).
FT                                {ECO:0000269|PubMed:21607748}.
FT                                /FTId=VAR_074237.
FT   VARIANT    2382   2382       P -> S (in dbSNP:rs3741626).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064372.
FT   VARIANT    2460   2460       R -> C (in dbSNP:rs570260017).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064373.
FT   VARIANT    2557   2557       P -> L (in dbSNP:rs189888707).
FT                                {ECO:0000269|PubMed:21280141,
FT                                ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_064374.
FT   VARIANT    2652   2652       M -> L (in dbSNP:rs147706410).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074238.
FT   VARIANT    2841   2841       P -> T (in KABUK1; unknown pathological
FT                                significance; dbSNP:rs763347763).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074239.
FT   VARIANT    3398   3398       M -> V (in dbSNP:rs75937132).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064375.
FT   VARIANT    3419   3419       D -> G (in dbSNP:rs146044282).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064376.
FT   VARIANT    3876   3876       L -> R (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074240.
FT   VARIANT    3897   3897       L -> S (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074241.
FT   VARIANT    4010   4010       S -> P (in dbSNP:rs80132640).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074242.
FT   VARIANT    4353   4353       P -> L (in KABUK1; unknown pathological
FT                                significance; dbSNP:rs778418522).
FT                                {ECO:0000269|PubMed:22126750}.
FT                                /FTId=VAR_074243.
FT   VARIANT    4357   4357       R -> S (in dbSNP:rs533214351).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064377.
FT   VARIANT    4420   4420       R -> Q (in KABUK1; unknown pathological
FT                                significance; dbSNP:rs375999143).
FT                                {ECO:0000269|PubMed:24739679}.
FT                                /FTId=VAR_074244.
FT   VARIANT    5028   5028       D -> E (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074245.
FT   VARIANT    5030   5030       R -> C (in KABUK1).
FT                                {ECO:0000269|PubMed:23320472,
FT                                ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074246.
FT   VARIANT    5034   5034       F -> V (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074247.
FT   VARIANT    5040   5040       D -> G (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074248.
FT   VARIANT    5047   5047       A -> V (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22126750}.
FT                                /FTId=VAR_074249.
FT   VARIANT    5048   5048       R -> C (in KABUK1; dbSNP:rs398123724).
FT                                {ECO:0000269|PubMed:21671394,
FT                                ECO:0000269|PubMed:22126750,
FT                                ECO:0000269|PubMed:23320472,
FT                                ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074250.
FT   VARIANT    5048   5048       R -> H (in KABUK1; dbSNP:rs886041404).
FT                                {ECO:0000269|PubMed:23320472,
FT                                ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074251.
FT   VARIANT    5059   5059       H -> P (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074252.
FT   VARIANT    5109   5109       C -> F (in KABUK1).
FT                                {ECO:0000269|PubMed:20711175,
FT                                ECO:0000269|PubMed:21671394}.
FT                                /FTId=VAR_063830.
FT   VARIANT    5154   5154       R -> Q (in KABUK1; dbSNP:rs886043497).
FT                                {ECO:0000269|PubMed:21607748,
FT                                ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074253.
FT   VARIANT    5179   5179       R -> H (in KABUK1; dbSNP:rs267607237).
FT                                {ECO:0000269|PubMed:20711175,
FT                                ECO:0000269|PubMed:21671394,
FT                                ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_063831.
FT   VARIANT    5189   5189       G -> R (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074254.
FT   VARIANT    5210   5210       Y -> C (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064378.
FT   VARIANT    5214   5214       R -> C (in KABUK1).
FT                                {ECO:0000269|PubMed:21671394,
FT                                ECO:0000269|PubMed:22126750,
FT                                ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074255.
FT   VARIANT    5214   5214       R -> H (in KABUK1; dbSNP:rs398123729).
FT                                {ECO:0000269|PubMed:20711175,
FT                                ECO:0000269|PubMed:21671394}.
FT                                /FTId=VAR_063832.
FT   VARIANT    5224   5224       R -> H (in dbSNP:rs3782356).
FT                                /FTId=VAR_017115.
FT   VARIANT    5340   5340       R -> L (in KABUK1).
FT                                {ECO:0000269|PubMed:20711175,
FT                                ECO:0000269|PubMed:21671394}.
FT                                /FTId=VAR_063833.
FT   VARIANT    5340   5340       R -> Q (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21658225}.
FT                                /FTId=VAR_074256.
FT   VARIANT    5351   5351       R -> Q (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23913813}.
FT                                /FTId=VAR_074257.
FT   VARIANT    5428   5428       G -> D (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21280141}.
FT                                /FTId=VAR_064379.
FT   VARIANT    5432   5432       R -> W (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074258.
FT   VARIANT    5464   5464       T -> M (in KABUK1; dbSNP:rs267607238).
FT                                {ECO:0000269|PubMed:20711175,
FT                                ECO:0000269|PubMed:21671394}.
FT                                /FTId=VAR_063834.
FT   VARIANT    5471   5471       R -> T (in KABUK1).
FT                                {ECO:0000269|PubMed:21671394,
FT                                ECO:0000269|PubMed:22126750}.
FT                                /FTId=VAR_074259.
FT   VARIANT    5481   5481       C -> Y (in KABUK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22126750}.
FT                                /FTId=VAR_074260.
FT   VARIANT    5498   5498       S -> F (in KABUK1).
FT                                {ECO:0000269|PubMed:21607748,
FT                                ECO:0000269|PubMed:23320472}.
FT                                /FTId=VAR_074261.
FT   CONFLICT      5      5       K -> N (in Ref. 1; AAC51734).
FT                                {ECO:0000305}.
FT   CONFLICT     14     14       E -> Q (in Ref. 1; AAC51734).
FT                                {ECO:0000305}.
FT   CONFLICT     75     75       S -> A (in Ref. 1; AAC51734).
FT                                {ECO:0000305}.
FT   CONFLICT    156    156       E -> Q (in Ref. 1; AAC51734).
FT                                {ECO:0000305}.
FT   CONFLICT    674    948       Missing (in Ref. 1; AAC51734).
FT                                {ECO:0000305}.
FT   CONFLICT   1178   1178       Q -> R (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   1544   1547       EQAA -> DHAP (in Ref. 1; AAC51734/
FT                                AAC51735). {ECO:0000305}.
FT   CONFLICT   1761   1761       K -> R (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   1766   1766       D -> G (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   2171   2171       V -> A (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   2413   2413       A -> V (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   3079   3079       K -> E (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   3287   3287       S -> P (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   3319   3319       G -> V (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   3422   3422       D -> G (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   4478   4478       R -> Q (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   4747   4747       A -> D (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   4793   4793       A -> D (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   4826   4826       A -> G (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   4865   4865       P -> A (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   4871   4871       S -> R (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   4893   4893       S -> R (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   4974   4974       S -> T (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   5116   5116       A -> G (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   CONFLICT   5522   5522       K -> E (in Ref. 1; AAC51734/AAC51735).
FT                                {ECO:0000305}.
FT   HELIX      5339   5341       {ECO:0000244|PDB:3UVK}.
FT   HELIX      5384   5398       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5399   5403       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5405   5415       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5422   5425       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5428   5432       {ECO:0000244|PDB:4Z4P}.
FT   HELIX      5433   5444       {ECO:0000244|PDB:4Z4P}.
FT   TURN       5445   5447       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5452   5454       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5456   5462       {ECO:0000244|PDB:4Z4P}.
FT   TURN       5464   5466       {ECO:0000244|PDB:4Z4P}.
FT   HELIX      5469   5472       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5480   5488       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5491   5500       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5516   5520       {ECO:0000244|PDB:4Z4P}.
FT   STRAND     5534   5536       {ECO:0000244|PDB:4Z4P}.
SQ   SEQUENCE   5537 AA;  593389 MW;  31C6DAB0A754F72A CRC64;
     MDSQKLAGED KDSEPAADGP AASEDPSATE SDLPNPHVGE VSVLSSGSPR LQETPQDCSG
     GPVRRCALCN CGEPSLHGQR ELRRFELPFD WPRCPVVSPG GSPGPNEAVL PSEDLSQIGF
     PEGLTPAHLG EPGGSCWAHH WCAAWSAGVW GQEGPELCGV DKAIFSGISQ RCSHCTRLGA
     SIPCRSPGCP RLYHFPCATA SGSFLSMKTL QLLCPEHSEG AAYLEEARCA VCEGPGELCD
     LFFCTSCGHH YHGACLDTAL TARKRAGWQC PECKVCQACR KPGNDSKMLV CETCDKGYHT
     FCLKPPMEEL PAHSWKCKAC RVCRACGAGS AELNPNSEWF ENYSLCHRCH KAQGGQTIRS
     VAEQHTPVCS RFSPPEPGDT PTDEPDALYV ACQGQPKGGH VTSMQPKEPG PLQCEAKPLG
     KAGVQLEPQL EAPLNEEMPL LPPPEESPLS PPPEESPTSP PPEASRLSPP PEELPASPLP
     EALHLSRPLE ESPLSPPPEE SPLSPPPESS PFSPLEESPL SPPEESPPSP ALETPLSPPP
     EASPLSPPFE ESPLSPPPEE LPTSPPPEAS RLSPPPEESP MSPPPEESPM SPPPEASRLF
     PPFEESPLSP PPEESPLSPP PEASRLSPPP EDSPMSPPPE ESPMSPPPEV SRLSPLPVVS
     RLSPPPEESP LSPPPEESPT SPPPEASRLS PPPEDSPTSP PPEDSPASPP PEDSLMSLPL
     EESPLLPLPE EPQLCPRSEG PHLSPRPEEP HLSPRPEEPH LSPQAEEPHL SPQPEEPCLC
     AVPEEPHLSP QAEGPHLSPQ PEELHLSPQT EEPHLSPVPE EPCLSPQPEE SHLSPQSEEP
     CLSPRPEESH LSPELEKPPL SPRPEKPPEE PGQCPAPEEL PLFPPPGEPS LSPLLGEPAL
     SEPGEPPLSP LPEELPLSPS GEPSLSPQLM PPDPLPPPLS PIITAAAPPA LSPLGELEYP
     FGAKGDSDPE SPLAAPILET PISPPPEANC TDPEPVPPMI LPPSPGSPVG PASPILMEPL
     PPQCSPLLQH SLVPQNSPPS QCSPPALPLS VPSPLSPIGK VVGVSDEAEL HEMETEKVSE
     PECPALEPSA TSPLPSPMGD LSCPAPSPAP ALDDFSGLGE DTAPLDGIDA PGSQPEPGQT
     PGSLASELKG SPVLLDPEEL APVTPMEVYP ECKQTAGQGS PCEEQEEPRA PVAPTPPTLI
     KSDIVNEISN LSQGDASASF PGSEPLLGSP DPEGGGSLSM ELGVSTDVSP ARDEGSLRLC
     TDSLPETDDS LLCDAGTAIS GGKAEGEKGR RRSSPARSRI KQGRSSSFPG RRRPRGGAHG
     GRGRGRARLK STASSIETLV VADIDSSPSK EEEEEDDDTM QNTVVLFSNT DKFVLMQDMC
     VVCGSFGRGA EGHLLACSQC SQCYHPYCVN SKITKVMLLK GWRCVECIVC EVCGQASDPS
     RLLLCDDCDI SYHTYCLDPP LLTVPKGGWK CKWCVSCMQC GAASPGFHCE WQNSYTHCGP
     CASLVTCPIC HAPYVEEDLL IQCRHCERWM HAGCESLFTE DDVEQAADEG FDCVSCQPYV
     VKPVAPVAPP ELVPMKVKEP EPQYFRFEGV WLTETGMALL RNLTMSPLHK RRQRRGRLGL
     PGEAGLEGSE PSDALGPDDK KDGDLDTDEL LKGEGGVEHM ECEIKLEGPV SPDVEPGKEE
     TEESKKRKRK PYRPGIGGFM VRQRKSHTRT KKGPAAQAEV LSGDGQPDEV IPADLPAEGA
     VEQSLAEGDE KKKQQRRGRK KSKLEDMFPA YLQEAFFGKE LLDLSRKALF AVGVGRPSFG
     LGTPKAKGDG GSERKELPTS QKGDDGPDIA DEESRGLEGK ADTPGPEDGG VKASPVPSDP
     EKPGTPGEGM LSSDLDRIST EELPKMESKD LQQLFKDVLG SEREQHLGCG TPGLEGSRTP
     LQRPFLQGGL PLGNLPSSSP MDSYPGLCQS PFLDSRERGG FFSPEPGEPD SPWTGSGGTT
     PSTPTTPTTE GEGDGLSYNQ RSLQRWEKDE ELGQLSTISP VLYANINFPN LKQDYPDWSS
     RCKQIMKLWR KVPAADKAPY LQKAKDNRAA HRINKVQKQA ESQINKQTKV GDIARKTDRP
     ALHLRIPPQP GALGSPPPAA APTIFIGSPT TPAGLSTSAD GFLKPPAGSV PGPDSPGELF
     LKLPPQVPAQ VPSQDPFGLA PAYPLEPRFP TAPPTYPPYP SPTGAPAQPP MLGASSRPGA
     GQPGEFHTTP PGTPRHQPST PDPFLKPRCP SLDNLAVPES PGVGGGKASE PLLSPPPFGE
     SRKALEVKKE ELGASSPSYG PPNLGFVDSP SSGTHLGGLE LKTPDVFKAP LTPRASQVEP
     QSPGLGLRPQ EPPPAQALAP SPPSHPDIFR PGSYTDPYAQ PPLTPRPQPP PPESCCALPP
     RSLPSDPFSR VPASPQSQSS SQSPLTPRPL SAEAFCPSPV TPRFQSPDPY SRPPSRPQSR
     DPFAPLHKPP RPQPPEVAFK AGSLAHTSLG AGGFPAALPA GPAGELHAKV PSGQPPNFVR
     SPGTGAFVGT PSPMRFTFPQ AVGEPSLKPP VPQPGLPPPH GINSHFGPGP TLGKPQSTNY
     TVATGNFHPS GSPLGPSSGS TGESYGLSPL RPPSVLPPPA PDGSLPYLSH GASQRSGITS
     PVEKREDPGT GMGSSLATAE LPGTQDPGMS GLSQTELEKQ RQRQRLRELL IRQQIQRNTL
     RQEKETAAAA AGAVGPPGSW GAEPSSPAFE QLSRGQTPFA GTQDKSSLVG LPPSKLSGPI
     LGPGSFPSDD RLSRPPPPAT PSSMDVNSRQ LVGGSQAFYQ RAPYPGSLPL QQQQQQLWQQ
     QQATAATSMR FAMSARFPST PGPELGRQAL GSPLAGISTR LPGPGEPVPG PAGPAQFIEL
     RHNVQKGLGP GGTPFPGQGP PQRPRFYPVS EDPHRLAPEG LRGLAVSGLP PQKPSAPPAP
     ELNNSLHPTP HTKGPTLPTG LELVNRPPSS TELGRPNPLA LEAGKLPCED PELDDDFDAH
     KALEDDEELA HLGLGVDVAK GDDELGTLEN LETNDPHLDD LLNGDEFDLL AYTDPELDTG
     DKKDIFNEHL RLVESANEKA EREALLRGVE PGPLGPEERP PPAADASEPR LASVLPEVKP
     KVEEGGRHPS PCQFTIATPK VEPAPAANSL GLGLKPGQSM MGSRDTRMGT GPFSSSGHTA
     EKASFGATGG PPAHLLTPSP LSGPGGSSLL EKFELESGAL TLPGGPAASG DELDKMESSL
     VASELPLLIE DLLEHEKKEL QKKQQLSAQL QPAQQQQQQQ QQHSLLSAPG PAQAMSLPHE
     GSSPSLAGSQ QQLSLGLAGA RQPGLPQPLM PTQPPAHALQ QRLAPSMAMV SNQGHMLSGQ
     HGGQAGLVPQ QSSQPVLSQK PMGTMPPSMC MKPQQLAMQQ QLANSFFPDT DLDKFAAEDI
     IDPIAKAKMV ALKGIKKVMA QGSIGVAPGM NRQQVSLLAQ RLSGGPSSDL QNHVAAGSGQ
     ERSAGDPSQP RPNPPTFAQG VINEADQRQY EEWLFHTQQL LQMQLKVLEE QIGVHRKSRK
     ALCAKQRTAK KAGREFPEAD AEKLKLVTEQ QSKIQKQLDQ VRKQQKEHTN LMAEYRNKQQ
     QQQQQQQQQQ QQHSAVLALS PSQSPRLLTK LPGQLLPGHG LQPPQGPPGG QAGGLRLTPG
     GMALPGQPGG PFLNTALAQQ QQQQHSGGAG SLAGPSGGFF PGNLALRSLG PDSRLLQERQ
     LQLQQQRMQL AQKLQQQQQQ QQQQQHLLGQ VAIQQQQQQG PGVQTNQALG PKPQGLMPPS
     SHQGLLVQQL SPQPPQGPQG MLGPAQVAVL QQQHPGALGP QGPHRQVLMT QSRVLSSPQL
     AQQGQGLMGH RLVTAQQQQQ QQQHQQQGSM AGLSHLQQSL MSHSGQPKLS AQPMGSLQQL
     QQQQQLQQQQ QLQQQQQQQL QQQQQLQQQQ LQQQQQQQQL QQQQQQQLQQ QQQQLQQQQQ
     QQQQQFQQQQ QQQQMGLLNQ SRTLLSPQQQ QQQQVALGPG MPAKPLQHFS SPGALGPTLL
     LTGKEQNTVD PAVSSEATEG PSTHQGGPLA IGTTPESMAT EPGEVKPSLS GDSQLLLVQP
     QPQPQPSSLQ LQPPLRLPGQ QQQQVSLLHT AGGGSHGQLG SGSSSEASSV PHLLAQPSVS
     LGDQPGSMTQ NLLGPQQPML ERPMQNNTGP QPPKPGPVLQ SGQGLPGVGI MPTVGQLRAQ
     LQGVLAKNPQ LRHLSPQQQQ QLQALLMQRQ LQQSQAVRQT PPYQEPGTQT SPLQGLLGCQ
     PQLGGFPGPQ TGPLQELGAG PRPQGPPRLP APPGALSTGP VLGPVHPTPP PSSPQEPKRP
     SQLPSPSSQL PTEAQLPPTH PGTPKPQGPT LEPPPGRVSP AAAQLADTLF SKGLGPWDPP
     DNLAETQKPE QSSLVPGHLD QVNGQVVPEA SQLSIKQEPR EEPCALGAQS VKREANGEPI
     GAPGTSNHLL LAGPRSEAGH LLLQKLLRAK NVQLSTGRGS EGLRAEINGH IDSKLAGLEQ
     KLQGTPSNKE DAAARKPLTP KPKRVQKASD RLVSSRKKLR KEDGVRASEA LLKQLKQELS
     LLPLTEPAIT ANFSLFAPFG SGCPVNGQSQ LRGAFGSGAL PTGPDYYSQL LTKNNLSNPP
     TPPSSLPPTP PPSVQQKMVN GVTPSEELGE HPKDAASARD SERALRDTSE VKSLDLLAAL
     PTPPHNQTED VRMESDEDSD SPDSIVPASS PESILGEEAP RFPHLGSGRW EQEDRALSPV
     IPLIPRASIP VFPDTKPYGA LGLEVPGKLP VTTWEKGKGS EVSVMLTVSA AAAKNLNGVM
     VAVAELLSMK IPNSYEVLFP ESPARAGTEP KKGEAEGPGG KEKGLEGKSP DTGPDWLKQF
     DAVLPGYTLK SQLDILSLLK QESPAPEPPT QHSYTYNVSN LDVRQLSAPP PEEPSPPPSP
     LAPSPASPPT EPLVELPTEP LAEPPVPSPL PLASSPESAR PKPRARPPEE GEDSRPPRLK
     KWKGVRWKRL RLLLTIQKGS GRQEDEREVA EFMEQLGTAL RPDKVPRDMR RCCFCHEEGD
     GATDGPARLL NLDLDLWVHL NCALWSTEVY ETQGGALMNV EVALHRGLLT KCSLCQRTGA
     TSSCNRMRCP NVYHFACAIR AKCMFFKDKT MLCPMHKIKG PCEQELSSFA VFRRVYIERD
     EVKQIASIIQ RGERLHMFRV GGLVFHAIGQ LLPHQMADFH SATALYPVGY EATRIYWSLR
     TNNRRCCYRC SIGENNGRPE FVIKVIEQGL EDLVFTDASP QAVWNRIIEP VAAMRKEADM
     LRLFPEYLKG EELFGLTVHA VLRIAESLPG VESCQNYLFR YGRHPLMELP LMINPTGCAR
     SEPKILTHYK RPHTLNSTSM SKAYQSTFTG ETNTPYSKQF VHSKSSQYRR LRTEWKNNVY
     LARSRIQGLG LYAAKDLEKH TMVIEYIGTI IRNEVANRRE KIYEEQNRGI YMFRINNEHV
     IDATLTGGPA RYINHSCAPN CVAEVVTFDK EDKIIIISSR RIPKGEELTY DYQFDFEDDQ
     HKIPCHCGAW NCRKWMN
//
ID   Q59FG6_HUMAN            Unreviewed;      2704 AA.
AC   Q59FG6;
DT   26-APR-2005, integrated into UniProtKB/TrEMBL.
DT   26-APR-2005, sequence version 1.
DT   28-FEB-2018, entry version 84.
DE   SubName: Full=Myeloid/lymphoid or mixed-lineage leukemia 2 variant {ECO:0000313|EMBL:BAD92731.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD92731.1};
RN   [1] {ECO:0000313|EMBL:BAD92731.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAD92731.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + L-lysine-[histone] =
CC       S-adenosyl-L-homocysteine + N(6)-methyl-L-lysine-[histone].
CC       {ECO:0000256|SAAS:SAAS00591578}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB209494; BAD92731.1; -; mRNA.
DR   RefSeq; NP_003473.3; NM_003482.3.
DR   UniGene; Hs.731384; -.
DR   ProteinModelPortal; Q59FG6; -.
DR   PeptideAtlas; Q59FG6; -.
DR   PRIDE; Q59FG6; -.
DR   GeneID; 8085; -.
DR   KEGG; hsa:8085; -.
DR   CTD; 8085; -.
DR   PharmGKB; PA30846; -.
DR   eggNOG; KOG4443; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   HOGENOM; HOG000168503; -.
DR   HOVERGEN; HBG006738; -.
DR   KO; K09187; -.
DR   GenomeRNAi; 8085; -.
DR   Genevisible; Q59FG6; HS.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008168; F:methyltransferase activity; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR034732; EPHD.
DR   InterPro; IPR003889; FYrich_C.
DR   InterPro; IPR003888; FYrich_N.
DR   InterPro; IPR003616; Post-SET_dom.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF05965; FYRC; 1.
DR   Pfam; PF05964; FYRN; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM00542; FYRC; 1.
DR   SMART; SM00541; FYRN; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00508; PostSET; 1.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51805; EPHD; 1.
DR   PROSITE; PS51543; FYRC; 1.
DR   PROSITE; PS51542; FYRN; 1.
DR   PROSITE; PS50868; POST_SET; 1.
DR   PROSITE; PS50280; SET; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|SAAS:SAAS00981487};
KW   Methyltransferase {ECO:0000256|SAAS:SAAS00590675};
KW   S-adenosyl-L-methionine {ECO:0000256|SAAS:SAAS00591079};
KW   Transferase {ECO:0000256|SAAS:SAAS00590675};
KW   Zinc {ECO:0000256|SAAS:SAAS00981487};
KW   Zinc-finger {ECO:0000256|SAAS:SAAS00981487}.
FT   DOMAIN     2196   2304       PHD-type. {ECO:0000259|PROSITE:PS51805}.
FT   DOMAIN     2342   2402       FYR N-terminal.
FT                                {ECO:0000259|PROSITE:PS51542}.
FT   DOMAIN     2403   2488       FYR C-terminal.
FT                                {ECO:0000259|PROSITE:PS51543}.
FT   DOMAIN     2564   2680       SET. {ECO:0000259|PROSITE:PS50280}.
FT   DOMAIN     2688   2704       Post-SET. {ECO:0000259|PROSITE:PS50868}.
FT   COILED      230    250       {ECO:0000256|SAM:Coils}.
FT   COILED      416    436       {ECO:0000256|SAM:Coils}.
FT   COILED      731    779       {ECO:0000256|SAM:Coils}.
FT   COILED      883    910       {ECO:0000256|SAM:Coils}.
FT   COILED     1064   1139       {ECO:0000256|SAM:Coils}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:BAD92731.1}.
SQ   SEQUENCE   2704 AA;  293186 MW;  41D0C6900D23C5ED CRC64;
     SARFPSTPGP ELGRQALGSP LAGISTRLPG PGEPVPGPAG PAQFIELRHN VQKGLGPGGT
     PFPGQGPPQR PRFYPVSEDP HRLAPEGLRG LAVSGLPPQK PSAPPAPELN NSLHPTPHTK
     GPTLPTGLEL VNRPPSSTEL GRPNPLALEA GKLPCEDPEL DDDFDAHKAL EDDEELAHLG
     LGVDVAKGDD ELGTLENLET NDPHLDDLLN GDEFDLLAYT DPELDTGDKK DIFNEHLRLV
     ESANEKAERE ALLRGVEPGP LGPEERPPPA ADASEPRLAS VLPEVKPKVE EGGRHPSPCQ
     FTIATPKVEP APAANSLGLG LKPGQSMMGS RDTRMGTGPF SSSGHTAEKA SFGATGGPPA
     HLLTPSPLSG PGGSSLLEKF ELESGALTLP GGPAASGDEL DKMESSLVAS ELPLLIEDLL
     EHEKKELQKK QQLSAQLQPA QQQQQQQQQH SLLSAPGPAQ AMSLPHEGSS PSLAGSQQQL
     SLGLAGARQP GLPQPLMPTQ PPAHALQQRL APSMAMVSNQ GHMLSGQHGG QAGLVPQQSS
     QPVLSQKPMG TMPPSMCMKP QQLAMQQQLA NSFFPDTDLD KFAAEDIIDP IAKAKMVALK
     GIKKVMAQGS IGVAPGMNRQ QVSLLAQRLS GGPSSDLQNH VAAGSGQERS AGDPSQPRPN
     PPTFAQGVIN EADQRQYEEW LFHTQQLLQM QLKVLEEQIG VHRKSRKALC AKQRTAKKAG
     REFPEADAEK LKLVTEQQSK IQKQLDQVRK QQKEHTNLMA EYRNKQQQQQ QQQQQQQQQH
     SAVLALSPSQ SPRLLTKLPG QLLPGHGLQP PQGPPGGQAG GLRLTPGGMA LPGQPGGPFL
     NTALAQQQQQ QHSGGAGSLA GPSGGFFPGN LALRSLGPDS RLLQERQLQL QQQRMQLAQK
     LQQQQQQQQQ QQHLLGQVAI QQQQQQGPGV QTNQALGPKP QGLMPPSSHQ GLLVQQLSPQ
     PPQGPQGMLG PAQVAVLQQQ HPGALGPQGP HRQVLMTQSR VLSSPQLAQQ GQGLMGHRLV
     TAQQQQQQQQ HQQQGSMAGL SHLQQSLMSH SGQPKLSAQP MGSLQQLQQQ QQLQQQQQLQ
     QQQQQQLQQQ QQLQQQQLQQ QQQQQQLQQQ QQQQLQQQQQ QLQQQQQQQQ QQFQQQQQQQ
     QMGLLNQSRT LLSPQQQQQQ QVALGPGMPA KPLQHFSSPG ALGPTLLLTG KEQNTVDPAV
     SSEATEGPST HQGGPLAIGT TPESMATEPG EVKPSLSGDS QLLLVQPQPQ PQPSSLQLQP
     PLRLPGQQQQ QVSLLHTAGG GSHGQLGSGS SSEASSVPHL LAQPSVSLGD QPGSMTQNLL
     GPQQPMLERP MQNNTGPQPP KPGPVLQSGQ GLPGVGIMPT VGQLRAQLQG VLAKNPQLRH
     LSPQQQQQLQ ALLMQRQLQQ SQAVRQTPPY QEPGTQTSPL QGLLGCQPQL GGFPGPQTGP
     LQELGAGPRP QGPPRLPAPP GALSTGPVLG PVHPTPPPSS PQEPKRPSQL PSPSSQLPTE
     AQLPPTHPGT PKPQGPTLEP PPGRVSPAAA QLADTLFSKG LGPWDPPDNL AETQKPEQSS
     LVPGHLDQVN GQVVPEASQL SIKQEPREEP CALGAQSVKR EANGEPIGAP GTSNHLLLAG
     PRSEAGHLLL QKLLRAKNVQ LSTGRGSEGL RAEINGHIDS KLAGLEQKLQ GTPSNKEDAA
     ARKPLTPKPK RVQKASDRLV SSRKKLRKED GVRASEALLK QLKQELSLLP LTEPAITANF
     SLFAPFGSGC PVNGQSQLRG AFGSGALPTG PDYYSQLLTK NNLSNPPTPP SSLPPTPPPS
     VQQKMVNGVT PSEELGEHPK DAASARDSER ALRDTSEVKS LDLLAALPTP PHNQTEDVRM
     ESDEDSDSPD SIVPASSPES ILGEEAPRFP HLGSGRWEQE DRALSPVIPL IPRASIPVFP
     DTKPYGALGL EVPGKLPVTT WEKGKGSEVS VMLTVSAAAA KNLNGVMVAV AELLSMKIPN
     SYEVLFPESP ARAGTEPKKG EAEGPGGKEK GLEGKSPDTG PDWLKQFDAV LPGYTLKSQL
     DILSLLKQES PAPEPPTQHS YTYNVSNLDV RQLSAPPPEE PSPPPSPLAP SPASPPTEPL
     VELPTEPLAE PPVPSPLPLA SSPESARPKP RARPPEEGED SRPPRLKKWK GVRWKRLRLL
     LTIQKGSGRQ EDEREVAEFM EQLGTALRPD KVPRDMRRCC FCHEEGDGAT DGPARLLNLD
     LDLWVHLNCA LWSTEVYETQ GGALMNVEVA LHRGLLTKCS LCQRTGATSS CNRMRCPNVY
     HFACAIRAKC MFFKDKTMLC PMHKIKGPCE QELSSFAVFR RVYIERDEVK QIASIIQRGE
     RLHMFRVGGL VFHAIGQLLP HQMADFHSAT ALYPVGYEAT RIYWSLRTNN RRCCYRCSIG
     ENNGRPEFVI KVIEQGLEDL VFTDASPQAV WNRIIEPVAA MRKEADMLRL FPEYLKGEEL
     FGLTVHAVLR IAESLPGVES CQNYLFRYGR HPLMELPLMI NPTGCARSEP KILTHYKRPH
     TLNSTSMSKA YQSTFTGETN TPYSKQFVHS KSSQYRRLRT EWKNNVYLAR SRIQGLGLYA
     AKDLEKHTMV IEYIGTIIRN EVANRREKIY EEQNRGIYMF RINNEHVIDA TLTGGPARYI
     NHSCAPNCVA EVVTFDKEDK IIIISSRRIP KGEELTYDYQ FDFEDDQHKI PCHCGAWNCR
     KWMN
//
ID   Q6PIA1_HUMAN            Unreviewed;       395 AA.
AC   Q6PIA1;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   05-JUL-2004, sequence version 1.
DT   28-FEB-2018, entry version 87.
DE   SubName: Full=MLL2 protein {ECO:0000313|EMBL:AAH39197.1};
DE   Flags: Fragment;
GN   Name=MLL2 {ECO:0000313|EMBL:AAH39197.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH39197.1};
RN   [1] {ECO:0000313|EMBL:AAH39197.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAH39197.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + L-lysine-[histone] =
CC       S-adenosyl-L-homocysteine + N(6)-methyl-L-lysine-[histone].
CC       {ECO:0000256|SAAS:SAAS00591578}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC039197; AAH39197.1; -; mRNA.
DR   RefSeq; NP_003473.3; NM_003482.3.
DR   UniGene; Hs.731384; -.
DR   ProteinModelPortal; Q6PIA1; -.
DR   PeptideAtlas; Q6PIA1; -.
DR   GeneID; 8085; -.
DR   KEGG; hsa:8085; -.
DR   CTD; 8085; -.
DR   PharmGKB; PA30846; -.
DR   eggNOG; KOG4443; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   HOVERGEN; HBG084660; -.
DR   KO; K09187; -.
DR   GenomeRNAi; 8085; -.
DR   Genevisible; Q6PIA1; HS.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0008168; F:methyltransferase activity; IEA:UniProtKB-KW.
DR   InterPro; IPR003889; FYrich_C.
DR   InterPro; IPR003888; FYrich_N.
DR   InterPro; IPR003616; Post-SET_dom.
DR   InterPro; IPR001214; SET_dom.
DR   Pfam; PF05965; FYRC; 1.
DR   Pfam; PF05964; FYRN; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM00542; FYRC; 1.
DR   SMART; SM00541; FYRN; 1.
DR   SMART; SM00508; PostSET; 1.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51543; FYRC; 1.
DR   PROSITE; PS51542; FYRN; 1.
DR   PROSITE; PS50868; POST_SET; 1.
DR   PROSITE; PS50280; SET; 1.
PE   2: Evidence at transcript level;
KW   Methyltransferase {ECO:0000256|SAAS:SAAS00590675};
KW   S-adenosyl-L-methionine {ECO:0000256|SAAS:SAAS00591079};
KW   Transferase {ECO:0000256|SAAS:SAAS00590675}.
FT   DOMAIN       33     93       FYR N-terminal.
FT                                {ECO:0000259|PROSITE:PS51542}.
FT   DOMAIN       94    179       FYR C-terminal.
FT                                {ECO:0000259|PROSITE:PS51543}.
FT   DOMAIN      255    371       SET. {ECO:0000259|PROSITE:PS50280}.
FT   DOMAIN      379    395       Post-SET. {ECO:0000259|PROSITE:PS50868}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:AAH39197.1}.
SQ   SEQUENCE   395 AA;  45887 MW;  FFFB100760B8623B CRC64;
     EQELSSFAVF RRVYIERDEV KQIASIIQRG ERLHMFRVGG LVFHAIGQLL PHQMADFHSA
     TALYPVGYEA TRIYWSLRTN NRRCCYRCSI GENNGRPEFV IKVIEQGLED LVFTDASPQA
     VWNRIIEPVA AMRKEADMLR LFPEYLKGEE LFGLTVHAVL RIAESLPGVE SCQNYLFRYG
     RHPLMELPLM INPTGCARSE PKILTHYKRP HTLNSTSMSK AYQSTFTGET NTPYSKQFVH
     SKSSQYRRLR TEWKNNVYLA RSRIQGLGLY AAKDLEKHTM VIEYIGTIIR NEVANRREKI
     YEEQNRGIYM FRINNEHVID ATLTGGPARY INHSCAPNCV AEVVTFDKED KIIIISSRRI
     PKGEELTYDY QFDFEDDQHK IPCHCGAWNC RKWMN
//
ID   A0A024RDI7_HUMAN        Unreviewed;       399 AA.
AC   A0A024RDI7;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-FEB-2018, entry version 34.
DE   SubName: Full=Lymphoid enhancer-binding factor 1, isoform CRA_b {ECO:0000313|EMBL:EAX06224.1};
GN   Name=LEF1 {ECO:0000313|EMBL:EAX06224.1};
GN   ORFNames=hCG_21073 {ECO:0000313|EMBL:EAX06224.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAX06224.1};
RN   [1] {ECO:0000313|EMBL:EAX06224.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX06224.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471057; EAX06222.1; -; Genomic_DNA.
DR   EMBL; CH471057; EAX06224.1; -; Genomic_DNA.
DR   RefSeq; NP_057353.1; NM_016269.4.
DR   UniGene; Hs.743478; -.
DR   SMR; A0A024RDI7; -.
DR   GeneID; 51176; -.
DR   KEGG; hsa:51176; -.
DR   CTD; 51176; -.
DR   EuPathDB; HostDB:ENSG00000138795.9; -.
DR   eggNOG; KOG3248; Eukaryota.
DR   eggNOG; ENOG41109RU; LUCA.
DR   KO; K04492; -.
DR   OMA; QESYHDK; -.
DR   OrthoDB; EOG091G0705; -.
DR   ChiTaRS; LEF1; human.
DR   GenomeRNAi; 51176; -.
DR   Bgee; ENSG00000138795; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-UniRule.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:InterPro.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0008301; F:DNA binding, bending; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003705; F:transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0008134; F:transcription factor binding; IEA:Ensembl.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0060033; P:anatomical structure regression; IEA:Ensembl.
DR   GO; GO:1902262; P:apoptotic process involved in blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0042100; P:B cell proliferation; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0060710; P:chorio-allantoic fusion; IEA:Ensembl.
DR   GO; GO:0021542; P:dentate gyrus development; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl.
DR   GO; GO:0060325; P:face morphogenesis; IEA:Ensembl.
DR   GO; GO:0021873; P:forebrain neuroblast division; IEA:Ensembl.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0021943; P:formation of radial glial scaffolds; IEA:Ensembl.
DR   GO; GO:0030879; P:mammary gland development; IEA:Ensembl.
DR   GO; GO:0045843; P:negative regulation of striated muscle tissue development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0048341; P:paraxial mesoderm formation; IEA:Ensembl.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0050909; P:sensory perception of taste; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0002040; P:sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0045063; P:T-helper 1 cell differentiation; IEA:Ensembl.
DR   GO; GO:0043586; P:tongue development; IEA:Ensembl.
DR   GO; GO:0061153; P:trachea gland development; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:Ensembl.
DR   Gene3D; 1.10.30.10; -; 1.
DR   Gene3D; 4.10.900.10; -; 1.
DR   InterPro; IPR027397; Catenin_binding_dom_sf.
DR   InterPro; IPR013558; CTNNB1-bd_N.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR028769; LEF1.
DR   InterPro; IPR024940; TCF/LEF.
DR   PANTHER; PTHR10373; PTHR10373; 1.
DR   PANTHER; PTHR10373:SF11; PTHR10373:SF11; 1.
DR   Pfam; PF08347; CTNNB1_binding; 1.
DR   Pfam; PF00505; HMG_box; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   4: Predicted;
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00267,
KW   ECO:0000256|SAAS:SAAS00879239};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00267}.
FT   DOMAIN      299    367       HMG box. {ECO:0000259|PROSITE:PS50118}.
FT   DNA_BIND    299    367       HMG box. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00267}.
SQ   SEQUENCE   399 AA;  44201 MW;  D480D440698EEFE3 CRC64;
     MPQLSGGGGG GGGDPELCAT DEMIPFKDEG DPQKEKIFAE ISHPEEEGDL ADIKSSLVNE
     SEIIPASNGH EVARQAQTSQ EPYHDKAREH PDDGKHPDGG LYNKGPSYSS YSGYIMMPNM
     NNDPYMSNGS LSPPIPRTSN KVPVVQPSHA VHPLTPLITY SDEHFSPGSH PSHIPSDVNS
     KQGMSRHPPA PDIPTFYPLS PGGVGQITPP LGWQGQPVYP ITGGFRQPYP SSLSVDTSMS
     RFSHHMIPGP PGPHTTGIPH PAIVTPQVKQ EHPHTDSDLM HVKPQHEQRK EQEPKRPHIK
     KPLNAFMLYM KEMRANVVAE CTLKESAAIN QILGRRWHAL SREEQAKYYE LARKERQLHM
     QLYPGWSARD NYGKKKKRKR EKLQESASGT GPRMTAAYI
//
ID   Q659G9_HUMAN            Unreviewed;        69 AA.
AC   Q659G9;
DT   25-OCT-2004, integrated into UniProtKB/TrEMBL.
DT   25-OCT-2004, sequence version 1.
DT   31-JAN-2018, entry version 83.
DE   SubName: Full=Uncharacterized protein DKFZp586H0919 {ECO:0000313|EMBL:CAH56421.1};
DE   Flags: Fragment;
GN   Name=DKFZp586H0919 {ECO:0000313|EMBL:CAH56421.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:CAH56421.1};
RN   [1] {ECO:0000313|EMBL:CAH56421.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Uterus {ECO:0000313|EMBL:CAH56421.1};
RG   The German cDNA Consortium;
RA   Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA   Fobo G., Han M., Wiemann S.;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL049409; CAH56421.1; -; mRNA.
DR   RefSeq; NP_001124185.1; NM_001130713.2.
DR   RefSeq; NP_001124186.1; NM_001130714.2.
DR   RefSeq; NP_001159591.1; NM_001166119.1.
DR   RefSeq; NP_057353.1; NM_016269.4.
DR   UniGene; Hs.743478; -.
DR   ProteinModelPortal; Q659G9; -.
DR   PeptideAtlas; Q659G9; -.
DR   PRIDE; Q659G9; -.
DR   DNASU; 51176; -.
DR   GeneID; 51176; -.
DR   KEGG; hsa:51176; -.
DR   CTD; 51176; -.
DR   PharmGKB; PA30331; -.
DR   eggNOG; KOG3248; Eukaryota.
DR   eggNOG; ENOG41109RU; LUCA.
DR   KO; K04492; -.
DR   GenomeRNAi; 51176; -.
DR   Genevisible; Q659G9; HS.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-UniRule.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:InterPro.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IEA:InterPro.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:InterPro.
DR   Gene3D; 1.10.30.10; -; 1.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR028769; LEF1.
DR   InterPro; IPR024940; TCF/LEF.
DR   PANTHER; PTHR10373; PTHR10373; 1.
DR   PANTHER; PTHR10373:SF11; PTHR10373:SF11; 1.
DR   Pfam; PF00505; HMG_box; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00267};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00267}.
FT   DOMAIN        1     37       HMG box. {ECO:0000259|PROSITE:PS50118}.
FT   DNA_BIND      1     37       HMG box. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00267}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:CAH56421.1}.
SQ   SEQUENCE   69 AA;  8251 MW;  CBF29BD0C3287867 CRC64;
     QILGRRWHAL SREEQAKYYE LARKERQLHM QLYPGWSARD NYGKKKKRKR EKLQESASGT
     GPRMTAAYI
//
ID   LEF1_HUMAN              Reviewed;         399 AA.
AC   Q9UJU2; B4DG38; B7Z8E2; E9PDK3; Q3ZCU4; Q9HAZ0;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   28-FEB-2018, entry version 174.
DE   RecName: Full=Lymphoid enhancer-binding factor 1;
DE            Short=LEF-1;
DE   AltName: Full=T cell-specific transcription factor 1-alpha;
DE            Short=TCF1-alpha;
GN   Name=LEF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   FUNCTION.
RX   PubMed=2010090; DOI=10.1101/gad.5.4.656;
RA   Waterman M.L., Fischer W.H., Jones K.A.;
RT   "A thymus-specific member of the HMG protein family regulates the
RT   human T cell receptor C alpha enhancer.";
RL   Genes Dev. 5:656-669(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RX   PubMed=10756202; DOI=10.1093/nar/28.9.1994;
RA   Hovanes K., Li T.W., Waterman M.L.;
RT   "The human LEF-1 gene contains a promoter preferentially active in
RT   lymphocytes and encodes multiple isoforms derived from alternative
RT   splicing.";
RL   Nucleic Acids Res. 28:1994-2003(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 5), ALTERNATIVE SPLICING,
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=19653274; DOI=10.1002/ijc.24802;
RA   Jesse S., Koenig A., Ellenrieder V., Menke A.;
RT   "Lef-1 isoforms regulate different target genes and reduce cellular
RT   adhesion.";
RL   Int. J. Cancer 126:1109-1120(2010).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3).
RA   Kobielak A., Kobielak K., Trzeciak W.H.;
RT   "New transcript isoform of the human LEF-1 devoid of HMG domain,
RT   derived from alternative splicing of exon 8.";
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 5 AND 7).
RC   TISSUE=Amygdala, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 6).
RC   TISSUE=Skin, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH ALYREF/THOC4.
RX   PubMed=9119228; DOI=10.1101/gad.11.5.640;
RA   Bruhn L., Munnerlyn A., Grosschedl R.;
RT   "ALY, a context-dependent coactivator of LEF-1 and AML-1, is required
RT   for TCRalpha enhancer function.";
RL   Genes Dev. 11:640-653(1997).
RN   [10]
RP   INTERACTION WITH CTNNB1.
RX   PubMed=9488439; DOI=10.1128/MCB.18.3.1248;
RA   Korinek V., Barker N., Willert K., Molenaar M., Roose J., Wagenaar G.,
RA   Markman M., Lamers W., Destree O., Clevers H.;
RT   "Two members of the Tcf family implicated in Wnt/b-catenin signaling
RT   during embryogenesis in the mouse.";
RL   Mol. Cell. Biol. 18:1248-1256(1998).
RN   [11]
RP   INTERACTION WITH TLE1, AND INHIBITION OF TRANSCRIPTIONAL ACTIVATION BY
RP   TLE1.
RX   PubMed=9751710; DOI=10.1073/pnas.95.20.11590;
RA   Levanon D., Goldstein R.E., Bernstein Y., Tang H., Goldenberg D.,
RA   Stifani S., Paroush Z., Groner Y.;
RT   "Transcriptional repression by AML1 and LEF-1 is mediated by the
RT   TLE/Groucho corepressors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11590-11595(1998).
RN   [12]
RP   IDENTIFICATION (ISOFORM 3), AND EXPRESSION IN COLON CANCER.
RX   PubMed=11326276; DOI=10.1038/88264;
RA   Hovanes K., Li T.W.H., Munguia J.E., Truong T., Milovanovic T.,
RA   Lawrence Marsh J., Holcombe R.F., Waterman M.L.;
RT   "Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are
RT   selectively expressed in colon cancer.";
RL   Nat. Genet. 28:53-57(2001).
RN   [13]
RP   FUNCTIONAL INTERACTION WITH TLE1; TLE2; TLE3 AND TLE4.
RX   PubMed=11266540; DOI=10.1093/nar/29.7.1410;
RA   Brantjes H., Roose J., van De Wetering M., Clevers H.;
RT   "All Tcf HMG box transcription factors interact with Groucho-related
RT   co-repressors.";
RL   Nucleic Acids Res. 29:1410-1419(2001).
RN   [14]
RP   INTERACTION WITH MDFI AND MDFIC.
RX   PubMed=12192039; DOI=10.1128/MCB.22.18.6393-6405.2002;
RA   Kusano S., Raab-Traub N.;
RT   "I-mfa domain proteins interact with Axin and affect its regulation of
RT   the Wnt and c-Jun N-terminal kinase signaling pathways.";
RL   Mol. Cell. Biol. 22:6393-6405(2002).
RN   [15]
RP   INTERACTION WITH NLK, PHOSPHORYLATION AT THR-155 AND/OR SER-166 BY
RP   NLK, AND MUTAGENESIS OF THR-155 AND SER-166.
RX   PubMed=12556497; DOI=10.1128/MCB.23.4.1379-1389.2003;
RA   Ishitani T., Ninomiya-Tsuji J., Matsumoto K.;
RT   "Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-
RT   activated protein kinase-related Nemo-like kinase-dependent
RT   phosphorylation in Wnt/beta-catenin signaling.";
RL   Mol. Cell. Biol. 23:1379-1389(2003).
RN   [16]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-113.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Participates in the Wnt signaling pathway. Activates
CC       transcription of target genes in the presence of CTNNB1 and EP300.
CC       May play a role in hair cell differentiation and follicle
CC       morphogenesis. TLE1, TLE2, TLE3 and TLE4 repress transactivation
CC       mediated by LEF1 and CTNNB1. Regulates T-cell receptor alpha
CC       enhancer function. Binds DNA in a sequence-specific manner. PIAG
CC       antagonizes both Wnt-dependent and Wnt-independent activation by
CC       LEF1 (By similarity). Isoform 3 lacks the CTNNB1 interaction
CC       domain and may be an antagonist for Wnt signaling. Isoform 5
CC       transcriptionally activates the fibronectin promoter, binds to and
CC       represses transcription from the E-cadherin promoter in a CTNNB1-
CC       independent manner, and is involved in reducing cellular
CC       aggregation and increasing cell migration of pancreatic cancer
CC       cells. Isoform 1 transcriptionally activates MYC and CCND1
CC       expression and enhances proliferation of pancreatic tumor cells.
CC       {ECO:0000250, ECO:0000269|PubMed:11266540,
CC       ECO:0000269|PubMed:19653274, ECO:0000269|PubMed:2010090}.
CC   -!- SUBUNIT: Binds the armadillo repeat of CTNNB1 and forms a stable
CC       complex. Interacts with EP300, TLE1 and PIASG (By similarity).
CC       Binds ALYREF/THOC4, MDFI and MDFIC. Interacts with NLK.
CC       {ECO:0000250, ECO:0000269|PubMed:12192039,
CC       ECO:0000269|PubMed:12556497, ECO:0000269|PubMed:9119228,
CC       ECO:0000269|PubMed:9488439, ECO:0000269|PubMed:9751710}.
CC   -!- INTERACTION:
CC       P35222:CTNNB1; NbExp=9; IntAct=EBI-926131, EBI-491549;
CC       P49789:FHIT; NbExp=2; IntAct=EBI-926131, EBI-741760;
CC       P08069:IGF1R; NbExp=5; IntAct=EBI-926131, EBI-475981;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00267}. Note=Found in nuclear bodies upon PIASG
CC       binding. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=7;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=A;
CC         IsoId=Q9UJU2-1; Sequence=Displayed;
CC         Note=Produced by alternative promoter usage.;
CC       Name=2; Synonyms=B, 8A;
CC         IsoId=Q9UJU2-2; Sequence=VSP_002188;
CC         Note=Produced by alternative splicing of isoform 1. May be
CC         produced at very low levels due to a premature stop codon in the
CC         mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=3; Synonyms=LEF-1-DN;
CC         IsoId=Q9UJU2-3; Sequence=VSP_007022;
CC         Note=Produced by alternative promoter usage. Acts as dominant
CC         negative mutant.;
CC       Name=4;
CC         IsoId=Q9UJU2-4; Sequence=VSP_007022, VSP_002188;
CC         Note=Produced by alternative splicing of isoform 3.;
CC       Name=5;
CC         IsoId=Q9UJU2-5; Sequence=VSP_040068;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=6;
CC         IsoId=Q9UJU2-6; Sequence=VSP_040068, VSP_040069;
CC         Note=Produced by alternative splicing of isoform 1. No
CC         experimental confirmation available.;
CC       Name=7;
CC         IsoId=Q9UJU2-7; Sequence=VSP_044877, VSP_040068;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in thymus. Not detected in normal
CC       colon, but highly expressed in colon cancer biopsies and colon
CC       cancer cell lines. Expressed in several pancreatic tumors and
CC       weakly expressed in normal pancreatic tissue. Isoforms 1 and 5 are
CC       detected in several pancreatic cell lines.
CC       {ECO:0000269|PubMed:19653274}.
CC   -!- DOMAIN: Proline-rich and acidic regions are implicated in the
CC       activation functions of RNA polymerase II transcription factors.
CC   -!- PTM: Phosphorylated at Thr-155 and/or Ser-166 by NLK.
CC       Phosphorylation by NLK at these sites represses LEF1-mediated
CC       transcriptional activation of target genes of the canonical Wnt
CC       signaling pathway. {ECO:0000269|PubMed:12556497}.
CC   -!- SIMILARITY: Belongs to the TCF/LEF family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF288571; AAG01022.1; -; mRNA.
DR   EMBL; AF198532; AAF13268.1; -; mRNA.
DR   EMBL; AF294627; AAG26886.1; -; mRNA.
DR   EMBL; AK294395; BAG57649.1; -; mRNA.
DR   EMBL; AK303272; BAH13928.1; -; mRNA.
DR   EMBL; AC092539; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC097067; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118062; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC123576; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471057; EAX06223.1; -; Genomic_DNA.
DR   EMBL; CH471057; EAX06225.1; -; Genomic_DNA.
DR   EMBL; BC040559; AAH40559.1; -; mRNA.
DR   EMBL; BC050632; AAH50632.1; -; mRNA.
DR   CCDS; CCDS3679.1; -. [Q9UJU2-1]
DR   CCDS; CCDS47122.1; -. [Q9UJU2-6]
DR   CCDS; CCDS47123.1; -. [Q9UJU2-5]
DR   CCDS; CCDS54791.1; -. [Q9UJU2-7]
DR   PIR; A39625; A39625.
DR   RefSeq; NP_001124185.1; NM_001130713.2. [Q9UJU2-5]
DR   RefSeq; NP_001124186.1; NM_001130714.2. [Q9UJU2-6]
DR   RefSeq; NP_001159591.1; NM_001166119.1. [Q9UJU2-7]
DR   RefSeq; NP_057353.1; NM_016269.4. [Q9UJU2-1]
DR   UniGene; Hs.743478; -.
DR   ProteinModelPortal; Q9UJU2; -.
DR   SMR; Q9UJU2; -.
DR   BioGrid; 119354; 40.
DR   DIP; DIP-29946N; -.
DR   IntAct; Q9UJU2; 23.
DR   MINT; Q9UJU2; -.
DR   STRING; 9606.ENSP00000265165; -.
DR   ChEMBL; CHEMBL3217392; -.
DR   iPTMnet; Q9UJU2; -.
DR   PhosphoSitePlus; Q9UJU2; -.
DR   BioMuta; LEF1; -.
DR   DMDM; 8928194; -.
DR   PaxDb; Q9UJU2; -.
DR   PeptideAtlas; Q9UJU2; -.
DR   PRIDE; Q9UJU2; -.
DR   TopDownProteomics; Q9UJU2-2; -. [Q9UJU2-2]
DR   DNASU; 51176; -.
DR   Ensembl; ENST00000265165; ENSP00000265165; ENSG00000138795. [Q9UJU2-1]
DR   Ensembl; ENST00000379951; ENSP00000369284; ENSG00000138795. [Q9UJU2-6]
DR   Ensembl; ENST00000438313; ENSP00000406176; ENSG00000138795. [Q9UJU2-5]
DR   Ensembl; ENST00000506680; ENSP00000422334; ENSG00000138795. [Q9UJU2-2]
DR   Ensembl; ENST00000510624; ENSP00000422840; ENSG00000138795. [Q9UJU2-7]
DR   GeneID; 51176; -.
DR   KEGG; hsa:51176; -.
DR   UCSC; uc003hyt.3; human. [Q9UJU2-1]
DR   CTD; 51176; -.
DR   DisGeNET; 51176; -.
DR   EuPathDB; HostDB:ENSG00000138795.9; -.
DR   GeneCards; LEF1; -.
DR   HGNC; HGNC:6551; LEF1.
DR   HPA; CAB019405; -.
DR   HPA; HPA002087; -.
DR   MIM; 153245; gene.
DR   neXtProt; NX_Q9UJU2; -.
DR   OpenTargets; ENSG00000138795; -.
DR   PharmGKB; PA30331; -.
DR   eggNOG; KOG3248; Eukaryota.
DR   eggNOG; ENOG41109RU; LUCA.
DR   GeneTree; ENSGT00390000009964; -.
DR   HOGENOM; HOG000116032; -.
DR   HOVERGEN; HBG000419; -.
DR   InParanoid; Q9UJU2; -.
DR   KO; K04492; -.
DR   OMA; QESYHDK; -.
DR   OrthoDB; EOG091G0705; -.
DR   PhylomeDB; Q9UJU2; -.
DR   TreeFam; TF318448; -.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-4411364; Binding of TCF/LEF:CTNNB1 to target gene promoters.
DR   Reactome; R-HSA-4641265; Repression of WNT target genes.
DR   Reactome; R-HSA-8951430; RUNX3 regulates WNT signaling.
DR   SignaLink; Q9UJU2; -.
DR   SIGNOR; Q9UJU2; -.
DR   ChiTaRS; LEF1; human.
DR   GeneWiki; Lymphoid_enhancer-binding_factor_1; -.
DR   GenomeRNAi; 51176; -.
DR   PRO; PR:Q9UJU2; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000138795; -.
DR   CleanEx; HS_LEF1; -.
DR   ExpressionAtlas; Q9UJU2; baseline and differential.
DR   Genevisible; Q9UJU2; HS.
DR   GO; GO:1990907; C:beta-catenin-TCF complex; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:BHF-UCL.
DR   GO; GO:0005667; C:transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0070016; F:armadillo repeat domain binding; IPI:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL.
DR   GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0008301; F:DNA binding, bending; ISS:UniProtKB.
DR   GO; GO:0035326; F:enhancer binding; IDA:UniProtKB.
DR   GO; GO:0030284; F:estrogen receptor activity; IDA:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IDA:UniProtKB.
DR   GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0042393; F:histone binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003705; F:transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding; IBA:GO_Central.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IMP:BHF-UCL.
DR   GO; GO:0046632; P:alpha-beta T cell differentiation; IBA:GO_Central.
DR   GO; GO:0060033; P:anatomical structure regression; IEA:Ensembl.
DR   GO; GO:1902262; P:apoptotic process involved in blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0060561; P:apoptotic process involved in morphogenesis; IBA:GO_Central.
DR   GO; GO:0042100; P:B cell proliferation; IBA:GO_Central.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0030509; P:BMP signaling pathway; IBA:GO_Central.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IBA:GO_Central.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IMP:BHF-UCL.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IDA:UniProtKB.
DR   GO; GO:0060710; P:chorio-allantoic fusion; IBA:GO_Central.
DR   GO; GO:0021542; P:dentate gyrus development; IBA:GO_Central.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IBA:GO_Central.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0048069; P:eye pigmentation; IBA:GO_Central.
DR   GO; GO:0060325; P:face morphogenesis; IBA:GO_Central.
DR   GO; GO:0021873; P:forebrain neuroblast division; IBA:GO_Central.
DR   GO; GO:0021879; P:forebrain neuron differentiation; IBA:GO_Central.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IBA:GO_Central.
DR   GO; GO:0021943; P:formation of radial glial scaffolds; IBA:GO_Central.
DR   GO; GO:0043966; P:histone H3 acetylation; IMP:UniProtKB.
DR   GO; GO:0043967; P:histone H4 acetylation; IMP:UniProtKB.
DR   GO; GO:0021854; P:hypothalamus development; IBA:GO_Central.
DR   GO; GO:0030879; P:mammary gland development; IBA:GO_Central.
DR   GO; GO:0048747; P:muscle fiber development; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0071866; P:negative regulation of apoptotic process in bone marrow; IMP:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043392; P:negative regulation of DNA binding; IDA:UniProtKB.
DR   GO; GO:0071899; P:negative regulation of estrogen receptor binding; IDA:UniProtKB.
DR   GO; GO:0032696; P:negative regulation of interleukin-13 production; IDA:UniProtKB.
DR   GO; GO:0032713; P:negative regulation of interleukin-4 production; IDA:UniProtKB.
DR   GO; GO:0032714; P:negative regulation of interleukin-5 production; IDA:UniProtKB.
DR   GO; GO:0045843; P:negative regulation of striated muscle tissue development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; IBA:GO_Central.
DR   GO; GO:0030223; P:neutrophil differentiation; IMP:UniProtKB.
DR   GO; GO:0071895; P:odontoblast differentiation; IBA:GO_Central.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IEP:UniProtKB.
DR   GO; GO:0060021; P:palate development; ISS:BHF-UCL.
DR   GO; GO:0048341; P:paraxial mesoderm formation; IBA:GO_Central.
DR   GO; GO:0043923; P:positive regulation by host of viral transcription; IDA:UniProtKB.
DR   GO; GO:0090068; P:positive regulation of cell cycle process; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0071864; P:positive regulation of cell proliferation in bone marrow; IMP:UniProtKB.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:AgBase.
DR   GO; GO:0030854; P:positive regulation of granulocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IBA:GO_Central.
DR   GO; GO:0016202; P:regulation of striated muscle tissue development; IBA:GO_Central.
DR   GO; GO:0050909; P:sensory perception of taste; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IBA:GO_Central.
DR   GO; GO:0002040; P:sprouting angiogenesis; IBA:GO_Central.
DR   GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0045063; P:T-helper 1 cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043586; P:tongue development; IEA:Ensembl.
DR   GO; GO:0061153; P:trachea gland development; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0016055; P:Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; TAS:Reactome.
DR   Gene3D; 1.10.30.10; -; 1.
DR   Gene3D; 4.10.900.10; -; 1.
DR   InterPro; IPR027397; Catenin_binding_dom_sf.
DR   InterPro; IPR013558; CTNNB1-bd_N.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR028769; LEF1.
DR   InterPro; IPR024940; TCF/LEF.
DR   PANTHER; PTHR10373; PTHR10373; 1.
DR   PANTHER; PTHR10373:SF11; PTHR10373:SF11; 1.
DR   Pfam; PF08347; CTNNB1_binding; 1.
DR   Pfam; PF00505; HMG_box; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative promoter usage; Alternative splicing;
KW   Complete proteome; Direct protein sequencing; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation; Wnt signaling pathway.
FT   CHAIN         1    399       Lymphoid enhancer-binding factor 1.
FT                                /FTId=PRO_0000048595.
FT   DNA_BIND    299    367       HMG box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00267}.
FT   REGION        1     62       CTNNB1-binding. {ECO:0000250}.
FT   COMPBIAS      6     13       Poly-Gly.
FT   COMPBIAS     14     52       Asp/Glu-rich (acidic).
FT   COMPBIAS     77    273       Pro-rich.
FT   COMPBIAS    374    379       Poly-Lys.
FT   MOD_RES     132    132       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     155    155       Phosphothreonine; by NLK.
FT                                {ECO:0000305|PubMed:12556497}.
FT   MOD_RES     166    166       Phosphoserine; by NLK.
FT                                {ECO:0000305|PubMed:12556497}.
FT   CROSSLNK     27     27       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   CROSSLNK    269    269       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VAR_SEQ       1    115       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_007022.
FT   VAR_SEQ       1     70       MPQLSGGGGGGGGDPELCATDEMIPFKDEGDPQKEKIFAEI
FT                                SHPEEEGDLADIKSSLVNESEIIPASNGH -> MA (in
FT                                isoform 7).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044877.
FT   VAR_SEQ     214    241       Missing (in isoform 5, isoform 6 and
FT                                isoform 7). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:19653274}.
FT                                /FTId=VSP_040068.
FT   VAR_SEQ     283    399       KPQHEQRKEQEPKRPHIKKPLNAFMLYMKEMRANVVAECTL
FT                                KESAAINQILGRRWHALSREEQAKYYELARKERQLHMQLYP
FT                                GWSARDNYGKKKKRKREKLQESASGTGPRMTAAYI -> CS
FT                                AFLLPHPFLIPSTPSPNHHHHHLLGSLSMNRERSRSQKDLT
FT                                LRSL (in isoform 2 and isoform 4).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_002188.
FT   VAR_SEQ     390    399       TGPRMTAAYI -> GKRSSFPTCKAKAATPGPLLEMEAC
FT                                (in isoform 6).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_040069.
FT   VARIANT     113    113       G -> R (in a colorectal cancer sample;
FT                                somatic mutation; dbSNP:rs369649181).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035935.
FT   MUTAGEN     155    155       T->A: Reduced phosphorylation by NLK;
FT                                when associated with A-166.
FT                                {ECO:0000269|PubMed:12556497}.
FT   MUTAGEN     166    166       S->A: Reduced phosphorylation by NLK;
FT                                when associated with A-155.
FT                                {ECO:0000269|PubMed:12556497}.
FT   CONFLICT    146    146       Q -> R (in Ref. 5; BAH13928).
FT                                {ECO:0000305}.
SQ   SEQUENCE   399 AA;  44201 MW;  D480D440698EEFE3 CRC64;
     MPQLSGGGGG GGGDPELCAT DEMIPFKDEG DPQKEKIFAE ISHPEEEGDL ADIKSSLVNE
     SEIIPASNGH EVARQAQTSQ EPYHDKAREH PDDGKHPDGG LYNKGPSYSS YSGYIMMPNM
     NNDPYMSNGS LSPPIPRTSN KVPVVQPSHA VHPLTPLITY SDEHFSPGSH PSHIPSDVNS
     KQGMSRHPPA PDIPTFYPLS PGGVGQITPP LGWQGQPVYP ITGGFRQPYP SSLSVDTSMS
     RFSHHMIPGP PGPHTTGIPH PAIVTPQVKQ EHPHTDSDLM HVKPQHEQRK EQEPKRPHIK
     KPLNAFMLYM KEMRANVVAE CTLKESAAIN QILGRRWHAL SREEQAKYYE LARKERQLHM
     QLYPGWSARD NYGKKKKRKR EKLQESASGT GPRMTAAYI
//
ID   MP2K4_HUMAN             Reviewed;         399 AA.
AC   P45985; B2R7N7; B3KYB2; D3DTS5; Q5U0B8; Q6FHX4; Q6P9H2; Q6PIE6;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   28-FEB-2018, entry version 183.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 4;
DE            Short=MAP kinase kinase 4;
DE            Short=MAPKK 4;
DE            EC=2.7.12.2;
DE   AltName: Full=JNK-activating kinase 1;
DE   AltName: Full=MAPK/ERK kinase 4;
DE            Short=MEK 4;
DE   AltName: Full=SAPK/ERK kinase 1;
DE            Short=SEK1;
DE   AltName: Full=Stress-activated protein kinase kinase 1;
DE            Short=SAPK kinase 1;
DE            Short=SAPKK-1;
DE            Short=SAPKK1;
DE   AltName: Full=c-Jun N-terminal kinase kinase 1;
DE            Short=JNKK;
GN   Name=MAP2K4; Synonyms=JNKK1, MEK4, MKK4, PRKMK4, SEK1, SERK1, SKK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7839144; DOI=10.1126/science.7839144;
RA   Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J.,
RA   Ulevitch R.J., Davis R.J.;
RT   "Independent human MAP-kinase signal transduction pathways defined by
RT   MEK and MKK isoforms.";
RL   Science 267:682-685(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=7716521; DOI=10.1126/science.7716521;
RA   Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C.,
RA   Mercurio F., Johnson G.L., Karin M.;
RT   "Identification of a dual specificity kinase that activates the Jun
RT   kinases and p38-Mpk2.";
RL   Science 268:286-290(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9622070;
RA   Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H.,
RA   Kern S.E.;
RT   "Alterations in pancreatic, biliary, and breast carcinomas support
RT   MKK4 as a genetically targeted tumor suppressor gene.";
RL   Cancer Res. 58:2339-2342(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-16.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PHOSPHORYLATION AT THR-261, ENZYME REGULATION, AND INTERACTION WITH
RP   MAP3K11/MLK3.
RX   PubMed=9003778;
RA   Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R.,
RA   Lassam N.J.;
RT   "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and
RT   MKK3/6.";
RL   EMBO J. 15:7026-7035(1996).
RN   [12]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family
RT   members to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [13]
RP   INTERACTION WITH ARRB2.
RX   PubMed=11090355; DOI=10.1126/science.290.5496.1574;
RA   McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E.,
RA   Lin F.-T., Davis R.J., Lefkowitz R.J.;
RT   "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the
RT   activation of JNK3.";
RL   Science 290:1574-1577(2000).
RN   [14]
RP   INTERACTION WITH MAPK8IP3/JIP3.
RX   PubMed=12189133; DOI=10.1074/jbc.M202004200;
RA   Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M.,
RA   Yoshioka K., Ichijo H.;
RT   "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-
RT   JNK signaling pathway. A new mode of regulation of the MAP kinase
RT   cascade.";
RL   J. Biol. Chem. 277:40703-40709(2002).
RN   [15]
RP   DOMAIN, AND INTERACTION WITH MAPK8/JNK1; MAPK9/JNK2; MAPK10/JNK3;
RP   MAPK11 AND MAPK14.
RX   PubMed=12788955; DOI=10.1074/jbc.M304229200;
RA   Ho D.T., Bardwell A.J., Abdollahi M., Bardwell L.;
RT   "A docking site in MKK4 mediates high affinity binding to JNK MAPKs
RT   and competes with similar docking sites in JNK substrates.";
RL   J. Biol. Chem. 278:32662-32672(2003).
RN   [16]
RP   DOMAIN.
RX   PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001;
RA   Takekawa M., Tatebayashi K., Saito H.;
RT   "Conserved docking site is essential for activation of mammalian MAP
RT   kinase kinases by specific MAP kinase kinase kinases.";
RL   Mol. Cell 18:295-306(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=19782076; DOI=10.1016/j.febslet.2009.09.035;
RA   Li X., MacLeod R., Dunlop A.J., Edwards H.V., Advant N., Gibson L.C.,
RA   Devine N.M., Brown K.M., Adams D.R., Houslay M.D., Baillie G.S.;
RT   "A scanning peptide array approach uncovers association sites within
RT   the JNK/beta arrestin signalling complex.";
RL   FEBS Lett. 583:3310-3316(2009).
RN   [20]
RP   REVIEW ON ENZYME REGULATION.
RX   PubMed=17496909; DOI=10.1038/sj.onc.1210392;
RA   Raman M., Chen W., Cobb M.H.;
RT   "Differential regulation and properties of MAPKs.";
RL   Oncogene 26:3100-3112(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=20801953; DOI=10.1093/jb/mvq098;
RA   Asaoka Y., Nishina H.;
RT   "Diverse physiological functions of MKK4 and MKK7 during early
RT   embryogenesis.";
RL   J. Biochem. 148:393-401(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   REVIEW ON REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008;
RA   Haeusgen W., Herdegen T., Waetzig V.;
RT   "The bottleneck of JNK signaling: molecular and functional
RT   characteristics of MKK4 and MKK7.";
RL   Eur. J. Cell Biol. 90:536-544(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-58, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 80-399.
RX   PubMed=20732303; DOI=10.1016/j.bbrc.2010.08.071;
RA   Matsumoto T., Kinoshita T., Kirii Y., Yokota K., Hamada K., Tada T.;
RT   "Crystal structures of MKK4 kinase domain reveal that substrate
RT   peptide binds to an allosteric site and induces an auto-inhibition
RT   state.";
RL   Biochem. Biophys. Res. Commun. 400:369-373(2010).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-142; TRP-154; ILE-234; ASN-251 AND
RP   THR-279.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity protein kinase which acts as an
CC       essential component of the MAP kinase signal transduction pathway.
CC       Essential component of the stress-activated protein kinase/c-Jun
CC       N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,
CC       is the one of the only known kinase to directly activate the
CC       stress-activated protein kinase/c-Jun N-terminal kinases
CC       MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and
CC       MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they
CC       differ in their preference for the phosphorylation site in the
CC       Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of
CC       the Tyr residue and MAP2K7/MKK7 for the Thr residue. The
CC       phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the
CC       prerequisite for JNK activation at least in response to
CC       proinflammatory cytokines, while other stimuli activate both
CC       MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate
CC       JNKs. MAP2K4 is required for maintaining peripheral lymphoid
CC       homeostasis. The MKK/JNK signaling pathway is also involved in
CC       mitochondrial death signaling pathway, including the release
CC       cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7
CC       exclusively activates JNKs, MAP2K4/MKK4 additionally activates the
CC       p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.
CC       {ECO:0000269|PubMed:7716521}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated in response to a variety of cellular
CC       stresses, including UV and gamma-irradiation, heat shock,
CC       hyperosmolarity, T-cell receptor stimulation, peroxide and
CC       inflammatory cytokines. Also activated by developmental cues.
CC       MAP2K4/MKK4 is activated by the majority of MKKKs, such as
CC       MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,
CC       MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.
CC       {ECO:0000269|PubMed:9003778}.
CC   -!- SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via its
CC       D domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,
CC       MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ks
CC       activators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts with
CC       ARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,
CC       ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,
CC       ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,
CC       ECO:0000269|PubMed:9003778}.
CC   -!- INTERACTION:
CC       Q13233:MAP3K1; NbExp=3; IntAct=EBI-447868, EBI-49776;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P45985-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P45985-2; Sequence=VSP_038838;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal
CC       muscle. It is also widely expressed in other tissues.
CC   -!- DOMAIN: The DVD domain (residues 364-387) contains a conserved
CC       docking site and is found in the mammalian MAP kinase kinases
CC       (MAP2Ks). The DVD sites bind to their specific upstream MAP kinase
CC       kinase kinases (MAP3Ks) and are essential for activation.
CC   -!- DOMAIN: The D domain (residues 34-52) contains a conserved docking
CC       site and is required for the binding to MAPK substrates.
CC   -!- PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAP
CC       kinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/map2k4/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L36870; AAC41719.1; -; mRNA.
DR   EMBL; U17743; AAC50127.1; -; mRNA.
DR   EMBL; AF070090; AAC24130.1; -; Genomic_DNA.
DR   EMBL; AF070080; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070081; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070082; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070083; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070084; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070085; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070086; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070087; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070088; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070089; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; CR536564; CAG38801.1; -; mRNA.
DR   EMBL; BT019676; AAV38482.1; -; mRNA.
DR   EMBL; AK131544; BAG54774.1; -; mRNA.
DR   EMBL; AK313053; BAG35884.1; -; mRNA.
DR   EMBL; DQ015703; AAY22176.1; -; Genomic_DNA.
DR   EMBL; AC005244; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW89975.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW89974.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW89976.1; -; Genomic_DNA.
DR   EMBL; BC036032; AAH36032.1; -; mRNA.
DR   EMBL; BC060764; AAH60764.1; -; mRNA.
DR   CCDS; CCDS11162.1; -. [P45985-1]
DR   CCDS; CCDS62095.1; -. [P45985-2]
DR   PIR; I38901; I38901.
DR   RefSeq; NP_001268364.1; NM_001281435.1. [P45985-2]
DR   RefSeq; NP_003001.1; NM_003010.3. [P45985-1]
DR   UniGene; Hs.514681; -.
DR   PDB; 3ALN; X-ray; 2.30 A; A/B/C=80-399.
DR   PDB; 3ALO; X-ray; 2.60 A; A=80-399.
DR   PDB; 3VUT; X-ray; 3.50 A; A/B=80-399.
DR   PDBsum; 3ALN; -.
DR   PDBsum; 3ALO; -.
DR   PDBsum; 3VUT; -.
DR   ProteinModelPortal; P45985; -.
DR   SMR; P45985; -.
DR   BioGrid; 112315; 42.
DR   CORUM; P45985; -.
DR   IntAct; P45985; 17.
DR   MINT; P45985; -.
DR   STRING; 9606.ENSP00000262445; -.
DR   BindingDB; P45985; -.
DR   ChEMBL; CHEMBL2897; -.
DR   GuidetoPHARMACOLOGY; 2065; -.
DR   iPTMnet; P45985; -.
DR   PhosphoSitePlus; P45985; -.
DR   BioMuta; MAP2K4; -.
DR   DMDM; 1170596; -.
DR   EPD; P45985; -.
DR   MaxQB; P45985; -.
DR   PaxDb; P45985; -.
DR   PeptideAtlas; P45985; -.
DR   PRIDE; P45985; -.
DR   DNASU; 6416; -.
DR   Ensembl; ENST00000353533; ENSP00000262445; ENSG00000065559. [P45985-1]
DR   Ensembl; ENST00000415385; ENSP00000410402; ENSG00000065559. [P45985-2]
DR   GeneID; 6416; -.
DR   KEGG; hsa:6416; -.
DR   UCSC; uc002gnj.5; human. [P45985-1]
DR   CTD; 6416; -.
DR   DisGeNET; 6416; -.
DR   EuPathDB; HostDB:ENSG00000065559.14; -.
DR   GeneCards; MAP2K4; -.
DR   HGNC; HGNC:6844; MAP2K4.
DR   HPA; CAB007751; -.
DR   HPA; HPA060074; -.
DR   MIM; 601335; gene.
DR   neXtProt; NX_P45985; -.
DR   OpenTargets; ENSG00000065559; -.
DR   PharmGKB; PA30589; -.
DR   eggNOG; KOG0984; Eukaryota.
DR   eggNOG; ENOG410XT3F; LUCA.
DR   GeneTree; ENSGT00760000119199; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; P45985; -.
DR   KO; K04430; -.
DR   OMA; VMKSNDC; -.
DR   OrthoDB; EOG091G0A9H; -.
DR   PhylomeDB; P45985; -.
DR   TreeFam; TF350701; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   SignaLink; P45985; -.
DR   SIGNOR; P45985; -.
DR   ChiTaRS; MAP2K4; human.
DR   EvolutionaryTrace; P45985; -.
DR   GeneWiki; MAP2K4; -.
DR   GenomeRNAi; 6416; -.
DR   PMAP-CutDB; P45985; -.
DR   PRO; PR:P45985; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000065559; -.
DR   CleanEx; HS_MAP2K4; -.
DR   ExpressionAtlas; P45985; baseline and differential.
DR   Genevisible; P45985; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0032839; C:dendrite cytoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008545; F:JUN kinase kinase activity; IEA:Ensembl.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0032147; P:activation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0061049; P:cell growth involved in cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0072709; P:cellular response to sorbitol; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0035897; P:proteolysis in other organism; TAS:Reactome.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IBA:GO_Central.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Complete proteome; Cytoplasm; Kinase; Methylation;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Stress response;
KW   Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    399       Dual specificity mitogen-activated
FT                                protein kinase kinase 4.
FT                                /FTId=PRO_0000086381.
FT   DOMAIN      102    367       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     108    116       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       37     52       D domain.
FT   REGION      364    387       DVD domain.
FT   COMPBIAS      5     19       Gly/Ser-rich.
FT   ACT_SITE    229    229       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     131    131       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         45     46       Cleavage; by anthrax lethal factor.
FT   SITE         58     59       Cleavage; by anthrax lethal factor.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      58     58       Asymmetric dimethylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      58     58       Omega-N-methylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      90     90       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     257    257       Phosphoserine; by MAP3K.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     261    261       Phosphothreonine; by MAP3K.
FT                                {ECO:0000269|PubMed:9003778}.
FT   VAR_SEQ      39     39       G -> GFQINFCEKAQS (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038838.
FT   VARIANT      16     16       S -> R (in dbSNP:rs17855590).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_062963.
FT   VARIANT     142    142       Q -> L (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040818.
FT   VARIANT     154    154       R -> W (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040819.
FT   VARIANT     234    234       N -> I (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040820.
FT   VARIANT     251    251       S -> N (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040821.
FT   VARIANT     279    279       A -> T (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs753665559).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040822.
FT   CONFLICT    118    118       K -> R (in Ref. 4; CAG38801).
FT                                {ECO:0000305}.
FT   CONFLICT    179    179       E -> G (in Ref. 6; BAG35884).
FT                                {ECO:0000305}.
FT   CONFLICT    356    356       P -> L (in Ref. 10; AAH60764).
FT                                {ECO:0000305}.
FT   STRAND       81     83       {ECO:0000244|PDB:3VUT}.
FT   STRAND       85     88       {ECO:0000244|PDB:3ALN}.
FT   STRAND       93     95       {ECO:0000244|PDB:3ALN}.
FT   STRAND      101    103       {ECO:0000244|PDB:3ALN}.
FT   STRAND      107    110       {ECO:0000244|PDB:3ALN}.
FT   STRAND      112    121       {ECO:0000244|PDB:3ALN}.
FT   TURN        122    124       {ECO:0000244|PDB:3ALN}.
FT   STRAND      127    134       {ECO:0000244|PDB:3ALN}.
FT   HELIX       139    153       {ECO:0000244|PDB:3ALN}.
FT   STRAND      164    169       {ECO:0000244|PDB:3ALN}.
FT   STRAND      171    178       {ECO:0000244|PDB:3ALN}.
FT   STRAND      182    184       {ECO:0000244|PDB:3ALN}.
FT   HELIX       185    194       {ECO:0000244|PDB:3ALN}.
FT   HELIX       202    223       {ECO:0000244|PDB:3ALN}.
FT   HELIX       232    234       {ECO:0000244|PDB:3ALN}.
FT   STRAND      235    237       {ECO:0000244|PDB:3ALN}.
FT   STRAND      243    245       {ECO:0000244|PDB:3ALN}.
FT   STRAND      249    251       {ECO:0000244|PDB:3ALN}.
FT   STRAND      255    259       {ECO:0000244|PDB:3VUT}.
FT   STRAND      267    270       {ECO:0000244|PDB:3ALO}.
FT   HELIX       272    274       {ECO:0000244|PDB:3ALO}.
FT   HELIX       287    302       {ECO:0000244|PDB:3ALN}.
FT   STRAND      312    314       {ECO:0000244|PDB:3ALO}.
FT   STRAND      316    321       {ECO:0000244|PDB:3ALO}.
FT   HELIX       338    347       {ECO:0000244|PDB:3ALN}.
FT   HELIX       352    354       {ECO:0000244|PDB:3ALN}.
FT   HELIX       358    361       {ECO:0000244|PDB:3ALN}.
FT   HELIX       365    372       {ECO:0000244|PDB:3ALN}.
FT   HELIX       377    387       {ECO:0000244|PDB:3ALN}.
SQ   SEQUENCE   399 AA;  44288 MW;  A472537F2F26770B CRC64;
     MAAPSPSGGG GSGGGSGSGT PGPVGSPAPG HPAVSSMQGK RKALKLNFAN PPFKSTARFT
     LNPNPTGVQN PHIERLRTHS IESSGKLKIS PEQHWDFTAE DLKDLGEIGR GAYGSVNKMV
     HKPSGQIMAV KRIRSTVDEK EQKQLLMDLD VVMRSSDCPY IVQFYGALFR EGDCWICMEL
     MSTSFDKFYK YVYSVLDDVI PEEILGKITL ATVKALNHLK ENLKIIHRDI KPSNILLDRS
     GNIKLCDFGI SGQLVDSIAK TRDAGCRPYM APERIDPSAS RQGYDVRSDV WSLGITLYEL
     ATGRFPYPKW NSVFDQLTQV VKGDPPQLSN SEEREFSPSF INFVNLCLTK DESKRPKYKE
     LLKHPFILMY EERAVEVACY VCKILDQMPA TPSSPMYVD
//
ID   M3K1_HUMAN              Reviewed;        1512 AA.
AC   Q13233;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 4.
DT   28-FEB-2018, entry version 181.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 1;
DE            EC=2.7.11.25;
DE   AltName: Full=MAPK/ERK kinase kinase 1;
DE            Short=MEK kinase 1;
DE            Short=MEKK 1;
GN   Name=MAP3K1; Synonyms=MAPKKK1, MEKK, MEKK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-1512, FUNCTION, AND INTERACTION WITH
RP   MAP2K4.
RX   PubMed=9808624; DOI=10.1101/gad.12.21.3369;
RA   Xia Y., Wu Z., Su B., Murray B., Karin M.;
RT   "JNKK1 organizes a MAP kinase module through specific and sequential
RT   interactions with upstream and downstream components mediated by its
RT   amino-terminal extension.";
RL   Genes Dev. 12:3369-3381(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1238-1274.
RC   TISSUE=Leukocyte;
RX   PubMed=8597633; DOI=10.1007/BF00539003;
RA   Vinik B.S., Kay E.S., Fiedorek F.T. Jr.;
RT   "Mapping of the MEK kinase gene (Mekk) to mouse chromosome 13 and
RT   human chromosome 5.";
RL   Mamm. Genome 6:782-783(1995).
RN   [4]
RP   INTERACTION WITH AXIN1.
RX   PubMed=12223491; DOI=10.1074/jbc.M208099200;
RA   Rui H.L., Fan E., Zhou H.M., Xu Z., Zhang Y., Lin S.C.;
RT   "SUMO-1 modification of the C-terminal KVEKVD of Axin is required for
RT   JNK activation but has no effect on Wnt signaling.";
RL   J. Biol. Chem. 277:42981-42986(2002).
RN   [5]
RP   INTERACTION WITH AXIN1.
RX   PubMed=15262978; DOI=10.1074/jbc.M404598200;
RA   Wong C.K., Luo W., Deng Y., Zou H., Ye Z., Lin S.-C.;
RT   "The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal
RT   kinase activation by Axin and dishevelled through distinct
RT   mechanisms.";
RL   J. Biol. Chem. 279:39366-39373(2004).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH GRIPAP1.
RX   PubMed=17761173; DOI=10.1016/j.febslet.2007.08.008;
RA   Ye B., Yu W.P., Thomas G.M., Huganir R.L.;
RT   "GRASP-1 is a neuronal scaffold protein for the JNK signaling
RT   pathway.";
RL   FEBS Lett. 581:4403-4410(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-154 AND SER-1043, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   INTERACTION WITH STK38.
RX   PubMed=17906693; DOI=10.1038/sj.onc.1210828;
RA   Enomoto A., Kido N., Ito M., Morita A., Matsumoto Y., Takamatsu N.,
RA   Hosoi Y., Miyagawa K.;
RT   "Negative regulation of MEKK1/2 signaling by serine-threonine kinase
RT   38 (STK38).";
RL   Oncogene 27:1930-1938(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292; SER-297; SER-300;
RP   SER-507 AND SER-1018, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-275 AND SER-292, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-35; SER-275;
RP   THR-285; SER-292; SER-531; SER-923 AND SER-1018, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-92 AND SER-443.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [15]
RP   VARIANTS SRXY6 PRO-189; ARG-189; ILE-GLN-211 INS AND ARG-616, AND
RP   CHARACTERIZATION OF VARIANTS SRXY6 PRO-189 AND ARG-189.
RX   PubMed=21129722; DOI=10.1016/j.ajhg.2010.11.003;
RA   Pearlman A., Loke J., Le Caignec C., White S., Chin L., Friedman A.,
RA   Warr N., Willan J., Brauer D., Farmer C., Brooks E., Oddoux C.,
RA   Riley B., Shajahan S., Camerino G., Homfray T., Crosby A.H.,
RA   Couper J., David A., Greenfield A., Sinclair A., Ostrer H.;
RT   "Mutations in MAP3K1 cause 46,XY disorders of sex development and
RT   implicate a common signal transduction pathway in human testis
RT   determination.";
RL   Am. J. Hum. Genet. 87:898-904(2010).
CC   -!- FUNCTION: Component of a protein kinase signal transduction
CC       cascade (PubMed:9808624). Activates the ERK and JNK kinase
CC       pathways by phosphorylation of MAP2K1 and MAP2K4 (PubMed:9808624).
CC       May phosphorylate the MAPK8/JNK1 kinase (PubMed:17761173).
CC       Activates CHUK and IKBKB, the central protein kinases of the NF-
CC       kappa-B pathway (PubMed:9808624). {ECO:0000269|PubMed:17761173,
CC       ECO:0000269|PubMed:9808624}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by autophosphorylation on Thr-1400
CC       and Thr-1412 following oligomerization.
CC   -!- SUBUNIT: Binds both upstream activators and downstream substrates
CC       in multimolecular complexes through its N-terminus
CC       (PubMed:9808624). Oligomerizes after binding MAP2K4 or TRAF2
CC       (PubMed:9808624). Interacts with AXIN1 (PubMed:12223491,
CC       PubMed:15262978). Interacts (via the kinase catalytic domain) with
CC       STK38 (PubMed:17906693). Interacts with GRIPAP1 (PubMed:17761173).
CC       {ECO:0000269|PubMed:12223491, ECO:0000269|PubMed:15262978,
CC       ECO:0000269|PubMed:17761173, ECO:0000269|PubMed:17906693,
CC       ECO:0000269|PubMed:9808624}.
CC   -!- INTERACTION:
CC       P32121:ARRB2; NbExp=2; IntAct=EBI-49776, EBI-714559;
CC       P15056:BRAF; NbExp=2; IntAct=EBI-49776, EBI-365980;
CC       P61962:DCAF7; NbExp=7; IntAct=EBI-49776, EBI-359808;
CC       O75369:FLNB; NbExp=2; IntAct=EBI-49776, EBI-352089;
CC       P45985:MAP2K4; NbExp=3; IntAct=EBI-49776, EBI-447868;
CC       Q12851:MAP4K2; NbExp=2; IntAct=EBI-49776, EBI-49783;
CC       Q12933:TRAF2; NbExp=2; IntAct=EBI-49776, EBI-355744;
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- DISEASE: 46,XY sex reversal 6 (SRXY6) [MIM:613762]: A disorder of
CC       sex development. Affected individuals have a 46,XY karyotype but
CC       present as phenotypically normal females.
CC       {ECO:0000269|PubMed:21129722}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC008937; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF042838; AAC97073.1; -; mRNA.
DR   EMBL; U29671; AAB05828.1; -; Genomic_DNA.
DR   CCDS; CCDS43318.1; -.
DR   PIR; G01887; G01887.
DR   RefSeq; NP_005912.1; NM_005921.1.
DR   UniGene; Hs.653654; -.
DR   ProteinModelPortal; Q13233; -.
DR   SMR; Q13233; -.
DR   BioGrid; 110378; 137.
DR   DIP; DIP-27520N; -.
DR   ELM; Q13233; -.
DR   IntAct; Q13233; 39.
DR   MINT; Q13233; -.
DR   STRING; 9606.ENSP00000382423; -.
DR   BindingDB; Q13233; -.
DR   ChEMBL; CHEMBL3956; -.
DR   DrugBank; DB06061; AZD-8330.
DR   GuidetoPHARMACOLOGY; 2069; -.
DR   iPTMnet; Q13233; -.
DR   PhosphoSitePlus; Q13233; -.
DR   BioMuta; MAP3K1; -.
DR   DMDM; 218512139; -.
DR   SWISS-2DPAGE; Q13233; -.
DR   EPD; Q13233; -.
DR   MaxQB; Q13233; -.
DR   PaxDb; Q13233; -.
DR   PeptideAtlas; Q13233; -.
DR   PRIDE; Q13233; -.
DR   DNASU; 4214; -.
DR   Ensembl; ENST00000399503; ENSP00000382423; ENSG00000095015.
DR   GeneID; 4214; -.
DR   KEGG; hsa:4214; -.
DR   UCSC; uc003jqw.5; human.
DR   CTD; 4214; -.
DR   DisGeNET; 4214; -.
DR   EuPathDB; HostDB:ENSG00000095015.5; -.
DR   GeneCards; MAP3K1; -.
DR   GeneReviews; MAP3K1; -.
DR   H-InvDB; HIX0024789; -.
DR   HGNC; HGNC:6848; MAP3K1.
DR   HPA; CAB004500; -.
DR   HPA; HPA046509; -.
DR   MalaCards; MAP3K1; -.
DR   MIM; 600982; gene.
DR   MIM; 613762; phenotype.
DR   neXtProt; NX_Q13233; -.
DR   OpenTargets; ENSG00000095015; -.
DR   Orphanet; 242; 46,XY complete gonadal dysgenesis.
DR   Orphanet; 251510; 46,XY partial gonadal dysgenesis.
DR   PharmGKB; PA30592; -.
DR   eggNOG; KOG4279; Eukaryota.
DR   eggNOG; ENOG410XQGS; LUCA.
DR   GeneTree; ENSGT00800000124036; -.
DR   HOGENOM; HOG000113437; -.
DR   HOVERGEN; HBG006302; -.
DR   InParanoid; Q13233; -.
DR   KO; K04416; -.
DR   OMA; STHFTRM; -.
DR   OrthoDB; EOG091G03WB; -.
DR   PhylomeDB; Q13233; -.
DR   TreeFam; TF105112; -.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane.
DR   SignaLink; Q13233; -.
DR   SIGNOR; Q13233; -.
DR   ChiTaRS; MAP3K1; human.
DR   GeneWiki; MAP3K1; -.
DR   GenomeRNAi; 4214; -.
DR   PRO; PR:Q13233; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000095015; -.
DR   CleanEx; HS_MAP3K1; -.
DR   Genevisible; Q13233; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; NAS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0032147; P:activation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IBA:GO_Central.
DR   Gene3D; 1.25.10.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR007527; Znf_SWIM.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   PROSITE; PS50966; ZF_SWIM; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Complete proteome; Kinase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2   1512       Mitogen-activated protein kinase kinase
FT                                kinase 1.
FT                                /FTId=PRO_0000086240.
FT   DOMAIN     1243   1508       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     338    366       SWIM-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00325}.
FT   ZN_FING     443    492       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   NP_BIND    1249   1257       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS      2      5       Poly-Ala.
FT   COMPBIAS     25     29       Poly-Gly.
FT   COMPBIAS     36     41       Poly-Ala.
FT   COMPBIAS    422    431       Poly-Ser.
FT   COMPBIAS    842    847       Poly-Ser.
FT   COMPBIAS    942    949       Poly-Thr.
FT   COMPBIAS   1182   1187       Poly-Glu.
FT   COMPBIAS   1216   1219       Poly-Ile.
FT   ACT_SITE   1369   1369       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING    1272   1272       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      35     35       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     137    137       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P53349}.
FT   MOD_RES     154    154       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     275    275       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     285    285       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     292    292       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     297    297       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     300    300       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     507    507       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     531    531       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     923    923       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1018   1018       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1043   1043       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES    1400   1400       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P53349}.
FT   MOD_RES    1412   1412       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P53349}.
FT   VARIANT      92     92       S -> N. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040680.
FT   VARIANT     189    189       L -> P (in SRXY6; increases
FT                                phosphorylation of the downstream target
FT                                MAPK3/MAPK1 compared to wild-type and
FT                                enhances binding of RHOA to the mutant
FT                                MAP3K1 complex; dbSNP:rs387906788).
FT                                {ECO:0000269|PubMed:21129722}.
FT                                /FTId=VAR_065504.
FT   VARIANT     189    189       L -> R (in SRXY6; increases
FT                                phosphorylation of the downstream targets
FT                                MAPK14 and MAPK3/MAPK1 compared to wild-
FT                                type and enhances binding of RHOA to the
FT                                mutant MAP3K1 complex;
FT                                dbSNP:rs387906788).
FT                                {ECO:0000269|PubMed:21129722}.
FT                                /FTId=VAR_065505.
FT   VARIANT     211    211       V -> VIQ (in SRXY6).
FT                                /FTId=VAR_065506.
FT   VARIANT     443    443       C -> S. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040681.
FT   VARIANT     616    616       G -> R (in SRXY6; dbSNP:rs143853590).
FT                                {ECO:0000269|PubMed:21129722}.
FT                                /FTId=VAR_065507.
FT   VARIANT     806    806       D -> N (in dbSNP:rs702689).
FT                                /FTId=VAR_051636.
FT   VARIANT     906    906       V -> I (in dbSNP:rs832582).
FT                                /FTId=VAR_051637.
FT   CONFLICT     20     20       T -> P (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT     37     37       P -> R (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    120    120       G -> R (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    351    351       R -> H (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    845    845       S -> SV (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    859    859       I -> Y (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    878    902       DGQQDSFLQASVPNNYLETTENSSP -> QRQQHNSFCRHL
FT                                FPTTIWKPQRTVPL (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    933    933       S -> R (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT   1097   1097       C -> L (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT   1104   1107       AVIP -> CCYT (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT   1200   1200       D -> V (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1512 AA;  164470 MW;  5CB78242295411D9 CRC64;
     MAAAAGNRAS SSGFPGARAT SPEAGGGGGA LKASSAPAAA AGLLREAGSG GRERADWRRR
     QLRKVRSVEL DQLPEQPLFL AASPPASSTS PSPEPADAAG SGTGFQPVAV PPPHGAASRG
     GAHLTESVAA PDSGASSPAA AEPGEKRAPA AEPSPAAAPA GREMENKETL KGLHKMDDRP
     EERMIREKLK ATCMPAWKHE WLERRNRRGP VVVKPIPVKG DGSEMNHLAA ESPGEVQASA
     ASPASKGRRS PSPGNSPSGR TVKSESPGVR RKRVSPVPFQ SGRITPPRRA PSPDGFSPYS
     PEETNRRVNK VMRARLYLLQ QIGPNSFLIG GDSPDNKYRV FIGPQNCSCA RGTFCIHLLF
     VMLRVFQLEP SDPMLWRKTL KNFEVESLFQ KYHSRRSSRI KAPSRNTIQK FVSRMSNSHT
     LSSSSTSTSS SENSIKDEEE QMCPICLLGM LDEESLTVCE DGCRNKLHHH CMSIWAEECR
     RNREPLICPL CRSKWRSHDF YSHELSSPVD SPSSLRAAQQ QTVQQQPLAG SRRNQESNFN
     LTHYGTQQIP PAYKDLAEPW IQVFGMELVG CLFSRNWNVR EMALRRLSHD VSGALLLANG
     ESTGNSGGSS GSSPSGGATS GSSQTSISGD VVEACCSVLS MVCADPVYKV YVAALKTLRA
     MLVYTPCHSL AERIKLQRLL QPVVDTILVK CADANSRTSQ LSISTLLELC KGQAGELAVG
     REILKAGSIG IGGVDYVLNC ILGNQTESNN WQELLGRLCL IDRLLLEFPA EFYPHIVSTD
     VSQAEPVEIR YKKLLSLLTF ALQSIDNSHS MVGKLSRRIY LSSARMVTTV PHVFSKLLEM
     LSVSSSTHFT RMRRRLMAIA DEVEIAEAIQ LGVEDTLDGQ QDSFLQASVP NNYLETTENS
     SPECTVHLEK TGKGLCATKL SASSEDISER LASISVGPSS STTTTTTTTE QPKPMVQTKG
     RPHSQCLNSS PLSHHSQLMF PALSTPSSST PSVPAGTATD VSKHRLQGFI PCRIPSASPQ
     TQRKFSLQFH RNCPENKDSD KLSPVFTQSR PLPSSNIHRP KPSRPTPGNT SKQGDPSKNS
     MTLDLNSSSK CDDSFGCSSN SSNAVIPSDE TVFTPVEEKC RLDVNTELNS SIEDLLEASM
     PSSDTTVTFK SEVAVLSPEK AENDDTYKDD VNHNQKCKEK MEAEEEEALA IAMAMSASQD
     ALPIVPQLQV ENGEDIIIIQ QDTPETLPGH TKAKQPYRED TEWLKGQQIG LGAFSSCYQA
     QDVGTGTLMA VKQVTYVRNT SSEQEEVVEA LREEIRMMSH LNHPNIIRML GATCEKSNYN
     LFIEWMAGGS VAHLLSKYGA FKESVVINYT EQLLRGLSYL HENQIIHRDV KGANLLIDST
     GQRLRIADFG AAARLASKGT GAGEFQGQLL GTIAFMAPEV LRGQQYGRSC DVWSVGCAII
     EMACAKPPWN AEKHSNHLAL IFKIASATTA PSIPSHLSPG LRDVALRCLE LQPQDRPPSR
     ELLKHPVFRT TW
//
ID   M3K13_HUMAN             Reviewed;         966 AA.
AC   O43283; B2R6U2; B4DLE3; B4DMV2; B4DZJ4; D3DNU1; Q05BY6; Q15450;
AC   Q2NKN3;
DT   21-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   28-FEB-2018, entry version 153.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 13;
DE            EC=2.7.11.25;
DE   AltName: Full=Leucine zipper-bearing kinase;
DE   AltName: Full=Mixed lineage kinase;
DE            Short=MLK;
GN   Name=MAP3K13 {ECO:0000312|HGNC:HGNC:6852};
GN   Synonyms=LZK {ECO:0000312|EMBL:BAA24817.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:BAA24817.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   ENZYME REGULATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Cerebellum {ECO:0000269|PubMed:9353328};
RX   PubMed=9353328; DOI=10.1074/jbc.272.45.28622;
RA   Sakuma H., Ikeda A., Oka S., Kozutsumi Y., Zanetta J., Kawasaki T.;
RT   "Molecular cloning and functional expression of a cDNA encoding a new
RT   member of mixed lineage protein kinase from human brain.";
RL   J. Biol. Chem. 272:28622-28629(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4).
RC   TISSUE=Brain, Testis, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 230-340 (ISOFORM 1).
RX   PubMed=8274451;
RA   Schultz S.J., Nigg E.A.;
RT   "Identification of 21 novel human protein kinases, including 3 members
RT   of a family related to the cell cycle regulator nimA of Aspergillus
RT   nidulans.";
RL   Cell Growth Differ. 4:821-830(1993).
RN   [7] {ECO:0000305}
RP   HOMODIMERIZATION.
RX   PubMed=11163770; DOI=10.1016/S0014-5793(00)02432-7;
RA   Ikeda A., Masaki M., Kozutsumi Y., Oka S., Kawasaki T.;
RT   "Identification and characterization of functional domains in a mixed
RT   lineage kinase LZK.";
RL   FEBS Lett. 488:190-195(2001).
RN   [8] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH MAPK8IP1.
RX   PubMed=11726277; DOI=10.1093/oxfordjournals.jbchem.a003048;
RA   Ikeda A., Hasegawa K., Masaki M., Moriguchi T., Nishida E.,
RA   Kozutsumi Y., Oka S., Kawasaki T.;
RT   "Mixed lineage kinase LZK forms a functional signaling complex with
RT   JIP-1, a scaffold protein of the c-Jun NH(2)-terminal kinase
RT   pathway.";
RL   J. Biochem. 130:773-781(2001).
RN   [9] {ECO:0000305}
RP   FUNCTION, INTERACTION WITH PRDX3, AND MUTAGENESIS OF LYS-195.
RX   PubMed=12492477; DOI=10.1046/j.1432-1033.2003.03363.x;
RA   Masaki M., Ikeda A., Shiraki E., Oka S., Kawasaki T.;
RT   "Mixed lineage kinase LZK and antioxidant protein-1 activate NF-kappaB
RT   synergistically.";
RL   Eur. J. Biochem. 270:76-83(2003).
RN   [10]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-517; LYS-712 AND LEU-746.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Activates the JUN N-terminal pathway through activation
CC       of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3
CC       to regulate the activation of NF-kappa-B in the cytosol. This
CC       activation is kinase-dependent and involves activating the IKK
CC       complex, the IKBKB-containing complex that phosphorylates
CC       inhibitors of NF-kappa-B. {ECO:0000269|PubMed:11726277,
CC       ECO:0000269|PubMed:12492477, ECO:0000269|PubMed:9353328}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:9353328}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q60700};
CC   -!- ENZYME REGULATION: Activated by autophosphorylation and
CC       homodimerization. {ECO:0000269|PubMed:11163770,
CC       ECO:0000269|PubMed:9353328}.
CC   -!- SUBUNIT: Homodimer; forms dimers through the leucine-zipper motif.
CC       Interacts with the C-terminus of MAPK8IP1 through the kinase
CC       catalytic domain. Binds PRDX3. Associates with the IKK complex
CC       through the kinase domain. {ECO:0000269|PubMed:11163770,
CC       ECO:0000269|PubMed:11726277, ECO:0000269|PubMed:12492477}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-1168480, EBI-1168480;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9353328}.
CC       Membrane {ECO:0000269|PubMed:9353328}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:9353328}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O43283-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43283-3; Sequence=VSP_036567, VSP_036568;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay. No
CC         experimental confirmation available.;
CC       Name=3;
CC         IsoId=O43283-4; Sequence=VSP_036563, VSP_036566;
CC       Name=4;
CC         IsoId=O43283-5; Sequence=VSP_036562, VSP_036569;
CC       Name=5;
CC         IsoId=O43283-6; Sequence=VSP_036564, VSP_036565;
CC   -!- TISSUE SPECIFICITY: Expressed in the adult brain, liver, placenta
CC       and pancreas, with expression strongest in the pancreas.
CC       {ECO:0000269|PubMed:9353328}.
CC   -!- PTM: Autophosphorylated on serine and threonine residues.
CC       {ECO:0000269|PubMed:9353328}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAI11727.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC       Sequence=BAG59505.1; Type=Erroneous termination; Positions=740; Note=Translated as Tyr.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB001872; BAA24817.1; -; mRNA.
DR   EMBL; AK296961; BAG59505.1; ALT_SEQ; mRNA.
DR   EMBL; AK297646; BAG60014.1; -; mRNA.
DR   EMBL; AK302951; BAG64106.1; -; mRNA.
DR   EMBL; AK312714; BAG35589.1; -; mRNA.
DR   EMBL; AC099661; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC128680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC132516; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78224.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78225.1; -; Genomic_DNA.
DR   EMBL; BC031677; AAH31677.1; -; mRNA.
DR   EMBL; BC111726; AAI11727.1; ALT_SEQ; mRNA.
DR   EMBL; Z25428; CAA80915.1; -; mRNA.
DR   CCDS; CCDS3270.1; -. [O43283-1]
DR   CCDS; CCDS56298.1; -. [O43283-5]
DR   PIR; I38218; I38218.
DR   RefSeq; NP_001229243.1; NM_001242314.1. [O43283-1]
DR   RefSeq; NP_001229246.1; NM_001242317.1. [O43283-5]
DR   RefSeq; NP_004712.1; NM_004721.4. [O43283-1]
DR   RefSeq; XP_011511612.1; XM_011513310.2. [O43283-1]
DR   RefSeq; XP_016862945.1; XM_017007456.1. [O43283-1]
DR   UniGene; Hs.591306; -.
DR   UniGene; Hs.634586; -.
DR   ProteinModelPortal; O43283; -.
DR   SMR; O43283; -.
DR   BioGrid; 114614; 12.
DR   IntAct; O43283; 3.
DR   STRING; 9606.ENSP00000265026; -.
DR   BindingDB; O43283; -.
DR   ChEMBL; CHEMBL1163124; -.
DR   GuidetoPHARMACOLOGY; 2073; -.
DR   iPTMnet; O43283; -.
DR   PhosphoSitePlus; O43283; -.
DR   BioMuta; MAP3K13; -.
DR   PaxDb; O43283; -.
DR   PeptideAtlas; O43283; -.
DR   PRIDE; O43283; -.
DR   Ensembl; ENST00000265026; ENSP00000265026; ENSG00000073803. [O43283-1]
DR   Ensembl; ENST00000424227; ENSP00000399910; ENSG00000073803. [O43283-1]
DR   Ensembl; ENST00000433092; ENSP00000389798; ENSG00000073803. [O43283-6]
DR   Ensembl; ENST00000438053; ENSP00000403561; ENSG00000073803. [O43283-3]
DR   Ensembl; ENST00000443863; ENSP00000409325; ENSG00000073803. [O43283-4]
DR   Ensembl; ENST00000446828; ENSP00000411483; ENSG00000073803. [O43283-5]
DR   GeneID; 9175; -.
DR   KEGG; hsa:9175; -.
DR   UCSC; uc003fph.5; human. [O43283-1]
DR   CTD; 9175; -.
DR   DisGeNET; 9175; -.
DR   EuPathDB; HostDB:ENSG00000073803.13; -.
DR   GeneCards; MAP3K13; -.
DR   HGNC; HGNC:6852; MAP3K13.
DR   HPA; HPA016497; -.
DR   HPA; HPA036691; -.
DR   HPA; HPA036692; -.
DR   MIM; 604915; gene.
DR   neXtProt; NX_O43283; -.
DR   OpenTargets; ENSG00000073803; -.
DR   PharmGKB; PA30596; -.
DR   eggNOG; KOG4721; Eukaryota.
DR   eggNOG; ENOG410YKX2; LUCA.
DR   GeneTree; ENSGT00900000140790; -.
DR   HOVERGEN; HBG052383; -.
DR   InParanoid; O43283; -.
DR   KO; K04422; -.
DR   OMA; ENPMQFE; -.
DR   OrthoDB; EOG091G0905; -.
DR   PhylomeDB; O43283; -.
DR   TreeFam; TF105119; -.
DR   SignaLink; O43283; -.
DR   SIGNOR; O43283; -.
DR   ChiTaRS; MAP3K13; human.
DR   GeneWiki; MAP3K13; -.
DR   GenomeRNAi; 9175; -.
DR   PRO; PR:O43283; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000073803; -.
DR   CleanEx; HS_MAP3K13; -.
DR   ExpressionAtlas; O43283; baseline and differential.
DR   Genevisible; O43283; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017419; MAP3K12_MAP3K13.
DR   InterPro; IPR027258; MAPKKK13.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF038165; MAPKKK12_MAPKKK13; 1.
DR   PIRSF; PIRSF500742; MAPKKK13; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome; Cytoplasm;
KW   Kinase; Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    966       Mitogen-activated protein kinase kinase
FT                                kinase 13.
FT                                /FTId=PRO_0000086264.
FT   DOMAIN      168    409       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     174    182       ATP. {ECO:0000250|UniProtKB:Q12852,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   REGION      433    454       Leucine-zipper 1.
FT   REGION      486    507       Leucine-zipper 2.
FT   REGION      815    828       Acidic. {ECO:0000305}.
FT   ACT_SITE    279    279       Proton acceptor.
FT                                {ECO:0000250|UniProtKB:Q12852,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000255|PROSITE-ProRule:PRU10027}.
FT   BINDING     195    195       ATP. {ECO:0000250|UniProtKB:Q60700,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   VAR_SEQ       1    207       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036562.
FT   VAR_SEQ       1    144       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036563.
FT   VAR_SEQ     122    128       RSGSGSG -> RYLGSAI (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_036564.
FT   VAR_SEQ     129    966       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_036565.
FT   VAR_SEQ     145    159       IGKAYSTDYKLQQQD -> MSYVECKCLQLENKN (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036566.
FT   VAR_SEQ     159    160       DT -> VF (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_036567.
FT   VAR_SEQ     161    966       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_036568.
FT   VAR_SEQ     208    220       LRKLKHPNIIAFK -> MYCGIQILALWER (in
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036569.
FT   VARIANT      44     44       E -> K (in dbSNP:rs35266179).
FT                                /FTId=VAR_051640.
FT   VARIANT     517    517       R -> G (in dbSNP:rs56408536).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040708.
FT   VARIANT     712    712       E -> K (in dbSNP:rs56309231).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040709.
FT   VARIANT     746    746       P -> L (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040710.
FT   VARIANT     915    915       R -> H (in dbSNP:rs3732576).
FT                                /FTId=VAR_030577.
FT   MUTAGEN     195    195       K->A: Kinase inactive. Fails to activate
FT                                NF-kappa-B.
FT                                {ECO:0000269|PubMed:12492477}.
FT   CONFLICT    106    106       D -> G (in Ref. 2; BAG59505).
FT                                {ECO:0000305}.
FT   CONFLICT    230    232       CII -> YLY (in Ref. 6; CAA80915).
FT                                {ECO:0000305}.
FT   CONFLICT    268    268       N -> D (in Ref. 2; BAG59505).
FT                                {ECO:0000305}.
FT   CONFLICT    339    340       FG -> MV (in Ref. 6; CAA80915).
FT                                {ECO:0000305}.
FT   CONFLICT    508    508       E -> G (in Ref. 2; BAG64106).
FT                                {ECO:0000305}.
FT   CONFLICT    821    821       G -> R (in Ref. 2; BAG60014).
FT                                {ECO:0000305}.
SQ   SEQUENCE   966 AA;  108296 MW;  9687F38C8AB20AB1 CRC64;
     MANFQEHLSC SSSPHLPFSE SKTFNGLQDE LTAMGNHPSP KLLEDQQEKG MVRTELIESV
     HSPVTTTVLT SVSEDSRDQF ENSVLQLREH DESETAVSQG NSNTVDGEST SGTEDIKIQF
     SRSGSGSGGF LEGLFGCLRP VWNIIGKAYS TDYKLQQQDT WEVPFEEISE LQWLGSGAQG
     AVFLGKFRAE EVAIKKVREQ NETDIKHLRK LKHPNIIAFK GVCTQAPCYC IIMEYCAHGQ
     LYEVLRAGRK ITPRLLVDWS TGIASGMNYL HLHKIIHRDL KSPNVLVTHT DAVKISDFGT
     SKELSDKSTK MSFAGTVAWM APEVIRNEPV SEKVDIWSFG VVLWELLTGE IPYKDVDSSA
     IIWGVGSNSL HLPVPSTCPD GFKILMKQTW QSKPRNRPSF RQTLMHLDIA SADVLATPQE
     TYFKSQAEWR EEVKKHFEKI KSEGTCIHRL DEELIRRRRE ELRHALDIRE HYERKLERAN
     NLYMELSAIM LQLEMREKEL IKREQAVEKK YPGTYKRHPV RPIIHPNAME KLMKRKGVPH
     KSGMQTKRPD LLRSEGIPTT EVAPTASPLS GSPKMSTSSS KSRYRSKPRH RRGNSRGSHS
     DFAAILKNQP AQENSPHPTY LHQAQSQYPS LHHHNSLQQQ YQQPPPAMSQ SHHPRLNMHG
     QDIATCANNL RYFGPAAALR SPLSNHAQRQ LPGSSPDLIS TAMAADCWRS SEPDKGQAGP
     WGCCQADAYD PCLQCRPEQY GSLDIPSAEP VGRSPDLSKS PAHNPLLENA QSSEKTEENE
     FSGCRSESSL GTSHLGTPPA LPRKTRPLQK SGDDSSEEEE GEVDSEVEFP RRQRPHRCIS
     SCQSYSTFSS ENFSVSDGEE GNTSDHSNSP DELADKLEDR LAEKLDDLLS QTPEIPIDIS
     SHSDGLSDKE CAVRRVKTQM SLGKLCVEER GYENPMQFEE SDCDSSDGEC SDATVRTNKH
     YSSATW
//
ID   NF2L2_HUMAN             Reviewed;         605 AA.
AC   Q16236; B2RBU2; B4E338; E9PGJ7; Q53RW6; Q59HH2; Q96F71;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2002, sequence version 3.
DT   28-FEB-2018, entry version 180.
DE   RecName: Full=Nuclear factor erythroid 2-related factor 2;
DE            Short=NF-E2-related factor 2;
DE            Short=NFE2-related factor 2;
DE   AltName: Full=HEBP1;
DE   AltName: Full=Nuclear factor, erythroid derived 2, like 2;
GN   Name=NFE2L2; Synonyms=NRF2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Tongue, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Myeloid leukemia cell;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-202 (ISOFORM 1).
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4-605 (ISOFORM 1).
RC   TISSUE=Fetal liver;
RX   PubMed=7937919; DOI=10.1073/pnas.91.21.9926;
RA   Moi P., Chan K., Asunis I., Cao A., Kan Y.W.;
RT   "Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic
RT   leucine zipper transcriptional activator that binds to the tandem NF-
RT   E2/AP1 repeat of the beta-globin locus control region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9926-9930(1994).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY PKC.
RX   PubMed=11035812; DOI=10.1073/pnas.220418997;
RA   Huang H.-C., Nguyen T., Pickett C.B.;
RT   "Regulation of the antioxidant response element by protein kinase C-
RT   mediated phosphorylation of NF-E2-related factor 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:12475-12480(2000).
RN   [9]
RP   INTERACTION WITH PMF1.
RX   PubMed=11256947; DOI=10.1042/0264-6021:3550045;
RA   Wang Y., Devereux W., Stewart T.M., Casero R.A. Jr.;
RT   "Characterization of the interaction between the transcription factors
RT   human polyamine modulated factor (PMF-1) and NF-E2-related factor 2
RT   (Nrf-2) in the transcriptional regulation of the spermidine/spermine
RT   N1-acetyltransferase (SSAT) gene.";
RL   Biochem. J. 355:45-49(2001).
RN   [10]
RP   UBIQUITINATION.
RX   PubMed=15983046; DOI=10.1074/jbc.M501279200;
RA   Zhang D.D., Lo S.C., Sun Z., Habib G.M., Lieberman M.W., Hannink M.;
RT   "Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for
RT   Cul3, targets Keap1 for degradation by a proteasome-independent
RT   pathway.";
RL   J. Biol. Chem. 280:30091-30099(2005).
RN   [11]
RP   INTERACTION WITH PGAM5 AND KEAP1.
RX   PubMed=18387606; DOI=10.1016/j.yexcr.2008.02.014;
RA   Lo S.-C., Hannink M.;
RT   "PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to
RT   mitochondria.";
RL   Exp. Cell Res. 314:1789-1803(2008).
RN   [12]
RP   DOWN-REGULATION BY ENC1.
RX   PubMed=19424503; DOI=10.1371/journal.pone.0005492;
RA   Wang X.J., Zhang D.D.;
RT   "Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational
RT   level.";
RL   PLoS ONE 4:E5492-E5492(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-215, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   INTERACTION WITH EEF1D.
RX   PubMed=21597468; DOI=10.1038/embor.2011.82;
RA   Kaitsuka T., Tomizawa K., Matsushita M.;
RT   "Transformation of eEF1Bdelta into heat-shock response transcription
RT   factor by alternative splicing.";
RL   EMBO Rep. 12:673-681(2011).
RN   [15]
RP   ACETYLATION AT LYS-596 AND LYS-599, DEACETYLATION BY SIRT1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=21196497; DOI=10.1074/jbc.M110.208173;
RA   Kawai Y., Garduno L., Theodore M., Yang J., Arinze I.J.;
RT   "Acetylation-deacetylation of the transcription factor Nrf2 (nuclear
RT   factor erythroid 2-related factor 2) regulates its transcriptional
RT   activity and nucleocytoplasmic localization.";
RL   J. Biol. Chem. 286:7629-7640(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-215, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 69-84 IN COMPLEX WITH KEAP1,
RP   AND MUTAGENESIS OF THR-80.
RX   PubMed=16888629; DOI=10.1038/sj.emboj.7601243;
RA   Lo S.-C., Li X., Henzl M.T., Beamer L.J., Hannink M.;
RT   "Structure of the Keap1:Nrf2 interface provides mechanistic insight
RT   into Nrf2 signaling.";
RL   EMBO J. 25:3605-3617(2006).
CC   -!- FUNCTION: Transcription activator that binds to antioxidant
CC       response (ARE) elements in the promoter regions of target genes.
CC       Important for the coordinated up-regulation of genes in response
CC       to oxidative stress. May be involved in the transcriptional
CC       activation of genes of the beta-globin cluster by mediating
CC       enhancer activity of hypersensitive site 2 of the beta-globin
CC       locus control region. {ECO:0000269|PubMed:11035812}.
CC   -!- SUBUNIT: Heterodimer. Forms a ternary complex with PGAM5 and
CC       KEAP1. May bind DNA with an unknown protein. Interacts via its
CC       leucine-zipper domain with the coiled-coil domain of PMF1.
CC       Interacts with EEF1D at heat shock promoter elements (HSE).
CC       Interacts (via the bZIP domain) with MAFK; required for binding to
CC       antioxidant response (ARE) elements on DNA. Interacts with CHD6;
CC       involved in activation of the transcription. Interacts with ESRRB;
CC       represses NFE2L2 transcriptional activity (By similarity).
CC       {ECO:0000250|UniProtKB:Q60795, ECO:0000269|PubMed:11256947,
CC       ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:18387606,
CC       ECO:0000269|PubMed:21597468}.
CC   -!- INTERACTION:
CC       Q14145:KEAP1; NbExp=22; IntAct=EBI-2007911, EBI-751001;
CC       O15525:MAFG; NbExp=5; IntAct=EBI-2007911, EBI-713514;
CC       O60675:MAFK; NbExp=3; IntAct=EBI-2007911, EBI-2559512;
CC       P10276:RARA; NbExp=2; IntAct=EBI-2007911, EBI-413374;
CC       P13805:TNNT1; NbExp=3; IntAct=EBI-2007911, EBI-726527;
CC       Q9BTA9:WAC; NbExp=3; IntAct=EBI-2007911, EBI-749118;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Nucleus. Note=Cytosolic
CC       under unstressed conditions, translocates into the nucleus upon
CC       induction by electrophilic agents.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16236-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16236-2; Sequence=VSP_025045;
CC       Name=3;
CC         IsoId=Q16236-3; Sequence=VSP_025045, VSP_046168;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest expression in adult
CC       muscle, kidney, lung, liver and in fetal muscle.
CC   -!- INDUCTION: Down-regulated by ENC1 via a proteasomal ubiquitin-
CC       independent protein catabolic process.
CC   -!- DOMAIN: Acidic activation domain in the N-terminus, and DNA
CC       binding domain in the C-terminus.
CC   -!- PTM: Phosphorylation of Ser-40 by PKC in response to oxidative
CC       stress dissociates NFE2L2 from its cytoplasmic inhibitor KEAP1,
CC       promoting its translocation into the nucleus.
CC       {ECO:0000250|UniProtKB:O54968}.
CC   -!- PTM: Acetylation at Lys-596 and Lys-599 increases nuclear
CC       localization whereas deacetylation by SIRT1 enhances cytoplasmic
CC       presence. {ECO:0000269|PubMed:21196497}.
CC   -!- PTM: Ubiquitinated by the KEAP1-CUL3-RBX1 E3 ubiquitin ligase
CC       complex and subject to proteasomal degradation. Ubiquitination is
CC       inhibited by sulforaphane. {ECO:0000269|PubMed:15983046}.
CC   -!- SIMILARITY: Belongs to the bZIP family. CNC subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB32188.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAD92023.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK304555; BAG65350.1; -; mRNA.
DR   EMBL; AK314816; BAG37339.1; -; mRNA.
DR   EMBL; AB208786; BAD92023.1; ALT_INIT; mRNA.
DR   EMBL; AC019080; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079305; AAY14710.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11062.1; -; Genomic_DNA.
DR   EMBL; BC011558; AAH11558.1; -; mRNA.
DR   EMBL; AL135266; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S74017; AAB32188.1; ALT_INIT; mRNA.
DR   CCDS; CCDS42782.1; -. [Q16236-1]
DR   CCDS; CCDS46457.1; -. [Q16236-2]
DR   CCDS; CCDS46458.1; -. [Q16236-3]
DR   RefSeq; NP_001138884.1; NM_001145412.3. [Q16236-2]
DR   RefSeq; NP_001138885.1; NM_001145413.3. [Q16236-3]
DR   RefSeq; NP_001300829.1; NM_001313900.1. [Q16236-2]
DR   RefSeq; NP_001300830.1; NM_001313901.1. [Q16236-2]
DR   RefSeq; NP_006155.2; NM_006164.4. [Q16236-1]
DR   UniGene; Hs.744006; -.
DR   PDB; 2FLU; X-ray; 1.50 A; P=69-84.
DR   PDB; 2LZ1; NMR; -; A=445-523.
DR   PDB; 3ZGC; X-ray; 2.20 A; C=76-82.
DR   PDB; 4IFL; X-ray; 1.80 A; P=69-84.
DR   PDBsum; 2FLU; -.
DR   PDBsum; 2LZ1; -.
DR   PDBsum; 3ZGC; -.
DR   PDBsum; 4IFL; -.
DR   ProteinModelPortal; Q16236; -.
DR   SMR; Q16236; -.
DR   BioGrid; 110852; 67.
DR   CORUM; Q16236; -.
DR   DIP; DIP-29971N; -.
DR   ELM; Q16236; -.
DR   IntAct; Q16236; 22.
DR   MINT; Q16236; -.
DR   STRING; 9606.ENSP00000380252; -.
DR   BindingDB; Q16236; -.
DR   ChEMBL; CHEMBL1075094; -.
DR   iPTMnet; Q16236; -.
DR   PhosphoSitePlus; Q16236; -.
DR   BioMuta; NFE2L2; -.
DR   DMDM; 25453452; -.
DR   EPD; Q16236; -.
DR   MaxQB; Q16236; -.
DR   PaxDb; Q16236; -.
DR   PeptideAtlas; Q16236; -.
DR   PRIDE; Q16236; -.
DR   DNASU; 4780; -.
DR   Ensembl; ENST00000397062; ENSP00000380252; ENSG00000116044. [Q16236-1]
DR   Ensembl; ENST00000397063; ENSP00000380253; ENSG00000116044. [Q16236-2]
DR   Ensembl; ENST00000446151; ENSP00000411575; ENSG00000116044. [Q16236-3]
DR   Ensembl; ENST00000464747; ENSP00000467401; ENSG00000116044. [Q16236-2]
DR   GeneID; 4780; -.
DR   KEGG; hsa:4780; -.
DR   UCSC; uc002ulg.6; human. [Q16236-1]
DR   CTD; 4780; -.
DR   DisGeNET; 4780; -.
DR   EuPathDB; HostDB:ENSG00000116044.15; -.
DR   GeneCards; NFE2L2; -.
DR   HGNC; HGNC:7782; NFE2L2.
DR   HPA; CAB020317; -.
DR   HPA; HPA002990; -.
DR   HPA; HPA043438; -.
DR   MIM; 600492; gene.
DR   neXtProt; NX_Q16236; -.
DR   OpenTargets; ENSG00000116044; -.
DR   PharmGKB; PA31588; -.
DR   eggNOG; ENOG410ISV3; Eukaryota.
DR   eggNOG; ENOG41100FB; LUCA.
DR   GeneTree; ENSGT00910000144085; -.
DR   HOGENOM; HOG000234410; -.
DR   HOVERGEN; HBG052609; -.
DR   InParanoid; Q16236; -.
DR   KO; K05638; -.
DR   OMA; ALHIPFP; -.
DR   OrthoDB; EOG091G02EB; -.
DR   PhylomeDB; Q16236; -.
DR   TreeFam; TF326681; -.
DR   SignaLink; Q16236; -.
DR   SIGNOR; Q16236; -.
DR   ChiTaRS; NFE2L2; human.
DR   EvolutionaryTrace; Q16236; -.
DR   GeneWiki; NFE2L2; -.
DR   GenomeRNAi; 4780; -.
DR   PMAP-CutDB; Q16236; -.
DR   PRO; PR:Q16236; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000116044; -.
DR   CleanEx; HS_NFE2L2; -.
DR   ExpressionAtlas; Q16236; baseline and differential.
DR   Genevisible; Q16236; HS.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0032993; C:protein-DNA complex; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0000980; F:RNA polymerase II distal enhancer sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001221; F:transcription cofactor binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0001205; F:transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0046223; P:aflatoxin catabolic process; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0045454; P:cell redox homeostasis; IEA:Ensembl.
DR   GO; GO:1904385; P:cellular response to angiotensin; IEA:Ensembl.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IDA:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IMP:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:0034599; P:cellular response to oxidative stress; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IMP:BHF-UCL.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:1902037; P:negative regulation of hematopoietic stem cell differentiation; IEA:Ensembl.
DR   GO; GO:1903206; P:negative regulation of hydrogen peroxide-induced cell death; IGI:ParkinsonsUK-UCL.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:1904753; P:negative regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0036499; P:PERK-mediated unfolded protein response; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IEA:Ensembl.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:1903071; P:positive regulation of ER-associated ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:1903788; P:positive regulation of glutathione biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0036091; P:positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0036003; P:positive regulation of transcription from RNA polymerase II promoter in response to stress; IMP:BHF-UCL.
DR   GO; GO:0010499; P:proteasomal ubiquitin-independent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0045995; P:regulation of embryonic development; IEA:Ensembl.
DR   GO; GO:2000121; P:regulation of removal of superoxide radicals; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR004826; bZIP_Maf.
DR   InterPro; IPR029845; Nrf2.
DR   InterPro; IPR008917; TF_DNA-bd_sf.
DR   PANTHER; PTHR24411:SF3; PTHR24411:SF3; 1.
DR   Pfam; PF03131; bZIP_Maf; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   SUPFAM; SSF47454; SSF47454; 1.
DR   PROSITE; PS50217; BZIP; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Complete proteome; Cytoplasm; DNA-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1    605       Nuclear factor erythroid 2-related factor
FT                                2.
FT                                /FTId=PRO_0000076449.
FT   DOMAIN      497    560       bZIP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00978}.
FT   REGION      499    518       Basic motif. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00978}.
FT   REGION      522    529       Leucine-zipper. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00978}.
FT   REGION      591    596       Mediates interaction with CHD6 and is
FT                                necessary to activate transcription.
FT                                {ECO:0000250}.
FT   MOD_RES      40     40       Phosphoserine; by PKC.
FT                                {ECO:0000250|UniProtKB:O54968}.
FT   MOD_RES     215    215       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     596    596       N6-acetyllysine; by CREBBP.
FT                                {ECO:0000269|PubMed:21196497}.
FT   MOD_RES     599    599       N6-acetyllysine; by CREBBP.
FT                                {ECO:0000269|PubMed:21196497}.
FT   VAR_SEQ       1     16       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_025045.
FT   VAR_SEQ     135    141       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046168.
FT   VARIANT      43     43       R -> Q (in dbSNP:rs35248500).
FT                                /FTId=VAR_032110.
FT   VARIANT      99     99       S -> P (in dbSNP:rs5031039).
FT                                /FTId=VAR_020322.
FT   VARIANT     268    268       V -> M (in dbSNP:rs34154613).
FT                                /FTId=VAR_032111.
FT   MUTAGEN      80     80       T->A: Loss of interaction with KEAP1.
FT                                {ECO:0000269|PubMed:16888629}.
FT   CONFLICT     72     72       A -> T (in Ref. 7; AAB32188).
FT                                {ECO:0000305}.
FT   CONFLICT     92     92       I -> T (in Ref. 7; AAB32188).
FT                                {ECO:0000305}.
FT   CONFLICT    178    178       D -> Y (in Ref. 3; AL135266).
FT                                {ECO:0000305}.
FT   CONFLICT    521    521       N -> D (in Ref. 1; BAG65350).
FT                                {ECO:0000305}.
FT   TURN         78     80       {ECO:0000244|PDB:2FLU}.
FT   HELIX       456    464       {ECO:0000244|PDB:2LZ1}.
FT   HELIX       470    475       {ECO:0000244|PDB:2LZ1}.
FT   HELIX       478    487       {ECO:0000244|PDB:2LZ1}.
FT   HELIX       492    504       {ECO:0000244|PDB:2LZ1}.
SQ   SEQUENCE   605 AA;  67827 MW;  99FAFD811B6C1416 CRC64;
     MMDLELPPPG LPSQQDMDLI DILWRQDIDL GVSREVFDFS QRRKEYELEK QKKLEKERQE
     QLQKEQEKAF FAQLQLDEET GEFLPIQPAQ HIQSETSGSA NYSQVAHIPK SDALYFDDCM
     QLLAQTFPFV DDNEVSSATF QSLVPDIPGH IESPVFIATN QAQSPETSVA QVAPVDLDGM
     QQDIEQVWEE LLSIPELQCL NIENDKLVET TMVPSPEAKL TEVDNYHFYS SIPSMEKEVG
     NCSPHFLNAF EDSFSSILST EDPNQLTVNS LNSDATVNTD FGDEFYSAFI AEPSISNSMP
     SPATLSHSLS ELLNGPIDVS DLSLCKAFNQ NHPESTAEFN DSDSGISLNT SPSVASPEHS
     VESSSYGDTL LGLSDSEVEE LDSAPGSVKQ NGPKTPVHSS GDMVQPLSPS QGQSTHVHDA
     QCENTPEKEL PVSPGHRKTP FTKDKHSSRL EAHLTRDELR AKALHIPFPV EKIINLPVVD
     FNEMMSKEQF NEAQLALIRD IRRRGKNKVA AQNCRKRKLE NIVELEQDLD HLKDEKEKLL
     KEKGENDKSL HLLKKQLSTL YLEVFSMLRD EDGKPYSPSE YSLQQTRDGN VFLVPKSKKP
     DVKKN
//
ID   NKX21_HUMAN             Reviewed;         371 AA.
AC   P43699; D3DSA3; O14954; O14955; Q7KZF6; Q9BRJ8;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   28-FEB-2018, entry version 177.
DE   RecName: Full=Homeobox protein Nkx-2.1;
DE   AltName: Full=Homeobox protein NK-2 homolog A;
DE   AltName: Full=Thyroid nuclear factor 1;
DE   AltName: Full=Thyroid transcription factor 1;
DE            Short=TTF-1;
DE   AltName: Full=Thyroid-specific enhancer-binding protein;
DE            Short=T/EBP;
GN   Name=NKX2-1 {ECO:0000312|HGNC:HGNC:11825};
GN   Synonyms=NKX2A, TITF1, TTF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=7711079; DOI=10.1016/0167-4781(95)00033-D;
RA   Oguchi H., Pan Y.-T., Kimura S.;
RT   "The complete nucleotide sequence of the mouse thyroid-specific
RT   enhancer-binding protein (T/EBP) gene: extensive identity of the
RT   deduced amino acid sequence with the human protein.";
RL   Biochim. Biophys. Acta 1261:304-306(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Thyroid;
RX   PubMed=7711080; DOI=10.1016/0167-4781(95)00034-E;
RA   Saiardi A., Tassi V., de Filippis V., Civitareale D.;
RT   "Cloning and sequence analysis of human thyroid transcription factor
RT   1.";
RL   Biochim. Biophys. Acta 1261:307-310(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=7713914; DOI=10.1074/jbc.270.14.8108;
RA   Ikeda K., Clark J.C., Shaw-White J.R., Stahlman M.T., Boutell C.J.,
RA   Whitsett J.A.;
RT   "Gene structure and expression of human thyroid transcription factor-1
RT   in respiratory epithelial cells.";
RL   J. Biol. Chem. 270:8108-8114(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung;
RX   PubMed=9545595; DOI=10.1016/S0167-4781(97)00210-8;
RA   Hamdan H., Liu H., Li C., Jones C., Lee M., deLemos R., Minoo P.;
RT   "Structure of the human Nkx2.1 gene.";
RL   Biochim. Biophys. Acta 1396:336-348(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RC   TISSUE=Thyroid;
RA   Endo T., Ohno M., Nakazato M.;
RT   "Cloning of the human TTF-1 gene.";
RL   Submitted (MAY-1995) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH WWTR1.
RX   PubMed=19010321; DOI=10.1016/j.yexcr.2008.10.016;
RA   Di Palma T., D'Andrea B., Liguori G.L., Liguoro A., de Cristofaro T.,
RA   Del Prete D., Pappalardo A., Mascia A., Zannini M.;
RT   "TAZ is a coactivator for Pax8 and TTF-1, two transcription factors
RT   involved in thyroid differentiation.";
RL   Exp. Cell Res. 315:162-175(2009).
RN   [11]
RP   INVOLVEMENT IN NMTC1, VARIANT NMTC1 VAL-339, AND CHARACTERIZATION OF
RP   VARIANT NMTC1 VAL-339.
RX   PubMed=19176457; DOI=10.1093/jnci/djn471;
RA   Ngan E.S., Lang B.H., Liu T., Shum C.K., So M.T., Lau D.K., Leon T.Y.,
RA   Cherny S.S., Tsai S.Y., Lo C.Y., Khoo U.S., Tam P.K.,
RA   Garcia-Barcelo M.M.;
RT   "A germline mutation (A339V) in thyroid transcription factor-1 (TITF-
RT   1/NKX2.1) in patients with multinodular goiter and papillary thyroid
RT   carcinoma.";
RL   J. Natl. Cancer Inst. 101:162-175(2009).
RN   [12]
RP   VARIANTS BHC LEU-208 AND SER-213, AND INVOLVEMENT IN BHC.
RX   PubMed=11971878; DOI=10.1093/hmg/11.8.971;
RA   Breedveld G.J., van Dongen J.W.F., Danesino C., Guala A., Percy A.K.,
RA   Dure L.S., Harper P., Lazarou L.P., van der Linde H., Joosse M.,
RA   Grueters A., MacDonald M.E., de Vries B.B.A., Arts W.F.M.,
RA   Oostra B.A., Krude H., Heutink P.;
RT   "Mutations in TITF-1 are associated with benign hereditary chorea.";
RL   Hum. Mol. Genet. 11:971-979(2002).
RN   [13]
RP   INVOLVEMENT IN CAHTP.
RX   PubMed=11854318; DOI=10.1172/JCI0214192;
RA   Pohlenz J., Dumitrescu A., Zundel D., Martine U., Schoenberger W.,
RA   Koo E., Weiss R.E., Cohen R.N., Kimura S., Refetoff S.;
RT   "Partial deficiency of thyroid transcription factor 1 produces
RT   predominantly neurological defects in humans and mice.";
RL   J. Clin. Invest. 109:469-473(2002).
RN   [14]
RP   VARIANT CAHTP PHE-205.
RX   PubMed=11854319; DOI=10.1172/JCI0214341;
RA   Krude H., Schuetz B., Biebermann H., von Moers A., Schnabel D.,
RA   Neitzel H., Toennies H., Weise D., Lafferty A., Schwarz S.,
RA   DeFelice M., von Deimling A., van Landeghem F., DiLauro R.,
RA   Grueters A.;
RT   "Choreoathetosis, hypothyroidism, and pulmonary alterations due to
RT   human NKX2-1 haploinsufficiency.";
RL   J. Clin. Invest. 109:475-480(2002).
RN   [15]
RP   INVOLVEMENT IN CAHTP.
RX   PubMed=15289765; DOI=10.1016/j.jpeds.2004.04.011;
RA   Doyle D.A., Gonzalez I., Thomas B., Scavina M.;
RT   "Autosomal dominant transmission of congenital hypothyroidism,
RT   neonatal respiratory distress, and ataxia caused by a mutation of
RT   NKX2-1.";
RL   J. Pediatr. 145:190-193(2004).
RN   [16]
RP   INVOLVEMENT IN CAHTP AND IN BHC.
RX   PubMed=15955952; DOI=10.1212/01.WNL.0000164000.75046.CC;
RA   Asmus F., Horber V., Pohlenz J., Schwabe D., Zimprich A., Munz M.,
RA   Schoening M., Gasser T.;
RT   "A novel TITF-1 mutation causes benign hereditary chorea with response
RT   to levodopa.";
RL   Neurology 64:1952-1954(2005).
RN   [17]
RP   VARIANT BHC PRO-179.
RX   PubMed=24453141; DOI=10.1177/0883073813518243;
RA   Williamson S., Kirkpatrick M., Greene S., Goudie D.;
RT   "A novel mutation of NKX2-1 affecting 2 generations with
RT   hypothyroidism and choreoathetosis: part of the spectrum of brain-
RT   thyroid-lung syndrome.";
RL   J. Child Neurol. 29:666-669(2014).
RN   [18]
RP   VARIANTS CAHTP ARG-203 AND PHE-205.
RX   PubMed=24714694; DOI=10.1136/jmedgenet-2013-102248;
RA   Thorwarth A., Schnittert-Huebener S., Schrumpf P., Mueller I.,
RA   Jyrch S., Dame C., Biebermann H., Kleinau G., Katchanov J.,
RA   Schuelke M., Ebert G., Steininger A., Boennemann C., Brockmann K.,
RA   Christen H.J., Crock P., deZegher F., Griese M., Hewitt J.,
RA   Ivarsson S., Huebner C., Kapelari K., Plecko B., Rating D., Stoeva I.,
RA   Ropers H.H., Grueters A., Ullmann R., Krude H.;
RT   "Comprehensive genotyping and clinical characterisation reveal 27
RT   novel NKX2-1 mutations and expand the phenotypic spectrum.";
RL   J. Med. Genet. 51:375-387(2014).
RN   [19]
RP   VARIANTS BHC HIS-172 AND SER-208, AND CHARACTERIZATION OF VARIANTS BHC
RP   HIS-172 AND SER-208.
RX   PubMed=26723978; DOI=10.1016/j.jns.2015.11.050;
RA   Provenzano C., Zamboni M., Veneziano L., Mantuano E., Garavaglia B.,
RA   Zorzi G., Pagonabarraga J., Giunti P., Civitareale D.;
RT   "Functional characterization of two novel mutations in TTF-1/NKX2.1
RT   homeodomain in patients with benign hereditary chorea.";
RL   J. Neurol. Sci. 360:78-83(2016).
CC   -!- FUNCTION: Transcription factor that binds and activates the
CC       promoter of thyroid specific genes such as thyroglobulin,
CC       thyroperoxidase, and thyrotropin receptor. Crucial in the
CC       maintenance of the thyroid differentiation phenotype. May play a
CC       role in lung development and surfactant homeostasis. Forms a
CC       regulatory loop with GRHL2 that coordinates lung epithelial cell
CC       morphogenesis and differentiation. Activates the transcription of
CC       GNRHR and plays a role in enhancing the circadian oscillation of
CC       its gene expression. Represses the transcription of the circadian
CC       transcriptional repressor NR1D1 (By similarity).
CC       {ECO:0000250|UniProtKB:P23441, ECO:0000250|UniProtKB:P50220}.
CC   -!- SUBUNIT: Interacts with WWTR1. {ECO:0000269|PubMed:19010321}.
CC   -!- INTERACTION:
CC       Q9P031:CCDC59; NbExp=4; IntAct=EBI-1391923, EBI-1047110;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-1391923, EBI-389883;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P50220}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P43699-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=P43699-3; Sequence=VSP_037890;
CC   -!- TISSUE SPECIFICITY: Thyroid and lung.
CC   -!- PTM: Phosphorylated on serine residues by STK3/MST2.
CC       {ECO:0000250}.
CC   -!- DISEASE: Chorea, hereditary benign (BHC) [MIM:118700]: A rare
CC       autosomal dominant movement disorder, defined by early onset in
CC       childhood, a stable or non-progressive course of chorea, and no
CC       mental deterioration. Chorea is characterized by involuntary,
CC       forcible, rapid, jerky movements that may be subtle or become
CC       confluent, markedly altering normal patterns of movement.
CC       {ECO:0000269|PubMed:11971878, ECO:0000269|PubMed:15955952,
CC       ECO:0000269|PubMed:24453141, ECO:0000269|PubMed:26723978}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Choreoathetosis and congenital hypothyroidism with or
CC       without pulmonary dysfunction (CAHTP) [MIM:610978]: An autosomal
CC       dominant disorder that manifests in infancy with neurological
CC       disturbances, hypothyroidism, and respiratory problems. It is
CC       characterized by movement abnormalities beginning with muscular
CC       hypotonia followed by the development of chorea, athetosis,
CC       dystonia, ataxia, and dysarthria. {ECO:0000269|PubMed:11854318,
CC       ECO:0000269|PubMed:11854319, ECO:0000269|PubMed:15289765,
CC       ECO:0000269|PubMed:15955952, ECO:0000269|PubMed:24714694}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Thyroid cancer, non-medullary, 1 (NMTC1) [MIM:188550]: A
CC       form of non-medullary thyroid cancer (NMTC), a cancer
CC       characterized by tumors originating from the thyroid follicular
CC       cells. NMTCs represent approximately 95% of all cases of thyroid
CC       cancer and are classified into papillary, follicular, Hurthle
CC       cell, and anaplastic neoplasms. {ECO:0000269|PubMed:19176457}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the NK-2 homeobox family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH06221.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA23527.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NKX2-1ID44015ch14q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U19756; AAA86099.1; -; mRNA.
DR   EMBL; X82850; CAA58053.1; -; mRNA.
DR   EMBL; U19816; AAC50125.1; -; Genomic_DNA.
DR   EMBL; U33749; AAB52381.1; -; mRNA.
DR   EMBL; U43203; AAA89066.1; -; mRNA.
DR   EMBL; D50739; BAA23527.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; D50740; BAA23529.1; -; mRNA.
DR   EMBL; BT009773; AAP88775.1; -; mRNA.
DR   EMBL; AL132857; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471078; EAW65858.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW65856.1; -; Genomic_DNA.
DR   EMBL; CH471078; EAW65859.1; -; Genomic_DNA.
DR   EMBL; BC006221; AAH06221.2; ALT_INIT; mRNA.
DR   CCDS; CCDS41945.1; -. [P43699-3]
DR   CCDS; CCDS9659.1; -. [P43699-1]
DR   PIR; G02321; G02321.
DR   RefSeq; NP_001073136.1; NM_001079668.2. [P43699-3]
DR   RefSeq; NP_003308.1; NM_003317.3. [P43699-1]
DR   UniGene; Hs.94367; -.
DR   ProteinModelPortal; P43699; -.
DR   SMR; P43699; -.
DR   BioGrid; 112936; 10.
DR   IntAct; P43699; 8.
DR   MINT; P43699; -.
DR   STRING; 9606.ENSP00000346879; -.
DR   iPTMnet; P43699; -.
DR   PhosphoSitePlus; P43699; -.
DR   BioMuta; NKX2-1; -.
DR   DMDM; 1174819; -.
DR   MaxQB; P43699; -.
DR   PaxDb; P43699; -.
DR   PeptideAtlas; P43699; -.
DR   PRIDE; P43699; -.
DR   DNASU; 7080; -.
DR   Ensembl; ENST00000354822; ENSP00000346879; ENSG00000136352. [P43699-3]
DR   Ensembl; ENST00000498187; ENSP00000429607; ENSG00000136352. [P43699-1]
DR   Ensembl; ENST00000518149; ENSP00000428341; ENSG00000136352. [P43699-1]
DR   Ensembl; ENST00000522719; ENSP00000429519; ENSG00000136352. [P43699-1]
DR   GeneID; 7080; -.
DR   KEGG; hsa:7080; -.
DR   UCSC; uc001wtt.4; human. [P43699-1]
DR   CTD; 7080; -.
DR   DisGeNET; 7080; -.
DR   EuPathDB; HostDB:ENSG00000136352.17; -.
DR   GeneCards; NKX2-1; -.
DR   HGNC; HGNC:11825; NKX2-1.
DR   HPA; CAB000078; -.
DR   HPA; CAB053633; -.
DR   HPA; HPA074316; -.
DR   MalaCards; NKX2-1; -.
DR   MIM; 118700; phenotype.
DR   MIM; 188550; phenotype.
DR   MIM; 600635; gene.
DR   MIM; 610978; phenotype.
DR   neXtProt; NX_P43699; -.
DR   OpenTargets; ENSG00000136352; -.
DR   Orphanet; 95713; Athyreosis.
DR   Orphanet; 1429; Benign familial chorea.
DR   Orphanet; 209905; Brain-lung-thyroid syndrome.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   Orphanet; 95720; Thyroid hypoplasia.
DR   PharmGKB; PA36531; -.
DR   eggNOG; KOG0842; Eukaryota.
DR   eggNOG; ENOG410XR21; LUCA.
DR   GeneTree; ENSGT00910000144003; -.
DR   HOGENOM; HOG000231923; -.
DR   HOVERGEN; HBG006689; -.
DR   InParanoid; P43699; -.
DR   KO; K09342; -.
DR   OMA; MGHNGTV; -.
DR   OrthoDB; EOG091G0LZ2; -.
DR   PhylomeDB; P43699; -.
DR   TreeFam; TF351204; -.
DR   SIGNOR; P43699; -.
DR   GeneWiki; NK2_homeobox_1; -.
DR   GenomeRNAi; 7080; -.
DR   PRO; PR:P43699; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000136352; -.
DR   CleanEx; HS_NKX2-1; -.
DR   CleanEx; HS_TTF1; -.
DR   ExpressionAtlas; P43699; baseline and differential.
DR   Genevisible; P43699; HS.
DR   GO; GO:0005654; C:nucleoplasm; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IMP:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0044213; F:intronic transcription regulatory region DNA binding; IDA:MGI.
DR   GO; GO:0001161; F:intronic transcription regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0001012; F:RNA polymerase II regulatory region DNA binding; IDA:MGI.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0003705; F:transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IMP:UniProtKB.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl.
DR   GO; GO:0021892; P:cerebral cortex GABAergic interneuron differentiation; IEA:Ensembl.
DR   GO; GO:0060486; P:Clara cell differentiation; IEA:Ensembl.
DR   GO; GO:0031128; P:developmental induction; IEA:Ensembl.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEP:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEP:UniProtKB.
DR   GO; GO:0021798; P:forebrain dorsal/ventral pattern formation; IEA:Ensembl.
DR   GO; GO:0021877; P:forebrain neuron fate commitment; IEA:Ensembl.
DR   GO; GO:0021759; P:globus pallidus development; IMP:UniProtKB.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0033327; P:Leydig cell differentiation; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEP:UniProtKB.
DR   GO; GO:0060430; P:lung saccule development; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:Ensembl.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0042753; P:positive regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0009725; P:response to hormone; IEP:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0030878; P:thyroid gland development; IMP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0060510; P:Type II pneumocyte differentiation; IEA:Ensembl.
DR   CDD; cd00086; homeodomain; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR020479; Homeobox_metazoa.
DR   Pfam; PF00046; Homeobox; 1.
DR   PRINTS; PR00024; HOMEOBOX.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; Biological rhythms;
KW   Complete proteome; Congenital hypothyroidism; Disease mutation;
KW   DNA-binding; Homeobox; Nucleus; Phosphoprotein; Reference proteome;
KW   Repressor; Transcription; Transcription regulation.
FT   CHAIN         1    371       Homeobox protein Nkx-2.1.
FT                                /FTId=PRO_0000049343.
FT   DNA_BIND    161    220       Homeobox. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00108}.
FT   COMPBIAS    234    243       Poly-Gly.
FT   COMPBIAS    246    253       Poly-Gln.
FT   COMPBIAS    294    303       Poly-Ala.
FT   MOD_RES     254    254       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23441}.
FT   VAR_SEQ       1      1       M -> MWSGGSGKARGWEAAAGGRSSPGRLSRRRIM (in
FT                                isoform 3). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9545595,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_037890.
FT   VARIANT     172    172       Q -> H (in BHC; decrease in DNA-binding;
FT                                no effect on transcription activation
FT                                from thyroglobulin/TG, nor from pulmonary
FT                                surfactant-associated protein C/SFTPC
FT                                gene promoters).
FT                                {ECO:0000269|PubMed:26723978}.
FT                                /FTId=VAR_075209.
FT   VARIANT     179    179       R -> P (in BHC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24453141}.
FT                                /FTId=VAR_077542.
FT   VARIANT     203    203       T -> R (in CAHTP).
FT                                {ECO:0000269|PubMed:24714694}.
FT                                /FTId=VAR_073040.
FT   VARIANT     205    205       V -> F (in CAHTP; dbSNP:rs137852692).
FT                                {ECO:0000269|PubMed:11854319,
FT                                ECO:0000269|PubMed:24714694}.
FT                                /FTId=VAR_034906.
FT   VARIANT     208    208       W -> L (in BHC; dbSNP:rs28936672).
FT                                {ECO:0000269|PubMed:11971878}.
FT                                /FTId=VAR_015188.
FT   VARIANT     208    208       W -> S (in BHC; loss of transcription
FT                                activation).
FT                                {ECO:0000269|PubMed:26723978}.
FT                                /FTId=VAR_075210.
FT   VARIANT     213    213       R -> S (in BHC; dbSNP:rs28936671).
FT                                {ECO:0000269|PubMed:11971878}.
FT                                /FTId=VAR_015189.
FT   VARIANT     339    339       A -> V (in NMTC1; loss of transcription
FT                                regulatory region DNA binding; decreased
FT                                transcription factor activity, sequence-
FT                                specific DNA binding; tested for the
FT                                thyroglobulin gene; associated with
FT                                dominant impairment of thyroid-specific
FT                                genes transcription and increased thyroid
FT                                cells proliferation; dbSNP:rs537209983).
FT                                {ECO:0000269|PubMed:19176457}.
FT                                /FTId=VAR_075769.
FT   CONFLICT     49     49       P -> H (in Ref. 5; BAA23527/BAA23529).
FT                                {ECO:0000305}.
FT   CONFLICT     61     61       H -> P (in Ref. 5; BAA23527/BAA23529).
FT                                {ECO:0000305}.
FT   CONFLICT    158    158       S -> T (in Ref. 5; BAA23527/BAA23529).
FT                                {ECO:0000305}.
FT   CONFLICT    161    161       R -> G (in Ref. 5; BAA23527/BAA23529).
FT                                {ECO:0000305}.
SQ   SEQUENCE   371 AA;  38596 MW;  5F1E3B40A1BBD862 CRC64;
     MSMSPKHTTP FSVSDILSPL EESYKKVGME GGGLGAPLAA YRQGQAAPPT AAMQQHAVGH
     HGAVTAAYHM TAAGVPQLSH SAVGGYCNGN LGNMSELPPY QDTMRNSASG PGWYGANPDP
     RFPAISRFMG PASGMNMSGM GGLGSLGDVS KNMAPLPSAP RRKRRVLFSQ AQVYELERRF
     KQQKYLSAPE REHLASMIHL TPTQVKIWFQ NHRYKMKRQA KDKAAQQQLQ QDSGGGGGGG
     GTGCPQQQQA QQQSPRRVAV PVLVKDGKPC QAGAPAPGAA SLQGHAQQQA QHQAQAAQAA
     AAAISVGSGG AGLGAHPGHQ PGSAGQSPDL AHHAASPAAL QGQVSSLSHL NSSGSDYGTM
     SCSTLLYGRT W
//
ID   NOTC2_HUMAN             Reviewed;        2471 AA.
AC   Q04721; Q5T3X7; Q99734; Q9H240;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 3.
DT   28-FEB-2018, entry version 209.
DE   RecName: Full=Neurogenic locus notch homolog protein 2;
DE            Short=Notch 2;
DE            Short=hN2;
DE   Contains:
DE     RecName: Full=Notch 2 extracellular truncation;
DE              Short=N2ECD {ECO:0000303|PubMed:25985737};
DE   Contains:
DE     RecName: Full=Notch 2 intracellular domain;
DE              Short=N2ICD {ECO:0000303|PubMed:25985737};
DE   Flags: Precursor;
GN   Name=NOTCH2 {ECO:0000312|HGNC:HGNC:7882};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Blaumueller C.M., Mann R.S.;
RT   "Complete human notch 2 (hN2) cDNA sequence.";
RL   Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary tumor;
RA   Correa R.G., Camargo A.A., Moreira E.S., Simpson A.J.G.;
RT   "Human Notch2, a novel member of cell-fate determining NOTCH family.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 967-1229.
RC   TISSUE=T-cell;
RA   Lemasson I., Devaux C., Mesnard J.-M.;
RT   "Partial sequence of EGF-like repeat domain of human Notch2 mRNA.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1810-2447.
RC   TISSUE=Brain;
RX   PubMed=1303260; DOI=10.1038/ng1092-119;
RA   Stifani S., Blaumueller C.M., Redhead N.J., Hill R.E.,
RA   Artavanis-Tsakonas S.;
RT   "Human homologs of a Drosophila enhancer of split gene product define
RT   a novel family of nuclear proteins.";
RL   Nat. Genet. 2:119-127(1992).
RN   [6]
RP   PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION.
RX   PubMed=9244302; DOI=10.1016/S0092-8674(00)80336-0;
RA   Blaumueller C.M., Qi H., Zagouras P., Artavanis-Tsakonas S.;
RT   "Intracellular cleavage of Notch leads to a heterodimeric receptor on
RT   the plasma membrane.";
RL   Cell 90:281-291(1997).
RN   [7]
RP   IDENTIFICATION OF LIGANDS.
RX   PubMed=10079256; DOI=10.1016/S0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L.,
RA   Banks A., Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [8]
RP   INTERACTION WITH MAML1.
RX   PubMed=11101851; DOI=10.1038/82644;
RA   Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S.,
RA   Griffin J.D.;
RT   "MAML1, a human homologue of Drosophila mastermind, is a
RT   transcriptional co-activator for NOTCH receptors.";
RL   Nat. Genet. 26:484-489(2000).
RN   [9]
RP   INTERACTION WITH MAML2 AND MAML3.
RX   PubMed=12370315; DOI=10.1128/MCB.22.21.7688-7700.2002;
RA   Wu L., Sun T., Kobayashi K., Gao P., Griffin J.D.;
RT   "Identification of a family of mastermind-like transcriptional
RT   coactivators for mammalian notch receptors.";
RL   Mol. Cell. Biol. 22:7688-7700(2002).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   INTERACTION WITH HIF1AN.
RX   PubMed=17573339; DOI=10.1074/jbc.M704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by
RT   factor inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1716; THR-1802;
RP   SER-1804; THR-1808; SER-1845; SER-2070; SER-2081 AND THR-2097, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   HYDROXYLATION BY HIF1AN.
RX   PubMed=18299578; DOI=10.1073/pnas.0711591105;
RA   Zheng X., Linke S., Dias J.M., Zheng X., Gradin K., Wallis T.P.,
RA   Hamilton B.R., Gustafsson M., Ruas J.L., Wilkins S., Bilton R.L.,
RA   Brismar K., Whitelaw M.L., Pereira T., Gorman J.J., Ericson J.,
RA   Peet D.J., Lendahl U., Poellinger L.;
RT   "Interaction with factor inhibiting HIF-1 defines an additional mode
RT   of cross-coupling between the Notch and hypoxia signaling pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3368-3373(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778 AND SER-1845, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   FUNCTION, AND INVOLVEMENT IN HJCYS.
RX   PubMed=21378989; DOI=10.1038/ng.778;
RA   Isidor B., Lindenbaum P., Pichon O., Bezieau S., Dina C.,
RA   Jacquemont S., Martin-Coignard D., Thauvin-Robinet C., Le Merrer M.,
RA   Mandel J.L., David A., Faivre L., Cormier-Daire V., Redon R.,
RA   Le Caignec C.;
RT   "Truncating mutations in the last exon of NOTCH2 cause a rare skeletal
RT   disorder with osteoporosis.";
RL   Nat. Genet. 43:306-308(2011).
RN   [17]
RP   FUNCTION, INVOLVEMENT IN HJCYS, AND TISSUE SPECIFICITY.
RX   PubMed=21378985; DOI=10.1038/ng.779;
RA   Simpson M.A., Irving M.D., Asilmaz E., Gray M.J., Dafou D.,
RA   Elmslie F.V., Mansour S., Holder S.E., Brain C.E., Burton B.K.,
RA   Kim K.H., Pauli R.M., Aftimos S., Stewart H., Kim C.A.,
RA   Holder-Espinasse M., Robertson S.P., Drake W.M., Trembath R.C.;
RT   "Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe
RT   and progressive bone loss.";
RL   Nat. Genet. 43:303-305(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   FUNCTION, INTERACTION WITH TCIM, AND SUBCELLULAR LOCATION.
RX   PubMed=25985737; DOI=10.1038/ncomms8122;
RA   Zhu P., Wang Y., Du Y., He L., Huang G., Zhang G., Yan X., Fan Z.;
RT   "C8orf4 negatively regulates self-renewal of liver cancer stem cells
RT   via suppression of NOTCH2 signalling.";
RL   Nat. Commun. 6:7122-7122(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1426-1677, AND DISULFIDE
RP   BONDS.
RX   PubMed=17401372; DOI=10.1038/nsmb1227;
RA   Gordon W.R., Vardar-Ulu D., Histen G., Sanchez-Irizarry C.,
RA   Aster J.C., Blacklow S.C.;
RT   "Structural basis for autoinhibition of Notch.";
RL   Nat. Struct. Mol. Biol. 14:295-300(2007).
RN   [21]
RP   VARIANT ALGS2 TYR-444.
RX   PubMed=16773578; DOI=10.1086/505332;
RA   McDaniell R., Warthen D.M., Sanchez-Lara P.A., Pai A., Krantz I.D.,
RA   Piccoli D.A., Spinner N.B.;
RT   "NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of
RT   the notch signaling pathway.";
RL   Am. J. Hum. Genet. 79:169-173(2006).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands
CC       Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
CC       Upon ligand activation through the released notch intracellular
CC       domain (NICD) it forms a transcriptional activator complex with
CC       RBPJ/RBPSUH and activates genes of the enhancer of split locus.
CC       Affects the implementation of differentiation, proliferation and
CC       apoptotic programs (By similarity). Involved in bone remodeling
CC       and homeostasis. In collaboration with RELA/p65 enhances NFATc1
CC       promoter activity and positively regulates RANKL-induced
CC       osteoclast differentiation. Positively regulates self-renewal of
CC       liver cancer cells (PubMed:25985737).
CC       {ECO:0000250|UniProtKB:O35516, ECO:0000269|PubMed:21378985,
CC       ECO:0000269|PubMed:21378989, ECO:0000269|PubMed:25985737}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-
CC       terminal fragment N(EC) which are probably linked by disulfide
CC       bonds (By similarity). Interacts with MAML1, MAML2 and MAML3 which
CC       act as transcriptional coactivators for NOTCH2. Interacts with
CC       RELA/p65 (By similarity). Interacts with HIF1AN. Interacts (via
CC       ANK repeats) with TCIM, the interaction inhibits the nuclear
CC       translocation of NOTCH2 N2ICD (PubMed:25985737). {ECO:0000250,
CC       ECO:0000269|PubMed:11101851, ECO:0000269|PubMed:12370315,
CC       ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:25985737}.
CC   -!- SUBCELLULAR LOCATION: Notch 2 extracellular truncation: Cell
CC       membrane {ECO:0000269|PubMed:9244302}; Single-pass type I membrane
CC       protein {ECO:0000269|PubMed:9244302}.
CC   -!- SUBCELLULAR LOCATION: Notch 2 intracellular domain: Nucleus
CC       {ECO:0000269|PubMed:25985737}. Cytoplasm
CC       {ECO:0000269|PubMed:25985737}. Note=Following proteolytical
CC       processing NICD is translocated to the nucleus. Retained at the
CC       cytoplasm by TCIM (PubMed:25985737).
CC       {ECO:0000269|PubMed:25985737}.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain, heart, kidney, lung,
CC       skeletal muscle and liver. Ubiquitously expressed in the embryo.
CC       {ECO:0000269|PubMed:21378985}.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form
CC       which is proteolytically cleaved by a furin-like convertase in the
CC       trans-Golgi network before it reaches the plasma membrane to yield
CC       an active, ligand-accessible form. Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC). Following
CC       ligand binding, it is cleaved by TNF-alpha converting enzyme
CC       (TACE) to yield a membrane-associated intermediate fragment called
CC       notch extracellular truncation (NEXT). This fragment is then
CC       cleaved by presenilin dependent gamma-secretase to release a
CC       notch-derived peptide containing the intracellular domain (NICD)
CC       from the membrane (By similarity). {ECO:0000250}.
CC   -!- PTM: Hydroxylated by HIF1AN. {ECO:0000269|PubMed:18299578}.
CC   -!- PTM: Can be either O-glucosylated or O-xylosylated at Ser-613 by
CC       POGLUT1. {ECO:0000250}.
CC   -!- DISEASE: Alagille syndrome 2 (ALGS2) [MIM:610205]: A form of
CC       Alagille syndrome, an autosomal dominant multisystem disorder. It
CC       is clinically defined by hepatic bile duct paucity and cholestasis
CC       in association with cardiac, skeletal, and ophthalmologic
CC       manifestations. There are characteristic facial features and less
CC       frequent clinical involvement of the renal and vascular systems.
CC       {ECO:0000269|PubMed:16773578}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hajdu-Cheney syndrome (HJCYS) [MIM:102500]: A rare
CC       skeletal disorder characterized by the association of facial
CC       anomalies, acro-osteolysis, general osteoporosis, insufficient
CC       ossification of the skull, and periodontal disease (premature loss
CC       of permanent teeth). Other features include cleft palate,
CC       congenital heart defects, polycystic kidneys, orthopedic problems
CC       and anomalies of the genitalia, intestines and eyes.
CC       {ECO:0000269|PubMed:21378985, ECO:0000269|PubMed:21378989}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. NOTCH2 mutations associated with Hajdu-
CC       Cheney syndrome cluster to the last coding exon of the gene. This
CC       suggests that the mutant mRNA products may escape nonsense-
CC       mediated decay and the resulting truncated NOTCH2 proteins act in
CC       a gain-of-function manner.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NOTCH2ID41556ch1p12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF308601; AAA36377.2; -; mRNA.
DR   EMBL; AF315356; AAG37073.1; -; mRNA.
DR   EMBL; AL359752; CAI18974.1; -; Genomic_DNA.
DR   EMBL; AL512503; CAI18974.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAI18974.1; JOINED; Genomic_DNA.
DR   EMBL; AL512503; CAH72483.1; -; Genomic_DNA.
DR   EMBL; AL359752; CAH72483.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAH72483.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAH70182.1; -; Genomic_DNA.
DR   EMBL; AL359752; CAH70182.1; JOINED; Genomic_DNA.
DR   EMBL; AL512503; CAH70182.1; JOINED; Genomic_DNA.
DR   EMBL; U77493; AAB19224.1; -; mRNA.
DR   CCDS; CCDS908.1; -.
DR   RefSeq; NP_001186930.1; NM_001200001.1.
DR   RefSeq; NP_077719.2; NM_024408.3.
DR   UniGene; Hs.487360; -.
DR   PDB; 2OO4; X-ray; 2.00 A; A/B=1423-1677.
DR   PDB; 5MWB; X-ray; 1.86 A; A=414-532.
DR   PDBsum; 2OO4; -.
DR   PDBsum; 5MWB; -.
DR   ProteinModelPortal; Q04721; -.
DR   SMR; Q04721; -.
DR   BioGrid; 110915; 52.
DR   CORUM; Q04721; -.
DR   ELM; Q04721; -.
DR   IntAct; Q04721; 31.
DR   MINT; Q04721; -.
DR   STRING; 9606.ENSP00000256646; -.
DR   BindingDB; Q04721; -.
DR   ChEMBL; CHEMBL3407320; -.
DR   GuidetoPHARMACOLOGY; 2859; -.
DR   iPTMnet; Q04721; -.
DR   PhosphoSitePlus; Q04721; -.
DR   BioMuta; NOTCH2; -.
DR   DMDM; 143811429; -.
DR   EPD; Q04721; -.
DR   MaxQB; Q04721; -.
DR   PaxDb; Q04721; -.
DR   PeptideAtlas; Q04721; -.
DR   PRIDE; Q04721; -.
DR   Ensembl; ENST00000256646; ENSP00000256646; ENSG00000134250.
DR   GeneID; 4853; -.
DR   KEGG; hsa:4853; -.
DR   UCSC; uc001eik.4; human.
DR   CTD; 4853; -.
DR   DisGeNET; 4853; -.
DR   EuPathDB; HostDB:ENSG00000134250.17; -.
DR   GeneCards; NOTCH2; -.
DR   GeneReviews; NOTCH2; -.
DR   HGNC; HGNC:7882; NOTCH2.
DR   HPA; HPA046392; -.
DR   HPA; HPA048743; -.
DR   MalaCards; NOTCH2; -.
DR   MIM; 102500; phenotype.
DR   MIM; 600275; gene.
DR   MIM; 610205; phenotype.
DR   neXtProt; NX_Q04721; -.
DR   OpenTargets; ENSG00000134250; -.
DR   Orphanet; 955; Acroosteolysis dominant type.
DR   Orphanet; 261629; Alagille syndrome due to a NOTCH2 point mutation.
DR   PharmGKB; PA31684; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   HOGENOM; HOG000234369; -.
DR   HOVERGEN; HBG052650; -.
DR   InParanoid; Q04721; -.
DR   KO; K20994; -.
DR   OrthoDB; EOG091G01NU; -.
DR   PhylomeDB; Q04721; -.
DR   TreeFam; TF351641; -.
DR   Reactome; R-HSA-1912399; Pre-NOTCH Processing in the Endoplasmic Reticulum.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-2197563; NOTCH2 intracellular domain regulates transcription.
DR   Reactome; R-HSA-2979096; NOTCH2 Activation and Transmission of Signal to the Nucleus.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-5083630; Defective LFNG causes SCDO3.
DR   SignaLink; Q04721; -.
DR   SIGNOR; Q04721; -.
DR   ChiTaRS; NOTCH2; human.
DR   EvolutionaryTrace; Q04721; -.
DR   GeneWiki; Notch-2; -.
DR   GenomeRNAi; 4853; -.
DR   PRO; PR:Q04721; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000134250; -.
DR   CleanEx; HS_NOTCH2; -.
DR   ExpressionAtlas; Q04721; baseline and differential.
DR   Genevisible; Q04721; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0004872; F:receptor activity; NAS:UniProtKB.
DR   GO; GO:0038049; F:transcription factor activity, ligand-activated RNA polymerase II transcription factor binding; TAS:UniProtKB.
DR   GO; GO:0009887; P:animal organ morphogenesis; IEP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0060413; P:atrial septum morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0046849; P:bone remodeling; IMP:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0001709; P:cell fate determination; TAS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0002315; P:marginal zone B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; NAS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045967; P:negative regulation of growth rate; IDA:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; NAS:UniProtKB.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IC:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0050793; P:regulation of developmental process; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; TAS:UniProtKB.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   CDD; cd00204; ANK; 2.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR035993; Notch-like_dom_sf.
DR   InterPro; IPR022336; Notch_2.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 24.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF12661; hEGF; 4.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01985; NOTCH2.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM01334; DUF3454; 1.
DR   SMART; SM00181; EGF; 36.
DR   SMART; SM00179; EGF_CA; 34.
DR   SMART; SM00004; NL; 3.
DR   SMART; SM01338; NOD; 1.
DR   SMART; SM01339; NODP; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 6.
DR   SUPFAM; SSF90193; SSF90193; 2.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 34.
DR   PROSITE; PS01186; EGF_2; 29.
DR   PROSITE; PS50026; EGF_3; 35.
DR   PROSITE; PS01187; EGF_CA; 22.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; ANK repeat; Cell membrane; Complete proteome;
KW   Cytoplasm; Developmental protein; Differentiation; Disease mutation;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Membrane;
KW   Notch signaling pathway; Nucleus; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transcription;
KW   Transcription regulation; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26   2471       Neurogenic locus notch homolog protein 2.
FT                                /FTId=PRO_0000007683.
FT   CHAIN      1666   2471       Notch 2 extracellular truncation.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007684.
FT   CHAIN      1697   2471       Notch 2 intracellular domain.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007685.
FT   TOPO_DOM     26   1677       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1678   1698       Helical. {ECO:0000255}.
FT   TOPO_DOM   1699   2471       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       26     63       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN       64    102       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      105    143       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      144    180       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      182    219       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      221    258       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      260    296       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      298    336       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      338    374       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      375    413       EGF-like 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      415    454       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      456    492       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      494    530       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      532    568       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      570    605       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      607    643       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      645    680       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      682    718       EGF-like 18; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      720    755       EGF-like 19. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      757    793       EGF-like 20; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      795    831       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      833    871       EGF-like 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      873    909       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      911    947       EGF-like 24; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      949    985       EGF-like 25; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      987   1023       EGF-like 26; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1025   1061       EGF-like 27; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1063   1099       EGF-like 28. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1101   1147       EGF-like 29. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1149   1185       EGF-like 30; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1187   1223       EGF-like 31; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1225   1262       EGF-like 32; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1264   1302       EGF-like 33. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1304   1343       EGF-like 34. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1374   1412       EGF-like 35. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1425   1465       LNR 1.
FT   REPEAT     1466   1502       LNR 2.
FT   REPEAT     1503   1544       LNR 3.
FT   REPEAT     1827   1871       ANK 1.
FT   REPEAT     1876   1905       ANK 2.
FT   REPEAT     1909   1939       ANK 3.
FT   REPEAT     1943   1972       ANK 4.
FT   REPEAT     1976   2005       ANK 5.
FT   REPEAT     2009   2038       ANK 6.
FT   REGION     1425   1677       Negative regulatory region (NRR).
FT   COMPBIAS   1645   1648       Poly-Ala.
FT   COMPBIAS   1994   1997       Poly-Leu.
FT   COMPBIAS   2426   2429       Poly-Ser.
FT   SITE        614    614       Essential for O-xylosylation.
FT                                {ECO:0000250}.
FT   MOD_RES    1716   1716       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1778   1778       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1802   1802       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1804   1804       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1808   1808       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1842   1842       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O35516}.
FT   MOD_RES    1845   1845       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES    2070   2070       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2078   2078       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9QW30}.
FT   MOD_RES    2081   2081       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2097   2097       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   CARBOHYD     46     46       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    155    155       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    613    613       O-linked (Glc...) serine; alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    613    613       O-linked (Xyl...) serine; alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    733    733       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1102   1102       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1465   1465       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     28     41       {ECO:0000250}.
FT   DISULFID     35     51       {ECO:0000250}.
FT   DISULFID     53     62       {ECO:0000250}.
FT   DISULFID     68     79       {ECO:0000250}.
FT   DISULFID     73     90       {ECO:0000250}.
FT   DISULFID     92    101       {ECO:0000250}.
FT   DISULFID    109    121       {ECO:0000250}.
FT   DISULFID    115    131       {ECO:0000250}.
FT   DISULFID    133    142       {ECO:0000250}.
FT   DISULFID    148    159       {ECO:0000250}.
FT   DISULFID    153    168       {ECO:0000250}.
FT   DISULFID    170    179       {ECO:0000250}.
FT   DISULFID    186    198       {ECO:0000250}.
FT   DISULFID    192    207       {ECO:0000250}.
FT   DISULFID    209    218       {ECO:0000250}.
FT   DISULFID    225    236       {ECO:0000250}.
FT   DISULFID    230    246       {ECO:0000250}.
FT   DISULFID    248    257       {ECO:0000250}.
FT   DISULFID    264    275       {ECO:0000250}.
FT   DISULFID    269    284       {ECO:0000250}.
FT   DISULFID    286    295       {ECO:0000250}.
FT   DISULFID    302    315       {ECO:0000250}.
FT   DISULFID    309    324       {ECO:0000250}.
FT   DISULFID    326    335       {ECO:0000250}.
FT   DISULFID    342    353       {ECO:0000250}.
FT   DISULFID    347    362       {ECO:0000250}.
FT   DISULFID    364    373       {ECO:0000250}.
FT   DISULFID    379    390       {ECO:0000250}.
FT   DISULFID    384    401       {ECO:0000250}.
FT   DISULFID    403    412       {ECO:0000250}.
FT   DISULFID    419    433       {ECO:0000250}.
FT   DISULFID    427    442       {ECO:0000250}.
FT   DISULFID    444    453       {ECO:0000250}.
FT   DISULFID    460    471       {ECO:0000250}.
FT   DISULFID    465    480       {ECO:0000250}.
FT   DISULFID    482    491       {ECO:0000250}.
FT   DISULFID    498    509       {ECO:0000250}.
FT   DISULFID    503    518       {ECO:0000250}.
FT   DISULFID    520    529       {ECO:0000250}.
FT   DISULFID    536    547       {ECO:0000250}.
FT   DISULFID    541    556       {ECO:0000250}.
FT   DISULFID    558    567       {ECO:0000250}.
FT   DISULFID    574    584       {ECO:0000250}.
FT   DISULFID    579    593       {ECO:0000250}.
FT   DISULFID    595    604       {ECO:0000250}.
FT   DISULFID    611    622       {ECO:0000250}.
FT   DISULFID    616    631       {ECO:0000250}.
FT   DISULFID    633    642       {ECO:0000250}.
FT   DISULFID    649    659       {ECO:0000250}.
FT   DISULFID    654    668       {ECO:0000250}.
FT   DISULFID    670    679       {ECO:0000250}.
FT   DISULFID    686    697       {ECO:0000250}.
FT   DISULFID    691    706       {ECO:0000250}.
FT   DISULFID    708    717       {ECO:0000250}.
FT   DISULFID    724    734       {ECO:0000250}.
FT   DISULFID    729    743       {ECO:0000250}.
FT   DISULFID    745    754       {ECO:0000250}.
FT   DISULFID    761    772       {ECO:0000250}.
FT   DISULFID    766    781       {ECO:0000250}.
FT   DISULFID    783    792       {ECO:0000250}.
FT   DISULFID    799    810       {ECO:0000250}.
FT   DISULFID    804    819       {ECO:0000250}.
FT   DISULFID    821    830       {ECO:0000250}.
FT   DISULFID    837    848       {ECO:0000250}.
FT   DISULFID    842    859       {ECO:0000250}.
FT   DISULFID    861    870       {ECO:0000250}.
FT   DISULFID    877    888       {ECO:0000250}.
FT   DISULFID    882    897       {ECO:0000250}.
FT   DISULFID    899    908       {ECO:0000250}.
FT   DISULFID    915    926       {ECO:0000250}.
FT   DISULFID    920    935       {ECO:0000250}.
FT   DISULFID    937    946       {ECO:0000250}.
FT   DISULFID    953    964       {ECO:0000250}.
FT   DISULFID    958    973       {ECO:0000250}.
FT   DISULFID    975    984       {ECO:0000250}.
FT   DISULFID    991   1002       {ECO:0000250}.
FT   DISULFID    996   1011       {ECO:0000250}.
FT   DISULFID   1013   1022       {ECO:0000250}.
FT   DISULFID   1029   1040       {ECO:0000250}.
FT   DISULFID   1034   1049       {ECO:0000250}.
FT   DISULFID   1051   1060       {ECO:0000250}.
FT   DISULFID   1067   1078       {ECO:0000250}.
FT   DISULFID   1072   1087       {ECO:0000250}.
FT   DISULFID   1089   1098       {ECO:0000250}.
FT   DISULFID   1105   1126       {ECO:0000250}.
FT   DISULFID   1120   1135       {ECO:0000250}.
FT   DISULFID   1137   1146       {ECO:0000250}.
FT   DISULFID   1153   1164       {ECO:0000250}.
FT   DISULFID   1158   1173       {ECO:0000250}.
FT   DISULFID   1175   1184       {ECO:0000250}.
FT   DISULFID   1191   1202       {ECO:0000250}.
FT   DISULFID   1196   1211       {ECO:0000250}.
FT   DISULFID   1213   1222       {ECO:0000250}.
FT   DISULFID   1229   1241       {ECO:0000250}.
FT   DISULFID   1235   1250       {ECO:0000250}.
FT   DISULFID   1252   1261       {ECO:0000250}.
FT   DISULFID   1268   1281       {ECO:0000250}.
FT   DISULFID   1273   1290       {ECO:0000250}.
FT   DISULFID   1292   1301       {ECO:0000250}.
FT   DISULFID   1308   1319       {ECO:0000250}.
FT   DISULFID   1313   1331       {ECO:0000250}.
FT   DISULFID   1333   1342       {ECO:0000250}.
FT   DISULFID   1378   1389       {ECO:0000250}.
FT   DISULFID   1383   1400       {ECO:0000250}.
FT   DISULFID   1402   1411       {ECO:0000250}.
FT   DISULFID   1425   1448       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1430   1443       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1439   1455       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1466   1489       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1472   1484       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1480   1496       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1503   1527       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1509   1522       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1518   1534       {ECO:0000269|PubMed:17401372}.
FT   DISULFID   1632   1639       {ECO:0000269|PubMed:17401372}.
FT   VARIANT     444    444       C -> Y (in ALGS2; dbSNP:rs111033632).
FT                                {ECO:0000269|PubMed:16773578}.
FT                                /FTId=VAR_029361.
FT   VARIANT    1667   1667       V -> F (in dbSNP:rs17024517).
FT                                /FTId=VAR_031463.
FT   CONFLICT     21     21       A -> T (in Ref. 2; AAG37073).
FT                                {ECO:0000305}.
FT   CONFLICT    210    210       P -> L (in Ref. 2; AAG37073).
FT                                {ECO:0000305}.
FT   CONFLICT   1037   1037       E -> D (in Ref. 4; AAB19224).
FT                                {ECO:0000305}.
FT   CONFLICT   1084   1085       ES -> SP (in Ref. 4; AAB19224).
FT                                {ECO:0000305}.
FT   CONFLICT   1094   1094       A -> V (in Ref. 4; AAB19224).
FT                                {ECO:0000305}.
FT   CONFLICT   1139   1139       L -> V (in Ref. 4; AAB19224).
FT                                {ECO:0000305}.
FT   CONFLICT   1519   1519       D -> N (in Ref. 1; AAA36377).
FT                                {ECO:0000305}.
FT   CONFLICT   2053   2053       R -> H (in Ref. 2; AAG37073).
FT                                {ECO:0000305}.
FT   TURN        418    420       {ECO:0000244|PDB:5MWB}.
FT   STRAND      426    428       {ECO:0000244|PDB:5MWB}.
FT   STRAND      432    436       {ECO:0000244|PDB:5MWB}.
FT   STRAND      439    443       {ECO:0000244|PDB:5MWB}.
FT   STRAND      448    450       {ECO:0000244|PDB:5MWB}.
FT   HELIX       459    462       {ECO:0000244|PDB:5MWB}.
FT   STRAND      470    474       {ECO:0000244|PDB:5MWB}.
FT   STRAND      477    481       {ECO:0000244|PDB:5MWB}.
FT   STRAND      486    488       {ECO:0000244|PDB:5MWB}.
FT   HELIX       497    500       {ECO:0000244|PDB:5MWB}.
FT   STRAND      508    512       {ECO:0000244|PDB:5MWB}.
FT   STRAND      515    519       {ECO:0000244|PDB:5MWB}.
FT   HELIX      1428   1433       {ECO:0000244|PDB:2OO4}.
FT   STRAND     1436   1438       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1441   1443       {ECO:0000244|PDB:2OO4}.
FT   TURN       1446   1448       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1449   1452       {ECO:0000244|PDB:2OO4}.
FT   TURN       1453   1458       {ECO:0000244|PDB:2OO4}.
FT   TURN       1462   1465       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1472   1474       {ECO:0000244|PDB:2OO4}.
FT   STRAND     1477   1479       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1482   1484       {ECO:0000244|PDB:2OO4}.
FT   TURN       1487   1490       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1491   1494       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1506   1512       {ECO:0000244|PDB:2OO4}.
FT   STRAND     1515   1517       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1520   1522       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1525   1532       {ECO:0000244|PDB:2OO4}.
FT   STRAND     1544   1553       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1555   1560       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1562   1573       {ECO:0000244|PDB:2OO4}.
FT   STRAND     1575   1579       {ECO:0000244|PDB:2OO4}.
FT   STRAND     1589   1595       {ECO:0000244|PDB:2OO4}.
FT   STRAND     1618   1628       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1632   1635       {ECO:0000244|PDB:2OO4}.
FT   HELIX      1643   1656       {ECO:0000244|PDB:2OO4}.
FT   STRAND     1663   1670       {ECO:0000244|PDB:2OO4}.
SQ   SEQUENCE   2471 AA;  265405 MW;  605B1B963C812BE1 CRC64;
     MPALRPALLW ALLALWLCCA APAHALQCRD GYEPCVNEGM CVTYHNGTGY CKCPEGFLGE
     YCQHRDPCEK NRCQNGGTCV AQAMLGKATC RCASGFTGED CQYSTSHPCF VSRPCLNGGT
     CHMLSRDTYE CTCQVGFTGK ECQWTDACLS HPCANGSTCT TVANQFSCKC LTGFTGQKCE
     TDVNECDIPG HCQHGGTCLN LPGSYQCQCP QGFTGQYCDS LYVPCAPSPC VNGGTCRQTG
     DFTFECNCLP GFEGSTCERN IDDCPNHRCQ NGGVCVDGVN TYNCRCPPQW TGQFCTEDVD
     ECLLQPNACQ NGGTCANRNG GYGCVCVNGW SGDDCSENID DCAFASCTPG STCIDRVASF
     SCMCPEGKAG LLCHLDDACI SNPCHKGALC DTNPLNGQYI CTCPQGYKGA DCTEDVDECA
     MANSNPCEHA GKCVNTDGAF HCECLKGYAG PRCEMDINEC HSDPCQNDAT CLDKIGGFTC
     LCMPGFKGVH CELEINECQS NPCVNNGQCV DKVNRFQCLC PPGFTGPVCQ IDIDDCSSTP
     CLNGAKCIDH PNGYECQCAT GFTGVLCEEN IDNCDPDPCH HGQCQDGIDS YTCICNPGYM
     GAICSDQIDE CYSSPCLNDG RCIDLVNGYQ CNCQPGTSGV NCEINFDDCA SNPCIHGICM
     DGINRYSCVC SPGFTGQRCN IDIDECASNP CRKGATCING VNGFRCICPE GPHHPSCYSQ
     VNECLSNPCI HGNCTGGLSG YKCLCDAGWV GINCEVDKNE CLSNPCQNGG TCDNLVNGYR
     CTCKKGFKGY NCQVNIDECA SNPCLNQGTC FDDISGYTCH CVLPYTGKNC QTVLAPCSPN
     PCENAAVCKE SPNFESYTCL CAPGWQGQRC TIDIDECISK PCMNHGLCHN TQGSYMCECP
     PGFSGMDCEE DIDDCLANPC QNGGSCMDGV NTFSCLCLPG FTGDKCQTDM NECLSEPCKN
     GGTCSDYVNS YTCKCQAGFD GVHCENNINE CTESSCFNGG TCVDGINSFS CLCPVGFTGS
     FCLHEINECS SHPCLNEGTC VDGLGTYRCS CPLGYTGKNC QTLVNLCSRS PCKNKGTCVQ
     KKAESQCLCP SGWAGAYCDV PNVSCDIAAS RRGVLVEHLC QHSGVCINAG NTHYCQCPLG
     YTGSYCEEQL DECASNPCQH GATCSDFIGG YRCECVPGYQ GVNCEYEVDE CQNQPCQNGG
     TCIDLVNHFK CSCPPGTRGL LCEENIDDCA RGPHCLNGGQ CMDRIGGYSC RCLPGFAGER
     CEGDINECLS NPCSSEGSLD CIQLTNDYLC VCRSAFTGRH CETFVDVCPQ MPCLNGGTCA
     VASNMPDGFI CRCPPGFSGA RCQSSCGQVK CRKGEQCVHT ASGPRCFCPS PRDCESGCAS
     SPCQHGGSCH PQRQPPYYSC QCAPPFSGSR CELYTAPPST PPATCLSQYC ADKARDGVCD
     EACNSHACQW DGGDCSLTME NPWANCSSPL PCWDYINNQC DELCNTVECL FDNFECQGNS
     KTCKYDKYCA DHFKDNHCDQ GCNSEECGWD GLDCAADQPE NLAEGTLVIV VLMPPEQLLQ
     DARSFLRALG TLLHTNLRIK RDSQGELMVY PYYGEKSAAM KKQRMTRRSL PGEQEQEVAG
     SKVFLEIDNR QCVQDSDHCF KNTDAAAALL ASHAIQGTLS YPLVSVVSES LTPERTQLLY
     LLAVAVVIIL FIILLGVIMA KRKRKHGSLW LPEGFTLRRD ASNHKRREPV GQDAVGLKNL
     SVQVSEANLI GTGTSEHWVD DEGPQPKKVK AEDEALLSEE DDPIDRRPWT QQHLEAADIR
     RTPSLALTPP QAEQEVDVLD VNVRGPDGCT PLMLASLRGG SSDLSDEDED AEDSSANIIT
     DLVYQGASLQ AQTDRTGEMA LHLAARYSRA DAAKRLLDAG ADANAQDNMG RCPLHAAVAA
     DAQGVFQILI RNRVTDLDAR MNDGTTPLIL AARLAVEGMV AELINCQADV NAVDDHGKSA
     LHWAAAVNNV EATLLLLKNG ANRDMQDNKE ETPLFLAARE GSYEAAKILL DHFANRDITD
     HMDRLPRDVA RDRMHHDIVR LLDEYNVTPS PPGTVLTSAL SPVICGPNRS FLSLKHTPMG
     KKSRRPSAKS TMPTSLPNLA KEAKDAKGSR RKKSLSEKVQ LSESSVTLSP VDSLESPHTY
     VSDTTSSPMI TSPGILQASP NPMLATAAPP APVHAQHALS FSNLHEMQPL AHGASTVLPS
     VSQLLSHHHI VSPGSGSAGS LSRLHPVPVP ADWMNRMEVN ETQYNEMFGM VLAPAEGTHP
     GIAPQSRPPE GKHITTPREP LPPIVTFQLI PKGSIAQPAG APQPQSTCPP AVAGPLPTMY
     QIPEMARLPS VAFPTAMMPQ QDGQVAQTIL PAYHPFPASV GKYPTPPSQH SYASSNAAER
     TPSHSGHLQG EHPYLTPSPE SPDQWSSSSP HSASDWSDVT TSPTPGGAGG GQRGPGTHMS
     EPPHNNMQVY A
//
ID   Q6IQ50_HUMAN            Unreviewed;      1235 AA.
AC   Q6IQ50;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   30-AUG-2005, sequence version 2.
DT   31-JAN-2018, entry version 110.
DE   SubName: Full=NOTCH2 protein {ECO:0000313|EMBL:AAH71562.2};
GN   Name=NOTCH2 {ECO:0000313|EMBL:AAH71562.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH71562.2};
RN   [1] {ECO:0000313|EMBL:AAH71562.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis {ECO:0000313|EMBL:AAH71562.2};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- CAUTION: Lacks conserved residue(s) required for the propagation
CC       of feature annotation. {ECO:0000256|PROSITE-ProRule:PRU00076}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC071562; AAH71562.2; -; mRNA.
DR   RefSeq; NP_001186930.1; NM_001200001.1.
DR   RefSeq; NP_077719.2; NM_024408.3.
DR   UniGene; Hs.487360; -.
DR   ProteinModelPortal; Q6IQ50; -.
DR   PeptideAtlas; Q6IQ50; -.
DR   PRIDE; Q6IQ50; -.
DR   GeneID; 4853; -.
DR   KEGG; hsa:4853; -.
DR   CTD; 4853; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   KO; K20994; -.
DR   ChiTaRS; NOTCH2; human.
DR   GenomeRNAi; 4853; -.
DR   Genevisible; Q6IQ50; HS.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   Pfam; PF00008; EGF; 21.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF12661; hEGF; 5.
DR   SMART; SM00181; EGF; 31.
DR   SMART; SM00179; EGF_CA; 30.
DR   SUPFAM; SSF57184; SSF57184; 5.
DR   PROSITE; PS00010; ASX_HYDROXYL; 21.
DR   PROSITE; PS00022; EGF_1; 28.
DR   PROSITE; PS01186; EGF_2; 25.
DR   PROSITE; PS50026; EGF_3; 31.
DR   PROSITE; PS01187; EGF_CA; 9.
PE   2: Evidence at transcript level;
KW   Calcium {ECO:0000256|SAAS:SAAS00909960};
KW   Disulfide bond {ECO:0000256|PROSITE-ProRule:PRU00076,
KW   ECO:0000256|SAAS:SAAS00601599};
KW   EGF-like domain {ECO:0000256|PROSITE-ProRule:PRU00076,
KW   ECO:0000256|SAAS:SAAS00032677};
KW   Repeat {ECO:0000256|SAAS:SAAS00594563};
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL        1     25       {ECO:0000256|SAM:SignalP}.
FT   CHAIN        26   1235       {ECO:0000256|SAM:SignalP}.
FT                                /FTId=PRO_5004275902.
FT   DOMAIN       24     63       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN       64    102       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      105    143       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      144    180       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      182    219       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      221    258       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      260    296       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      298    336       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      338    374       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      375    413       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      415    454       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      456    492       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      494    530       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      532    568       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      570    605       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      607    643       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      645    680       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      682    718       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      720    755       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      757    793       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      795    831       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      833    871       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      873    909       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      911    947       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      949    985       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN      987   1023       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN     1025   1061       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN     1063   1099       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN     1112   1147       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN     1149   1185       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DOMAIN     1187   1223       EGF-like. {ECO:0000259|PROSITE:PS50026}.
FT   DISULFID     53     62       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID     73     90       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID     92    101       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    133    142       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    170    179       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    209    218       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    248    257       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    286    295       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    326    335       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    364    373       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    384    401       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    403    412       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    444    453       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    482    491       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    520    529       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    558    567       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    574    584       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    595    604       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    633    642       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    649    659       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    670    679       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    708    717       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    724    734       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    745    754       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    783    792       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    821    830       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    842    859       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    861    870       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    899    908       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID    975    984       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1013   1022       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1051   1060       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1089   1098       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1116   1126       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1137   1146       {ECO:0000256|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1175   1184       {ECO:0000256|PROSITE-ProRule:PRU00076}.
SQ   SEQUENCE   1235 AA;  132112 MW;  2ADBD704B1552B61 CRC64;
     MPALRPALLW ALLALWLCCA APAHALQCRD GYEPCVNEGM CVTYHNGTGY CKCPEGFLGE
     YCQHRDPCEK NRCQNGGTCV AQAMLGKATC RCASGFTGED CQYSTSHPCF VSRPCLNGGT
     CHMLSRDTYE CTCQVGFTGK ECQWTDACLS HPCANGSTCT TVANQFSCKC LTGFTGQKCE
     TDVNECDIPG HCQHGGTCLN LPGSYQCQCP QGFTGQYCDS LYVPCAPSPC VNGGTCRQTG
     DFTFECNCLP GFEGSTCERN IDDCPNHRCQ NGGVCVDGVN TYNCRCPPQW TGQFCTEDVD
     ECLLQPNACQ NGGTCANRNG GYGCVCVNGW SGDDCSENID DCAFASCTPG STCIDRVASF
     SCMCPEGKAG LLCHLDDACI SNPCHKGALC DTNPLNGQYI CTCPQGYKGA DCTEDVDECA
     MANSNPCEHA GKCVNTDGAF HCECLKGYAG PRCEMDINEC HSDPCQNDAT CLDKIGGFTC
     LCMPGFKGVH CELEINECQS NPCVNNGQCV DKVNRFQCLC PPGFTGPVCQ IDIDDCSSTP
     CLNGAKCIDH PNGYECQCAT GFTGVLCEEN IDNCDPDPCH HGQCQDGIDS YTCICNPGYM
     GAICSDQIDE CYSSPCLNDG RCIDLVNGYQ CNCQPGTSGV NCEINFDDCA SNPCIHGICM
     DGINRYSCVC SPGFTGQRCN IDIDECASNP CRKGATCING VNGFRCICPE GPHHPSCYSQ
     VNECLSNPCI HGNCTGGLSG YKCLCDAGWV GINCEVDKNE CLSNPCQNGG TCDNLVNGYR
     CTCKKGFKGY NCQVNIDECA SNPCLNQGTC FDDISGYTCH CVLPYTGKNC QTVLAPCSPN
     PCENAAVCKE SPNFESYTCL CAPGWQGQRC TIDIDECISK PCMNHGLCHN TQGSYMCECP
     PGFSGMDCEE DIDDCLANPC QNGGSCMDGV NTFSCLCLPG FTGDKYQTDM NECLSEPCKN
     GGTCSDYVNS YTCKCQAGFD GVHCENNINE CTESSCFNGG TCVDGINSFS CLCPVGFTGS
     FCLHEINECS SHPCLNEGTC VDGLGTYRCS CPLGYTGKNC QTLVNLCSRS PCKNKGTCVQ
     KKAESQCLCP SGWAGAYCDV PNVSCDIAAS RRGVLVEHLC QHSGVCINAG NTHYCQCPLG
     YTGSYCEEQL DECASNPCQH GATCSDFIGG YRCECVPGYQ GVNCEYEVDE CQNQPCQNGG
     TCIDLVNHFK CSCPPGTRGM KSSLSIFHPG HCLKL
//
ID   Q9UFD5_HUMAN            Unreviewed;       462 AA.
AC   Q9UFD5;
DT   01-MAY-2000, integrated into UniProtKB/TrEMBL.
DT   01-MAY-2000, sequence version 1.
DT   31-JAN-2018, entry version 95.
DE   SubName: Full=Uncharacterized protein DKFZp434N181 {ECO:0000313|EMBL:CAB61366.1};
DE   Flags: Fragment;
GN   Name=DKFZp434N181 {ECO:0000313|EMBL:CAB61366.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:CAB61366.1};
RN   [1] {ECO:0000313|EMBL:CAB61366.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Testis {ECO:0000313|EMBL:CAB61366.1};
RG   The German cDNA Consortium;
RA   Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA   Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL133036; CAB61366.1; -; mRNA.
DR   PIR; A56695; A56695.
DR   PIR; T42679; T42679.
DR   RefSeq; NP_077719.2; NM_024408.3.
DR   UniGene; Hs.487360; -.
DR   ProteinModelPortal; Q9UFD5; -.
DR   PeptideAtlas; Q9UFD5; -.
DR   PRIDE; Q9UFD5; -.
DR   GeneID; 4853; -.
DR   KEGG; hsa:4853; -.
DR   CTD; 4853; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   HOVERGEN; HBG062747; -.
DR   KO; K20994; -.
DR   GenomeRNAi; 4853; -.
DR   Genevisible; Q9UFD5; HS.
DR   GO; GO:0004872; F:receptor activity; IEA:InterPro.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   CDD; cd00204; ANK; 1.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR022336; Notch_2.
DR   Pfam; PF11936; DUF3454; 1.
DR   PRINTS; PR01985; NOTCH2.
DR   SMART; SM01334; DUF3454; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 1.
PE   2: Evidence at transcript level;
KW   ANK repeat {ECO:0000256|PROSITE-ProRule:PRU00023}.
FT   DOMAIN        1     53       ANK_REP_REGION.
FT                                {ECO:0000259|PROSITE:PS50297}.
FT   REPEAT        1     32       ANK. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00023}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:CAB61366.1}.
SQ   SEQUENCE   462 AA;  49309 MW;  CB86B0969BA26678 CRC64;
     EETPLFLAAR EGSYEAAKIL LDHFANRDIT DHMDRLPRDV ARDRMHHDIV RLLDEYNVTP
     SPPGTVLTSA LSPVICGPNR SFLSLKHTPM GKKSRRPSAK STMPTSLPNL AKEAKDAKGS
     RRKKSLSEKV QLSESSVTLS PVDSLESPHT YVSDTTSSPM ITSPGILQAS PNPMLATAAP
     PAPVHAQHAL SFSNLHEMQP LAHGASTVLP SVSQLLSHHH IVSPGSGSAG SLSRLHPVPV
     PADWMNRMEV NETQYNEMFG MVLAPAEGTH PGIAPQSRPP EGKHITTPRE PLPPIVTFQL
     IPKGSIAQPA GAPQPQSTCP PAVAGPLPTM YQIPEMARLP SVAFPTAMMP QQDGQVAQTI
     LPAYHPFPAS VGKYPTPPSQ HSYASSNAAE RTPSHSGHLQ GEHPYLTPSP ESPDQWSSSS
     PHSASDWSDV TTSPTPGGAG GGQRGPGTHM SEPPHNNMQV YA
//
ID   DPOLQ_HUMAN             Reviewed;        2590 AA.
AC   O75417; O95160; Q6VMB5;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   08-MAR-2011, sequence version 2.
DT   28-FEB-2018, entry version 136.
DE   RecName: Full=DNA polymerase theta {ECO:0000303|PubMed:10395804, ECO:0000303|PubMed:14576298, ECO:0000312|HGNC:HGNC:9186};
DE            EC=2.7.7.7 {ECO:0000269|PubMed:14576298, ECO:0000269|PubMed:22135286};
DE   AltName: Full=DNA polymerase eta {ECO:0000303|Ref.4};
GN   Name=POLQ {ECO:0000303|PubMed:10395804, ECO:0000303|PubMed:14576298,
GN   ECO:0000312|HGNC:HGNC:9186}; Synonyms=POLH {ECO:0000303|Ref.4};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Spleen;
RX   PubMed=10395804; DOI=10.1006/geno.1999.5843;
RA   Sharief F.S., Vojta P.J., Ropp P.A., Copeland W.C.;
RT   "Cloning and chromosomal mapping of the human DNA polymerase theta
RT   (POLQ), the eighth human DNA polymerase.";
RL   Genomics 59:90-96(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=14576298; DOI=10.1093/nar/gkg814;
RA   Seki M., Marini F., Wood R.D.;
RT   "POLQ (Pol theta), a DNA polymerase and DNA-dependent ATPase in human
RT   cells.";
RL   Nucleic Acids Res. 31:6117-6126(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1435-2590.
RA   Harris P.V., Kaelin C.B., Burtis K.C.;
RT   "Catalytic activity of Pol eta, a new human DNA polymerase related to
RT   the bacterial DNA polymerase I family and Drosophila Mus308.";
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   FUNCTION.
RX   PubMed=18503084; DOI=10.1093/nar/gkn310;
RA   Arana M.E., Seki M., Wood R.D., Rogozin I.B., Kunkel T.A.;
RT   "Low-fidelity DNA synthesis by human DNA polymerase theta.";
RL   Nucleic Acids Res. 36:3847-3856(2008).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF 2540-ASP-GLU-2541.
RX   PubMed=19188258; DOI=10.1093/nar/gkp035;
RA   Prasad R., Longley M.J., Sharief F.S., Hou E.W., Copeland W.C.,
RA   Wilson S.H.;
RT   "Human DNA polymerase theta possesses 5'-dRP lyase activity and
RT   functions in single-nucleotide base excision repair in vitro.";
RL   Nucleic Acids Res. 37:1868-1877(2009).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-990, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [8]
RP   INVOLVEMENT IN BC.
RX   PubMed=20700469;
RA   Higgins G.S., Harris A.L., Prevo R., Helleday T., McKenna W.G.,
RA   Buffa F.M.;
RT   "Overexpression of POLQ confers a poor prognosis in early breast
RT   cancer patients.";
RL   Oncotarget 1:175-184(2010).
RN   [9]
RP   INVOLVEMENT IN BC.
RX   PubMed=20624954; DOI=10.1073/pnas.0910759107;
RA   Lemee F., Bergoglio V., Fernandez-Vidal A., Machado-Silva A.,
RA   Pillaire M.J., Bieth A., Gentil C., Baker L., Martin A.L., Leduc C.,
RA   Lam E., Magdeleine E., Filleron T., Oumouhou N., Kaina B., Seki M.,
RA   Grimal F., Lacroix-Triki M., Thompson A., Roche H., Bourdon J.C.,
RA   Wood R.D., Hoffmann J.S., Cazaux C.;
RT   "DNA polymerase theta up-regulation is associated with poor survival
RT   in breast cancer, perturbs DNA replication, and promotes genetic
RT   instability.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:13390-13395(2010).
RN   [10]
RP   FUNCTION.
RX   PubMed=21050863; DOI=10.1016/j.jmb.2010.10.041;
RA   Hogg M., Seki M., Wood R.D., Doublie S., Wallace S.S.;
RT   "Lesion bypass activity of DNA polymerase theta (POLQ) is an intrinsic
RT   property of the pol domain and depends on unique sequence inserts.";
RL   J. Mol. Biol. 405:642-652(2011).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=22135286; DOI=10.1093/nar/gkr1102;
RA   Hogg M., Sauer-Eriksson A.E., Johansson E.;
RT   "Promiscuous DNA synthesis by human DNA polymerase theta.";
RL   Nucleic Acids Res. 40:2611-2622(2012).
RN   [12]
RP   INVOLVEMENT IN BC.
RX   PubMed=25409685; DOI=10.1186/1471-2407-14-850;
RA   Brandalize A.P., Schueler-Faccini L., Hoffmann J.S., Caleffi M.,
RA   Cazaux C., Ashton-Prolla P.;
RT   "A DNA repair variant in POLQ (c.-1060A > G) is associated to
RT   hereditary breast cancer patients: a case-control study.";
RL   BMC Cancer 14:850-850(2014).
RN   [13]
RP   FUNCTION, AND MUTAGENESIS OF 2540-ASP-GLU-2541.
RX   PubMed=24648516; DOI=10.1074/jbc.M114.556977;
RA   Yoon J.H., Roy Choudhury J., Park J., Prakash S., Prakash L.;
RT   "A role for DNA polymerase theta in promoting replication through
RT   oxidative DNA lesion, thymine glycol, in human cells.";
RL   J. Biol. Chem. 289:13177-13185(2014).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH ORC2 AND ORC4.
RX   PubMed=24989122; DOI=10.1038/ncomms5285;
RA   Fernandez-Vidal A., Guitton-Sert L., Cadoret J.C., Drac M., Schwob E.,
RA   Baldacci G., Cazaux C., Hoffmann J.S.;
RT   "A role for DNA polymerase theta in the timing of DNA replication.";
RL   Nat. Commun. 5:4285-4285(2014).
RN   [15]
RP   FUNCTION, INTERACTION WITH RAD51, AND SUBCELLULAR LOCATION.
RX   PubMed=25642963; DOI=10.1038/nature14184;
RA   Ceccaldi R., Liu J.C., Amunugama R., Hajdu I., Primack B.,
RA   Petalcorin M.I., O'Connor K.W., Konstantinopoulos P.A., Elledge S.J.,
RA   Boulton S.J., Yusufzai T., D'Andrea A.D.;
RT   "Homologous-recombination-deficient tumours are dependent on Poltheta-
RT   mediated repair.";
RL   Nature 518:258-262(2015).
RN   [16]
RP   FUNCTION, SUBUNIT, AND DOMAIN.
RX   PubMed=25643323; DOI=10.1038/nsmb.2961;
RA   Kent T., Chandramouly G., McDevitt S.M., Ozdemir A.Y., Pomerantz R.T.;
RT   "Mechanism of microhomology-mediated end-joining promoted by human DNA
RT   polymerase theta.";
RL   Nat. Struct. Mol. Biol. 22:230-237(2015).
CC   -!- FUNCTION: DNA polymerase that promotes microhomology-mediated end-
CC       joining (MMEJ), an alternative non-homologous end-joining (NHEJ)
CC       machinery triggered in response to double-strand breaks in DNA
CC       (PubMed:25642963, PubMed:25643323). MMEJ is an error-prone repair
CC       pathway that produces deletions of sequences from the strand being
CC       repaired and promotes genomic rearrangements, such as telomere
CC       fusions, some of them leading to cellular transformation
CC       (PubMed:25642963, PubMed:25643323). POLQ acts as an inhibitor of
CC       homology-recombination repair (HR) pathway by limiting RAD51
CC       accumulation at resected ends (PubMed:25642963). POLQ-mediated
CC       MMEJ may be required to promote the survival of cells with a
CC       compromised HR repair pathway, thereby preventing genomic havoc by
CC       resolving unrepaired lesions (By similarity). The polymerase acts
CC       by binding directly the 2 ends of resected double-strand breaks,
CC       allowing microhomologous sequences in the overhangs to form base
CC       pairs. It then extends each strand from the base-paired region
CC       using the opposing overhang as a template. Requires partially
CC       resected DNA containing 2 to 6 base pairs of microhomology to
CC       perform MMEJ (PubMed:25643323). The polymerase activity is highly
CC       promiscuous: unlike most polymerases, promotes extension of ssDNA
CC       and partial ssDNA (pssDNA) substrates (PubMed:18503084,
CC       PubMed:21050863, PubMed:22135286). Also exhibits low-fidelity DNA
CC       synthesis, translesion synthesis and lyase activity, and it is
CC       implicated in interstrand-cross-link repair, base excision repair
CC       and DNA end-joining (PubMed:14576298, PubMed:18503084,
CC       PubMed:19188258, PubMed:24648516). Involved in somatic
CC       hypermutation of immunoglobulin genes, a process that requires the
CC       activity of DNA polymerases to ultimately introduce mutations at
CC       both A/T and C/G base pairs (By similarity).
CC       {ECO:0000250|UniProtKB:Q8CGS6, ECO:0000269|PubMed:14576298,
CC       ECO:0000269|PubMed:18503084, ECO:0000269|PubMed:19188258,
CC       ECO:0000269|PubMed:21050863, ECO:0000269|PubMed:22135286,
CC       ECO:0000269|PubMed:24648516, ECO:0000269|PubMed:25642963,
CC       ECO:0000269|PubMed:25643323}.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1). {ECO:0000269|PubMed:14576298,
CC       ECO:0000269|PubMed:22135286}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.095 uM for dATP:T {ECO:0000269|PubMed:22135286};
CC         KM=0.622 uM for dATP: abasic site {ECO:0000269|PubMed:22135286};
CC         KM=3.08 uM for dGTP: no template {ECO:0000269|PubMed:22135286};
CC   -!- SUBUNIT: Homomultimer; forms dimers and multimers
CC       (PubMed:25643323). Interacts with RAD51 (PubMed:25642963).
CC       Interacts with ORC2 and ORC4 (PubMed:24989122).
CC       {ECO:0000269|PubMed:24989122, ECO:0000269|PubMed:25642963,
CC       ECO:0000269|PubMed:25643323}.
CC   -!- INTERACTION:
CC       Q06609:RAD51; NbExp=3; IntAct=EBI-16141065, EBI-297202;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:O18475}.
CC       Chromosome {ECO:0000269|PubMed:25642963}. Note=Enriched in
CC       chromatin in response to ultaviolet (UV) light (PubMed:25642963).
CC       Binds to chromatin during early G1 (PubMed:24989122).
CC       {ECO:0000269|PubMed:24989122, ECO:0000269|PubMed:25642963}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O75417-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75417-2; Sequence=VSP_040747, VSP_040748;
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis.
CC       {ECO:0000269|PubMed:14576298}.
CC   -!- DOMAIN: The loop 2 region is involved in the binding of the 2 ends
CC       of resected double-strand breaks and homomultimerization.
CC       {ECO:0000269|PubMed:25643323}.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal
CC       carcinoma is by far the most common type. Breast cancer is
CC       etiologically and genetically heterogeneous. Important genetic
CC       factors have been indicated by familial occurrence and bilateral
CC       involvement. Mutations at more than one locus can be involved in
CC       different families or even in the same case.
CC       {ECO:0000269|PubMed:20624954, ECO:0000269|PubMed:20700469,
CC       ECO:0000269|PubMed:25409685}. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis.
CC   -!- SIMILARITY: Belongs to the DNA polymerase type-A family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Was wrongly named DNA polymerase eta (POLH) somne authors
CC       (Ref.4). This protein corresponds to DNA polymerase theta (POLQ)
CC       and should not be confused with DNA polymerase eta (POLH) (AC
CC       Q9Y253). {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD05272.1; Type=Frameshift; Positions=1754; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF052573; AAC33565.1; -; mRNA.
DR   EMBL; AY338826; AAR08421.2; -; mRNA.
DR   EMBL; AC069239; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079841; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF043628; AAD05272.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS33833.1; -. [O75417-1]
DR   RefSeq; NP_955452.3; NM_199420.3. [O75417-1]
DR   UniGene; Hs.241517; -.
DR   PDB; 4X0P; X-ray; 3.91 A; A/B/C/D=1792-2590.
DR   PDB; 4X0Q; X-ray; 3.90 A; A/B=1819-2590.
DR   PDB; 5A9F; X-ray; 3.20 A; A=67-894.
DR   PDB; 5A9J; X-ray; 3.55 A; A/B/C/D=1-894.
DR   PDB; 5AGA; X-ray; 2.90 A; A=67-894.
DR   PDBsum; 4X0P; -.
DR   PDBsum; 4X0Q; -.
DR   PDBsum; 5A9F; -.
DR   PDBsum; 5A9J; -.
DR   PDBsum; 5AGA; -.
DR   ProteinModelPortal; O75417; -.
DR   SMR; O75417; -.
DR   BioGrid; 115946; 2.
DR   DIP; DIP-61500N; -.
DR   IntAct; O75417; 2.
DR   STRING; 9606.ENSP00000264233; -.
DR   ChEMBL; CHEMBL6025; -.
DR   iPTMnet; O75417; -.
DR   PhosphoSitePlus; O75417; -.
DR   BioMuta; POLQ; -.
DR   EPD; O75417; -.
DR   MaxQB; O75417; -.
DR   PaxDb; O75417; -.
DR   PeptideAtlas; O75417; -.
DR   PRIDE; O75417; -.
DR   DNASU; 10721; -.
DR   Ensembl; ENST00000264233; ENSP00000264233; ENSG00000051341. [O75417-1]
DR   GeneID; 10721; -.
DR   KEGG; hsa:10721; -.
DR   UCSC; uc003eee.5; human. [O75417-1]
DR   CTD; 10721; -.
DR   DisGeNET; 10721; -.
DR   EuPathDB; HostDB:ENSG00000051341.13; -.
DR   GeneCards; POLQ; -.
DR   H-InvDB; HIX0030706; -.
DR   HGNC; HGNC:9186; POLQ.
DR   HPA; HPA048931; -.
DR   HPA; HPA053359; -.
DR   MIM; 114480; phenotype.
DR   MIM; 604419; gene.
DR   neXtProt; NX_O75417; -.
DR   OpenTargets; ENSG00000051341; -.
DR   PharmGKB; PA33506; -.
DR   eggNOG; KOG0950; Eukaryota.
DR   eggNOG; COG0749; LUCA.
DR   eggNOG; COG1204; LUCA.
DR   GeneTree; ENSGT00640000091272; -.
DR   HOGENOM; HOG000146444; -.
DR   HOVERGEN; HBG005525; -.
DR   InParanoid; O75417; -.
DR   KO; K02349; -.
DR   PhylomeDB; O75417; -.
DR   TreeFam; TF105018; -.
DR   Reactome; R-HSA-5685939; HDR through MMEJ (alt-NHEJ).
DR   ChiTaRS; POLQ; human.
DR   GeneWiki; POLQ; -.
DR   GenomeRNAi; 10721; -.
DR   PRO; PR:O75417; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000051341; -.
DR   CleanEx; HS_POLH; -.
DR   CleanEx; HS_POLQ; -.
DR   ExpressionAtlas; O75417; baseline and differential.
DR   Genevisible; O75417; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0051575; F:5'-deoxyribose-5-phosphate lyase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; TAS:ProtInc.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043142; F:single-stranded DNA-dependent ATPase activity; IDA:UniProtKB.
DR   GO; GO:0006284; P:base-excision repair; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006261; P:DNA-dependent DNA replication; IBA:GO_Central.
DR   GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB.
DR   GO; GO:0097681; P:double-strand break repair via alternative nonhomologous end joining; IDA:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; TAS:Reactome.
DR   GO; GO:2000042; P:negative regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; ISS:UniProtKB.
DR   CDD; cd00079; HELICc; 1.
DR   Gene3D; 3.30.420.10; -; 1.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR019760; DNA-dir_DNA_pol_A_CS.
DR   InterPro; IPR001098; DNA-dir_DNA_pol_A_palm_dom.
DR   InterPro; IPR002298; DNA_polymerase_A.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR012337; RNaseH-like_sf.
DR   InterPro; IPR036397; RNaseH_sf.
DR   PANTHER; PTHR10133; PTHR10133; 1.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF00476; DNA_pol_A; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   PRINTS; PR00868; DNAPOLI.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SMART; SM00482; POLAc; 1.
DR   SUPFAM; SSF52540; SSF52540; 3.
DR   SUPFAM; SSF53098; SSF53098; 1.
DR   PROSITE; PS00447; DNA_POLYMERASE_A; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Chromosome; Coiled coil; Complete proteome; DNA damage; DNA repair;
KW   DNA-directed DNA polymerase; Nucleotide-binding;
KW   Nucleotidyltransferase; Nucleus; Polymorphism; Reference proteome;
KW   Transferase.
FT   CHAIN         1   2590       DNA polymerase theta.
FT                                /FTId=PRO_0000101279.
FT   DOMAIN      102    286       Helicase ATP-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00541}.
FT   DOMAIN      321    554       Helicase C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00542}.
FT   NP_BIND     115    122       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00541}.
FT   REGION      847    894       Interaction with RAD51.
FT                                {ECO:0000269|PubMed:25642963}.
FT   REGION     2142   2177       Loop 1. {ECO:0000269|PubMed:21050863}.
FT   REGION     2257   2322       Loop 2. {ECO:0000269|PubMed:21050863,
FT                                ECO:0000269|PubMed:25643323}.
FT   REGION     2491   2535       Loop 3. {ECO:0000269|PubMed:21050863}.
FT   COILED     1655   1716       {ECO:0000255}.
FT   MOTIF       216    219       DEAH box.
FT   MOD_RES     990    990       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ       1    828       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10395804}.
FT                                /FTId=VSP_040747.
FT   VAR_SEQ     829    840       VEVILKNAVPFK -> MNSFLSFPISLC (in isoform
FT                                2). {ECO:0000303|PubMed:10395804}.
FT                                /FTId=VSP_040748.
FT   VARIANT    1056   1056       P -> L (in dbSNP:rs34778629).
FT                                /FTId=VAR_055707.
FT   MUTAGEN    2540   2541       DE->AA: Abolishes DNA polymerase
FT                                activity. {ECO:0000269|PubMed:19188258,
FT                                ECO:0000269|PubMed:24648516}.
FT   CONFLICT     66     66       R -> I (in Ref. 2; AAR08421).
FT                                {ECO:0000305}.
FT   CONFLICT    982    982       T -> R (in Ref. 2; AAR08421).
FT                                {ECO:0000305}.
FT   CONFLICT   2013   2013       L -> F (in Ref. 4; AAD05272).
FT                                {ECO:0000305}.
FT   CONFLICT   2513   2513       Q -> R (in Ref. 1; AAC33565 and 2;
FT                                AAR08421). {ECO:0000305}.
FT   CONFLICT   2547   2547       A -> V (in Ref. 1; AAC33565).
FT                                {ECO:0000305}.
FT   HELIX        71     73       {ECO:0000244|PDB:5AGA}.
FT   HELIX        78     85       {ECO:0000244|PDB:5AGA}.
FT   HELIX        94    101       {ECO:0000244|PDB:5AGA}.
FT   STRAND      102    104       {ECO:0000244|PDB:5AGA}.
FT   TURN        105    108       {ECO:0000244|PDB:5AGA}.
FT   STRAND      111    114       {ECO:0000244|PDB:5AGA}.
FT   HELIX       121    135       {ECO:0000244|PDB:5AGA}.
FT   STRAND      139    146       {ECO:0000244|PDB:5AGA}.
FT   HELIX       147    161       {ECO:0000244|PDB:5AGA}.
FT   HELIX       162    164       {ECO:0000244|PDB:5AGA}.
FT   STRAND      168    171       {ECO:0000244|PDB:5AGA}.
FT   HELIX       181    183       {ECO:0000244|PDB:5AGA}.
FT   STRAND      185    190       {ECO:0000244|PDB:5AGA}.
FT   HELIX       191    203       {ECO:0000244|PDB:5AGA}.
FT   HELIX       207    209       {ECO:0000244|PDB:5AGA}.
FT   STRAND      210    216       {ECO:0000244|PDB:5AGA}.
FT   HELIX       218    221       {ECO:0000244|PDB:5AGA}.
FT   HELIX       229    243       {ECO:0000244|PDB:5AGA}.
FT   HELIX       245    247       {ECO:0000244|PDB:5AGA}.
FT   STRAND      260    266       {ECO:0000244|PDB:5AGA}.
FT   HELIX       271    277       {ECO:0000244|PDB:5AGA}.
FT   STRAND      281    284       {ECO:0000244|PDB:5AGA}.
FT   STRAND      292    298       {ECO:0000244|PDB:5AGA}.
FT   STRAND      301    303       {ECO:0000244|PDB:5AGA}.
FT   STRAND      309    312       {ECO:0000244|PDB:5AGA}.
FT   HELIX       326    335       {ECO:0000244|PDB:5AGA}.
FT   STRAND      340    343       {ECO:0000244|PDB:5AGA}.
FT   HELIX       347    366       {ECO:0000244|PDB:5AGA}.
FT   STRAND      380    383       {ECO:0000244|PDB:5AGA}.
FT   HELIX       384    395       {ECO:0000244|PDB:5AGA}.
FT   HELIX       403    408       {ECO:0000244|PDB:5AGA}.
FT   HELIX       409    411       {ECO:0000244|PDB:5AGA}.
FT   STRAND      413    416       {ECO:0000244|PDB:5AGA}.
FT   HELIX       422    433       {ECO:0000244|PDB:5AGA}.
FT   STRAND      439    442       {ECO:0000244|PDB:5AGA}.
FT   HELIX       444    447       {ECO:0000244|PDB:5AGA}.
FT   STRAND      454    460       {ECO:0000244|PDB:5AGA}.
FT   STRAND      462    464       {ECO:0000244|PDB:5AGA}.
FT   HELIX       471    478       {ECO:0000244|PDB:5AGA}.
FT   TURN        484    486       {ECO:0000244|PDB:5AGA}.
FT   STRAND      490    496       {ECO:0000244|PDB:5AGA}.
FT   STRAND      498    500       {ECO:0000244|PDB:5A9F}.
FT   HELIX       501    509       {ECO:0000244|PDB:5AGA}.
FT   HELIX       529    540       {ECO:0000244|PDB:5AGA}.
FT   HELIX       547    556       {ECO:0000244|PDB:5AGA}.
FT   TURN        559    562       {ECO:0000244|PDB:5AGA}.
FT   HELIX       581    591       {ECO:0000244|PDB:5AGA}.
FT   STRAND      594    598       {ECO:0000244|PDB:5AGA}.
FT   STRAND      607    611       {ECO:0000244|PDB:5AGA}.
FT   HELIX       613    620       {ECO:0000244|PDB:5AGA}.
FT   HELIX       625    638       {ECO:0000244|PDB:5AGA}.
FT   STRAND      645    647       {ECO:0000244|PDB:5AGA}.
FT   HELIX       648    653       {ECO:0000244|PDB:5AGA}.
FT   HELIX       666    674       {ECO:0000244|PDB:5AGA}.
FT   HELIX       678    687       {ECO:0000244|PDB:5AGA}.
FT   HELIX       691    698       {ECO:0000244|PDB:5AGA}.
FT   TURN        708    711       {ECO:0000244|PDB:5AGA}.
FT   HELIX       712    728       {ECO:0000244|PDB:5AGA}.
FT   TURN        729    731       {ECO:0000244|PDB:5AGA}.
FT   HELIX       734    741       {ECO:0000244|PDB:5AGA}.
FT   HELIX       745    768       {ECO:0000244|PDB:5AGA}.
FT   HELIX       772    778       {ECO:0000244|PDB:5AGA}.
FT   HELIX       781    787       {ECO:0000244|PDB:5AGA}.
FT   HELIX       791    794       {ECO:0000244|PDB:5AGA}.
FT   HELIX       796    798       {ECO:0000244|PDB:5AGA}.
FT   HELIX       804    811       {ECO:0000244|PDB:5AGA}.
FT   TURN        812    814       {ECO:0000244|PDB:5AGA}.
FT   HELIX       818    822       {ECO:0000244|PDB:5AGA}.
FT   HELIX       826    834       {ECO:0000244|PDB:5AGA}.
FT   STRAND      840    842       {ECO:0000244|PDB:5AGA}.
FT   STRAND      856    858       {ECO:0000244|PDB:5A9F}.
FT   HELIX       872    889       {ECO:0000244|PDB:5AGA}.
SQ   SEQUENCE   2590 AA;  289619 MW;  F5550BED2DAD8013 CRC64;
     MNLLRRSGKR RRSESGSDSF SGSGGDSSAS PQFLSGSVLS PPPGLGRCLK AAAAGECKPT
     VPDYERDKLL LANWGLPKAV LEKYHSFGVK KMFEWQAECL LLGQVLEGKN LVYSAPTSAG
     KTLVAELLIL KRVLEMRKKA LFILPFVSVA KEKKYYLQSL FQEVGIKVDG YMGSTSPSRH
     FSSLDIAVCT IERANGLINR LIEENKMDLL GMVVVDELHM LGDSHRGYLL ELLLTKICYI
     TRKSASCQAD LASSLSNAVQ IVGMSATLPN LELVASWLNA ELYHTDFRPV PLLESVKVGN
     SIYDSSMKLV REFEPMLQVK GDEDHVVSLC YETICDNHSV LLFCPSKKWC EKLADIIARE
     FYNLHHQAEG LVKPSECPPV ILEQKELLEV MDQLRRLPSG LDSVLQKTVP WGVAFHHAGL
     TFEERDIIEG AFRQGLIRVL AATSTLSSGV NLPARRVIIR TPIFGGRPLD ILTYKQMVGR
     AGRKGVDTVG ESILICKNSE KSKGIALLQG SLKPVRSCLQ RREGEEVTGS MIRAILEIIV
     GGVASTSQDM HTYAACTFLA ASMKEGKQGI QRNQESVQLG AIEACVMWLL ENEFIQSTEA
     SDGTEGKVYH PTHLGSATLS SSLSPADTLD IFADLQRAMK GFVLENDLHI LYLVTPMFED
     WTTIDWYRFF CLWEKLPTSM KRVAELVGVE EGFLARCVKG KVVARTERQH RQMAIHKRFF
     TSLVLLDLIS EVPLREINQK YGCNRGQIQS LQQSAAVYAG MITVFSNRLG WHNMELLLSQ
     FQKRLTFGIQ RELCDLVRVS LLNAQRARVL YASGFHTVAD LARANIVEVE VILKNAVPFK
     SARKAVDEEE EAVEERRNMR TIWVTGRKGL TEREAAALIV EEARMILQQD LVEMGVQWNP
     CALLHSSTCS LTHSESEVKE HTFISQTKSS YKKLTSKNKS NTIFSDSYIK HSPNIVQDLN
     KSREHTSSFN CNFQNGNQEH QTCSIFRARK RASLDINKEK PGASQNEGKT SDKKVVQTFS
     QKTKKAPLNF NSEKMSRSFR SWKRRKHLKR SRDSSPLKDS GACRIHLQGQ TLSNPSLCED
     PFTLDEKKTE FRNSGPFAKN VSLSGKEKDN KTSFPLQIKQ NCSWNITLTN DNFVEHIVTG
     SQSKNVTCQA TSVVSEKGRG VAVEAEKINE VLIQNGSKNQ NVYMKHHDIH PINQYLRKQS
     HEQTSTITKQ KNIIERQMPC EAVSSYINRD SNVTINCERI KLNTEENKPS HFQALGDDIS
     RTVIPSEVLP SAGAFSKSEG QHENFLNISR LQEKTGTYTT NKTKNNHVSD LGLVLCDFED
     SFYLDTQSEK IIQQMATENA KLGAKDTNLA AGIMQKSLVQ QNSMNSFQKE CHIPFPAEQH
     PLGATKIDHL DLKTVGTMKQ SSDSHGVDIL TPESPIFHSP ILLEENGLFL KKNEVSVTDS
     QLNSFLQGYQ TQETVKPVIL LIPQKRTPTG VEGECLPVPE TSLNMSDSLL FDSFSDDYLV
     KEQLPDMQMK EPLPSEVTSN HFSDSLCLQE DLIKKSNVNE NQDTHQQLTC SNDESIIFSE
     MDSVQMVEAL DNVDIFPVQE KNHTVVSPRA LELSDPVLDE HHQGDQDGGD QDERAEKSKL
     TGTRQNHSFI WSGASFDLSP GLQRILDKVS SPLENEKLKS MTINFSSLNR KNTELNEEQE
     VISNLETKQV QGISFSSNNE VKSKIEMLEN NANHDETSSL LPRKESNIVD DNGLIPPTPI
     PTSASKLTFP GILETPVNPW KTNNVLQPGE SYLFGSPSDI KNHDLSPGSR NGFKDNSPIS
     DTSFSLQLSQ DGLQLTPASS SSESLSIIDV ASDQNLFQTF IKEWRCKKRF SISLACEKIR
     SLTSSKTATI GSRFKQASSP QEIPIRDDGF PIKGCDDTLV VGLAVCWGGR DAYYFSLQKE
     QKHSEISASL VPPSLDPSLT LKDRMWYLQS CLRKESDKEC SVVIYDFIQS YKILLLSCGI
     SLEQSYEDPK VACWLLDPDS QEPTLHSIVT SFLPHELPLL EGMETSQGIQ SLGLNAGSEH
     SGRYRASVES ILIFNSMNQL NSLLQKENLQ DVFRKVEMPS QYCLALLELN GIGFSTAECE
     SQKHIMQAKL DAIETQAYQL AGHSFSFTSS DDIAEVLFLE LKLPPNREMK NQGSKKTLGS
     TRRGIDNGRK LRLGRQFSTS KDVLNKLKAL HPLPGLILEW RRITNAITKV VFPLQREKCL
     NPFLGMERIY PVSQSHTATG RITFTEPNIQ NVPRDFEIKM PTLVGESPPS QAVGKGLLPM
     GRGKYKKGFS VNPRCQAQME ERAADRGMPF SISMRHAFVP FPGGSILAAD YSQLELRILA
     HLSHDRRLIQ VLNTGADVFR SIAAEWKMIE PESVGDDLRQ QAKQICYGII YGMGAKSLGE
     QMGIKENDAA CYIDSFKSRY TGINQFMTET VKNCKRDGFV QTILGRRRYL PGIKDNNPYR
     KAHAERQAIN TIVQGSAADI VKIATVNIQK QLETFHSTFK SHGHREGMLQ SDQTGLSRKR
     KLQGMFCPIR GGFFILQLHD ELLYEVAEED VVQVAQIVKN EMESAVKLSV KLKVKVKIGA
     SWGELKDFDV
//
ID   Q59EE4_HUMAN            Unreviewed;      2214 AA.
AC   Q59EE4;
DT   26-APR-2005, integrated into UniProtKB/TrEMBL.
DT   26-APR-2005, sequence version 1.
DT   28-FEB-2018, entry version 75.
DE   SubName: Full=DNA polymerase theta variant {ECO:0000313|EMBL:BAD93104.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD93104.1};
RN   [1] {ECO:0000313|EMBL:BAD93104.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Aorta endothelial cell {ECO:0000313|EMBL:BAD93104.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB209867; BAD93104.1; -; mRNA.
DR   RefSeq; NP_955452.3; NM_199420.3.
DR   UniGene; Hs.241517; -.
DR   ProteinModelPortal; Q59EE4; -.
DR   PeptideAtlas; Q59EE4; -.
DR   PRIDE; Q59EE4; -.
DR   DNASU; 10721; -.
DR   GeneID; 10721; -.
DR   KEGG; hsa:10721; -.
DR   CTD; 10721; -.
DR   PharmGKB; PA33506; -.
DR   eggNOG; KOG0950; Eukaryota.
DR   eggNOG; COG0749; LUCA.
DR   eggNOG; COG1204; LUCA.
DR   HOVERGEN; HBG005525; -.
DR   KO; K02349; -.
DR   GenomeRNAi; 10721; -.
DR   Genevisible; Q59EE4; HS.
DR   GO; GO:0003677; F:DNA binding; IEA:InterPro.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:InterPro.
DR   GO; GO:0006261; P:DNA-dependent DNA replication; IEA:InterPro.
DR   CDD; cd00079; HELICc; 1.
DR   Gene3D; 3.30.420.10; -; 1.
DR   InterPro; IPR019760; DNA-dir_DNA_pol_A_CS.
DR   InterPro; IPR001098; DNA-dir_DNA_pol_A_palm_dom.
DR   InterPro; IPR002298; DNA_polymerase_A.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR012337; RNaseH-like_sf.
DR   InterPro; IPR036397; RNaseH_sf.
DR   PANTHER; PTHR10133; PTHR10133; 1.
DR   Pfam; PF00476; DNA_pol_A; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   PRINTS; PR00868; DNAPOLI.
DR   SMART; SM00490; HELICc; 1.
DR   SMART; SM00482; POLAc; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF53098; SSF53098; 1.
DR   PROSITE; PS00447; DNA_POLYMERASE_A; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN        1    178       Helicase C-terminal.
FT                                {ECO:0000259|PROSITE:PS51194}.
FT   COILED     1282   1312       {ECO:0000256|SAM:Coils}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:BAD93104.1}.
SQ   SEQUENCE   2214 AA;  247978 MW;  327C2D6AC85F7753 CRC64;
     MPTSNSGQKE LLEVMDQLRR LPSGLDSVLQ KTVPWGVAFH HAGLTFEERD IIEGAFRQGL
     IRVLAATSTL SSGVNLPARR VIIRTPIFGG RPLDILTYKQ MVGRAGRKGV DTVGESILIC
     KNSEKSKGIA LLQGSLKPVR SCLQRREGEE VTGSMIRAIL EIIVGGVAST SQDMHTYAAC
     TFLAASMKEG KQGIQRNQES VQLGAIEACV MWLLENEFIQ STEASDGTEG KVYHPTHLGS
     ATLSSSLSPA DTLDIFADLQ RAMKGFVLEN DLHILYLVTP MFEDWTTIDW YRFFCLWEKL
     PTSMKRVAEL VGVEEGFLAR CVKGKVVART ERQHRQMAIH KRFFTSLVLL DLISEVPLRE
     INQKYGCNRG QIQSLQQSAA VYAGMITVFS NRLGWHNMEL LLSQFQKRLT FGIQRELCDL
     VRVSLLNAQR ARVLYASGFH TVADLARANI VEVEVILKNA VPFKSARKAV DEEEEAVEER
     RNMRTIWVTG RKGLTEREAA ALIVEEARMI LQQDLVEMGV QWNPCALLHS STCSLTHSES
     EVKEHTFISQ TKSSYKKLTS KNKSNTIFSD SYIKHSPNIV QDLNKSREHT SSFNCNFQNG
     NQEHQRCSIF RARKRASLDI NKEKPGASQN EGKTSDKKVV QTFSQKTKKA PLNFNSEKMS
     RSFRSWKRRK HLKRSRDSSP LKDSGACRIH LQGQTLSNPS LCEDPFTLDE KKTEFRNSGP
     FAKNVSLSGK EKDNKTSFPL QIKQNCSWNI TLTNDNFVEH IVTGSQSKNV TCQATSVVSE
     KGRGVAVEAE KINEVLIQNG SKNQNVYMKH HDIHPINQYL RKQSHEQTST ITKQKNIIER
     QMPCEAVSSY INRDSNVTIN CERIKLNTEE NKPSHFQALG DDISRTVIPS EVLPSAGAFS
     KSEGQHENFL NISRLQEKTG TYTTNKTKNN HVSDLGLVLC DFEDSFYLDT QSEKIIQQMA
     TENAKLGAKD TNLAAGIMQK SLVQQNSMNS FQKECHIPFP AEQHPLGATK IDHLDLKTVG
     TMKQSSDSHG VDILTPESPI FHSPILLEEN GLFLKKNEVS VTDSQLNSFL QGYQTQETVK
     PVILLIPQKR TPTGVEGECL PVPETSLNMS DSLLFDSFSD DYLVKEQLPD MQMKEPLPSE
     VTSNHFSDSL CLQEDLIKKS NVNENQDTHQ QLTCSNDESI IFSEMDSVQM VEALDNVDIF
     PVQEKNHTVV SPRALELSDP VLDEHHQGDQ DGGDQDERAE KSKLTGTRQN HSFIWSGASF
     DLSPGLQRIL DKVSSPLENE KLKSMTINFS SLNRKNTELN EEQEVISNLE TKQVQGISFS
     SNNEVKSKIE MLENNANHDE TSSLLPRKES NIVDDNGLIP PTPIPTSASK LTFPGILETP
     VNPWKTNNVL QPGESYLFGS PSDIKNHDLS PGSRNGFKDN SPISDTSFSL QLSQDGLQLT
     PASSSSESLS IIDVASDQNL FQTFIKEWRC KKRFSISLAC EKIRSLTSSK TATIGSRFKQ
     ASSPQEIPIR DDGFPIKGCD DTLVVGLAVC WGGRDAYYFS LQKEQKHSEI SASLVPPSLD
     PSLTLKDRMW YLQSCLRKES DKECSVVIYD FIQSYKILLL SCGISLEQSY EDPKVACWLL
     DPDSQEPTLH SIVTSFLPHE LPLLEGMETS QGIQSLGLNA GSEHSGRYRA SVESILIFNS
     MNQLNSLLQK ENLQDVFRKV EMPSQYCLAL LELNGIGFST AECESQKHIM QAKLDAIETQ
     AYQLAGHSFS FTSSDDIAEV LFLELKLPPN REMKNQGSKK TLGSTRRGID NGRKLRLGRQ
     FSTSKDVLNK LKALHPLPGL ILEWRRITNA ITKVVFPLQR EKCLNPFLGM ERIYPVSQSH
     TATGRITFTE PNIQNVPRDF EIKMPTLVGE SPPSQAVGKG LLPMGRGKYK KGFSVNPRCQ
     AQMEERAADR GMPFSISMRH AFVPFPGGSI LAADYSQLEL RILAHLSHDR RLIQVLNTGA
     DVFRSIAAEW KMIEPESVGD DLRQQAKQIC YGIIYGMGAK SLGEQMGIKE NDAACYIDSF
     KSRYTGINQF MTETVKNCKR DGFVQTILGR RRYLPGIKDN NPYRKAHAER QAINTIVQGS
     AADIVKIATV NIQKQLETFH STFKSHGHRE GMLQSDRTGL SRKRKLQGMF CPIRGGFFIL
     QLHDELLYEV AEEDVVQVAQ IVKNEMESAV KLSVKLKVKV KIGASWGELK DFDV
//
ID   PTK6_HUMAN              Reviewed;         451 AA.
AC   Q13882; B2RCR3; B4DW46; Q58F01;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-FEB-2018, entry version 187.
DE   RecName: Full=Protein-tyrosine kinase 6;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680};
DE   AltName: Full=Breast tumor kinase;
DE   AltName: Full=Tyrosine-protein kinase BRK;
GN   Name=PTK6; Synonyms=BRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary tumor;
RX   PubMed=8036022;
RA   Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N.,
RA   Page M.J., Gusterson B.A., Crompton M.R.;
RT   "Cloning and characterisation of cDNAs encoding a novel non-receptor
RT   tyrosine kinase, brk, expressed in human breast tumours.";
RL   Oncogene 9:2383-2390(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=9333026; DOI=10.1038/sj.onc.1201292;
RA   Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.;
RT   "Characterisation and chromosome mapping of the human non receptor
RT   tyrosine kinase gene, brk.";
RL   Oncogene 15:1497-1502(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Melanocyte;
RX   PubMed=9749526;
RA   Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.;
RT   "Exon-intron structure of the human PTK6 gene demonstrates that PTK6
RT   constitutes a distinct family of non-receptor tyrosine kinase.";
RL   Mol. Cells 8:401-407(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219
RP   AND TYR-447.
RX   PubMed=8940083; DOI=10.1074/jbc.271.48.30956;
RA   Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E.,
RA   Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.;
RT   "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase,
RT   sensitizes mammary epithelial cells to epidermal growth factor.";
RL   J. Biol. Chem. 271:30956-30963(1996).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=9185712;
RX   DOI=10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F;
RA   Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A.,
RA   Bennett D.C.;
RT   "Loss of expression of receptor tyrosine kinase family genes PTK7 and
RT   SEK in metastatic melanoma.";
RL   Int. J. Cancer 71:1061-1065(1997).
RN   [9]
RP   FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66;
RP   ARG-105 AND LYS-219.
RX   PubMed=10980601; DOI=10.1038/sj.onc.1203775;
RA   Mitchell P.J., Sara E.A., Crompton M.R.;
RT   "A novel adaptor-like protein which is a substrate for the non-
RT   receptor tyrosine kinase, BRK.";
RL   Oncogene 19:4273-4282(2000).
RN   [10]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH
RP   KHDRBS1.
RX   PubMed=10913193; DOI=10.1128/MCB.20.16.6114-6126.2000;
RA   Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V.,
RA   Cochrane A.W., Chen T., Tyner A.L.;
RT   "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively
RT   regulates its RNA binding ability.";
RL   Mol. Cell. Biol. 20:6114-6126(2000).
RN   [11]
RP   PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND
RP   TYR-351, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   MUTAGENESIS OF TYR-342 AND TYR-447, ENZYME REGULATION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12121988; DOI=10.1074/jbc.M203877200;
RA   Qiu H., Miller W.T.;
RT   "Regulation of the nonreceptor tyrosine kinase Brk by
RT   autophosphorylation and by autoinhibition.";
RL   J. Biol. Chem. 277:34634-34641(2002).
RN   [12]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12833144; DOI=10.1038/sj.onc.1206465;
RA   Derry J.J., Prins G.S., Ray V., Tyner A.L.;
RT   "Altered localization and activity of the intracellular tyrosine
RT   kinase BRK/Sik in prostate tumor cells.";
RL   Oncogene 22:4212-4220(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447,
RP   AND PHOSPHORYLATION.
RX   PubMed=15471878; DOI=10.1074/jbc.M409579200;
RA   Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.;
RT   "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the
RT   RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and
RT   SLM-2.";
RL   J. Biol. Chem. 279:54398-54404(2004).
RN   [14]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PXN.
RX   PubMed=15572663; DOI=10.1128/MCB.24.24.10558-10572.2004;
RA   Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.;
RT   "Brk activates rac1 and promotes cell migration and invasion by
RT   phosphorylating paxillin.";
RL   Mol. Cell. Biol. 24:10558-10572(2004).
RN   [15]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010;
RA   Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.;
RT   "Differential expression of the non-receptor tyrosine kinase BRK in
RT   oral squamous cell carcinoma and normal oral epithelium.";
RL   Oral Oncol. 40:1040-1047(2004).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK.
RX   PubMed=15539407; DOI=10.1074/jbc.M412038200;
RA   Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D.,
RA   Lange C.A.;
RT   "Regulated association of protein kinase B/Akt with breast tumor
RT   kinase.";
RL   J. Biol. Chem. 280:1982-1991(2005).
RN   [17]
RP   MUTAGENESIS OF TRP-184, AND ENZYME REGULATION.
RX   PubMed=15961400; DOI=10.1074/jbc.M504568200;
RA   Kim H.I.E., Lee S.T.;
RT   "An intramolecular interaction between SH2-kinase linker and kinase
RT   domain is essential for the catalytic activity of protein-tyrosine
RT   kinase-6.";
RL   J. Biol. Chem. 280:28973-28980(2005).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF KHDRBS1.
RX   PubMed=16179349; DOI=10.1074/jbc.M505802200;
RA   Lukong K.E., Larocque D., Tyner A.L., Richard S.;
RT   "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates
RT   intranuclear localization and cell cycle progression.";
RL   J. Biol. Chem. 280:38639-38647(2005).
RN   [19]
RP   INTERACTION WITH IRS4, AND ENZYME REGULATION.
RX   PubMed=15870689; DOI=10.1038/sj.onc.1208721;
RA   Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.;
RT   "Interaction between Brk kinase and insulin receptor substrate-4.";
RL   Oncogene 24:5656-5664(2005).
RN   [20]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=16651629; DOI=10.2353/ajpath.2006.050521;
RA   Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M.,
RA   Zhang Q., Marzec M., Gimotty P., Crompton M.R., Wasik M.A.;
RT   "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine
RT   kinase in lymphocytes.";
RL   Am. J. Pathol. 168:1631-1641(2006).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF STAT3, AND ENZYME REGULATION.
RX   PubMed=16568091; DOI=10.1038/sj.onc.1209501;
RA   Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.;
RT   "Identification of STAT3 as a specific substrate of breast tumor
RT   kinase.";
RL   Oncogene 25:4904-4912(2006).
RN   [22]
RP   ENZYME REGULATION, AND MUTAGENESIS OF TRP-44.
RX   PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055;
RA   Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.;
RT   "Molecular dissection of the interaction between the SH3 domain and
RT   the SH2-Kinase Linker region in PTK6.";
RL   Biochem. Biophys. Res. Commun. 362:829-834(2007).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF STAT5B.
RX   PubMed=17997837; DOI=10.1186/bcr1794;
RA   Weaver A.M., Silva C.M.;
RT   "Signal transducer and activator of transcription 5b: a new target of
RT   breast tumor kinase/protein tyrosine kinase 6.";
RL   Breast Cancer Res. 9:R79-R79(2007).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF ARHGAP35.
RX   PubMed=18829532; DOI=10.1158/0008-5472.CAN-08-0997;
RA   Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L.,
RA   Settleman J., Chen R.H.;
RT   "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras
RT   and promote breast carcinoma growth, migration, and invasion.";
RL   Cancer Res. 68:7779-7787(2008).
RN   [25]
RP   INTERACTION WITH ADAM15.
RX   PubMed=18296648; DOI=10.1158/1541-7786.MCR-07-2028;
RA   Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M.,
RA   Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C.,
RA   Edwards D.R.;
RT   "Distinct functions of natural ADAM-15 cytoplasmic domain variants in
RT   human mammary carcinoma.";
RL   Mol. Cancer Res. 6:383-394(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [27]
RP   INTERACTION WITH ERBB2.
RX   PubMed=18719096; DOI=10.1073/pnas.0805009105;
RA   Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M.,
RA   Miller W.T., Muthuswamy S.K.;
RT   "Brk is coamplified with ErbB2 to promote proliferation in breast
RT   cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008).
RN   [28]
RP   INTERACTION WITH SFPQ.
RX   PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008;
RA   Lukong K.E., Huot M.E., Richard S.;
RT   "BRK phosphorylates PSF promoting its cytoplasmic localization and
RT   cell cycle arrest.";
RL   Cell. Signal. 21:1415-1422(2009).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003;
RA   Brauer P.M., Tyner A.L.;
RT   "Building a better understanding of the intracellular tyrosine kinase
RT   PTK6 - BRK by BRK.";
RL   Biochim. Biophys. Acta 1806:66-73(2010).
RN   [30]
RP   PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1.
RX   PubMed=20026641; DOI=10.1242/jcs.053264;
RA   Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y.,
RA   Asara J.M., Tyner A.L.;
RT   "Identification of beta-catenin as a target of the intracellular
RT   tyrosine kinase PTK6.";
RL   J. Cell Sci. 123:236-245(2010).
RN   [31]
RP   FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND
RP   CTNNB1.
RX   PubMed=21479203; DOI=10.1371/journal.pone.0014789;
RA   Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M.,
RA   Tyner A.L.;
RT   "The alternative splice variant of protein tyrosine kinase 6
RT   negatively regulates growth and enhances PTK6-mediated inhibition of
RT   beta-catenin.";
RL   PLoS ONE 6:E14789-E14789(2011).
RN   [32]
RP   STRUCTURE BY NMR OF 75-174.
RX   PubMed=15056653; DOI=10.1074/jbc.M313185200;
RA   Hong E., Shin J., Kim H.I., Lee S.T., Lee W.;
RT   "Solution structure and backbone dynamics of the non-receptor protein-
RT   tyrosine kinase-6 Src homology 2 domain.";
RL   J. Biol. Chem. 279:29700-29708(2004).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY,
RP   AND MUTAGENESIS OF LYS-219.
RX   PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121;
RA   Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R.,
RA   Gosu R.;
RT   "Crystal structure of the kinase domain of human protein tyrosine
RT   kinase 6 (PTK6) at 2.33 A resolution.";
RL   Biochem. Biophys. Res. Commun. 478:637-642(2016).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH
RP   INHIBITORS, AND CATALYTIC ACTIVITY.
RX   PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030;
RA   Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S.,
RA   Tyagi R., Gosu R.;
RT   "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel
RT   imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A
RT   resolution.";
RL   Biochem. Biophys. Res. Commun. 482:1289-1295(2017).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the
CC       regulation of a variety of signaling pathways that control the
CC       differentiation and maintenance of normal epithelia, as well as
CC       tumor growth. Function seems to be context dependent and differ
CC       depending on cell type, as well as its intracellular localization.
CC       A number of potential nuclear and cytoplasmic substrates have been
CC       identified. These include the RNA-binding proteins: KHDRBS1/SAM68,
CC       KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors:
CC       STAT3 and STAT5A/B and a variety of signaling molecules:
CC       ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates
CC       also with a variety of proteins that are likely upstream of PTK6
CC       in various signaling pathways, or for which PTK6 may play an
CC       adapter-like role. These proteins include ADAM15, EGFR, ERBB2,
CC       ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6
CC       promotes cellular differentiation and apoptosis. In tumors PTK6
CC       contributes to cancer progression by sensitizing cells to
CC       mitogenic signals and enhancing proliferation, anchorage-
CC       independent survival and migration/invasion. Association with
CC       EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and
CC       growth through enhancement of EGF-induced signaling via BTK/AKT
CC       and PI3 kinase. Contributes to migration and proliferation by
CC       contributing to EGF-mediated phosphorylation of
CC       ARHGAP35/p190RhoGAP, which promotes association with
CC       RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF
CC       stimulation resulted in phosphorylation of PNX/Paxillin by PTK6
CC       and activation of RAC1 via CRK/CrKII, thereby promoting migration
CC       and invasion. PTK6 activates STAT3 and STAT5B to promote
CC       proliferation. Nuclear PTK6 may be important for regulating growth
CC       in normal epithelia, while cytoplasmic PTK6 might activate
CC       oncogenic signaling pathways.
CC   -!- FUNCTION: Isoform 2 inhibits PTK6 phosphorylation and PTK6
CC       association with other tyrosine-phosphorylated proteins.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:12121988,
CC       ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680}.
CC   -!- ENZYME REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by
CC       SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by
CC       an association between the SH3 domain and the SH2-TK linker
CC       region. Interaction between Trp-184 within SH2-TK linker region
CC       and the catalytic domain appears essential for positive regulation
CC       of kinase activity. {ECO:0000269|PubMed:12121988,
CC       ECO:0000269|PubMed:15870689, ECO:0000269|PubMed:15961400,
CC       ECO:0000269|PubMed:16568091, ECO:0000269|PubMed:17822667}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=83 uM for ATP {ECO:0000269|PubMed:12121988};
CC         Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988};
CC   -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via
CC       SH3 and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2
CC       domains) with phosphorylated IRS4. Interacts with ADAM15.
CC       Interacts (via SH3 domain) with SFPQ. Interacts with EGFR and
CC       ERBB2. Interacts with STAP2. Interacts with PNX. Interacts with
CC       SFPQ. Interacts with PTK/ATK. Interacts with CTNNB1. {ECO:0000250,
CC       ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:10980601,
CC       ECO:0000269|PubMed:15539407, ECO:0000269|PubMed:15572663,
CC       ECO:0000269|PubMed:15870689, ECO:0000269|PubMed:18296648,
CC       ECO:0000269|PubMed:18719096, ECO:0000269|PubMed:19439179,
CC       ECO:0000269|PubMed:20026641, ECO:0000269|PubMed:8940083}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-1383632, EBI-1383632;
CC       Q5JST6:EFHC2; NbExp=5; IntAct=EBI-1383632, EBI-2349927;
CC       P04626:ERBB2; NbExp=4; IntAct=EBI-1383632, EBI-641062;
CC       O00471:EXOC5; NbExp=5; IntAct=EBI-1383632, EBI-949824;
CC       O14526:FCHO1; NbExp=3; IntAct=EBI-1383632, EBI-719823;
CC       Q13480:GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684;
CC       Q5VWX1:KHDRBS2; NbExp=3; IntAct=EBI-1383632, EBI-742808;
CC       P10721:KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503;
CC       Q04864:REL; NbExp=3; IntAct=EBI-1383632, EBI-307352;
CC       P23246:SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453;
CC       O00401:WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle.
CC       Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or
CC       KHDRBS3, within the nucleus. Nuclear localization in epithelial
CC       cells of normal prostate but cytoplasmic localization in cancer
CC       prostate.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13882-1; Sequence=Displayed;
CC       Name=2; Synonyms=ALT-PTK6, LambdaM5;
CC         IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067;
CC   -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon
CC       and high levels in small intestine and prostate, and low levels in
CC       some fetal tissues. Not expressed in breast or ovarian tissue but
CC       expressed in high percentage of breast and ovarian cancers. Also
CC       overexpressed in some metastatic melanomas, lymphomas, colon
CC       cancers, squamous cell carcinomas and prostate cancers. Also found
CC       in melanocytes. Not expressed in heart, brain, placenta, lung,
CC       liver, skeletal muscle, kidney and pancreas. Isoform 2 is present
CC       in prostate epithelial cell lines derived from normal prostate and
CC       prostate adenocarcinomas, as well as in a variety of cell lines.
CC       {ECO:0000269|PubMed:12833144, ECO:0000269|PubMed:15509496,
CC       ECO:0000269|PubMed:16651629, ECO:0000269|PubMed:9185712}.
CC   -!- DOMAIN: The SH3 domain plays a major role in substrate
CC       interactions. The SH2 domain of PTK6 plays a role in protein-
CC       protein interactions, but is likely more important for the
CC       regulation of catalytic activity.
CC   -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to
CC       an increase of kinase activity. Tyr-447 binds to the SH2 domain
CC       when phosphorylated and negatively regulates kinase activity.
CC       {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988,
CC       ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}.
CC   -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket.
CC       {ECO:0000269|PubMed:27993680}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X78549; CAA55295.1; -; mRNA.
DR   EMBL; U61412; AAC34935.1; -; Genomic_DNA.
DR   EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA.
DR   EMBL; AK315232; BAG37660.1; -; mRNA.
DR   EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA.
DR   EMBL; AL121829; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035843; AAH35843.1; -; mRNA.
DR   CCDS; CCDS13524.1; -. [Q13882-1]
DR   CCDS; CCDS74750.1; -. [Q13882-2]
DR   PIR; S49016; S49016.
DR   RefSeq; NP_001243287.1; NM_001256358.1. [Q13882-2]
DR   RefSeq; NP_005966.1; NM_005975.3. [Q13882-1]
DR   UniGene; Hs.51133; -.
DR   PDB; 1RJA; NMR; -; A=75-174.
DR   PDB; 2KGT; NMR; -; A=1-72.
DR   PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446.
DR   PDB; 5DA3; X-ray; 1.70 A; A=185-446.
DR   PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446.
DR   PDBsum; 1RJA; -.
DR   PDBsum; 2KGT; -.
DR   PDBsum; 5D7V; -.
DR   PDBsum; 5DA3; -.
DR   PDBsum; 5H2U; -.
DR   ProteinModelPortal; Q13882; -.
DR   SMR; Q13882; -.
DR   BioGrid; 111720; 23.
DR   DIP; DIP-39785N; -.
DR   IntAct; Q13882; 29.
DR   MINT; Q13882; -.
DR   STRING; 9606.ENSP00000217185; -.
DR   BindingDB; Q13882; -.
DR   ChEMBL; CHEMBL4601; -.
DR   DrugBank; DB05294; Vandetanib.
DR   GuidetoPHARMACOLOGY; 2182; -.
DR   iPTMnet; Q13882; -.
DR   PhosphoSitePlus; Q13882; -.
DR   BioMuta; PTK6; -.
DR   DMDM; 8928302; -.
DR   MaxQB; Q13882; -.
DR   PaxDb; Q13882; -.
DR   PeptideAtlas; Q13882; -.
DR   PRIDE; Q13882; -.
DR   DNASU; 5753; -.
DR   Ensembl; ENST00000217185; ENSP00000217185; ENSG00000101213. [Q13882-2]
DR   Ensembl; ENST00000542869; ENSP00000442460; ENSG00000101213. [Q13882-1]
DR   GeneID; 5753; -.
DR   KEGG; hsa:5753; -.
DR   UCSC; uc002yfg.5; human. [Q13882-1]
DR   CTD; 5753; -.
DR   DisGeNET; 5753; -.
DR   EuPathDB; HostDB:ENSG00000101213.6; -.
DR   GeneCards; PTK6; -.
DR   HGNC; HGNC:9617; PTK6.
DR   HPA; CAB032952; -.
DR   HPA; HPA036070; -.
DR   HPA; HPA036071; -.
DR   MIM; 602004; gene.
DR   neXtProt; NX_Q13882; -.
DR   OpenTargets; ENSG00000101213; -.
DR   PharmGKB; PA33960; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOGENOM; HOG000233858; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; Q13882; -.
DR   KO; K08894; -.
DR   OMA; VRHYKIW; -.
DR   OrthoDB; EOG091G0596; -.
DR   PhylomeDB; Q13882; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing.
DR   Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   Reactome; R-HSA-8849472; PTK6 Down-Regulation.
DR   Reactome; R-HSA-8849473; PTK6 Expression.
DR   Reactome; R-HSA-8849474; PTK6 Activates STAT3.
DR   Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization.
DR   SignaLink; Q13882; -.
DR   SIGNOR; Q13882; -.
DR   EvolutionaryTrace; Q13882; -.
DR   GeneWiki; PTK6; -.
DR   GenomeRNAi; 5753; -.
DR   PRO; PR:Q13882; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000101213; -.
DR   CleanEx; HS_PTK6; -.
DR   Genevisible; Q13882; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0060575; P:intestinal epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl.
DR   GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0009968; P:negative regulation of signal transduction; TAS:Reactome.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; TAS:Reactome.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:UniProtKB.
DR   CDD; cd10358; SH2_PTK6_Brk; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR035846; PTK6_SH2.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Complete proteome; Cytoplasm; Kinase; Membrane; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; SH2 domain;
KW   SH3 domain; Transferase; Tyrosine-protein kinase.
FT   CHAIN         1    451       Protein-tyrosine kinase 6.
FT                                /FTId=PRO_0000088133.
FT   DOMAIN        8     72       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN       78    170       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      191    445       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     197    205       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      171    190       Linker.
FT   ACT_SITE    312    312       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     219    219       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000305|PubMed:27480927,
FT                                ECO:0000305|PubMed:27993680}.
FT   MOD_RES      13     13       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES      61     61       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES      66     66       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES     114    114       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000269|PubMed:12121988}.
FT   MOD_RES     342    342       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES     351    351       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12121988}.
FT   MOD_RES     447    447       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:10913193}.
FT   VAR_SEQ      78    134       WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSV
FT                                RDTQAVRHYKIWRRAG -> AGHAGCAALQDLAACRGPAAP
FT                                ERGGVLPQPARACELPQGPEPVPRPAAGRALPEARA (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:9333026}.
FT                                /FTId=VSP_042066.
FT   VAR_SEQ     135    451       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:9333026}.
FT                                /FTId=VSP_042067.
FT   VARIANT      16     16       L -> F (in a renal papillary sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041760.
FT   VARIANT     436    436       A -> T (in dbSNP:rs56145017).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041761.
FT   MUTAGEN      44     44       W->A: Strong decrease in STAP2
FT                                phosphorylation. Markedly decreased
FT                                interaction between SH3 domain the linker
FT                                region. {ECO:0000269|PubMed:10980601,
FT                                ECO:0000269|PubMed:17822667}.
FT   MUTAGEN      66     66       Y->A: Decrease in STAP2 phosphorylation.
FT                                {ECO:0000269|PubMed:10980601}.
FT   MUTAGEN     105    105       R->L: Decrease in STAP2 phosphorylation.
FT                                {ECO:0000269|PubMed:10980601}.
FT   MUTAGEN     184    184       W->A: Abrogates interaction between PTK6-
FT                                domain kinase and PTK6-linker. Abrogates
FT                                autophosphorylation and phosphorylation
FT                                of KHDRBS1.
FT                                {ECO:0000269|PubMed:15961400}.
FT   MUTAGEN     219    219       K->M: Abolishes kinase activity and cell
FT                                transformation, and phosphorylation of
FT                                STAP2. {ECO:0000269|PubMed:10980601,
FT                                ECO:0000269|PubMed:15471878,
FT                                ECO:0000269|PubMed:8940083}.
FT   MUTAGEN     219    219       K->R: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:27480927}.
FT   MUTAGEN     342    342       Y->A: 3-fold lower specific kinase
FT                                activity. Decreased, but still
FT                                significant, autophosphorylation.
FT                                Decreased, but still significant,
FT                                autophosphorylation; when associated with
FT                                A-447. {ECO:0000269|PubMed:12121988}.
FT   MUTAGEN     447    447       Y->F: Decrease in transforming potential
FT                                and increase in the kinase activity
FT                                level. Decreased, but still significant,
FT                                autophosphorylation; when associated with
FT                                A-342. {ECO:0000269|PubMed:12121988,
FT                                ECO:0000269|PubMed:15471878,
FT                                ECO:0000269|PubMed:8940083}.
FT   STRAND       12     14       {ECO:0000244|PDB:2KGT}.
FT   STRAND       35     40       {ECO:0000244|PDB:2KGT}.
FT   STRAND       45     50       {ECO:0000244|PDB:2KGT}.
FT   STRAND       56     62       {ECO:0000244|PDB:2KGT}.
FT   TURN         64     66       {ECO:0000244|PDB:2KGT}.
FT   STRAND       67     70       {ECO:0000244|PDB:2KGT}.
FT   HELIX        85     92       {ECO:0000244|PDB:1RJA}.
FT   STRAND      102    106       {ECO:0000244|PDB:1RJA}.
FT   STRAND      108    112       {ECO:0000244|PDB:1RJA}.
FT   STRAND      114    118       {ECO:0000244|PDB:1RJA}.
FT   STRAND      125    131       {ECO:0000244|PDB:1RJA}.
FT   STRAND      133    135       {ECO:0000244|PDB:1RJA}.
FT   STRAND      137    140       {ECO:0000244|PDB:1RJA}.
FT   STRAND      143    147       {ECO:0000244|PDB:1RJA}.
FT   HELIX       148    157       {ECO:0000244|PDB:1RJA}.
FT   STRAND      162    164       {ECO:0000244|PDB:1RJA}.
FT   HELIX       188    190       {ECO:0000244|PDB:5DA3}.
FT   STRAND      191    200       {ECO:0000244|PDB:5DA3}.
FT   STRAND      203    210       {ECO:0000244|PDB:5DA3}.
FT   TURN        211    213       {ECO:0000244|PDB:5DA3}.
FT   STRAND      214    221       {ECO:0000244|PDB:5DA3}.
FT   HELIX       223    225       {ECO:0000244|PDB:5DA3}.
FT   HELIX       233    240       {ECO:0000244|PDB:5DA3}.
FT   STRAND      250    254       {ECO:0000244|PDB:5DA3}.
FT   STRAND      256    264       {ECO:0000244|PDB:5DA3}.
FT   HELIX       272    277       {ECO:0000244|PDB:5DA3}.
FT   TURN        281    283       {ECO:0000244|PDB:5DA3}.
FT   HELIX       286    305       {ECO:0000244|PDB:5DA3}.
FT   HELIX       315    317       {ECO:0000244|PDB:5DA3}.
FT   STRAND      318    320       {ECO:0000244|PDB:5DA3}.
FT   HELIX       322    324       {ECO:0000244|PDB:5DA3}.
FT   STRAND      326    328       {ECO:0000244|PDB:5DA3}.
FT   HELIX       333    336       {ECO:0000244|PDB:5DA3}.
FT   HELIX       339    343       {ECO:0000244|PDB:5DA3}.
FT   HELIX       345    348       {ECO:0000244|PDB:5DA3}.
FT   HELIX       349    352       {ECO:0000244|PDB:5DA3}.
FT   HELIX       356    361       {ECO:0000244|PDB:5DA3}.
FT   HELIX       366    380       {ECO:0000244|PDB:5DA3}.
FT   TURN        381    384       {ECO:0000244|PDB:5DA3}.
FT   HELIX       393    401       {ECO:0000244|PDB:5DA3}.
FT   HELIX       414    423       {ECO:0000244|PDB:5DA3}.
FT   HELIX       428    430       {ECO:0000244|PDB:5DA3}.
FT   HELIX       434    442       {ECO:0000244|PDB:5DA3}.
SQ   SEQUENCE   451 AA;  51834 MW;  CDCAC0EE242E1BD7 CRC64;
     MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG
     YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD
     TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH
     WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK
     KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM
     CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS
     RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM
     LTCWCRDPEQ RPCFKALRER LSSFTSYENP T
//
ID   Q8WY44_HUMAN            Unreviewed;       193 AA.
AC   Q8WY44;
DT   01-MAR-2002, integrated into UniProtKB/TrEMBL.
DT   01-MAR-2002, sequence version 1.
DT   28-FEB-2018, entry version 67.
DE   SubName: Full=Quaking protein 3 {ECO:0000313|EMBL:AAL36980.1};
DE   Flags: Fragment;
GN   Name=QK3 {ECO:0000313|EMBL:AAL36980.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAL36980.1};
RN   [1] {ECO:0000313|EMBL:AAL36980.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=12511597; DOI=10.1073/pnas.0234478100;
RA   Moore F.L., Jaruzelska J., Fox M.S., Urano J., Firpo M.T., Turek P.J.,
RA   Dorfman D.M., Reijo Pera R.A.;
RT   "Human Pumilio-2 is expressed in embryonic stem cells and germ cells
RT   and interacts with DAZ (Deleted in AZoospermia) and DAZ-like
RT   proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:538-543(2003).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF272349; AAL36980.1; -; mRNA.
DR   RefSeq; NP_006766.1; NM_006775.2.
DR   RefSeq; NP_996735.1; NM_206853.2.
DR   RefSeq; NP_996736.1; NM_206854.2.
DR   RefSeq; NP_996737.1; NM_206855.2.
DR   UniGene; Hs.510324; -.
DR   ProteinModelPortal; Q8WY44; -.
DR   SMR; Q8WY44; -.
DR   IntAct; Q8WY44; 1.
DR   PRIDE; Q8WY44; -.
DR   DNASU; 9444; -.
DR   GeneID; 9444; -.
DR   KEGG; hsa:9444; -.
DR   CTD; 9444; -.
DR   PharmGKB; PA134912180; -.
DR   KO; K14945; -.
DR   ChiTaRS; QKI; human.
DR   GenomeRNAi; 9444; -.
DR   Genevisible; Q8WY44; HS.
PE   2: Evidence at transcript level;
FT   NON_TER       1      1       {ECO:0000313|EMBL:AAL36980.1}.
SQ   SEQUENCE   193 AA;  20673 MW;  631052977044AF13 CRC64;
     TSPERPPEPA AQAAAALSGL DQPSERRPRL LLVRRQQPAP RARTRPAETR LPPARRPREG
     RAEPGGRERR RLGARRARAE SACGGRASAR CRPPRGSARE PEREPARSGT PGPERPAAGA
     RPRPSLLSGG GGGGGGRSEL RSLEYGRGNG NEGEAEAHPR LPDAADERQE AHEQPAQLLR
     DLQPPRAAAG RRN
//
ID   QKI_HUMAN               Reviewed;         341 AA.
AC   Q96PU8; Q2I375; Q5MJQ1; Q969L9; Q96EJ3; Q96KA3; Q96PU6; Q96PU7;
AC   Q9P0X6; Q9P0X7; Q9P0X8; Q9P0X9; Q9P0Y0; Q9P0Y1;
DT   13-JUN-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   28-FEB-2018, entry version 145.
DE   RecName: Full=Protein quaking;
DE            Short=Hqk;
DE            Short=HqkI;
GN   Name=QKI; Synonyms=HKQ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 4 AND 5).
RC   TISSUE=Brain;
RX   PubMed=11856480; DOI=10.1111/j.1349-7006.2002.tb01255.x;
RA   Li Z.Z., Kondo T., Murata T., Ebersole T.A., Nishi T., Tada K.,
RA   Ushio Y., Yamamura K., Abe K.;
RT   "Expression of Hqk encoding a KH RNA binding protein is altered in
RT   human glioma.";
RL   Jpn. J. Cancer Res. 93:167-177(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 4), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 5-341 (ISOFORM 6).
RA   Xia J.-H., Xiao J.-F., He Y.-G., Yu K.-P., Pan Q., Dai H.-P.;
RT   "Molecular cloning of human QUAKING gene.";
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 5-341 (ISOFORM 3).
RA   Li H., Nong W., Zhou G., Ke R., Shen C., Zhong G., Liang M., Tang Z.,
RA   Huang B., Lin L., Yang S.;
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 15-341 (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   METHYLATION.
RX   PubMed=12529443; DOI=10.1091/mbc.E02-08-0484;
RA   Cote J., Boisvert F.-M., Boulanger M.-C., Bedford M.T., Richard S.;
RT   "Sam68 RNA binding protein is an in vivo substrate for protein
RT   arginine N-methyltransferase 1.";
RL   Mol. Biol. Cell 14:274-287(2003).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=16342280; DOI=10.1002/ajmg.b.30243;
RA   Aeberg K., Saetre P., Lindholm E., Ekholm B., Pettersson U.,
RA   Adolfsson R., Jazin E.;
RT   "Human QKI, a new candidate gene for schizophrenia involved in
RT   myelination.";
RL   Am. J. Med. Genet. B Neuropsychiatr. Genet. 141:84-90(2006).
RN   [9]
RP   FUNCTION AS REGULATOR OF OLIGODENDROCYTE DIFFERENTIATION.
RX   PubMed=16641098; DOI=10.1073/pnas.0601213103;
RA   Aberg K., Saetre P., Jareborg N., Jazin E.;
RT   "Human QKI, a potential regulator of mRNA expression of human
RT   oligodendrocyte-related genes involved in schizophrenia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7482-7487(2006).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   METHYLATION AT ARG-242 BY CARM1.
RX   PubMed=23455924; DOI=10.1038/nmeth.2397;
RA   Weimann M., Grossmann A., Woodsmith J., Ozkan Z., Birth P.,
RA   Meierhofer D., Benlasfer N., Valovka T., Timmermann B., Wanker E.E.,
RA   Sauer S., Stelzl U.;
RT   "A Y2H-seq approach defines the human protein methyltransferase
RT   interactome.";
RL   Nat. Methods 10:339-342(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-227 AND ARG-242, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-336.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS) OF 7-204 IN COMPLEX WITH RNA,
RP   RNA-BINDING, FUNCTION, SUBUNIT, DOMAIN, AND MUTAGENESIS OF ASN-97;
RP   LYS-120; ARG-124; ARG-130; LYS-190 AND GLN-193.
RX   PubMed=23630077; DOI=10.1101/gad.216531.113;
RA   Teplova M., Hafner M., Teplov D., Essig K., Tuschl T., Patel D.J.;
RT   "Structure-function studies of STAR family Quaking proteins bound to
RT   their in vivo RNA target sites.";
RL   Genes Dev. 27:928-940(2013).
CC   -!- FUNCTION: RNA-binding protein that plays a central role in
CC       myelinization (PubMed:16641098). Binds to the 5'-NACUAAY-N(1,20)-
CC       UAAY-3' RNA core sequence. Regulates target mRNA stability
CC       (PubMed:23630077). In addition, acts by regulating pre-mRNA
CC       splicing, mRNA export and protein translation. Required to protect
CC       and promote stability of mRNAs such as MBP and CDKN1B. Regulator
CC       of oligodendrocyte differentiation and maturation in the brain
CC       that may play a role in myelin and oligodendrocyte dysfunction in
CC       schizophrenia (PubMed:16641098). Participates in mRNA transport by
CC       regulating the nuclear export of MBP mRNA. Also involved in
CC       regulation of mRNA splicing of MAG pre-mRNA. Acts as a
CC       translational repressor (By similarity).
CC       {ECO:0000250|UniProtKB:Q9QYS9, ECO:0000269|PubMed:16641098,
CC       ECO:0000269|PubMed:23630077}.
CC   -!- SUBUNIT: Homodimer (PubMed:23630077). Does not require RNA to
CC       homodimerize. Able to heterodimerize with BICC1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q9QYS9, ECO:0000269|PubMed:23630077}.
CC   -!- INTERACTION:
CC       Q86X55:CARM1; NbExp=2; IntAct=EBI-945792, EBI-2339854;
CC       Q96I24:FUBP3; NbExp=4; IntAct=EBI-945792, EBI-954200;
CC       P61978:HNRNPK; NbExp=6; IntAct=EBI-945792, EBI-304185;
CC       Q8WVV9:HNRNPLL; NbExp=3; IntAct=EBI-945792, EBI-535849;
CC       Q96AH0:NABP1; NbExp=3; IntAct=EBI-945792, EBI-2889252;
CC       Q15365:PCBP1; NbExp=2; IntAct=EBI-945792, EBI-946095;
CC       P26599:PTBP1; NbExp=3; IntAct=EBI-945792, EBI-350540;
CC       Q9NWB1:RBFOX1; NbExp=2; IntAct=EBI-945792, EBI-945906;
CC       O43251:RBFOX2; NbExp=3; IntAct=EBI-945792, EBI-746056;
CC       P57052:RBM11; NbExp=3; IntAct=EBI-945792, EBI-741332;
CC       Q93062:RBPMS; NbExp=5; IntAct=EBI-945792, EBI-740322;
CC       P09012:SNRPA; NbExp=3; IntAct=EBI-945792, EBI-607085;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=HQK-5, QKI-5;
CC         IsoId=Q96PU8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96PU8-3; Sequence=VSP_019188;
CC       Name=3;
CC         IsoId=Q96PU8-5; Sequence=VSP_019188, VSP_019190;
CC       Name=4; Synonyms=HQK-7;
CC         IsoId=Q96PU8-6; Sequence=VSP_019190;
CC       Name=5; Synonyms=HQK-7B;
CC         IsoId=Q96PU8-8; Sequence=VSP_019191;
CC       Name=6;
CC         IsoId=Q96PU8-9; Sequence=VSP_019189;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in the frontal cortex of brain.
CC       Down-regulated in the brain of schizophrenic patients.
CC       {ECO:0000269|PubMed:16342280}.
CC   -!- DOMAIN: The KH domain and the Qua2 region are involved in RNA
CC       binding. {ECO:0000269|PubMed:23630077}.
CC   -!- PTM: Methylated by PRMT1. {ECO:0000250}.
CC   -!- PTM: Tyrosine phosphorylated at its C-terminus, probably by FYN.
CC       Phosphorylation leads to decreased mRNA-binding affinity,
CC       affecting transport and/or stabilization of MBP mRNA (By
CC       similarity). {ECO:0000250}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF63412.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC       Sequence=AAF63413.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAF63413.1; Type=Miscellaneous discrepancy; Note=Cloning artifact in N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF63414.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAF63414.1; Type=Miscellaneous discrepancy; Note=Cloning artifact in N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF63415.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC       Sequence=AAF63416.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC       Sequence=AAF63417.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAF63417.1; Type=Miscellaneous discrepancy; Note=Cloning artifact in N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB55032.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB067798; BAB69496.1; -; mRNA.
DR   EMBL; AB067799; BAB69497.1; -; mRNA.
DR   EMBL; AB067800; BAB69498.1; -; mRNA.
DR   EMBL; AB067801; BAB69499.1; -; mRNA.
DR   EMBL; AB067808; BAB69681.1; -; Genomic_DNA.
DR   EMBL; AF142417; AAF63412.1; ALT_SEQ; mRNA.
DR   EMBL; AF142418; AAF63413.1; ALT_SEQ; mRNA.
DR   EMBL; AF142419; AAF63414.1; ALT_SEQ; mRNA.
DR   EMBL; AF142420; AAF63415.1; ALT_SEQ; mRNA.
DR   EMBL; AF142421; AAF63416.1; ALT_SEQ; mRNA.
DR   EMBL; AF142422; AAF63417.1; ALT_SEQ; mRNA.
DR   EMBL; AY780788; AAV98358.1; -; mRNA.
DR   EMBL; DQ323998; ABC88600.1; -; mRNA.
DR   EMBL; AL356119; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012222; AAH12222.1; -; mRNA.
DR   EMBL; BC019917; AAH19917.1; -; mRNA.
DR   EMBL; AK027309; BAB55032.1; ALT_INIT; mRNA.
DR   CCDS; CCDS43525.1; -. [Q96PU8-8]
DR   CCDS; CCDS5285.1; -. [Q96PU8-1]
DR   CCDS; CCDS5286.1; -. [Q96PU8-9]
DR   CCDS; CCDS5287.1; -. [Q96PU8-6]
DR   CCDS; CCDS75546.1; -. [Q96PU8-3]
DR   RefSeq; NP_001288014.1; NM_001301085.1. [Q96PU8-3]
DR   RefSeq; NP_006766.1; NM_006775.2. [Q96PU8-1]
DR   RefSeq; NP_996735.1; NM_206853.2. [Q96PU8-9]
DR   RefSeq; NP_996736.1; NM_206854.2. [Q96PU8-6]
DR   RefSeq; NP_996737.1; NM_206855.2. [Q96PU8-8]
DR   RefSeq; XP_011534561.1; XM_011536259.2. [Q96PU8-5]
DR   UniGene; Hs.510324; -.
DR   PDB; 4JVH; X-ray; 3.50 A; A=7-214.
DR   PDBsum; 4JVH; -.
DR   ProteinModelPortal; Q96PU8; -.
DR   SMR; Q96PU8; -.
DR   BioGrid; 114834; 75.
DR   IntAct; Q96PU8; 38.
DR   MINT; Q96PU8; -.
DR   STRING; 9606.ENSP00000355094; -.
DR   iPTMnet; Q96PU8; -.
DR   PhosphoSitePlus; Q96PU8; -.
DR   BioMuta; QKI; -.
DR   DMDM; 74761039; -.
DR   EPD; Q96PU8; -.
DR   MaxQB; Q96PU8; -.
DR   PaxDb; Q96PU8; -.
DR   PeptideAtlas; Q96PU8; -.
DR   PRIDE; Q96PU8; -.
DR   DNASU; 9444; -.
DR   Ensembl; ENST00000275262; ENSP00000275262; ENSG00000112531. [Q96PU8-6]
DR   Ensembl; ENST00000361195; ENSP00000354867; ENSG00000112531. [Q96PU8-3]
DR   Ensembl; ENST00000361752; ENSP00000355094; ENSG00000112531. [Q96PU8-1]
DR   Ensembl; ENST00000361758; ENSP00000354951; ENSG00000112531. [Q96PU8-9]
DR   Ensembl; ENST00000392127; ENSP00000375973; ENSG00000112531. [Q96PU8-8]
DR   Ensembl; ENST00000424802; ENSP00000408382; ENSG00000112531. [Q96PU8-5]
DR   Ensembl; ENST00000453779; ENSP00000408775; ENSG00000112531. [Q96PU8-9]
DR   GeneID; 9444; -.
DR   KEGG; hsa:9444; -.
DR   UCSC; uc003que.4; human. [Q96PU8-1]
DR   CTD; 9444; -.
DR   DisGeNET; 9444; -.
DR   EuPathDB; HostDB:ENSG00000112531.16; -.
DR   GeneCards; QKI; -.
DR   HGNC; HGNC:21100; QKI.
DR   HPA; CAB022602; -.
DR   HPA; HPA019123; -.
DR   MalaCards; QKI; -.
DR   MIM; 609590; gene.
DR   neXtProt; NX_Q96PU8; -.
DR   OpenTargets; ENSG00000112531; -.
DR   PharmGKB; PA134912180; -.
DR   eggNOG; KOG1588; Eukaryota.
DR   eggNOG; COG5176; LUCA.
DR   GeneTree; ENSGT00550000074434; -.
DR   HOVERGEN; HBG093883; -.
DR   InParanoid; Q96PU8; -.
DR   KO; K14945; -.
DR   OMA; TVEDTHN; -.
DR   OrthoDB; EOG091G0EED; -.
DR   PhylomeDB; Q96PU8; -.
DR   TreeFam; TF314878; -.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   ChiTaRS; QKI; human.
DR   GeneWiki; QKI; -.
DR   GenomeRNAi; 9444; -.
DR   PRO; PR:Q96PU8; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000112531; -.
DR   ExpressionAtlas; Q96PU8; baseline and differential.
DR   Genevisible; Q96PU8; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003729; F:mRNA binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0061158; P:3'-UTR-mediated mRNA destabilization; IEA:Ensembl.
DR   GO; GO:0042759; P:long-chain fatty acid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0051028; P:mRNA transport; IEA:UniProtKB-KW.
DR   GO; GO:0042692; P:muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   Gene3D; 3.30.1370.10; -; 1.
DR   InterPro; IPR004087; KH_dom.
DR   InterPro; IPR004088; KH_dom_type_1.
DR   InterPro; IPR036612; KH_dom_type_1_sf.
DR   InterPro; IPR032367; Quaking_NLS.
DR   InterPro; IPR032377; STAR_dimer.
DR   Pfam; PF00013; KH_1; 1.
DR   Pfam; PF16551; Quaking_NLS; 1.
DR   Pfam; PF16544; STAR_dimer; 1.
DR   SMART; SM00322; KH; 1.
DR   SUPFAM; SSF54791; SSF54791; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Developmental protein; Differentiation; Methylation; mRNA processing;
KW   mRNA splicing; mRNA transport; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; RNA-binding; SH3-binding; Translation regulation;
KW   Transport.
FT   CHAIN         1    341       Protein quaking.
FT                                /FTId=PRO_0000239373.
FT   DOMAIN       87    153       KH.
FT   REGION       11     82       Qua1 domain; involved in
FT                                homodimerization.
FT                                {ECO:0000250|UniProtKB:Q17339}.
FT   REGION      182    213       Qua2 domain; involved in RNA binding.
FT                                {ECO:0000269|PubMed:23630077}.
FT   MOTIF       276    279       SH3-binding.
FT   MOTIF       324    330       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   SITE         97     97       Involved in RNA binding.
FT                                {ECO:0000269|PubMed:23630077}.
FT   SITE        120    120       Involved in RNA binding.
FT                                {ECO:0000269|PubMed:23630077}.
FT   SITE        124    124       Involved in RNA binding.
FT                                {ECO:0000269|PubMed:23630077}.
FT   SITE        130    130       Involved in RNA binding.
FT                                {ECO:0000269|PubMed:23630077}.
FT   SITE        190    190       Involved in RNA binding.
FT                                {ECO:0000269|PubMed:23630077}.
FT   SITE        193    193       Involved in RNA binding.
FT                                {ECO:0000269|PubMed:23630077}.
FT   MOD_RES     188    188       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     227    227       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     242    242       Asymmetric dimethylarginine; by CARM1;
FT                                alternate. {ECO:0000269|PubMed:23455924}.
FT   MOD_RES     242    242       Omega-N-methylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     256    256       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q9QYS9}.
FT   VAR_SEQ     213    220       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_019188.
FT   VAR_SEQ     312    341       GAVATKVRRHDMRVHPYQRIVTADRAATGN -> EWIEMPV
FT                                MPDISAH (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:11856480,
FT                                ECO:0000303|Ref.2, ECO:0000303|Ref.3}.
FT                                /FTId=VSP_019190.
FT   VAR_SEQ     312    341       GAVATKVRRHDMRVHPYQRIVTADRAATGN -> GKFFSPW
FT                                G (in isoform 5).
FT                                {ECO:0000303|PubMed:11856480}.
FT                                /FTId=VSP_019191.
FT   VAR_SEQ     312    341       GAVATKVRRHDMRVHPYQRIVTADRAATGN -> GMAFPTK
FT                                G (in isoform 6). {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_019189.
FT   VARIANT     336    336       R -> Q (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036051.
FT   MUTAGEN      97     97       N->A: Decrease in target mRNA abundance
FT                                and 10-fold decrease in RNA binding
FT                                affinity; when associated with A-130.
FT                                {ECO:0000269|PubMed:23630077}.
FT   MUTAGEN     120    120       K->A: Decrease in target mRNA abundance
FT                                and 20-fold decrease in RNA binding
FT                                affinity; when associated with A-124.
FT                                {ECO:0000269|PubMed:23630077}.
FT   MUTAGEN     124    124       R->A: Decrease in target mRNA abundance
FT                                and 20-fold decrease in RNA binding
FT                                affinity; when associated with A-120.
FT                                {ECO:0000269|PubMed:23630077}.
FT   MUTAGEN     130    130       R->A: Decrease in target mRNA abundance
FT                                and 10-fold decrease in RNA binding
FT                                affinity; when associated with A-97.
FT                                {ECO:0000269|PubMed:23630077}.
FT   MUTAGEN     190    190       K->A: Decrease in target mRNA abundance
FT                                and 124-fold decrease in RNA binding
FT                                affinity; when associated with A-193.
FT                                {ECO:0000269|PubMed:23630077}.
FT   MUTAGEN     193    193       Q->A: Decrease in target mRNA abundance
FT                                and 124-fold decrease in RNA binding
FT                                affinity; when associated with A-190.
FT                                {ECO:0000269|PubMed:23630077}.
FT   CONFLICT     30     30       S -> G (in Ref. 3; ABC88600).
FT                                {ECO:0000305}.
FT   CONFLICT    208    208       N -> D (in Ref. 5; AAH12222).
FT                                {ECO:0000305}.
SQ   SEQUENCE   341 AA;  37671 MW;  43E7F3A426A494C4 CRC64;
     MVGEMETKEK PKPTPDYLMQ LMNDKKLMSS LPNFCGIFNH LERLLDEEIS RVRKDMYNDT
     LNGSTEKRSA ELPDAVGPIV QLQEKLYVPV KEYPDFNFVG RILGPRGLTA KQLEAETGCK
     IMVRGKGSMR DKKKEEQNRG KPNWEHLNED LHVLITVEDA QNRAEIKLKR AVEEVKKLLV
     PAAEGEDSLK KMQLMELAIL NGTYRDANIK SPALAFSLAA TAQAAPRIIT GPAPVLPPAA
     LRTPTPAGPT IMPLIRQIQT AVMPNGTPHP TAAIVPPGPE AGLIYTPYEY PYTLAPATSI
     LEYPIEPSGV LGAVATKVRR HDMRVHPYQR IVTADRAATG N
//
ID   A0A024R9J0_HUMAN        Unreviewed;       631 AA.
AC   A0A024R9J0;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-FEB-2018, entry version 25.
DE   SubName: Full=RAD21 homolog (S. pombe), isoform CRA_a {ECO:0000313|EMBL:EAW91965.1};
GN   Name=RAD21 {ECO:0000313|EMBL:EAW91965.1};
GN   ORFNames=hCG_19969 {ECO:0000313|EMBL:EAW91965.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW91965.1};
RN   [1] {ECO:0000313|EMBL:EAW91965.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW91965.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471060; EAW91965.1; -; Genomic_DNA.
DR   RefSeq; NP_006256.1; NM_006265.2.
DR   UniGene; Hs.81848; -.
DR   ProteinModelPortal; A0A024R9J0; -.
DR   SMR; A0A024R9J0; -.
DR   PRIDE; A0A024R9J0; -.
DR   GeneID; 5885; -.
DR   KEGG; hsa:5885; -.
DR   CTD; 5885; -.
DR   EuPathDB; HostDB:ENSG00000164754.12; -.
DR   eggNOG; KOG1213; Eukaryota.
DR   eggNOG; ENOG410XRB4; LUCA.
DR   KO; K06670; -.
DR   OMA; ENMGYDQ; -.
DR   OrthoDB; EOG091G03QW; -.
DR   PhylomeDB; A0A024R9J0; -.
DR   ChiTaRS; RAD21; human.
DR   GenomeRNAi; 5885; -.
DR   Bgee; ENSG00000164754; -.
DR   ExpressionAtlas; A0A024R9J0; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0008278; C:cohesin complex; IEA:Ensembl.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0010972; P:negative regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045841; P:negative regulation of mitotic metaphase/anaphase transition; IEA:Ensembl.
DR   InterPro; IPR006909; Rad21/Rec8_C_eu.
DR   InterPro; IPR006910; Rad21_Rec8_N.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF04824; Rad21_Rec8; 1.
DR   Pfam; PF04825; Rad21_Rec8_N; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
PE   4: Predicted;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN        1    103       Rad21_Rec8_N. {ECO:0000259|Pfam:PF04825}.
FT   DOMAIN      575    628       Rad21_Rec8. {ECO:0000259|Pfam:PF04824}.
FT   COILED      522    544       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   631 AA;  71690 MW;  7D4A6EA6392BE73D CRC64;
     MFYAHFVLSK RGPLAKIWLA AHWDKKLTKA HVFECNLESS VESIISPKVK MALRTSGHLL
     LGVVRIYHRK AKYLLADCNE AFIKIKMAFR PGVVDLPEEN REAAYNAITL PEEFHDFDQP
     LPDLDDIDVA QQFSLNQSRV EEITMREEVG NISILQENDF GDFGMDDREI MREGSAFEDD
     DMLVSTTTSN LLLESEQSTS NLNEKINHLE YEDQYKDDNF GEGNDGGILD DKLISNNDGG
     IFDDPPALSE AGVMLPEQPA HDDMDEDDNV SMGGPDSPDS VDPVEPMPTM TDQTTLVPNE
     EEAFALEPID ITVKETKAKR KRKLIVDSVK ELDSKTIRAQ LSDYSDIVTT LDLAPPTKKL
     MMWKETGGVE KLFSLPAQPL WNNRLLKLFT RCLTPLVPED LRKRRKGGEA DNLDEFLKEF
     ENPEVPREDQ QQQHQQRDVI DEPIIEEPSR LQESVMEASR TNIDESAMPP PPPQGVKRKA
     GQIDPEPVMP PQQVEQMEIP PVELPPEEPP NICQLIPELE LLPEKEKEKE KEKEDDEEEE
     DEDASGGDQD QEERRWNKRT QQMLHGLQRA LAKTGAESIS LLELCRNTNR KQAAAKFYSF
     LVLKKQQAIE LTQEEPYSDI IATPGPRFHI I
//
ID   RAD21_HUMAN             Reviewed;         631 AA.
AC   O60216; A8K0E0; Q15001; Q99568;
DT   15-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   15-NOV-2002, sequence version 2.
DT   28-FEB-2018, entry version 168.
DE   RecName: Full=Double-strand-break repair protein rad21 homolog;
DE            Short=hHR21;
DE   AltName: Full=Nuclear matrix protein 1;
DE            Short=NXP-1;
DE   AltName: Full=SCC1 homolog;
GN   Name=RAD21; Synonyms=HR21, KIAA0078, NXP1, SCC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RX   PubMed=8812457; DOI=10.1006/geno.1996.0466;
RA   McKay M.J., Troelstra C., van der Spek P., Kanaar R., Smit B.,
RA   Hagemeijer A., Bootsma D., Hoeijmakers J.H.J.;
RT   "Sequence conservation of the rad21 Schizosaccharomyces pombe DNA
RT   double-strand break repair gene in human and mouse.";
RL   Genomics 36:305-315(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=10623634; DOI=10.1006/bbrc.1999.1969;
RA   Sadano H., Sugimoto H., Sakai F., Nomura N., Osumi T.;
RT   "NXP-1, a human protein related to Rad21/Scc1/Mcd1, is a component of
RT   the nuclear matrix.";
RL   Biochem. Biophys. Res. Commun. 267:418-422(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S.,
RA   Seki N., Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II.
RT   The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 406-418, AND IDENTIFICATION IN A COHESIN COMPLEX
RP   WITH SMC1A; SMC3; STAG1 OR STAG2.
RX   PubMed=11590136; DOI=10.1074/jbc.M103364200;
RA   Gregson H.C., Schmiesing J.A., Kim J.-S., Kobayashi T., Zhou S.,
RA   Yokomori K.;
RT   "A potential role for human cohesin in mitotic spindle aster
RT   assembly.";
RL   J. Biol. Chem. 276:47575-47582(2001).
RN   [9]
RP   PROTEIN SEQUENCE OF 275-279 (60 KDA PRODUCT), PROTEIN SEQUENCE OF
RP   280-286 (64 KDA C-TERMINAL PRODUCT), CLEAVAGE BY CASPASE-3, FUNCTION,
RP   AND MUTAGENESIS OF ASP-279.
RX   PubMed=12417729; DOI=10.1128/MCB.22.23.8267-8277.2002;
RA   Pati D., Zhang N., Plon S.E.;
RT   "Linking sister chromatid cohesion and apoptosis: role of rad21.";
RL   Mol. Cell. Biol. 22:8267-8277(2002).
RN   [10]
RP   SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND PHOSPHORYLATION.
RX   PubMed=11073952; DOI=10.1074/jbc.M007809200;
RA   Hoque M.T., Ishikawa F.;
RT   "Human chromatid cohesin component hRad21 is phosphorylated in M phase
RT   and associated with metaphase centromeres.";
RL   J. Biol. Chem. 276:5059-5067(2001).
RN   [11]
RP   CLEAVAGE BY ESPL1, AND MUTAGENESIS OF ARG-172 AND ARG-450.
RX   PubMed=11509732; DOI=10.1126/science.1061376;
RA   Hauf S., Waizenegger I.C., Peters J.-M.;
RT   "Cohesin cleavage by separase required for anaphase and cytokinesis in
RT   human cells.";
RL   Science 293:1320-1323(2001).
RN   [12]
RP   FUNCTION, CLEAVAGE BY CASPASE-3, AND MUTAGENESIS OF ASP-279.
RX   PubMed=11875078; DOI=10.1074/jbc.M201322200;
RA   Chen F., Kamradt M., Mulcahy M., Byun Y., Xu H., McKay M.J.,
RA   Cryns V.L.;
RT   "Caspase proteolysis of the cohesin component RAD21 promotes
RT   apoptosis.";
RL   J. Biol. Chem. 277:16775-16781(2002).
RN   [13]
RP   IDENTIFICATION IN A COMPLEX WITH SMC1A; SMC3; CDCA5; PDS5A AND PDS5B.
RX   PubMed=15837422; DOI=10.1016/j.molcel.2005.03.017;
RA   Rankin S., Ayad N.G., Kirschner M.W.;
RT   "Sororin, a substrate of the anaphase-promoting complex, is required
RT   for sister chromatid cohesion in vertebrates.";
RL   Mol. Cell 18:185-200(2005).
RN   [14]
RP   ERRATUM.
RA   Rankin S., Ayad N.G., Kirschner M.W.;
RL   Mol. Cell 18:609-609(2005).
RN   [15]
RP   INTERACTION WITH DDX11.
RX   PubMed=17105772; DOI=10.1242/jcs.03262;
RA   Parish J.L., Rosa J., Wang X., Lahti J.M., Doxsey S.J., Androphy E.J.;
RT   "The DNA helicase ChlR1 is required for sister chromatid cohesion in
RT   mammalian cells.";
RL   J. Cell Sci. 119:4857-4865(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-175, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   INTERACTION WITH PDS5B; STAG1 AND WAPL.
RX   PubMed=19696148; DOI=10.1101/gad.1844309;
RA   Shintomi K., Hirano T.;
RT   "Releasing cohesin from chromosome arms in early mitosis: opposing
RT   actions of Wapl-Pds5 and Sgo1.";
RL   Genes Dev. 23:2224-2236(2009).
RN   [18]
RP   POLYMORPHISM, AND VARIANT ARG-481.
RX   PubMed=11483345; DOI=10.1016/S0360-3016(01)01608-X;
RA   Severin D.M., Leong T., Cassidy B., Elsaleh H., Peters L., Venter D.,
RA   Southey M., McKay M.;
RT   "Novel DNA sequence variants in the hHR21 DNA repair gene in
RT   radiosensitive cancer patients.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 50:1323-1331(2001).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-153 AND SER-175, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-153, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   IDENTIFICATION IN A COHESIN COMPLEX WITH SMC1A; SMC3 AND STAG1.
RX   PubMed=22628566; DOI=10.1073/pnas.1206840109;
RA   Bermudez V.P., Farina A., Higashi T.L., Du F., Tappin I.,
RA   Takahashi T.S., Hurwitz J.;
RT   "In vitro loading of human cohesin on DNA by the human Scc2-Scc4
RT   loader complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9366-9371(2012).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394; SER-454; SER-545
RP   AND THR-623, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-153 AND SER-249, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-48; LYS-216 AND LYS-418, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [26]
RP   VARIANTS CDLS4 ARG-376 AND ARG-585.
RX   PubMed=22633399; DOI=10.1016/j.ajhg.2012.04.019;
RA   Deardorff M.A., Wilde J.J., Albrecht M., Dickinson E., Tennstedt S.,
RA   Braunholz D., Monnich M., Yan Y., Xu W., Gil-Rodriguez M.C., Clark D.,
RA   Hakonarson H., Halbach S., Michelis L.D., Rampuria A., Rossier E.,
RA   Spranger S., Van Maldergem L., Lynch S.A., Gillessen-Kaesbach G.,
RA   Ludecke H.J., Ramsay R.G., McKay M.J., Krantz I.D., Xu H.,
RA   Horsfield J.A., Kaiser F.J.;
RT   "RAD21 mutations cause a human cohesinopathy.";
RL   Am. J. Hum. Genet. 90:1014-1027(2012).
CC   -!- FUNCTION: Cleavable component of the cohesin complex, involved in
CC       chromosome cohesion during cell cycle, in DNA repair, and in
CC       apoptosis. The cohesin complex is required for the cohesion of
CC       sister chromatids after DNA replication. The cohesin complex
CC       apparently forms a large proteinaceous ring within which sister
CC       chromatids can be trapped. At metaphase-anaphase transition, this
CC       protein is cleaved by separase/ESPL1 and dissociates from
CC       chromatin, allowing sister chromatids to segregate. The cohesin
CC       complex may also play a role in spindle pole assembly during
CC       mitosis. Also plays a role in apoptosis, via its cleavage by
CC       caspase-3/CASP3 or caspase-7/CASP7 during early steps of
CC       apoptosis: the C-terminal 64 kDa cleavage product may act as a
CC       nuclear signal to initiate cytoplasmic events involved in the
CC       apoptotic pathway. {ECO:0000269|PubMed:11875078,
CC       ECO:0000269|PubMed:12417729}.
CC   -!- SUBUNIT: Cohesin complexes are composed of the SMC1 (SMC1A or
CC       SMC1B) and SMC3 heterodimer attached via their hinge domain, RAD21
CC       which link them, and one STAG protein (STAG1, STAG2 or STAG3),
CC       which interacts with RAD21 (PubMed:11590136). Found in a complex
CC       with SMC1A, SMC3, CDCA5, PDS5A/SCC-112 and PDS5B/APRIN
CC       (PubMed:15837422). Interacts with PDS5B and WAPL; the interaction
CC       is direct (PubMed:19696148). Interacts with SMC1A and SMC3 (By
CC       similarity). Interacts with DDX11 (PubMed:17105772). Found in a
CC       cohesin complex with SMC1A, SMC3 and STAG1 (PubMed:22628566).
CC       {ECO:0000250|UniProtKB:Q61550, ECO:0000269|PubMed:11590136,
CC       ECO:0000269|PubMed:15837422, ECO:0000269|PubMed:17105772,
CC       ECO:0000269|PubMed:19696148, ECO:0000269|PubMed:22628566}.
CC   -!- INTERACTION:
CC       Q13643:FHL3; NbExp=3; IntAct=EBI-80739, EBI-741101;
CC       Q29RF7:PDS5A; NbExp=4; IntAct=EBI-80739, EBI-1175454;
CC       Q9NTI5:PDS5B; NbExp=4; IntAct=EBI-80739, EBI-1175604;
CC       Q14683:SMC1A; NbExp=14; IntAct=EBI-80739, EBI-80690;
CC       Q9UQE7:SMC3; NbExp=15; IntAct=EBI-80739, EBI-80718;
CC       Q9NP77:SSU72; NbExp=9; IntAct=EBI-80739, EBI-2515416;
CC       Q8N3U4:STAG2; NbExp=13; IntAct=EBI-80739, EBI-1057252;
CC       Q7Z5K2:WAPL; NbExp=15; IntAct=EBI-80739, EBI-1022242;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10623634}.
CC       Chromosome {ECO:0000269|PubMed:11073952}. Chromosome, centromere
CC       {ECO:0000269|PubMed:11073952}. Note=Associates with chromatin.
CC       Before prophase it is scattered along chromosome arms. During
CC       prophase, most of cohesin complexes dissociate from chromatin
CC       probably because of phosphorylation by PLK, except at centromeres,
CC       where cohesin complexes remain. At anaphase, it is cleaved by
CC       separase/ESPL1, leading to the dissociation of the complex from
CC       chromosomes, allowing chromosome separation. Once cleaved by
CC       caspase-3, the C-terminal 64 kDa cleavage product translocates to
CC       the cytoplasm, where it may trigger apoptosis.
CC       {ECO:0000269|PubMed:11073952}.
CC   -!- DOMAIN: The C-terminal part associates with the head of SMC1A,
CC       while the N-terminal part binds to the head of SMC3.
CC       {ECO:0000250}.
CC   -!- PTM: Cleaved by separase/ESPL1 at the onset of anaphase. Cleaved
CC       by caspase-3 and caspase-7 at the beginning of apoptosis. The
CC       cleavage by ESPL1 and caspase-3 take place at different sites.
CC       {ECO:0000269|PubMed:11509732, ECO:0000269|PubMed:11875078,
CC       ECO:0000269|PubMed:12417729}.
CC   -!- PTM: Phosphorylated; becomes hyperphosphorylated in M phase of
CC       cell cycle. The large dissociation of cohesin from chromosome arms
CC       during prophase may be partly due to its phosphorylation by PLK.
CC       {ECO:0000269|PubMed:11073952}.
CC   -!- POLYMORPHISM: Some radiosensitive cancer patients seem to have
CC       Arg-481 instead of the conserved Gly-481. It may be that this
CC       mutation could contribute to radiosensitivity.
CC       {ECO:0000269|PubMed:11483345}.
CC   -!- DISEASE: Cornelia de Lange syndrome 4 (CDLS4) [MIM:614701]: A form
CC       of Cornelia de Lange syndrome, a clinically heterogeneous
CC       developmental disorder associated with malformations affecting
CC       multiple systems. It is characterized by facial dysmorphisms,
CC       abnormal hands and feet, growth delay, cognitive retardation,
CC       hirsutism, gastroesophageal dysfunction and cardiac,
CC       ophthalmologic and genitourinary anomalies.
CC       {ECO:0000269|PubMed:22633399}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the rad21 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA07554.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/rad21/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X98294; CAA66940.1; -; mRNA.
DR   EMBL; D38551; BAA07554.2; ALT_INIT; mRNA.
DR   EMBL; AY675320; AAT70725.1; -; Genomic_DNA.
DR   EMBL; AK289505; BAF82194.1; -; mRNA.
DR   EMBL; CH471060; EAW91963.1; -; Genomic_DNA.
DR   EMBL; BC050381; AAH50381.1; -; mRNA.
DR   CCDS; CCDS6321.1; -.
DR   RefSeq; NP_006256.1; NM_006265.2.
DR   UniGene; Hs.81848; -.
DR   PDB; 4PJU; X-ray; 3.05 A; B=281-420.
DR   PDB; 4PJW; X-ray; 2.85 A; B=281-420.
DR   PDB; 4PK7; X-ray; 2.95 A; B=281-420.
DR   PDBsum; 4PJU; -.
DR   PDBsum; 4PJW; -.
DR   PDBsum; 4PK7; -.
DR   ProteinModelPortal; O60216; -.
DR   SMR; O60216; -.
DR   BioGrid; 111822; 278.
DR   CORUM; O60216; -.
DR   DIP; DIP-29201N; -.
DR   ELM; O60216; -.
DR   IntAct; O60216; 34.
DR   MINT; O60216; -.
DR   STRING; 9606.ENSP00000297338; -.
DR   iPTMnet; O60216; -.
DR   PhosphoSitePlus; O60216; -.
DR   SwissPalm; O60216; -.
DR   BioMuta; RAD21; -.
DR   EPD; O60216; -.
DR   MaxQB; O60216; -.
DR   PaxDb; O60216; -.
DR   PeptideAtlas; O60216; -.
DR   PRIDE; O60216; -.
DR   Ensembl; ENST00000297338; ENSP00000297338; ENSG00000164754.
DR   GeneID; 5885; -.
DR   KEGG; hsa:5885; -.
DR   UCSC; uc003yod.4; human.
DR   CTD; 5885; -.
DR   DisGeNET; 5885; -.
DR   EuPathDB; HostDB:ENSG00000164754.12; -.
DR   GeneCards; RAD21; -.
DR   GeneReviews; RAD21; -.
DR   HGNC; HGNC:9811; RAD21.
DR   HPA; CAB022065; -.
DR   HPA; HPA020044; -.
DR   MalaCards; RAD21; -.
DR   MIM; 606462; gene.
DR   MIM; 614701; phenotype.
DR   neXtProt; NX_O60216; -.
DR   OpenTargets; ENSG00000164754; -.
DR   Orphanet; 199; Cornelia de Lange syndrome.
DR   PharmGKB; PA34170; -.
DR   eggNOG; KOG1213; Eukaryota.
DR   eggNOG; ENOG410XRB4; LUCA.
DR   GeneTree; ENSGT00390000011606; -.
DR   HOGENOM; HOG000233800; -.
DR   HOVERGEN; HBG059956; -.
DR   InParanoid; O60216; -.
DR   KO; K06670; -.
DR   OMA; ENMGYDQ; -.
DR   OrthoDB; EOG091G03QW; -.
DR   PhylomeDB; O60216; -.
DR   TreeFam; TF101215; -.
DR   BioCyc; MetaCyc:ENSG00000164754-MONOMER; -.
DR   Reactome; R-HSA-1221632; Meiotic synapsis.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2468052; Establishment of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-2470946; Cohesin Loading onto Chromatin.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   SIGNOR; O60216; -.
DR   ChiTaRS; RAD21; human.
DR   GeneWiki; RAD21; -.
DR   GenomeRNAi; 5885; -.
DR   PMAP-CutDB; O60216; -.
DR   PRO; PR:O60216; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000164754; -.
DR   CleanEx; HS_RAD21; -.
DR   ExpressionAtlas; O60216; baseline and differential.
DR   Genevisible; O60216; HS.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005694; C:chromosome; TAS:Reactome.
DR   GO; GO:0000775; C:chromosome, centromeric region; TAS:Reactome.
DR   GO; GO:0008278; C:cohesin complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0000798; C:nuclear cohesin complex; IBA:GO_Central.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; TAS:ProtInc.
DR   GO; GO:0006302; P:double-strand break repair; TAS:ProtInc.
DR   GO; GO:0010972; P:negative regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045841; P:negative regulation of mitotic metaphase/anaphase transition; IEA:Ensembl.
DR   GO; GO:0045876; P:positive regulation of sister chromatid cohesion; IMP:UniProtKB.
DR   GO; GO:0071168; P:protein localization to chromatin; IMP:UniProtKB.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0007062; P:sister chromatid cohesion; TAS:Reactome.
DR   InterPro; IPR006909; Rad21/Rec8_C_eu.
DR   InterPro; IPR006910; Rad21_Rec8_N.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF04824; Rad21_Rec8; 1.
DR   Pfam; PF04825; Rad21_Rec8_N; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Cell cycle; Cell division; Centromere;
KW   Chromosome; Chromosome partition; Complete proteome;
KW   Direct protein sequencing; Disease mutation; DNA damage; DNA repair;
KW   Isopeptide bond; Mental retardation; Mitosis; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Ubl conjugation.
FT   CHAIN         1    631       Double-strand-break repair protein rad21
FT                                homolog.
FT                                /FTId=PRO_0000097872.
FT   REGION      287    403       Interaction with WAPL and PDS5B.
FT                                {ECO:0000269|PubMed:19696148}.
FT   REGION      362    403       Interaction with STAG1.
FT                                {ECO:0000269|PubMed:19696148}.
FT   COMPBIAS    469    510       Pro-rich.
FT   SITE        172    173       Cleavage; by ESPL1.
FT   SITE        279    280       Cleavage; by caspase-3 or caspase-7.
FT   SITE        450    451       Cleavage; by ESPL1.
FT   MOD_RES      46     46       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     153    153       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     175    175       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     249    249       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     394    394       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     454    454       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     545    545       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     623    623       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK     48     48       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    216    216       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    418    418       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VARIANT     376    376       P -> R (in CDLS4; dbSNP:rs387907212).
FT                                {ECO:0000269|PubMed:22633399}.
FT                                /FTId=VAR_068691.
FT   VARIANT     481    481       G -> R (in dbSNP:rs755168088).
FT                                {ECO:0000269|PubMed:11483345}.
FT                                /FTId=VAR_014281.
FT   VARIANT     585    585       C -> R (in CDLS4; dbSNP:rs387907213).
FT                                {ECO:0000269|PubMed:22633399}.
FT                                /FTId=VAR_068692.
FT   MUTAGEN     172    172       R->A: Abolishes first cleavage by ESPL1.
FT                                {ECO:0000269|PubMed:11509732}.
FT   MUTAGEN     279    279       D->A: Abolishes cleavage by caspase-3.
FT                                {ECO:0000269|PubMed:11875078,
FT                                ECO:0000269|PubMed:12417729}.
FT   MUTAGEN     450    450       R->A: Abolishes second cleavage by ESPL1.
FT                                {ECO:0000269|PubMed:11509732}.
FT   CONFLICT    136    136       N -> I (in Ref. 1; CAA66940).
FT                                {ECO:0000305}.
FT   HELIX       334    342       {ECO:0000244|PDB:4PJW}.
FT   HELIX       345    347       {ECO:0000244|PDB:4PK7}.
FT   HELIX       358    366       {ECO:0000244|PDB:4PJW}.
FT   HELIX       369    372       {ECO:0000244|PDB:4PJW}.
FT   HELIX       383    390       {ECO:0000244|PDB:4PJW}.
FT   TURN        391    393       {ECO:0000244|PDB:4PK7}.
SQ   SEQUENCE   631 AA;  71690 MW;  7D4A6EA6392BE73D CRC64;
     MFYAHFVLSK RGPLAKIWLA AHWDKKLTKA HVFECNLESS VESIISPKVK MALRTSGHLL
     LGVVRIYHRK AKYLLADCNE AFIKIKMAFR PGVVDLPEEN REAAYNAITL PEEFHDFDQP
     LPDLDDIDVA QQFSLNQSRV EEITMREEVG NISILQENDF GDFGMDDREI MREGSAFEDD
     DMLVSTTTSN LLLESEQSTS NLNEKINHLE YEDQYKDDNF GEGNDGGILD DKLISNNDGG
     IFDDPPALSE AGVMLPEQPA HDDMDEDDNV SMGGPDSPDS VDPVEPMPTM TDQTTLVPNE
     EEAFALEPID ITVKETKAKR KRKLIVDSVK ELDSKTIRAQ LSDYSDIVTT LDLAPPTKKL
     MMWKETGGVE KLFSLPAQPL WNNRLLKLFT RCLTPLVPED LRKRRKGGEA DNLDEFLKEF
     ENPEVPREDQ QQQHQQRDVI DEPIIEEPSR LQESVMEASR TNIDESAMPP PPPQGVKRKA
     GQIDPEPVMP PQQVEQMEIP PVELPPEEPP NICQLIPELE LLPEKEKEKE KEKEDDEEEE
     DEDASGGDQD QEERRWNKRT QQMLHGLQRA LAKTGAESIS LLELCRNTNR KQAAAKFYSF
     LVLKKQQAIE LTQEEPYSDI IATPGPRFHI I
//
ID   RECQ4_HUMAN             Reviewed;        1208 AA.
AC   O94761; Q3Y424; Q96DW2; Q96F55;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   28-FEB-2018, entry version 170.
DE   RecName: Full=ATP-dependent DNA helicase Q4;
DE            EC=3.6.4.12;
DE   AltName: Full=DNA helicase, RecQ-like type 4;
DE            Short=RecQ4;
DE   AltName: Full=RTS;
DE   AltName: Full=RecQ protein-like 4;
GN   Name=RECQL4; Synonyms=RECQ4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=9878247; DOI=10.1006/geno.1998.5595;
RA   Kitao S., Ohsugi I., Ichikawa K., Goto M., Furuichi Y., Shimamoto A.;
RT   "Cloning of two new human helicase genes of the RecQ family:
RT   biological significance of multiple species in higher eukaryotes.";
RL   Genomics 54:443-452(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBCELLULAR LOCATION, AND
RP   INVOLVEMENT IN ROTHMUND-THOMSON SYNDROME.
RX   PubMed=10552928; DOI=10.1006/geno.1999.5959;
RA   Kitao S., Lindor N.M., Shiratori M., Furuichi Y., Shimamoto A.;
RT   "Rothmund-Thomson syndrome responsible gene, RECQL4: genomic structure
RT   and products.";
RL   Genomics 61:268-276(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-54; GLY-71;
RP   SER-92; SER-189; ASP-267; THR-273; LYS-301; CYS-522; HIS-522; LEU-591;
RP   SER-793; MET-799; THR-964; LYS-976; TRP-1004; GLN-1005; GLN-1021;
RP   THR-1045; SER-1105; ASP-1105; HIS-1106; ARG-1113 AND PHE-1148.
RG   NIEHS SNPs program;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 468-1208.
RC   TISSUE=Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INDUCTION.
RX   PubMed=11032027; DOI=10.1038/sj.onc.1203841;
RA   Kawabe T., Tsuyama N., Kitao S., Nishikawa K., Shimamoto A.,
RA   Shiratori M., Matsumoto T., Anno K., Sato T., Mitsui Y., Seki M.,
RA   Enomoto T., Goto M., Ellis N.A., Ide T., Furuichi Y., Sugimoto M.;
RT   "Differential regulation of human RecQ family helicases in cell
RT   transformation and cell cycle.";
RL   Oncogene 19:4764-4772(2000).
RN   [6]
RP   INVOLVEMENT IN RAPADILINOS.
RX   PubMed=12952869; DOI=10.1093/hmg/ddg306;
RA   Siitonen H.A., Kopra O., Kaeaeriaeinen H., Haravuori H., Winter R.M.,
RA   Saeaemaenen A.-M., Peltonen L., Kestilae M.;
RT   "Molecular defect of RAPADILINO syndrome expands the phenotype
RT   spectrum of RECQL diseases.";
RL   Hum. Mol. Genet. 12:2837-2844(2003).
RN   [7]
RP   INTERACTION WITH UBR1 AND UBR2, SUBCELLULAR LOCATION, FUNCTION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15317757; DOI=10.1093/hmg/ddh269;
RA   Yin J., Kwon Y.T., Varshavsky A., Wang W.;
RT   "RECQL4, mutated in the Rothmund-Thomson and RAPADILINO syndromes,
RT   interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule
RT   pathway.";
RL   Hum. Mol. Genet. 13:2421-2430(2004).
RN   [8]
RP   INTERACTION WITH MCM10.
RX   PubMed=19696745; DOI=10.1038/emboj.2009.235;
RA   Xu X., Rochette P.J., Feyissa E.A., Su T.V., Liu Y.;
RT   "MCM10 mediates RECQ4 association with MCM2-7 helicase complex during
RT   DNA replication.";
RL   EMBO J. 28:3005-3014(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-178 AND SER-180,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   VARIANTS ASP-267 AND GLN-1005.
RX   PubMed=12601557; DOI=10.1007/s100380300016;
RA   Roversi G., Beghini A., Zambruno G., Paradisi M., Larizza L.;
RT   "Identification of two novel RECQL4exonic SNPs and genomic
RT   characterization of the IVS12 minisatellite.";
RL   J. Hum. Genet. 48:107-109(2003).
RN   [11]
RP   VARIANTS GLN-355; SER-441 AND 857-CYS--THR-858 DEL.
RX   PubMed=15221963; DOI=10.1002/ijc.20269;
RA   Nishijo K., Nakayama T., Aoyama T., Okamoto T., Ishibe T., Yasura K.,
RA   Shima Y., Shibata K.R., Tsuboyama T., Nakamura T., Toguchida J.;
RT   "Mutation analysis of the RECQL4 gene in sporadic osteosarcomas.";
RL   Int. J. Cancer 111:367-372(2004).
RN   [12]
RP   VARIANT BGS TRP-1021, AND VARIANT THR-523.
RX   PubMed=15964893; DOI=10.1136/jmg.2005.031781;
RA   Van Maldergem L., Siitonen H.A., Jalkh N., Chouery E., De Roy M.,
RA   Delague V., Muenke M., Jabs E.W., Cai J., Wang L.L., Plon S.E.,
RA   Fourneau C., Kestilae M., Gillerot Y., Megarbane A., Verloes A.;
RT   "Revisiting the craniosynostosis-radial ray hypoplasia association:
RT   Baller-Gerold syndrome caused by mutations in the RECQL4 gene.";
RL   J. Med. Genet. 43:148-152(2006).
CC   -!- FUNCTION: DNA-dependent ATPase. May modulate chromosome
CC       segregation. {ECO:0000269|PubMed:15317757}.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O = ADP + phosphate.
CC   -!- SUBUNIT: Interacts with UBR1 and UBR2. Interacts with MCM10; this
CC       interaction regulates RECQL4 unwinding activity.
CC       {ECO:0000269|PubMed:15317757, ECO:0000269|PubMed:19696745}.
CC   -!- INTERACTION:
CC       P54274:TERF1; NbExp=2; IntAct=EBI-722861, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15317757}.
CC       Nucleus {ECO:0000269|PubMed:10552928}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       thymus and testis. {ECO:0000269|PubMed:9878247}.
CC   -!- INDUCTION: Up-regulated in actively dividing cells.
CC       {ECO:0000269|PubMed:11032027}.
CC   -!- DISEASE: Rothmund-Thomson syndrome (RTS) [MIM:268400]:
CC       Characterized by dermatological features such as atrophy,
CC       pigmentation, and telangiectasia and frequently accompanied by
CC       juvenile cataract, saddle nose, congenital bone defects,
CC       disturbances of hair growth, and hypogonadism.
CC       {ECO:0000269|PubMed:10552928}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: RAPADILINO syndrome (RAPADILINOS) [MIM:266280]: Disease
CC       characterized by radial and patellar aplasia or hypoplasia.
CC       {ECO:0000269|PubMed:12952869}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Baller-Gerold syndrome (BGS) [MIM:218600]: An autosomal
CC       recessive syndrome characterized by short stature,
CC       craniosynostosis, absent or hypoplastic radii, short and curved
CC       ulna, fused carpal bones and absent carpals, metacarpals and
CC       phalanges. Some patients manifest poikiloderma. Cases reported as
CC       Baller-Gerold syndrome have phenotypic overlap with several other
CC       disorders, including Saethre-Chotzen syndrome.
CC       {ECO:0000269|PubMed:15964893}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the helicase family. RecQ subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH13277.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RECQL4ID285.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/recql4/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB006532; BAA74453.1; -; mRNA.
DR   EMBL; AB026546; BAA86899.1; -; Genomic_DNA.
DR   EMBL; DQ176868; AAZ85145.1; -; Genomic_DNA.
DR   EMBL; BC011602; AAH11602.2; -; mRNA.
DR   EMBL; BC013277; AAH13277.2; ALT_INIT; mRNA.
DR   CCDS; CCDS75804.1; -.
DR   RefSeq; NP_004251.3; NM_004260.3.
DR   UniGene; Hs.31442; -.
DR   PDB; 2KMU; NMR; -; A=1-54.
DR   PDB; 5LST; X-ray; 2.75 A; A=427-1116.
DR   PDBsum; 2KMU; -.
DR   PDBsum; 5LST; -.
DR   ProteinModelPortal; O94761; -.
DR   SMR; O94761; -.
DR   BioGrid; 114798; 30.
DR   DIP; DIP-48475N; -.
DR   IntAct; O94761; 8.
DR   iPTMnet; O94761; -.
DR   PhosphoSitePlus; O94761; -.
DR   BioMuta; RECQL4; -.
DR   EPD; O94761; -.
DR   MaxQB; O94761; -.
DR   PeptideAtlas; O94761; -.
DR   PRIDE; O94761; -.
DR   GeneID; 9401; -.
DR   KEGG; hsa:9401; -.
DR   CTD; 9401; -.
DR   DisGeNET; 9401; -.
DR   GeneCards; RECQL4; -.
DR   GeneReviews; RECQL4; -.
DR   HGNC; HGNC:9949; RECQL4.
DR   HPA; HPA025821; -.
DR   MalaCards; RECQL4; -.
DR   MIM; 218600; phenotype.
DR   MIM; 266280; phenotype.
DR   MIM; 268400; phenotype.
DR   MIM; 603780; gene.
DR   neXtProt; NX_O94761; -.
DR   Orphanet; 1225; Baller-Gerold syndrome.
DR   Orphanet; 3021; RAPADILINO syndrome.
DR   Orphanet; 221016; Rothmund-Thomson syndrome type 2.
DR   PharmGKB; PA34316; -.
DR   HOGENOM; HOG000264957; -.
DR   HOVERGEN; HBG065925; -.
DR   InParanoid; O94761; -.
DR   KO; K10730; -.
DR   PhylomeDB; O94761; -.
DR   SIGNOR; O94761; -.
DR   ChiTaRS; RECQL4; human.
DR   EvolutionaryTrace; O94761; -.
DR   GeneWiki; RECQL4; -.
DR   GenomeRNAi; 9401; -.
DR   PRO; PR:O94761; -.
DR   Proteomes; UP000005640; Unplaced.
DR   CleanEx; HS_RECQL4; -.
DR   GO; GO:0000781; C:chromosome, telomeric region; IMP:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0036310; F:annealing helicase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0043140; F:ATP-dependent 3'-5' DNA helicase activity; IMP:UniProtKB.
DR   GO; GO:0000405; F:bubble DNA binding; IDA:UniProtKB.
DR   GO; GO:0009378; F:four-way junction helicase activity; IBA:GO_Central.
DR   GO; GO:0004386; F:helicase activity; TAS:BHF-UCL.
DR   GO; GO:0032357; F:oxidized purine DNA binding; IDA:BHF-UCL.
DR   GO; GO:0061821; F:telomeric D-loop binding; IDA:BHF-UCL.
DR   GO; GO:0006284; P:base-excision repair; IBA:GO_Central.
DR   GO; GO:0032508; P:DNA duplex unwinding; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006260; P:DNA replication; IDA:UniProtKB.
DR   GO; GO:0000733; P:DNA strand renaturation; IDA:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IBA:GO_Central.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0000723; P:telomere maintenance; IMP:BHF-UCL.
DR   GO; GO:0061820; P:telomeric D-loop disassembly; IDA:BHF-UCL.
DR   CDD; cd00079; HELICc; 1.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR004589; DNA_helicase_ATP-dep_RecQ.
DR   InterPro; IPR021110; DNA_rep_checkpnt_protein.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF11719; Drc1-Sld2; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00614; recQ_fam; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cataract; Complete proteome;
KW   Craniosynostosis; Cytoplasm; Disease mutation; Dwarfism; Helicase;
KW   Hydrolase; Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1   1208       ATP-dependent DNA helicase Q4.
FT                                /FTId=PRO_0000205053.
FT   DOMAIN      489    662       Helicase ATP-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00541}.
FT   DOMAIN      683    850       Helicase C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00542}.
FT   NP_BIND     502    509       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00541}.
FT   MOTIF       605    608       DEAH box.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     178    178       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     180    180       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT      54     54       Q -> R (in dbSNP:rs35198096).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025117.
FT   VARIANT      71     71       E -> G (in dbSNP:rs34642881).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025118.
FT   VARIANT      92     92       P -> S (in dbSNP:rs2721190).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025119.
FT   VARIANT     189    189       G -> S (in dbSNP:rs34371341).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025120.
FT   VARIANT     267    267       E -> D (common polymorphism;
FT                                dbSNP:rs4244612).
FT                                {ECO:0000269|PubMed:12601557,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_023295.
FT   VARIANT     273    273       A -> T (in dbSNP:rs34103564).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025121.
FT   VARIANT     301    301       E -> K (in dbSNP:rs34633809).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025122.
FT   VARIANT     355    355       R -> Q. {ECO:0000269|PubMed:15221963}.
FT                                /FTId=VAR_023296.
FT   VARIANT     441    441       P -> S. {ECO:0000269|PubMed:15221963}.
FT                                /FTId=VAR_023297.
FT   VARIANT     522    522       R -> C (in dbSNP:rs35407712).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025123.
FT   VARIANT     522    522       R -> H (in dbSNP:rs35842750).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025124.
FT   VARIANT     523    523       S -> T. {ECO:0000269|PubMed:15964893}.
FT                                /FTId=VAR_026590.
FT   VARIANT     591    591       P -> L (in dbSNP:rs2721191).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025125.
FT   VARIANT     793    793       P -> L (in dbSNP:rs35098923).
FT                                /FTId=VAR_057125.
FT   VARIANT     793    793       P -> S (in dbSNP:rs35098923).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025126.
FT   VARIANT     799    799       V -> M (in dbSNP:rs34293591).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025127.
FT   VARIANT     857    858       Missing.
FT                                /FTId=VAR_023298.
FT   VARIANT     964    964       P -> T (in dbSNP:rs33972310).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025128.
FT   VARIANT     976    976       E -> K (in dbSNP:rs35070885).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025129.
FT   VARIANT    1004   1004       R -> W (in dbSNP:rs36023964).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025130.
FT   VARIANT    1005   1005       R -> Q (in dbSNP:rs4251691).
FT                                {ECO:0000269|PubMed:12601557,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_023299.
FT   VARIANT    1021   1021       R -> Q (in dbSNP:rs34666647).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025131.
FT   VARIANT    1021   1021       R -> W (in BGS).
FT                                {ECO:0000269|PubMed:15964893}.
FT                                /FTId=VAR_026591.
FT   VARIANT    1043   1043       L -> P (in dbSNP:rs4925828).
FT                                /FTId=VAR_057126.
FT   VARIANT    1045   1045       A -> T (in dbSNP:rs35348691).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025132.
FT   VARIANT    1105   1105       G -> D (in dbSNP:rs36078464).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025133.
FT   VARIANT    1105   1105       G -> S (in dbSNP:rs34915097).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025134.
FT   VARIANT    1106   1106       R -> H (in dbSNP:rs34236392).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025135.
FT   VARIANT    1113   1113       G -> R (in dbSNP:rs35101495).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025136.
FT   VARIANT    1148   1148       S -> F (in dbSNP:rs35346077).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025137.
FT   HELIX         1     21       {ECO:0000244|PDB:2KMU}.
FT   HELIX        28     31       {ECO:0000244|PDB:2KMU}.
FT   HELIX        36     52       {ECO:0000244|PDB:2KMU}.
FT   HELIX       458    460       {ECO:0000244|PDB:5LST}.
FT   HELIX       467    476       {ECO:0000244|PDB:5LST}.
FT   HELIX       485    492       {ECO:0000244|PDB:5LST}.
FT   TURN        493    495       {ECO:0000244|PDB:5LST}.
FT   STRAND      498    501       {ECO:0000244|PDB:5LST}.
FT   STRAND      503    505       {ECO:0000244|PDB:5LST}.
FT   TURN        506    509       {ECO:0000244|PDB:5LST}.
FT   HELIX       510    522       {ECO:0000244|PDB:5LST}.
FT   STRAND      526    530       {ECO:0000244|PDB:5LST}.
FT   HELIX       533    536       {ECO:0000244|PDB:5LST}.
FT   TURN        544    546       {ECO:0000244|PDB:5LST}.
FT   STRAND      548    551       {ECO:0000244|PDB:5LST}.
FT   TURN        556    558       {ECO:0000244|PDB:5LST}.
FT   HELIX       559    570       {ECO:0000244|PDB:5LST}.
FT   STRAND      575    579       {ECO:0000244|PDB:5LST}.
FT   HELIX       581    585       {ECO:0000244|PDB:5LST}.
FT   STRAND      586    588       {ECO:0000244|PDB:5LST}.
FT   TURN        593    595       {ECO:0000244|PDB:5LST}.
FT   STRAND      599    605       {ECO:0000244|PDB:5LST}.
FT   HELIX       607    610       {ECO:0000244|PDB:5LST}.
FT   HELIX       620    630       {ECO:0000244|PDB:5LST}.
FT   STRAND      637    642       {ECO:0000244|PDB:5LST}.
FT   HELIX       646    655       {ECO:0000244|PDB:5LST}.
FT   STRAND      674    679       {ECO:0000244|PDB:5LST}.
FT   HELIX       684    693       {ECO:0000244|PDB:5LST}.
FT   TURN        695    699       {ECO:0000244|PDB:5LST}.
FT   STRAND      703    709       {ECO:0000244|PDB:5LST}.
FT   HELIX       710    723       {ECO:0000244|PDB:5LST}.
FT   STRAND      739    744       {ECO:0000244|PDB:5LST}.
FT   HELIX       750    761       {ECO:0000244|PDB:5LST}.
FT   STRAND      765    771       {ECO:0000244|PDB:5LST}.
FT   TURN        772    774       {ECO:0000244|PDB:5LST}.
FT   STRAND      785    790       {ECO:0000244|PDB:5LST}.
FT   HELIX       795    802       {ECO:0000244|PDB:5LST}.
FT   STRAND      807    810       {ECO:0000244|PDB:5LST}.
FT   STRAND      812    817       {ECO:0000244|PDB:5LST}.
FT   HELIX       823    835       {ECO:0000244|PDB:5LST}.
FT   HELIX       839    849       {ECO:0000244|PDB:5LST}.
FT   STRAND      900    905       {ECO:0000244|PDB:5LST}.
FT   HELIX       906    913       {ECO:0000244|PDB:5LST}.
FT   HELIX       917    929       {ECO:0000244|PDB:5LST}.
FT   STRAND      931    933       {ECO:0000244|PDB:5LST}.
FT   STRAND      936    948       {ECO:0000244|PDB:5LST}.
FT   HELIX       952    957       {ECO:0000244|PDB:5LST}.
FT   TURN        958    962       {ECO:0000244|PDB:5LST}.
FT   HELIX       964    972       {ECO:0000244|PDB:5LST}.
FT   STRAND      985    988       {ECO:0000244|PDB:5LST}.
FT   HELIX       989    996       {ECO:0000244|PDB:5LST}.
FT   HELIX      1000   1008       {ECO:0000244|PDB:5LST}.
FT   HELIX      1009   1011       {ECO:0000244|PDB:5LST}.
FT   STRAND     1016   1018       {ECO:0000244|PDB:5LST}.
FT   STRAND     1027   1039       {ECO:0000244|PDB:5LST}.
FT   HELIX      1045   1078       {ECO:0000244|PDB:5LST}.
FT   STRAND     1082   1085       {ECO:0000244|PDB:5LST}.
FT   HELIX      1086   1088       {ECO:0000244|PDB:5LST}.
FT   STRAND     1089   1091       {ECO:0000244|PDB:5LST}.
FT   HELIX      1094   1108       {ECO:0000244|PDB:5LST}.
SQ   SEQUENCE   1208 AA;  133077 MW;  CB809A7765AB48A1 CRC64;
     MERLRDVRER LQAWERAFRR QRGRRPSQDD VEAAPEETRA LYREYRTLKR TTGQAGGGLR
     SSESLPAAAE EAPEPRCWGP HLNRAATKSP QPTPGRSRQG SVPDYGQRLK ANLKGTLQAG
     PALGRRPWPL GRASSKASTP KPPGTGPVPS FAEKVSDEPP QLPEPQPRPG RLQHLQASLS
     QRLGSLDPGW LQRCHSEVPD FLGAPKACRP DLGSEESQLL IPGESAVLGP GAGSQGPEAS
     AFQEVSIRVG SPQPSSSGGE KRRWNEEPWE SPAQVQQESS QAGPPSEGAG AVAVEEDPPG
     EPVQAQPPQP CSSPSNPRYH GLSPSSQARA GKAEGTAPLH IFPRLARHDR GNYVRLNMKQ
     KHYVRGRALR SRLLRKQAWK QKWRKKGECF GGGGATVTTK ESCFLNEQFD HWAAQCPRPA
     SEEDTDAVGP EPLVPSPQPV PEVPSLDPTV LPLYSLGPSG QLAETPAEVF QALEQLGHQA
     FRPGQERAVM RILSGISTLL VLPTGAGKSL CYQLPALLYS RRSPCLTLVV SPLLSLMDDQ
     VSGLPPCLKA ACIHSGMTRK QRESVLQKIR AAQVHVLMLT PEALVGAGGL PPAAQLPPVA
     FACIDEAHCL SQWSHNFRPC YLRVCKVLRE RMGVHCFLGL TATATRRTAS DVAQHLAVAE
     EPDLHGPAPV PTNLHLSVSM DRDTDQALLT LLQGKRFQNL DSIIIYCNRR EDTERIAALL
     RTCLHAAWVP GSGGRAPKTT AEAYHAGMCS RERRRVQRAF MQGQLRVVVA TVAFGMGLDR
     PDVRAVLHLG LPPSFESYVQ AVGRAGRDGQ PAHCHLFLQP QGEDLRELRR HVHADSTDFL
     AVKRLVQRVF PACTCTCTRP PSEQEGAVGG ERPVPKYPPQ EAEQLSHQAA PGPRRVCMGH
     ERALPIQLTV QALDMPEEAI ETLLCYLELH PHHWLELLAT TYTHCRLNCP GGPAQLQALA
     HRCPPLAVCL AQQLPEDPGQ GSSSVEFDMV KLVDSMGWEL ASVRRALCQL QWDHEPRTGV
     RRGTGVLVEF SELAFHLRSP GDLTAEEKDQ ICDFLYGRVQ ARERQALARL RRTFQAFHSV
     AFPSCGPCLE QQDEERSTRL KDLLGRYFEE EEGQEPGGME DAQGPEPGQA RLQDWEDQVR
     CDIRQFLSLR PEEKFSSRAV ARIFHGIGSP CYPAQVYGQD RRFWRKYLHL SFHALVGLAT
     EELLQVAR
//
ID   A0A024R324_HUMAN        Unreviewed;       193 AA.
AC   A0A024R324;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-FEB-2018, entry version 36.
DE   SubName: Full=Ras homolog gene family, member A, isoform CRA_a {ECO:0000313|EMBL:EAW64979.1};
GN   Name=RHOA {ECO:0000313|EMBL:EAW64979.1};
GN   ORFNames=hCG_20136 {ECO:0000313|EMBL:EAW64979.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW64979.1};
RN   [1] {ECO:0000313|EMBL:EAW64979.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW64979.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471055; EAW64978.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64979.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64980.1; -; Genomic_DNA.
DR   RefSeq; NP_001300870.1; NM_001313941.1.
DR   RefSeq; NP_001655.1; NM_001664.3.
DR   UniGene; Hs.247077; -.
DR   SMR; A0A024R324; -.
DR   GeneID; 387; -.
DR   KEGG; hsa:387; -.
DR   CTD; 387; -.
DR   EuPathDB; HostDB:ENSG00000067560.10; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   KO; K04513; -.
DR   OMA; QKIGARH; -.
DR   OrthoDB; EOG091G0QVS; -.
DR   ChiTaRS; RHOA; human.
DR   GenomeRNAi; 387; -.
DR   Bgee; ENSG00000067560; -.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0030027; C:lamellipodium; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0032587; C:ruffle membrane; IEA:Ensembl.
DR   GO; GO:0019003; F:GDP binding; IEA:Ensembl.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0051022; F:Rho GDP-dissociation inhibitor binding; IEA:Ensembl.
DR   GO; GO:0002363; P:alpha-beta T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0001998; P:angiotensin-mediated vasoconstriction involved in regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0043297; P:apical junction assembly; IEA:Ensembl.
DR   GO; GO:0043366; P:beta selection; IEA:Ensembl.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0046039; P:GTP metabolic process; IEA:Ensembl.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0033144; P:negative regulation of intracellular steroid hormone receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0090324; P:negative regulation of oxidative phosphorylation; IEA:Ensembl.
DR   GO; GO:1903427; P:negative regulation of reactive oxygen species biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   GO; GO:0042476; P:odontogenesis; IEA:Ensembl.
DR   GO; GO:0043931; P:ossification involved in bone maturation; IEA:Ensembl.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:1904695; P:positive regulation of vascular smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0050773; P:regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:1905244; P:regulation of modification of synaptic structure; IEA:Ensembl.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0033688; P:regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0003100; P:regulation of systemic arterial blood pressure by endothelin; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007266; P:Rho protein signal transduction; IEA:Ensembl.
DR   GO; GO:1902766; P:skeletal muscle satellite cell migration; ISS:AgBase.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IEA:Ensembl.
DR   GO; GO:0061383; P:trabecula morphogenesis; IEA:Ensembl.
DR   GO; GO:0044319; P:wound healing, spreading of cells; ISS:AgBase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   4: Predicted;
KW   GTP-binding {ECO:0000256|SAAS:SAAS00512948};
KW   Nucleotide-binding {ECO:0000256|SAAS:SAAS00512948}.
SQ   SEQUENCE   193 AA;  21768 MW;  C4DA2DC31FF858BC CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT
     AGQEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD
     LRNDEHTRRE LAKMKQEPVK PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ
     ARRGKKKSGC LVL
//
ID   B4DKN9_HUMAN            Unreviewed;       173 AA.
AC   B4DKN9;
DT   23-SEP-2008, integrated into UniProtKB/TrEMBL.
DT   23-SEP-2008, sequence version 1.
DT   28-FEB-2018, entry version 56.
DE   SubName: Full=cDNA FLJ57740, highly similar to Transforming protein RhoA {ECO:0000313|EMBL:BAG59251.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG59251.1};
RN   [1] {ECO:0000313|EMBL:BAG59251.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Colon {ECO:0000313|EMBL:BAG59251.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK296654; BAG59251.1; -; mRNA.
DR   RefSeq; NP_001300873.1; NM_001313944.1.
DR   UniGene; Hs.247077; -.
DR   ProteinModelPortal; B4DKN9; -.
DR   PeptideAtlas; B4DKN9; -.
DR   PRIDE; B4DKN9; -.
DR   GeneID; 387; -.
DR   CTD; 387; -.
DR   HOVERGEN; HBG009351; -.
DR   GO; GO:0005622; C:intracellular; IEA:InterPro.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   Pfam; PF00071; Ras; 2.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   2: Evidence at transcript level;
KW   GTP-binding {ECO:0000256|SAAS:SAAS00512948};
KW   Nucleotide-binding {ECO:0000256|SAAS:SAAS00512948}.
SQ   SEQUENCE   173 AA;  19570 MW;  32B8F0A4C2DB820D CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADYDRLR PLSYPDTDVI
     LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD LRNDEHTRRE LAKMKQEPVK
     PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ ARRGKKKSGC LVL
//
ID   C9JRM1_HUMAN            Unreviewed;        90 AA.
AC   C9JRM1;
DT   03-NOV-2009, integrated into UniProtKB/TrEMBL.
DT   03-NOV-2009, sequence version 1.
DT   31-JAN-2018, entry version 56.
DE   SubName: Full=Transforming protein RhoA {ECO:0000313|Ensembl:ENSP00000394483};
GN   Name=RHOA {ECO:0000313|Ensembl:ENSP00000394483};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000394483, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000394483}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [2] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [3] {ECO:0000313|Ensembl:ENSP00000394483}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
RN   [4] {ECO:0000213|PubMed:25944712}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000394483}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC104452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC121247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001300876.1; NM_001313947.1.
DR   UniGene; Hs.247077; -.
DR   ProteinModelPortal; C9JRM1; -.
DR   MaxQB; C9JRM1; -.
DR   PeptideAtlas; C9JRM1; -.
DR   PRIDE; C9JRM1; -.
DR   Ensembl; ENST00000454011; ENSP00000394483; ENSG00000067560.
DR   GeneID; 387; -.
DR   UCSC; uc062jta.1; human.
DR   CTD; 387; -.
DR   EuPathDB; HostDB:ENSG00000067560.10; -.
DR   HGNC; HGNC:667; RHOA.
DR   OpenTargets; ENSG00000067560; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   GeneTree; ENSGT00760000119020; -.
DR   ChiTaRS; RHOA; human.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000067560; -.
DR   ExpressionAtlas; C9JRM1; baseline and differential.
DR   GO; GO:0005525; F:GTP binding; IEA:InterPro.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Proteomics identification {ECO:0000213|EPD:C9JRM1,
KW   ECO:0000213|MaxQB:C9JRM1, ECO:0000213|PeptideAtlas:C9JRM1};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
SQ   SEQUENCE   90 AA;  9715 MW;  D149B6073D36E321 CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQKTSQKSGP
     QKSSISVPTC PSSWLGIRRI FGMMSTQGGS
//
ID   C9JX21_HUMAN            Unreviewed;       187 AA.
AC   C9JX21;
DT   03-NOV-2009, integrated into UniProtKB/TrEMBL.
DT   03-NOV-2009, sequence version 1.
DT   28-FEB-2018, entry version 66.
DE   SubName: Full=Transforming protein RhoA {ECO:0000313|Ensembl:ENSP00000413587};
GN   Name=RHOA {ECO:0000313|Ensembl:ENSP00000413587};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000413587, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000413587}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [2] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [3] {ECO:0000313|Ensembl:ENSP00000413587}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
RN   [4] {ECO:0000213|PubMed:25944712}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000413587}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC104452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC121247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001300872.1; NM_001313943.1.
DR   UniGene; Hs.247077; -.
DR   ProteinModelPortal; C9JX21; -.
DR   SMR; C9JX21; -.
DR   iPTMnet; C9JX21; -.
DR   MaxQB; C9JX21; -.
DR   PeptideAtlas; C9JX21; -.
DR   PRIDE; C9JX21; -.
DR   Ensembl; ENST00000422781; ENSP00000413587; ENSG00000067560.
DR   GeneID; 387; -.
DR   UCSC; uc062jtb.1; human.
DR   CTD; 387; -.
DR   EuPathDB; HostDB:ENSG00000067560.10; -.
DR   HGNC; HGNC:667; RHOA.
DR   OpenTargets; ENSG00000067560; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   GeneTree; ENSGT00760000119020; -.
DR   HOGENOM; HOG000233974; -.
DR   ChiTaRS; RHOA; human.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000067560; -.
DR   ExpressionAtlas; C9JX21; baseline and differential.
DR   GO; GO:0005622; C:intracellular; IEA:InterPro.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   GTP-binding {ECO:0000256|SAAS:SAAS00512948};
KW   Nucleotide-binding {ECO:0000256|SAAS:SAAS00512948};
KW   Proteomics identification {ECO:0000213|EPD:C9JX21,
KW   ECO:0000213|MaxQB:C9JX21, ECO:0000213|PeptideAtlas:C9JX21};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
SQ   SEQUENCE   187 AA;  21164 MW;  FC5FBC55C61CFE2A CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT
     AGQEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD
     LRNDEHTRRE LAKMKQEPHC VARLECCGTI LAQLQPPPPR FKRFPCLSLL SSWGYRRPLP
     HPGAGET
//
ID   RHOA_HUMAN              Reviewed;         193 AA.
AC   P61586; P06749; Q53HM4; Q5U024; Q9UDJ0; Q9UEJ4;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   28-FEB-2018, entry version 172.
DE   RecName: Full=Transforming protein RhoA;
DE   AltName: Full=Rho cDNA clone 12;
DE            Short=h12;
DE   Flags: Precursor;
GN   Name=RHOA; Synonyms=ARH12, ARHA, RHO12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3822842; DOI=10.1093/nar/15.4.1869;
RA   Yeramian P., Chardin P., Madaule P., Tavitian A.;
RT   "Nucleotide sequence of human rho cDNA clone 12.";
RL   Nucleic Acids Res. 15:1869-1869(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Retina;
RX   PubMed=7835413; DOI=10.1006/exer.1994.1102;
RA   Fagan K.P., Oliveira L., Pittler S.J.;
RT   "Sequence of rho small GTP-binding protein cDNAs from human retina and
RT   identification of novel 5' end cloning artifacts.";
RL   Exp. Eye Res. 59:235-237(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Adipose tissue;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Esophageal carcinoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 5-193.
RC   TISSUE=Mammary cancer;
RX   PubMed=8039707; DOI=10.1016/0378-1119(94)90382-4;
RA   Moscow J.A., He R., Gudas J.M., Cowan K.H.;
RT   "Utilization of multiple polyadenylation signals in the human RHOA
RT   protooncogene.";
RL   Gene 144:229-236(1994).
RN   [10]
RP   PROTEIN SEQUENCE OF 28-39; 45-57; 78-86; 130-144; 146-162 AND 165-184,
RP   AND ADP-RIBOSYLATION AT ASN-41 (MICROBIAL INFECTION).
RC   TISSUE=Platelet;
RX   PubMed=1328215;
RA   Nemoto Y., Namba T., Teru-uchi T., Ushikubi F., Morii N., Narumiya S.;
RT   "A rho gene product in human blood platelets. I. Identification of the
RT   platelet substrate for botulinum C3 ADP-ribosyltransferase as rhoA
RT   protein.";
RL   J. Biol. Chem. 267:20916-20920(1992).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 137-193.
RX   PubMed=1556108;
RA   Moscow J.A., Morrow C.S., He R., Mullenbach G.T., Cowan K.H.;
RT   "Structure and function of the 5'-flanking sequence of the human
RT   cytosolic selenium-dependent glutathione peroxidase gene (hgpx1).";
RL   J. Biol. Chem. 267:5949-5958(1992).
RN   [12]
RP   INTERACTION WITH ROCK1.
RX   PubMed=8617235;
RA   Ishizaki T., Maekawa M., Fujisawa K., Okawa K., Iwamatsu A.,
RA   Fujita A., Watanabe N., Saito Y., Kakizuka A., Morii N., Narumiya S.;
RT   "The small GTP-binding protein Rho binds to and activates a 160 kDa
RT   Ser/Thr protein kinase homologous to myotonic dystrophy kinase.";
RL   EMBO J. 15:1885-1893(1996).
RN   [13]
RP   INTERACTION WITH ROCK2.
RX   PubMed=8641286;
RA   Matsui T., Amano M., Yamamoto T., Chihara K., Nakafuku M., Ito M.,
RA   Nakano T., Okawa K., Iwamatsu A., Kaibuchi K.;
RT   "Rho-associated kinase, a novel serine/threonine kinase, as a putative
RT   target for small GTP binding protein Rho.";
RL   EMBO J. 15:2208-2216(1996).
RN   [14]
RP   FUNCTION.
RX   PubMed=8910519; DOI=10.1074/jbc.271.46.28772;
RA   Quilliam L.A., Lambert Q.T., Mickelson-Young L.A., Westwick J.K.,
RA   Sparks A.B., Kay B.K., Jenkins N.A., Gilbert D.J., Copeland N.G.,
RA   Der C.J.;
RT   "Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein
RT   and potential effector of Rho protein signaling.";
RL   J. Biol. Chem. 271:28772-28776(1996).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH PKN2.
RX   PubMed=9121475; DOI=10.1128/MCB.17.4.2247;
RA   Vincent S., Settleman J.;
RT   "The PRK2 kinase is a potential effector target of both Rho and Rac
RT   GTPases and regulates actin cytoskeletal organization.";
RL   Mol. Cell. Biol. 17:2247-2256(1997).
RN   [16]
RP   FUNCTION, INTERACTION WITH KCNA2, AND SUBCELLULAR LOCATION.
RX   PubMed=9635436; DOI=10.1016/S0092-8674(00)81212-X;
RA   Cachero T.G., Morielli A.D., Peralta E.G.;
RT   "The small GTP-binding protein RhoA regulates a delayed rectifier
RT   potassium channel.";
RL   Cell 93:1077-1085(1998).
RN   [17]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=9857026; DOI=10.1074/jbc.273.52.34954;
RA   Ren Y., Li R., Zheng Y., Busch H.;
RT   "Cloning and characterization of GEF-H1, a microtubule-associated
RT   guanine nucleotide exchange factor for Rac and Rho GTPases.";
RL   J. Biol. Chem. 273:34954-34960(1998).
RN   [18]
RP   INTERACTION WITH DGKQ, AND MUTAGENESIS OF TYR-34.
RX   PubMed=10066731; DOI=10.1074/jbc.274.11.6820;
RA   Houssa B., de Widt J., Kranenburg O., Moolenaar W.H.,
RA   van Blitterswijk W.J.;
RT   "Diacylglycerol kinase theta binds to and is negatively regulated by
RT   active RhoA.";
RL   J. Biol. Chem. 274:6820-6822(1999).
RN   [19]
RP   INTERACTION WITH HRSV PROTEIN F.
RX   PubMed=10438814;
RA   Pastey M.K., Crowe J.E. Jr., Graham B.S.;
RT   "RhoA interacts with the fusion glycoprotein of respiratory syncytial
RT   virus and facilitates virus-induced syncytium formation.";
RL   J. Virol. 73:7262-7270(1999).
RN   [20]
RP   INTERACTION WITH RTKN.
RX   PubMed=10940294; DOI=10.1074/jbc.M000465200;
RA   Reynaud C., Fabre S., Jalinot P.;
RT   "The PDZ protein TIP-1 interacts with the Rho effector rhotekin and is
RT   involved in Rho signaling to the serum response element.";
RL   J. Biol. Chem. 275:33962-33968(2000).
RN   [21]
RP   PHOSPHORYLATION AT SER-188 BY PRKG1.
RX   PubMed=11162591; DOI=10.1006/bbrc.2000.4194;
RA   Sawada N., Itoh H., Yamashita J., Doi K., Inoue M., Masatsugu K.,
RA   Fukunaga Y., Sakaguchi S., Sone M., Yamahara K., Yurugi T., Nakao K.;
RT   "cGMP-dependent protein kinase phosphorylates and inactivates RhoA.";
RL   Biochem. Biophys. Res. Commun. 280:798-805(2001).
RN   [22]
RP   INTERACTION WITH AKAP13.
RX   PubMed=11696353; DOI=10.1016/S0014-5793(01)02995-7;
RA   Klussmann E., Edemir B., Pepperle B., Tamma G., Henn V.,
RA   Klauschenz E., Hundsrucker C., Maric K., Rosenthal W.;
RT   "Ht31: the first protein kinase A anchoring protein to integrate
RT   protein kinase A and Rho signaling.";
RL   FEBS Lett. 507:264-268(2001).
RN   [23]
RP   INTERACTION WITH ARHGEF3.
RX   PubMed=12221096; DOI=10.1074/jbc.M207401200;
RA   Arthur W.T., Ellerbroek S.M., Der C.J., Burridge K., Wennerberg K.;
RT   "XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not
RT   RhoC.";
RL   J. Biol. Chem. 277:42964-42972(2002).
RN   [24]
RP   INTERACTION WITH YERSINIA PESTIS YOPT, CLEAVAGE (MICROBIAL INFECTION),
RP   AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=12062101; DOI=10.1016/S0092-8674(02)00766-3;
RA   Shao F., Merritt P.M., Bao Z., Innes R.W., Dixon J.E.;
RT   "A Yersinia effector and a Pseudomonas avirulence protein define a
RT   family of cysteine proteases functioning in bacterial pathogenesis.";
RL   Cell 109:575-588(2002).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH PLCE1.
RX   PubMed=12900402; DOI=10.1074/jbc.M306904200;
RA   Wing M.R., Snyder J.T., Sondek J., Harden T.K.;
RT   "Direct activation of phospholipase C-epsilon by Rho.";
RL   J. Biol. Chem. 278:41253-41258(2003).
RN   [26]
RP   INTERACTION WITH YERSINIA PSEUDOTUBERCULOSIS YOPT, CLEAVAGE (MICROBIAL
RP   INFECTION), MUTAGENESIS OF LEU-193, AND FUNCTION (MICROBIAL
RP   INFECTION).
RX   PubMed=12538863; DOI=10.1073/pnas.252770599;
RA   Shao F., Vacratsis P.O., Bao Z., Bowers K.E., Fierke C.A., Dixon J.E.;
RT   "Biochemical characterization of the Yersinia YopT protease: cleavage
RT   site and recognition elements in Rho GTPases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:904-909(2003).
RN   [27]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16103226; DOI=10.1083/jcb.200501097;
RA   Yuce O., Piekny A., Glotzer M.;
RT   "An ECT2-centralspindlin complex regulates the localization and
RT   function of RhoA.";
RL   J. Cell Biol. 170:571-582(2005).
RN   [28]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16236794; DOI=10.1091/mbc.E05-06-0569;
RA   Kamijo K., Ohara N., Abe M., Uchimura T., Hosoya H., Lee J.S.,
RA   Miki T.;
RT   "Dissecting the role of Rho-mediated signaling in contractile ring
RT   formation.";
RL   Mol. Biol. Cell 17:43-55(2006).
RN   [29]
RP   INTERACTION WITH PKP4, AND SUBCELLULAR LOCATION.
RX   PubMed=17115030; DOI=10.1038/ncb1504;
RA   Wolf A., Keil R., Gotzl O., Mun A., Schwarze K., Lederer M.,
RA   Huttelmaier S., Hatzfeld M.;
RT   "The armadillo protein p0071 regulates Rho signalling during
RT   cytokinesis.";
RL   Nat. Cell Biol. 8:1432-1440(2006).
RN   [30]
RP   FUNCTION.
RX   PubMed=19934221; DOI=10.1242/jcs.053728;
RA   Bristow J.M., Sellers M.H., Majumdar D., Anderson B., Hu L.,
RA   Webb D.J.;
RT   "The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin
RT   dynamics and thereby regulate cell migration.";
RL   J. Cell Sci. 122:4535-4546(2009).
RN   [31]
RP   FUNCTION.
RX   PubMed=19403695; DOI=10.1091/mbc.E08-10-1074;
RA   Stirling L., Williams M.R., Morielli A.D.;
RT   "Dual roles for RHOA/RHO-kinase in the regulated trafficking of a
RT   voltage-sensitive potassium channel.";
RL   Mol. Biol. Cell 20:2991-3002(2009).
RN   [32]
RP   AMPYLATION AT TYR-34 (MICROBIAL INFECTION), AND MUTAGENESIS OF TYR-34.
RX   PubMed=19362538; DOI=10.1016/j.molcel.2009.03.008;
RA   Worby C.A., Mattoo S., Kruger R.P., Corbeil L.B., Koller A.,
RA   Mendez J.C., Zekarias B., Lazar C., Dixon J.E.;
RT   "The fic domain: regulation of cell signaling by adenylylation.";
RL   Mol. Cell 34:93-103(2009).
RN   [33]
RP   UBIQUITINATION.
RX   PubMed=19782033; DOI=10.1016/j.molcel.2009.09.004;
RA   Chen Y., Yang Z., Meng M., Zhao Y., Dong N., Yan H., Liu L., Ding M.,
RA   Peng H.B., Shao F.;
RT   "Cullin mediates degradation of RhoA through evolutionarily conserved
RT   BTB adaptors to control actin cytoskeleton structure and cell
RT   movement.";
RL   Mol. Cell 35:841-855(2009).
RN   [34]
RP   AMPYLATION AT THR-37 (MICROBIAL INFECTION).
RX   PubMed=19039103; DOI=10.1126/science.1166382;
RA   Yarbrough M.L., Li Y., Kinch L.N., Grishin N.V., Ball H.L., Orth K.;
RT   "AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding
RT   and downstream signaling.";
RL   Science 323:269-272(2009).
RN   [35]
RP   MUTAGENESIS OF GLY-14.
RX   PubMed=19948726; DOI=10.1074/jbc.M109.088427;
RA   Chatterjee A., Wang L., Armstrong D.L., Rossie S.;
RT   "Activated Rac1 GTPase translocates protein phosphatase 5 to the cell
RT   membrane and stimulates phosphatase activity in vitro.";
RL   J. Biol. Chem. 285:3872-3882(2010).
RN   [36]
RP   INTERACTION WITH ARHGDIA.
RX   PubMed=20400958; DOI=10.1038/ncb2049;
RA   Boulter E., Garcia-Mata R., Guilluy C., Dubash A., Rossi G.,
RA   Brennwald P.J., Burridge K.;
RT   "Regulation of Rho GTPase crosstalk, degradation and activity by
RT   RhoGDI1.";
RL   Nat. Cell Biol. 12:477-483(2010).
RN   [37]
RP   FUNCTION.
RX   PubMed=20937854; DOI=10.1073/pnas.1000975107;
RA   Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.;
RT   "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the
RT   plasma membrane of migrating cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   ENZYME REGULATION.
RX   PubMed=21565175; DOI=10.1016/j.bbrc.2011.04.116;
RA   Naji L., Pacholsky D., Aspenstrom P.;
RT   "ARHGAP30 is a Wrch-1-interacting protein involved in actin dynamics
RT   and cell adhesion.";
RL   Biochem. Biophys. Res. Commun. 409:96-102(2011).
RN   [40]
RP   INTERACTION WITH RACK1.
RX   PubMed=20499158; DOI=10.1007/s10549-010-0955-3;
RA   Cao X.X., Xu J.D., Xu J.W., Liu X.L., Cheng Y.Y., Li Q.Q., Xu Z.D.,
RA   Liu X.P.;
RT   "RACK1 promotes breast carcinoma migration/metastasis via activation
RT   of the RhoA/Rho kinase pathway.";
RL   Breast Cancer Res. Treat. 126:555-563(2011).
RN   [41]
RP   FUNCTION, AND INTERACTION WITH PKN2.
RX   PubMed=20974804; DOI=10.1128/MCB.01001-10;
RA   Wallace S.W., Magalhaes A., Hall A.;
RT   "The Rho target PRK2 regulates apical junction formation in human
RT   bronchial epithelial cells.";
RL   Mol. Cell. Biol. 31:81-91(2011).
RN   [42]
RP   INTERACTION WITH DIAPH1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23325789; DOI=10.1091/mbc.E12-08-0597;
RA   Li D., Dammer E.B., Lucki N.C., Sewer M.B.;
RT   "cAMP-stimulated phosphorylation of diaphanous 1 regulates protein
RT   stability and interaction with binding partners in adrenocortical
RT   cells.";
RL   Mol. Biol. Cell 24:848-857(2013).
RN   [43]
RP   GLYCOSYLATION AT TYR-34 (MICROBIAL INFECTION).
RX   PubMed=24141704; DOI=10.1038/nsmb.2688;
RA   Jank T., Bogdanovic X., Wirth C., Haaf E., Spoerner M., Boehmer K.E.,
RA   Steinemann M., Orth J.H., Kalbitzer H.R., Warscheid B., Hunte C.,
RA   Aktories K.;
RT   "A bacterial toxin catalyzing tyrosine glycosylation of Rho and
RT   deamidation of Gq and Gi proteins.";
RL   Nat. Struct. Mol. Biol. 20:1273-1280(2013).
RN   [44]
RP   INTERACTION WITH RIPOR2.
RX   PubMed=25588844; DOI=10.1242/jcs.161497;
RA   Gao K., Tang W., Li Y., Zhang P., Wang D., Yu L., Wang C., Wu D.;
RT   "Front-signal-dependent accumulation of the RHOA inhibitor FAM65B at
RT   leading edges polarizes neutrophils.";
RL   J. Cell Sci. 128:992-1000(2015).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [46]
RP   INTERACTION WITH RIPOR1.
RX   PubMed=27807006; DOI=10.1242/jcs.198614;
RA   Mardakheh F.K., Self A., Marshall C.J.;
RT   "RHO binding to FAM65A regulates Golgi reorientation during cell
RT   migration.";
RL   J. Cell Sci. 129:4466-4479(2016).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   PubMed=9302995; DOI=10.1038/nsb0997-699;
RA   Wei Y., Zhang Y., Derewenda U., Liu X., Minor W., Nakamoto R.K.,
RA   Somlyo A.V., Somlyo A.P., Derewenda Z.S.;
RT   "Crystal structure of RhoA-GDP and its functional implications.";
RL   Nat. Struct. Biol. 4:699-703(1997).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 4-181 OF MUTANT VAL-14.
RX   PubMed=9545299; DOI=10.1074/jbc.273.16.9656;
RA   Ihara K., Muraguchi S., Kato M., Shimizu T., Shirakawa M., Kuroda S.,
RA   Kaibuchi K., Hakoshima T.;
RT   "Crystal structure of human RhoA in a dominantly active form complexed
RT   with a GTP analogue.";
RL   J. Biol. Chem. 273:9656-9666(1998).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-181 IN COMPLEX WITH PRKCL1.
RX   PubMed=10388627; DOI=10.1006/jsbi.1999.4114;
RA   Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K.,
RA   Hakoshima T.;
RT   "Biochemical and crystallographic characterization of a Rho effector
RT   domain of the protein serine/threonine kinase N in a complex with
RT   RhoA.";
RL   J. Struct. Biol. 126:166-170(1999).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 3-180 IN COMPLEX WITH GDP.
RX   PubMed=10748207; DOI=10.1074/jbc.M910274199;
RA   Shimizu T., Ihara K., Maesaki R., Kuroda S., Kaibuchi K.,
RA   Hakoshima T.;
RT   "An open conformation of switch I revealed by the crystal structure of
RT   a Mg2+-free form of RHOA complexed with GDP. Implications for the
RT   GDP/GTP exchange mechanism.";
RL   J. Biol. Chem. 275:18311-18317(2000).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   PubMed=11927263; DOI=10.1016/S1074-5521(02)00112-6;
RA   Graham D.L., Lowe P.N., Grime G.W., Marsh M., Rittinger K.,
RA   Smerdon S.J., Gamblin S.J., Eccleston J.F.;
RT   "MgF(3)(-) as a transition state analog of phosphoryl transfer.";
RL   Chem. Biol. 9:375-381(2002).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.81 ANGSTROMS) IN COMPLEX WITH MCF2.
RX   PubMed=12006984; DOI=10.1038/nsb796;
RA   Snyder J.T., Worthylake D.K., Rossman K.L., Betts L., Pruitt W.M.,
RA   Siderovski D.P., Der C.J., Sondek J.;
RT   "Structural basis for the selective activation of Rho GTPases by Dbl
RT   exchange factors.";
RL   Nat. Struct. Biol. 9:468-475(2002).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF MUTANT LEU-63 IN COMPLEX WITH
RP   A GTP ANALOG AND MG(2+).
RX   PubMed=12777804; DOI=10.1107/S0907444903005390;
RA   Longenecker K., Read P., Lin S.-K., Somlyo A.P., Nakamoto R.K.,
RA   Derewenda Z.S.;
RT   "Structure of a constitutively activated RhoA mutant (Q63L) at 1.55 A
RT   resolution.";
RL   Acta Crystallogr. D 59:876-880(2003).
CC   -!- FUNCTION: Regulates a signal transduction pathway linking plasma
CC       membrane receptors to the assembly of focal adhesions and actin
CC       stress fibers. Involved in a microtubule-dependent signal that is
CC       required for the myosin contractile ring formation during cell
CC       cycle cytokinesis. Plays an essential role in cleavage furrow
CC       formation. Required for the apical junction formation of
CC       keratinocyte cell-cell adhesion. Stimulates PKN2 kinase activity.
CC       May be an activator of PLCE1. Activated by ARHGEF2, which promotes
CC       the exchange of GDP for GTP. Essential for the SPATA13-mediated
CC       regulation of cell migration and adhesion assembly and
CC       disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an
CC       important role in ERBB2-dependent stabilization of microtubules at
CC       the cell cortex. It controls the localization of APC and CLASP2 to
CC       the cell membrane, via the regulation of GSK3B activity. In turn,
CC       membrane-bound APC allows the localization of the MACF1 to the
CC       cell membrane, which is required for microtubule capture and
CC       stabilization. Regulates a signal transduction pathway linking
CC       plasma membrane receptors to the assembly of focal adhesions and
CC       actin stress fibers. Involved in a microtubule-dependent signal
CC       that is required for the myosin contractile ring formation during
CC       cell cycle cytokinesis. Plays an essential role in cleavage furrow
CC       formation. Required for the apical junction formation of
CC       keratinocyte cell-cell adhesion. May be an activator of PLCE1.
CC       Activated by ARHGEF2, which promotes the exchange of GDP for GTP.
CC       Essential for the SPATA13-mediated regulation of cell migration
CC       and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1
CC       signaling pathway plays an important role in ERBB2-dependent
CC       stabilization of microtubules at the cell cortex. It controls the
CC       localization of APC and CLASP2 to the cell membrane, via the
CC       regulation of GSK3B activity. In turn, membrane-bound APC allows
CC       the localization of the MACF1 to the cell membrane, which is
CC       required for microtubule capture and stabilization (By
CC       similarity). Regulates KCNA2 potassium channel activity by
CC       reducing its location at the cell surface in response to CHRM1
CC       activation; promotes KCNA2 endocytosis (PubMed:9635436,
CC       PubMed:19403695). {ECO:0000250, ECO:0000269|PubMed:12900402,
CC       ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16236794,
CC       ECO:0000269|PubMed:19934221, ECO:0000269|PubMed:20937854,
CC       ECO:0000269|PubMed:20974804, ECO:0000269|PubMed:8910519,
CC       ECO:0000269|PubMed:9121475, ECO:0000269|PubMed:9635436}.
CC   -!- FUNCTION: (Microbial infection) Serves as a target for the yopT
CC       cysteine peptidase from Yersinia pestis, vector of the plague.
CC       {ECO:0000269|PubMed:12062101, ECO:0000269|PubMed:12538863}.
CC   -!- FUNCTION: (Microbial infection) Serves as a target for the yopT
CC       cysteine peptidase from Yersinia pseudotuberculosis, which causes
CC       gastrointestinal disorders. {ECO:0000269|PubMed:12062101,
CC       ECO:0000269|PubMed:12538863}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:12777804};
CC   -!- ENZYME REGULATION: GTP hydrolysis is stimulated by ARHGAP30.
CC       {ECO:0000269|PubMed:21565175}.
CC   -!- SUBUNIT: Interacts with ARHGEF28 (By similarity). Interacts (via
CC       GTP-bound form) with RIPOR1 (via N-terminus); this interaction
CC       links RHOA to STK24 and STK26 kinases (PubMed:27807006). Interacts
CC       with RIPOR2 (via active GTP- or inactive GDP-bound forms) isoform
CC       1 and isoform 2; these interactions are direct, block the loading
CC       of GTP to RHOA and decrease upon chemokine CCL19 stimulation in
CC       primary T lymphocytes (PubMed:25588844). Binds PRKCL1, ROCK1 and
CC       ROCK2. Interacts with ARHGEF2, ARHGEF3, NET1 and RTKN. Interacts
CC       with PLCE1 and AKAP13. Interacts with DIAPH1 (PubMed:23325789).
CC       Interacts (in the constitutively activated, GTP-bound form) with
CC       DGKQ. Interacts with human respiratory syncytial virus (HRSV)
CC       protein F; this interaction facilitates virus-induced syncytium
CC       formation. Interacts with RACK1; enhances RHOA activation.
CC       Interacts with PKP4; the interaction is detected at the midbody.
CC       Interacts (GTP-bound form preferentially) with PKN2; the
CC       interaction stimulates autophosphorylation and phosphorylation of
CC       PKN2. Interacts with ARHGDIA; this interaction inactivates and
CC       stabilizes RHOA. Interacts with ARHGDIB. Interacts (GTP-bound
CC       form) with KCNA2 (via cytoplasmic N-terminal domain)
CC       (PubMed:9635436). {ECO:0000250|UniProtKB:P61589,
CC       ECO:0000250|UniProtKB:Q9QUI0, ECO:0000269|PubMed:10066731,
CC       ECO:0000269|PubMed:10388627, ECO:0000269|PubMed:10438814,
CC       ECO:0000269|PubMed:10748207, ECO:0000269|PubMed:10940294,
CC       ECO:0000269|PubMed:11696353, ECO:0000269|PubMed:12006984,
CC       ECO:0000269|PubMed:12062101, ECO:0000269|PubMed:12221096,
CC       ECO:0000269|PubMed:12538863, ECO:0000269|PubMed:12777804,
CC       ECO:0000269|PubMed:12900402, ECO:0000269|PubMed:17115030,
CC       ECO:0000269|PubMed:19403695, ECO:0000269|PubMed:20400958,
CC       ECO:0000269|PubMed:20499158, ECO:0000269|PubMed:20974804,
CC       ECO:0000269|PubMed:23325789, ECO:0000269|PubMed:25588844,
CC       ECO:0000269|PubMed:27807006, ECO:0000269|PubMed:8617235,
CC       ECO:0000269|PubMed:8641286, ECO:0000269|PubMed:9121475,
CC       ECO:0000269|PubMed:9857026, ECO:0000305|PubMed:9635436}.
CC   -!- INTERACTION:
CC       Q15109:AGER; NbExp=2; IntAct=EBI-446668, EBI-1646426;
CC       Q07960:ARHGAP1; NbExp=2; IntAct=EBI-446668, EBI-602762;
CC       P52565:ARHGDIA; NbExp=5; IntAct=EBI-446668, EBI-712693;
CC       O15085:ARHGEF11; NbExp=8; IntAct=EBI-446668, EBI-311099;
CC       Q9NZN5:ARHGEF12; NbExp=2; IntAct=EBI-446668, EBI-821440;
CC       Q8IW93:ARHGEF19; NbExp=2; IntAct=EBI-446668, EBI-7799822;
CC       P46527:CDKN1B; NbExp=3; IntAct=EBI-446668, EBI-519280;
CC       Q9Y4D1:DAAM1; NbExp=5; IntAct=EBI-446668, EBI-2817289;
CC       O60610:DIAPH1; NbExp=3; IntAct=EBI-446668, EBI-3959709;
CC       O08808:Diaph1 (xeno); NbExp=3; IntAct=EBI-446668, EBI-1026445;
CC       Q9UKT9:IKZF3; NbExp=3; IntAct=EBI-446668, EBI-747204;
CC       Q6PDM6:Mcf2l (xeno); NbExp=3; IntAct=EBI-446668, EBI-602149;
CC       P19338:NCL; NbExp=3; IntAct=EBI-446668, EBI-346967;
CC       Q9Z0S9:Rabac1 (xeno); NbExp=3; IntAct=EBI-446668, EBI-476965;
CC       Q9Y4F9:RIPOR2; NbExp=4; IntAct=EBI-446668, EBI-2798942;
CC       Q13464:ROCK1; NbExp=4; IntAct=EBI-446668, EBI-876651;
CC       Q9BST9:RTKN; NbExp=6; IntAct=EBI-446668, EBI-446694;
CC       Q8C6B2:Rtkn (xeno); NbExp=4; IntAct=EBI-446668, EBI-1162441;
CC       Q15796:SMAD2; NbExp=2; IntAct=EBI-446668, EBI-1040141;
CC       Q9HCE7-2:SMURF1; NbExp=2; IntAct=EBI-446668, EBI-9845742;
CC       A0A0F6B1Q8:sseJ (xeno); NbExp=7; IntAct=EBI-446668, EBI-10760263;
CC       Q9FD10:sseJ (xeno); NbExp=3; IntAct=EBI-446668, EBI-10690199;
CC       Q15654:TRIP6; NbExp=3; IntAct=EBI-446668, EBI-742327;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor; Cytoplasmic
CC       side. Cytoplasm, cytoskeleton. Cleavage furrow. Cytoplasm, cell
CC       cortex {ECO:0000269|PubMed:9635436}. Midbody. Cell projection,
CC       lamellipodium {ECO:0000250}. Note=Localized to cell-cell contacts
CC       in calcium-treated keratinocytes (By similarity). Translocates to
CC       the equatorial region before furrow formation in a ECT2-dependent
CC       manner. Localizes to the equatorial cell cortex (at the site of
CC       the presumptive furrow) in early anaphase in a activated form and
CC       in a myosin- and actin-independent manner. {ECO:0000250}.
CC   -!- DOMAIN: The basic-rich region is essential for yopT recognition
CC       and cleavage.
CC   -!- PTM: (Microbial infection) Substrate for botulinum ADP-
CC       ribosyltransferase. {ECO:0000269|PubMed:1328215}.
CC   -!- PTM: (Microbial infection) Cleaved by yopT protease when the cell
CC       is infected by some Yersinia pathogens. This removes the lipid
CC       attachment, and leads to its displacement from plasma membrane and
CC       to subsequent cytoskeleton cleavage. {ECO:0000269|PubMed:12062101,
CC       ECO:0000269|PubMed:12538863}.
CC   -!- PTM: (Microbial infection) AMPylation at Tyr-34 and Thr-37 are
CC       mediated by bacterial enzymes in case of infection by H.somnus and
CC       V.parahaemolyticus, respectively. AMPylation occurs in the
CC       effector region and leads to inactivation of the GTPase activity
CC       by preventing the interaction with downstream effectors, thereby
CC       inhibiting actin assembly in infected cells. It is unclear whether
CC       some human enzyme mediates AMPylation; FICD has such ability in
CC       vitro but additional experiments remain to be done to confirm
CC       results in vivo. {ECO:0000269|PubMed:19039103,
CC       ECO:0000269|PubMed:19362538}.
CC   -!- PTM: (Microbial infection) Glycosylated at Tyr-34 by Photorhabdus
CC       asymbiotica toxin PAU_02230. Mono-O-GlcNAcylation by PAU_02230
CC       inhibits downstream signaling by an impaired interaction with
CC       diverse regulator and effector proteins of Rho and leads to actin
CC       disassembly. {ECO:0000269|PubMed:24141704}.
CC   -!- PTM: Phosphorylation by PRKG1 at Ser-188 inactivates RHOA
CC       signaling (PubMed:11162591). Phosphorylation by SLK at Ser-188 in
CC       response to AGTR2 activation (By similarity).
CC       {ECO:0000250|UniProtKB:P61589, ECO:0000269|PubMed:11162591}.
CC   -!- PTM: Ubiquitinated by the BCR(KCTD13) and BCR(TNFAIP1) E3
CC       ubiquitin ligase complexes, leading to its degradation by the
CC       proteasome, thereby regulating the actin cytoskeleton and synaptic
CC       transmission in neurons. {ECO:0000269|PubMed:19782033}.
CC   -!- SIMILARITY: Belongs to the small GTPase superfamily. Rho family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RHOAID42107ch3p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05026; CAA28690.1; -; mRNA.
DR   EMBL; L25080; AAC33178.1; -; mRNA.
DR   EMBL; AF498970; AAM21117.1; -; mRNA.
DR   EMBL; BT019870; AAV38673.1; -; mRNA.
DR   EMBL; AK222556; BAD96276.1; -; mRNA.
DR   EMBL; BX647063; CAE46190.1; -; mRNA.
DR   EMBL; AC104452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC121247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001360; AAH01360.1; -; mRNA.
DR   EMBL; BC005976; AAH05976.1; -; mRNA.
DR   EMBL; L09159; AAA50612.1; -; mRNA.
DR   EMBL; M83094; AAA67539.1; -; Genomic_DNA.
DR   CCDS; CCDS2795.1; -.
DR   PIR; A26675; TVHU12.
DR   RefSeq; NP_001300870.1; NM_001313941.1.
DR   RefSeq; NP_001655.1; NM_001664.3.
DR   UniGene; Hs.247077; -.
DR   PDB; 1A2B; X-ray; 2.40 A; A=1-181.
DR   PDB; 1CC0; X-ray; 5.00 A; A/C=1-190.
DR   PDB; 1CXZ; X-ray; 2.20 A; A=1-181.
DR   PDB; 1DPF; X-ray; 2.00 A; A=1-180.
DR   PDB; 1FTN; X-ray; 2.10 A; A=1-193.
DR   PDB; 1KMQ; X-ray; 1.55 A; A=4-181.
DR   PDB; 1LB1; X-ray; 2.81 A; B/D/F/H=1-190.
DR   PDB; 1OW3; X-ray; 1.80 A; B=1-193.
DR   PDB; 1S1C; X-ray; 2.60 A; A/B=1-181.
DR   PDB; 1TX4; X-ray; 1.65 A; B=3-179.
DR   PDB; 1X86; X-ray; 3.22 A; B/D/F/H=1-193.
DR   PDB; 1XCG; X-ray; 2.50 A; B/F=3-180.
DR   PDB; 2RGN; X-ray; 3.50 A; C/F=1-193.
DR   PDB; 3KZ1; X-ray; 2.70 A; E/F=1-181.
DR   PDB; 3LW8; X-ray; 1.85 A; A/B/C/D=2-181.
DR   PDB; 3LWN; X-ray; 2.28 A; A/B=2-181.
DR   PDB; 3LXR; X-ray; 1.68 A; A=2-181.
DR   PDB; 3MSX; X-ray; 1.65 A; A=1-180.
DR   PDB; 3T06; X-ray; 2.84 A; B/F=3-180.
DR   PDB; 4D0N; X-ray; 2.10 A; A=1-184.
DR   PDB; 4XH9; X-ray; 2.00 A; B/E=2-180.
DR   PDB; 4XOI; X-ray; 2.09 A; A/C=1-180.
DR   PDB; 4XSG; X-ray; 1.80 A; A=1-179.
DR   PDB; 4XSH; X-ray; 2.50 A; A=1-179.
DR   PDB; 5A0F; X-ray; 2.00 A; A=1-181.
DR   PDB; 5BWM; X-ray; 2.50 A; A=1-179.
DR   PDB; 5C2K; X-ray; 1.42 A; A=1-193.
DR   PDB; 5C4M; X-ray; 1.30 A; A=1-193.
DR   PDB; 5EZ6; X-ray; 1.80 A; B=1-181.
DR   PDB; 5FR1; X-ray; 2.75 A; A=1-193.
DR   PDB; 5FR2; X-ray; 3.35 A; A=1-193.
DR   PDB; 5HPY; X-ray; 2.40 A; B/F=3-181.
DR   PDB; 5IRC; X-ray; 1.72 A; D/F=2-181.
DR   PDB; 5JCP; X-ray; 2.10 A; A/B=1-181.
DR   PDB; 5JHG; X-ray; 2.50 A; B/F=1-181.
DR   PDB; 5JHH; X-ray; 2.30 A; B/F=1-181.
DR   PDB; 5M6X; X-ray; 2.40 A; B/I=2-193.
DR   PDB; 5M70; X-ray; 2.20 A; B/G=2-193.
DR   PDB; 6BC0; X-ray; 2.20 A; F=1-181.
DR   PDB; 6BCA; X-ray; 2.00 A; C/F=1-181.
DR   PDB; 6BCB; X-ray; 1.40 A; F=1-181.
DR   PDBsum; 1A2B; -.
DR   PDBsum; 1CC0; -.
DR   PDBsum; 1CXZ; -.
DR   PDBsum; 1DPF; -.
DR   PDBsum; 1FTN; -.
DR   PDBsum; 1KMQ; -.
DR   PDBsum; 1LB1; -.
DR   PDBsum; 1OW3; -.
DR   PDBsum; 1S1C; -.
DR   PDBsum; 1TX4; -.
DR   PDBsum; 1X86; -.
DR   PDBsum; 1XCG; -.
DR   PDBsum; 2RGN; -.
DR   PDBsum; 3KZ1; -.
DR   PDBsum; 3LW8; -.
DR   PDBsum; 3LWN; -.
DR   PDBsum; 3LXR; -.
DR   PDBsum; 3MSX; -.
DR   PDBsum; 3T06; -.
DR   PDBsum; 4D0N; -.
DR   PDBsum; 4XH9; -.
DR   PDBsum; 4XOI; -.
DR   PDBsum; 4XSG; -.
DR   PDBsum; 4XSH; -.
DR   PDBsum; 5A0F; -.
DR   PDBsum; 5BWM; -.
DR   PDBsum; 5C2K; -.
DR   PDBsum; 5C4M; -.
DR   PDBsum; 5EZ6; -.
DR   PDBsum; 5FR1; -.
DR   PDBsum; 5FR2; -.
DR   PDBsum; 5HPY; -.
DR   PDBsum; 5IRC; -.
DR   PDBsum; 5JCP; -.
DR   PDBsum; 5JHG; -.
DR   PDBsum; 5JHH; -.
DR   PDBsum; 5M6X; -.
DR   PDBsum; 5M70; -.
DR   PDBsum; 6BC0; -.
DR   PDBsum; 6BCA; -.
DR   PDBsum; 6BCB; -.
DR   ProteinModelPortal; P61586; -.
DR   SMR; P61586; -.
DR   BioGrid; 106880; 178.
DR   CORUM; P61586; -.
DR   DIP; DIP-29642N; -.
DR   IntAct; P61586; 76.
DR   MINT; P61586; -.
DR   STRING; 9606.ENSP00000400175; -.
DR   BindingDB; P61586; -.
DR   ChEMBL; CHEMBL6052; -.
DR   DrugBank; DB04315; Guanosine-5'-Diphosphate.
DR   iPTMnet; P61586; -.
DR   PhosphoSitePlus; P61586; -.
DR   SwissPalm; P61586; -.
DR   BioMuta; RHOA; -.
DR   DMDM; 47606458; -.
DR   EPD; P61586; -.
DR   MaxQB; P61586; -.
DR   PaxDb; P61586; -.
DR   PeptideAtlas; P61586; -.
DR   PRIDE; P61586; -.
DR   TopDownProteomics; P61586; -.
DR   DNASU; 387; -.
DR   Ensembl; ENST00000418115; ENSP00000400175; ENSG00000067560.
DR   GeneID; 387; -.
DR   KEGG; hsa:387; -.
DR   UCSC; uc003cwu.4; human.
DR   CTD; 387; -.
DR   DisGeNET; 387; -.
DR   EuPathDB; HostDB:ENSG00000067560.10; -.
DR   GeneCards; RHOA; -.
DR   HGNC; HGNC:667; RHOA.
DR   HPA; CAB005052; -.
DR   MIM; 165390; gene.
DR   neXtProt; NX_P61586; -.
DR   OpenTargets; ENSG00000067560; -.
DR   PharmGKB; PA134865095; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   GeneTree; ENSGT00760000119020; -.
DR   HOGENOM; HOG000233974; -.
DR   HOVERGEN; HBG009351; -.
DR   InParanoid; P61586; -.
DR   KO; K04513; -.
DR   OMA; QKIGARH; -.
DR   OrthoDB; EOG091G0QVS; -.
DR   PhylomeDB; P61586; -.
DR   TreeFam; TF300837; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-193634; Axonal growth inhibition (RHOA activation).
DR   Reactome; R-HSA-194840; Rho GTPase cycle.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-209563; Axonal growth stimulation.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-4086400; PCP/CE pathway.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-416550; Sema4D mediated inhibition of cell attachment and migration.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5625900; RHO GTPases activate CIT.
DR   Reactome; R-HSA-5625970; RHO GTPases activate KTN1.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-5666185; RHO GTPases Activate Rhotekin and Rhophilins.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   Reactome; R-HSA-8985586; SLIT2:ROBO1 increases RHOA activity.
DR   SignaLink; P61586; -.
DR   SIGNOR; P61586; -.
DR   ChiTaRS; RHOA; human.
DR   EvolutionaryTrace; P61586; -.
DR   GeneWiki; RHOA; -.
DR   GenomeRNAi; 387; -.
DR   PMAP-CutDB; P61586; -.
DR   PRO; PR:P61586; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000067560; -.
DR   CleanEx; HS_RHOA; -.
DR   ExpressionAtlas; P61586; baseline and differential.
DR   Genevisible; P61586; HS.
DR   GO; GO:0043296; C:apical junction complex; IDA:UniProtKB.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0030054; C:cell junction; TAS:Reactome.
DR   GO; GO:0071944; C:cell periphery; IMP:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IEA:UniProtKB-SubCell.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IDA:SynGO.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IMP:AgBase.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0030496; C:midbody; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032587; C:ruffle membrane; IEA:Ensembl.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0031982; C:vesicle; IDA:AgBase.
DR   GO; GO:0019003; F:GDP binding; IEA:Ensembl.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; IDA:UniProtKB.
DR   GO; GO:0017022; F:myosin binding; IPI:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0051022; F:Rho GDP-dissociation inhibitor binding; IEA:Ensembl.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0002363; P:alpha-beta T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0001998; P:angiotensin-mediated vasoconstriction involved in regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0043297; P:apical junction assembly; IMP:UniProtKB.
DR   GO; GO:0038027; P:apolipoprotein A-I-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043366; P:beta selection; IEA:Ensembl.
DR   GO; GO:0034329; P:cell junction assembly; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:1990869; P:cellular response to chemokine; IMP:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl.
DR   GO; GO:0036089; P:cleavage furrow formation; IDA:UniProtKB.
DR   GO; GO:0043542; P:endothelial cell migration; IGI:MGI.
DR   GO; GO:0097498; P:endothelial tube lumen extension; IGI:MGI.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045198; P:establishment of epithelial cell apical/basal polarity; IMP:UniProtKB.
DR   GO; GO:0021861; P:forebrain radial glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0046039; P:GTP metabolic process; IEA:Ensembl.
DR   GO; GO:1903673; P:mitotic cleavage furrow formation; IMP:UniProtKB.
DR   GO; GO:0090307; P:mitotic spindle assembly; IMP:BHF-UCL.
DR   GO; GO:0050919; P:negative chemotaxis; IMP:UniProtKB.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; TAS:Reactome.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IGI:MGI.
DR   GO; GO:0045792; P:negative regulation of cell size; IMP:CAFA.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; ISS:ARUK-UCL.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0033144; P:negative regulation of intracellular steroid hormone receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0090324; P:negative regulation of oxidative phosphorylation; IEA:Ensembl.
DR   GO; GO:1903427; P:negative regulation of reactive oxygen species biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0042476; P:odontogenesis; IEA:Ensembl.
DR   GO; GO:0043931; P:ossification involved in bone maturation; ISS:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; TAS:Reactome.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0060193; P:positive regulation of lipase activity; IDA:AgBase.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:MGI.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; NAS:UniProtKB.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:MGI.
DR   GO; GO:2000406; P:positive regulation of T cell migration; IMP:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:1904695; P:positive regulation of vascular smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:Reactome.
DR   GO; GO:0050773; P:regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; TAS:ARUK-UCL.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:1905244; P:regulation of modification of synaptic structure; IEA:Ensembl.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0033688; P:regulation of osteoblast proliferation; ISS:BHF-UCL.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0003100; P:regulation of systemic arterial blood pressure by endothelin; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007266; P:Rho protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0035385; P:Roundabout signaling pathway; IDA:UniProtKB.
DR   GO; GO:1902766; P:skeletal muscle satellite cell migration; ISS:AgBase.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0043149; P:stress fiber assembly; IMP:UniProtKB.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IEA:Ensembl.
DR   GO; GO:0021762; P:substantia nigra development; HEP:UniProtKB.
DR   GO; GO:0061383; P:trabecula morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; TAS:Reactome.
DR   GO; GO:0044319; P:wound healing, spreading of cells; ISS:AgBase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR003578; Small_GTPase_Rho.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51420; RHO; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Cell cycle; Cell division;
KW   Cell membrane; Cell projection; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Glycoprotein; GTP-binding;
KW   Host-virus interaction; Lipoprotein; Magnesium; Membrane; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Prenylation; Proto-oncogene;
KW   Reference proteome; Ubl conjugation.
FT   CHAIN         1    190       Transforming protein RhoA.
FT                                /FTId=PRO_0000030411.
FT   PROPEP      191    193       Removed in mature form.
FT                                /FTId=PRO_0000030412.
FT   NP_BIND      12     19       GTP. {ECO:0000269|PubMed:10748207,
FT                                ECO:0000269|PubMed:12777804}.
FT   NP_BIND      59     63       GTP. {ECO:0000250}.
FT   NP_BIND     117    120       GTP. {ECO:0000269|PubMed:10748207,
FT                                ECO:0000269|PubMed:12777804}.
FT   MOTIF        34     42       Effector region. {ECO:0000255}.
FT   COMPBIAS    182    187       Arg/Lys-rich (basic).
FT   SITE        189    190       Cleavage; by yopT.
FT   MOD_RES      34     34       O-AMP-tyrosine; by Haemophilus IbpA;
FT                                alternate. {ECO:0000269|PubMed:19362538}.
FT   MOD_RES      37     37       O-AMP-threonine; by Vibrio VopS.
FT                                {ECO:0000269|PubMed:19039103}.
FT   MOD_RES      41     41       ADP-ribosylasparagine; by botulinum
FT                                toxin. {ECO:0000305|PubMed:1328215}.
FT   MOD_RES     188    188       Phosphoserine; by PKG/PRKG1.
FT                                {ECO:0000269|PubMed:11162591}.
FT   MOD_RES     190    190       Cysteine methyl ester.
FT                                {ECO:0000250|UniProtKB:P62745}.
FT   LIPID       190    190       S-geranylgeranyl cysteine.
FT                                {ECO:0000250|UniProtKB:P62745}.
FT   CARBOHYD     34     34       O-linked (GlcNAc) tyrosine; by
FT                                Photorhabdus PAU_02230; alternate.
FT                                {ECO:0000269|PubMed:24141704}.
FT   MUTAGEN      14     14       G->V: Causes constitutive activation.
FT                                {ECO:0000269|PubMed:19948726}.
FT   MUTAGEN      34     34       Y->A: Abolishes interaction with DGKQ.
FT                                {ECO:0000269|PubMed:10066731,
FT                                ECO:0000269|PubMed:19362538}.
FT   MUTAGEN      34     34       Y->F: Abolishes AMPylation by Haemophilus
FT                                IbpA. {ECO:0000269|PubMed:10066731,
FT                                ECO:0000269|PubMed:19362538}.
FT   MUTAGEN      63     63       Q->L: Causes constitutive activation.
FT   MUTAGEN     193    193       L->M: Converts geranyl-geranylation to
FT                                farnesylation; does not prevent the
FT                                cleavage by yopT.
FT                                {ECO:0000269|PubMed:12538863}.
FT   CONFLICT     23     23       I -> T (in Ref. 5; BAD96276).
FT                                {ECO:0000305}.
FT   STRAND        4     13       {ECO:0000244|PDB:5C4M}.
FT   HELIX        14     16       {ECO:0000244|PDB:4XH9}.
FT   HELIX        18     27       {ECO:0000244|PDB:5C4M}.
FT   STRAND       43     47       {ECO:0000244|PDB:5C4M}.
FT   STRAND       52     58       {ECO:0000244|PDB:5C4M}.
FT   HELIX        63     69       {ECO:0000244|PDB:5C4M}.
FT   HELIX        70     73       {ECO:0000244|PDB:5C4M}.
FT   STRAND       78     85       {ECO:0000244|PDB:5C4M}.
FT   HELIX        89     97       {ECO:0000244|PDB:5C4M}.
FT   HELIX        99    106       {ECO:0000244|PDB:5C4M}.
FT   STRAND      107    109       {ECO:0000244|PDB:5FR2}.
FT   STRAND      112    117       {ECO:0000244|PDB:5C4M}.
FT   HELIX       119    121       {ECO:0000244|PDB:5C4M}.
FT   HELIX       125    132       {ECO:0000244|PDB:5C4M}.
FT   TURN        133    135       {ECO:0000244|PDB:5C4M}.
FT   HELIX       141    151       {ECO:0000244|PDB:5C4M}.
FT   STRAND      154    158       {ECO:0000244|PDB:5C4M}.
FT   TURN        161    163       {ECO:0000244|PDB:5C4M}.
FT   HELIX       167    179       {ECO:0000244|PDB:5C4M}.
FT   STRAND      190    193       {ECO:0000244|PDB:5FR1}.
SQ   SEQUENCE   193 AA;  21768 MW;  C4DA2DC31FF858BC CRC64;
     MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT
     AGQEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD
     LRNDEHTRRE LAKMKQEPVK PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ
     ARRGKKKSGC LVL
//
ID   Q9BVT0_HUMAN            Unreviewed;       101 AA.
AC   Q9BVT0;
DT   01-JUN-2001, integrated into UniProtKB/TrEMBL.
DT   01-MAR-2004, sequence version 2.
DT   31-JAN-2018, entry version 98.
DE   SubName: Full=ARHA protein {ECO:0000313|EMBL:AAH00946.2};
DE   Flags: Fragment;
GN   Name=ARHA {ECO:0000313|EMBL:AAH00946.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH00946.2};
RN   [1] {ECO:0000313|EMBL:AAH00946.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta {ECO:0000313|EMBL:AAH00946.2};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC000946; AAH00946.2; -; mRNA.
DR   RefSeq; NP_001655.1; NM_001664.3.
DR   UniGene; Hs.247077; -.
DR   ProteinModelPortal; Q9BVT0; -.
DR   PeptideAtlas; Q9BVT0; -.
DR   PRIDE; Q9BVT0; -.
DR   DNASU; 387; -.
DR   GeneID; 387; -.
DR   CTD; 387; -.
DR   PharmGKB; PA134865095; -.
DR   eggNOG; KOG0393; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   HOVERGEN; HBG009351; -.
DR   ChiTaRS; RHOA; human.
DR   Genevisible; Q9BVT0; HS.
DR   GO; GO:0005525; F:GTP binding; IEA:InterPro.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   Pfam; PF00071; Ras; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
PE   2: Evidence at transcript level;
FT   NON_TER       1      1       {ECO:0000313|EMBL:AAH00946.2}.
SQ   SEQUENCE   101 AA;  11523 MW;  5067AD783510BA63 CRC64;
     ENIPEKWTPE VKHFCPNVPI ILVGNKKDLR NDEHTRRELA KMKQEPVKPE EGRDMANRIG
     AFGYMECSAK TKDGVREVFE MATRAALQAR RGKKKSGCLV L
//
ID   A0A024RBL6_HUMAN        Unreviewed;       743 AA.
AC   A0A024RBL6;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-FEB-2018, entry version 38.
DE   SubName: Full=T-box 3 (Ulnar mammary syndrome), isoform CRA_c {ECO:0000313|EMBL:EAW98073.1};
GN   Name=TBX3 {ECO:0000313|EMBL:EAW98073.1};
GN   ORFNames=hCG_40340 {ECO:0000313|EMBL:EAW98073.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW98073.1};
RN   [1] {ECO:0000313|EMBL:EAW98073.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW98073.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-
CC       ProRule:PRU00201, ECO:0000256|SAAS:SAAS00114217}.
CC   -!- CAUTION: Lacks conserved residue(s) required for the propagation
CC       of feature annotation. {ECO:0000256|PROSITE-ProRule:PRU00201}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471054; EAW98071.1; -; Genomic_DNA.
DR   EMBL; CH471054; EAW98073.1; -; Genomic_DNA.
DR   RefSeq; NP_057653.3; NM_016569.3.
DR   UniGene; Hs.744016; -.
DR   SMR; A0A024RBL6; -.
DR   GeneID; 6926; -.
DR   KEGG; hsa:6926; -.
DR   CTD; 6926; -.
DR   EuPathDB; HostDB:ENSG00000135111.14; -.
DR   eggNOG; KOG3585; Eukaryota.
DR   eggNOG; ENOG410XSTS; LUCA.
DR   KO; K10177; -.
DR   OMA; PSQFAMG; -.
DR   OrthoDB; EOG091G0I8R; -.
DR   ChiTaRS; TBX3; human.
DR   GenomeRNAi; 6926; -.
DR   Bgee; ENSG00000135111; -.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; IEA:Ensembl.
DR   GO; GO:0003167; P:atrioventricular bundle cell differentiation; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0060923; P:cardiac muscle cell fate commitment; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0001947; P:heart looping; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0021761; P:limbic system development; IEA:Ensembl.
DR   GO; GO:0060596; P:mammary placode formation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0060931; P:sinoatrial node cell development; IEA:Ensembl.
DR   GO; GO:0010159; P:specification of animal organ position; IEA:Ensembl.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IEA:Ensembl.
DR   CDD; cd00182; TBOX; 1.
DR   Gene3D; 2.60.40.820; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR036960; T-box_sf.
DR   InterPro; IPR022582; TBX.
DR   InterPro; IPR001699; TF_T-box.
DR   InterPro; IPR018186; TF_T-box_CS.
DR   PANTHER; PTHR11267; PTHR11267; 1.
DR   Pfam; PF00907; T-box; 1.
DR   Pfam; PF12598; TBX; 1.
DR   PRINTS; PR00937; TBOX.
DR   SMART; SM00425; TBOX; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS01283; TBOX_1; 1.
DR   PROSITE; PS01264; TBOX_2; 1.
DR   PROSITE; PS50252; TBOX_3; 1.
PE   4: Predicted;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00201,
KW   ECO:0000256|SAAS:SAAS00114223};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00201,
KW   ECO:0000256|SAAS:SAAS00114236};
KW   Transcription {ECO:0000256|SAAS:SAAS00114203};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00114203}.
FT   DOMAIN      323    405       TBX. {ECO:0000259|Pfam:PF12598}.
FT   COILED      714    734       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   743 AA;  79389 MW;  D5572F9CF871E89F CRC64;
     MSLSMRDPVI PGTSMAYHPF LPHRAPDFAM SAVLGHQPPF FPALTLPPNG AAALSLPGAL
     AKPIMDQLVG AAETGIPFSS LGPQAHLRPL KTMEPEEEVE DDPKVHLEAK ELWDQFHKRG
     TEMVITKSGR RMFPPFKVRC SGLDKKAKYI LLMDIIAADD CRYKFHNSRW MVAGKADPEM
     PKRMYIHPDS PATGEQWMSK VVTFHKLKLT NNISDKHGFT LAFPSDHATW QGNYSFGTQT
     ILNSMHKYQP RFHIVRANDI LKLPYSTFRT YLFPETEFIA VTAYQNDKIT QLKIDNNPFA
     KGFRDTGNGR REKRKQLTLQ SMRVFDERHK KENGTSDESS SEQAAFNCFA QASSPAASTV
     GTSNLKDLCP SEGESDAEAE SKEEHGPEAC DAAKISTTTS EEPCRDKGSP AVKAHLFAAE
     RPRDSGRLDK ASPDSRHSPA TISSSTRGLG AEERRSPVRE GTAPAKVEEA RALPGKEAFA
     PLTVQTDAAA AHLAQGPLPG LGFAPGLAGQ QFFNGHPLFL HPSQFAMGGA FSSMAAAGMG
     PLLATVSGAS TGVSGLDSTA MASAAAAQGL SGASAATLPF HLQQHVLASQ GLAMSPFGSL
     FPYPYTYMAA AAAASSAAAS SSVHRHPFLN LNTMRPRLRY SPYSIPVPVP DGSSLLTTAL
     PSMAAAAGPL DGKVAALAAS PASVAVDSGS ELNSRSSTLS SSSMSLSPKL CAEKEAATSE
     LQSIQRLVSG LEAKPDRSRS ASP
//
ID   A0A024RBQ4_HUMAN        Unreviewed;       723 AA.
AC   A0A024RBQ4;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-FEB-2018, entry version 39.
DE   SubName: Full=T-box 3 (Ulnar mammary syndrome), isoform CRA_a {ECO:0000313|EMBL:EAW98074.1};
GN   Name=TBX3 {ECO:0000313|EMBL:EAW98074.1};
GN   ORFNames=hCG_40340 {ECO:0000313|EMBL:EAW98074.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW98074.1};
RN   [1] {ECO:0000313|EMBL:EAW98074.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW98074.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-
CC       ProRule:PRU00201, ECO:0000256|SAAS:SAAS00114217}.
CC   -!- CAUTION: Lacks conserved residue(s) required for the propagation
CC       of feature annotation. {ECO:0000256|PROSITE-ProRule:PRU00201}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471054; EAW98069.1; -; Genomic_DNA.
DR   EMBL; CH471054; EAW98074.1; -; Genomic_DNA.
DR   RefSeq; NP_005987.3; NM_005996.3.
DR   UniGene; Hs.744016; -.
DR   SMR; A0A024RBQ4; -.
DR   GeneID; 6926; -.
DR   CTD; 6926; -.
DR   EuPathDB; HostDB:ENSG00000135111.14; -.
DR   eggNOG; KOG3585; Eukaryota.
DR   eggNOG; ENOG410XSTS; LUCA.
DR   ChiTaRS; TBX3; human.
DR   GenomeRNAi; 6926; -.
DR   Bgee; ENSG00000135111; -.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00182; TBOX; 1.
DR   Gene3D; 2.60.40.820; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR036960; T-box_sf.
DR   InterPro; IPR022582; TBX.
DR   InterPro; IPR002070; TF_Brachyury.
DR   InterPro; IPR001699; TF_T-box.
DR   InterPro; IPR018186; TF_T-box_CS.
DR   PANTHER; PTHR11267; PTHR11267; 1.
DR   Pfam; PF00907; T-box; 1.
DR   Pfam; PF12598; TBX; 1.
DR   PRINTS; PR00938; BRACHYURY.
DR   PRINTS; PR00937; TBOX.
DR   SMART; SM00425; TBOX; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS01283; TBOX_1; 1.
DR   PROSITE; PS01264; TBOX_2; 1.
DR   PROSITE; PS50252; TBOX_3; 1.
PE   4: Predicted;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00201,
KW   ECO:0000256|SAAS:SAAS00114223};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00201,
KW   ECO:0000256|SAAS:SAAS00114236};
KW   Transcription {ECO:0000256|SAAS:SAAS00114203};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00114203}.
FT   DOMAIN      303    385       TBX. {ECO:0000259|Pfam:PF12598}.
FT   COILED      694    714       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   723 AA;  77178 MW;  08A64D15A005F0CF CRC64;
     MSLSMRDPVI PGTSMAYHPF LPHRAPDFAM SAVLGHQPPF FPALTLPPNG AAALSLPGAL
     AKPIMDQLVG AAETGIPFSS LGPQAHLRPL KTMEPEEEVE DDPKVHLEAK ELWDQFHKRG
     TEMVITKSGR RMFPPFKVRC SGLDKKAKYI LLMDIIAADD CRYKFHNSRW MVAGKADPEM
     PKRMYIHPDS PATGEQWMSK VVTFHKLKLT NNISDKHGFT ILNSMHKYQP RFHIVRANDI
     LKLPYSTFRT YLFPETEFIA VTAYQNDKIT QLKIDNNPFA KGFRDTGNGR REKRKQLTLQ
     SMRVFDERHK KENGTSDESS SEQAAFNCFA QASSPAASTV GTSNLKDLCP SEGESDAEAE
     SKEEHGPEAC DAAKISTTTS EEPCRDKGSP AVKAHLFAAE RPRDSGRLDK ASPDSRHSPA
     TISSSTRGLG AEERRSPVRE GTAPAKVEEA RALPGKEAFA PLTVQTDAAA AHLAQGPLPG
     LGFAPGLAGQ QFFNGHPLFL HPSQFAMGGA FSSMAAAGMG PLLATVSGAS TGVSGLDSTA
     MASAAAAQGL SGASAATLPF HLQQHVLASQ GLAMSPFGSL FPYPYTYMAA AAAASSAAAS
     SSVHRHPFLN LNTMRPRLRY SPYSIPVPVP DGSSLLTTAL PSMAAAAGPL DGKVAALAAS
     PASVAVDSGS ELNSRSSTLS SSSMSLSPKL CAEKEAATSE LQSIQRLVSG LEAKPDRSRS
     ASP
//
ID   TBX3_HUMAN              Reviewed;         743 AA.
AC   O15119; Q8TB20; Q9UKF8;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   12-FEB-2003, sequence version 4.
DT   28-FEB-2018, entry version 183.
DE   RecName: Full=T-box transcription factor TBX3;
DE            Short=T-box protein 3;
GN   Name=TBX3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I), AND FUNCTION.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=10468588; DOI=10.1073/pnas.96.18.10212;
RA   He M.-L., Wen L., Campbell C.E., Wu J.Y., Rao Y.;
RT   "Transcription repression by Xenopus ET and its human ortholog TBX3, a
RT   gene involved in ulnar-mammary syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:10212-10217(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-488 (ISOFORM I).
RC   TISSUE=Kidney;
RX   PubMed=9207801; DOI=10.1038/ng0797-311;
RA   Bamshad M., Lin R.C., Law D.J., Watkins W.S., Krakowiak P.A.,
RA   Moore M.E., Franceschini P., Lala R., Holmes L.B., Gebuhr T.C.,
RA   Schinzel A., Bruneau B.G., Seidman J.G., Seidman C.E., Jorde L.B.;
RT   "Mutations in human TBX3 alter limb, apocrine and genital development
RT   in ulnar-mammary syndrome.";
RL   Nat. Genet. 16:311-315(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 592-743, ALTERNATIVE SPLICING, AND
RP   VARIANTS UMS PRO-143 AND SER-149.
RX   PubMed=10330342; DOI=10.1086/302417;
RA   Bamshad M., Le T., Watkins W.S., Dixon M.E., Kramer B.E., Roeder A.D.,
RA   Carey J.C., Root S., Schinzel A., Van Maldergem L., Gardner R.J.M.,
RA   Lin R.C., Seidman C.E., Seidman J.G., Wallerstein R., Moran E.,
RA   Sutphen R., Campbell C.E., Jorde L.B.;
RT   "The spectrum of mutations in TBX3: genotype/phenotype relationship in
RT   ulnar-mammary syndrome.";
RL   Am. J. Hum. Genet. 64:1550-1562(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM III).
RC   TISSUE=Adrenal gland;
RA   Song H., Gao G., Peng Y., Ren S., Chen Z., Han Z.;
RT   "A novel gene expressed in human adrenal gland.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM II).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-432 AND SER-438, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-371; SER-707; SER-738;
RP   SER-740 AND SER-742, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH PML.
RX   PubMed=22002537; DOI=10.1038/emboj.2011.370;
RA   Martin N., Benhamed M., Nacerddine K., Demarque M.D., van Lohuizen M.,
RA   Dejean A., Bischof O.;
RT   "Physical and functional interaction between PML and TBX2 in the
RT   establishment of cellular senescence.";
RL   EMBO J. 31:95-109(2012).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438; SER-456; SER-707
RP   AND SER-738, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-438, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 101-311.
RX   PubMed=12005433; DOI=10.1016/S0969-2126(02)00722-0;
RA   Coll M., Seidman J.G., Muller C.W.;
RT   "Structure of the DNA-bound T-box domain of human TBX3, a
RT   transcription factor responsible for ulnar-mammary syndrome.";
RL   Structure 10:343-356(2002).
CC   -!- FUNCTION: Transcriptional repressor involved in developmental
CC       processes. Probably plays a role in limb pattern formation. Acts
CC       as a negative regulator of PML function in cellular senescence.
CC       {ECO:0000269|PubMed:10468588, ECO:0000269|PubMed:22002537}.
CC   -!- SUBUNIT: Interacts with PML (isoform PML-4).
CC       {ECO:0000269|PubMed:22002537}.
CC   -!- INTERACTION:
CC       Q08117:AES; NbExp=3; IntAct=EBI-3452216, EBI-717810;
CC       P35219:CA8; NbExp=3; IntAct=EBI-3452216, EBI-718700;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00201}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=II;
CC         IsoId=O15119-1; Sequence=Displayed;
CC         Note=Contains an interrupted T-box domain.;
CC       Name=I;
CC         IsoId=O15119-2; Sequence=VSP_006384;
CC       Name=III;
CC         IsoId=O15119-3; Sequence=VSP_006385, VSP_006386;
CC         Note=Contains an interrupted T-box domain.;
CC       Name=IV;
CC         IsoId=O15119-4; Sequence=Not described;
CC         Note=May be produced by joining exon 1 to exon 7 thereby
CC         eliminating the T-box.;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DISEASE: Ulnar-mammary syndrome (UMS) [MIM:181450]: Characterized
CC       by ulnar ray defects, obesity, hypogenitalism, delayed puberty,
CC       hypoplasia of nipples and apocrine glands.
CC       {ECO:0000269|PubMed:10330342}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TBX3ID42486ch12q24.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF170708; AAD50989.2; -; mRNA.
DR   EMBL; AF002228; AAC12947.1; -; mRNA.
DR   EMBL; AF140240; AAF61816.1; -; mRNA.
DR   EMBL; AF216750; AAF61207.1; -; mRNA.
DR   EMBL; BC025258; AAH25258.1; -; mRNA.
DR   CCDS; CCDS9175.1; -. [O15119-2]
DR   CCDS; CCDS9176.1; -. [O15119-1]
DR   RefSeq; NP_005987.3; NM_005996.3. [O15119-2]
DR   RefSeq; NP_057653.3; NM_016569.3. [O15119-1]
DR   UniGene; Hs.744016; -.
DR   PDB; 1H6F; X-ray; 1.70 A; A/B=101-311.
DR   PDBsum; 1H6F; -.
DR   ProteinModelPortal; O15119; -.
DR   SMR; O15119; -.
DR   BioGrid; 112788; 22.
DR   IntAct; O15119; 19.
DR   MINT; O15119; -.
DR   STRING; 9606.ENSP00000257566; -.
DR   iPTMnet; O15119; -.
DR   PhosphoSitePlus; O15119; -.
DR   BioMuta; TBX3; -.
DR   PaxDb; O15119; -.
DR   PeptideAtlas; O15119; -.
DR   PRIDE; O15119; -.
DR   DNASU; 6926; -.
DR   Ensembl; ENST00000257566; ENSP00000257566; ENSG00000135111. [O15119-1]
DR   Ensembl; ENST00000349155; ENSP00000257567; ENSG00000135111. [O15119-2]
DR   GeneID; 6926; -.
DR   KEGG; hsa:6926; -.
DR   UCSC; uc001tvt.2; human. [O15119-1]
DR   CTD; 6926; -.
DR   DisGeNET; 6926; -.
DR   EuPathDB; HostDB:ENSG00000135111.14; -.
DR   GeneCards; TBX3; -.
DR   HGNC; HGNC:11602; TBX3.
DR   HPA; HPA005799; -.
DR   MalaCards; TBX3; -.
DR   MIM; 181450; phenotype.
DR   MIM; 601621; gene.
DR   neXtProt; NX_O15119; -.
DR   OpenTargets; ENSG00000135111; -.
DR   Orphanet; 3138; Ulnar-mammary syndrome.
DR   PharmGKB; PA36365; -.
DR   eggNOG; KOG3585; Eukaryota.
DR   eggNOG; ENOG410XSTS; LUCA.
DR   GeneTree; ENSGT00760000118897; -.
DR   HOGENOM; HOG000038046; -.
DR   HOVERGEN; HBG000412; -.
DR   InParanoid; O15119; -.
DR   KO; K10177; -.
DR   OMA; PSQFAMG; -.
DR   OrthoDB; EOG091G0I8R; -.
DR   PhylomeDB; O15119; -.
DR   TreeFam; TF106341; -.
DR   SIGNOR; O15119; -.
DR   ChiTaRS; TBX3; human.
DR   EvolutionaryTrace; O15119; -.
DR   GeneWiki; TBX3; -.
DR   GenomeRNAi; 6926; -.
DR   PRO; PR:O15119; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000135111; -.
DR   CleanEx; HS_TBX3; -.
DR   ExpressionAtlas; O15119; baseline and differential.
DR   Genevisible; O15119; HS.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0009887; P:animal organ morphogenesis; IDA:MGI.
DR   GO; GO:0008595; P:anterior/posterior axis specification, embryo; IMP:UniProtKB.
DR   GO; GO:0003167; P:atrioventricular bundle cell differentiation; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0060923; P:cardiac muscle cell fate commitment; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IDA:UniProtKB.
DR   GO; GO:0090398; P:cellular senescence; IDA:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IMP:UniProtKB.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IMP:UniProtKB.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0030540; P:female genitalia development; IMP:UniProtKB.
DR   GO; GO:0046884; P:follicle-stimulating hormone secretion; IMP:UniProtKB.
DR   GO; GO:0035136; P:forelimb morphogenesis; IDA:MGI.
DR   GO; GO:0001947; P:heart looping; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0021761; P:limbic system development; IEA:Ensembl.
DR   GO; GO:0032275; P:luteinizing hormone secretion; IMP:UniProtKB.
DR   GO; GO:0030539; P:male genitalia development; IMP:UniProtKB.
DR   GO; GO:0030879; P:mammary gland development; IMP:UniProtKB.
DR   GO; GO:0060596; P:mammary placode formation; IEA:Ensembl.
DR   GO; GO:0048332; P:mesoderm morphogenesis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:NTNU_SB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:UniProtKB.
DR   GO; GO:0060931; P:sinoatrial node cell development; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IMP:UniProtKB.
DR   GO; GO:0010159; P:specification of animal organ position; IEA:Ensembl.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IEA:Ensembl.
DR   CDD; cd00182; TBOX; 1.
DR   Gene3D; 2.60.40.820; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR036960; T-box_sf.
DR   InterPro; IPR022582; TBX.
DR   InterPro; IPR001699; TF_T-box.
DR   InterPro; IPR018186; TF_T-box_CS.
DR   PANTHER; PTHR11267; PTHR11267; 1.
DR   Pfam; PF00907; T-box; 1.
DR   Pfam; PF12598; TBX; 1.
DR   PRINTS; PR00937; TBOX.
DR   SMART; SM00425; TBOX; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS01283; TBOX_1; 1.
DR   PROSITE; PS01264; TBOX_2; 1.
DR   PROSITE; PS50252; TBOX_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Developmental protein; Disease mutation; DNA-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation.
FT   CHAIN         1    743       T-box transcription factor TBX3.
FT                                /FTId=PRO_0000184428.
FT   DNA_BIND    107    220       T-box; first part. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00201}.
FT   DNA_BIND    241    305       T-box; second part. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00201}.
FT   REGION      544    695       Transcription repression.
FT   MOD_RES     371    371       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     432    432       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336}.
FT   MOD_RES     438    438       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     456    456       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     707    707       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     738    738       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     740    740       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     742    742       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   VAR_SEQ     221    240       Missing (in isoform I).
FT                                {ECO:0000303|PubMed:10468588,
FT                                ECO:0000303|PubMed:9207801}.
FT                                /FTId=VSP_006384.
FT   VAR_SEQ     490    615       Missing (in isoform III).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_006385.
FT   VAR_SEQ     661    677       Missing (in isoform III).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_006386.
FT   VARIANT     143    143       L -> P (in UMS).
FT                                {ECO:0000269|PubMed:10330342}.
FT                                /FTId=VAR_009601.
FT   VARIANT     149    149       Y -> S (in UMS).
FT                                {ECO:0000269|PubMed:10330342}.
FT                                /FTId=VAR_009602.
FT   CONFLICT    315    315       K -> Q (in Ref. 4; AAF61207).
FT                                {ECO:0000305}.
FT   CONFLICT    616    628       SAAASSSVHRHPF -> LRQPQLRCTAPL (in Ref.
FT                                1). {ECO:0000305}.
FT   CONFLICT    674    674       V -> A (in Ref. 1; AAD50989).
FT                                {ECO:0000305}.
FT   CONFLICT    692    692       L -> P (in Ref. 1; AAD50989).
FT                                {ECO:0000305}.
FT   STRAND      104    107       {ECO:0000244|PDB:1H6F}.
FT   HELIX       110    119       {ECO:0000244|PDB:1H6F}.
FT   STRAND      122    124       {ECO:0000244|PDB:1H6F}.
FT   STRAND      137    142       {ECO:0000244|PDB:1H6F}.
FT   STRAND      145    166       {ECO:0000244|PDB:1H6F}.
FT   STRAND      169    175       {ECO:0000244|PDB:1H6F}.
FT   STRAND      191    193       {ECO:0000244|PDB:1H6F}.
FT   HELIX       194    197       {ECO:0000244|PDB:1H6F}.
FT   STRAND      246    255       {ECO:0000244|PDB:1H6F}.
FT   HELIX       260    265       {ECO:0000244|PDB:1H6F}.
FT   STRAND      269    272       {ECO:0000244|PDB:1H6F}.
FT   HELIX       274    276       {ECO:0000244|PDB:1H6F}.
FT   STRAND      278    283       {ECO:0000244|PDB:1H6F}.
FT   HELIX       287    296       {ECO:0000244|PDB:1H6F}.
FT   HELIX       298    303       {ECO:0000244|PDB:1H6F}.
SQ   SEQUENCE   743 AA;  79389 MW;  D5572F9CF871E89F CRC64;
     MSLSMRDPVI PGTSMAYHPF LPHRAPDFAM SAVLGHQPPF FPALTLPPNG AAALSLPGAL
     AKPIMDQLVG AAETGIPFSS LGPQAHLRPL KTMEPEEEVE DDPKVHLEAK ELWDQFHKRG
     TEMVITKSGR RMFPPFKVRC SGLDKKAKYI LLMDIIAADD CRYKFHNSRW MVAGKADPEM
     PKRMYIHPDS PATGEQWMSK VVTFHKLKLT NNISDKHGFT LAFPSDHATW QGNYSFGTQT
     ILNSMHKYQP RFHIVRANDI LKLPYSTFRT YLFPETEFIA VTAYQNDKIT QLKIDNNPFA
     KGFRDTGNGR REKRKQLTLQ SMRVFDERHK KENGTSDESS SEQAAFNCFA QASSPAASTV
     GTSNLKDLCP SEGESDAEAE SKEEHGPEAC DAAKISTTTS EEPCRDKGSP AVKAHLFAAE
     RPRDSGRLDK ASPDSRHSPA TISSSTRGLG AEERRSPVRE GTAPAKVEEA RALPGKEAFA
     PLTVQTDAAA AHLAQGPLPG LGFAPGLAGQ QFFNGHPLFL HPSQFAMGGA FSSMAAAGMG
     PLLATVSGAS TGVSGLDSTA MASAAAAQGL SGASAATLPF HLQQHVLASQ GLAMSPFGSL
     FPYPYTYMAA AAAASSAAAS SSVHRHPFLN LNTMRPRLRY SPYSIPVPVP DGSSLLTTAL
     PSMAAAAGPL DGKVAALAAS PASVAVDSGS ELNSRSSTLS SSSMSLSPKL CAEKEAATSE
     LQSIQRLVSG LEAKPDRSRS ASP
//
ID   TERT_HUMAN              Reviewed;        1132 AA.
AC   O14746; O14783; Q2XS35; Q8N6C3; Q8NG38; Q8NG46;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   28-FEB-2018, entry version 172.
DE   RecName: Full=Telomerase reverse transcriptase;
DE            EC=2.7.7.49;
DE   AltName: Full=HEST2;
DE   AltName: Full=Telomerase catalytic subunit;
DE   AltName: Full=Telomerase-associated protein 2;
DE            Short=TP2;
GN   Name=TERT; Synonyms=EST2, TCS1, TRT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9288757; DOI=10.1016/S0092-8674(00)80538-3;
RA   Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P.,
RA   Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q.,
RA   Bacchetti S., Haber D.A., Weinberg R.A.;
RT   "hEST2, the putative human telomerase catalytic subunit gene, is up-
RT   regulated in tumor cells and during immortalization.";
RL   Cell 90:785-795(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Embryonic kidney;
RX   PubMed=9252327; DOI=10.1126/science.277.5328.955;
RA   Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H.,
RA   Lingner J., Harley C.B., Cech T.R.;
RT   "Telomerase catalytic subunit homologs from fission yeast and human.";
RL   Science 277:955-959(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10333526; DOI=10.1016/S0378-1119(99)00108-0;
RA   Wick M., Zubov D., Hagen G.;
RT   "Genomic organization and promoter characterization of the gene
RT   encoding the human telomerase reverse transcriptase (hTERT).";
RL   Gene 232:97-106(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=12869302; DOI=10.1016/S1476-5586(03)80051-9;
RA   Hisatomi H., Ohyashiki K., Ohyashiki J.H., Nagao K., Kanamaru T.,
RA   Hirata H., Hibi N., Tsukada Y.;
RT   "Expression profile of a gamma-deletion variant of the human
RT   telomerase reverse transcriptase gene.";
RL   Neoplasia 5:193-197(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Stomach cancer;
RX   PubMed=14654914;
RA   Nagao K., Katsumata K., Aizawa Y., Saito N., Hirata H., Sasaki H.,
RA   Yamamoto S., Hikiji K., Koiwa T., Hisatomi H.;
RT   "Differential alternative splicing expressions of telomerase reverse
RT   transcriptase in gastrointestinal cell lines.";
RL   Oncol. Rep. 11:127-131(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Londono-Vallejo J.A.;
RT   "Sequence of a BAC carrying the entire hTERT gene.";
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TYR-412 AND THR-1062.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=8676067; DOI=10.1084/jem.183.6.2471;
RA   Weng N.P., Levine B.L., June C.H., Hodes R.J.;
RT   "Regulated expression of telomerase activity in human T lymphocyte
RT   development and activation.";
RL   J. Exp. Med. 183:2471-2479(1996).
RN   [11]
RP   FUNCTION IN TELOMERASE ACTIVITY, TISSUE SPECIFICITY, ASSOCIATION WITH
RP   TEP1, AND MUTAGENESIS OF ASP-712; ASP-868 AND ASP-869.
RX   PubMed=9389643; DOI=10.1101/gad.11.23.3109;
RA   Harrington L., Zhou W., McPhail T., Oulton R., Yeung D.S., Mar V.,
RA   Bass M.B., Robinson M.O.;
RT   "Human telomerase contains evolutionarily conserved catalytic and
RT   structural subunits.";
RL   Genes Dev. 11:3109-3115(1997).
RN   [12]
RP   RECONSTITUTION OF THE TELOMERASE COMPLEX, AND MUTAGENESIS OF ASP-712;
RP   ASP-868 AND ASP-869.
RX   PubMed=9443919; DOI=10.1016/S0960-9822(98)70067-3;
RA   Beattie T.L., Zhou W., Robinson M.O., Harrington L.;
RT   "Reconstitution of human telomerase activity in vitro.";
RL   Curr. Biol. 8:177-180(1998).
RN   [13]
RP   ASSOCIATION WITH TEP1.
RX   PubMed=11029039; DOI=10.1091/mbc.11.10.3329;
RA   Beattie T.L., Zhou W., Robinson M.O., Harrington L.;
RT   "Polymerization defects within human telomerase are distinct from
RT   telomerase RNA and TEP1 binding.";
RL   Mol. Biol. Cell 11:3329-3340(2000).
RN   [14]
RP   INTERACTION WITH HSPA1A; HSP90A AND PTGES3.
RX   PubMed=11274138; DOI=10.1074/jbc.C100055200;
RA   Forsythe H.L., Jarvis J.L., Turner J.W., Elmore L.W., Holt S.E.;
RT   "Stable association of hsp90 and p23, but Not hsp70, with active human
RT   telomerase.";
RL   J. Biol. Chem. 276:15571-15574(2001).
RN   [15]
RP   PHOSPHORYLATION AT TYR-707, SUBCELLULAR LOCATION, INTERACTION WITH RAN
RP   AND XP01, AND MUTAGENESIS OF TYR-707.
RX   PubMed=12808100; DOI=10.1128/MCB.23.13.4598-4610.2003;
RA   Haendeler J., Hoffmann J., Brandes R.P., Zeiher A.M., Dimmeler S.;
RT   "Hydrogen peroxide triggers nuclear export of telomerase reverse
RT   transcriptase via Src kinase family-dependent phosphorylation of
RT   tyrosine 707.";
RL   Mol. Cell. Biol. 23:4598-4610(2003).
RN   [16]
RP   INTERACTION WITH MCRS1.
RX   PubMed=15044100; DOI=10.1016/j.bbrc.2004.02.166;
RA   Song H., Li Y., Chen G., Xing Z., Zhao J., Yokoyama K.K., Li T.,
RA   Zhao M.;
RT   "Human MCRS2, a cell-cycle-dependent protein, associates with
RT   LPTS/PinX1 and reduces the telomere length.";
RL   Biochem. Biophys. Res. Commun. 316:1116-1123(2004).
RN   [17]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=14963003; DOI=10.1161/01.RES.0000121104.05977.F3;
RA   Haendeler J., Hoffmann J., Diehl J.F., Vasa M., Spyridopoulos I.,
RA   Zeiher A.M., Dimmeler S.;
RT   "Antioxidants inhibit nuclear export of telomerase reverse
RT   transcriptase and delay replicative senescence of endothelial cells.";
RL   Circ. Res. 94:768-775(2004).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15138842; DOI=10.1007/s00418-004-0645-5;
RA   Yan P., Benhattar J., Seelentag W., Stehle J.C., Bosman F.T.;
RT   "Immunohistochemical localization of hTERT protein in human tissues.";
RL   Histochem. Cell Biol. 121:391-397(2004).
RN   [19]
RP   INTERACTION WITH NCL, AND SUBCELLULAR LOCATION.
RX   PubMed=15371412; DOI=10.1074/jbc.M407643200;
RA   Khurts S., Masutomi K., Delgermaa L., Arai K., Oishi N., Mizuno H.,
RA   Hayashi N., Hahn W.C., Murakami S.;
RT   "Nucleolin interacts with telomerase.";
RL   J. Biol. Chem. 279:51508-51515(2004).
RN   [20]
RP   FUNCTIONAL DOMAINS, AND MUTAGENESIS OF TRP-547 AND ASP-868.
RX   PubMed=15082768; DOI=10.1128/MCB.24.9.3720-3733.2004;
RA   Moriarty T.J., Marie-Egyptienne D.T., Autexier C.;
RT   "Functional organization of repeat addition processivity and DNA
RT   synthesis determinants in the human telomerase multimer.";
RL   Mol. Cell. Biol. 24:3720-3733(2004).
RN   [21]
RP   INTERACTION WITH MKRN1, AND UBIQUITINATION.
RX   PubMed=15805468; DOI=10.1101/gad.1289405;
RA   Kim J.H., Park S.-M., Kang M.R., Oh S.-Y., Lee T.H., Muller M.T.,
RA   Chung I.K.;
RT   "Ubiquitin ligase MKRN1 modulates telomere length homeostasis through
RT   a proteolysis of hTERT.";
RL   Genes Dev. 19:776-781(2005).
RN   [22]
RP   FUNCTION, AND MUTAGENESIS OF ASP-868.
RX   PubMed=15857955; DOI=10.1091/mbc.E05-02-0148;
RA   Moriarty T.J., Ward R.J., Taboski M.A., Autexier C.;
RT   "An anchor site-type defect in human telomerase that disrupts telomere
RT   length maintenance and cellular immortalization.";
RL   Mol. Biol. Cell 16:3152-3161(2005).
RN   [23]
RP   FUNCTION, AND MUTAGENESIS OF ARG-631; ASP-712 AND ASP-868.
RX   PubMed=17026956; DOI=10.1016/j.bbrc.2006.09.125;
RA   Rahman R., Mo L., Cui W.;
RT   "Telomerase with mutated catalytic motifs has dominant negative
RT   effects on telomerase activity and inhibits cell growth.";
RL   Biochem. Biophys. Res. Commun. 350:796-802(2006).
RN   [24]
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=17548608; DOI=10.4049/jimmunol.178.12.7710;
RA   Plunkett F.J., Franzese O., Finney H.M., Fletcher J.M.,
RA   Belaramani L.L., Salmon M., Dokal I., Webster D., Lawson A.D.,
RA   Akbar A.N.;
RT   "The loss of telomerase activity in highly differentiated CD8+CD28-
RT   CD27- T cells is associated with decreased Akt (Ser473)
RT   phosphorylation.";
RL   J. Immunol. 178:7710-7719(2007).
RN   [25]
RP   INTERACTION WITH NAT10.
RX   PubMed=18082603; DOI=10.1016/j.molcel.2007.09.023;
RA   Fu D., Collins K.;
RT   "Purification of human telomerase complexes identifies factors
RT   involved in telomerase biogenesis and telomere length regulation.";
RL   Mol. Cell 28:773-785(2007).
RN   [26]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF 137-TRP--LEU-141; ASP-712
RP   AND 930-TRP--LEU-934.
RX   PubMed=17296728; DOI=10.1128/MCB.02368-06;
RA   Wyatt H.D., Lobb D.A., Beattie T.L.;
RT   "Characterization of physical and functional anchor site interactions
RT   in human telomerase.";
RL   Mol. Cell. Biol. 27:3226-3240(2007).
RN   [27]
RP   FUNCTION, AND MUTAGENESIS OF LEU-866 AND VAL-867.
RX   PubMed=17264120; DOI=10.1093/nar/gkm002;
RA   Drosopoulos W.C., Prasad V.R.;
RT   "The active site residue Valine 867 in human telomerase reverse
RT   transcriptase influences nucleotide incorporation and fidelity.";
RL   Nucleic Acids Res. 35:1155-1168(2007).
RN   [28]
RP   INTERACTION WITH PTPN11, PHOSPHORYLATION AT TYR-707, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF TYR-707.
RX   PubMed=18829466; DOI=10.1074/jbc.M805138200;
RA   Jakob S., Schroeder P., Lukosz M., Buchner N., Spyridopoulos I.,
RA   Altschmied J., Haendeler J.;
RT   "Nuclear protein tyrosine phosphatase Shp-2 is one important negative
RT   regulator of nuclear export of telomerase reverse transcriptase.";
RL   J. Biol. Chem. 283:33155-33161(2008).
RN   [29]
RP   PHOSPHORYLATION, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19188162; DOI=10.1158/1078-0432.CCR-08-0792;
RA   Ram R., Uziel O., Eldan O., Fenig E., Beery E., Lichtenberg S.,
RA   Nordenberg Y., Lahav M.;
RT   "Ionizing radiation up-regulates telomerase activity in cancer cell
RT   lines by post-translational mechanism via ras/phosphatidylinositol 3-
RT   kinase/Akt pathway.";
RL   Clin. Cancer Res. 15:914-923(2009).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=19567472; DOI=10.1242/jcs.048066;
RA   Oh W., Ghim J., Lee E.W., Yang M.R., Kim E.T., Ahn J.H., Song J.;
RT   "PML-IV functions as a negative regulator of telomerase by interacting
RT   with TERT.";
RL   J. Cell Sci. 122:2613-2622(2009).
RN   [31]
RP   INTERACTION WITH SMARCA4, AND FUNCTION.
RX   PubMed=19571879; DOI=10.1038/nature08137;
RA   Park J.I., Venteicher A.S., Hong J.Y., Choi J., Jun S., Shkreli M.,
RA   Chang W., Meng Z., Cheung P., Ji H., McLaughlin M., Veenstra T.D.,
RA   Nusse R., McCrea P.D., Artandi S.E.;
RT   "Telomerase modulates Wnt signalling by association with target gene
RT   chromatin.";
RL   Nature 460:66-72(2009).
RN   [32]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF GLN-169.
RX   PubMed=19777057; DOI=10.1371/journal.pone.0007176;
RA   Wyatt H.D., Tsang A.R., Lobb D.A., Beattie T.L.;
RT   "Human telomerase reverse transcriptase (hTERT) Q169 is essential for
RT   telomerase function in vitro and in vivo.";
RL   PLoS ONE 4:E7176-E7176(2009).
RN   [33]
RP   IDENTIFICATION IN THE TELOMERASE HOLOENZYME COMPLEX.
RX   PubMed=19179534; DOI=10.1126/science.1165357;
RA   Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M.,
RA   Veenstra T.D., Terns M.P., Artandi S.E.;
RT   "A human telomerase holoenzyme protein required for Cajal body
RT   localization and telomere synthesis.";
RL   Science 323:644-648(2009).
RN   [34]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NVL.
RX   PubMed=22226966; DOI=10.1016/j.bbrc.2011.12.101;
RA   Her J., Chung I.K.;
RT   "The AAA-ATPase NVL2 is a telomerase component essential for
RT   holoenzyme assembly.";
RL   Biochem. Biophys. Res. Commun. 417:1086-1092(2012).
RN   [35]
RP   PHOSPHORYLATION AT SER-227, SUBCELLULAR LOCATION, AND NUCLEAR
RP   LOCALIZATION SIGNAL.
RX   PubMed=22366458; DOI=10.1242/jcs.099267;
RA   Chung J., Khadka P., Chung I.K.;
RT   "Nuclear import of hTERT requires a bipartite nuclear localization
RT   signal and Akt-mediated phosphorylation.";
RL   J. Cell Sci. 125:2684-2697(2012).
RN   [36]
RP   PHOSPHORYLATION AT SER-457, UBIQUITINATION, AND MUTAGENESIS OF
RP   SER-457.
RX   PubMed=23362280; DOI=10.1074/jbc.M112.416792;
RA   Jung H.Y., Wang X., Jun S., Park J.I.;
RT   "Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT
RT   degradation.";
RL   J. Biol. Chem. 288:7252-7262(2013).
RN   [37]
RP   UBIQUITINATION.
RX   PubMed=23612978; DOI=10.1074/jbc.M112.416735;
RA   Wang X., Singh S., Jung H.Y., Yang G., Jun S., Sastry K.J., Park J.I.;
RT   "HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP
RT   E3 ligase complex.";
RL   J. Biol. Chem. 288:15474-15480(2013).
RN   [38]
RP   INVOLVEMENT IN CMM9.
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 461-469 IN COMPLEX WITH CLASS
RP   I MAJOR HISTOCOMPATIBILITY COMPLEX (MHC).
RX   PubMed=16323248; DOI=10.1002/eji.200535424;
RA   Cole D.K., Rizkallah P.J., Gao F., Watson N.I., Boulter J.M.,
RA   Bell J.I., Sami M., Gao G.F., Jakobsen B.K.;
RT   "Crystal structure of HLA-A*2402 complexed with a telomerase
RT   peptide.";
RL   Eur. J. Immunol. 36:170-179(2006).
RN   [40]
RP   VARIANT AA THR-202, VARIANTS DKCA2 TRP-979 AND LEU-1127,
RP   CHARACTERIZATION OF VARIANT AA THR-202, AND CHARACTERIZATION OF
RP   VARIANTS DKCA2 TRP-979 AND LEU-1127.
RX   PubMed=15885610; DOI=10.1016/j.bcmd.2004.12.008;
RA   Vulliamy T.J., Walne A., Baskaradas A., Mason P.J., Marrone A.,
RA   Dokal I.;
RT   "Mutations in the reverse transcriptase component of telomerase (TERT)
RT   in patients with bone marrow failure.";
RL   Blood Cells Mol. Dis. 34:257-263(2005).
RN   [41]
RP   VARIANTS PFBMFT1 THR-202; TYR-412; MET-694; CYS-772 AND MET-1090, AND
RP   VARIANTS THR-279; GLU-441 DEL AND THR-1062.
RX   PubMed=15814878; DOI=10.1056/NEJMoa042980;
RA   Yamaguchi H., Calado R.T., Ly H., Kajigaya S., Baerlocher G.M.,
RA   Chanock S.J., Lansdorp P.M., Young N.S.;
RT   "Mutations in TERT, the gene for telomerase reverse transcriptase, in
RT   aplastic anemia.";
RL   N. Engl. J. Med. 352:1413-1424(2005).
RN   [42]
RP   VARIANT DKCA2 ASN-902, AND CHARACTERIZATION OF VARIANT DKCA2 ASN-902.
RX   PubMed=16247010; DOI=10.1073/pnas.0508124102;
RA   Armanios M., Chen J.-L., Chang Y.-P.C., Brodsky R.A., Hawkins A.,
RA   Griffin C.A., Eshleman J.R., Cohen A.R., Chakravarti A., Hamosh A.,
RA   Greider C.W.;
RT   "Haploinsufficiency of telomerase reverse transcriptase leads to
RT   anticipation in autosomal dominant dyskeratosis congenita.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15960-15964(2005).
RN   [43]
RP   INVOLVEMENT IN CAD SUSCEPTIBILITY.
RX   PubMed=16890917; DOI=10.1016/j.bbrc.2006.07.103;
RA   Matsubara Y., Murata M., Watanabe K., Saito I., Miyaki K., Omae K.,
RA   Ishikawa M., Matsushita K., Iwanaga S., Ogawa S., Ikeda Y.;
RT   "Coronary artery disease and a functional polymorphism of hTERT.";
RL   Biochem. Biophys. Res. Commun. 348:669-672(2006).
RN   [44]
RP   VARIANT DKCB4 ARG-721.
RX   PubMed=16332973; DOI=10.1182/blood-2005-07-2622;
RA   Vulliamy T.J., Marrone A., Knight S.W., Walne A., Mason P.J.,
RA   Dokal I.;
RT   "Mutations in dyskeratosis congenita: their impact on telomere length
RT   and the diversity of clinical presentation.";
RL   Blood 107:2680-2685(2006).
RN   [45]
RP   VARIANTS AA ASP-682 AND MET-726, AND CHARACTERIZATION OF VARIANT AA
RP   MET-726.
RX   PubMed=16627250;
RA   Liang J., Yagasaki H., Kamachi Y., Hama A., Matsumoto K., Kato K.,
RA   Kudo K., Kojima S.;
RT   "Mutations in telomerase catalytic protein in Japanese children with
RT   aplastic anemia.";
RL   Haematologica 91:656-658(2006).
RN   [46]
RP   VARIANT AA ASN-570, AND CHARACTERIZATION OF VARIANTS ASN-570; ASP-682;
RP   ARG-721; MET-726; ASN-902; TRP-979 AND LEU-1127.
RX   PubMed=16990594; DOI=10.1182/blood-2006-07-035089;
RA   Xin Z.T., Beauchamp A.D., Calado R.T., Bradford J.W., Regal J.A.,
RA   Shenoy A., Liang Y., Lansdorp P.M., Young N.S., Ly H.;
RT   "Functional characterization of natural telomerase mutations found in
RT   patients with hematologic disorders.";
RL   Blood 109:524-532(2007).
RN   [47]
RP   VARIANTS DKCB4 CYS-811 AND TRP-901, AND CHARACTERIZATION OF VARIANTS
RP   DKCB4 CYS-811 AND TRP-901.
RX   PubMed=17785587; DOI=10.1182/blood-2006-12-062851;
RA   Marrone A., Walne A., Tamary H., Masunari Y., Kirwan M., Beswick R.,
RA   Vulliamy T., Dokal I.;
RT   "Telomerase reverse-transcriptase homozygous mutations in autosomal
RT   recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome.";
RL   Blood 110:4198-4205(2007).
RN   [48]
RP   VARIANTS IDIOPATHIC PULMONARY FIBROSIS SUSCEPTIBILITY GLN-55 AND
RP   MET-1110, AND CHARACTERIZATION OF VARIANTS GLN-55 AND MET-1110.
RX   PubMed=17392301; DOI=10.1056/NEJMoa066157;
RA   Armanios M.Y., Chen J.J., Cogan J.D., Alder J.K., Ingersoll R.G.,
RA   Markin C., Lawson W.E., Xie M., Vulto I., Phillips J.A.,
RA   Lansdorp P.M., Greider C.W., Loyd J.E.;
RT   "Telomerase mutations in families with idiopathic pulmonary
RT   fibrosis.";
RL   N. Engl. J. Med. 356:1317-1326(2007).
RN   [49]
RP   VARIANT PFBMFT1 HIS-865.
RX   PubMed=17460043; DOI=10.1073/pnas.0701009104;
RA   Tsakiri K.D., Cronkhite J.T., Kuan P.J., Xing C., Raghu G.,
RA   Weissler J.C., Rosenblatt R.L., Shay J.W., Garcia C.K.;
RT   "Adult-onset pulmonary fibrosis caused by mutations in telomerase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7552-7557(2007).
RN   [50]
RP   VARIANTS DKCB4 TYR-412 AND SER-704, AND CHARACTERIZATION OF VARIANTS
RP   DKCB4 TYR-412 AND SER-704.
RX   PubMed=18042801; DOI=10.1182/blood-2007-10-120907;
RA   Du H.Y., Pumbo E., Manley P., Field J.J., Bayliss S.J., Wilson D.B.,
RA   Mason P.J., Bessler M.;
RT   "Complex inheritance pattern of dyskeratosis congenita in two families
RT   with 2 different mutations in the telomerase reverse transcriptase
RT   gene.";
RL   Blood 111:1128-1130(2008).
RN   [51]
RP   VARIANTS ALA-65; MET-299; LYS-522 AND THR-1062, AND VARIANTS AA
RP   THR-202; TYR-412; GLU-441 DEL; ASN-570; GLN-631; MET-694 AND LEU-785.
RX   PubMed=19760749; DOI=10.1002/humu.21115;
RA   Kirwan M., Vulliamy T., Marrone A., Walne A.J., Beswick R.,
RA   Hillmen P., Kelly R., Stewart A., Bowen D., Schonland S.O.,
RA   Whittle A.M., McVerry A., Gilleece M., Dokal I.;
RT   "Defining the pathogenic role of telomerase mutations in
RT   myelodysplastic syndrome and acute myeloid leukemia.";
RL   Hum. Mutat. 30:1567-1573(2009).
RN   [52]
RP   VARIANTS ALA-65; MET-299; TYR-412; GLU-441 DEL; LYS-522 AND THR-1062.
RX   PubMed=19147845; DOI=10.1073/pnas.0807057106;
RA   Calado R.T., Regal J.A., Hills M., Yewdell W.T., Dalmazzo L.F.,
RA   Zago M.A., Lansdorp P.M., Hogge D., Chanock S.J., Estey E.H.,
RA   Falcao R.P., Young N.S.;
RT   "Constitutional hypomorphic telomerase mutations in patients with
RT   acute myeloid leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:1187-1192(2009).
RN   [53]
RP   VARIANTS PFBMFT1 MET-170; THR-716; PHE-841; ARG-902 AND PHE-1025, AND
RP   CHARACTERIZATION OF VARIANTS PFBMFT1 MET-170; THR-716; PHE-841 AND
RP   PHE-1025.
RX   PubMed=21436073; DOI=10.1182/blood-2010-11-322149;
RA   Parry E.M., Alder J.K., Qi X., Chen J.J., Armanios M.;
RT   "Syndrome complex of bone marrow failure and pulmonary fibrosis
RT   predicts germline defects in telomerase.";
RL   Blood 117:5607-5611(2011).
RN   [54]
RP   VARIANTS PFBMFT1 ILE-791 AND MET-867, AND CHARACTERIZATION OF VARIANTS
RP   PFBMFT1 ILE-791 AND MET-867.
RX   PubMed=21483807; DOI=10.1371/journal.pgen.1001352;
RA   Alder J.K., Cogan J.D., Brown A.F., Anderson C.J., Lawson W.E.,
RA   Lansdorp P.M., Phillips J.A. III, Loyd J.E., Chen J.J., Armanios M.;
RT   "Ancestral mutation in telomerase causes defects in repeat addition
RT   processivity and manifests as familial pulmonary fibrosis.";
RL   PLoS Genet. 7:E1001352-E1001352(2011).
RN   [55]
RP   VARIANT PFBMFT1 LEU-923.
RX   PubMed=22512499; DOI=10.1056/NEJMc1200999;
RA   Gansner J.M., Rosas I.O., Ebert B.L.;
RT   "Pulmonary fibrosis, bone marrow failure, and telomerase mutation.";
RL   N. Engl. J. Med. 366:1551-1553(2012).
CC   -!- FUNCTION: Telomerase is a ribonucleoprotein enzyme essential for
CC       the replication of chromosome termini in most eukaryotes. Active
CC       in progenitor and cancer cells. Inactive, or very low activity, in
CC       normal somatic cells. Catalytic component of the teleromerase
CC       holoenzyme complex whose main activity is the elongation of
CC       telomeres by acting as a reverse transcriptase that adds simple
CC       sequence repeats to chromosome ends by copying a template sequence
CC       within the RNA component of the enzyme. Catalyzes the RNA-
CC       dependent extension of 3'-chromosomal termini with the 6-
CC       nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic
CC       cycle involves primer binding, primer extension and release of
CC       product once the template boundary has been reached or nascent
CC       product translocation followed by further extension. More active
CC       on substrates containing 2 or 3 telomeric repeats. Telomerase
CC       activity is regulated by a number of factors including telomerase
CC       complex-associated proteins, chaperones and polypeptide modifiers.
CC       Modulates Wnt signaling. Plays important roles in aging and
CC       antiapoptosis. {ECO:0000269|PubMed:14963003,
CC       ECO:0000269|PubMed:15082768, ECO:0000269|PubMed:15857955,
CC       ECO:0000269|PubMed:17026956, ECO:0000269|PubMed:17264120,
CC       ECO:0000269|PubMed:17296728, ECO:0000269|PubMed:17548608,
CC       ECO:0000269|PubMed:19188162, ECO:0000269|PubMed:19567472,
CC       ECO:0000269|PubMed:19571879, ECO:0000269|PubMed:19777057,
CC       ECO:0000269|PubMed:9389643}.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1). {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- SUBUNIT: Homodimer; dimerization is required to produce a
CC       functional complex. Oligomer; can form oligomers in the absence of
CC       the telomerase RNA template component (TERC). Catalytic subunit of
CC       the telomerase holoenzyme complex composed minimally of TERT and
CC       TERC. The telomerase complex is composed of TERT, DKC1,
CC       WDR79/TCAB1, NOP10, NHP2, GAR1, TEP1, EST1A, POT1 and a telomerase
CC       RNA template component (TERC). The molecular chaperone HSP90/P23
CC       complex is required for correct assembly and stabilization of the
CC       active telomerase. Interacts directly with HSP90A and PTGES3.
CC       Interacts with HSPA1A; the interaction occurs in the absence of
CC       TERC and dissociates once the complex has formed. Interacts with
CC       RAN; the interaction promotes nuclear export of TERT. Interacts
CC       with XPO1. Interacts with PTPN11; the interaction retains TERT in
CC       the nucleus. Interacts with NCL (via RRM1 and C-terminal
CC       RRM4/Arg/Gly-rich domains); the interaction is important for
CC       nucleolar localization of TERT. Interacts with SMARCA4 (via the
CC       bromodomain); the interaction regulates Wnt-mediated signaling.
CC       Interacts with MCRS1 (isoform MCRS2); the interaction inhibits in
CC       vitro telomerase activity. Interacts with PIF1; the interaction
CC       has no effect on the elongation activity of TERT. Interacts with
CC       PML; the interaction recruits TERT to PML bodies and inhibits
CC       telomerase activity. Interacts with GNL3L (By similarity).
CC       Interacts with isoform 1 and isoform 2 of NVL (PubMed:22226966).
CC       {ECO:0000250|UniProtKB:O70372, ECO:0000269|PubMed:22226966}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-1772203, EBI-1772203;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-1772203, EBI-491549;
CC       P03126:E6 (xeno); NbExp=7; IntAct=EBI-1772203, EBI-1177242;
CC       Q9BVP2:GNL3; NbExp=3; IntAct=EBI-1772203, EBI-641642;
CC       P29590-5:PML; NbExp=7; IntAct=EBI-1772203, EBI-304008;
CC       Q9Y265:RUVBL1; NbExp=11; IntAct=EBI-1772203, EBI-353675;
CC       P51532:SMARCA4; NbExp=8; IntAct=EBI-1772203, EBI-302489;
CC       O14773-1:TPP1; NbExp=2; IntAct=EBI-1772203, EBI-15619703;
CC       Q92900:UPF1; NbExp=3; IntAct=EBI-1772203, EBI-373471;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus
CC       {ECO:0000269|PubMed:22226966}. Nucleus, nucleoplasm. Nucleus.
CC       Chromosome, telomere. Cytoplasm. Nucleus, PML body. Note=Shuttling
CC       between nuclear and cytoplasm depends on cell cycle,
CC       phosphorylation states, transformation and DNA damage. Diffuse
CC       localization in the nucleoplasm. Enriched in nucleoli of certain
CC       cell types. Translocated to the cytoplasm via nuclear pores in a
CC       CRM1/RAN-dependent manner involving oxidative stress-mediated
CC       phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2
CC       retains TERT in the nucleus. Translocated to the nucleus by
CC       phosphorylation by AKT.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O14746-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14746-2; Sequence=VSP_019587, VSP_019588;
CC       Name=3;
CC         IsoId=O14746-3; Sequence=VSP_021727;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay. No
CC         experimental confirmation available.;
CC       Name=4;
CC         IsoId=O14746-4; Sequence=VSP_053369, VSP_019587, VSP_019588;
CC   -!- TISSUE SPECIFICITY: Expressed at a high level in thymocyte
CC       subpopulations, at an intermediate level in tonsil T-lymphocytes,
CC       and at a low to undetectable level in peripheral blood T-
CC       lymphocytes. {ECO:0000269|PubMed:8676067,
CC       ECO:0000269|PubMed:9389643}.
CC   -!- INDUCTION: Activated by cytotoxic events and down-regulated during
CC       aging. In peripheral T-lymphocytes, induced By CD3 and by
CC       PMA/ionomycin. Inhibited by herbimycin B.
CC       {ECO:0000269|PubMed:8676067}.
CC   -!- DOMAIN: The primer grip sequence in the RT domain is required for
CC       telomerase activity and for stable association with short
CC       telomeric primers.
CC   -!- DOMAIN: The RNA-interacting domain 1 (RD1)/N-terminal extension
CC       (NTE) is required for interaction with the pseudoknot-template
CC       domain of each of TERC dimers. It contains anchor sites that bind
CC       primer nucleotides upstream of the RNA-DNA hybrid and is thus an
CC       essential determinant of repeat addition processivity.
CC   -!- DOMAIN: The RNA-interacting domain 2 (RD2) is essential for both
CC       interaction with the CR4-CR5 domain of TERC and for DNA synthesis.
CC   -!- PTM: Phosphorylation at Tyr-707 under oxidative stress leads to
CC       translocation of TERT to the cytoplasm and reduces its
CC       antiapoptotic activity. Dephosphorylated by SHP2/PTPN11 leading to
CC       nuclear retention. Phosphorylation at Ser-227 by the AKT pathway
CC       promotes nuclear location. Phosphorylation at the G2/M phase at
CC       Ser-457 by DYRK2 promotes ubiquitination by the EDVP complex and
CC       degradation. {ECO:0000269|PubMed:12808100,
CC       ECO:0000269|PubMed:18829466, ECO:0000269|PubMed:22366458,
CC       ECO:0000269|PubMed:23362280}.
CC   -!- PTM: Ubiquitinated by the EDVP complex, a E3 ligase complex
CC       following phosphorylation at Ser-457 by DYRK2. Ubiquitinated leads
CC       to proteasomal degradation. In case of infection by HIV-1, the
CC       EDVP complex is hijacked by HIV-1 via interaction between HIV-1
CC       Vpr and DCAF1/VPRBP, leading to ubiquitination and degradation.
CC       {ECO:0000269|PubMed:23362280}.
CC   -!- DISEASE: Note=Activation of telomerase has been implicated in cell
CC       immortalization and cancer cell pathogenesis.
CC   -!- DISEASE: Aplastic anemia (AA) [MIM:609135]: A form of anemia in
CC       which the bone marrow fails to produce adequate numbers of
CC       peripheral blood elements. It is characterized by peripheral
CC       pancytopenia and marrow hypoplasia. {ECO:0000269|PubMed:15885610,
CC       ECO:0000269|PubMed:16627250, ECO:0000269|PubMed:16990594,
CC       ECO:0000269|PubMed:19760749}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Genetic variations in TERT are associated with
CC       coronary artery disease (CAD).
CC   -!- DISEASE: Dyskeratosis congenita, autosomal dominant, 2 (DKCA2)
CC       [MIM:613989]: A rare multisystem disorder caused by defective
CC       telomere maintenance. It is characterized by progressive bone
CC       marrow failure, and the clinical triad of reticulated skin
CC       hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common
CC       but variable features include premature graying, aplastic anemia,
CC       low platelets, osteoporosis, pulmonary fibrosis, and liver
CC       fibrosis among others. Early mortality is often associated with
CC       bone marrow failure, infections, fatal pulmonary complications, or
CC       malignancy. {ECO:0000269|PubMed:15885610,
CC       ECO:0000269|PubMed:16247010}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pulmonary fibrosis, and/or bone marrow failure, telomere-
CC       related, 1 (PFBMFT1) [MIM:614742]: A disease associated with
CC       shortened telomeres. Pulmonary fibrosis is the most common
CC       manifestation. Other manifestations include aplastic anemia due to
CC       bone marrow failure, hepatic fibrosis, and increased cancer risk,
CC       particularly myelodysplastic syndrome and acute myeloid leukemia.
CC       Phenotype, age at onset, and severity are determined by telomere
CC       length. {ECO:0000269|PubMed:15814878, ECO:0000269|PubMed:17460043,
CC       ECO:0000269|PubMed:21436073, ECO:0000269|PubMed:21483807,
CC       ECO:0000269|PubMed:22512499}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Dyskeratosis congenita, autosomal recessive, 4 (DKCB4)
CC       [MIM:613989]: A severe form of dyskeratosis congenita, a rare
CC       multisystem disorder caused by defective telomere maintenance. It
CC       is characterized by progressive bone marrow failure, and the
CC       clinical triad of reticulated skin hyperpigmentation, nail
CC       dystrophy, and mucosal leukoplakia. Common but variable features
CC       include premature graying, aplastic anemia, low platelets,
CC       osteoporosis, pulmonary fibrosis, and liver fibrosis among others.
CC       Early mortality is often associated with bone marrow failure,
CC       infections, fatal pulmonary complications, or malignancy.
CC       {ECO:0000269|PubMed:16332973, ECO:0000269|PubMed:17785587,
CC       ECO:0000269|PubMed:18042801}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pulmonary fibrosis, idiopathic (IPF) [MIM:178500]: A lung
CC       disease characterized by shortness of breath, radiographically
CC       evident diffuse pulmonary infiltrates, and varying degrees of
CC       inflammation and fibrosis on biopsy. In some cases, the disorder
CC       can be rapidly progressive and characterized by sequential acute
CC       lung injury with subsequent scarring and end-stage lung disease.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Melanoma, cutaneous malignant 9 (CMM9) [MIM:615134]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but
CC       also may involve other sites. {ECO:0000269|PubMed:23348503}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the reverse transcriptase family.
CC       Telomerase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tert/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF018167; AAC51724.1; -; mRNA.
DR   EMBL; AF015950; AAC51672.1; -; mRNA.
DR   EMBL; AF128894; AAD30037.1; -; Genomic_DNA.
DR   EMBL; AF128893; AAD30037.1; JOINED; Genomic_DNA.
DR   EMBL; AB085628; BAC11010.1; -; mRNA.
DR   EMBL; AB086379; BAC11014.1; -; mRNA.
DR   EMBL; AB086950; BAC11015.1; -; mRNA.
DR   EMBL; AY007685; AAG23289.1; -; Genomic_DNA.
DR   EMBL; DQ264729; ABB72674.1; -; Genomic_DNA.
DR   EMBL; AC114291; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471102; EAX08167.1; -; Genomic_DNA.
DR   CCDS; CCDS3861.2; -. [O14746-1]
DR   CCDS; CCDS54831.1; -. [O14746-3]
DR   PIR; T03844; T03844.
DR   RefSeq; NP_001180305.1; NM_001193376.1. [O14746-3]
DR   RefSeq; NP_937983.2; NM_198253.2. [O14746-1]
DR   UniGene; Hs.492203; -.
DR   PDB; 2BCK; X-ray; 2.80 A; C/F=461-469.
DR   PDB; 4B18; X-ray; 2.52 A; B=222-240.
DR   PDB; 4MNQ; X-ray; 2.74 A; C=540-548.
DR   PDB; 5MEN; X-ray; 2.81 A; C=540-548.
DR   PDB; 5MEO; X-ray; 1.77 A; C=540-548.
DR   PDB; 5MEP; X-ray; 2.71 A; C/F=540-548.
DR   PDB; 5MEQ; X-ray; 2.27 A; C=540-546.
DR   PDB; 5MER; X-ray; 1.88 A; C/F=540-546.
DR   PDB; 5UGW; X-ray; 2.31 A; A=961-1132.
DR   PDBsum; 2BCK; -.
DR   PDBsum; 4B18; -.
DR   PDBsum; 4MNQ; -.
DR   PDBsum; 5MEN; -.
DR   PDBsum; 5MEO; -.
DR   PDBsum; 5MEP; -.
DR   PDBsum; 5MEQ; -.
DR   PDBsum; 5MER; -.
DR   PDBsum; 5UGW; -.
DR   ProteinModelPortal; O14746; -.
DR   SMR; O14746; -.
DR   BioGrid; 112874; 67.
DR   CORUM; O14746; -.
DR   DIP; DIP-40646N; -.
DR   ELM; O14746; -.
DR   IntAct; O14746; 23.
DR   MINT; O14746; -.
DR   STRING; 9606.ENSP00000309572; -.
DR   BindingDB; O14746; -.
DR   ChEMBL; CHEMBL2916; -.
DR   DrugBank; DB05036; Grn163l.
DR   DrugBank; DB04937; GV1001.
DR   DrugBank; DB00495; Zidovudine.
DR   iPTMnet; O14746; -.
DR   PhosphoSitePlus; O14746; -.
DR   BioMuta; TERT; -.
DR   EPD; O14746; -.
DR   PaxDb; O14746; -.
DR   PeptideAtlas; O14746; -.
DR   PRIDE; O14746; -.
DR   DNASU; 7015; -.
DR   Ensembl; ENST00000310581; ENSP00000309572; ENSG00000164362. [O14746-1]
DR   Ensembl; ENST00000334602; ENSP00000334346; ENSG00000164362. [O14746-3]
DR   Ensembl; ENST00000460137; ENSP00000425003; ENSG00000164362. [O14746-4]
DR   Ensembl; ENST00000508104; ENSP00000426042; ENSG00000164362. [O14746-2]
DR   GeneID; 7015; -.
DR   KEGG; hsa:7015; -.
DR   UCSC; uc003jcb.2; human. [O14746-1]
DR   CTD; 7015; -.
DR   DisGeNET; 7015; -.
DR   EuPathDB; HostDB:ENSG00000164362.18; -.
DR   GeneCards; TERT; -.
DR   GeneReviews; TERT; -.
DR   HGNC; HGNC:11730; TERT.
DR   HPA; HPA054641; -.
DR   HPA; HPA065897; -.
DR   MalaCards; TERT; -.
DR   MIM; 178500; phenotype.
DR   MIM; 187270; gene+phenotype.
DR   MIM; 609135; phenotype.
DR   MIM; 613989; phenotype.
DR   MIM; 614742; phenotype.
DR   MIM; 615134; phenotype.
DR   neXtProt; NX_O14746; -.
DR   OpenTargets; ENSG00000164362; -.
DR   Orphanet; 1775; Dyskeratosis congenita.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 3322; Hoyeraal-Hreidarsson syndrome.
DR   Orphanet; 88; Idiopathic aplastic anemia.
DR   Orphanet; 2032; Idiopathic pulmonary fibrosis.
DR   PharmGKB; PA36447; -.
DR   eggNOG; KOG1005; Eukaryota.
DR   eggNOG; ENOG410XQJH; LUCA.
DR   GeneTree; ENSGT00390000018531; -.
DR   HOGENOM; HOG000148780; -.
DR   HOVERGEN; HBG000460; -.
DR   InParanoid; O14746; -.
DR   KO; K11126; -.
DR   OMA; QCQGIPQ; -.
DR   OrthoDB; EOG091G04DO; -.
DR   PhylomeDB; O14746; -.
DR   TreeFam; TF329048; -.
DR   Reactome; R-HSA-171319; Telomere Extension By Telomerase.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   SIGNOR; O14746; -.
DR   ChiTaRS; TERT; human.
DR   EvolutionaryTrace; O14746; -.
DR   GeneWiki; Telomerase_reverse_transcriptase; -.
DR   GenomeRNAi; 7015; -.
DR   PRO; PR:O14746; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000164362; -.
DR   CleanEx; HS_TERT; -.
DR   Genevisible; O14746; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IC:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:BHF-UCL.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0000783; C:nuclear telomere cap complex; IC:BHF-UCL.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0031379; C:RNA-directed RNA polymerase complex; IPI:BHF-UCL.
DR   GO; GO:0000333; C:telomerase catalytic core complex; IDA:BHF-UCL.
DR   GO; GO:0005697; C:telomerase holoenzyme complex; IDA:UniProtKB.
DR   GO; GO:1990572; C:TERT-RMRP complex; IDA:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016779; F:nucleotidyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IPI:BHF-UCL.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IDA:BHF-UCL.
DR   GO; GO:0003720; F:telomerase activity; IDA:UniProtKB.
DR   GO; GO:0070034; F:telomerase RNA binding; IDA:BHF-UCL.
DR   GO; GO:0003721; F:telomerase RNA reverse transcriptase activity; IDA:BHF-UCL.
DR   GO; GO:0042162; F:telomeric DNA binding; TAS:ProtInc.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL.
DR   GO; GO:0000049; F:tRNA binding; IDA:BHF-UCL.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0071897; P:DNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0022616; P:DNA strand elongation; IDA:BHF-UCL.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; IDA:BHF-UCL.
DR   GO; GO:0007005; P:mitochondrion organization; IDA:BHF-UCL.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IDA:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:1903704; P:negative regulation of production of siRNA involved in RNA interference; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:0042635; P:positive regulation of hair cycle; ISS:BHF-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:BHF-UCL.
DR   GO; GO:1904751; P:positive regulation of protein localization to nucleolus; IDA:BHF-UCL.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; ISS:BHF-UCL.
DR   GO; GO:1903620; P:positive regulation of transdifferentiation; IEA:Ensembl.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IGI:BHF-UCL.
DR   GO; GO:0030422; P:production of siRNA involved in RNA interference; IDA:BHF-UCL.
DR   GO; GO:0031647; P:regulation of protein stability; IDA:BHF-UCL.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0032774; P:RNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006278; P:RNA-dependent DNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0000723; P:telomere maintenance; TAS:UniProtKB.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; IDA:BHF-UCL.
DR   GO; GO:0001172; P:transcription, RNA-templated; IDA:BHF-UCL.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR021891; Telomerase_RBD.
DR   InterPro; IPR003545; Telomerase_RT.
DR   PANTHER; PTHR12066; PTHR12066; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF12009; Telomerase_RBD; 1.
DR   PRINTS; PR01365; TELOMERASERT.
DR   SMART; SM00975; Telomerase_RBD; 1.
DR   PROSITE; PS50878; RT_POL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosome; Complete proteome;
KW   Cytoplasm; Disease mutation; DNA-binding; Dyskeratosis congenita;
KW   Magnesium; Metal-binding; Nucleotidyltransferase; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Ribonucleoprotein;
KW   RNA-directed DNA polymerase; Telomere; Transferase; Ubl conjugation.
FT   CHAIN         1   1132       Telomerase reverse transcriptase.
FT                                /FTId=PRO_0000054925.
FT   DOMAIN      605    935       Reverse transcriptase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   REGION        1    230       RNA-interacting domain 1.
FT   REGION       58    197       GQ motif.
FT   REGION      137    141       Required for regulating specificity for
FT                                telomeric DNA and for processivity for
FT                                primer elongation.
FT   REGION      231    324       Linker.
FT   REGION      301    538       Required for oligomerization.
FT   REGION      325    550       RNA-interacting domain 2.
FT   REGION      376    521       QFP motif.
FT   REGION      397    417       CP motif.
FT   REGION      914    928       Required for oligomerization.
FT   REGION      930    934       Primer grip sequence.
FT   REGION      936   1132       CTE.
FT   MOTIF       222    240       Bipartite nuclear localization signal.
FT   MOTIF       328    333       TFLY; involved in RNA binding.
FT                                {ECO:0000250|UniProtKB:Q4KTA7}.
FT   METAL       712    712       Magnesium; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   METAL       868    868       Magnesium; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   METAL       869    869       Magnesium; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   SITE        169    169       Required for optimal binding of telomeric
FT                                ssDNA and incorporation of nucleotides at
FT                                the second position of the template.
FT   SITE        867    867       Required for nucleotide incorporation and
FT                                primer extension rate.
FT   MOD_RES     227    227       Phosphoserine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:22366458}.
FT   MOD_RES     457    457       Phosphoserine; by DYRK2.
FT                                {ECO:0000269|PubMed:23362280}.
FT   MOD_RES     707    707       Phosphotyrosine; by SRC-type Tyr-kinases.
FT                                {ECO:0000269|PubMed:12808100,
FT                                ECO:0000269|PubMed:18829466}.
FT   VAR_SEQ     711    722       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14654914}.
FT                                /FTId=VSP_053369.
FT   VAR_SEQ     764    807       STLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSG
FT                                LFD -> LRPVPGDPAGLHPLHAALQPVLRRHGEQAVCGDS
FT                                AGRAAPAFGG (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:12869302,
FT                                ECO:0000303|PubMed:14654914}.
FT                                /FTId=VSP_019587.
FT   VAR_SEQ     808   1132       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:12869302,
FT                                ECO:0000303|PubMed:14654914}.
FT                                /FTId=VSP_019588.
FT   VAR_SEQ     885    947       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14654914}.
FT                                /FTId=VSP_021727.
FT   VARIANT      55     55       L -> Q (in idiopathic pulmonary fibrosis
FT                                susceptibility; impaired telomerase
FT                                activity; dbSNP:rs387907247).
FT                                {ECO:0000269|PubMed:17392301}.
FT                                /FTId=VAR_062535.
FT   VARIANT      65     65       P -> A (associated with acute myeloid
FT                                leukemia; dbSNP:rs544215765).
FT                                {ECO:0000269|PubMed:19147845,
FT                                ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_062780.
FT   VARIANT     170    170       V -> M (in PFBMFT1; the mutant protein is
FT                                demonstrated to cause decreased
FT                                telomerase activity; dbSNP:rs387907248).
FT                                {ECO:0000269|PubMed:21436073}.
FT                                /FTId=VAR_068792.
FT   VARIANT     202    202       A -> T (in PFBMFT1 and AA; severe and
FT                                moderate; associated with disease
FT                                susceptibility; shorter telomeres;
FT                                dbSNP:rs121918661).
FT                                {ECO:0000269|PubMed:15814878,
FT                                ECO:0000269|PubMed:15885610,
FT                                ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_036863.
FT   VARIANT     279    279       A -> T (in dbSNP:rs61748181).
FT                                {ECO:0000269|PubMed:15814878}.
FT                                /FTId=VAR_036864.
FT   VARIANT     299    299       V -> M (associated with acute myeloid
FT                                leukemia; dbSNP:rs756624928).
FT                                {ECO:0000269|PubMed:19147845,
FT                                ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_062781.
FT   VARIANT     412    412       H -> Y (in PFBMFT1, AA and DKCB4; severe
FT                                and moderate; associated with
FT                                susceptibility to acute myelogenous
FT                                leukemia; the mutant protein has 36%
FT                                residual activity; dbSNP:rs34094720).
FT                                {ECO:0000269|PubMed:15814878,
FT                                ECO:0000269|PubMed:18042801,
FT                                ECO:0000269|PubMed:19147845,
FT                                ECO:0000269|PubMed:19760749,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_025149.
FT   VARIANT     441    441       Missing (in AA; associated with
FT                                susceptibility to acute myeloid
FT                                leukemia). {ECO:0000269|PubMed:15814878,
FT                                ECO:0000269|PubMed:19147845,
FT                                ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_036865.
FT   VARIANT     522    522       R -> K (associated with acute myeloid
FT                                leukemia). {ECO:0000269|PubMed:19147845,
FT                                ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_062782.
FT   VARIANT     570    570       K -> N (in AA; abolishes telomerase
FT                                catalytic activity but no effect on
FT                                binding to TERC).
FT                                {ECO:0000269|PubMed:16990594,
FT                                ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_062536.
FT   VARIANT     631    631       R -> Q (in AA; dbSNP:rs199422294).
FT                                {ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_062783.
FT   VARIANT     682    682       G -> D (in AA; non-severe; abolishes
FT                                telomerase catalytic activity but little
FT                                effect on binding to TERC;
FT                                dbSNP:rs199422295).
FT                                {ECO:0000269|PubMed:16627250,
FT                                ECO:0000269|PubMed:16990594}.
FT                                /FTId=VAR_062537.
FT   VARIANT     694    694       V -> M (in PFBMFT1 and AA; moderate;
FT                                dbSNP:rs121918662).
FT                                {ECO:0000269|PubMed:15814878,
FT                                ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_036866.
FT   VARIANT     704    704       P -> S (in DKCB4; the mutant protein has
FT                                13% residual activity;
FT                                dbSNP:rs199422297).
FT                                {ECO:0000269|PubMed:18042801}.
FT                                /FTId=VAR_068793.
FT   VARIANT     716    716       A -> T (in PFBMFT1; the mutant protein is
FT                                demonstrated to cause severely
FT                                compromised telomerase activity;
FT                                dbSNP:rs387907249).
FT                                {ECO:0000269|PubMed:21436073}.
FT                                /FTId=VAR_068794.
FT   VARIANT     721    721       P -> R (in DKCB4; no effect on telomerase
FT                                catalytic activity and little effect on
FT                                binding to TERC; dbSNP:rs199422299).
FT                                {ECO:0000269|PubMed:16332973,
FT                                ECO:0000269|PubMed:16990594}.
FT                                /FTId=VAR_062538.
FT   VARIANT     726    726       T -> M (in AA; very severe; no effect on
FT                                telomerase catalytic activity but
FT                                shortened telomeres; dbSNP:rs149566858).
FT                                {ECO:0000269|PubMed:16627250,
FT                                ECO:0000269|PubMed:16990594}.
FT                                /FTId=VAR_062539.
FT   VARIANT     772    772       Y -> C (in PFBMFT1; moderate;
FT                                dbSNP:rs121918663).
FT                                {ECO:0000269|PubMed:15814878}.
FT                                /FTId=VAR_036867.
FT   VARIANT     785    785       P -> L (in AA).
FT                                {ECO:0000269|PubMed:19760749}.
FT                                /FTId=VAR_062784.
FT   VARIANT     791    791       V -> I (in PFBMFT1; associated with Met-
FT                                867 in cis on the same allele; the double
FT                                mutant shows severe defects in telomere
FT                                repeat addition processivity;
FT                                dbSNP:rs141425941).
FT                                {ECO:0000269|PubMed:21483807}.
FT                                /FTId=VAR_068795.
FT   VARIANT     811    811       R -> C (in DKCB4; 50% reduction in
FT                                telomerase activity; dbSNP:rs199422301).
FT                                {ECO:0000269|PubMed:17785587}.
FT                                /FTId=VAR_062540.
FT   VARIANT     841    841       L -> F (in PFBMFT1).
FT                                {ECO:0000269|PubMed:21436073}.
FT                                /FTId=VAR_068796.
FT   VARIANT     865    865       R -> H (in PFBMFT1; dbSNP:rs121918666).
FT                                {ECO:0000269|PubMed:17460043}.
FT                                /FTId=VAR_036868.
FT   VARIANT     867    867       V -> M (in PFBMFT1; associated with Ile-
FT                                791 in cis on the same allele; the double
FT                                mutant shows severe defects in telomere
FT                                repeat addition processivity; this
FT                                mutation causes most if not all of the
FT                                functional defects; dbSNP:rs201159197).
FT                                {ECO:0000269|PubMed:21483807}.
FT                                /FTId=VAR_068797.
FT   VARIANT     901    901       R -> W (in DKCB4; severe phenotype
FT                                overlapping with Hoyeraal-Hreidarsson
FT                                syndrome; very short telomeres and
FT                                greatly reduced telomerase activity;
FT                                dbSNP:rs199422304).
FT                                {ECO:0000269|PubMed:17785587}.
FT                                /FTId=VAR_062541.
FT   VARIANT     902    902       K -> N (in DKCA2; abolishes telomerase
FT                                catalytic activity but no effect on
FT                                binding to TERC; dbSNP:rs121918665).
FT                                {ECO:0000269|PubMed:16247010,
FT                                ECO:0000269|PubMed:16990594}.
FT                                /FTId=VAR_036869.
FT   VARIANT     902    902       K -> R (in PFBMFT1; dbSNP:rs387907250).
FT                                {ECO:0000269|PubMed:21436073}.
FT                                /FTId=VAR_068798.
FT   VARIANT     923    923       P -> L (in PFBMFT1; dbSNP:rs387907251).
FT                                {ECO:0000269|PubMed:22512499}.
FT                                /FTId=VAR_068799.
FT   VARIANT     948    948       S -> R (in dbSNP:rs34062885).
FT                                /FTId=VAR_053726.
FT   VARIANT     979    979       R -> W (in DKCA2; shortened telomeres but
FT                                no effect on telomerase catalytic
FT                                activity nor on binding to TERC;
FT                                dbSNP:rs199422305).
FT                                {ECO:0000269|PubMed:15885610,
FT                                ECO:0000269|PubMed:16990594}.
FT                                /FTId=VAR_062542.
FT   VARIANT    1025   1025       V -> F (in PFBMFT1).
FT                                {ECO:0000269|PubMed:21436073}.
FT                                /FTId=VAR_068800.
FT   VARIANT    1062   1062       A -> T (increased incidence in sporadic
FT                                acute myeloid leukemia;
FT                                dbSNP:rs35719940).
FT                                {ECO:0000269|PubMed:15814878,
FT                                ECO:0000269|PubMed:19147845,
FT                                ECO:0000269|PubMed:19760749,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_025150.
FT   VARIANT    1090   1090       V -> M (in PFBMFT1; severe;
FT                                dbSNP:rs121918664).
FT                                {ECO:0000269|PubMed:15814878}.
FT                                /FTId=VAR_036870.
FT   VARIANT    1110   1110       T -> M (in idiopathic pulmonary fibrosis
FT                                susceptibility; impaired telomerase
FT                                activity; dbSNP:rs199422306).
FT                                {ECO:0000269|PubMed:17392301}.
FT                                /FTId=VAR_062543.
FT   VARIANT    1127   1127       F -> L (in DKCA2; severe; shortened
FT                                telomeres but no effect on telomerase
FT                                catalytic activity nor on binding to
FT                                TERC). {ECO:0000269|PubMed:15885610,
FT                                ECO:0000269|PubMed:16990594}.
FT                                /FTId=VAR_062544.
FT   MUTAGEN     137    141       WGLLL->AAAAA: Reduced catalytic activity
FT                                and repeat addition processivity.
FT                                Complete loss of catalytic activity but
FT                                no loss of binding to telomeric primers;
FT                                when associated with 930-A--A-934.
FT                                {ECO:0000269|PubMed:17296728}.
FT   MUTAGEN     169    169       Q->A: About 80% loss of enzymatic
FT                                activity. Greatly reduced incorporation
FT                                of second nucleotide. Altered strength of
FT                                binding to ssDNA. Little effect on repeat
FT                                addition processivity, nor on TR
FT                                interaction nor on protein levels.
FT                                {ECO:0000269|PubMed:19777057}.
FT   MUTAGEN     169    169       Q->N: About 85% loss of enzymatic
FT                                activity. Greatly reduced incorporation
FT                                of second nucleotide. Altered strength of
FT                                binding to ssDNA. No effect on protein
FT                                levels nor on TR interaction.
FT                                {ECO:0000269|PubMed:19777057}.
FT   MUTAGEN     169    169       Q->T: About 90% loss of enzymatic
FT                                activity. Greatly reduced incorporation
FT                                of second nucleotide. Altered strength of
FT                                binding to ssDNA. No effect on protein
FT                                levels nor on TR interaction.
FT                                {ECO:0000269|PubMed:19777057}.
FT   MUTAGEN     457    457       S->A: Abolishes phosphorylation by DYRK2.
FT                                {ECO:0000269|PubMed:23362280}.
FT   MUTAGEN     547    547       W->A: Defective in high-affinity TERC
FT                                interactions.
FT                                {ECO:0000269|PubMed:15082768}.
FT   MUTAGEN     631    631       R->A: Abolishes telomerase catalytic
FT                                activity. {ECO:0000269|PubMed:17026956}.
FT   MUTAGEN     707    707       Y->F: Abolishes oxidative stress-induced
FT                                phosphorylation and RAN binding. Impaired
FT                                nuclear export and enhanced antiapoptotic
FT                                activity against ROS-dependent apoptosis
FT                                induction. Impaired interaction with
FT                                PTPN11. No dephosphorylation by PTPN11.
FT                                {ECO:0000269|PubMed:12808100,
FT                                ECO:0000269|PubMed:18829466}.
FT   MUTAGEN     712    712       D->A: Loss of telomerase activity. In the
FT                                absence of TR, no loss of binding to
FT                                telomeric primers.
FT                                {ECO:0000269|PubMed:17026956,
FT                                ECO:0000269|PubMed:17296728,
FT                                ECO:0000269|PubMed:9389643,
FT                                ECO:0000269|PubMed:9443919}.
FT   MUTAGEN     866    866       L->Y: Moderate reduction in telomerase
FT                                activity, no change in repeat extension
FT                                rate nor on nucleotide incorporation
FT                                fidelity. Little further reduction in
FT                                activity but 13.5-fold increase in
FT                                nucleotide incorporation fidelity; when
FT                                associated with M-867.
FT                                {ECO:0000269|PubMed:17264120}.
FT   MUTAGEN     867    867       V->A: About 75% reduction in telomerase
FT                                activity, about 80% reduction in repeat
FT                                reduction rate and 3.9-fold increase in
FT                                nucleotide incorporation fidelity.
FT                                {ECO:0000269|PubMed:17264120}.
FT   MUTAGEN     867    867       V->M: About 75% reduction in telomerase
FT                                activity, about 50% reduction in repeat
FT                                extension rate and 5.2-fold increase in
FT                                nucleotide incorporation fidelity. Little
FT                                further reduction in activity and 13.5-
FT                                fold increase in nucleotide incorporation
FT                                fidelity; when associated with Y-866.
FT                                {ECO:0000269|PubMed:17264120}.
FT   MUTAGEN     867    867       V->T: Severe reduction in telomerase
FT                                activity, about 50% reduction in repeat
FT                                extension rate and 2.2-fold increase in
FT                                nucleotide incorporation fidelity. No
FT                                further reduction in activity but 2.8-
FT                                fold increase in nucleotide incorporation
FT                                fidelity; when associated with Y-866.
FT                                {ECO:0000269|PubMed:17264120}.
FT   MUTAGEN     868    869       DD->AA: Loss of telomerase activity.
FT   MUTAGEN     868    868       D->A: Loss of telomerase activity.
FT                                {ECO:0000269|PubMed:15082768,
FT                                ECO:0000269|PubMed:15857955,
FT                                ECO:0000269|PubMed:17026956,
FT                                ECO:0000269|PubMed:9389643,
FT                                ECO:0000269|PubMed:9443919}.
FT   MUTAGEN     869    869       D->A: Loss of telomerase activity.
FT                                {ECO:0000269|PubMed:9389643,
FT                                ECO:0000269|PubMed:9443919}.
FT   MUTAGEN     930    934       WCGLL->AAAAA: Completely abolishes
FT                                telomerase-mediated primer extension and
FT                                reduced binding to short telomeric
FT                                primers. Complete loss of catalytic
FT                                activity but no further loss of binding
FT                                to telomeric primers; when associated
FT                                with 137-A--A-141.
FT                                {ECO:0000269|PubMed:17296728}.
FT   CONFLICT    516    516       D -> G (in Ref. 1; AAC51724).
FT                                {ECO:0000305}.
FT   HELIX       966    983       {ECO:0000244|PDB:5UGW}.
FT   HELIX       984    986       {ECO:0000244|PDB:5UGW}.
FT   TURN        989    991       {ECO:0000244|PDB:5UGW}.
FT   HELIX       994   1017       {ECO:0000244|PDB:5UGW}.
FT   HELIX      1025   1027       {ECO:0000244|PDB:5UGW}.
FT   HELIX      1029   1050       {ECO:0000244|PDB:5UGW}.
FT   TURN       1051   1053       {ECO:0000244|PDB:5UGW}.
FT   HELIX      1067   1082       {ECO:0000244|PDB:5UGW}.
FT   HELIX      1083   1085       {ECO:0000244|PDB:5UGW}.
FT   HELIX      1086   1104       {ECO:0000244|PDB:5UGW}.
FT   HELIX      1111   1118       {ECO:0000244|PDB:5UGW}.
SQ   SEQUENCE   1132 AA;  126997 MW;  94E35469C4CA33A0 CRC64;
     MPRAPRCRAV RSLLRSHYRE VLPLATFVRR LGPQGWRLVQ RGDPAAFRAL VAQCLVCVPW
     DARPPPAAPS FRQVSCLKEL VARVLQRLCE RGAKNVLAFG FALLDGARGG PPEAFTTSVR
     SYLPNTVTDA LRGSGAWGLL LRRVGDDVLV HLLARCALFV LVAPSCAYQV CGPPLYQLGA
     ATQARPPPHA SGPRRRLGCE RAWNHSVREA GVPLGLPAPG ARRRGGSASR SLPLPKRPRR
     GAAPEPERTP VGQGSWAHPG RTRGPSDRGF CVVSPARPAE EATSLEGALS GTRHSHPSVG
     RQHHAGPPST SRPPRPWDTP CPPVYAETKH FLYSSGDKEQ LRPSFLLSSL RPSLTGARRL
     VETIFLGSRP WMPGTPRRLP RLPQRYWQMR PLFLELLGNH AQCPYGVLLK THCPLRAAVT
     PAAGVCAREK PQGSVAAPEE EDTDPRRLVQ LLRQHSSPWQ VYGFVRACLR RLVPPGLWGS
     RHNERRFLRN TKKFISLGKH AKLSLQELTW KMSVRDCAWL RRSPGVGCVP AAEHRLREEI
     LAKFLHWLMS VYVVELLRSF FYVTETTFQK NRLFFYRKSV WSKLQSIGIR QHLKRVQLRE
     LSEAEVRQHR EARPALLTSR LRFIPKPDGL RPIVNMDYVV GARTFRREKR AERLTSRVKA
     LFSVLNYERA RRPGLLGASV LGLDDIHRAW RTFVLRVRAQ DPPPELYFVK VDVTGAYDTI
     PQDRLTEVIA SIIKPQNTYC VRRYAVVQKA AHGHVRKAFK SHVSTLTDLQ PYMRQFVAHL
     QETSPLRDAV VIEQSSSLNE ASSGLFDVFL RFMCHHAVRI RGKSYVQCQG IPQGSILSTL
     LCSLCYGDME NKLFAGIRRD GLLLRLVDDF LLVTPHLTHA KTFLRTLVRG VPEYGCVVNL
     RKTVVNFPVE DEALGGTAFV QMPAHGLFPW CGLLLDTRTL EVQSDYSSYA RTSIRASLTF
     NRGFKAGRNM RRKLFGVLRL KCHSLFLDLQ VNSLQTVCTN IYKILLLQAY RFHACVLQLP
     FHQQVWKNPT FFLRVISDTA SLCYSILKAK NAGMSLGAKG AAGPLPSEAV QWLCHQAFLL
     KLTRHRVTYV PLLGSLRTAQ TQLSRKLPGT TLTALEAAAN PALPSDFKTI LD
//
ID   A0A0S2Z4N5_HUMAN        Unreviewed;       680 AA.
AC   A0A0S2Z4N5;
DT   17-FEB-2016, integrated into UniProtKB/TrEMBL.
DT   17-FEB-2016, sequence version 1.
DT   28-FEB-2018, entry version 20.
DE   SubName: Full=Tumor protein p63 isoform 1 {ECO:0000313|EMBL:ALQ33893.1};
DE   SubName: Full=Tumor protein p73-like, isoform CRA_a {ECO:0000313|EMBL:EAW78112.1};
DE   Flags: Fragment;
GN   Name=TP63 {ECO:0000313|EMBL:ALQ33893.1};
GN   Synonyms=TP73L {ECO:0000313|EMBL:EAW78112.1};
GN   ORFNames=hCG_16028 {ECO:0000313|EMBL:EAW78112.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ALQ33893.1};
RN   [1] {ECO:0000313|EMBL:EAW78112.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW78112.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:ALQ33893.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=26871637; DOI=10.1016/j.cell.2016.01.029;
RA   Yang X., Coulombe-Huntington J., Kang S., Sheynkman G.M., Hao T.,
RA   Richardson A., Sun S., Yang F., Shen Y.A., Murray R., Spirohn K.,
RA   Begg B.E., Duran-Frigola M., MacWilliams A., Pevzner S.J., Zhong Q.,
RA   Trigg S.A., Tam S., Ghamsari L., Sahni N., Yi S., Rodriguez M.D.,
RA   Balcha D., Tan G., Costanzo M., Andrews B., Boone C., Zhou X.J.,
RA   Salehi-Ashtiani K., Charloteaux B., Chen A., Calderwood M.A., Aloy P.,
RA   Roth F.P., Hill D.E., Iakoucheva L.M., Xia Y., Vidal M.;
RT   "Widespread Expansion of Protein Interaction Capabilities by
RT   Alternative Splicing.";
RL   Cell 164:805-817(2016).
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; KU178435; ALQ33893.1; -; mRNA.
DR   EMBL; CH471052; EAW78112.1; -; Genomic_DNA.
DR   RefSeq; NP_003713.3; NM_003722.4.
DR   UniGene; Hs.137569; -.
DR   SMR; A0A0S2Z4N5; -.
DR   GeneID; 8626; -.
DR   KEGG; hsa:8626; -.
DR   CTD; 8626; -.
DR   KO; K10149; -.
DR   OMA; YQIENYN; -.
DR   ChiTaRS; TP63; human.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl.
DR   GO; GO:0003690; F:double-stranded DNA binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0000989; F:transcription factor activity, transcription factor binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0060197; P:cloacal septation; IEA:Ensembl.
DR   GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl.
DR   GO; GO:0007499; P:ectoderm and mesoderm interaction; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0010481; P:epidermal cell division; IEA:Ensembl.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl.
DR   GO; GO:0061436; P:establishment of skin barrier; IEA:Ensembl.
DR   GO; GO:0048807; P:female genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0043616; P:keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0010259; P:multicellular organism aging; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045617; P:negative regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:2000381; P:negative regulation of mesoderm development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0030859; P:polarized epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:1904674; P:positive regulation of somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0060513; P:prostatic bud formation; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0010482; P:regulation of epidermal cell division; IEA:Ensembl.
DR   GO; GO:0001302; P:replicative cell aging; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0043589; P:skin morphogenesis; IEA:Ensembl.
DR   GO; GO:0048745; P:smooth muscle tissue development; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; IEA:Ensembl.
DR   GO; GO:0060157; P:urinary bladder development; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   CDD; cd09572; SAM_tumor-p63; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR032645; Tp63.
DR   InterPro; IPR037611; Tumor-p63_SAM.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Nucleus {ECO:0000256|RuleBase:RU003401}.
FT   DOMAIN      541    607       SAM. {ECO:0000259|SMART:SM00454}.
FT   NON_TER     680    680       {ECO:0000313|EMBL:ALQ33893.1}.
SQ   SEQUENCE   680 AA;  76785 MW;  F66ECD45E87D9799 CRC64;
     MNFETSRCAT LQYCPDPYIQ RFVETPAHFS WKESYYRSTM SQSTQTNEFL SPEVFQHIWD
     FLEQPICSVQ PIDLNFVDEP SEDGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNSM
     DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
     FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
     VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
     TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
     KQQVSDSTKN GDGTKRPFRQ NTHGIQMTSI KKRRSPDDEL LYLPVRGRET YEMLLKIKES
     LELMQYLPQH TIETYRQQQQ QQHQHLLQKQ TSIQSPSSYG NSSPPLNKMN SMNKLPSVSQ
     LINPQQRNAL TPTTIPDGMG ANIPMMGTHM PMAGDMNGLS PTQALPPPLS MPSTSHCTPP
     PPYPTDCSIV SFLARLGCSS CLDYFTTQGL TTIYQIEHYS MDDLASLKIP EQFRHAIWKG
     ILDHRQLHEF SSPSHLLRTP SSASTVSVGS SETRGERVID AVRFTLRQTI SFPPRDEWND
     FNFDMDARRN KQQRIKEEGE
//
ID   A0A0S2Z4N6_HUMAN        Unreviewed;       676 AA.
AC   A0A0S2Z4N6;
DT   17-FEB-2016, integrated into UniProtKB/TrEMBL.
DT   17-FEB-2016, sequence version 1.
DT   28-FEB-2018, entry version 19.
DE   SubName: Full=Tumor protein p63 isoform 2 {ECO:0000313|EMBL:ALQ33894.1};
DE   Flags: Fragment;
GN   Name=TP63 {ECO:0000313|EMBL:ALQ33894.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ALQ33894.1};
RN   [1] {ECO:0000313|EMBL:ALQ33894.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=26871637; DOI=10.1016/j.cell.2016.01.029;
RA   Yang X., Coulombe-Huntington J., Kang S., Sheynkman G.M., Hao T.,
RA   Richardson A., Sun S., Yang F., Shen Y.A., Murray R., Spirohn K.,
RA   Begg B.E., Duran-Frigola M., MacWilliams A., Pevzner S.J., Zhong Q.,
RA   Trigg S.A., Tam S., Ghamsari L., Sahni N., Yi S., Rodriguez M.D.,
RA   Balcha D., Tan G., Costanzo M., Andrews B., Boone C., Zhou X.J.,
RA   Salehi-Ashtiani K., Charloteaux B., Chen A., Calderwood M.A., Aloy P.,
RA   Roth F.P., Hill D.E., Iakoucheva L.M., Xia Y., Vidal M.;
RT   "Widespread Expansion of Protein Interaction Capabilities by
RT   Alternative Splicing.";
RL   Cell 164:805-817(2016).
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; KU178436; ALQ33894.1; -; mRNA.
DR   RefSeq; NP_001316077.1; NM_001329148.1.
DR   UniGene; Hs.137569; -.
DR   SMR; A0A0S2Z4N6; -.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   ChiTaRS; TP63; human.
DR   ExpressionAtlas; A0A0S2Z4N6; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:InterPro.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   CDD; cd08367; P53; 1.
DR   CDD; cd09572; SAM_tumor-p63; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR032645; Tp63.
DR   InterPro; IPR037611; Tumor-p63_SAM.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Nucleus {ECO:0000256|RuleBase:RU003401}.
FT   DOMAIN      537    603       SAM. {ECO:0000259|SMART:SM00454}.
FT   NON_TER     676    676       {ECO:0000313|EMBL:ALQ33894.1}.
SQ   SEQUENCE   676 AA;  76317 MW;  EB0E2C9E93C6D34A CRC64;
     MNFETSRCAT LQYCPDPYIQ RFVETPAHFS WKESYYRSTM SQSTQTNEFL SPEVFQHIWD
     FLEQPICSVQ PIDLNFVDEP SEDGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNSM
     DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
     FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
     VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
     TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
     KQQVSDSTKN GDAFRQNTHG IQMTSIKKRR SPDDELLYLP VRGRETYEML LKIKESLELM
     QYLPQHTIET YRQQQQQQHQ HLLQKQTSIQ SPSSYGNSSP PLNKMNSMNK LPSVSQLINP
     QQRNALTPTT IPDGMGANIP MMGTHMPMAG DMNGLSPTQA LPPPLSMPST SHCTPPPPYP
     TDCSIVSFLA RLGCSSCLDY FTTQGLTTIY QIEHYSMDDL ASLKIPEQFR HAIWKGILDH
     RQLHEFSSPS HLLRTPSSAS TVSVGSSETR GERVIDAVRF TLRQTISFPP RDEWNDFNFD
     MDARRNKQQR IKEEGE
//
ID   A0A141PNN3_HUMAN        Unreviewed;       412 AA.
AC   A0A141PNN3;
DT   08-JUN-2016, integrated into UniProtKB/TrEMBL.
DT   08-JUN-2016, sequence version 1.
DT   28-FEB-2018, entry version 14.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP63 {ECO:0000313|EMBL:AMC39812.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AMC39812.1};
RN   [1] {ECO:0000313|EMBL:AMC39812.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Bladder tumor {ECO:0000313|EMBL:AMC39812.1};
RA   Banday A.R., Kiss E., Prokunina-Olsson L.;
RT   "Analysis of TP63 in bladder cancer.";
RL   Submitted (MAR-2015) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; KP881230; AMC39812.1; -; mRNA.
DR   RefSeq; NP_001316078.1; NM_001329149.1.
DR   UniGene; Hs.137569; -.
DR   PeptideAtlas; A0A141PNN3; -.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   ChiTaRS; TP63; human.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR032645; Tp63.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN       70    264       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      293    332       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
SQ   SEQUENCE   412 AA;  46121 MW;  6825355B5928466B CRC64;
     MLYLENNAQT QFSEPQYTNL GLLNSMDQQI QNGSSSTSPY NTDHAQNSVT APSPYAQPSS
     TFDALSPSPA IPSNTDYPGP HSFDVSFQQS STAKSATWTY STELKKLYCQ IAKTCPIQIK
     VMTPPPQGAV IRAMPVYKKA EHVTEVVKRC PNHELSREFN EGQIAPPSHL IRVEGNSHAQ
     YVEDPITGRQ SVLVPYEPPQ VGTEFTTVLY NFMCNSSCVG GMNRRPILII VTLETRDGQV
     LGRRCFEARI CACPGRDRKA DEDSIRKQQV SDSTKNGDAF RQNTHGIQMT SIKKRRSPDD
     ELLYLPVRGR ETYEMLLKIK ESLELMQYLP QHTIETYRQQ QQQQHQHLLQ KQTSIQSPSS
     YGNSSPPLNK MNSMNKLPSV SQLINPQQRN ALTPTTIPDG MGANRSGKSE NP
//
ID   A0A141PNN4_HUMAN        Unreviewed;       327 AA.
AC   A0A141PNN4;
DT   08-JUN-2016, integrated into UniProtKB/TrEMBL.
DT   08-JUN-2016, sequence version 1.
DT   28-FEB-2018, entry version 14.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP63 {ECO:0000313|EMBL:AMC39813.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AMC39813.1};
RN   [1] {ECO:0000313|EMBL:AMC39813.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Bladder tumor {ECO:0000313|EMBL:AMC39813.1};
RA   Banday A.R., Kiss E., Prokunina-Olsson L.;
RT   "Analysis of TP63 in bladder cancer.";
RL   Submitted (MAR-2015) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; KP881231; AMC39813.1; -; mRNA.
DR   RefSeq; NP_001316079.1; NM_001329150.1.
DR   UniGene; Hs.137569; -.
DR   PeptideAtlas; A0A141PNN4; -.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   ChiTaRS; TP63; human.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR032645; Tp63.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN        8    179       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      208    247       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
SQ   SEQUENCE   327 AA;  37114 MW;  EE191C8F74C65DBC CRC64;
     MLYLENNAQT QFSEYSTELK KLYCQIAKTC PIQIKVMTPP PQGAVIRAMP VYKKAEHVTE
     VVKRCPNHEL SREFNEGQIA PPSHLIRVEG NSHAQYVEDP ITGRQSVLVP YEPPQVGTEF
     TTVLYNFMCN SSCVGGMNRR PILIIVTLET RDGQVLGRRC FEARICACPG RDRKADEDSI
     RKQQVSDSTK NGDAFRQNTH GIQMTSIKKR RSPDDELLYL PVRGRETYEM LLKIKESLEL
     MQYLPQHTIE TYRQQQQQQH QHLLQKQTSI QSPSSYGNSS PPLNKMNSMN KLPSVSQLIN
     PQQRNALTPT TIPDGMGANR SGKSENP
//
ID   B7Z8X6_HUMAN            Unreviewed;       369 AA.
AC   B7Z8X6;
DT   03-MAR-2009, integrated into UniProtKB/TrEMBL.
DT   03-MAR-2009, sequence version 1.
DT   31-JAN-2018, entry version 63.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAH14112.1};
RN   [1] {ECO:0000313|EMBL:BAH14112.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Trachea {ECO:0000313|EMBL:BAH14112.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK304127; BAH14112.1; -; mRNA.
DR   RefSeq; NP_001316074.1; NM_001329145.1.
DR   RefSeq; NP_001316075.1; NM_001329146.1.
DR   RefSeq; NP_001316078.1; NM_001329149.1.
DR   RefSeq; NP_001316079.1; NM_001329150.1.
DR   UniGene; Hs.137569; -.
DR   PeptideAtlas; B7Z8X6; -.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   HOGENOM; HOG000039956; -.
DR   HOVERGEN; HBG005201; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR032645; Tp63.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN       70    264       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      297    336       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
SQ   SEQUENCE   369 AA;  41549 MW;  C81C1C2A3AE4CE51 CRC64;
     MLYLENNAQT QFSEPQYTNL GLLNSMDQQI QNGSSSTSPY NTDHAQNSVT APSPYAQPSS
     TFDALSPSPA IPSNTDYPGP HSFDVSFQQS STAKSATWTY STELKKLYCQ IAKTCPIQIK
     VMTPPPQGAV IRAMPVYKKA EHVTEVVKRC PNHELSREFN EGQIAPPSHL IRVEGNSHAQ
     YVEDPITGRQ SVLVPYEPPQ VGTEFTTVLY NFMCNSSCVG GMNRRPILII VTLETRDGQV
     LGRRCFEARI CACPGRDRKA DEDSIRKQQV SDSTKNGDGT KRPFRQNTHG IQMTSIKKRR
     SPDDELLYLP VRGRETYEML LKIKESLELM QYLPQHTIET YRQQHEQAAF CEPAYQPSAA
     QRPHSYNHS
//
ID   C9D7D0_HUMAN            Unreviewed;       416 AA.
AC   C9D7D0;
DT   03-NOV-2009, integrated into UniProtKB/TrEMBL.
DT   03-NOV-2009, sequence version 1.
DT   31-JAN-2018, entry version 73.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP63 {ECO:0000313|EMBL:ACV53610.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ACV53610.1};
RN   [1] {ECO:0000313|EMBL:ACV53610.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=19700772; DOI=10.1093/nar/gkp674;
RA   Mangiulli M., Valletti A., Caratozzolo M.F., Tullo A., Sbisa E.,
RA   Pesole G., D'Erchia A.M.;
RT   "Identification and functional characterization of two new
RT   transcriptional variants of the human p63 gene.";
RL   Nucleic Acids Res. 0:0-0(2009).
RN   [2] {ECO:0000313|EMBL:AMC39811.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Normal bladder {ECO:0000313|EMBL:AMC39811.1};
RA   Banday A.R., Kiss E., Prokunina-Olsson L.;
RT   "Analysis of TP63 in bladder cancer.";
RL   Submitted (MAR-2015) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; GQ202690; ACV53610.1; -; mRNA.
DR   EMBL; KP881229; AMC39811.1; -; mRNA.
DR   RefSeq; NP_001316073.1; NM_001329144.1.
DR   RefSeq; NP_001316074.1; NM_001329145.1.
DR   RefSeq; NP_001316075.1; NM_001329146.1.
DR   RefSeq; NP_001316077.1; NM_001329148.1.
DR   RefSeq; NP_001316078.1; NM_001329149.1.
DR   RefSeq; NP_001316079.1; NM_001329150.1.
DR   UniGene; Hs.137569; -.
DR   SMR; C9D7D0; -.
DR   GeneID; 8626; -.
DR   CTD; 8626; -.
DR   EuPathDB; HostDB:ENSG00000073282.12; -.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   HOGENOM; HOG000039956; -.
DR   ChiTaRS; TP63; human.
DR   Bgee; ENSG00000073282; -.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0032502; P:developmental process; IEA:InterPro.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR032645; Tp63.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN       70    264       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      297    336       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
SQ   SEQUENCE   416 AA;  46589 MW;  A5974A14B25E3118 CRC64;
     MLYLENNAQT QFSEPQYTNL GLLNSMDQQI QNGSSSTSPY NTDHAQNSVT APSPYAQPSS
     TFDALSPSPA IPSNTDYPGP HSFDVSFQQS STAKSATWTY STELKKLYCQ IAKTCPIQIK
     VMTPPPQGAV IRAMPVYKKA EHVTEVVKRC PNHELSREFN EGQIAPPSHL IRVEGNSHAQ
     YVEDPITGRQ SVLVPYEPPQ VGTEFTTVLY NFMCNSSCVG GMNRRPILII VTLETRDGQV
     LGRRCFEARI CACPGRDRKA DEDSIRKQQV SDSTKNGDGT KRPFRQNTHG IQMTSIKKRR
     SPDDELLYLP VRGRETYEML LKIKESLELM QYLPQHTIET YRQQQQQQHQ HLLQKQTSIQ
     SPSSYGNSSP PLNKMNSMNK LPSVSQLINP QQRNALTPTT IPDGMGANRS GKSENP
//
ID   P63_HUMAN               Reviewed;         680 AA.
AC   Q9H3D4; O75080; O75195; O75922; O76078; Q6VEG2; Q6VEG3; Q6VEG4;
AC   Q6VFJ1; Q6VFJ2; Q6VFJ3; Q6VH20; Q7LDI3; Q7LDI4; Q7LDI5; Q96KR0;
AC   Q9H3D2; Q9H3D3; Q9H3P8; Q9NPH7; Q9P1B4; Q9P1B5; Q9P1B6; Q9P1B7;
AC   Q9UBV9; Q9UE10; Q9UP26; Q9UP27; Q9UP28; Q9UP74;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   28-FEB-2018, entry version 179.
DE   RecName: Full=Tumor protein 63;
DE            Short=p63;
DE   AltName: Full=Chronic ulcerative stomatitis protein;
DE            Short=CUSP;
DE   AltName: Full=Keratinocyte transcription factor KET;
DE   AltName: Full=Transformation-related protein 63;
DE            Short=TP63;
DE   AltName: Full=Tumor protein p73-like;
DE            Short=p73L;
DE   AltName: Full=p40;
DE   AltName: Full=p51;
GN   Name=TP63; Synonyms=KET, P63, P73H, P73L, TP73L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=9703973; DOI=10.1006/bbrc.1998.9013;
RA   Senoo M., Seki N., Ohira M., Sugano S., Watanabe M., Tachibana M.,
RA   Tanaka T., Shinkai Y., Kato H.;
RT   "A second p53-related protein, p73L, with high homology to p73.";
RL   Biochem. Biophys. Res. Commun. 248:603-607(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Keratinocyte, and Skeletal muscle;
RX   PubMed=9799841; DOI=10.1007/s003359900891;
RA   Augustin M., Bamberger C., Paul D., Schmale H.;
RT   "Cloning and chromosomal mapping of the human p53-related KET gene to
RT   chromosome 3q27 and its murine homolog Ket to mouse chromosome 16.";
RL   Mamm. Genome 9:899-902(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 4 AND 6), NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 32-680 (ISOFORMS 1; 3 AND 5), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=9774969; DOI=10.1016/S1097-2765(00)80275-0;
RA   Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Doetsch V.,
RA   Andrews N.C., Caput D., McKeon F.;
RT   "p63, a p53 homolog at 3q27-29, encodes multiple products with
RT   transactivating, death-inducing, and dominant-negative activities.";
RL   Mol. Cell 2:305-316(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 5), VARIANT HEAD AND NECK
RP   CANCER LEU-184, VARIANT LUNG CARCINOMA PRO-187, AND VARIANT CERVICAL
RP   CANCER LEU-204.
RC   TISSUE=Skeletal muscle;
RX   PubMed=9662378; DOI=10.1038/nm0798-839;
RA   Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I.,
RA   Ikawa Y., Nimura Y., Nakagawara A., Obinata M., Ikawa S.;
RT   "Cloning and functional analysis of human p51, which structurally and
RT   functionally resembles p53.";
RL   Nat. Med. 4:839-843(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT COLON CANCER HIS-279, AND
RP   VARIANT OVARIAN CANCER ALA-560.
RX   PubMed=10485447;
RA   Hagiwara K., McMenamin M.G., Miura K., Harris C.C.;
RT   "Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human
RT   cancer cell lines using intronic primers.";
RL   Cancer Res. 59:4165-4169(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=10469295; DOI=10.1046/j.1523-1747.1999.00651.x;
RA   Lee L.A., Walsh P., Prater C.A., Su L.-J., Marchbank A., Egbert T.B.,
RA   Dellavalle R.P., Targoff I.N., Kaufman K.M., Chorzelski T.P.,
RA   Jablonska S.;
RT   "Characterization of an autoantigen associated with chronic ulcerative
RT   stomatitis: the CUSP autoantigen is a member of the p53 family.";
RL   J. Invest. Dermatol. 113:146-151(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 7), AND ALTERNATIVE
RP   SPLICING (ISOFORM 8).
RX   PubMed=10935472; DOI=10.1038/sj.neo.7900008;
RA   Tani M., Shimizu K., Kawahara C., Kohno T., Ishimoto O., Ikawa S.,
RA   Yokota J.;
RT   "Mutation and expression of the p51 gene in human lung cancer.";
RL   Neoplasia 1:71-79(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10), AND TISSUE SPECIFICITY
RP   (ISOFORM 10).
RX   PubMed=11336476; DOI=10.1054/bjoc.2000.1735;
RA   Senoo M., Tsuchiya I., Matsumura Y., Mori T., Saito Y., Kato H.,
RA   Okamoto T., Habu S.;
RT   "Transcriptional dysregulation of the p73L/p63/p51/p40/KET gene in
RT   human squamous cell carcinomas: expression of Delta Np73L, a novel
RT   dominant-negative isoform, and loss of expression of the potential
RT   tumour suppressor p51.";
RL   Br. J. Cancer 84:1235-1241(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-450 (ISOFORMS 2/4/8), SUBUNIT,
RP   ZINC-BINDING, AND DNA-BINDING.
RC   TISSUE=Prostate;
RX   PubMed=9662346; DOI=10.1038/nm0798-747;
RA   Trink B., Okami K., Wu L., Sriuranpong V., Jen J., Sidransky D.;
RT   "A new human p53 homologue.";
RL   Nat. Med. 4:747-748(1998).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21; 95-255; 295-330; 378-502
RP   AND 583-680.
RA   Vieira A.R., Murray J.C.;
RT   "Sequencing of candidate genes for non-syndromic cleft lip and
RT   palate.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 153-388 (ISOFORM 11).
RC   TISSUE=Placenta;
RX   PubMed=11477076; DOI=10.1074/jbc.M103801200;
RA   Klein C., Georges G., Kunkele K.P., Huber R., Engh R.A., Hansen S.;
RT   "High thermostability and lack of cooperative DNA binding distinguish
RT   the p63 core domain from the homologous tumor suppressor p53.";
RL   J. Biol. Chem. 276:37390-37401(2001).
RN   [13]
RP   SUBUNIT.
RX   PubMed=10373484; DOI=10.1074/jbc.274.26.18709;
RA   Davison T.S., Vagner C., Kaghad M., Ayed A., Caput D.,
RA   Arrowsmith C.H.;
RT   "p73 and p63 are homotetramers capable of weak heterotypic
RT   interactions with each other but not with p53.";
RL   J. Biol. Chem. 274:18709-18714(1999).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=11248048; DOI=10.1073/pnas.061032098;
RA   Pellegrini G., Dellambra E., Golisano O., Martinelli E., Fantozzi I.,
RA   Bondanza S., Ponzin D., McKeon F., De Luca M.;
RT   "p63 identifies keratinocyte stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:3156-3161(2001).
RN   [15]
RP   FUNCTION IN NOTCH SIGNALING.
RX   PubMed=11641404; DOI=10.1074/jbc.M108080200;
RA   Sasaki Y., Ishida S., Morimoto I., Yamashita T., Kojima T., Kihara C.,
RA   Tanaka T., Imai K., Nakamura Y., Tokino T.;
RT   "The p53 family member genes are involved in the Notch signal
RT   pathway.";
RL   J. Biol. Chem. 277:719-724(2002).
RN   [16]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [17]
RP   FUNCTION, DOMAIN, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-55;
RP   TRP-59 AND LEU-62.
RX   PubMed=12446779; DOI=10.1128/MCB.22.24.8601-8611.2002;
RA   Serber Z., Lai H.C., Yang A., Ou H.D., Sigal M.S., Kelly A.E.,
RA   Darimont B.D., Duijf P.H.G., Van Bokhoven H., McKeon F., Doetsch V.;
RT   "A C-terminal inhibitory domain controls the activity of p63 by an
RT   intramolecular mechanism.";
RL   Mol. Cell. Biol. 22:8601-8611(2002).
RN   [18]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=12446784; DOI=10.1128/MCB.22.24.8659-8668.2002;
RA   Ghioni P., Bolognese F., Duijf P.H.G., Van Bokhoven H., Mantovani R.,
RA   Guerrini L.;
RT   "Complex transcriptional effects of p63 isoforms: identification of
RT   novel activation and repression domains.";
RL   Mol. Cell. Biol. 22:8659-8668(2002).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH SSRP1.
RX   PubMed=12374749; DOI=10.1093/emboj/cdf540;
RA   Zeng S.X., Dai M.-S., Keller D.M., Lu H.;
RT   "SSRP1 functions as a co-activator of the transcriptional activator
RT   p63.";
RL   EMBO J. 21:5487-5497(2002).
RN   [20]
RP   ERRATUM.
RA   Zeng S.X., Dai M.-S., Keller D.M., Lu H.;
RL   EMBO J. 23:1679-1679(2004).
RN   [21]
RP   UBIQUITINATION, INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-543.
RX   PubMed=18806757; DOI=10.1038/cdd.2008.134;
RA   Li Y., Zhou Z., Chen C.;
RT   "WW domain-containing E3 ubiquitin protein ligase 1 targets p63
RT   transcription factor for ubiquitin-mediated proteasomal degradation
RT   and regulates apoptosis.";
RL   Cell Death Differ. 15:1941-1951(2008).
RN   [22]
RP   INTERACTION WITH PDS5A.
RX   PubMed=17846787; DOI=10.1007/s00432-007-0306-x;
RA   Zheng M.Z., Zheng L.M., Zeng Y.X.;
RT   "SCC-112 gene is involved in tumor progression and promotes the cell
RT   proliferation in G2/M phase.";
RL   J. Cancer Res. Clin. Oncol. 134:453-462(2008).
RN   [23]
RP   FUNCTION, INTERACTION WITH NOC2L, AND SUBCELLULAR LOCATION.
RX   PubMed=20123734; DOI=10.1093/nar/gkq016;
RA   Heyne K., Willnecker V., Schneider J., Conrad M., Raulf N., Schule R.,
RA   Roemer K.;
RT   "NIR, an inhibitor of histone acetyltransferases, regulates
RT   transcription factor TAp63 and is controlled by the cell cycle.";
RL   Nucleic Acids Res. 38:3159-3171(2010).
RN   [24]
RP   FUNCTION.
RX   PubMed=22197488; DOI=10.1016/j.ajhg.2011.11.013;
RA   Mitchell K., O'Sullivan J., Missero C., Blair E., Richardson R.,
RA   Anderson B., Antonini D., Murray J.C., Shanske A.L., Schutte B.C.,
RA   Romano R.A., Sinha S., Bhaskar S.S., Black G.C., Dixon J., Dixon M.J.;
RT   "Exome sequence identifies RIPK4 as the Bartsocas-Papas syndrome
RT   locus.";
RL   Am. J. Hum. Genet. 90:69-75(2012).
RN   [25]
RP   STRUCTURE BY NMR OF 540-610.
RA   Cadot B., Candi E., Cicero D.O., Desideri A., Mele S., Melino G.,
RA   Paci M.;
RT   "Solution structure of the C-terminal domain of p63.";
RL   Submitted (NOV-2004) to the PDB data bank.
RN   [26]
RP   VARIANTS EEC3 TRP-243; GLN-243 AND ARG-345.
RX   PubMed=10535733; DOI=10.1016/S0092-8674(00)81646-3;
RA   Celli J., Duijf P.H.G., Hamel B.C.J., Bamshad M., Kramer B.,
RA   Smits A.P.T., Newbury-Ecob R., Hennekam R.C.M., Van Buggenhout G.,
RA   van Haeringen A., Woods C.G., van Essen A.J., de Waal R., Vriend G.,
RA   Haber D.A., Yang A., McKeon F., Brunner H.G., van Bokhoven H.;
RT   "Heterozygous germline mutations in the p53 homolog p63 are the cause
RT   of EEC syndrome.";
RL   Cell 99:143-153(1999).
RN   [27]
RP   VARIANTS SHFM4 GLU-233 AND CYS-319, AND VARIANTS EEC3 HIS-318 AND
RP   GLN-343.
RX   PubMed=10839977; DOI=10.1086/302972;
RA   Ianakiev P., Kilpatrick M.W., Toudjarska I., Basel D., Beighton P.,
RA   Tsipouras P.;
RT   "Split-hand/split-foot malformation is caused by mutations in the p63
RT   gene on 3q27.";
RL   Am. J. Hum. Genet. 67:59-66(2000).
RN   [28]
RP   VARIANT ADULT IN NDELTA-TYPE ISOFORMS.
RX   PubMed=11528512; DOI=10.1038/sj.ejhg.5200676;
RA   Amiel J., Bougeard G., Francannet C., Raclin V., Munnich A.,
RA   Lyonnet S., Frebourg T.;
RT   "TP63 gene mutation in ADULT syndrome.";
RL   Eur. J. Hum. Genet. 9:642-645(2001).
RN   [29]
RP   VARIANTS AEC PHE-553 AND GLY-561.
RX   PubMed=11159940; DOI=10.1093/hmg/10.3.221;
RA   McGrath J.A., Duijf P.H.G., Doetsch V., Irvine A.D., de Waal R.,
RA   Vanmolkot K.R., Wessagowit V., Kelly A., Atherton D.J.,
RA   Griffiths W.A., Orlow S.J., van Haeringen A., Ausems M.G., Yang A.,
RA   McKeon F., Bamshad M.A., Brunner H.G., Hamel B.C.J., van Bokhoven H.;
RT   "Hay-Wells syndrome is caused by heterozygous missense mutations in
RT   the SAM domain of p63.";
RL   Hum. Mol. Genet. 10:221-229(2001).
RN   [30]
RP   VARIANTS EEC3 GLN-243; TRP-243; GLN-266; TYR-308; ASN-311; CYS-318;
RP   HIS-318; GLN-318; CYS-319; HIS-319; SER-319; TRP-343; GLN-343;
RP   ARG-345; SER-347; SER-348 AND HIS-351, VARIANTS SHFM4 PRO-193 INS;
RP   GLU-232 AND HIS-319, AND INVOLVEMENT IN LMS.
RX   PubMed=11462173; DOI=10.1086/323123;
RA   van Bokhoven H., Hamel B.C.J., Bamshad M., Sangiorgi E., Gurrieri F.,
RA   Duijf P.H.G., Vanmolkot K.R.J., van Beusekom E., van Beersum S.E.C.,
RA   Celli J., Merkx G.F.M., Tenconi R., Fryns J.-P., Verloes A.,
RA   Newbury-Ecob R.A., Raas-Rotschild A., Majewski F., Beemer F.A.,
RA   Janecke A., Chitayat D., Crisponi G., Kayserili H., Yates J.R.W.,
RA   Neri G., Brunner H.G.;
RT   "p63 gene mutations in EEC syndrome, limb-mammary syndrome, and
RT   isolated split hand-split foot malformation suggest a genotype-
RT   phenotype correlation.";
RL   Am. J. Hum. Genet. 69:481-492(2001).
RN   [31]
RP   VARIANT ADULT SYNDROME GLN-337.
RX   PubMed=11929852; DOI=10.1093/hmg/11.7.799;
RA   Duijf P.H.G., Vanmolkot K.R., Propping P., Friedl W., Krieger E.,
RA   McKeon F., Doetsch V., Brunner H.G., van Bokhoven H.;
RT   "Gain-of-function mutation in ADULT syndrome reveals the presence of a
RT   second transactivation domain in p63.";
RL   Hum. Mol. Genet. 11:799-804(2002).
RN   [32]
RP   VARIANT EEC3 GLY-351.
RX   PubMed=12838557; DOI=10.1002/ajmg.a.20064;
RA   Akahoshi K., Sakazume S., Kosaki K., Ohashi H., Fukushima Y.;
RT   "EEC syndrome type 3 with a heterozygous germline mutation in the P63
RT   gene and B cell lymphoma.";
RL   Am. J. Med. Genet. A 120:370-373(2003).
RN   [33]
RP   VARIANT EDRH HIS-318, AND CHARACTERIZATION OF VARIANT EDRH HIS-318.
RX   PubMed=12939657; DOI=10.1038/sj.ejhg.5201004;
RA   Bougeard G., Hadj-Rabia S., Faivre L., Sarafan-Vasseur N.,
RA   Frebourg T.;
RT   "The Rapp-Hodgkin syndrome results from mutations of the TP63 gene.";
RL   Eur. J. Hum. Genet. 11:700-704(2003).
RN   [34]
RP   VARIANT EDRH PRO-580.
RX   PubMed=12766194; DOI=10.1177/154405910308200606;
RA   Kantaputra P.N., Hamada T., Kumchai T., McGrath J.A.;
RT   "Heterozygous mutation in the SAM domain of p63 underlies Rapp-Hodgkin
RT   ectodermal dysplasia.";
RL   J. Dent. Res. 82:433-437(2003).
RN   [35]
RP   VARIANT EDRH THR-549.
RX   PubMed=15200513; DOI=10.1111/j.0009-9163.2004.00278.x;
RA   Bertola D.R., Kim C.A., Albano L.M.J., Scheffer H., Meijer R.,
RA   van Bokhoven H.;
RT   "Molecular evidence that AEC syndrome and Rapp-Hodgkin syndrome are
RT   variable expression of a single genetic disorder.";
RL   Clin. Genet. 66:79-80(2004).
RN   [36]
RP   VARIANT EDRH/OFC8 GLY-352, AND VARIANTS LEU-129 AND HIS-603.
RX   PubMed=16740912; DOI=10.1136/jmg.2005.036442;
RA   Leoyklang P., Siriwan P., Shotelersuk V.;
RT   "A mutation of the p63 gene in non-syndromic cleft lip.";
RL   J. Med. Genet. 43:E28-E28(2006).
CC   -!- FUNCTION: Acts as a sequence specific DNA binding transcriptional
CC       activator or repressor. The isoforms contain a varying set of
CC       transactivation and auto-regulating transactivation inhibiting
CC       domains thus showing an isoform specific activity. Isoform 2
CC       activates RIPK4 transcription. May be required in conjunction with
CC       TP73/p73 for initiation of p53/TP53 dependent apoptosis in
CC       response to genotoxic insults and the presence of activated
CC       oncogenes. Involved in Notch signaling by probably inducing JAG1
CC       and JAG2. Plays a role in the regulation of epithelial
CC       morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may
CC       govern the maintenance of epithelial stem cell compartments and
CC       regulate the initiation of epithelial stratification from the
CC       undifferentiated embryonal ectoderm. Required for limb formation
CC       from the apical ectodermal ridge. Activates transcription of the
CC       p21 promoter. {ECO:0000269|PubMed:11641404,
CC       ECO:0000269|PubMed:12374749, ECO:0000269|PubMed:12446779,
CC       ECO:0000269|PubMed:12446784, ECO:0000269|PubMed:20123734,
CC       ECO:0000269|PubMed:22197488, ECO:0000269|PubMed:9774969}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Isoform composition of the
CC       tetramer may determine transactivation activity. Isoforms Alpha
CC       and Gamma interact with HIPK2. Interacts with SSRP1, leading to
CC       stimulate coactivator activity. Isoform 1 and isoform 2 interact
CC       with WWP1. Interacts with PDS5A. Isoform 5 (via activation domain)
CC       interacts with NOC2L. {ECO:0000269|PubMed:10373484,
CC       ECO:0000269|PubMed:11925430, ECO:0000269|PubMed:12374749,
CC       ECO:0000269|PubMed:17846787, ECO:0000269|PubMed:18806757,
CC       ECO:0000269|PubMed:20123734, ECO:0000269|PubMed:9662346}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-2337775, EBI-2337775;
CC       Q8TDN4:CABLES1; NbExp=7; IntAct=EBI-2400586, EBI-604615;
CC       P35637:FUS; NbExp=2; IntAct=EBI-2337775, EBI-400434;
CC       P61978:HNRNPK; NbExp=2; IntAct=EBI-2337775, EBI-304185;
CC       Q96J02:ITCH; NbExp=2; IntAct=EBI-2337775, EBI-1564678;
CC       Q9UFN0:NIPSNAP3A; NbExp=2; IntAct=EBI-2337775, EBI-716291;
CC       Q13526:PIN1; NbExp=4; IntAct=EBI-2337775, EBI-714158;
CC       Q05655:PRKCD; NbExp=2; IntAct=EBI-2337775, EBI-704279;
CC       Q9UPW6:SATB2; NbExp=5; IntAct=EBI-6481107, EBI-8298169;
CC       Q15796:SMAD2; NbExp=3; IntAct=EBI-2337775, EBI-1040141;
CC       P04637:TP53; NbExp=5; IntAct=EBI-2337775, EBI-366083;
CC       Q13625:TP53BP2; NbExp=2; IntAct=EBI-2337775, EBI-77642;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12446779,
CC       ECO:0000269|PubMed:20123734}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=12;
CC       Name=1; Synonyms=TA*-alpha, TAp63alpha, P51B;
CC         IsoId=Q9H3D4-1; Sequence=Displayed;
CC         Note=Produced by alternative promoter usage.;
CC       Name=2; Synonyms=DeltaN-alpha, DeltaNp63 alpha, P51delNalpha;
CC         IsoId=Q9H3D4-2; Sequence=VSP_012465;
CC         Note=Produced by alternative promoter usage. Variant in
CC         position: 6:N->H (in ADULT syndrome).;
CC       Name=3; Synonyms=TA*-beta, TAp63beta;
CC         IsoId=Q9H3D4-3; Sequence=VSP_012470;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=4; Synonyms=DeltaN-beta, DeltaNp63 beta, P51delNbeta;
CC         IsoId=Q9H3D4-4; Sequence=VSP_012465, VSP_012470;
CC         Note=Produced by alternative splicing of isoform 2. Variant in
CC         position: 6:N->H (in ADULT syndrome).;
CC       Name=5; Synonyms=TA*-gamma, TAp63gamma, P51A;
CC         IsoId=Q9H3D4-5; Sequence=VSP_012468;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=6; Synonyms=DeltaN-gamma, DeltaNp63gamma, P51delNgamma;
CC         IsoId=Q9H3D4-6; Sequence=VSP_012465, VSP_012468;
CC         Note=Produced by alternative splicing of isoform 2. Variant in
CC         position: 6:N->H (in ADULT syndrome).;
CC       Name=7; Synonyms=TA*-delta, TAp63delta, P51delta;
CC         IsoId=Q9H3D4-7; Sequence=VSP_012469;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=8; Synonyms=DeltaN-delta;
CC         IsoId=Q9H3D4-8; Sequence=VSP_012465, VSP_012469;
CC         Note=Produced by alternative splicing of isoform 2. No
CC         experimental confirmation available. Variant in position: 6:N->H
CC         (in ADULT syndrome).;
CC       Name=9; Synonyms=TA*-epsilon;
CC         IsoId=Q9H3D4-9; Sequence=VSP_012466;
CC         Note=Produced by alternative splicing of isoform 1. No
CC         experimental confirmation available.;
CC       Name=10; Synonyms=DeltaN-epsilon, DeltaNp73L;
CC         IsoId=Q9H3D4-10; Sequence=VSP_012465, VSP_012466;
CC         Note=Produced by alternative splicing of isoform 2. Variant in
CC         position: 6:N->H (in ADULT syndrome).;
CC       Name=11; Synonyms=P63 delta;
CC         IsoId=Q9H3D4-11; Sequence=VSP_012467;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=12;
CC         IsoId=Q9H3D4-12; Sequence=VSP_012465, VSP_012467;
CC         Note=Produced by alternative splicing of isoform 2. No
CC         experimental confirmation available. Variant in position: 6:N->H
CC         (in ADULT syndrome).;
CC   -!- TISSUE SPECIFICITY: Widely expressed, notably in heart, kidney,
CC       placenta, prostate, skeletal muscle, testis and thymus, although
CC       the precise isoform varies according to tissue type. Progenitor
CC       cell layers of skin, breast, eye and prostate express high levels
CC       of DeltaN-type isoforms. Isoform 10 is predominantly expressed in
CC       skin squamous cell carcinomas, but not in normal skin tissues.
CC       {ECO:0000269|PubMed:11248048, ECO:0000269|PubMed:9774969}.
CC   -!- DOMAIN: The transactivation inhibitory domain (TID) can interact
CC       with, and inhibit the activity of the N-terminal transcriptional
CC       activation domain of TA*-type isoforms.
CC       {ECO:0000269|PubMed:12446779, ECO:0000269|PubMed:12446784}.
CC   -!- PTM: May be sumoylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Polyubiquitination involves WWP1 and leads to
CC       proteasomal degradation of this protein.
CC       {ECO:0000269|PubMed:18806757}.
CC   -!- DISEASE: Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT
CC       syndrome) [MIM:103285]: A form of ectodermal dysplasia. Ectodermal
CC       dysplasia defines a heterogeneous group of disorders due to
CC       abnormal development of two or more ectodermal structures. ADULT
CC       syndrome involves ectrodactyly, syndactyly, finger- and toenail
CC       dysplasia, hypoplastic breasts and nipples, intensive freckling,
CC       lacrimal duct atresia, frontal alopecia, primary hypodontia and
CC       loss of permanent teeth. ADULT syndrome differs significantly from
CC       EEC3 syndrome by the absence of facial clefting.
CC       {ECO:0000269|PubMed:11929852}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC)
CC       [MIM:106260]: An autosomal dominant condition characterized by
CC       congenital ectodermal dysplasia with coarse, wiry, sparse hair,
CC       dystrophic nails, slight hypohidrosis, scalp infections,
CC       ankyloblepharon filiform adnatum, maxillary hypoplasia, hypodontia
CC       and cleft lip/palate. {ECO:0000269|PubMed:11159940}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Ectrodactyly, ectodermal dysplasia, and cleft lip/palate
CC       syndrome 3 (EEC3) [MIM:604292]: A form of ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of
CC       two or more ectodermal structures. It is an autosomal dominant
CC       syndrome characterized by ectrodactyly of hands and feet,
CC       ectodermal dysplasia and facial clefting.
CC       {ECO:0000269|PubMed:10535733, ECO:0000269|PubMed:10839977,
CC       ECO:0000269|PubMed:11462173, ECO:0000269|PubMed:12838557}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Split-hand/foot malformation 4 (SHFM4) [MIM:605289]: A
CC       limb malformation involving the central rays of the autopod and
CC       presenting with syndactyly, median clefts of the hands and feet,
CC       and aplasia and/or hypoplasia of the phalanges, metacarpals, and
CC       metatarsals. Some patients have been found to have mental
CC       retardation, ectodermal and craniofacial findings, and orofacial
CC       clefting. {ECO:0000269|PubMed:10839977,
CC       ECO:0000269|PubMed:11462173}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Limb-mammary syndrome (LMS) [MIM:603543]: Characterized
CC       by ectrodactyly, cleft palate and mammary-gland abnormalities.
CC       {ECO:0000269|PubMed:11462173}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in TP63 are a cause of cervical, colon, head
CC       and neck, lung and ovarian cancers.
CC   -!- DISEASE: Ectodermal dysplasia, Rapp-Hodgkin type (EDRH)
CC       [MIM:129400]: A form of ectodermal dysplasia, a heterogeneous
CC       group of disorders due to abnormal development of two or more
CC       ectodermal structures. Characterized by the combination of
CC       anhidrotic ectodermal dysplasia, cleft lip, and cleft palate. The
CC       clinical syndrome is comprised of a characteristic facies (narrow
CC       nose and small mouth), wiry, slow-growing, and uncombable hair,
CC       sparse eyelashes and eyebrows, obstructed lacrimal
CC       puncta/epiphora, bilateral stenosis of external auditory canals,
CC       microsomia, hypodontia, cone-shaped incisors, enamel hypoplasia,
CC       dystrophic nails, and cleft lip/cleft palate.
CC       {ECO:0000269|PubMed:12766194, ECO:0000269|PubMed:12939657,
CC       ECO:0000269|PubMed:15200513, ECO:0000269|PubMed:16740912}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Non-syndromic orofacial cleft 8 (OFC8) [MIM:129400]: A
CC       birth defect consisting of cleft lips with or without cleft
CC       palate. Cleft lips are associated with cleft palate in two-third
CC       of cases. A cleft lip can occur on one or both sides and range in
CC       severity from a simple notch in the upper lip to a complete
CC       opening in the lip extending into the floor of the nostril and
CC       involving the upper gum. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF43486.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43487.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43488.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43489.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF61624.1; Type=Frameshift; Positions=26; Evidence={ECO:0000305};
CC       Sequence=BAA32592.1; Type=Frameshift; Positions=26; Evidence={ECO:0000305};
CC       Sequence=BAA32593.1; Type=Frameshift; Positions=26; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TP63ID365ch3q27.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB010153; BAA32433.1; -; mRNA.
DR   EMBL; Y16961; CAA76562.1; -; mRNA.
DR   EMBL; AF075428; AAC62633.1; -; mRNA.
DR   EMBL; AF075429; AAC62634.1; -; mRNA.
DR   EMBL; AF075430; AAC62635.1; -; mRNA.
DR   EMBL; AF075431; AAC62636.1; -; mRNA.
DR   EMBL; AF075432; AAC62637.1; -; mRNA.
DR   EMBL; AF075433; AAC62638.1; -; mRNA.
DR   EMBL; AF124539; AAG45607.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124538; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45608.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124540; AAG45609.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45610.1; -; Genomic_DNA.
DR   EMBL; AF124530; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124538; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45611.1; -; Genomic_DNA.
DR   EMBL; AF124530; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124540; AAG45612.1; -; Genomic_DNA.
DR   EMBL; AF124531; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124530; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AB016072; BAA32592.1; ALT_FRAME; mRNA.
DR   EMBL; AB016073; BAA32593.1; ALT_FRAME; mRNA.
DR   EMBL; AF091627; AAC43038.1; -; mRNA.
DR   EMBL; AF116770; AAF43486.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43487.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116768; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43488.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43489.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116770; AAF43490.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43491.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116768; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43492.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43493.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116771; AAF61624.1; ALT_FRAME; mRNA.
DR   EMBL; AB042841; BAB20591.1; -; mRNA.
DR   EMBL; BC039815; AAH39815.1; -; mRNA.
DR   EMBL; AF061512; AAC24830.1; -; mRNA.
DR   EMBL; AY342152; AAQ63448.1; -; Genomic_DNA.
DR   EMBL; AY341145; AAQ63448.1; JOINED; Genomic_DNA.
DR   EMBL; AY339663; AAQ63449.1; -; Genomic_DNA.
DR   EMBL; AY341143; AAQ63450.1; -; Genomic_DNA.
DR   EMBL; AY339664; AAQ63450.1; JOINED; Genomic_DNA.
DR   EMBL; AY341142; AAQ63450.1; JOINED; Genomic_DNA.
DR   EMBL; AY341143; AAQ63451.1; -; Genomic_DNA.
DR   EMBL; AY341142; AAQ63451.1; JOINED; Genomic_DNA.
DR   EMBL; AY341144; AAQ63452.1; -; Genomic_DNA.
DR   EMBL; AY342153; AAQ63453.1; -; Genomic_DNA.
DR   EMBL; AY342154; AAQ63454.1; -; Genomic_DNA.
DR   EMBL; AJ315499; CAC48053.1; -; mRNA.
DR   CCDS; CCDS3293.1; -. [Q9H3D4-1]
DR   CCDS; CCDS46976.1; -. [Q9H3D4-3]
DR   CCDS; CCDS46977.1; -. [Q9H3D4-5]
DR   CCDS; CCDS46978.1; -. [Q9H3D4-2]
DR   CCDS; CCDS46979.1; -. [Q9H3D4-4]
DR   CCDS; CCDS46980.1; -. [Q9H3D4-6]
DR   CCDS; CCDS82887.1; -. [Q9H3D4-11]
DR   RefSeq; NP_001108450.1; NM_001114978.1. [Q9H3D4-3]
DR   RefSeq; NP_001108451.1; NM_001114979.1. [Q9H3D4-5]
DR   RefSeq; NP_001108452.1; NM_001114980.1. [Q9H3D4-2]
DR   RefSeq; NP_001108453.1; NM_001114981.1. [Q9H3D4-4]
DR   RefSeq; NP_001108454.1; NM_001114982.1. [Q9H3D4-6]
DR   RefSeq; NP_001316073.1; NM_001329144.1. [Q9H3D4-7]
DR   RefSeq; NP_001316074.1; NM_001329145.1. [Q9H3D4-8]
DR   RefSeq; NP_001316075.1; NM_001329146.1. [Q9H3D4-10]
DR   RefSeq; NP_001316077.1; NM_001329148.1. [Q9H3D4-11]
DR   RefSeq; NP_003713.3; NM_003722.4. [Q9H3D4-1]
DR   RefSeq; XP_016862876.1; XM_017007387.1. [Q9H3D4-12]
DR   UniGene; Hs.137569; -.
DR   PDB; 1RG6; NMR; -; A=540-614.
DR   PDB; 2NB1; NMR; -; A/C=397-455.
DR   PDB; 2RMN; NMR; -; A=153-388.
DR   PDB; 2Y9T; NMR; -; A=543-622.
DR   PDB; 2Y9U; X-ray; 1.60 A; A=545-611.
DR   PDB; 3QYM; X-ray; 3.20 A; A/B/C/D/E/F/G/H=166-362.
DR   PDB; 3QYN; X-ray; 2.50 A; A/B/C/D=166-362.
DR   PDB; 3US0; X-ray; 2.50 A; A/B/C/D=166-362.
DR   PDB; 3US1; X-ray; 2.80 A; A/D=166-362.
DR   PDB; 3US2; X-ray; 4.20 A; A/B/C/D/G/H/I/J=166-362.
DR   PDB; 3ZY0; X-ray; 1.90 A; A/B/C/D=398-427.
DR   PDB; 3ZY1; X-ray; 2.15 A; A=398-441.
DR   PDB; 4A9Z; X-ray; 2.29 A; A/B/C/D=397-455.
DR   PDBsum; 1RG6; -.
DR   PDBsum; 2NB1; -.
DR   PDBsum; 2RMN; -.
DR   PDBsum; 2Y9T; -.
DR   PDBsum; 2Y9U; -.
DR   PDBsum; 3QYM; -.
DR   PDBsum; 3QYN; -.
DR   PDBsum; 3US0; -.
DR   PDBsum; 3US1; -.
DR   PDBsum; 3US2; -.
DR   PDBsum; 3ZY0; -.
DR   PDBsum; 3ZY1; -.
DR   PDBsum; 4A9Z; -.
DR   ProteinModelPortal; Q9H3D4; -.
DR   SMR; Q9H3D4; -.
DR   BioGrid; 114181; 127.
DR   DIP; DIP-29588N; -.
DR   ELM; Q9H3D4; -.
DR   IntAct; Q9H3D4; 75.
DR   MINT; Q9H3D4; -.
DR   STRING; 9606.ENSP00000264731; -.
DR   iPTMnet; Q9H3D4; -.
DR   PhosphoSitePlus; Q9H3D4; -.
DR   BioMuta; TP63; -.
DR   DMDM; 57013009; -.
DR   MaxQB; Q9H3D4; -.
DR   PaxDb; Q9H3D4; -.
DR   PeptideAtlas; Q9H3D4; -.
DR   PRIDE; Q9H3D4; -.
DR   DNASU; 8626; -.
DR   Ensembl; ENST00000264731; ENSP00000264731; ENSG00000073282. [Q9H3D4-1]
DR   Ensembl; ENST00000320472; ENSP00000317510; ENSG00000073282. [Q9H3D4-7]
DR   Ensembl; ENST00000354600; ENSP00000346614; ENSG00000073282. [Q9H3D4-2]
DR   Ensembl; ENST00000392460; ENSP00000376253; ENSG00000073282. [Q9H3D4-3]
DR   Ensembl; ENST00000392461; ENSP00000376254; ENSG00000073282. [Q9H3D4-8]
DR   Ensembl; ENST00000392463; ENSP00000376256; ENSG00000073282. [Q9H3D4-4]
DR   Ensembl; ENST00000418709; ENSP00000407144; ENSG00000073282. [Q9H3D4-5]
DR   Ensembl; ENST00000437221; ENSP00000392488; ENSG00000073282. [Q9H3D4-6]
DR   Ensembl; ENST00000440651; ENSP00000394337; ENSG00000073282. [Q9H3D4-11]
DR   Ensembl; ENST00000449992; ENSP00000387839; ENSG00000073282. [Q9H3D4-10]
DR   Ensembl; ENST00000456148; ENSP00000389485; ENSG00000073282. [Q9H3D4-12]
DR   GeneID; 8626; -.
DR   KEGG; hsa:8626; -.
DR   UCSC; uc003frx.3; human. [Q9H3D4-1]
DR   CTD; 8626; -.
DR   DisGeNET; 8626; -.
DR   EuPathDB; HostDB:ENSG00000073282.12; -.
DR   GeneCards; TP63; -.
DR   GeneReviews; TP63; -.
DR   HGNC; HGNC:15979; TP63.
DR   HPA; CAB000083; -.
DR   HPA; HPA006288; -.
DR   HPA; HPA007010; -.
DR   MalaCards; TP63; -.
DR   MIM; 103285; phenotype.
DR   MIM; 106260; phenotype.
DR   MIM; 129400; phenotype.
DR   MIM; 603273; gene.
DR   MIM; 603543; phenotype.
DR   MIM; 604292; phenotype.
DR   MIM; 605289; phenotype.
DR   neXtProt; NX_Q9H3D4; -.
DR   OpenTargets; ENSG00000073282; -.
DR   Orphanet; 978; ADULT syndrome.
DR   Orphanet; 1071; Ankyloblepharon - ectodermal defects - cleft lip/palate.
DR   Orphanet; 93930; Bladder exstrophy.
DR   Orphanet; 1991; Cleft lip with or without cleft palate.
DR   Orphanet; 1896; EEC syndrome.
DR   Orphanet; 69085; Limb-mammary syndrome.
DR   Orphanet; 2440; Split hand-split foot malformation.
DR   PharmGKB; PA162406776; -.
DR   eggNOG; ENOG410IGE4; Eukaryota.
DR   eggNOG; ENOG410XV9W; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; Q9H3D4; -.
DR   KO; K10149; -.
DR   OMA; YQIENYN; -.
DR   OrthoDB; EOG091G0XY5; -.
DR   PhylomeDB; Q9H3D4; -.
DR   TreeFam; TF106101; -.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   SignaLink; Q9H3D4; -.
DR   SIGNOR; Q9H3D4; -.
DR   ChiTaRS; TP63; human.
DR   EvolutionaryTrace; Q9H3D4; -.
DR   GeneWiki; TP63; -.
DR   GenomeRNAi; 8626; -.
DR   PRO; PR:Q9H3D4; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000073282; -.
DR   ExpressionAtlas; Q9H3D4; baseline and differential.
DR   Genevisible; Q9H3D4; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005667; C:transcription factor complex; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IMP:CAFA.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IPI:CAFA.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; IPI:CAFA.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0000989; F:transcription factor activity, transcription factor binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0050699; F:WW domain binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IBA:GO_Central.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0060197; P:cloacal septation; IEA:Ensembl.
DR   GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:GO_Central.
DR   GO; GO:0007499; P:ectoderm and mesoderm interaction; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0010481; P:epidermal cell division; IEA:Ensembl.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl.
DR   GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB.
DR   GO; GO:0048807; P:female genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IBA:GO_Central.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0043616; P:keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0010259; P:multicellular organism aging; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IMP:UniProtKB.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045617; P:negative regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:2000381; P:negative regulation of mesoderm development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0030859; P:polarized epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; IMP:UniProtKB.
DR   GO; GO:2000271; P:positive regulation of fibroblast apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:1904674; P:positive regulation of somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0060513; P:prostatic bud formation; IEA:Ensembl.
DR   GO; GO:0051289; P:protein homotetramerization; IPI:UniProtKB.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0010482; P:regulation of epidermal cell division; ISS:UniProtKB.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0001302; P:replicative cell aging; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:GO_Central.
DR   GO; GO:0010165; P:response to X-ray; IBA:GO_Central.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0043589; P:skin morphogenesis; IEA:Ensembl.
DR   GO; GO:0048745; P:smooth muscle tissue development; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; IEA:Ensembl.
DR   GO; GO:0060157; P:urinary bladder development; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   CDD; cd09572; SAM_tumor-p63; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR032645; Tp63.
DR   InterPro; IPR037611; Tumor-p63_SAM.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Complete proteome;
KW   Developmental protein; Disease mutation; DNA-binding;
KW   Ectodermal dysplasia; Isopeptide bond; Metal-binding;
KW   Notch signaling pathway; Nucleus; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc.
FT   CHAIN         1    680       Tumor protein 63.
FT                                /FTId=PRO_0000185729.
FT   DOMAIN      541    607       SAM.
FT   DNA_BIND    170    362
FT   REGION        1    107       Transcription activation.
FT   REGION      352    388       Interaction with HIPK2.
FT                                {ECO:0000269|PubMed:11925430}.
FT   REGION      394    443       Oligomerization.
FT   REGION      610    680       Transactivation inhibition.
FT   COMPBIAS    437    444       Poly-Gln.
FT   METAL       244    244       Zinc. {ECO:0000250}.
FT   METAL       247    247       Zinc. {ECO:0000250}.
FT   METAL       308    308       Zinc. {ECO:0000250}.
FT   METAL       312    312       Zinc. {ECO:0000250}.
FT   CROSSLNK    676    676       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VAR_SEQ       1    108       MNFETSRCATLQYCPDPYIQRFVETPAHFSWKESYYRSTMS
FT                                QSTQTNEFLSPEVFQHIWDFLEQPICSVQPIDLNFVDEPSE
FT                                DGATNKIEISMDCIRMQDSDLSDPMW -> MLYLENNAQTQ
FT                                FSE (in isoform 2, isoform 4, isoform 6,
FT                                isoform 8, isoform 10 and isoform 12).
FT                                {ECO:0000303|PubMed:10469295,
FT                                ECO:0000303|PubMed:11336476,
FT                                ECO:0000303|PubMed:9703973,
FT                                ECO:0000303|PubMed:9774969}.
FT                                /FTId=VSP_012465.
FT   VAR_SEQ     109    193       Missing (in isoform 9 and isoform 10).
FT                                {ECO:0000303|PubMed:11336476}.
FT                                /FTId=VSP_012466.
FT   VAR_SEQ     373    377       GTKRP -> A (in isoform 11 and isoform
FT                                12). {ECO:0000303|PubMed:11477076}.
FT                                /FTId=VSP_012467.
FT   VAR_SEQ     450    680       QTSIQSPSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNAL
FT                                TPTTIPDGMGANIPMMGTHMPMAGDMNGLSPTQALPPPLSM
FT                                PSTSHCTPPPPYPTDCSIVSFLARLGCSSCLDYFTTQGLTT
FT                                IYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHEFSSP
FT                                SHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPP
FT                                RDEWNDFNFDMDARRNKQQRIKEEGE -> HLLSACFRNEL
FT                                VEPRRETPKQSDVFFRHSKPPNRSVYP (in isoform 5
FT                                and isoform 6).
FT                                {ECO:0000303|PubMed:9662378,
FT                                ECO:0000303|PubMed:9774969}.
FT                                /FTId=VSP_012468.
FT   VAR_SEQ     503    680       IPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPY
FT                                PTDCSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDL
FT                                ASLKIPEQFRHAIWKGILDHRQLHEFSSPSHLLRTPSSAST
FT                                VSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMD
FT                                ARRNKQQRIKEEGE -> RSGKSENP (in isoform 7
FT                                and isoform 8).
FT                                {ECO:0000303|PubMed:10935472}.
FT                                /FTId=VSP_012469.
FT   VAR_SEQ     551    680       SFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPE
FT                                QFRHAIWKGILDHRQLHEFSSPSHLLRTPSSASTVSVGSSE
FT                                TRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQQ
FT                                RIKEEGE -> RIWQV (in isoform 3 and
FT                                isoform 4). {ECO:0000303|PubMed:9774969}.
FT                                /FTId=VSP_012470.
FT   VARIANT     129    129       S -> L (in dbSNP:rs193287780).
FT                                {ECO:0000269|PubMed:16740912}.
FT                                /FTId=VAR_035126.
FT   VARIANT     184    184       S -> L (in head and neck cancer).
FT                                {ECO:0000269|PubMed:9662378}.
FT                                /FTId=VAR_020866.
FT   VARIANT     187    187       A -> P (in lung carcinoma; somatic
FT                                mutation). {ECO:0000269|PubMed:9662378}.
FT                                /FTId=VAR_020867.
FT   VARIANT     193    193       T -> TP (in SHFM4).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032736.
FT   VARIANT     204    204       Q -> L (in cervical cancer).
FT                                {ECO:0000269|PubMed:9662378}.
FT                                /FTId=VAR_020868.
FT   VARIANT     232    232       K -> E (in SHFM4).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032737.
FT   VARIANT     233    233       K -> E (in SHFM4; dbSNP:rs121908838).
FT                                {ECO:0000269|PubMed:10839977}.
FT                                /FTId=VAR_020869.
FT   VARIANT     243    243       R -> Q (in EEC3; dbSNP:rs121908836).
FT                                {ECO:0000269|PubMed:10535733,
FT                                ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_020870.
FT   VARIANT     243    243       R -> W (in EEC3; dbSNP:rs121908835).
FT                                {ECO:0000269|PubMed:10535733,
FT                                ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_020871.
FT   VARIANT     266    266       R -> Q (in EEC3; dbSNP:rs121908849).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032738.
FT   VARIANT     279    279       P -> H (in colon cancer).
FT                                {ECO:0000269|PubMed:10485447}.
FT                                /FTId=VAR_020872.
FT   VARIANT     308    308       C -> Y (in EEC3).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032739.
FT   VARIANT     311    311       S -> N (in EEC3).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032740.
FT   VARIANT     318    318       R -> C (in EEC3).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032741.
FT   VARIANT     318    318       R -> H (in EEC3 and EDRH; does not
FT                                decrease the transcriptional activity of
FT                                the isoform 5 on a TP53 reporter system
FT                                but disrupts the dominant-negative
FT                                activity of isoform 2 and isoform 5 on
FT                                the transcriptional activity of TP53;
FT                                dbSNP:rs121908840).
FT                                {ECO:0000269|PubMed:10839977,
FT                                ECO:0000269|PubMed:11462173,
FT                                ECO:0000269|PubMed:12939657}.
FT                                /FTId=VAR_020873.
FT   VARIANT     318    318       R -> Q (in EEC3).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032742.
FT   VARIANT     319    319       R -> C (in EEC3; dbSNP:rs121908839).
FT                                {ECO:0000269|PubMed:10839977,
FT                                ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_020874.
FT   VARIANT     319    319       R -> H (in EEC3 and SHFM4;
FT                                dbSNP:rs886039442).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032743.
FT   VARIANT     319    319       R -> S (in EEC3).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032744.
FT   VARIANT     337    337       R -> Q (in ADULT syndrome; confers novel
FT                                transcription activation capacity on
FT                                isoform 6; dbSNP:rs113993967).
FT                                {ECO:0000269|PubMed:11929852}.
FT                                /FTId=VAR_020875.
FT   VARIANT     343    343       R -> Q (in EEC3; dbSNP:rs121908841).
FT                                {ECO:0000269|PubMed:10839977,
FT                                ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_020876.
FT   VARIANT     343    343       R -> W (in EEC3; dbSNP:rs886041251).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032745.
FT   VARIANT     345    345       C -> R (in EEC3; abolishes transcription
FT                                activation; dbSNP:rs121908837).
FT                                {ECO:0000269|PubMed:10535733,
FT                                ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_020877.
FT   VARIANT     347    347       C -> S (in EEC3).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032746.
FT   VARIANT     348    348       P -> S (in EEC3).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032747.
FT   VARIANT     351    351       D -> G (in EEC3; dbSNP:rs121908844).
FT                                {ECO:0000269|PubMed:12838557}.
FT                                /FTId=VAR_020878.
FT   VARIANT     351    351       D -> H (in EEC3).
FT                                {ECO:0000269|PubMed:11462173}.
FT                                /FTId=VAR_032748.
FT   VARIANT     352    352       R -> G (in EDRH and OFC8;
FT                                dbSNP:rs121908847).
FT                                {ECO:0000269|PubMed:16740912}.
FT                                /FTId=VAR_035127.
FT   VARIANT     549    549       I -> T (in EDRH; dbSNP:rs121908845).
FT                                {ECO:0000269|PubMed:15200513}.
FT                                /FTId=VAR_035128.
FT   VARIANT     553    553       L -> F (in AEC; dbSNP:rs121908842).
FT                                {ECO:0000269|PubMed:11159940}.
FT                                /FTId=VAR_020879.
FT   VARIANT     560    560       S -> A (in ovarian cancer).
FT                                {ECO:0000269|PubMed:10485447}.
FT                                /FTId=VAR_020880.
FT   VARIANT     561    561       C -> G (in AEC; dbSNP:rs121908843).
FT                                {ECO:0000269|PubMed:11159940}.
FT                                /FTId=VAR_020881.
FT   VARIANT     580    580       S -> P (in EDRH; dbSNP:rs121908846).
FT                                {ECO:0000269|PubMed:12766194}.
FT                                /FTId=VAR_035129.
FT   VARIANT     603    603       D -> H (in dbSNP:rs767906723).
FT                                {ECO:0000269|PubMed:16740912}.
FT                                /FTId=VAR_035130.
FT   MUTAGEN      55     55       F->A: Abrogates transcriptional activity
FT                                and interaction with transactivation
FT                                inhibition domain; when associated with
FT                                A-59 and A-62.
FT                                {ECO:0000269|PubMed:12446779}.
FT   MUTAGEN      59     59       W->A: Abrogates transcriptional activity
FT                                and interaction with transactivation
FT                                inhibition domain; when associated with
FT                                A-55 and A-62.
FT                                {ECO:0000269|PubMed:12446779}.
FT   MUTAGEN      62     62       L->A: Abrogates transcriptional activity
FT                                and interaction with transactivation
FT                                inhibition domain; when associated with
FT                                A-55 and A-59.
FT                                {ECO:0000269|PubMed:12446779}.
FT   MUTAGEN     543    543       Y->F: Abolishes ubiquitination.
FT                                {ECO:0000269|PubMed:18806757}.
FT   CONFLICT    125    125       Q -> R (in Ref. 1; BAA32433).
FT                                {ECO:0000305}.
FT   CONFLICT    154    154       S -> P (in Ref. 1; BAA32433).
FT                                {ECO:0000305}.
FT   CONFLICT    177    177       F -> S (in Ref. 1; BAA32433).
FT                                {ECO:0000305}.
FT   CONFLICT    378    378       F -> S (in Ref. 10; AAC24830).
FT                                {ECO:0000305}.
FT   CONFLICT    536    536       H -> Q (in Ref. 2; CAA76562).
FT                                {ECO:0000305}.
FT   CONFLICT    551    551       S -> G (in Ref. 4; BAA32593 and 7;
FT                                AAF43487/AAF43491). {ECO:0000305}.
FT   STRAND      156    161       {ECO:0000244|PDB:2RMN}.
FT   HELIX       173    175       {ECO:0000244|PDB:3QYN}.
FT   STRAND      178    180       {ECO:0000244|PDB:3QYN}.
FT   STRAND      187    189       {ECO:0000244|PDB:3QYN}.
FT   STRAND      191    195       {ECO:0000244|PDB:3QYN}.
FT   TURN        196    199       {ECO:0000244|PDB:3QYN}.
FT   STRAND      200    203       {ECO:0000244|PDB:3QYN}.
FT   STRAND      209    214       {ECO:0000244|PDB:3QYN}.
FT   STRAND      224    233       {ECO:0000244|PDB:3QYN}.
FT   TURN        234    238       {ECO:0000244|PDB:3QYN}.
FT   HELIX       245    249       {ECO:0000244|PDB:3QYN}.
FT   TURN        252    256       {ECO:0000244|PDB:3QYN}.
FT   STRAND      263    269       {ECO:0000244|PDB:3QYN}.
FT   STRAND      274    277       {ECO:0000244|PDB:3QYN}.
FT   TURN        279    281       {ECO:0000244|PDB:3QYN}.
FT   STRAND      284    289       {ECO:0000244|PDB:3QYN}.
FT   STRAND      300    306       {ECO:0000244|PDB:3QYN}.
FT   TURN        313    318       {ECO:0000244|PDB:3QYN}.
FT   STRAND      321    328       {ECO:0000244|PDB:3QYN}.
FT   STRAND      330    332       {ECO:0000244|PDB:3QYM}.
FT   STRAND      334    343       {ECO:0000244|PDB:3QYN}.
FT   HELIX       348    355       {ECO:0000244|PDB:3QYN}.
FT   STRAND      369    372       {ECO:0000244|PDB:2RMN}.
FT   STRAND      401    407       {ECO:0000244|PDB:3ZY0}.
FT   HELIX       408    426       {ECO:0000244|PDB:3ZY0}.
FT   HELIX       429    436       {ECO:0000244|PDB:3ZY1}.
FT   HELIX       444    449       {ECO:0000244|PDB:4A9Z}.
FT   STRAND      546    548       {ECO:0000244|PDB:2Y9T}.
FT   HELIX       549    554       {ECO:0000244|PDB:2Y9U}.
FT   TURN        555    557       {ECO:0000244|PDB:2Y9U}.
FT   HELIX       559    561       {ECO:0000244|PDB:2Y9U}.
FT   HELIX       562    566       {ECO:0000244|PDB:2Y9U}.
FT   TURN        567    569       {ECO:0000244|PDB:2Y9U}.
FT   HELIX       573    576       {ECO:0000244|PDB:2Y9U}.
FT   HELIX       581    586       {ECO:0000244|PDB:2Y9U}.
FT   HELIX       591    609       {ECO:0000244|PDB:2Y9U}.
FT   STRAND      613    615       {ECO:0000244|PDB:2Y9T}.
SQ   SEQUENCE   680 AA;  76785 MW;  F66ECD45E87D9799 CRC64;
     MNFETSRCAT LQYCPDPYIQ RFVETPAHFS WKESYYRSTM SQSTQTNEFL SPEVFQHIWD
     FLEQPICSVQ PIDLNFVDEP SEDGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNSM
     DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
     FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
     VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
     TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
     KQQVSDSTKN GDGTKRPFRQ NTHGIQMTSI KKRRSPDDEL LYLPVRGRET YEMLLKIKES
     LELMQYLPQH TIETYRQQQQ QQHQHLLQKQ TSIQSPSSYG NSSPPLNKMN SMNKLPSVSQ
     LINPQQRNAL TPTTIPDGMG ANIPMMGTHM PMAGDMNGLS PTQALPPPLS MPSTSHCTPP
     PPYPTDCSIV SFLARLGCSS CLDYFTTQGL TTIYQIEHYS MDDLASLKIP EQFRHAIWKG
     ILDHRQLHEF SSPSHLLRTP SSASTVSVGS SETRGERVID AVRFTLRQTI SFPPRDEWND
     FNFDMDARRN KQQRIKEEGE
//
